0001493152-24-04525810-Q PAVmed Inc. 20241113202411132129302129302129302930 0 0001493152-24-045258 10-Q 88 20240930 20241114 20241113 PAVmed Inc. 0001624326 3841 471214177 DE 1231 10-Q 34 001-37685 241456585 360 MADISON AVENUE 25TH FLOOR NEW YORK NY 10017 (212) 949-4319 360 MADISON AVENUE 25TH FLOOR NEW YORK NY 10017 PAXmed Inc. 20141105 10-Q 1 form10-q.htm false --12-31 Q3 0001624326 0001624326 2024-01-01 2024-09-30 0001624326 PAVM:CommonStock0.001ParValuePerShareMember 2024-01-01 2024-09-30 0001624326 PAVM:SeriesZWarrantsEachToPurchase115thOfOneShareOfCommonStockMember 2024-01-01 2024-09-30 0001624326 2024-09-30 0001624326 2024-11-11 0001624326 2023-12-31 0001624326 PAVM:SeriesBConvertiblePreferredStockMember 2024-09-30 0001624326 PAVM:SeriesBConvertiblePreferredStockMember 2023-12-31 0001624326 2024-07-01 2024-09-30 0001624326 2023-07-01 2023-09-30 0001624326 2023-01-01 2023-09-30 0001624326 us-gaap:PreferredStockMember PAVM:SeriesBConvertiblePreferredStockMember 2024-06-30 0001624326 us-gaap:CommonStockMember 2024-06-30 0001624326 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001624326 us-gaap:RetainedEarningsMember 2024-06-30 0001624326 us-gaap:TreasuryStockCommonMember 2024-06-30 0001624326 us-gaap:NoncontrollingInterestMember 2024-06-30 0001624326 2024-06-30 0001624326 us-gaap:PreferredStockMember PAVM:SeriesBConvertiblePreferredStockMember 2023-12-31 0001624326 us-gaap:CommonStockMember 2023-12-31 0001624326 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001624326 us-gaap:RetainedEarningsMember 2023-12-31 0001624326 us-gaap:TreasuryStockCommonMember 2023-12-31 0001624326 us-gaap:NoncontrollingInterestMember 2023-12-31 0001624326 us-gaap:PreferredStockMember PAVM:SeriesBConvertiblePreferredStockMember 2023-06-30 0001624326 us-gaap:CommonStockMember 2023-06-30 0001624326 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001624326 us-gaap:RetainedEarningsMember 2023-06-30 0001624326 us-gaap:TreasuryStockCommonMember 2023-06-30 0001624326 us-gaap:NoncontrollingInterestMember 2023-06-30 0001624326 2023-06-30 0001624326 us-gaap:PreferredStockMember PAVM:SeriesBConvertiblePreferredStockMember 2022-12-31 0001624326 us-gaap:CommonStockMember 2022-12-31 0001624326 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001624326 us-gaap:RetainedEarningsMember 2022-12-31 0001624326 us-gaap:TreasuryStockCommonMember 2022-12-31 0001624326 us-gaap:NoncontrollingInterestMember 2022-12-31 0001624326 2022-12-31 0001624326 us-gaap:PreferredStockMember PAVM:SeriesBConvertiblePreferredStockMember 2024-07-01 2024-09-30 0001624326 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001624326 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001624326 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001624326 us-gaap:TreasuryStockCommonMember 2024-07-01 2024-09-30 0001624326 us-gaap:NoncontrollingInterestMember 2024-07-01 2024-09-30 0001624326 us-gaap:PreferredStockMember PAVM:SeriesBConvertiblePreferredStockMember 2024-01-01 2024-09-30 0001624326 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001624326 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-09-30 0001624326 us-gaap:RetainedEarningsMember 2024-01-01 2024-09-30 0001624326 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-09-30 0001624326 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-09-30 0001624326 us-gaap:PreferredStockMember PAVM:SeriesBConvertiblePreferredStockMember 2023-07-01 2023-09-30 0001624326 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001624326 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001624326 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001624326 us-gaap:TreasuryStockCommonMember 2023-07-01 2023-09-30 0001624326 us-gaap:NoncontrollingInterestMember 2023-07-01 2023-09-30 0001624326 us-gaap:PreferredStockMember PAVM:SeriesBConvertiblePreferredStockMember 2023-01-01 2023-09-30 0001624326 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001624326 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0001624326 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001624326 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-09-30 0001624326 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-09-30 0001624326 us-gaap:PreferredStockMember PAVM:SeriesBConvertiblePreferredStockMember 2024-09-30 0001624326 us-gaap:CommonStockMember 2024-09-30 0001624326 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001624326 us-gaap:RetainedEarningsMember 2024-09-30 0001624326 us-gaap:TreasuryStockCommonMember 2024-09-30 0001624326 us-gaap:NoncontrollingInterestMember 2024-09-30 0001624326 us-gaap:PreferredStockMember PAVM:SeriesBConvertiblePreferredStockMember 2023-09-30 0001624326 us-gaap:CommonStockMember 2023-09-30 0001624326 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001624326 us-gaap:RetainedEarningsMember 2023-09-30 0001624326 us-gaap:TreasuryStockCommonMember 2023-09-30 0001624326 us-gaap:NoncontrollingInterestMember 2023-09-30 0001624326 2023-09-30 0001624326 us-gaap:LetterOfCreditMember 2024-09-30 0001624326 us-gaap:LetterOfCreditMember 2023-12-31 0001624326 PAVM:LucidDiagnosticsIncMember srt:MinimumMember 2024-09-30 0001624326 PAVM:LucidDiagnosticsIncMember srt:MaximumMember 2024-09-30 0001624326 PAVM:LucidDiagnosticsIncMember srt:MaximumMember 2024-09-10 0001624326 PAVM:LucidDiagnosticsIncMember 2024-09-10 2024-09-10 0001624326 PAVM:LucidDiagnosticsIncMember 2024-07-01 2024-09-30 0001624326 PAVM:LucidDiagnosticsIncMember 2024-01-01 2024-09-30 0001624326 PAVM:LucidDiagnosticsIncMember 2024-09-10 0001624326 PAVM:LucidDiagnosticsIncMember 2024-09-30 0001624326 PAVM:LucidDiagnosticsIncMember us-gaap:CommonStockMember 2024-09-10 0001624326 PAVM:LucidDiagnosticsIncMember us-gaap:CommonStockMember 2024-09-30 0001624326 PAVM:LucidDiagnosticsIncMember us-gaap:CommonStockMember 2024-09-10 0001624326 PAVM:LucidDiagnosticsIncMember us-gaap:CommonStockMember 2024-09-30 0001624326 PAVM:ManagementServicesAgreementMember srt:BoardOfDirectorsChairmanMember PAVM:LucidDiagnosticsIncMember 2024-01-01 2024-09-30 0001624326 PAVM:ManagementServicesAgreementMember srt:BoardOfDirectorsChairmanMember PAVM:LucidDiagnosticsIncMember 2024-07-01 2024-09-30 0001624326 PAVM:ManagementServicesAgreementMember srt:BoardOfDirectorsChairmanMember PAVM:LucidDiagnosticsIncMember 2024-09-11 2024-09-30 0001624326 us-gaap:IntellectualPropertyMember 2024-09-27 2024-09-27 0001624326 PAVM:LucidDiagnosticsIncMember PAVM:JulyOneTwoThousandTwentyFourToSeptemberTenTwoThousandTwentyFourMember 2024-07-01 2024-09-30 0001624326 PAVM:LucidDiagnosticsIncMember PAVM:SeptemberElevenTwoThousandTwentyFourToSeptemberThirtyTwoThousandTwentyFourMember 2024-07-01 2024-09-30 0001624326 PAVM:LucidDiagnosticsIncMember PAVM:JanuaryOneTwoThousandTwentyFourToSeptemberTenTwoThousandTwentyFourMember 2024-01-01 2024-09-30 0001624326 PAVM:LucidDiagnosticsIncMember PAVM:SeptemberElevenTwoThousandTwentyFourToSeptemberThirtyTwoThousandTwentyFourMember 2024-01-01 2024-09-30 0001624326 PAVM:DefensiveAssetMember 2024-09-30 0001624326 PAVM:DefensiveAssetMember 2023-12-31 0001624326 PAVM:LaboratoryInformationManagementSoftwareMember 2024-09-30 0001624326 PAVM:LaboratoryInformationManagementSoftwareMember 2023-12-31 0001624326 PAVM:OtherInfiniteLivedIntangibleAssetMember 2024-09-30 0001624326 PAVM:OtherInfiniteLivedIntangibleAssetMember 2023-12-31 0001624326 PAVM:LucidCommonStockMember us-gaap:FairValueInputsLevel1Member 2024-09-30 0001624326 PAVM:LucidCommonStockMember us-gaap:FairValueInputsLevel2Member 2024-09-30 0001624326 PAVM:LucidCommonStockMember us-gaap:FairValueInputsLevel3Member 2024-09-30 0001624326 PAVM:LucidCommonStockMember 2024-09-30 0001624326 us-gaap:FairValueInputsLevel1Member 2024-09-30 0001624326 us-gaap:FairValueInputsLevel2Member 2024-09-30 0001624326 us-gaap:FairValueInputsLevel3Member 2024-09-30 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember us-gaap:FairValueInputsLevel1Member 2024-09-30 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember us-gaap:FairValueInputsLevel2Member 2024-09-30 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember us-gaap:FairValueInputsLevel3Member 2024-09-30 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2024-09-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:FairValueInputsLevel1Member 2024-09-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:FairValueInputsLevel2Member 2024-09-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:FairValueInputsLevel3Member 2024-09-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2024-09-30 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2023-12-31 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2023-12-31 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-12-31 0001624326 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001624326 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001624326 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2022-04-04 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2022-09-08 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-03-21 0001624326 PAVM:MeasurementInputRequiredRateOfReturnMember PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2024-09-30 0001624326 PAVM:MeasurementInputRequiredRateOfReturnMember PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2024-09-30 0001624326 us-gaap:MeasurementInputConversionPriceMember PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2024-09-30 0001624326 us-gaap:MeasurementInputConversionPriceMember PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2024-09-30 0001624326 us-gaap:MeasurementInputSharePriceMember PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2024-09-30 0001624326 us-gaap:MeasurementInputSharePriceMember PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2024-09-30 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember us-gaap:MeasurementInputExpectedTermMember 2024-01-01 2024-09-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:MeasurementInputExpectedTermMember 2024-01-01 2024-09-30 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember us-gaap:MeasurementInputPriceVolatilityMember 2024-09-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:MeasurementInputPriceVolatilityMember 2024-09-30 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-09-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-09-30 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-09-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-09-30 0001624326 PAVM:MeasurementInputRequiredRateOfReturnMember PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember srt:MinimumMember 2023-12-31 0001624326 PAVM:MeasurementInputRequiredRateOfReturnMember PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember srt:MaximumMember 2023-12-31 0001624326 PAVM:MeasurementInputRequiredRateOfReturnMember PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember srt:MinimumMember 2023-12-31 0001624326 PAVM:MeasurementInputRequiredRateOfReturnMember PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember srt:MaximumMember 2023-12-31 0001624326 PAVM:MeasurementInputRequiredRateOfReturnMember PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-12-31 0001624326 us-gaap:MeasurementInputConversionPriceMember PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2023-12-31 0001624326 us-gaap:MeasurementInputConversionPriceMember PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2023-12-31 0001624326 us-gaap:MeasurementInputConversionPriceMember PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-12-31 0001624326 us-gaap:MeasurementInputSharePriceMember PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2023-12-31 0001624326 us-gaap:MeasurementInputSharePriceMember PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2023-12-31 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember us-gaap:MeasurementInputSharePriceMember 2023-12-31 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember 2023-01-01 2023-12-31 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2023-01-01 2023-12-31 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember 2023-01-01 2023-12-31 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2023-01-01 2023-12-31 0001624326 us-gaap:MeasurementInputExpectedTermMember PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-01-01 2023-12-31 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001624326 us-gaap:MeasurementInputPriceVolatilityMember PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-12-31 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2023-12-31 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2023-12-31 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2023-12-31 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2023-12-31 0001624326 us-gaap:MeasurementInputRiskFreeInterestRateMember PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-12-31 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember us-gaap:MeasurementInputExpectedDividendRateMember 2023-12-31 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:MeasurementInputExpectedDividendRateMember 2023-12-31 0001624326 us-gaap:MeasurementInputExpectedDividendRateMember PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-12-31 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2024-01-01 2024-09-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2024-01-01 2024-09-30 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2023-01-01 2023-12-31 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2023-01-01 2023-12-31 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-01-01 2023-12-31 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2024-06-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2024-06-30 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2024-06-30 0001624326 PAVM:OtherIncomeExpenseMember 2024-06-30 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2024-07-01 2024-09-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2024-07-01 2024-09-30 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2024-07-01 2024-09-30 0001624326 PAVM:OtherIncomeExpenseMember 2024-07-01 2024-09-30 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2024-09-30 0001624326 PAVM:OtherIncomeExpenseMember 2024-09-30 0001624326 PAVM:OtherIncomeExpenseMember 2023-12-31 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2024-01-01 2024-09-30 0001624326 PAVM:OtherIncomeExpenseMember 2024-01-01 2024-09-30 0001624326

PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2023-06-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2023-06-30 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-06-30 0001624326 PAVM:OtherIncomeExpenseMember 2023-06-30 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2023-07-01 2023-09-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2023-07-01 2023-09-30 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-07-01 2023-09-30 0001624326 PAVM:OtherIncomeExpenseMember 2023-07-01 2023-09-30 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2023-09-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2023-09-30 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-09-30 0001624326 PAVM:OtherIncomeExpenseMember 2023-09-30 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2022-12-31 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2022-12-31 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2022-12-31 0001624326 PAVM:OtherIncomeExpenseMember 2022-12-31 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2023-01-01 2023-09-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2023-01-01 2023-09-30 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-01-01 2023-09-30 0001624326 PAVM:OtherIncomeExpenseMember 2023-01-01 2023-09-30 0001624326 PAVM:SecuritiesPurchaseAgreementMember PAVM:AccreditedInstitutionalInvestorMember 2022-03-31 0001624326 PAVM:SecuritiesPurchaseAgreementMember PAVM:AccreditedInstitutionalInvestorMember PAVM:InitialIssuanceMember 2022-03-31 0001624326 PAVM:SecuritiesPurchaseAgreementMember PAVM:AccreditedInstitutionalInvestorMember PAVM:AdditionalIssuanceMember 2022-03-31 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2022-04-02 2022-04-04 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2022-09-07 2022-09-08 0001624326 PAVM:AprilAndSeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2024-09-30 0001624326 PAVM:AprilAndSeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember PAVM:JuneThirtyTwentyTwentyFourThroughSeptemberThreeTwentyTwentyFourMember 2024-09-30 0001624326 PAVM:AprilAndSeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2024-01-01 2024-09-30 0001624326 us-gaap:CashMember 2024-09-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:InvestorMember 2024-07-01 2024-09-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:InvestorMember 2024-01-01 2024-09-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:InterestRateFloorMember 2024-07-01 2024-09-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:InterestRateFloorMember 2024-01-01 2024-09-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:InterestRateFloorMember 2024-09-30 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2024-01-01 2024-09-10 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember us-gaap:InvestorMember 2024-01-01 2024-09-10 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2024-07-01 2024-09-10 0001624326 PAVM:TwoThousandAndFourteenEquityPlanMember 2024-09-30 0001624326 PAVM:TwoThousandAndFourteenEquityPlanMember 2024-01-31 0001624326 PAVM:TwoThousandAndFourteenEquityPlanMember srt:ParentCompanyMember 2024-02-22 2024-02-22 0001624326 PAVM:TwoThousandAndFourteenEquityPlanMember us-gaap:RestrictedStockMember srt:ParentCompanyMember 2024-02-22 2024-02-22 0001624326 PAVM:LucidDiagnosticsIncMember PAVM:TwoThousandEighteenEquityPlanMember 2024-02-22 2024-02-22 0001624326 PAVM:TwoThousandEighteenEquityPlanMember PAVM:LucidDiagnosticsIncMember us-gaap:RestrictedStockMember 2024-05-01 2024-05-31 0001624326 PAVM:TwoThousandAndFourteenEquityPlanMember 2024-01-01 2024-09-30 0001624326 PAVM:TwoThousandAndFourteenEquityPlanMember 2023-01-01 2023-09-30 0001624326 PAVM:TwoThousandEighteenEquityPlanMember 2024-01-01 2024-09-30 0001624326 PAVM:TwoThousandEighteenEquityPlanMember 2023-01-01 2023-09-30 0001624326 PAVM:EmployeeStockPurchasePlanMember 2024-01-01 2024-03-31 0001624326 PAVM:EmployeeStockPurchasePlanMember 2023-01-01 2023-03-31 0001624326 PAVM:EmployeeStockPurchasePlanMember 2023-01-01 2023-09-30 0001624326 PAVM:EmployeeStockPurchasePlanMember 2024-09-30 0001624326 PAVM:EmployeeStockPurchasePlanMember 2024-01-01 2024-01-31 0001624326 PAVM:EmployeeStockPurchasePlanMember PAVM:LucidDiagnosticsIncMember 2024-01-01 2024-03-31 0001624326 PAVM:EmployeeStockPurchasePlanMember PAVM:LucidDiagnosticsIncMember 2023-01-01 2023-03-31 0001624326 PAVM:EmployeeStockPurchasePlanMember PAVM:LucidDiagnosticsIncMember 2023-01-01 2023-09-30 0001624326 PAVM:TwoThousandAndFourteenEquityPlanMember 2023-12-31 0001624326 PAVM:TwoThousandAndFourteenEquityPlanMember 2023-01-01 2023-12-31 0001624326 PAVM:TwoThousandEighteenEquityPlanMember 2023-12-31 0001624326 PAVM:TwoThousandEighteenEquityPlanMember 2023-01-01 2023-12-31 0001624326 PAVM:TwoThousandEighteenEquityPlanMember 2024-09-30 0001624326 srt:ParentCompanyMember PAVM:TwoThousandAndFourteenEquityPlanMember 2024-01-01 2024-09-30 0001624326 srt:ParentCompanyMember PAVM:TwoThousandAndFourteenEquityPlanMember 2023-01-01 2023-12-31 0001624326 PAVM:LucidDiagnosticsIncMember PAVM:TwoThousandEighteenEquityPlanMember 2024-09-10 2024-09-10 0001624326 PAVM:LucidDiagnosticsIncMember PAVM:TwoThousandEighteenEquityPlanMember 2023-01-01 2023-12-31 0001624326 us-gaap:RestrictedStockUnitsRSUMember PAVM:TwoThousandAndFourteenEquityPlanMember 2023-12-31 0001624326 us-gaap:RestrictedStockUnitsRSUMember PAVM:TwoThousandAndFourteenEquityPlanMember 2024-01-01 2024-09-30 0001624326 us-gaap:RestrictedStockUnitsRSUMember PAVM:TwoThousandAndFourteenEquityPlanMember 2024-09-30 0001624326 us-gaap:RestrictedStockUnitsRSUMember PAVM:TwoThousandEighteenEquityPlanMember 2023-12-31 0001624326 us-gaap:RestrictedStockUnitsRSUMember PAVM:TwoThousandEighteenEquityPlanMember 2024-01-01 2024-09-30 0001624326 us-gaap:RestrictedStockUnitsRSUMember PAVM:TwoThousandEighteenEquityPlanMember 2024-09-30 0001624326 PAVM:CostOfRevenueMember 2024-07-01 2024-09-30 0001624326 PAVM:CostOfRevenueMember 2023-07-01 2023-09-30 0001624326 PAVM:CostOfRevenueMember 2024-01-01 2024-09-30 0001624326 PAVM:CostOfRevenueMember 2023-01-01 2023-09-30 0001624326 us-gaap:SellingAndMarketingExpenseMember 2024-07-01 2024-09-30 0001624326 us-gaap:SellingAndMarketingExpenseMember 2023-07-01 2023-09-30 0001624326 us-gaap:SellingAndMarketingExpenseMember 2024-01-01 2024-09-30 0001624326 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-09-30 0001624326 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-01 2024-09-30 0001624326 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-01 2023-09-30 0001624326 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-09-30 0001624326 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-09-30 0001624326 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0001624326 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001624326 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0001624326 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001624326 PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember PAVM:CostOfRevenueMember 2024-07-01 2024-09-30 0001624326 PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember PAVM:CostOfRevenueMember 2023-07-01 2023-09-30 0001624326 PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember PAVM:CostOfRevenueMember 2024-01-01 2024-09-30 0001624326 PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember PAVM:CostOfRevenueMember 2023-01-01 2023-09-30 0001624326 PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember us-gaap:SellingAndMarketingExpenseMember 2024-07-01 2024-09-30 0001624326 PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember us-gaap:SellingAndMarketingExpenseMember 2023-07-01 2023-09-30 0001624326 PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember us-gaap:SellingAndMarketingExpenseMember 2024-01-01 2024-09-30 0001624326 PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-09-30 0001624326 PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-01 2024-09-30 0001624326 PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-01 2023-09-30 0001624326 PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-09-30 0001624326 PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-09-30 0001624326 PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0001624326 PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001624326 PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0001624326 PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001624326 PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember PAVM:CostOfRevenueMember 2024-07-01 2024-09-30 0001624326 PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember PAVM:CostOfRevenueMember 2023-07-01 2023-09-30 0001624326 PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember PAVM:CostOfRevenueMember 2024-01-01 2024-09-30 0001624326 PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember PAVM:CostOfRevenueMember 2023-01-01 2023-09-30 0001624326 PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember us-gaap:SellingAndMarketingExpenseMember 2024-07-01 2024-09-30 0001624326 PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember us-gaap:SellingAndMarketingExpenseMember 2023-07-01 2023-09-30 0001624326 PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember us-gaap:SellingAndMarketingExpenseMember 2024-01-01 2024-09-30 0001624326 PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-09-30 0001624326 PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-01 2024-09-30 0001624326 PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-01 2023-09-30 0001624326 PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-09-30 0001624326 PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-09-30 0001624326 PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0001624326 PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001624326 PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0001624326 PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001624326 PAVM:LucidDiagnosticsIncMember 2024-07-01 2024-09-30 0001624326 PAVM:LucidDiagnosticsIncMember 2023-07-01 2023-09-30 0001624326 PAVM:LucidDiagnosticsIncMember 2024-01-01 2024-09-30 0001624326 PAVM:LucidDiagnosticsIncMember 2023-01-01 2023-09-30 0001624326 us-gaap:StockOptionMember PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember 2024-09-30 0001624326 PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember us-gaap:StockOptionMember 2024-01-01 2024-09-30 0001624326 us-gaap:RestrictedStockMember PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember 2024-09-30 0001624326 PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember us-gaap:RestrictedStockMember 2024-01-01 2024-09-30 0001624326 PAVM:SeriesBConvertiblePreferredStockMember 2024-01-01 2024-09-30 0001624326 PAVM:SeriesBConvertiblePreferredStockMember 2024-07-01 2024-09-30 0001624326 PAVM:SeriesBConvertiblePreferredStockMember 2023-07-01 2023-09-30 0001624326 PAVM:SeriesBConvertiblePreferredStockMember 2023-01-01 2023-09-30 0001624326 PAVM:SeriesBConvertiblePreferredStockMember PAVM:BoardOfDirectorsMember 2023-01-01 2023-12-31 0001624326 PAVM:SeriesBConvertiblePreferredStockMember PAVM:BoardOfDirectorsMember 2024-01-01 2024-03-31 0001624326 PAVM:SeriesBConvertiblePreferredStockMember PAVM:BoardOfDirectorsMember 2024-01-01 2024-06-30 0001624326 PAVM:SeriesBConvertiblePreferredStockMember PAVM:BoardOfDirectorsMember 2024-01-01 2024-09-30 0001624326 PAVM:SeriesBConvertiblePreferredStockMember PAVM:BoardOfDirectorsMember 2022-01-01 2022-12-31 0001624326 PAVM:SeriesBConvertiblePreferredStockMember PAVM:BoardOfDirectorsMember 2023-01-01 2023-03-31 0001624326 PAVM:SeriesBConvertiblePreferredStockMember PAVM:BoardOfDirectorsMember 2023-01-01 2023-06-30 0001624326 PAVM:SeriesBConvertiblePreferredStockMember PAVM:BoardOfDirectorsMember 2023-01-01 2023-09-30 0001624326 PAVM:SeriesBConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2024-11-01 2024-11-30 0001624326 srt:MinimumMember 2023-02-01 2023-02-28 0001624326 srt:MaximumMember 2023-02-01 2023-02-28 0001624326 srt:MaximumMember 2023-02-28 0001624326 srt:MinimumMember 2023-02-28 0001624326 2023-11-28 2023-11-28 0001624326 2023-12-07 2023-12-07 0001624326 2024-03-07 2024-03-07 0001624326 PAVM:EmployeeStockPurchasePlanMember 2024-01-01 2024-09-30 0001624326 PAVM:VendorsMember 2024-01-01 2024-09-30 0001624326 PAVM:LucidDiagnosticsIncMember 2024-02-14 2024-02-15 0001624326 PAVM:LucidDiagnosticsIncMember 2024-01-14 2024-01-15 0001624326 PAVM:LucidDiagnosticsIncMember us-gaap:CommonStockMember 2024-01-14 2024-01-15 0001624326 2024-02-14 2024-02-15 0001624326 2024-02-15 0001624326 PAVM:SeriesZWarrantsMember 2024-09-30 0001624326 PAVM:SeriesZWarrantsMember 2023-12-31 0001624326 PAVM:SeriesZWarrantsMember srt:MinimumMember 2024-09-30 0001624326 PAVM:SeriesZWarrantsMember srt:MinimumMember 2023-12-31 0001624326 PAVM:LucidDiagnosticsIncMember 2024-09-30 0001624326 PAVM:LucidDiagnosticsIncMember 2024-09-10 2024-09-10 0001624326 PAVM:LucidDiagnosticsIncMember 2024-01-26 2024-01-26 0001624326 PAVM:SeriesAConvertiblePreferredStockMember 2023-03-05 2023-03-07 0001624326 PAVM:SeriesAConvertiblePreferredStockMember 2023-03-07 0001624326 PAVM:SeriesAOnePreferredStockMember 2024-03-12 2024-03-13 0001624326 PAVM:SeriesBConvertiblePreferredStockMember 2024-03-12 2024-03-13 0001624326 PAVM:SeriesBConvertiblePreferredStockMember 2024-03-13 0001624326 PAVM:LucidSeriesAAndLucidSeriesAOnePreferredStockMember 2024-03-12 2024-03-13 0001624326 PAVM:SeriesBOnePreferredStockMember 2024-05-06 2024-05-06 0001624326 PAVM:SeriesBOnePreferredStockMember 2024-05-06 0001624326 2024-03-13 2024-03-13 0001624326 PAVM:StockOptionsMember 2024-01-01 2024-09-30 0001624326 PAVM:StockOptionsMember 2023-01-01 2023-09-30 0001624326 us-gaap:RestrictedStockMember 2024-01-01 2024-09-30 0001624326 us-gaap:RestrictedStockMember 2023-01-01 2023-09-30 0001624326 PAVM:SeriesZWarrantsMember 2024-01-01 2024-09-30 0001624326 PAVM:SeriesZWarrantsMember 2023-01-01 2023-09-30 0001624326 PAVM:SeriesBConvertiblePreferredStockMember 2024-01-01 2024-09-30 0001624326 PAVM:SeriesBConvertiblePreferredStockMember 2023-01-01 2023-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure Â Â Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Â FORM 10-Q Â (Mark One) Â â˜’ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the quarterly period ended September 30, 2024 Â OR Â â˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the transition period from _____ to _____ Â Commission File Number: 001-37685 Â PAVMED INC. (Exact Name of Registrant as Specified in Its Charter) Â Delaware Â 47-1214177 (State or Other Jurisdiction of Â (IRS Employer Incorporation or Organization) Â Identification No.) Â Â Â Â Â Â Â 360 Madison Avenue Â Â 25th Floor Â Â New York, NY Â 10017 (Address of Principal Executive Offices) Â (Zip Code) Â (917) 813-1828 (Registrantâ€™s Telephone Number, Including Area Code) Â Securities registered pursuant to Section 12(b) of the Exchange Act: Â Title of each Class Â Trading Symbol(s) Â Name of each Exchange on which Registered Common Stock, $0.001 par value per share Â PAVM Â The NASDAQ Stock Market LLC Series Z Warrants, each to purchase 1/15th of one share of Common Stock Â PAVMZ Â The NASDAQ Stock Market LLC Â Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yesâ€‰â˜’ No â˜ Â Indicate by check mark whether the registrant has submitted electronically Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yesâ€‰â˜’ No â˜ Â Indicate by check mark whether the registrant is a large accelerated filer, an

accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions ofâ€‰â€œlarge accelerated filerâ€, â€œaccelerated filerâ€ , â€œsmaller reporting companyâ€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Â Large Accelerated filer â˜ Accelerated filed â˜ Non-accelerated filer â˜’ Smaller reporting company â˜’ Â Â Emerging growth company â˜ Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(c) of the Exchange Act â˜ Â Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yesâ€‰â˜ No â˜’ Â As of September 30, 2024 and November 11, 2024, there were 10,985,841 and 11,068,566 shares, respectively, of the registrantâ€™s Common Stock, par value $0.001 per share, issued and outstanding (with such number of shares inclusive of shares of common stock underlying unvested restricted stock awards granted under the PAVmed Inc. 2014 Long-Term Incentive Equity Plan as of such date). Â Â Â Â Â Â TABLE OF CONTENTS Â Â Â Â Page Â Part I - Financial Information Â Â Â Â Â Item 1. Financial Statements Â Â Â Condensed Consolidated Balance Sheets (unaudited) as of September 30, 2024 and December 31, 2023 Â 1 Â Condensed Consolidated Statements of Operations (unaudited) for the three and nine months ended September 30, 2024 and 2023 Â 2 Â Condensed Consolidated Statements of Changes in Stockholdersâ€™ Equity (Deficit) (unaudited) for the three and nine months ended September 30, 2024 and 2023 Â 3 Â Condensed Consolidated Statements of Cash Flows (unaudited) for the nine months ended September 30, 2024 and 2023 Â 7 Â Notes to Unaudited Condensed Consolidated Financial Statements Â 8 Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations Â 31 Item 4. Controls and Procedures Â 42 Â Â Â Â Â Part II - Other Information Â Â Â Â Â Item 1. Legal Proceedings Â 43 Item 5. Other Information Â 43 Item 6. Exhibits Â 43 Â Signature Â 44 Â Exhibit Index Â 45 Â i Â Â Part I - Financial Information Â Item 1. Financial Statements Â PAVMED INC. and SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands except number of shares and per share data - unaudited) Â Â Â September 30, 2024Â Â December 31, 2023Â Assets:Â Â Â Â Â Â Â Current assets:Â Â Â Â Â Â Â Â CashÂ $765Â Â $19,639Â Accounts receivableÂ Â 16Â Â Â 61Â InventoryÂ Â 6Â Â Â 278Â Prepaid expenses, deposits, and other current assetsÂ Â 1,343Â Â Â 4,520Â Total current assetsÂ Â 2,130Â Â Â 24,498Â Fixed assets, netÂ Â 216Â Â Â 1,783Â Operating lease right-of-use assetsÂ Â 2,618Â Â Â 4,267Â Intangible assets, netÂ Â â€”Â Â Â 1,424Â Equity method investment - at fair valueÂ Â 25,511Â Â Â â€”Â Other assetsÂ Â 75Â Â Â 1,147Â Total assetsÂ $30,550Â Â $33,119Â Liabilities, Preferred Stock and Stockholdersâ€™ EquityÂ Â Â Â Â Â Â Current liabilities:Â Â Â Â Â Â Â Accounts payableÂ $465Â Â $1,786Â Accrued expenses and other current liabilitiesÂ Â 4,543Â Â Â 6,626Â Operating lease liabilities, current portionÂ Â 499Â Â Â 1,565Â Senior Secured Convertible Notes - at fair valueÂ Â 32,050Â Â Â 44,200Â Total current liabilitiesÂ Â 37,557Â Â Â 54,177Â Operating lease liabilities, less current portionÂ Â 2,380Â Â Â 2,960Â Total liabilitiesÂ Â 39,937Â Â Â 57,137Â Commitments and contingencies (Note 9)Â Â -Â Â Â -Â Stockholdersâ€™ Equity:Â Â Â Â Â Â Â Preferred stock, $0.001 par value. Authorized, 20,000,000 shares; Series B Convertible Preferred Stock, par value $0.001, issued and outstanding 1,385,149 at September 30, 2024 and 1,305,213 shares at December 31, 2023Â Â 3,232Â Â Â 2,993Â Common stock, $0.001 par value. Authorized, 50,000,000 shares; 10,660,394 and 8,578,505 shares outstanding as of September 30, 2024 and December 31, 2023, respectivelyÂ Â 11Â Â Â 9Â Additional paid-in capitalÂ Â 248,200Â Â Â 237,600Â Accumulated deficitÂ Â (256,312)Â Â (294,433) Total PAVmed Inc. Stockholdersâ€™ Equity (Deficit)Â Â (4,869)Â Â (53,831) Noncontrolling interestsÂ Â (4,518)Â Â 29,813Â Total Stockholdersâ€™ Equity (Deficit)Â Â (9,387)Â Â (24,018) Total Liabilities and Stockholdersâ€™ Equity (Deficit)Â $30,550Â Â $33,119Â Â See accompanying notes to the unaudited condensed consolidated financial statements. Â 1 Â Â PAVMED INC. and SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands except number of shares and per share data - unaudited) Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Â Three Months Ended September 30,Â Â Nine Months Ended September 30,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â RevenueÂ $996Â Â $791Â Â $2,985Â Â $1,403Â Operating expenses:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Cost of revenueÂ Â 1,381Â Â Â 1,779Â Â Â 4,792Â Â Â 4,809Â Sales and marketingÂ Â 2,920Â Â Â 4,016Â Â Â 11,472Â Â Â 12,893Â General and administrativeÂ Â 6,649Â Â Â 6,858Â Â Â 20,337Â Â Â 23,916Â Amortization of acquired intangible assetsÂ Â 82Â Â Â 505Â Â Â 559Â Â Â 1,516Â Research and developmentÂ Â 1,542Â Â Â 3,161Â Â Â 5,125Â Â Â 10,681Â Total operating expensesÂ Â 12,574Â Â Â 16,319Â Â Â 42,285Â Â Â 53,815Â Operating lossÂ Â (11,578)Â Â (15,528)Â Â (39,300)Â Â (52,412) Other income (expense):Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Interest incomeÂ Â 70Â Â Â 124Â Â Â 252Â Â Â 408Â Interest expenseÂ Â (12)Â Â (159)Â Â (38)Â Â (570) Gain on deconsolidation of subsidiaryÂ Â 72,287Â Â Â â€”Â Â Â 72,287Â Â Â â€”Â Change in fair value - equity method investmentÂ Â 407Â Â Â â€”Â Â Â 407Â Â Â â€”Â Change in fair value - Senior Secured Convertible NotesÂ Â 240Â Â Â (4,392)Â Â (2,488)Â Â (5,772) Loss on issue and offering costs - Senior Secured Convertible NoteÂ Â â€”Â Â Â â€”Â Â Â â€”Â Â Â (1,186) Debt extinguishments loss - Senior Secured Convertible NotesÂ Â (1,403)Â Â (1,764)Â Â (2,535)Â Â (3,032) Debt modification expenseÂ Â â€”Â Â Â â€”Â Â Â (2,000)Â Â â€”Â Change in fair value - derivative liabilityÂ Â â€”Â Â Â (31)Â Â â€”Â Â Â (291) Management fee incomeÂ Â 700Â Â Â â€”Â Â Â 700Â Â Â â€”Â Gain on sale of intellectual propertyÂ Â â€”Â Â Â â€”Â Â Â â€”Â Â Â 1,000Â Other income (expense), netÂ Â 72,289Â Â Â (6,222)Â Â 66,585Â Â Â (9,443) Income (loss) before provision for income taxÂ Â 60,711Â Â Â (21,750)Â Â 27,285Â Â Â (61,855) Provision for income taxesÂ Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Net income (loss) before noncontrolling interestsÂ Â 60,711Â Â Â (21,750)Â Â 27,285Â Â Â (61,855) Net loss attributable to the noncontrolling interestsÂ Â 3,688Â Â Â 4,079Â Â Â 11,075Â Â Â 11,716Â Net income (loss) attributable to PAVmed Inc.Â Â 64,399Â Â Â (17,671)Â Â 38,360Â Â Â (50,139) Less: Series B Convertible Preferred Stock dividends earnedÂ Â (83)Â Â (77)Â Â (244)Â Â (226) Less: Deemed dividend on Subsidiary Preferred Stock attributable to the noncontrolling interestsÂ Â â€”Â Â Â â€”Â Â Â (7,496)Â Â â€”Â Net income (loss) attributable to PAVmed Inc. common stockholdersÂ $64,316Â Â $(17,748)Â $30,620Â Â $(50,365) Per share information:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net income (loss) per share attributable to PAVmed Inc. common stockholders â€“ basicÂ $6.43Â Â $(2.38)Â $3.30Â Â $(7.23) Net income (loss) per share attributable to PAVmed Inc. common stockholders â€“ dilutedÂ $1.44Â Â $(2.38)Â $0.79Â Â $(7.23) Weighted average common shares outstanding, basicÂ Â 10,005,379Â Â Â 7,462,751Â Â Â 9,286,999Â Â Â 6,967,764Â Weighted average common shares outstanding, dilutedÂ Â 44,475,638Â Â Â 7,462,751Â Â Â 43,069,449Â Â Â 6,967,764Â Â See accompanying notes to the unaudited condensed consolidated financial statements. Â 2 Â Â PAVMED INC. and SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERSâ€™ EQUITY (DEFICIT) for the THREE MONTHS ENDED September 30, 2024 (in thousands except number of shares and per share data - unaudited) Â Â Â SharesÂ Â AmountÂ Â SharesÂ Â AmountÂ Â In CapitalÂ Â DeficitÂ Â InterestÂ Â TotalÂ Â Â PAVmed Inc. Stockholdersâ€™ Equity (Deficit)Â Â Â Â Â Â Â Â Â Â Series B Convertible Preferred StockÂ Â Common StockÂ Â Additional Paid-Â Â AccumulatedÂ Â Non controllingÂ Â Â Â Â Â SharesÂ Â AmountÂ Â SharesÂ Â AmountÂ Â In CapitalÂ Â DeficitÂ Â InterestÂ Â TotalÂ Balance - June 30, 2024Â Â 1,357,976Â Â $3,151Â Â Â 9,554,381Â Â $10Â Â $243,524Â Â Â $(320,630)- $55,303Â Â $(18,642) Dividends declared - Series B Convertible Preferred StockÂ Â 27,173Â Â Â 81Â Â Â â€”Â Â Â â€”Â Â Â (81)Â Â â€”Â Â Â â€”Â Issue common stock - PAVM ATM FacilityÂ Â â€”Â Â Â â€”Â Â Â 294,003Â Â Â â€”Â Â Â 284Â Â Â â€”Â Â Â â€”Â Â Â 284Â Â Â Vest - restricted stock awardsÂ Â â€”Â Â Â â€”Â Â Â 131,016Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Conversions - Senior Secured Convertible NoteÂ Â â€”Â Â Â â€”Â Â Â 509,942Â Â Â 1Â Â Â 907Â Â Â â€”Â Â Â â€”Â Â Â 908Â Conversions - subsidiary common stock - Senior Secured Convertible NoteÂ Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â 1,260Â Â Â 1,260Â Impact of subsidiary equity transactionsÂ Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â 2,245Â Â Â â€”Â - Â (2,245)Â Â â€”Â Issuance - vendor service agreementÂ Â â€”Â Â Â â€”Â Â Â 171,052Â Â Â â€”Â Â Â 150Â Â Â â€”Â Â Â 150Â Stock-based compensation - PAVmed Inc.Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â 696Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â 696Â Stock-based compensation - subsidiaryÂ Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â 44Â Â Â â€”Â Â Â 1,191Â Â Â 1,235Â Transfer of intellectual property to Lucid Diagnostics IncÂ Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â 350Â Â Â â€”Â Â Â 350Â Deconsolidation of subsidiaryÂ Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â (56,339)Â Â (56,339) Net income (loss)Â Â â€”Â Â Â â€”Â Â Â 38,360Â Â Â (11,075)Â Â 27,285Â Balance - September 30, 2024Â Â 1,385,149Â Â $3,232Â Â Â 10,660,394Â Â $11Â Â $248,200Â Â Â $(256,312)- $(4,518)Â $(9,387) Â See accompanying notes to the unaudited condensed consolidated financial statements. Â 3 Â Â PAVMED INC. and SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERSâ€™ EQUITY (DEFICIT) for the NINE MONTHS ENDED September 30, 2024 (in thousands, except number of shares and per share data - unaudited) Â Â Â SharesÂ Â AmountÂ Â SharesÂ Â AmountÂ Â In CapitalÂ Â DeficitÂ Â InterestÂ Â TotalÂ Â Â PAVmed Inc. Stockholdersâ€™ Equity (Deficit)Â Â Â Â Â Â Â Â Â Â Series B Convertible Preferred StockÂ Â Common StockÂ Â Additional Paid-Â Â AccumulatedÂ Â Non controllingÂ Â Â Â Â Â SharesÂ Â AmountÂ Â SharesÂ Â AmountÂ Â In CapitalÂ Â DeficitÂ Â InterestÂ Â TotalÂ Balance - December 31, 2023Â Â 1,305,213Â Â $2,993Â Â Â 8,578,505Â Â $9Â Â $237,600Â Â $(294,433)- $29,813Â Â $(24,018) Dividends declared - Series B Convertible Preferred StockÂ Â 79,936Â Â Â 239Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â (239)Â Â â€”Â Â Â â€”Â Issue common stock - PAVM ATM FacilityÂ Â â€”Â Â Â â€”Â Â Â 627,302Â Â Â â€”Â Â Â 977Â Â Â â€”Â Â Â â€”Â Â Â 977Â Vest - restricted stock awardsÂ Â â€”Â Â Â â€”Â Â Â 135,080Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Conversions - Senior Secured Convertible NoteÂ Â â€”Â Â Â â€”Â Â Â 1,084,366Â Â Â 2Â Â Â 2,019Â Â Â â€”Â Â Â â€”Â Â Â 2,021Â Conversions - subsidiary common stock - Senior Secured Convertible NoteÂ Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â 3,801Â Â Â 3,801Â Exercise - stock options of subsidiaryÂ Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â 4Â Â Â 4Â Purchase - Employee Stock Purchase PlanÂ Â â€”Â Â Â â€”Â Â Â 34,332Â Â Â â€”Â Â Â 62Â Â Â â€”Â - Â â€”Â Â Â 62Â Purchase - subsidiary common stock - Employee Stock Purchase PlanÂ Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â 353Â Â Â 353Â Impact of subsidiary equity transactionsÂ Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â 4,414Â Â Â â€”Â Â Â (4,414)Â Â â€”Â Issuance - vendor service agreementÂ Â â€”Â Â Â â€”Â Â Â 200,809Â Â Â â€”Â Â Â 200Â Â Â â€”Â Â Â 401Â Â Â 601Â Issuance - subsidiary preferred stock (Series A-1)Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â 5,670Â Â Â 5,670Â Exchange - subsidiary preferred stock (Series A and Series A-1)Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â

Proceeds â€“ issue of preferred stock - subsidiaryÂ Â 29,798Â Â Â 13,625Â Proceeds â€“ issue of Senior Secured Convertible NoteÂ Â â€”Â Â Â 10,000Â Payment â€“ Senior Secured Convertible Note â€“ acceleration floor paymentsÂ Â (531)Â Â â€”Â Proceeds â€“ issue of common stock - At-The-Market FacilityÂ Â 1,268Â Â Â 1,166Â Proceeds â€“ subsidiary common stock - Committed Equity Facility and At-The-Market FacilityÂ Â â€”Â Â Â 284Â Proceeds â€“ issue common stock â€“ Employee Stock Purchase PlanÂ Â 62Â Â Â 259Â Proceeds â€“ subsidiary common stock â€“ Employee Stock Purchase PlanÂ Â 353Â Â Â 551Â Proceeds â€“ exercise of stock options issued under equity plan of subsidiaryÂ Â 4Â Â Â â€”Â Net cash flows provided by financing activitiesÂ Â 30,954Â Â Â 25,885Â Net increase (decrease) in cashÂ Â (18,874)Â Â (13,336) Cash, beginning of periodÂ Â 19,639Â Â Â 39,744Â Cash, end of periodÂ $765Â Â $26,408Â Â See accompanying notes to the unaudited condensed consolidated financial statements. Â 7 Â Â PAVMED INC. and SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (amounts in these accompanying notes are presented in thousands, except number of shares and per-share amounts.) Â Note 1 â€” The Company Â Description of the Business Â PAVmed is structured to be a multi-product life sciences company organized to advance a pipeline of innovative healthcare technologies. Led by a team of highly skilled personnel with a track record of bringing innovative products to market, PAVmed is focused on innovating, developing, acquiring, and commercializing novel products that target unmet medical needs with large addressable market opportunities. Leveraging our corporate structureâ€”a parent company that will establish distinct subsidiaries for each financed assetâ€”we have the flexibility to raise capital at the PAVmed level to fund product development, or to structure financing directly into each subsidiary in a manner tailored to the applicable product, the latter of which is our current strategy given prevailing market conditions. Â Our current focus is multi-fold. We continue to pursue commercial expansion and execution of EsoGuard, which is the flagship product of our subsidiary, Lucid Diagnostics Inc. (Nasdaq: LUCD) (â€œLucidâ€). In addition, through a separate majority-owned subsidiary, Veris Health (â€œVerisâ€), we are focused in the immediate term on entering into strategic partnership opportunities with leading academic oncology systems to expand access to the Veris Platform, while concurrently developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris Platform. In terms of other existing products and technologies, we have adopted an incubator-type platform where we are looking to obtain financing on a product-by-product basis as necessary to advance each asset to a meaningful inflection point along its path to commercialization. Finally, as resources permit, we will continue to explore external innovations that fulfill our project selection criteria without limiting ourselves to any target sector, specialty or condition. Â Note 2 â€” Liquidity and Going Concern Â The Companyâ€™s management is required to assess the Companyâ€™s ability to continue as a going concern for the one year period following the date of the financial statements being issued. In each reporting period, including interim periods, an entity is required to assess conditions known and reasonably knowable as of the financial statement issuance date to determine whether it is probable an entity will not meet its financial obligations within one year from the financial statement issuance date. Substantial doubt about an entityâ€™s ability to continue as a going concern exists when conditions and events, considered in the aggregate, indicate it is probable the entity will be unable to meet its financial obligations as they become due within one year after the date the financial statements are issued. Â The Company has financed its operations principally through public and private issuances of its common stock, preferred stock, common stock purchase warrants, and debt. The Company is subject to all of the risks and uncertainties typically faced by medical device and diagnostic companies that devote substantially all of their efforts to the commercialization of their initial product and services and ongoing research and development activities and conducting clinical trials. The Company generated $1.0 million and $3.0 million of revenues for the three and nine month periods ended September 30, 2024, respectively, however the Company expects to continue to experience recurring losses and to generate negative cash flows from operating activities in the near future. Â The Company incurred a net income attributable to PAVmed Inc. common stockholders of approximately $30.6 million and had net cash flows used in operating activities of approximately $33.6 million for the nine month period ended September 30, 2024. As of September 30, 2024, the Company had negative working capital of approximately $35.4 million, with such working capital inclusive of the Senior Secured Convertible Notes classified as a current liability of an aggregate of approximately $32.1 million and approximately $0.8 million of cash. Â The Companyâ€™s ability to continue operations 12 months beyond the issuance of the financial statements, will depend upon its ability to control its operating costs within the limits of the amounts collected from its management service contracts with its non-consolidated subsidiaries, to substantially increase its revenues from the Veris Cancer Care platform, and to raise additional capital through various potential sources including equity or debt financings or refinancing or restructuring existing debt obligations. These factors raise substantial doubt about the Companyâ€™s ability to continue as a going concern within one year after the date the accompanying unaudited condensed consolidated financial statements are issued. Â 8 Â Â Note 3 â€” Summary of Significant Accounting Policies Â Significant Accounting Policies Â The Companyâ€™s significant accounting policies are as disclosed in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the SEC on March 25, 2024, except as otherwise noted herein below. Â Basis of Presentation Â The accompanying unaudited condensed consolidated financial statements of PAVmed and those of its wholly owned subsidiaries and variable interest entities have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œU.S. GAAPâ€), and applicable rules and regulations of the United States Securities and Exchange Commission (â€œSECâ€). All intercompany transactions and balances have been eliminated in consolidation. The Company has a controlling financial interest in Veris Health Inc., with the corresponding noncontrolling interest included as a separate component of consolidated stockholdersâ€™ equity (deficit), including the recognition in the unaudited condensed consolidated statement of operations of a net loss attributable to the noncontrolling interest based on the respective minority-interest equity ownership of each subsidiary. As of September 10, 2024, PAVmed ceased to have a controlling financial interest in Lucid Diagnostics and therefore PAVmedâ€™s consolidated results of operations include Lucid Diagnosticsâ€™ results of operations only through that date. The deconsolidation of Lucid Diagnostics has resulted in a gain recognized in PAVmedâ€™s statement of operations for the periods ended September 30, 2024. Moving forward, PAVmed will account for its investment in Lucid Diagnostics using the equity method and the fair value option. See below and Note 4, Equity Method Investment for a discussion on the impact of the deconsolidation of Lucid Diagnostics. See Note 15, Noncontrolling Interest, for a discussion of each of the subsidiaries noted above. The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. Â As permitted under SEC rules, certain footnotes or other financial information normally required by U.S. GAAP have been condensed or omitted. The balance sheet as of December 31, 2023 has been derived from audited consolidated financial statements at such date. The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the Companyâ€™s annual consolidated financial statements, and in the opinion of management, include all adjustments, consisting only of routine recurring adjustments, necessary for a fair statement of the Companyâ€™s unaudited condensed consolidated financial information. Â The unaudited condensed consolidated results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the consolidated results to be expected for the year ending December 31, 2024 or for any other interim period or for any other future periods. The accompanying unaudited condensed consolidated financial statements and related unaudited condensed consolidated financial information should be read in conjunction with the Companyâ€™s audited consolidated financial statements and related notes thereto as of and for the year ended December 31, 2023 included in the Companyâ€™s Annual Report on Form 10-K as filed with the SEC on March 25, 2024. Â All amounts in the accompanying unaudited condensed consolidated financial statements and the notes thereto are presented in thousands of dollars, if not otherwise noted as being presented in millions of dollars, except for shares and per share amounts. Â Cash Â The Company maintains its cash at a major financial institution with high credit quality. At times, the balance of its cash deposits may exceed federally insured limits. The Company has not experienced losses on deposits with commercial banks and financial institutions which exceed federally insured limits. Â Included in the Companyâ€™s cash as of September 30, 2024 and December 31, 2023 is $299 related to a restricted deposit account for a standby letter of credit associated with our corporate headquarters which has a lease maturity date in 2030. Â Use of Estimates Â In preparing the unaudited condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and the determination of corresponding carrying value reserve, if any, and liabilities and the disclosure of contingent losses, as of the date of the unaudited condensed consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Significant estimates in these unaudited condensed consolidated financial statements include those related to the estimated fair value of debt obligations, stock-based equity awards, intangible assets and common stock purchase warrants. Other significant estimates include the estimated incremental borrowing rate, the provision or benefit for income taxes and the corresponding valuation allowance on deferred tax assets. Additionally, managementâ€™s assessment of the Companyâ€™s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. On an ongoing basis, the Company evaluates its estimates and assumptions. The Company bases its estimates on historical experience and on various other assumptions believed to be reasonable. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. Â 9 Â Â Note 3 â€” Summary of Significant Accounting Policies - continued Â Revenue Recognition Â Revenues are recognized when the satisfaction of the performance obligation occurs, in an amount that reflects the consideration the Company expects to collect in exchange for those services. The Companyâ€™s revenue was primarily generated by Lucidâ€™s laboratory testing services utilizing its EsoGuard Esophageal DNA tests. The services were completed upon release of a patientâ€™s test result to the ordering healthcare provider. Revenue recognized is inclusive of both variable consideration in connection with an individual patientâ€™s third-party insurance coverage policy and fixed consideration in connection with a contracted services arrangement with an unrelated third party legal entity. To determine revenue recognition for the arrangements that the Company determines are within the scope of ASC 606, Revenue from Contracts with Customers, the Company performs the following five steps: (1) identify the contract(s) with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation. Â The key aspects considered by the Company include the following: Â Contractsâ€”The Companyâ€™s customer is primarily the patient, but the Company does not enter into a formal reimbursement contract with a patient. The Company establishes a contract with a patient in accordance with other customary business practices, which is the point in time an order is received from a provider and a patient specimen has been returned to the laboratory for testing. Payment terms are a function of a patientâ€™s existing insurance benefits, including the impact of coverage decisions with Center for Medicare & Medicaid Services (â€œCMSâ€) and applicable reimbursement contracts established between the Company and payers. However, when a patient is considered self-pay, the Company requires payment from the patient prior to the commencement of the Companyâ€™s performance obligations. The Companyâ€™s consideration can be deemed variable or fixed depending on the structure of specific payer contracts, and the Company considers collection of such consideration to be probable to the extent that it is unconstrained. Â Performance obligationsâ€”A performance obligation is a promise in a contract to transfer a distinct good or service (or a bundle of goods or services) to the customer. The Companyâ€™s contracts have a single performance obligation, which is satisfied upon rendering of services, which culminates in the release of a patientâ€™s test result to the ordering healthcare provider. The Company elects the practical expedient related to the disclosure of unsatisfied performance obligations, as the duration of time between providing testing supplies, the receipt of a sample, and the release of a test result to the ordering healthcare provider is far less than one year. Â Transaction priceâ€”The transaction price is the amount of consideration that the Company expects to collect in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). The consideration expected to be collected from a contract with a customer may include fixed amounts, variable amounts, or both. Â If the consideration derived from the contracts is deemed to be variable, the Company estimates the amount of consideration to which it will be entitled in exchange for the promised goods or services. The Company limits the amount of variable consideration included in the transaction price to the unconstrained portion of such consideration. In other words, the Company recognizes revenue up to the amount of variable consideration that is not subject to a significant reversal until additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved. Â When the Company does not have significant historical experience or that experience has limited predictive value, the constraint over estimates of variable consideration may result in no revenue being recognized upon delivery of patient EsoGuard test results to the ordering healthcare provider. As such, the Company recognizes revenue up to the amount of variable consideration not subject to a significant reversal until additional information is obtained or the uncertainty associated with additional payments or refunds, if any, is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in estimated expected variable consideration, with the change in estimate recognized in the period of such revised estimate. With respect to a contracted service arrangement, the fixed consideration revenue is recognized on an as-billed basis upon delivery of the laboratory test report with realization of such fixed consideration deemed probable based upon actual historical experience. Â Allocate transaction priceâ€”The transaction price is allocated entirely to the performance obligation contained within the contract with a customer on the basis of the relative standalone selling prices of each distinct good or service. Â Practical Expedientsâ€”The Company does not adjust the transaction price for the effects of a significant financing component, as at contract inception, the Company expects the collection cycle to be one year or less. Â 10 Â Â Note 3 â€” Summary of Significant Accounting Policies - continued Â Equity Method Investments Â Businesses that are not consolidated, but over which PAVmed exercises significant influence, are accounted for under the equity method of accounting. The determination as to whether or not PAVmed exercises significant influence with respect to a company depends on an evaluation of several factors, including, among others, representation on the companyâ€™s board of directors and equity ownership level, which is generally between a 20% and a 50% interest in the voting securities of an equity method business, as well as voting rights associated with PAVmedâ€™s holdings in common stock in that company. PAVmed accounts for Lucid Diagnostics as an equity method investment beginning on September 10, 2024, and the period ended September 30, 2024. Â Fair Value Option (â€œFVOâ€) Election Â Under a Securities Purchase Agreement dated March 31, 2022, the Company issued a Senior Secured Convertible Note dated April 4, 2022, referred to herein as the â€œApril 2022 Senior Convertible Noteâ€, and a Senior Secured Convertible Note dated September 8, 2022, referred to herein as the â€œSeptember 2022 Senior Convertible Noteâ€, which are accounted under the â€œfair value option electionâ€ as discussed below. Â Under a Securities Purchase Agreement dated March 13, 2023, Lucid Diagnostics issued a Senior Secured Convertible Note dated March 21, 2023, referred to herein as the â€œLucid March 2023 Senior Convertible Noteâ€, which is accounted under the â€œfair value option electionâ€, through September 10, 2024, the date of Lucidâ€™s deconsolidation from PAVmedâ€™s results of operations, as discussed below. Â Under Financial Accounting Standards Board (â€œFASBâ€) Accounting Standards Codification (â€œASCâ€) Topic 815, Derivative and Hedging, (â€œASC 815â€), a financial instrument containing embedded features and/or options may be required to be bifurcated from the financial instrument host and recognized as separate derivative asset or liability, with the bifurcated derivative asset or liability initially measured at estimated fair value as of the transaction issue date and then subsequently remeasured at estimated fair value as of each reporting period balance sheet date. Â Alternatively, FASB ASC Topic 825, Financial Instruments, (â€œASC 825â€) provides for the â€œfair value optionâ€ (â€œFVOâ€) election. In this regard, ASC 825-10-15-4 provides for the FVO election (to the extent not otherwise prohibited by ASC 825-10-15-5) to be afforded to financial instruments, wherein the financial instrument is initially measured at estimated fair value as of the transaction issue date and then subsequently remeasured at estimated fair value as of each reporting period balance sheet date, with changes in the estimated fair value recognized as other income (expense) in the statement of operations. The estimated fair value adjustment of the April 2022 Senior Convertible Note, the September 2022 Senior Convertible Note and (through September 10, 2024, Lucidâ€™s deconsolidation date) the Lucid March 2023 Senior Convertible Note, including the component related to accrued interest, is presented in a single line item within other income (expense) in the accompanying unaudited condensed consolidated statement of operations (as provided for by ASC 825-10-50-30(b)). Further, as required by ASC 825-10-45-5, to the extent a portion of the fair value adjustment is attributed to a change in the instrument-specific credit risk, such portion would be recognized as a component of other comprehensive income (â€œOCIâ€) (for which there was no such adjustment with respect to the April 2022 Senior Convertible Note, the September 2022 Senior Convertible Note or (through September 10, 2024, Lucidâ€™s deconsolidation date) the Lucid March 2023 Senior Convertible Note). Â See Note 10, Financial Instruments Fair Value Measurements, with respect to the FVO election; and Note 11, Debt, for a discussion of the April 2022 Senior Convertible Note, the September 2022 Senior Convertible Note and the Lucid March 2023 Senior Convertible Note. Â From and after September 10, 2024, the date of Lucidâ€™s deconsolidation from PAVmedâ€™s results of operation, the Companyâ€™s investment in Lucid is treated as an equity method investment accounted for using the fair value option. Shares of Lucid Diagnostics common stock have a readily determinable fair value classified as Level 1, in which the fair value is determined based upon quoted market prices in an active market. Â Recent Accounting Standards Updates Not Yet Adopted Â In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740)â€”Improvements to Income Tax Disclosures (â€œASU 2023-09â€), which is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 provide for enhanced

income tax information primarily through changes to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for the Company prospectively to all annual periods beginning after December 15, 2024. Early adoption is permitted. The Company does not expect the standard to have a significant impact on its unaudited condensed consolidated financial statements. Â In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280)â€”Improvements to Reportable Segment Disclosures (â€œASU 2023-07â€), which require public companies disclose significant segment expenses and other segment items on an annual and interim basis and to provide in interim periods all disclosures about a reportable segmentâ€™s profit or loss and assets that are currently required annually. The guidance is effective for public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The guidance is applied retrospectively to all periods presented in the financial statements, unless it is impracticable. The Company is currently evaluating the impact this update will have on its unaudited condensed consolidated financial statements and disclosures, however the Company does not expect the standard to have a significant impact. Â 11 Â Â Note 3 â€” Summary of Significant Accounting Policies - continued Â In October 2023, the FASB issued ASU No. 2023-06, Disclosure Improvements: Codification Amendments in Response to the SECâ€™s Disclosure Update and Simplification Initiative. This update modifies the disclosure or presentation requirements of a variety of topics in the Accounting Standards Codification to conform with certain SEC amendments in Release No. 33-10532, Disclosure Update and Simplification. The amendments in this update should be applied prospectively, and the effective date for each amendment will be the date on which the SECâ€™s removal of that related disclosure from Regulation S-X or S-K becomes effective. However, if the SEC has not removed the related disclosure from its regulations by June 30, 2027, the amendments will be removed from the Codification and not become effective. Early adoption is prohibited. The Company is currently evaluating the impact this update will have on its unaudited condensed consolidated financial statements and disclosures. Â Note 4 â€” Equity Method Investment Â On September 10, 2024, following preferred equity transactions completed by Lucid earlier in 2024 and the termination of voting proxies entered into between PAVmed and certain shareholders of Lucid, PAVmedâ€™s voting interest in the Company was reduced to less than 50.0%, resulting in the loss of a controlling financial interest. However, PAVmed retains the ability to exercise significant influence over Lucid. As a result, the Company deconsolidated Lucid. The following table reflects the net assets of Lucid at the time of deconsolidation: Schedule of Deconsolidation of Net AssetsÂ Â Â Â Â Â Assets:Â Â Â Â Current assets:Â Â Â Â CashÂ $16,479Â Prepaid expenses, deposits, and other current assetsÂ Â 3,474Â Total current assetsÂ Â 19,953Â Fixed assets, netÂ Â 964Â Operating lease right-of-use assetsÂ Â 2,871Â Intangible assets, netÂ Â 877Â Other assetsÂ Â 379Â Total assetsÂ Â 25,044Â Liabilities:Â Â Â Â Current liabilities:Â Â Â Â Accounts payableÂ Â 1,069Â Accrued expenses and other current liabilitiesÂ Â 1,674Â Operating lease liabilities, current portionÂ Â 865Â Senior Secured Convertible Notes - at fair valueÂ Â 10,268Â Total current liabilitiesÂ Â 13,876Â Operating lease liabilities, less current portionÂ Â 2,011Â Total liabilitiesÂ Â 15,887Â Net Assets of Lucid Diagnostics at September 10, 2024Â $9,157Â Â Upon deconsolidation, the Company owned 31,302,444 shares of Lucid Diagnostics common stock, which was valued at $25.1 million, resulting in a gain on deconsolidation of $72.3 million in the accompanying unaudited condensed consolidated statements of operations for the three and nine months ended September 30, 2024. The Company recorded the following: Â Schedule of Gain on Deconsolidation Â Â Â Â Â Investment in former Consolidated Subsidiary (Fair Value of Lucid common stock)Â $25,105Â Add: Noncontrolling interest - LucidÂ Â 56,339Â Less: Net Assets of Former Consolidated Subsidiary - LucidÂ Â (9,157) Gain on Deconsolidation of LucidÂ $72,287 Â After the Companyâ€™s deconsolidation of Lucid, the Company accounts for its investment in Lucid as an equity method investment with the election of the fair value option. Due to the Companyâ€™s continuing involvement and significant influence over operating and financial policies, Lucid is considered a related party of the Company. Â 12 Â Â Note 4 â€” Equity Method Investment - continued Â The following unaudited summarized financial information related to Lucid accounted for under the equity method of accounting as of September 30, 2024. This aggregate information has been compiled from the financial statements of those business. Â Schedule of Aggregate Information From the Financial Statements Â Â September 30, 2024Â CashÂ $14,489Â Other current assetsÂ Â 2,335Â Non-current assetsÂ Â 5,774Â Total assetsÂ Â 22,598Â Current liabilitiesÂ Â 14,249Â Non-current liabilitiesÂ Â 2,011Â Shareholdersâ€™ deficitÂ Â 6,338Â Total liabilities and stockholdersâ€™ deficitÂ $22,598Â Â Three months ended September 30, 2024Â July 1, 2024 - September 10, 2024Â Â September 11, 2024 - September 30, 2024Â Â TotalÂ Â Â Â Â Â Â Â Â Â Â RevenueÂ $942Â Â $230Â Â $1,172Â Net income (loss)Â $(9,039)Â $(3,332)Â $(12,371) Â Nine months ended September 30, 2024Â January 1, 2024 - September 10, 2024Â Â September 11, 2024 - September 30, 2024Â Â TotalÂ Â Â Â Â Â Â Â Â Â Â RevenueÂ $2,919Â Â $230Â Â $3,149Â Net income (loss)Â $(38,152)Â $(3,332)Â $(41,484) Â *Lucid was consolidated and included in PAVmedâ€™s consolidated results for the period of January 1, 2024 through September 10, 2024. The amounts from September 11, 2024 through September 30, 2024 were not included in PAVmedâ€™s consolidated results. Â At September 10, 2024 and September 30, 2024, the fair value of the Companyâ€™s investment in Lucid was $25.1 million and $25.5 million, respectively, with the company recognizing an unrealized gain on its investment in Lucid of $0.4 million in the accompanying condensed consolidated statements of operations for three and nine month periods ended September 30, 2024. The fair value of common shares held by the Company was determined using the closing price of Lucidâ€™s common stock per share on September 10, 2024 and September 30, 2024 of $0.802 and $0.815, respectively. At September 10, 2024 and September 30, 2024, PAVmed held approximately 40% of Lucidâ€™s common stock voting interest. Â Lucid - Management Services Agreement Â Lucidâ€™s daily operations are also managed in part by personnel employed by the Company, for which the Company records management fee income, referred to as the â€œMSA Feeâ€, according to the provisions of a Management Services Agreement (â€œMSAâ€) with Lucid. The MSA does not have a termination date, but may be terminated by Lucid. The MSA Fee is charged on a monthly basis and is subject-to periodic adjustment corresponding with changes in the services provided by the Companyâ€™s personnel to Lucid, with any such change in the MSA Fee being subject to approval of the boards of directors of each of the Company and Lucid. The respective companiesâ€™ boards of directors approved an amendment to the MSA to increase the MSA Fee to $833 per month, effective January 1, 2024. In August 2024, the respective companiesâ€™ boards of directors approved the Company to enter into a ninth amendment to the MSA. Under this amendment, the monthly fee due to the Company from Lucid was increased from $833 to $1,050, effective July 1, 2024. During the period of September 11, 2024 through September 30, 2024, MSA fee income was $700. Â Transfer of Intellectual Property to Lucid Â On September 27, 2024, the Company entered into an Assignment of Patent Rights with PAVmed, pursuant to which PAVmed assigned certain patent rights to the Company related to the EsoCheck device. In consideration of the assignment the Company agreed to pay PAVmed a $350 assignment fee. Â 13 Â Â Note 5 â€” Revenue from Contracts with Customers Â Revenue Recognized Â In the three and nine month periods ended September 30, 2024, the Company recognized total revenue of $996 and $2,985, respectively, primarily resulting from the delivery of patient EsoGuard test results. Revenue recognized from customer contracts deemed to include a variable consideration transaction price is limited to the unconstrained portion of the variable consideration. The Companyâ€™s revenue for the three and nine month periods ended September 30, 2023 was $791 and $1,403, respectively, primarily resulting from the delivery of patient EsoGuard test results. Â Cost of Revenue Â The cost of revenues principally includes the costs related to the Companyâ€™s laboratory operations (excluding estimated costs associated with research activities), the costs related to the EsoCheck cell collection device, cell sample mailing kits and license royalties. Â In the three and nine month periods ended September 30, 2024, the cost of revenue was $1,381 and $4,792, respectively, primarily related to costs for our laboratory operations and EsoCheck device supplies. The Companyâ€™s cost of revenue for the three and nine month periods ended September 30, 2023 was $1,779 and $4,809, respectively, primarily related to costs for our laboratory operations and EsoCheck device supplies. Â Note 6 â€” Prepaid Expenses, Deposits, and Other Current Assets Â Prepaid expenses and other current assets consisted of the following as of: Schedule of Prepaid Expenses and Other Current AssetsÂ Â Â September 30, 2024Â Â December 31, 2023Â Advanced payments to service providers and suppliersÂ $181Â Â $739Â Prepaid insuranceÂ Â 420Â Â Â 848Â DepositsÂ Â 480Â Â Â 2,672Â Veris Box suppliesÂ Â 262Â Â Â 261Â Total prepaid expenses, deposits and other current assetsÂ $1,343Â Â $4,520Â Â Â 14 Â Â Note 7 â€” Leases Â The Companyâ€™s future lease payments as of September 30, 2024, which are presented as operating lease liabilities, current portion and operating lease liabilities, less current portion on the Companyâ€™s unaudited condensed consolidated balance sheets are as follows: Schedule of Future Minimum Lease Payments for Operating LeasesÂ Â Â Â Â Â 2024 (remainder of year)Â $174Â 2025Â Â 708Â 2026Â Â 724Â 2027Â Â 594Â 2028Â Â 471Â ThereafterÂ Â 848Â Total lease paymentsÂ $3,519Â Less: imputed interestÂ Â (640) Present value of lease liabilitiesÂ $2,879Â Â Supplemental disclosure of cash flow information related to the Companyâ€™s cash and non-cash activities with its leases are as follows: Schedule of Supplemental Balance Sheet Information Related to Cash and Non-cash Activities with LeasesÂ Â Â 2024Â Â 2023Â Â Â Nine Months Ended September 30,Â Â Â 2024Â Â 2023Â Cash paid for amounts included in the measurement of lease liabilitiesÂ Â Â Â Â Â Â Â Operating cash flows from operating leasesÂ $1,407Â Â $1,080Â Non-cash investing and financing activitiesÂ Â Â Â Â Â Â Â Right-of-use assets obtained in exchange for new operating lease liabilitiesÂ $â€”Â Â $2,728Â Weighted-average remaining lease term - operating leases (in years)Â Â 5.25Â Â Â 6.68Â Weighted-average discount rate - operating leasesÂ Â 7.875%Â Â Â 7.875% Â As of September 30, 2024 and December 31, 2023, the Companyâ€™s right-of-use assets from operating leases were $2,618 and $4,267, respectively, which are reported in operating lease right-of-use assets in the unaudited condensed consolidated balance sheets. As of September 30, 2024 and December 31, 2023, the Company had outstanding operating lease obligations of $2,879 and $4,525, respectively, of which $499 and $1,565, respectively, are reported in operating lease liabilities, current portion and $2,380 and $2,960, respectively, are reported in operating lease liabilities less current portion in the Companyâ€™s unaudited condensed consolidated balance sheets. The Company calculates its incremental borrowing rates for specific lease terms, used to discount future lease payments, as a function of the financing terms the Company would likely receive on the open market. Following the deconsolidation of Lucid, the Company had removed right-of-use assets and operating lease liabilities related to Lucid. See Note 4, Equity Method Investment, for additional information on the Lucid deconsolidation. Â 15 Â Â Note 8 â€” Intangible Assets, net Â Intangible assets, less accumulated amortization, consisted of the following as of: Schedule of Intangible Assets, Less Accumulated AmortizationÂ Â Â Estimated Useful LifeÂ September 30, 2024Â Â December 31, 2023Â Defensive assetÂ 60 monthsÂ $â€”Â Â $2,105Â Laboratory licenses and certifications and laboratory information management softwareÂ 24 monthsÂ Â â€”Â Â Â 3,200Â OtherÂ 1 yearÂ Â 70Â Â Â 70Â Total Intangible assetsÂ Â Â Â 70Â Â Â 5,375Â Less Accumulated AmortizationÂ Â Â Â (70)Â Â (3,951) Intangible Assets, netÂ Â Â $â€”Â Â $1,424Â Â Amortization expense of the intangible assets discussed above was $82 and $505 for the three month periods ended September 30, 2024 and 2023, respectively, and $559 and $1,516 for the nine month periods ended September 30, 2024 and 2023, respectively, and is included in amortization of acquired intangible assets in the accompanying unaudited condensed consolidated statements of operations. Following the deconsolidation of Lucid, the Company had an intangible assets, net balance of $0, and no estimated future amortization expense. See Note 4, Equity Method Investment, for additional information on the Lucid deconsolidation. Â Note 9 â€” Commitment and Contingencies Â Other Matters Â In the ordinary course of PAVmed business, particularly as it begins commercialization of its products, the Company may be subject to certain other legal actions and claims, including product liability, consumer, commercial, tax and governmental matters, which may arise from time to time. The Company is not aware of any such pending legal or other proceedings that are reasonably likely to have a material impact on the Company. Notwithstanding, legal proceedings are subject-to inherent uncertainties, and an unfavorable outcome could include monetary damages, and excessive verdicts can result from litigation, and as such, could result in a material adverse impact on the Companyâ€™s business, financial position, results of operations, and /or cash flows. Additionally, although the Company has specific insurance for certain potential risks, the Company may in the future incur judgments or enter into settlements of claims which may have a material adverse impact on the Companyâ€™s business, financial position, results of operations, and /or cash flows. Â 16 Â Â Note 10 â€” Financial Instruments Fair Value Measurements Â Recurring Fair Value Measurements Â The fair value hierarchy table for the periods indicated is as follows: Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring BasisÂ Â Â Fair Value Measurement on a Recurring Basis at Reporting Date Using1Â Â Â Level-1 InputsÂ Â Level-2 InputsÂ Â Level-3 InputsÂ Â TotalÂ September 30, 2024Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Assets:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Investment in Lucid Diagnostics, Inc common stockÂ $25,511Â Â $â€”Â Â $â€”Â Â $25,511Â Total assets at fair valueÂ $25,511Â Â $â€”Â Â $â€”Â Â $25,511Â Liabilities:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Senior Secured Convertible Note - April 2022Â Â Â â€”Â Â Â Â â€”Â Â Â 19,850Â Â Â 19,850Â Senior Secured Convertible Note - September 2022Â Â Â â€”Â Â Â Â â€”Â Â Â 12,200Â Â Â 12,200Â Total liabilities at fair valueÂ $â€”Â Â $â€”Â Â $32,050Â Â $32,050Â Â Â Â Â Level-1 InputsÂ Â Level-2 InputsÂ Â Level-3 InputsÂ Â TotalÂ December 31, 2023Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Liabilities:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Senior Secured Convertible Note - April 2022Â $â€”Â Â $â€”Â Â $19,000Â Â $19,000Â Senior Secured Convertible Note - September 2022Â Â Â â€”Â Â Â Â â€”Â Â Â 11,250Â Â Â 11,250Â Lucid Senior Secured Convertible Note - March 2023Â Â Â â€”Â Â Â Â â€”Â Â Â 13,950Â Â Â 13,950Â Total liabilities at fair valueÂ $â€”Â Â $â€”Â Â $44,200Â Â $44,200Â Â Â 1There were no transfers between the respective Levels during the nine months ended September 30, 2024. Â As discussed in Note 11, Debt, the Company issued Senior Secured Convertible Notes dated April 4, 2022 and September 8, 2022, with an initial $27.5 million face value principal (â€œApril 2022 Senior Convertible Noteâ€) and an initial $11.25 million face value principal (â€œSeptember 2022 Senior Convertible Noteâ€), respectively. Both convertible notes are accounted for under the ASC 825-10-15-4 fair value option (â€œFVOâ€) election, wherein, the financial instrument is initially measured at its issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. Â As discussed in Note 11, Debt, Lucid Diagnostics issued a Senior Secured Convertible Note dated March 21, 2023, with an initial $11.1 million face value principal (â€œLucid March 2023 Senior Convertible Noteâ€). From and after September 10, 2024, the date of Lucidâ€™s deconsolidation from PAVmedâ€™s result of operation, the Companyâ€™s investment in Lucid has been accounted for as an equity method investment. For the periods prior to the deconsolidation, Lucidâ€™s convertible note is presented in PAVmedâ€™s balance sheets and is also accounted for under the ASC 825-10-15-4 fair value option (â€œFVOâ€) election, wherein, the financial instrument is initially measured at its issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. Â The estimated fair value of the financial instruments classified within the Level 3 category was determined using both observable inputs and unobservable inputs. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long- dated volatilities) inputs. Â 17 Â Â Note 10 â€” Financial Instruments Fair Value Measurements - continued Â The estimated fair value of the April 2022 Senior Convertible Note and the September 2022 Senior Convertible Note as of September 30, 2024 and the estimated fair value of the April 2022 Senior Convertible Note, the September 2022 Senior Convertible Note and the Lucid March 2023 Senior Convertible Note as of December 31, 2023, were computed using a Monte Carlo simulation of the present value of its cash flows using a synthetic credit rating analysis and a required rate-of-return, using the following assumptions: Schedule of Fair Value Assumption UsedÂ Â Â April 2022 Senior Convertible Note: September 30, 2024Â Â September 2022 Senior Convertible Note: September 30, 2024Â Fair ValueÂ $19,850Â Â $12,200Â Face value principal payableÂ $17,602Â Â $7,627Â Required rate of returnÂ Â 9.000%Â Â 8.800% Conversion PriceÂ $75.00Â Â $75.00Â Value of common stockÂ $1.23Â Â $1.23Â Expected term (years)Â Â 0.51Â Â Â 0.94Â VolatilityÂ Â 160.00%Â Â Â 160.00% Risk free rateÂ Â 4.28%Â Â Â 3.95% Dividend yieldÂ Â â€”%Â Â Â â€”% Â Â Â April 2022 Senior Convertible Note: December 31, 2023Â Â September 2022 Senior Convertible Note: December 31, 2023Â Â Lucid March 2023 Senior Convertible Note: December 31, 2023Â Fair ValueÂ $19,000Â Â $11,250Â Â $13,950Â Face value principal payableÂ $17,602Â Â $9,062Â Â $11,019Â Required rate of returnÂ Â 10.00% - 10.50%Â Â 10.00% - 10.20%Â Â 10.00% Conversion PriceÂ $75.00Â Â $75.00Â Â $5.00Â Value of common stockÂ $4.12Â Â $4.12Â Â $1.41Â Expected term (years)Â Â 0.26 - 1.26Â Â Â 0.69 - 1.69Â Â Â 1.22Â VolatilityÂ Â 85.00%Â Â Â 85.00%Â Â Â 60.00% Risk free rateÂ Â 4.54% - 5.25%Â Â Â 4.31% - 4.96%Â Â Â 4.56% Dividend yieldÂ Â â€”%Â Â Â â€”%Â Â Â â€”% Â The estimated fair values recognized utilized PAVmedâ€™s and Lucidâ€™s common stock prices, along with certain Level 3 inputs (as presented in the respective tables above), in the development of Monte Carlo simulation models, discounted cash flow analyses, and /or Black-Scholes valuation models. The estimated fair values are subjective and are affected by changes in inputs to the valuation models and analyses, including the respective common stock prices, as compared to the floor price on conversions, the dividend yields, the risk-free rates based on U.S. Treasury security yields, and certain other Level-3 inputs including, assumptions regarding the estimated volatility in the value of the respective common stock prices. Changes in these assumptions can materially affect the recognized estimated fair values. Â 18 Â Â Note 11 â€” Debt Â The fair value and face value principal outstanding of the Senior Convertible Notes as of the dates indicated are as follows: Summary of Outstanding DebtÂ Â Â Contractual Maturity DateÂ Stated Interest RateÂ Â Conversion Price per ShareÂ Â Face Value Principal OutstandingÂ Â Fair ValueÂ April 2022 Senior Convertible NoteÂ April 4, 2025Â Â 7.875%Â $75.00Â Â $17,602Â Â $19,850Â September 2022 Senior Convertible NoteÂ September 8, 2025Â Â 7.875%Â $75.00Â Â Â 7,627Â Â Â 12,200Â Balance as of September 30, 2024Â Â Â Â Â Â Â Â Â Â Â $25,229Â Â $32,050Â Â Â Contractual Maturity DateÂ Stated Interest RateÂ Â Conversion Price per ShareÂ Â Face Value Principal OutstandingÂ Â Fair ValueÂ April 2022 Senior Convertible NoteÂ April 4, 2025Â Â 7.875%Â $75.00Â Â $17,602Â Â $19,000Â

September 2022 Senior Convertible NoteÂ September 8, 2025Â Â 7.875%Â $75.00Â Â Â 9,062Â Â Â 11,250Â Lucid March 2023 Senior Convertible NoteÂ March 21, 2025Â Â 7.875%Â $5.00Â Â Â 11,019Â Â Â 13,950Â Balance as of December 31, 2023Â Â Â Â Â Â Â Â Â Â $37,683Â Â $44,200Â Â The changes in the fair value of debt during the three and nine month periods ended September 30, 2024 is as follows: Schedule of Changes in Fair Value of DebtÂ Â Â April 2022 Senior Convertible NoteÂ Â September 2022 Senior Convertible NoteÂ Â Lucid March 2023 Senior Convertible NoteÂ Â Sum of Balance Sheet Fair Value ComponentsÂ Â Other Income (expense)Â Fair Value - June 30, 2024Â $19,200Â Â $13,600Â Â $11,200Â Â $44,000Â Â $â€”Â Face value principal â€“ issue dateÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Fair value adjustment â€“ issue dateÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Installment repayments â€“ common stockÂ Â â€”Â Â Â (455)Â Â (797)Â Â (1,252)Â Â â€”Â Non-installment payments â€“ common stockÂ Â â€”Â Â Â (55)Â Â (135)Â Â (190)Â Â â€”Â Deconsolidation of Lucid DiagnosticsÂ Â â€”Â Â Â â€”Â Â Â (10,268)Â Â (10,268)Â Â â€”Â Change in fair valueÂ Â 650Â Â Â (890)Â Â â€”Â Â Â (240)Â Â 240Â Fair Value at September 30, 2024Â $19,850Â Â $12,200Â Â $â€”Â Â $32,050Â Â Â -Â Other Income (Expense) - Change in fair value â€“ three month period ended September 30, 2024Â $240Â Â Â Â April 2022 Senior Convertible NoteÂ Â September 2022 Senior Convertible NoteÂ Â Lucid March 2023 Senior Convertible NoteÂ Â Sum of Balance Sheet Fair Value ComponentsÂ Â Other Income (expense)Â Fair Value - December 31, 2023Â $19,000Â Â $11,250Â Â $13,950Â Â $44,200Â Â $â€”Â Installment repayments â€“ common stockÂ Â â€”Â Â Â (1,435)Â Â (2,005)Â Â (3,440)Â Â â€”Â Non-installment payments â€“ common stockÂ Â â€”Â Â Â (143)Â Â (787)Â Â (930)Â Â â€”Â Deconsolidation of Lucid DiagnosticsÂ Â â€”Â Â Â â€”Â Â Â (10,268)Â Â (10,268)Â Â â€”Â Change in fair valueÂ Â 850Â Â Â 2,528Â Â Â (890)Â Â 2,488Â Â Â (2,488) Fair Value at September 30, 2024Â $19,850Â Â $12,200Â Â $â€”Â Â $32,050Â Â Â -Â Other Income (Expense) - Change in fair value â€“ nine month period ended September 30, 2024Â $(2,488)Â 19Â Â Note 11 â€“ Debt - continued Â The changes in the fair value of debt during the three and nine month periods ended September 30, 2023 is as follows: Â Â Â April 2022 Senior Convertible NoteÂ Â September 2022 Senior Convertible NoteÂ Â Lucid March 2023 Senior Convertible NoteÂ Â Sum of Balance Sheet Fair Value ComponentsÂ Â Other Income (expense)Â Fair Value - June 30, 2023Â $19,530Â Â $11,850Â Â $11,610Â Â $42,990Â Â $â€”Â Installment repayments â€“ common stockÂ Â (952)Â Â (1,207)Â Â (92)Â Â (2,251)Â Â â€”Â Non-installment payments â€“ common stockÂ Â (41)Â Â (51)Â Â (49)Â Â (141)Â Â â€”Â Change in fair valueÂ Â 863Â Â Â 508Â Â Â 3,021Â Â Â 4,392Â Â Â (4,392) Fair Value at September 30, 2023Â $19,400Â Â $11,100Â Â $14,490Â Â $44,990Â Â Â -Â Other Income (Expense) - Change in fair value â€“ three month period ended September 30, 2023Â $(4,392) Â Â Â April 2022 Senior Convertible NoteÂ Â September 2022 Senior Convertible NoteÂ Â Lucid March 2023 Senior Convertible NoteÂ Â Sum of Balance Sheet Fair Value ComponentsÂ Â Other Income (expense)Â Fair Value - December 31, 2022Â $22,000Â Â $11,650Â Â $â€”Â Â $33,650Â Â $â€”Â Fair Value - Beginning of PeriodÂ $22,000Â Â $11,650Â Â $â€”Â Â $33,650Â Â $â€”Â Face value principal â€“ issue dateÂ Â â€”Â Â Â â€”Â Â Â 11,111Â Â Â 11,111Â Â Â â€”Â Fair value adjustment â€“ issue dateÂ Â â€”Â Â Â â€”Â Â Â 789Â Â Â 789Â Â Â (789) Installment repayments â€“ common stockÂ Â (3,895)Â Â (1,207)Â Â (92)Â Â (5,194)Â Â â€”Â Non-installment payments â€“ common stockÂ Â (249)Â Â (51)Â Â (49)Â Â (349)Â Â â€”Â Change in fair valueÂ Â 1,544Â Â Â 708Â Â Â 2,731Â Â Â 4,983Â Â Â (4,983) Fair Value at September 30, 2023Â $19,400Â Â $11,100Â Â $14,490Â Â $44,990Â Â Â -Â Fair Value - Ending of PeriodÂ $19,400Â Â $11,100Â Â $14,490Â Â $44,990Â Â Â -Â Other Income (Expense) - Change in fair value â€“ nine month period ended September 30, 2023Â $(5,772) Â PAVmed - Senior Secured Convertible Notes Â The Company entered into a Securities Purchase Agreement (â€œSPAâ€) dated March 31, 2022, with an accredited institutional investor (â€œInvestorâ€, â€œLenderâ€, and /or â€œHolderâ€), wherein, the Company agreed to sell, and the Investor agreed to purchase an aggregate of $50.0 million face value principal of debt - comprised of: an initial issuance of $27.5 million face value principal; and up to an additional $22.5 million of face value principal (upon the satisfaction of certain conditions). The debt was issued in a registered direct offering under the Companyâ€™s effective shelf registration statement. Â Under the SPA, the Company issued a Senior Secured Convertible Note dated April 4, 2022, referred to herein as the â€œApril 2022 Senior Convertible Noteâ€, with such note having a $27.5 million face value principal, a 7.875% annual stated interest rate, a contractual conversion price of $75.00 per share of the Companyâ€™s common stock (subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transaction), and a contractual maturity date of April 4, 2024, which maturity date the investor agreed to extend by one year, to April 4, 2025. The April 2022 Senior Convertible Note may be converted into shares of common stock of the Company at the Holderâ€™s election. Â Under the same SPA, the Company issued an additional Senior Secured Convertible Note dated September 8, 2022, referred to herein as the â€œSeptember 2022 Senior Convertible Noteâ€, with such note having a $11.25 million face value principal, a 7.875% annual stated interest rate, a contractual conversion price of $75.00 per share of the Companyâ€™s common stock (subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transaction), and a contractual maturity date of September 6, 2024, which maturity date the investor agreed to extend by one year, to September 8, 2025. The September 2022 Senior Convertible Note may be converted into shares of common stock of the Company at the Holderâ€™s election. Â 20 Â Â Note 11 â€“ Debt - continued Â The Company agreed to reduce temporarily, and the Investor consented to reducing temporarily, the contractual conversion price under the April 2022 Senior Convertible Note and the September 2022 Senior Convertible Note to equal to 82.5% of the two lowest VWAPs during the last 10 trading days preceding the date of conversion, subject to a conversion floor price of $0.40, during the period from June 30, 2024 through September 3, 2024; provided that the aggregate amount of conversions under the April 2022 Senior Convertible Note and the September 2022 Senior Convertible Note during such period may not exceed 1 million shares. Â The Company is subject to financial covenants requiring: (i) a minimum of $8.0 million of available cash at all times; (ii) the ratio of (a) the outstanding principal amount of the total senior convertible notes outstanding, accrued and unpaid interest thereon and accrued and unpaid late charges to (b) the Companyâ€™s average market capitalization over the prior ten trading days, to not exceed 30% (the â€œDebt to Market Cap Ratio Testâ€); and (iii) the Companyâ€™s market capitalization to at no time be less than $75 million (the â€œMarket Cap Testâ€ and, together with the Debt to Market Cap Ratio Test, the â€œFinancial Testsâ€). From time to time from and after September 1, 2024 through November 11, 2024, the Company was not in compliance with the Financial Tests. As of November 11, 2024, the Investor agreed to waive any such non-compliance during such time period and thereafter through December 31, 2024. Â In consideration of a prior covenant waiver and maturity extension agreed to in March 2024, the Company agreed to pay the holder of the notes $2,000 in cash (or in such other form as may be mutually agreed in writing). The covenant waiver and maturity extension fee was recognized as debt modification expense on the Companyâ€™s unaudited condensed consolidated statement of operations, and is currently included in accrued expenses and other current liabilities on the Companyâ€™s unaudited condensed consolidated balance sheets as of September 30, 2024. Â The April 2022 Senior Convertible Note and September 2022 Senior Convertible Note installment payments may be made in shares of PAVmed common stock at a conversion price that is the lower of the contractual conversion price and 82.5% of the two lowest VWAPs during the last 10 trading days preceding the date of conversion, subject to a conversion price floor of $2.70. The notes are also subject to certain provisions that may require redemption upon the occurrence of certain events, including an event of default, a change of control, or certain equity issuances. Â In the three and nine month periods ended September 30, 2024, approximately $455 and $1,435, respectively, of principal repayments along with approximately $55 and $143, respectively, of interest expense thereon, were settled through the issuance of 509,942 and 1,084,366, respectively, shares of common stock of the Company, with such shares having a fair value of approximately $907 and $2,002, respectively, (with such fair value measured as the respective conversion date quoted closing price of the common stock of the Company). In addition, during the three and nine month periods ended September 30, 2024, the Company agreed to pay $652 and $1,059, respectively, in cash related to acceleration floor payments on these notes related to the conversion price being below the floor price, which is included in debt extinguishment loss on the Companyâ€™s unaudited condensed consolidated statements of operations. As of September 30, 2024, approximately $652 of acceleration floor payments owed to the holder are included in accrued expenses and other current liabilities on the Companyâ€™s unaudited condensed consolidated balance sheets. The conversions and floor acceleration payments resulted in debt extinguishment losses of $1,050 and $1,501 in the three and nine month periods ended September 30, 2024, respectively. Â Lucid Diagnostics - Senior Secured Convertible Note Â Following the deconsolidation of Lucid, the Lucid March 2023 Senior Convertible Note is no longer reflected in the Companyâ€™s unaudited condensed consolidated balance sheets. See Note 4, Equity Method Investment, for additional information on the deconsolidation of Lucid. Â During the period of January 1, 2024 through September 10, 2024, the date of Lucidâ€™s deconsolidation, approximately $2,005 of principal repayments along with approximately $787 of interest expense thereon, were settled through the issuance of 4,172,002 shares of common stock of Lucid, with such shares having a fair value of approximately $3,801 (with such fair value measured as the respective conversion date quoted closing price of the common stock of Lucid). The conversions resulted in debt extinguishment losses of $328 in the period July 1, 2024 through September 10, 2024. The conversions resulted in debt extinguishment losses of $1,009 in the period of January 1, 2024 through September 10, 2024. Â During the three and nine month periods ended September 30, 2024, the Company recognized debt extinguishment losses in total of approximately $1,403 and $2,535, respectively, in connection with the Company or Lucid (as applicable) issuing shares of its common stock for principal repayments on convertible debt mentioned above. During the three and nine month periods ended September 30, 2023, the Company recognized debt extinguishment losses in total of approximately $1,764 and $3,032, respectively. Â See Note 10, Financial Instruments Fair Value Measurements, for a further discussion of fair value assumptions. Â 21 Â Â Note 12 â€“ Stock-Based Compensation Â PAVmed Inc. 2014 Long-Term Incentive Equity Plan Â The PAVmed Inc. 2014 Long-Term Incentive Equity Plan (the â€œPAVmed 2014 Equity Planâ€) is designed to enable PAVmed to offer employees, officers, directors, and consultants, as defined, an opportunity to acquire shares of common stock of PAVmed. The types of awards that may be granted under the PAVmed 2014 Equity Plan include stock options, stock appreciation rights, restricted stock, and other stock-based awards subject to limitations under applicable law. All awards are subject to approval by the PAVmed compensation committee. Â A total of 1,835,970 shares of common stock of PAVmed are reserved for issuance under the PAVmed 2014 Equity Plan, with 79,321 shares available for grant as of September 30, 2024. The share reservation is not diminished by a total of 66,720 PAVmed stock options and restricted stock awards granted outside the PAVmed 2014 Equity Plan as of September 30, 2024. In January 2024, the number of shares available for grant was increased by 432,452 in accordance with the evergreen provisions of the plan. Â PAVmed Stock Options Â PAVmed stock options granted under the PAVmed 2014 Equity Plan and stock options granted outside such plan are summarized as follows: Â Schedule of Summarizes Information About Stock Options Â Â Number of Stock OptionsÂ Â Weighted Average Exercise PriceÂ Â Remaining Contractual Term (Years)Â Â Intrinsic Value(2)Â Outstanding stock options at December 31, 2023Â Â 1,192,458Â Â $26.18Â Â Â 7.3Â Â $â€”Â Granted(1)Â Â 79,500Â Â $2.28Â Â Â Â Â Â Â Â ExercisedÂ Â â€”Â Â $â€”Â Â Â Â Â Â Â Â ForfeitedÂ Â (38,851)Â $13.47Â Â Â Â Â Â Â Â Outstanding stock options at September 30, 2024(3)Â Â 1,233,107Â Â $25.04Â Â Â 5.9Â Â $â€”Â Vested and exercisable stock options at September 30, 2024Â Â 956,977Â Â $30.27Â Â Â 5.1Â Â $â€”Â Â (1)Stock options granted under the PAVmed 2014 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant. (2)The intrinsic value is computed as the difference between the quoted price of the PAVmed common stock on each of September 30, 2024 and December 31, 2023 and the exercise price of the underlying PAVmed stock options, to the extent such quoted price is greater than the exercise price. (3)The outstanding stock options presented in the table above are inclusive of 60,054 stock options granted outside the PAVmed 2014 Equity Plan, as of September 30, 2024 and December 31, 2023. Â On February 22, 2024, the Company granted 59,500 stock options under the PAVmed Inc 2014 Equity Plan with a weighted average exercise price of $1.85. Each such option will vest one-third after one year then ratably over the next eight quarters. In addition, on February 22, 2024, a total of 390,000 restricted stock awards were granted to the Board of Directors under the PAVmed 2014 Equity Plan, with such restricted stock awards having an aggregate fair value of approximately $0.7 million, which was measured using the respective grant date quoted closing price per share of PAVmed common stock, with the fair value recognized as stock-based compensation expense ratably on a straight-line basis over the vesting period, which is commensurate with the service period. The vesting of the restricted stock awards vest ratably on an annual basis over a three year period with the initial annual vesting date of November 30, 2024. The restricted stock awards are subject to forfeiture if the requisite service period is not completed. Â PAVmed Restricted Stock Awards Â PAVmed restricted stock awards granted under the PAVmed 2014 Equity Plan and restricted stock awards granted outside such plan are summarized as follows: Â Schedule of Restricted Stock Award ActivityÂ Â Â Number of Restricted Stock AwardsÂ Â Weighted Average Grant Date Fair ValueÂ Unvested restricted stock awards as of December 31, 2023Â Â 70,527Â Â $38.77Â GrantedÂ Â 390,000Â Â Â 1.85Â VestedÂ Â (135,080)Â Â 2.00Â ForfeitedÂ Â â€”Â Â Â â€”Â Unvested restricted stock awards as of September 30, 2024Â Â 325,447Â Â $9.79Â Â Â 22 Â Â Note 12 â€“ Stock-Based Compensation - continued Â Lucid Diagnostics Inc. 2018 Long-Term Incentive Equity Plan Â The Lucid Diagnostics Inc. 2018 Long-Term Incentive Equity Plan (â€œLucid Diagnostics 2018 Equity Planâ€) is separate and apart from the PAVmed 2014 Equity Plan discussed above. The Lucid Diagnostics 2018 Equity Plan is designed to enable Lucid Diagnostics to offer employees, officers, directors, and consultants, an opportunity to acquire shares of common stock of Lucid Diagnostics. The types of awards that may be granted under the Lucid Diagnostics 2018 Equity Plan include stock options, stock appreciation rights, restricted stock, and other stock-based awards subject to limitations under applicable law. All awards are subject to approval by the Lucid Diagnostics compensation committee. Â Please note that following the deconsolidation of Lucid, the Lucid Diagnostics 2018 Long-Term Equity Plan is no longer reflected in the Companyâ€™s unaudited condensed consolidated statements of operations. Lucid continues to be responsible for administering its equity plan. See Note 4, Equity Method Investment, for additional information on the deconsolidation of Lucid Diagnostics. Â Lucid Diagnostics Stock Options Â Lucid Diagnostics stock options granted under the Lucid Diagnostics 2018 Equity Plan and stock options granted outside such plan are summarized as follows: Â Schedule of Summarizes Information About Stock Options Â Â Number of Stock OptionsÂ Â Weighted Average Exercise PriceÂ Â Remaining Contractual Term (Years)Â Â Intrinsic Value(2)Â Outstanding stock options at December 31, 2023Â Â 5,504,383Â Â $2.00Â Â Â 8.5Â Â $765Â Granted(1)Â Â 3,604,000Â Â $1.22Â Â Â Â Â Â Â Â ExercisedÂ Â (3,333)Â $1.31Â Â Â Â Â Â Â Â ForfeitedÂ Â (417,501)Â $1.63Â Â Â Â Â Â Â Â Outstanding stock options at September 10, 2024(3)Â Â 8,687,549Â Â $1.69Â Â Â 8.3Â Â $191Â Vested and exercisable stock options at September 10, 2024Â Â 3,084,682Â Â $2.25Â Â Â 7.1Â Â $191Â Â (1)Stock options granted under the Lucid Diagnostics 2018 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant. (2)The intrinsic value is computed as the difference between the quoted price of the Lucid Diagnostics common stock on each of September 10, 2024 and December 31, 2023 and the exercise price of the underlying Lucid Diagnostics stock options, to the extent such quoted price is greater than the exercise price. (3)The outstanding stock options presented in the table above are inclusive of 523,300 stock options granted outside the Lucid Diagnostics 2018 Equity Plan, as of September 10, 2024 and December 31, 2023. Â On February 22, 2024, Lucid granted 2,895,000 stock options under the Lucid Diagnostics 2018 Equity Plan with a weighted average exercise price of $1.25. Each option will vest one-third after one year then ratably over the next eight quarters. Â Lucid Diagnostics Restricted Stock Awards Â Lucid Diagnostics restricted stock awards granted under the Lucid Diagnostics 2018 Equity Plan and restricted stock awards granted outside such plan are summarized as follows: Â Schedule of Restricted Stock Award Activity Â Â Number of Restricted Stock AwardsÂ Â Weighted Average Grant Date Fair ValueÂ Unvested restricted stock awards as of December 31, 2023Â Â 2,337,440Â Â $8.99Â GrantedÂ Â 1,600,000Â Â Â 1.03Â VestedÂ Â (26,912)Â Â 4.56Â ForfeitedÂ Â (13,088)Â Â 4.56Â Unvested restricted stock awards as of September 10, 2024Â Â 3,897,440Â Â $5.77Â Â In May 2024, a total of 1,600,000 restricted stock awards were granted to management under the Lucid Diagnostics 2018 Equity Plan, with such restricted stock awards having an aggregate fair value of approximately $1.5 million, which was measured using the respective grant date quoted closing price per share of Lucid Diagnostics common stock, with the fair value recognized as stock-based compensation expense ratably on a straight-line basis over the vesting period, which is commensurate with the service period. The vesting of the restricted stock awards vest on a single vest date of May 20, 2026. The restricted stock awards are subject to forfeiture if the requisite service period is not completed. Â 23 Â Â Note 12 â€“ Stock-Based Compensation - continued Â Consolidated Stock-Based Compensation Expense Â The consolidated stock-based compensation expense recognized by each of PAVmed and (through September 10, 2024, the date of PAVmedâ€™s deconsolidation of Lucid) Lucid Diagnostics for both the PAVmed 2014 Equity Plan and the Lucid Diagnostics 2018 Equity Plan, with respect to stock options and restricted stock awards as discussed above, for the periods indicated, was as follows: Â Schedule of Stock-Based Compensation Expense Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Â Â Three Months Ended September 30,Â Â Nine Months Ended September 30,Â Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Cost of revenueÂ $32Â Â $32Â Â $112Â Â $86Â Sales and marketing expensesÂ Â 292Â Â Â 403Â Â Â 1,082Â Â Â 1,302Â General and administrative expensesÂ Â 1,426Â Â Â 1,499Â Â Â 3,717Â Â Â 6,761Â Research and development expensesÂ Â 181Â Â Â 311Â Â Â 805Â Â Â 1,022Â Total stock-based compensation expenseÂ $1,931Â Â $2,245Â Â $5,716Â Â $9,171Â Â Stock-Based Compensation Expense Recognized by Lucid Diagnostics Â As noted, the consolidated stock-based compensation expense presented above is inclusive of stock-based compensation

expense recognized by Lucid Diagnostics (through September 10, 2024, the date of PAVmedâ€™s deconsolidation of Lucid) inclusive of each of: stock options granted under the PAVmed 2014 Equity Plan to the three physician inventors of the intellectual property underlying the Amended CWRU License Agreement; and stock options and restricted stock awards granted to employees of PAVmed and non-employee consultants under the Lucid Diagnostics 2018 Equity Plan. The stock-based compensation expense recognized by Lucid Diagnostics (through September 10, 2024, the date of PAVmedâ€™s deconsolidation of Lucid) for both the PAVmed 2014 Equity Plan and the Lucid Diagnostics 2018 Equity Plan, with respect to stock options and restricted stock awards as discussed above, for the periods indicated, was as follows: Â Schedule of Stock-Based Compensation Expense Recognized by Lucid Diagnostics Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Â Â Three Months Ended September 30,Â Â Nine Months Ended September 30,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Lucid Diagnostics 2018 Equity Plan â€“ cost of revenueÂ $24Â Â $16Â Â $81Â Â $44Â Lucid Diagnostics 2018 Equity Plan â€“ sales and marketingÂ Â 252Â Â Â 228Â Â Â 849Â Â Â 697Â Lucid Diagnostics 2018 Equity Plan â€“ general and administrativeÂ Â 548Â Â Â 721Â Â Â 1,484Â Â Â 4,069Â Lucid Diagnostics 2018 Equity Plan â€“ research and developmentÂ Â 98Â Â Â 67Â Â Â 356Â Â Â 204Â PAVmed 2014 Equity Plan - cost of revenueÂ Â 9Â Â Â 10Â Â Â 30Â Â Â 26Â PAVmed 2014 Equity Plan - sales and marketingÂ Â 18Â Â Â 106Â Â Â 136Â Â Â 359Â PAVmed 2014 Equity Plan - general and administrativeÂ Â 1Â Â Â 7Â Â Â 5Â Â Â 170Â PAVmed 2014 Equity Plan - research and developmentÂ Â 5Â Â Â 97Â Â Â 148Â Â Â 290Â Total stock-based compensation expense â€“ recognized by Lucid DiagnosticsÂ $955Â Â $1,252Â Â $3,089Â Â $5,859Â Total stock-based compensation expenseÂ $955Â Â $1,252Â Â $3,089Â Â $5,859Â Â The consolidated unrecognized stock-based compensation expense and weighted average remaining requisite service period with respect to stock options and restricted stock awards issued under the PAVmed 2014 Equity Plan, as discussed above, is as follows: Â Schedule of Unrecognized Compensation Expense Â Â Unrecognized ExpenseÂ Â Weighted Average Remaining Service Period (Years)Â PAVmed 2014 Equity PlanÂ Â Â Â Â Â Â Â Stock OptionsÂ $1,377Â Â Â 1.5Â Restricted Stock AwardsÂ $397Â Â Â 2.2Â Â 24 Â Â Note 12 â€“ Stock-Based Compensation - continued Â Stock-based compensation expense recognized with respect to stock options granted under the PAVmed 2014 Equity Plan was based on a weighted average estimated fair value of such stock options of $1.47 per share and $5.25 per share during the nine month periods ended September 30, 2024 and 2023, respectively, calculated using the following weighted average Black-Scholes valuation model assumptions: Â Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions Â Â Nine Months Ended September 30,Â Â Â 2024Â Â 2023Â Expected term of stock options (in years)Â Â 5.8Â Â Â 5.7Â Expected stock price volatilityÂ Â 90%Â Â 88% Risk free interest rateÂ Â 4.3%Â Â 3.7% Expected dividend yieldÂ Â â€”%Â Â â€”% Â Stock-based compensation expense recognized with respect to stock options granted under the Lucid Diagnostics 2018 Equity Plan was based on a weighted average estimated fair value of such stock options of $0.79 per share and $0.88 per share during the nine month periods ended September 30, 2024 (through September 10, 2024, the date of PAVmedâ€™s consolidation of Lucid) and 2023, respectively, calculated using the following weighted average Black-Scholes valuation model assumptions: Â Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions Â Â Nine Months Ended September 30,Â Â Â 2024Â Â 2023Â Expected term of stock options (in years)Â Â 5.7Â Â Â 5.6Â Expected stock price volatilityÂ Â 73%Â Â 75% Risk free interest rateÂ Â 4.3%Â Â 3.7% Expected dividend yieldÂ Â â€”%Â Â â€”% Â PAVmed Inc. Employee Stock Purchase Plan (â€œPAVmed ESPPâ€) Â A total of 34,332 shares and 38,216 shares of common stock of the Company were purchased for proceeds of approximately $62 and $182, on March 31, 2024 and 2023, respectively, under the PAVmed ESPP. A total of 20,267 shares of common stock of the Company were purchased for proceeds of approximately $76 on September 30, 2023 under the PAVmed ESPP. The March 31, 2023 purchase was partially settled through the redeployment of 12,590 shares of treasury stock. The PAVmed ESPP has a total reserve of 300,001 shares of common stock of PAVmed of which 139,863 shares are available for issue as of September 30, 2024. In January 2024, the number of shares available-for-issue was increased by 166,667 in accordance with the evergreen provisions of the plan. Â Effective September 18, 2024, PAVmedâ€™s compensation committee temporarily suspended any participation in the PAVmed ESPP. Accordingly, no shares of common stock of the Company have been purchased under the PAVmed ESPP since March 31, 2024. Â Lucid Diagnostics Inc. Employee Stock Purchase Plan (â€œLucid ESPPâ€) Â A total of 511,884 shares and 231,987 shares of common stock of Lucid Diagnostics were purchased for proceeds of approximately $353 and $276 on March 31, 2024 and 2023, respectively, under the Lucid ESPP. A total 276,213 shares of common stock of Lucid Diagnostics were purchased for proceeds of approximately $275 on September 30, 2023 under the Lucid ESPP. Â 25 Â Â Note 13 â€“ Preferred Stock Â As of September 30, 2024 and December 31, 2023, there were 1,385,149 and 1,305,213 shares of PAVmed Series B Convertible Preferred Stock, classified in permanent equity, issued and outstanding, respectively. Â PAVmed Series B Convertible Preferred Stock Dividends Â The Series B Convertible Preferred Stock is issued pursuant to the PAVmed Inc. Certificate of Designation of Preferences, Rights, and Limitations of Series B Convertible Preferred Stock (â€œSeries B Convertible Preferred Stock Certificate of Designationâ€), has a par value of $0.001 per share, no voting rights, a stated value of $3.00 per share, and was immediately convertible upon its issuance. At the holdersâ€™ election, fifteen shares of Series B Convertible Preferred Stock are currently convertible into one share of common stock of the Company, subject to further adjustment for the effect of future stock dividends, stock splits or similar events affecting the Companyâ€™s common stock. The Series B Convertible Preferred Stock shall not be redeemed for cash and under no circumstances shall the Company be required to net cash settle the Series B Convertible Preferred Stock. Â The PAVmed Inc. Series B Convertible Preferred Stock dividends are 8.0% per annum based on the $3.00 per share stated value of the Series B Convertible Preferred Stock, with such dividends compounded quarterly, accumulate, and are payable in arrears upon being declared by the Companyâ€™s board of directors. Such dividends may be settled, at the discretion of the board of directors, through any combination of the issue of additional shares of Series B Convertible Preferred Stock, the issue shares of common stock of the Company, and /or cash payment. Â PAVmed Series B Convertible Preferred Stock Dividends Earned Â The Series B Convertible Preferred Stock dividends earned are included in the calculation of basic and diluted net loss attributable to PAVmed common stockholders for each of the respective corresponding periods presented in the accompanying unaudited condensed consolidated statement of operations, inclusive of $83 and $244 of such dividends earned in the three and nine month periods ended September 30, 2024, respectively; and $77 and $226 of such dividends earned in the three and nine month periods ended September 30, 2023, respectively. Â PAVmed Series B Convertible Preferred Stock Dividends Declared Â During the nine months ended September 30, 2024, the Companyâ€™s board of directors declared an aggregate of approximately $239 of Series B Convertible Preferred Stock dividends, inclusive of $78 earned as of December 31, 2023; and $80 earned as of March 31, 2024; and $81 earned as of June 30, 2024, with such dividends settled by the issue of an aggregate 79,936 additional shares of Series B Convertible Preferred Stock, inclusive of 26,123 shares issued with respect to the dividends earned as of December 31, 2023; and 26,640 shares issued with respect to the dividends earned as of March 31, 2024; and 27,173 shares issued with respect to the dividends earned as of June 30, 2024. Â During the nine months ended September 30, 2023, the Companyâ€™s board of directors declared an aggregate of approximately $221 of Series B Convertible Preferred Stock dividends, inclusive of $72 earned as of December 31, 2022; and $74 earned as of March 31, 2023; and $75 earned as of June 30, 2023, with such dividends settled by the issue of an aggregate 73,842 additional shares of Series B Convertible Preferred Stock, inclusive of 24,128 shares issued with respect to the dividends earned as of December 31, 2022; and 24,610 shares issued with respect to the dividends earned as of March 31, 2023; and 25,104 shares issued with respect to the dividends earned as of June 30, 2023. Â Subsequent to September 30, 2024, in November 2024, the Companyâ€™s board of directors declared a PAVmed Series B Convertible Preferred Stock dividend, earned as of September 30, 2024, of $83, to be settled by the issue of 27,716 additional shares of Series B Convertible Preferred Stock. Â The PAVmed Series B Convertible Preferred Stock dividends are recognized as a dividend payable liability only upon the dividend being declared payable by the Companyâ€™s board of directors. Accordingly, the dividends declared payable subsequent to the date of the accompanying unaudited condensed consolidated balance sheet were not recognized as a dividend payable liability as the Companyâ€™s board of directors had not declared the dividends payable as of each such date. Â 26 Â Â Note 14 â€“ Common Stock and Common Stock Purchase Warrants Â Common Stock Â In February 2023, the Company distributed a proxy statement for a special meeting of shareholders that was held on March 31, 2023 (the â€œSpecial Meetingâ€), at which the Company sought approval of an amendment to the Companyâ€™s Certificate of Incorporation, to effect, (i) a reverse split of the Companyâ€™s outstanding shares of common stock at a specific ratio, ranging from 1-for-5 to 1-for-15, to be determined by the board of directors of the Company in its sole discretion, and (ii) an associated reduction in the number of shares of common stock the Company is authorized to issue, from 250,000,000 shares to 50,000,000 shares. On March 31, 2023, the shareholders approved the above proposal to amend the Companyâ€™s Certificate of Incorporation, to effect, at any time prior to the one-year anniversary date of the Special Meeting. On November 28, 2023 the Companyâ€™s board of directors, unanimously authorized management to effect the reverse split at the ratio of 1-for-15. The reverse stock split became effective on December 7, 2023. At the effective date, every 15 shares of the Companyâ€™s common stock that were issued and outstanding were automatically combined into one issued and outstanding share, without any change in par value of such shares. No fractional shares were issued in connection with the reverse stock split. Instead, each fractional share remaining after completion of the reverse stock split that was less than a whole share was rounded up to one whole share. The reverse stock split also correspondingly affected all outstanding PAVmed equity awards and outstanding convertible securities. Â On March 7, 2024, the Company received a notice from the Listing Qualifications Department of The Nasdaq Stock Market (â€œNasdaqâ€) stating that, for the prior 30 consecutive business days (through March 6, 2024), the market value of the Companyâ€™s listed securities had been below the minimum of $35 million required for continued inclusion on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2). The Company was provided 180 calendar days, or until September 3, 2024, to regain compliance with the rule. The Company did not regain compliance with the rule during the allotted time period. Accordingly, on September 10, 2024, the Company received a staff determination letter from the Nasdaq Listing Qualifications Department, stating that unless the Company timely requested a hearing before a Nasdaq Hearings Panel (the â€œPanelâ€) to appeal the staff determination, the Companyâ€™s securities would be subject to suspension and delisting. The Company timely requested a hearing before the Panel, which was held on October 29, 2024. Â On November 8, 2024, the Panel granted the Company an extension, until January 31, 2025, to regain compliance with the Nasdaq continued listing standards. Â During the extension granted by the Panel, the Companyâ€™s common stock and Series Z warrants will continue to trade uninterrupted under the symbol â€œPAVMâ€ and â€œPAVMZâ€, respectively. Â During the nine months ended September 30, 2024 a total of 34,332 shares of common stock of the Company were issued under the PAVmed ESPP. See Note 12, Stock-Based Compensation, for a discussion of each of the PAVmed 2014 Equity Plan and the PAVmed ESPP. Â In the nine months ended September 30, 2024, 574,424 shares of the Companyâ€™s common stock were issued upon conversion, at the election of the holder, of the April 2022 Senior Convertible Note and the September 2022 Senior Convertible Note, for $980 face value principal repayments, as discussed in Note 11, Debt. Â In the nine months ended September 30, 2024, the Company sold 627,302 shares through their at-the-market equity facility for net proceeds of approximately $977, after payment of 3% commissions. Â In the nine months ended SeptemberÂ 30, 2024, the Company issued 200,809 shares of common stock to vendors in exchange for $200 of agreed upon services, which is included in general and administrative operating expenses on the Companyâ€™s unaudited condensed consolidated statement of operations. Â PAVmed Distribution of Lucid Diagnostics Common Stock to Shareholders Â On February 15, 2024, the Company distributed by special dividend to the Company stockholders 3,331,747 shares of Lucid Diagnostics common stock held by the Company. On such date, each PAVmed shareholder as of the January 15, 2024 record date received a stock dividend of approximately 38 shares of Lucid common stock for every 100 shares of PAVmed common stock they held as of such date. The shares distributed were approximately equal to the number of shares of common stock that Lucid issued to PAVmed on or about January 26, 2024 in satisfaction of certain intercompany obligations due to Lucid from PAVmed. Â The Companyâ€™s distribution of Lucid common stock to PAVmed stockholders, constituted an â€œExtraordinary Dividendâ€ as defined in the Warrant Agreement. Accordingly, as a result of the distribution, pursuant to Section 4.3 of the Warrant Agreement, the Warrant Price has been decreased by $0.52 (the fair market value of 0.37709668 of a share of Lucid Diagnosticsâ€™ common stock on the distribution date) to $23.48 per share. Â Common Stock Purchase Warrants Â As of September 30, 2024 and December 31, 2023, Series Z Warrants outstanding totaled 11,937,450 representing the right to purchase 795,830 shares of the Companyâ€™s common stock. The Series Z Warrants are now exercisable to purchase one whole share of common stock of the Company at an exercise price of $23.48 ($24.00 post reverse-split, decreased by $0.52 due to distribution of Lucid common stock to PAVmed stockholders, discussed further above). There were no Series Z Warrants exercised during the nine months ended September 30, 2024. Â 27 Â Â Note 15 â€“ Noncontrolling Interest Â The noncontrolling interest (â€œNCIâ€) included as a component of consolidated total stockholdersâ€™ equity is summarized for the periods indicated as follows: Â Schedule of Noncontrolling Interest of Stockholders' Equity Â Â September 30, 2024Â NCI â€“ equity - December 31, 2023Â $29,813Â Net loss attributable to NCIÂ Â (11,075) Impact of subsidiary equity transactionsÂ Â (4,414) Lucid Diagnostics proceeds from issuance of preferred stock Series A-1Â Â 5,670Â Lucid Diagnostics exchange of preferred stock Series A and Series A-1Â Â (24,294) Lucid Diagnostics issuance through exchange - Series B and Series B-1 Â Â 31,790Â Lucid Diagnostics issuance through sale - Series B and Series B-1Â Â 24,129Â Lucid Diagnostics deemed dividend on preferred stockÂ Â (7,496) Lucid Diagnostics issuance of common stock for settlement of vendor service agreementÂ Â 401Â Lucid Diagnostics 2018 Equity Plan stock option exerciseÂ Â 4Â Lucid Diagnostics Employee Stock Purchase Plan PurchaseÂ Â 353Â Conversion of Lucid Diagnostics common stock for Senior Secured Convertible DebtÂ Â 3,801Â Stock-based compensation expense - Lucid Diagnostics 2018 Equity PlanÂ Â 2,771Â Stock-based compensation expense - Veris Health 2021 Equity PlanÂ Â 368Â Deconsolidation of LucidÂ Â (56,339) NCI â€“ equity - September 30, 2024Â $(4,518) Â The consolidated NCI presented above is with respect to the Companyâ€™s consolidated subsidiaries as a component of consolidated total stockholdersâ€™ equity as of September 30, 2024 and December 31, 2023; and the recognition of a net loss attributable to the NCI in the unaudited condensed consolidated statement of operations for the periods beginning on the acquisition date of the respective subsidiaries. Â Lucid Diagnostics â€“ Deconsolidation Â As of September 30, 2024, there were 51,597,718 shares of common stock of Lucid Diagnostics issued and outstanding, of which, PAVmed held 31,302,444 shares. On September 10, 2024, following preferred equity transactions completed by Lucid earlier in 2024 and the termination of voting proxies entered into between PAVmed and certain shareholders of Lucid, PAVmedâ€™s voting interest in the Company was reduced to less than 50.0%, resulting in the loss of a controlling financial interest. However, PAVmed retains the ability to exercise significant influence over Lucid. Upon deconsolidation, the Companyâ€™s ownership of 31,302,444 shares of Lucid Diagnostics common stock was valued at $25.1 million, which resulted in a gain on deconsolidation of $72.3 million in the accompanying unaudited condensed consolidated statements of operations for the three and nine months ended September 30, 2024. Â Lucid Diagnostics â€“ Intercompany Obligation Settlement; Special Distribution Â On January 26, 2024 PAVmed elected to receive payment of $4,675 of fees and reimbursements due from Lucid, through the issuance of 3,331,771 shares of Lucid Diagnostics common stock. On February 15, 2024, the Company distributed by special dividend to the Company stockholders, as of the record date noted above, 3,331,747 shares of Lucid Diagnostics common stock held by the Company. Â Lucid Diagnostics â€“ Convertible Preferred Stock Offerings Â On March 7, 2023, Lucid issued 13,625 shares of newly designated Lucid Series A Convertible Preferred Stock (the â€œLucid Series A Preferred Stockâ€). Each share of the Lucid Series A Preferred Stock has a stated value of $1,000 and a conversion price of $1.394. The Lucid Series A Preferred Stock is convertible into shares of Lucid Diagnosticsâ€™ common stock at any time at the option of the holder from and after the six-month anniversary of its issuance, and automatically converts into shares of Lucid Diagnosticsâ€™ common stock on the second anniversary of its issuance. The terms of the Lucid Series A Preferred Stock also include a one times preference on liquidation and a right to receive dividends equal to 20% of the number of shares of Lucid common stock into which such Lucid Series A Preferred Stock is convertible, payable on the one-year and two-year anniversary of the issuance date. The Lucid Series A Preferred Stock is a non-voting security, other than with respect to limited matters related to changes in terms of the Lucid Series A Preferred Stock. The aggregate gross proceeds from the sale of shares in such offering were $13.625 million. Â 28 Â Â Note 15 â€“ Noncontrolling Interest - continued Â On March 13, 2024, Lucid issued an additional 5,670 shares of Lucid Series A-1 Preferred Stock, for aggregate gross proceeds of $5.67 million. Â On March 13, 2024, Lucid issued 44,285 shares of newly designated Lucid Series B Convertible Preferred Stock (the â€œLucid Series B Preferred Stockâ€). The terms of the Lucid Series B Preferred Stock are substantially identical to the terms of the Lucid Series A Preferred Stock and the Lucid Series A-1 Preferred Stock, except that the Lucid Series B Preferred Stock has a conversion price of $1.2444, and the holders of the Lucid Series B Preferred Stock vote with the common stock on an as-converted basis (subject to any applicable ownership limitations). On the same day, Lucid issued an additional 5,670 shares of Lucid Series A-1 Preferred Stock, for aggregate gross proceeds of $5.67 million (all of which shares were immediately exchanged for shares of Lucid Series B Preferred Stock). The aggregate gross proceeds from the sale of shares in such offering were $18.1 million. Â As a result of 100% of the then-outstanding shares of Lucid Series A Preferred Stock and Lucid Series A-1 Preferred Stock being exchanged for shares of Lucid Series B Preferred Stock in the Lucid Series B Offering and Exchange, no shares of Lucid Series A Preferred Stock or Lucid Series A-1 Preferred Stock remain outstanding. Â On May 6, 2024, Lucid issued approximately 11,634 shares of newly designated Lucid Series B-1 Convertible Preferred Stock (the â€œLucid

Series B-1 Preferred Stockâ€). The terms of the Lucid Series B-1 Preferred Stock are substantially identical to the terms of the Lucid Series B Preferred Stock, except that the Lucid Series B-1 Preferred Stock has a conversion price of $0.7228. The aggregate gross proceeds from the sale of shares in such offering were $11.6 million. Â Lucid Diagnostics â€” Deemed Dividend on Series A and Series A-1 Convertible Preferred Stock Exchange Offer Â The fair value of the consideration given in the form of the issue of 31,790 shares of Lucid Series B Convertible Preferred Stock, with such fair value recognized as the carrying value of such issued shares of Lucid Series B Convertible Preferred Stock, as compared to the carrying value of the extinguished Lucid Series A and Lucid Series A-1 Convertible Preferred Stock (carrying value of $24,294), resulting in an excess of fair value of $7.5 million recognized as a deemed dividend charged to accumulated deficit in the unaudited condensed consolidated balance sheet on March 13, 2024, with such deemed dividend included as a component of net loss attributable to common stockholders, summarized as follows: Â Schedule of Net Loss Attributable to Common Stockholders Lucid Series B Convertible Preferred Stock Issuance and Series A/A-1 Exchange OfferÂ March 13, 2024Â Fair Value - 31,790 shares of Lucid Series B Preferred Stock issuedÂ $31,790Â Fair Value - 31,790 shares of Lucid Series B Preferred Stock issued in exchange for Lucid Series A and Lucid Series A-1 Preferred StockÂ $31,790Â Less: Carrying value related to Lucid Series A and Lucid Series A-1 Preferred Stock Exchanged for Lucid Series B Preferred Stock (of 24,295 shares)Â Â (24,294) Deemed Dividend Charged to Accumulated DeficitÂ $7,496Â Â 29 Â Â Note 16 â€” Net Income (Loss) Per Share Â The Net income (loss) per share - attributable to PAVmed Inc. - basic and diluted and Net income (loss) per share - attributable to PAVmed Inc. common stockholders - basic and diluted - for the respective periods indicated - is as follows: Â Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Â Â Three Months Ended September 30,Â Â Nine Months Ended September 30,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â NumeratorÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net income (loss) - before noncontrolling interestÂ $60,711Â Â $(21,750)Â $27,285Â Â $(61,855) Net income (loss) attributable to noncontrolling interestÂ Â 3,688Â Â Â 4,079Â Â Â 11,075Â Â Â 11,716Â Net income (loss) - as reported, attributable to PAVmed Inc.Â $64,399Â Â $(17,671)Â $38,360Â Â $(50,139) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â

EsoGuardâ€™s regulatory strategy. Â Financing Â Extension to Regain Compliance with Nasdaq Listing Rules to January 31, 2025 Â On November 8, 2024, a Nasdaq Hearings Panel (the â€œPanelâ€) granted the Company an extension, until January 31, 2025, to regain compliance with the Nasdaq continued listing standards. Â As previously disclosed, on March 7, 2024, the Company received a notice from the Listing Qualifications Department of The Nasdaq Stock Market (â€œNasdaqâ€) stating that, for the prior 30 consecutive business days (through March 6, 2024), the market value of the Companyâ€™s listed securities had been below the minimum of $35 million required for continued inclusion on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2). The Company was provided 180 calendar days, or until September 3, 2024, to regain compliance with the rule. The Company did not regain compliance with the rule during the allotted time period. Accordingly, on September 10, 2024, the Company received a staff determination letter from the Nasdaq Listing Qualifications Department, stating that unless the Company timely requested a hearing before the Panel to appeal the staff determination, the Companyâ€™s securities would be subject to suspension and delisting. The Company timely requested a hearing before the Panel, which was held on October 29, 2024. Â During the extension granted by the Panel, the Companyâ€™s common stock and Series Z warrants will continue to trade uninterrupted under the symbol â€œPAVMâ€ and â€œPAVMZâ€, respectively. Â Extension of Senior Convertible Notes; Waiver Â Effective as of March 12, 2024, the Company entered into an amendment and waiver (the â€œNote Amendment and Waiverâ€) with the holder of the April 2022 Senior Convertible Note and the September 2022 Senior Convertible Note (each as defined in â€œLiquidity and Capital Resourcesâ€ below). Pursuant to the Note Amendment and Waiver, the maturity date of the April 2022 Senior Convertible Note was extended to April 4, 2025 and the maturity date of the September 2022 Senior Convertible Note was extended to September 8, 2025, in each case subject to further extension in certain circumstances. The holder of the such note also waived, for the period commencing on December 1, 2023 and ending on August 31, 2024, the financial covenant contained in such notes requiring that the ratio of (a) the outstanding principal amount of the notes, accrued and unpaid interest thereon and accrued and unpaid late charges to (b) the Companyâ€™s average market capitalization over the prior ten trading days, not exceed 30%, and that the Companyâ€™s market capitalization not be less than $75 million (the â€œFinancial Testsâ€). In consideration of the Note Amendment and Waiver, the Company agreed to pay the holder of the notes $2.0 million in cash (or in such other form as may be mutually agreed in writing), which currently is included in accrued expenses and other current liabilities on the Companyâ€™s unaudited condensed consolidated balance sheets as of September 30, 2024. Â In addition, from time to time from and after September 1, 2024 through November 11, 2024, the Company was not in compliance with the Financial Tests. As of November 11, 2024, the Investor agreed to waive any such non-compliance during such time period and thereafter through December 31, 2024. Â See our accompanying unaudited condensed consolidated financial statements Note 11, Debt, for further discussion of the senior convertible notes. Â Lucid March 2023 Senior Convertible Note Refinancing Â On November 8, 2024, Lucid gave notice to the holder of the Lucid March 2023 Senior Convertible Note that it was exercising its right pursuant to such note to redeem the same for the redemption price specified in such note (the â€œOptional Redemption Priceâ€). Pursuant to the terms of the Lucid March 2023 Senior Convertible Note, Lucid has not less than ten business days, and not more than twenty business days, from the date of the notice (the â€œOptional Redemption Notice Periodâ€) to pay the Optional Redemption Price. Â To finance the payment of the Optional Redemption Price, Lucid has entered into a securities purchase agreement with certain accredited investors (the â€œLucid 2024 Note Investorsâ€). Under the agreement, subject to customary closing conditions, Lucid has agreed to issue, and each 2024 Note Investor has agreed to purchase, 12.0% senior secured convertible notes due 2029 (collectively, the â€œLucid November 2024 Senior Convertible Notesâ€). As of the date hereof, the aggregate commitments of the Lucid 2024 Note Investors exceed the Optional Redemption Price. Â In connection with the purchase and sale of the Lucid 2024 Convertible Notes, Lucid will agree not to sell, transfer or dispose of, directly or indirectly, any shares of Lucid common stock for six months from the consummation of the offering, subject to certain limited exceptions, including in the event of a fundamental transaction involving Lucid. Â Lucid expects to complete the issuance of the Lucid November 2024 Senior Convertible Notes and the redemption of the Lucid March 2023 Senior Convertible Note on or prior to the end of the Optional Redemption Notice Period, although there can be no assurance that such issuance and redemption will be completed during such period, if at all. Â 33 Â Â Financing - continued Â Lucid Diagnostics - Preferred Stock Offerings Â On March 13, 2024, Lucid entered into subscription agreements (each, a â€œLucid Series B Subscription Agreementâ€) and exchange agreements (each, a â€œLucid Series B Exchange Agreementâ€) with certain accredited investors (collectively, the â€œLucid Series B Investorsâ€), which agreements provided for (i) the sale to the Lucid Series B Investors of 12,495 shares of Lucidâ€™s newly designated Series B Convertible Preferred Stock, par value $0.001 per share (the â€œLucid Series B Preferred Stockâ€), at a purchase price of $1,000 per share, and (ii) the exchange by the Lucid Series B Investors of 13,625 shares of Lucidâ€™s Series A Convertible Preferred Stock, par value $0.001 per share (the â€œLucid Series A Preferred Stockâ€), and 10,670 shares of Lucidâ€™s Series A-1 Convertible Preferred Stock, par value $0.001 per share (the â€œLucid Series A-1 Preferred Stockâ€), held by them for 31,790 shares of Lucid Series B Preferred Stock (collectively, the â€œLucid Series B Offering and Exchangeâ€). Prior to the execution of the Lucid Series B Subscription Agreements and the Lucid Series B Exchange Agreements, Lucid entered into subscription agreements with certain of the Lucid Series B Investors providing for the sale to such investors of 5,670 shares of Lucid Series A-1 Preferred Stock, at a purchase price of $1,000 per share, which shares the investors immediately agreed to exchange for shares of Lucid Series B Preferred Stock pursuant to the Lucid Series B Exchange Agreements (and are included in the 10,670 shares of Lucid Series A-1 Preferred Stock set forth above). Each share of the Lucid Series B Preferred Stock has a stated value of $1,000 and a conversion price of $1.2444. The terms of the Lucid Series B Preferred Stock also include a one times preference on liquidation and a right to receive dividends equal to 20% of the number of shares of Lucid common stock into which such Lucid Series B Preferred Stock is convertible, payable on the one-year and two-year anniversary of the issuance date. The holders of the Lucid Series B Preferred Stock also will be entitled to dividends equal, on an as-if-converted to shares of Lucid common stock basis, to and in the same form as dividends actually paid on shares of Lucid common stock when, as, and if such dividends are paid on shares of Lucid common stock. The Lucid Series B Preferred Stock is a voting security. The aggregate gross proceeds to Lucid of these transactions was $18.16 million (inclusive of $5.67 million of aggregate gross proceeds from the sale of the Lucid Series A-1 Preferred Stock that was immediately exchanged for Lucid Series B Preferred Stock in the transactions). Â As a result of 100% of the then-outstanding shares of Lucid Series A Preferred Stock and Lucid Series A-1 Preferred Stock being exchanged for shares of Lucid Series B Preferred Stock in the Lucid Series B Offering and Exchange, no shares of Lucid Series A Preferred Stock or Lucid Series A-1 Preferred Stock remain outstanding. Â On May 6, 2024, Lucid issued approximately 11,634 shares of newly designated Lucid Series B-1 Convertible Preferred Stock (the â€œLucid Series B-1 Preferred Stockâ€). The terms of the Lucid Series B-1 Preferred Stock are substantially identical to the terms of the Lucid Series B Preferred Stock, except that the Lucid Series B-1 Preferred Stock has a conversion price of $0.7228. The aggregate gross proceeds from the sale of shares in such offering were $11.6 million. Â PAVmed - ATM Facility Â In December 2021, we entered into an â€œat-the-market offeringâ€ for up to $50 million of our common stock that may be offered and sold under a Controlled Equity Offering Agreement between us and Cantor Fitzgerald & Co. (â€œCantorâ€). In March 2023, the â€œat-the-market offeringâ€ became subject to General Instruction I.B.6 of Form S-3, which limits sales of our securities under this instruction in any 12-month period to one-third of the aggregate market value of our public float (unless our public float rises to $75 million or more, in which case the instruction will cease to apply). As a result of this limitation and our then-current public float, in May 2023, we amended our â€œat-the-market offeringâ€ to cover up to $18 million of our common stock. In the nine month period ended September 30, 2024, the Company sold 627,302 shares through its at-the-market equity facility for net proceeds of approximately $1.0 million, after payment of 3% commissions. As of September 30, 2024, the Company had approximately $15.1 million remaining under the PAVmed ATM Facility. Â 34 Â Â Results of Operations Â Overview Â Revenue Â The Company recognized revenue primarily resulting from the delivery of patient EsoGuard test results when the Company considered the collection of such consideration to be probable to the extent that it is unconstrained. Â Cost of revenue Â Cost of revenues recognized primarily from the delivery of patient EsoGuard test results includes costs related to EsoCheck device usage, shipment of test collection kits, royalties and the cost of services to process tests and provide results to physicians. We have incurred expenses for tests in the period in which the activities occur, therefore, gross margin as a percentage of revenue has varied from quarter to quarter due to costs being incurred in one period that relate to revenues recognized in a later period. Â We expect that gross margin for our services will fluctuate based on the commercialization efforts of our majority-owned subsidiaries. Â Sales and marketing expenses Â Sales and marketing expenses consist primarily of salaries and related costs for employees engaged in sales, sales support and marketing activities, as well as advertising and promotion expenses. We anticipate our sales and marketing expenses to decrease in the future compared to historical periods due to the deconsolidation of Lucid, as the sales and marketing operations for the Lucid EsoGuard test is no longer recorded within the Companyâ€™s operating results. Â General and administrative expenses Â General and administrative expenses consist primarily of salaries and related costs for personnel, travel expenses, facility-related costs, professional fees for accounting, tax, audit and legal services, salaries and related costs for employees involved in third-party payor reimbursement contract negotiations and consulting fees and other expenses associated with obtaining and maintaining patents within our intellectual property portfolio. Â We anticipate our general and administrative expenses will decrease in the future compared to historical periods due to the deconsolidation of Lucid as the general and administrative expenses, including third-party payor reimbursement costs, incurred by Lucid will no longer be recorded within the Companyâ€™s operating results. In the future, general and administrative expenses will include those expenses related to being a public company, including fees and expenses for audit, legal, regulatory, tax-related services, insurance premiums and investor relations costs associated with maintaining compliance as a public company for PAVmed and its majority-owned subsidiaries. Â Research and development expenses Â Research and development expenses are recognized in the period they are incurred and consist principally of internal and external expenses incurred for the development of our products, including: Â Â â— consulting costs for engineering design and development; Â â— salary and benefit costs associated with our medical research personnel and engineering personnel; Â â— costs associated with regulatory filings; Â â— patent license fees; Â â— cost of laboratory supplies and acquiring, developing, and manufacturing preclinical prototypes; Â â— product design engineering studies; and Â â— expenses for facilities maintained solely for research and development purposes. Â The reported research and development activities, including our clinical trials, were focused principally on the acceleration of EsoGuard and Veris Cancer Care Platform commercialization. In the future, the research and development activities will focus on the Veris Cancer Care Platform, the PMX incubator program and other products in our pipeline as well as applicable new technologies, as resources permit. Â Other Income and Expense, net Â Other income and expense, net, consists principally of changes in fair value of our convertible notes and losses on extinguishment of debt upon repayment of such convertible notes. Â Presentation of Dollar Amounts Â All dollar amounts in this Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations are presented as dollars in millions, except for share and per share amounts. Â 35 Â Â The three months ended September 30, 2024 as compared to three months ended September 30, 2023 Â Revenue Â In the three months ended September 30, 2024, revenue was $1.0 million as compared to $0.8 million for the corresponding period in the prior year. The $0.2 million increase principally relates to the increase in volume of our EsoGuard Esophageal DNA Tests performed in our own CLIA laboratory for the period and the consideration received for the performance of the EsoGuard Esophageal DNA Tests. Â Cost of revenue Â In the three months ended September 30, 2024, cost of revenue costs were approximately $1.4 million, as compared to $1.8 million for the corresponding period in the prior year. The net decrease of $0.4 million was primarily related to: Â Â â— approximately $0.4 million decrease in manufacturing costs associated with the EsoCheck devices and EsoGuard Esophageal DNA Tests. Â Sales and marketing expenses Â In the three months ended September 30, 2024, sales and marketing costs were approximately $2.9 million as compared to $4.0 million for the corresponding period in the prior year. The net decrease of $1.1 million was principally related to: Â Â â— approximately $1.0 million decrease in compensation related costs; and Â â— approximately $0.1 million decrease in stock based compensation costs. Â General and administrative expenses Â In the three months ended September 30, 2024, general and administrative costs were approximately $6.6 million as compared to $6.9 million for the corresponding period in the prior year. The net decrease of $0.3 million was principally related to: Â Â â— approximately $0.2 million decrease in third-party professional fees and legal expenses; and Â â— approximately $0.1 million decrease in stock based compensation costs. Â Research and development expenses Â In the three months ended September 30, 2024, research and development costs were approximately $1.5 million as compared to $3.2 million for the corresponding period in the prior year. The net decrease of $1.7 million was principally related to: Â Â â— approximately $1.1 million decrease in development costs, particularly in clinical trial activities and outside professional and consulting fees; Â â— approximately $0.3 million decrease in compensation and stock based compensation from RSA and stock option grants to Lucid and PAVmed employees and non-employees; Â â— approximately $0.2 million decrease in third party consulting costs related to research and development activities; and Â â— approximately $0.1 million decrease in developmental milestones paid to third parties. Â Amortization of Acquired Intangible Assets Â The amortization of acquired intangible assets was approximately $0.1 million in the three months ended September 30, 2024, as compared to $0.5 million for the corresponding period in the prior year. The decrease of $0.4 million in the current period was due to certain acquired intangible assets being fully amortized in February 2024. Â 36 Â Â Other Income and Expense Â Results of Operations - continued Â The three months ended September 30, 2024 as compared to the three months ended September 30, 2023 - continued Â Other Income and Expense Â Change in fair value of convertible debt Â In the three months ended September 30, 2024, the change in the fair value of our convertible notes was approximately $0.2 million of income, related to the April 2022 Senior Convertible Note (as defined in â€œLiquidity and Capital Resourcesâ€ below), the September 2022 Senior Convertible Note (as defined in â€œLiquidity and Capital Resourcesâ€ below), and the Lucid March 2023 Senior Convertible Note (as defined in â€œLiquidity and Capital Resourcesâ€ below). The April 2022 Senior Convertible Note, the September 2022 Senior Convertible Note, and the Lucid March 2023 Senior Convertible Note were initially measured at their issue-date estimated fair value and subsequently remeasured at estimated fair value as of each reporting period date. The Company initially recognized an aggregate of $4.3 million of fair value non-cash expense on the issue dates. Â Loss on Debt Extinguishment Â In the three months ended September 30, 2024, a debt extinguishment loss in the aggregate of approximately $1.4 million was recognized in connection with our April 2022 Senior Convertible Note, September 2022 Senior Convertible Note and the Lucid March 2023 Senior Convertible Note as discussed below. Â Â â— In the three months ended September 30, 2024, approximately $0.5 million of principal repayments, along with less than $0.1 million of interest expense thereon, were settled through the issuance of 509,942 shares of common stock of the Company, with such shares having a fair value of approximately $0.9 million (with such fair value measured as the respective conversion date quoted closing price of the common stock of the Company). In addition, the Company agreed to pay $0.7 million in cash related to acceleration floor payments on these notes related to the conversion price being below the floor, recorded as debt extinguishment loss. The conversions and floor acceleration payments resulted in a debt extinguishment loss of $1.1 million in the three months ended September 30, 2024. Â â— During the period of July 1, 2024 through September 10, 2024, the date of PAVmedâ€™s deconsolidation, approximately $0.8 million of principal repayments along with approximately $0.1 million of interest expense thereon, were settled through the issuance of 1,510,821 shares of Lucid common stock, with such shares having a fair value of approximately $1.3 million (with such fair value measured as the quoted closing price of the common stock of Lucid on the respective conversion date). The conversions resulted in a debt extinguishment loss of $0.3 million in the period July 1, 2024 through September 10, 2024. Â In comparison, in the three months ended September 30, 2023, a debt extinguishment loss in the aggregate of approximately $1.8 million was recognized in connection with our April 2022 Senior Convertible Note as discussed below. Â Â â— In the three months ended September 30, 2023, approximately $2.2 million of principal repayments, along with less than $0.1 million of interest expense thereon, were settled through the issuance of 723,998 shares of common stock of the Company, with such shares having a fair value of approximately $4.0 million (with such fair value measured as the respective conversion date quoted closing price of the common stock of the Company). The conversions resulted in a debt extinguishment loss of $1.8 million in the three months ended September 30, 2023. Â See Note 11, Debt, to the Financial Statements, for additional information with respect to the April 2022 Senior Convertible Note, the September 2022 Senior Convertible Note, and the Lucid March 2023 Senior Convertible Note. Â Gain on Deconsolidation of Lucid Â As of September 30, 2024, there were 51,597,718 shares of common stock of Lucid Diagnostics issued and outstanding, of which, the Company held 31,302,444 shares. On September 10, 2024, as a result of certain changes in the composition of the Companyâ€™s board of directors as described above, in combination with the Company ceasing to have control over a majority of the voting power of Lucid, the Company was considered to cease to have control over Lucid for the purposes of U.S. GAAP, even though it continues to own, and has not disposed any of its, 31,302,444 shares of common stock of Lucid. However, PAVmed retained the ability to exercise significant influence over Lucid. Upon deconsolidation, the Companyâ€™s ownership of 31,302,444 shares of Lucid Diagnostics, Inc common stock was valued at $25.1 million, which resulted in a gain on deconsolidation of $72.3 million in the accompanying unaudited condensed consolidated statements of operations for the three months ended September 30, 2024. Â Change in fair value of Equity Method Investment Â At September 10, 2024 and September 30, 2024, the fair value of the Companyâ€™s investment in Lucid was $25.1 million and $25.5 million, respectively, with the

company recognizing an unrealized gain on its investment in Lucid of $0.4 million in the accompanying condensed consolidated statements of operations for three month period ended September 30, 2024. The fair value of common shares held by the Company was determined using the closing price of Lucidâ€™s common stock per share on September 10, 2024 and September 30, 2024 of $0.802 and $0.815, respectively. Â 37 Â Â Results of Operations - continued Â The nine months ended September 30, 2024 as compared to nine months ended September 30, 2023 Â Revenue Â In the nine months ended September 30, 2024, revenue was $3.0 million as compared to $1.4 million for the corresponding period in the prior year. The $1.6 million increase principally relates to the revenue for our EsoGuard Esophageal DNA Test performed in our own CLIA laboratory for the period and the consideration received for the performance of the EsoGuard Esophageal DNA Tests. Â Cost of revenue Â In the nine months ended September 30, 2024, cost of revenue remained relatively level, at approximately $4.8 million, as compared to the corresponding period in the prior year. Â Sales and marketing expenses Â In the nine months ended September 30, 2024, sales and marketing costs were approximately $11.5 million as compared to $12.9 million for the corresponding period in the prior year. The net decrease of $1.4 million was principally related to: Â Â â— approximately $1.2 million decrease in compensation related costs, including stock-based compensation; and Â â— approximately $0.2 million decrease in third party sales and marketing costs. Â General and administrative expenses Â In the nine months ended September 30, 2024, general and administrative costs were approximately $20.3 million as compared to $23.9 million for the corresponding period in the prior year. The net decrease of $3.6 million was principally related to: Â Â â— approximately $3.1 million decrease in stock-based compensation, related to decreases at both PAVmed and Lucid; and Â â— approximately $0.5 million decrease in third-party professional fees, expenses related to related to the termination of the management services agreement with our former laboratory provider, and expenses for finance and legal services. Â Research and development expenses Â In the nine months ended September 30, 2024, research and development costs were approximately $5.1 million as compared to $10.7 million for the corresponding period in the prior year. The net decrease of $5.6 million was principally related to: Â Â â— approximately $4.4 million decrease in development costs, particularly in clinical trials activities and outside professional and consulting fees; and Â â— approximately $1.2 million decrease in compensation related costs and stock-based compensation. Â Amortization of Acquired Intangible Assets Â The amortization of acquired intangible assets was approximately $0.6 million in the nine months ended September 30, 2024, as compared to $1.5 million for the corresponding period in the prior year. The decrease of $1.1 million in the current period was due to certain acquired intangible assets being fully amortized in February 2024. Â Other Income and Expense Â Change in fair value of convertible debt Â In the nine months ended September 30, 2024 and September 30, 2023, the change in the fair value of our convertible notes was approximately $2.5 million and $5.8 million of expense, respectively, related to the April 2022 Senior Convertible Note, the September 2022 Senior Convertible Note, and the Lucid March 2023 Senior Convertible Note. The April 2022 Senior Convertible Note, the September 2022 Senior Convertible Note, and the Lucid March 2023 Senior Convertible Note were initially measured at their issue-date estimated fair value and subsequently remeasured at estimated fair value as of each reporting period date. The Company initially recognized an aggregate of $4.3 million of fair value non-cash expense on the issue dates. Â Loss on Issue and Offering Costs - Senior Secured Convertible Note Â In the nine months ended September 30, 2023, in connection with the issue of the Lucid March 2023 Senior Convertible Note, we recognized a total of approximately $1.2 million of lender fees and offering costs. The Company did not incur lender fees and offering costs in the nine months ended September 30, 2024. Â 38 Â Â Results of Operations - continued Â The nine months ended September 30, 2024 as compared to nine months ended September 30, 2023 - continued Â Other Income and Expense - continued Â Loss on Debt Extinguishment Â In the nine months ended September 30, 2024, a debt extinguishment loss in the aggregate of approximately $2.5 million was recognized in connection with our April 2022 Senior Convertible Note and September 2022 Senior Convertible Note as discussed below. Â Â â— In the nine months ended September 30, 2024, approximately $1.4 million of principal repayments along with $0.1 million of interest expense thereon, were settled through the issuance of 1,084,366 shares of common stock of the Company, with such shares having a fair value of approximately $2.0 million (with such fair value measured as the quoted closing price of the common stock of the Company on the respective conversion date). In addition, the Company agreed to pay $1.1 million in cash related to acceleration floor payments on these notes related to the conversion price being below the floor, recorded as debt extinguishment loss. The conversions and cash paid resulted in a debt extinguishment loss of $1.5 million in the nine months ended September 30, 2024. Â â— During the period of January 1, 2024 through September 10, 2024, the date of PAVmedâ€™s deconsolidation of Lucid, approximately $2.0 million of principal repayments along with approximately $0.8 million of interest expense thereon, were settled through the issuance of 4,172,002 shares of Lucid common stock, with such shares having a fair value of approximately $3.8 million (with such fair value measured as the quoted closing price of the common stock of Lucid on the respective conversion date). The conversions resulted in a debt extinguishment loss of $1.0 million in the period of January 1, 2024 through September 10, 2024. Â In comparison, in the nine months ended September 30, 2023, a debt extinguishment loss in the aggregate of approximately $3.0 million was recognized in connection with our April 2022 Senior Convertible Note and the September 2022 Senior Convertible Note as discussed below. Â Â â— In the nine months ended September 30, 2023, approximately $5.1 million of principal repayments along with $0.3 million of interest expense thereon, were settled through the issuance of 1,358,896 shares of common stock of the Company, with such shares having a fair value of approximately $8.4 million (with such fair value measured as the quoted closing price of the common stock of the Company on the respective conversion date). The conversions resulted in a debt extinguishment loss of $3.0 million in the nine months ended September 30, 2023. Â See Note 11, Debt, to the Financial Statements, for additional information with respect to the April 2022 Senior Convertible Note, the September 2022 Senior Convertible Note, and the Lucid March 2023 Senior Convertible Note. Â Gain on Deconsolidation of Lucid Â As of SeptemberÂ 30, 2024, there were 51,597,718 shares of common stock of Lucid Diagnostics issued and outstanding, of which, the Company held 31,302,444 shares. On September 10, 2024, as a result of changes in the composition of the Companyâ€™s board of directors described above, in combination with the Company ceasing to have control over a majority of the voting power of Lucid, the Company was considered to cease to have control over Lucid for the purposes of U.S. GAAP, even though it continues to own, and has not disposed any of its, 31,302,444 shares of common stock of Lucid. However, PAVmed retained the ability to exercise significant influence over Lucid. As a result, the Company deconsolidated Lucid. Upon deconsolidation, the Companyâ€™s ownership of 31,302,444 shares of Lucid Diagnostics common stock was valued at $25.1 million, which resulted in a gain on deconsolidation of $72.3 million in the accompanying unaudited condensed consolidated statements of operations for the nine months ended September 30, 2024. Â Change in fair value of Equity Method Investment Â At September 10, 2024 and September 30, 2024, the fair value of the Companyâ€™s investment in Lucid was $25.1 million and $25.5 million, respectively, with the company recognizing an unrealized gain on its investment in Lucid of $0.4 million in the accompanying condensed consolidated statements of operations for nine month period ended September 30, 2024. The fair value of common shares held by the Company was determined using the closing price of Lucidâ€™s common stock per share on September 10, 2024 and September 30, 2024 of $0.802 and $0.815, respectively. Â Deemed Dividend on Series A and Series A-1 Convertible Preferred Stock Exchange Offer Â The fair value of the consideration given in the form of the issue of 31,790 shares of Lucid Series B Preferred Stock, with such fair value recognized as the carrying value of such issued shares of Lucid Series B Preferred Stock, as compared to the carrying value of the extinguished Lucid Series A and Series A-1 Preferred Stock (carrying value of $24.3 million), resulting in an excess of fair value of $7.5 million recognized as a deemed dividend charged to accumulated deficit in the unaudited condensed consolidated balance sheet on March 13, 2024, with such deemed dividend included as a component of net loss attributable to common stockholders, summarized as follows: Â Series B Convertible Preferred Stock Issuance and Series A/A-1 Exchange OfferÂ March 13, 2024Â Fair Value - 31,790 shares of Lucid Series B Preferred Stock issued in exchange for Lucid Series A and Lucid Series A-1 Preferred StockÂ $31,790Â Less: Carrying value related to Series A and Series A-1 Preferred Stock Exchanged for Series B Preferred Stock (of 24,295 shares)Â Â (24,294) Deemed Dividend Charged to Accumulated DeficitÂ $7,496Â Â 39 Â Â Liquidity and Capital Resources Â Our current financing strategy is to obtain capital directly into Lucid, Veris and other subsidiaries to fund any product development or other related activities, although we retain the flexibility to raise capital at the PAVmed level. There are no assurances, however, we will be able to obtain an adequate level of financial resources required for the short-term or long-term commercialization and development of our products and services. Â We have financed our operations principally through the public and private issuances of our common stock, preferred stock, common stock purchase warrants, and debt, both at the PAVmed level and, in the case of Lucid, at the subsidiary level. We are subject to all of the risks and uncertainties typically faced by medical device and diagnostic and medical device companies that devote substantially all of their efforts to the commercialization of their initial product and services and ongoing R&D and clinical trials. We experienced net income before noncontrolling interests of approximately $27.3 million and used approximately $33.6 million of cash in operations for the nine months ended September 30, 2024. Financing activities provided $31.0 million of cash during the nine months ended September 30, 2024. We ended the quarter with cash on-hand of $0.8 million as of September 30, 2024. We expect to continue to experience recurring losses and negative cash flows from operations, and will continue to fund our operations with debt and/or equity financing transactions, including current obligations on the Companyâ€™s existing convertible debt which in accordance with managementâ€™s plans may include conversions to equity and refinancing our existing debt obligations to extend the maturity date. The Companyâ€™s ability to continue operations 12 months beyond the issuance of the financial statements will depend upon generating substantial revenue that is conditioned on obtaining positive third-party reimbursement coverage for its EsoGuard Esophageal DNA Test from both government and private health insurance providers, increasing revenue through contracting directly with self-insured employers, and on its ability to raise additional capital through various potential sources including equity and/or debt financings or refinancing existing debt obligations. These factors raise substantial doubt about the Companyâ€™s ability to continue as a going concern within one year after the date the accompanying unaudited condensed consolidated financial statements are issued. Â Issue of Shares of Our Common Stock Â During the nine months ended September 30, 2024 Â Â â— We issued 34,332 shares of our common stock for proceeds of approximately $0.1 million under the PAVmed Employee Stock Purchase Plan (â€œESPPâ€). For more information about the ESPP, see Note 12, Stock-Based Compensation, to the Financial Statements. Â â— We issued 627,302 shares of our common stock for net proceeds of approximately $1.0 million, after payment of 3% commissions, through our at-the-market equity facility with Cantor. See below for more information. Â â— We issued 1,084,366 shares of our common stock in satisfaction of approximately $1.4 million of principal repayments along with $0.1 million of interest expense thereon under the April 2022 Senior Convertible Note and September 2022 Senior Convertible Note. Â Securities Purchase Agreement - March 31, 2022 - Senior Secured Convertible Notes - April 4, 2022 and September 8, 2022 Â Effective as of March 31, 2022, we entered into a Securities Purchase Agreement (the â€œSPAâ€) with an accredited investor, pursuant to which we agreed to sell, and the investor agreed to purchase an aggregate of $50.0 million face value principal of Senior Secured Convertible Notes. On April 4, 2022, we completed an initial closing under the SPA, in which we sold to the investor a Senior Secured Convertible Note with a face value principal of $27.5 million (the â€œApril 2022 Senior Convertible Noteâ€). The April 2022 Senior Secured Convertible Note had an initial contractual maturity date of April 4, 2024, which maturity date the investor agreed to extend by one year, to April 4, 2025. The April 2022 Senior Secured Convertible Note may be converted into or otherwise paid in shares of our common stock as described in Note 11, Debt. Â On September 8, 2022, we completed an additional closing under the SPA, in which we sold to the investor an additional Senior Secured Convertible Note with a face value principal of $11.25 million (the â€œSeptember 2022 Senior Convertible Noteâ€). The September 2022 Senior Secured Convertible Note had an initial contractual maturity date of September 6, 2024, which maturity date the investor agreed to extend by one year, to September 8, 2025. The September 2022 Senior Convertible Note may be converted into or otherwise paid in shares of our common stock as described in Note 11, Debt. Â Under the April 2022 Senior Convertible Note, the September 2022 Senior Convertible Note and the SPA, we are subject to certain customary affirmative and negative covenants regarding the incurrence of indebtedness, the existence of liens, the repayment of indebtedness and the making of investments, the payment of cash in respect of dividends, distributions or redemptions, the transfer of assets, the maturity of other indebtedness, and transactions with affiliates, among other customary matters. We also are subject to financial covenants requiring that (i) the amount of our available cash equal or exceed $8.0 million at all times, (ii) the ratio of (a) the outstanding principal amount of the notes issued under the SPA, accrued and unpaid interest thereon and accrued and unpaid late charges to (b) our average market capitalization over the prior ten trading days, not exceed 30% (the â€œDebt to Market Cap Ratio Testâ€), and (iii) that our market capitalization shall at no time be less than $75 million (the â€œMarket Cap Testâ€ and, together with the Debt to Market Cap Ratio Test, the â€œFinancial Testsâ€). From time to time from and after September 1, 2024 through November 11, 2024, the Company was not in compliance with the Financial Tests. As of November 11, 2024, the investor agreed to waive any such non-compliance during such time period and thereafter through December 31, 2024. Based on the waiver, as of September 30, 2024, the Company was in compliance with the Financial Tests. In addition, based on the waiver, the Company presently is in compliance with the Financial Tests. Â 40 Â Â Liquidity and Capital Resources - continued Â See Note 11, Debt, to the Financial Statements for additional information about the SPA, the April 2022 Senior Convertible Note, and the September 2022 Senior Convertible Note. Â Lucid Diagnostics - Preferred Stock Offerings Â On March 13, 2024, Lucid entered into Lucid Series B Subscription Agreements and Lucid Series B Exchange Agreements with the Lucid Series B Investors, which agreements provided for (i) the sale to the Lucid Series B Investors of 12,495 shares of newly designated Lucid Series B Preferred Stock, at a purchase price of $1,000 per share, and (ii) the exchange by the Lucid Series B Investors of 13,625 shares of Lucid Series A Preferred Stock, and 10,670 shares of Lucid Series A-1 Preferred Stock held by them for 31,790 shares of Lucid Series B Preferred Stock. Prior to the execution of the Lucid Series B Subscription Agreements and the Lucid Series B Exchange Agreements, Lucid entered into subscription agreements with certain of the Lucid Series B Investors providing for the sale to such investors of 5,670 shares of Lucid Series A-1 Preferred Stock, at a purchase price of $1,000 per share, which shares the investors immediately agreed to exchange for shares of Lucid Series B Preferred Stock pursuant to the Lucid Series B Exchange Agreements (and are included in the 10,670 shares of Lucid Series A-1 Preferred Stock set forth above). Each share of the Lucid Series B Preferred Stock has a stated value of $1,000 and a conversion price of $1.2444. The terms of the Lucid Series B Preferred Stock also include a one times preference on liquidation and a right to receive dividends equal to 20% of the number of shares of Lucid common stock into which such Lucid Series B Preferred Stock is convertible, payable on the one-year and two-year anniversary of the issuance date. The holders of the Lucid Series B Preferred Stock also will be entitled to dividends equal, on an as-if-converted to shares of Lucid common stock basis, to and in the same form as dividends actually paid on shares of the Lucid common stock when, as, and if such dividends are paid on shares of the Lucid common stock. The Lucid Series B Preferred Stock is a voting security. The aggregate gross proceeds to Lucid of these transactions was $18.16 million (inclusive of $5.67 million of aggregate gross proceeds from the sale of the Lucid Series A-1 Preferred Stock that was immediately exchanged for Lucid Series B Preferred Stock in the transactions). Â As a result of 100% of the then-outstanding shares of Lucid Series A Preferred Stock and Lucid Series A-1 Preferred Stock being exchanged for shares of Lucid Series B Preferred Stock in the Lucid Series B Offering and Exchange, no shares of Lucid Series A Preferred Stock or Lucid Series A-1 Preferred Stock remain outstanding. Â On May 6, 2024, Lucid issued approximately 11,634 shares of newly designated Lucid Series B-1 Preferred Stock. The terms of the Lucid Series B-1 Preferred Stock are substantially identical to the terms of the Lucid Series B Preferred Stock, except that the Lucid Series B-1 Preferred Stock has a conversion price of $0.7228. The aggregate gross proceeds from the sale of shares in such offering were $11.6 million. Â Lucid Diagnostics - Securities Purchase Agreement - March 13, 2023 - Senior Secured Convertible Note - March 21, 2023 Â Effective as of March 13, 2023, Lucid Diagnostics entered into a Securities Purchase Agreement (the â€œLucid SPAâ€) with an accredited institutional investor, pursuant to which Lucid Diagnostics agreed to sell, and the investor agreed to purchase a Senior Convertible Note (the â€œLucid March 2023 Senior Convertible Noteâ€) with a face value principal of $11.1 million. Lucid Diagnostics issued the Lucid March 2023 Senior Convertible Note on March 21, 2023 pursuant to the Lucid SPA. Â Under the Lucid March 2023 Senior Convertible Note, Lucid Diagnostics is subject to certain customary affirmative and negative covenants regarding the incurrence of indebtedness, the existence of liens, the repayment of indebtedness and the making of investments, the payment of cash in respect of dividends, distributions or redemptions, the transfer of assets, the maturity of other indebtedness, and transactions with affiliates, among other customary matters. Under the Lucid March 2023 Senior Convertible Note, Lucid Diagnostics is also subject to financial covenants requiring that (i) the amount of its available cash equal or exceed $5.0 million at all times, (ii) the ratio of (a) the outstanding principal amount of the notes issued under the Lucid SPA, accrued and unpaid interest thereon and accrued and unpaid late charges, as of the last day of any fiscal quarter commencing with September 30, 2023, to (b) Lucid Diagnosticsâ€™ average market capitalization over the prior ten trading days, not exceed 30%, and (iii) that Lucid Diagnosticsâ€™ market capitalization shall at no time be less than $30 million (the â€œLucid Financial Testsâ€). As of September 30, 2024, Lucid Diagnostics was in compliance with the Lucid Financial Tests. In addition, Lucid Diagnostics presently is in compliance with the Lucid Financial Tests. Â Liquidity and Capital Resources - continued Â On November 8, 2024, Lucid gave notice to the holder of the March 2023 Senior Convertible Note that it was exercising its right pursuant to such note to redeem the same for the Optional Redemption Price specified in such note. To finance the payment of the Optional Redemption Price, Lucid has entered into a securities purchase agreement

with the 2024 Note Investors. Under the agreement, subject to customary closing conditions, Lucid has agreed to issue, and each 2024 Note Investor has agreed to purchase he November 2024 Senior Convertible Notes, which are 12.0% senior secured convertible notes due 2029. As of the date hereof, the aggregate commitments of the 2024 Note Investors exceed the Lucid Optional Redemption Price. Â PAVmed Inc. ATM Facility Â In December 2021, we entered into an â€œat-the-market offeringâ€ for up to $50 million of our common stock that may be offered and sold under a Controlled Equity Offering Agreement between us and Cantor. In the nine months ended September 30, 2024, the Company sold 627,302 shares through its at-the-market equity facility for net proceeds of approximately $1.0 million, after payment of 3% commissions. Â 41 Â Â Liquidity and Capital Resources - continued Â Lucid Diagnostics Inc. - Committed Equity Facility and ATM Facility Â In March 2022, Lucid Diagnostics entered into a committed equity facility with a Cantor affiliate. Cumulatively, a total of 680,263 shares of Lucid Diagnosticsâ€™ common stock were issued for net proceeds of approximately $1.8 million, after a 4% discount, as of September 30, 2024. Â In November 2022, Lucid Diagnostics also entered into an â€œat-the-market offeringâ€ for up to $6.5 million of its common stock that may be offered and sold under a Controlled Equity Offering Agreement between Lucid Diagnostics and Cantor. Cumulatively, a total of 230,068 shares of Lucid Diagnosticsâ€™ common stock were issued through its at-the-market equity facility for net proceeds of approximately $0.3 million, after payment of 3% commissions, as of September 30, 2024. Â Critical Accounting Estimates Â The discussion and analysis of our financial condition and results of operations is based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States of America (â€œU.S. GAAPâ€). The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and assumptions that affect the amounts reporting in our unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgements. In accordance with U.S. GAAP, we base our estimates on historical experience and on various other factors that are believed to be appropriate under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. Our critical accounting policies are as disclosed in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the SEC on March 25, 2024. There have been no material changes to our critical accounting policies and estimates in the nine months ended September 30, 2024. Â Item 4. Controls and Procedures Â Evaluation of Disclosure Controls and Procedures Â Our management, with the participation of our principal executive officer and our principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2024. Based on such evaluation, our principal executive officer and principal financial officer concluded our disclosure controls and procedures (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) were effective as of such date to provide reasonable assurance the information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SECâ€™s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Â Changes to Internal Controls Over Financial Reporting Â There has been no change in internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during our fiscal quarter ended September 30, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Â 42 Â Â Part II - Other Information Â Item 1. Legal Proceedings Â In the ordinary course of PAVmed business, particularly as it begins commercialization of its products, the Company may be subject to legal actions and claims, including product liability, consumer, commercial, tax and governmental matters, which may arise from time to time. The Company is not aware of any such pending legal or other proceedings that are reasonably likely to have a material impact on the Company. Notwithstanding, legal proceedings are subject to inherent uncertainties, and an unfavorable outcome could include monetary damages, and excessive verdicts can result from litigation, and as such, could result in a material adverse impact on the Companyâ€™s business, financial position, results of operations, and /or cash flows. Additionally, although the Company has specific insurance for certain potential risks, the Company may in the future incur judgments or enter into settlements of claims which may have a material adverse impact on the Companyâ€™s business, financial position, results of operations, and /or cash flows. Â Item 2. Unregistered Sales of Equity Securities and Use of Proceeds Â Except as previously disclosed in our current reports on Form 8-K filed prior to the date of this Form 10-Q and in Note 13, Preferred Stock, to our accompanying unaudited condensed consolidated financial statements, we did not sell any unregistered securities or repurchase any of our securities during the three months ended September 30, 2024. The offers and sales disclosed in Note 13, Preferred Stock, to our accompanying unaudited condensed consolidated financial statements were exempt from the registration requirements of the Securities Act of 1933, as amended (the â€œSecurities Actâ€), pursuant to Section 4(a)(2) of the Securities Act, as transactions not involving public offerings. Â See Part I, Item 2 under the caption â€œLiquidity and Capital Resourcesâ€ for a description of limitations on the payment of dividends. Â Item 3. Defaults Upon Senior Securities Â The information set forth in Part I, Item 2 under the caption â€œLiquidity and Capital Resources â€” Securities Purchase Agreement - March 31, 2022 - Senior Secured Convertible Notes - April 4, 2022 and September 8, 2022â€ is incorporated herein by reference. Â Item 5. Other Information Â During the fiscal quarter ended September 30, 2024, none of our directors or officers (as defined in Rule 16a-1 under the Exchange Act) adopted or terminated a â€œRule 10b5-1 trading arrangementâ€ or â€œnon-Rule 10b5-1 trading arrangementâ€ (as those terms are defined in Item 408 of Regulation S-K). Â The information set forth in Part I, Item 2 in the first paragraph under the caption â€œRecent Developments â€” Management Services Agreement/Payroll Benefits and Expense Reimbursement Agreement with Lucid Diagnosticsâ€ is incorporated herein by reference. Â Item 6. Exhibits Â The exhibits filed as part of this Quarterly Report on Form 10-Q are set forth in the â€œExhibit Indexâ€ below. Â 43 Â Â SIGNATURES Â Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Â Â PAVmed Inc. Â Â Â November 13, 2024 By:Â /s/ Dennis M McGrath Â Â Dennis M McGrath Â Â President and Chief Financial Officer Â Â (Principal Financial and Accounting Officer) Â Â 44 Â Â EXHIBIT INDEX Â Exhibit Â Â Â Incorporation by Reference No. Â Description Â Form Â Exhibit No. Â Date 10.1 Â Ninth Amendment to Management Services Agreement, dated as of August 6, 2024, by and between PAVmed Inc. and Lucid Diagnostics Inc. Â 10-Q (Lucid) Â 10.2 Â 8/12/2024 31.1 Â Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Â * Â Â Â Â 31.2 Â Certification of Principal Financial and Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Â * Â Â Â Â 32.1 Â Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Â * Â Â Â Â 32.2 Â Certification of Principal Financial and Accounting Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Â * Â Â Â Â Â Â Â Â Â Â Â Â 101.INS Â Inline XBRL Instance Document Â * Â Â Â Â 101.CAL Â Inline XBRL Taxonomy Extension Schema Â * Â Â Â Â 101.DEF Â Inline XBRL Taxonomy Extension Calculation Linkbase Â * Â Â Â Â 101.LAB Â Inline XBRL Taxonomy Extension Label Linkbase Â * Â Â Â Â 101.PRE Â Inline XBRL Taxonomy Extension Presentation Linkbase Â * Â Â Â Â 104 Â Cover Page Interactive Data File (embedded within the Inline XBRL document) Â * Â Â Â Â 45 Â EX-31.1 2 ex31-1.htm Â Exhibit 31.1 Â CERTIFICATION BY PRINCIPAL EXECUTIVE OFFICER Â I, Lishan Aklog, M.D., certify that: Â 1 I have reviewed this Quarterly Report on Form 10-Q of PAVmed Inc. and Subsidiaries; Â Â 2 Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â Â 3 Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â Â 4 The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â Â a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â Â Â Â b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â Â Â Â c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â Â Â Â d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â 5 The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â Â a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â Â Â Â b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: November 13, 2024 By:Â /s/ Lishan Aklog, M.D. Â Â Lishan Aklog, M.D., Chief Executive Officer (Principal Executive Officer) Â Â Â EX-31.2 3 ex31-2.htm Â Exhibit 31.2 Â CERTIFICATION BY PRINCIPAL FINANCIAL OFFICER Â I, Dennis M. McGrath, certify that: Â 1 I have reviewed this Quarterly Report on Form 10-Q of PAVmed Inc. and Subsidiaries; Â Â 2 Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â Â 3 Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â Â 4 The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â Â a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â Â Â Â b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â Â Â Â c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â Â Â Â d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â 5 The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â Â a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â Â Â Â b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: November 13, 2024 By:Â /s/ Dennis M. McGrath Â Â Dennis M. McGrath President & Chief Financial Officer (Principal Financial and Accounting Officer) Â Â Â EX-32.1 4 ex32-1.htm Â Exhibit 32.1 Â CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â In connection with the Quarterly Report on Form 10-Q of PAVmed Inc. and Subsidiaries (the â€œCompanyâ€) for the quarter ended September 30, 2024 as filed with the Securities and Exchange Commission on the date hereofâ€‰(the â€œReportâ€), the undersigned, Lishan Aklog, M.D., Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that to his knowledge: Â (1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and Â Â (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Â Date: November 13, 2024 By:Â /s/ Lishan Aklog, M.D. Â Â Lishan Aklog, M.D. Chief Executive Officer (Principal Executive Officer) Â Â Â EX-32.2 5 ex32-2.htm Â Exhibit 32.2 Â CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â In connection with the Quarterly Report on Form 10-Q of PAVmed Inc. and Subsidiaries (the â€œCompanyâ€) for the quarter ended September 30, 2024 as filed with the Securities and Exchange Commission on the date hereofâ€‰(the â€œReportâ€), the undersigned, Dennis M. McGrath, President & Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that to his knowledge: Â (1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and Â Â (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Â Date: November 13, 2024 By:Â /s/ Dennis M. McGrath Â Â Dennis M. McGrath President & Chief Financial Officer (Principal Financial and Accounting Officer) Â Â Â EX-101.SCH 6 pavm-20240930.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Equity (Deficit) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 995612 - Disclosure - The Company link:presentationLink link:calculationLink link:definitionLink 995613 - Disclosure - Liquidity and Going Concern link:presentationLink link:calculationLink link:definitionLink 995614 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Equity Method Investment link:presentationLink link:calculationLink link:definitionLink 995616 - Disclosure - Revenue from Contracts with Customers link:presentationLink link:calculationLink link:definitionLink 995617 - Disclosure - Prepaid Expenses, Deposits, and Other Current Assets link:presentationLink link:calculationLink link:definitionLink 995618 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 995619 - Disclosure - Intangible Assets, net link:presentationLink link:calculationLink link:definitionLink 995620 - Disclosure - Commitment and Contingencies link:presentationLink link:calculationLink link:definitionLink 995621 - Disclosure - Financial Instruments Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995622 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 995623 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 995624 - Disclosure - Preferred Stock link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Common Stock and Common Stock Purchase Warrants link:presentationLink link:calculationLink link:definitionLink 995626 - Disclosure - Noncontrolling Interest link:presentationLink link:calculationLink link:definitionLink 995627 - Disclosure - Net Income (Loss) Per Share link:presentationLink link:calculationLink link:definitionLink 995628 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995629 - Disclosure - Equity Method Investment (Tables) link:presentationLink link:calculationLink link:definitionLink 995630 - Disclosure - Prepaid Expenses, Deposits, and Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 995631 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 995632 - Disclosure - Intangible Assets, net (Tables) link:presentationLink link:calculationLink link:definitionLink 995633 - Disclosure - Financial Instruments Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 995634 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 995636 - Disclosure - Noncontrolling Interest (Tables) link:presentationLink link:calculationLink link:definitionLink 995637 - Disclosure - Net Income (Loss) Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 995638 - Disclosure - Liquidity and Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995639 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995640 - Disclosure - Schedule of

Deconsolidation of Net Assets (Details) link:presentationLink link:calculationLink link:definitionLink 995641 - Disclosure - Schedule of Gain on Deconsolidation (Details) link:presentationLink link:calculationLink link:definitionLink 995642 - Disclosure - Schedule of Aggregate Information From the Financial Statements (Details) link:presentationLink link:calculationLink link:definitionLink 995643 - Disclosure - Equity Method Investment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995644 - Disclosure - Revenue from Contracts with Customers (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Schedule of Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 995646 - Disclosure - Schedule of Future Minimum Lease Payments for Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 995647 - Disclosure - Schedule of Supplemental Balance Sheet Information Related to Cash and Non-cash Activities with Leases (Details) link:presentationLink link:calculationLink link:definitionLink 995648 - Disclosure - Leases (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995649 - Disclosure - Schedule of Intangible Assets, Less Accumulated Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 995650 - Disclosure - Intangible Assets, net (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995651 - Disclosure - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 995652 - Disclosure - Schedule of Fair Value Assumption Used (Details) link:presentationLink link:calculationLink link:definitionLink 995653 - Disclosure - Financial Instruments Fair Value Measurements (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995654 - Disclosure - Summary of Outstanding Debt (Details) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Schedule of Changes in Fair Value of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 995656 - Disclosure - Debt (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995657 - Disclosure - Schedule of Summarizes Information About Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 995658 - Disclosure - Schedule of Summarizes Information About Stock Options (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995659 - Disclosure - Schedule of Restricted Stock Award Activity (Details) link:presentationLink link:calculationLink link:definitionLink 995660 - Disclosure - Schedule of Stock-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 995661 - Disclosure - Schedule of Stock-Based Compensation Expense Recognized by Lucid Diagnostics (Details) link:presentationLink link:calculationLink link:definitionLink 995662 - Disclosure - Schedule of Unrecognized Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 995663 - Disclosure - Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 995664 - Disclosure - Stock-Based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Preferred Stock (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995666 - Disclosure - Common Stock and Common Stock Purchase Warrants (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995667 - Disclosure - Schedule of Noncontrolling Interest of Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 995668 - Disclosure - Schedule of Net Loss Attributable to Common Stockholders (Details) link:presentationLink link:calculationLink link:definitionLink 995669 - Disclosure - Schedule of Net Loss Attributable to Common Stockholders (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995670 - Disclosure - Noncontrolling Interest (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995671 - Disclosure - Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 995672 - Disclosure - Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 995673 - Disclosure - Net Income (Loss) Per Share (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 pavm-20240930_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 pavm-20240930_def.xml XBRL DEFINITION FILE EX-101.LAB 9 pavm-20240930_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Stock, $0.001 par value per share [Member] Series Z Warrants, each to purchase 1/15th of one share of Common Stock [Member] Series B Convertible Preferred Stock [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Treasury Stock, Common [Member] Noncontrolling Interest [Member] Pledging Purpose [Axis] Letter of Credit [Member] Ownership [Axis] Lucid Diagnostics Inc [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Consolidated Entities [Axis] Business Acquisition [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Management Services Agreement [Member] Title and Position [Axis] Board of Directors Chairman [Member] Finite-Lived Intangible Assets by Major Class [Axis] Intellectual Property [Member] Award Date [Axis] July 1, 2024 - September 10, 2024 [Member] September 11, 2024 - September 30, 2024 [Member] January 1, 2024 - September 10, 2024 [Member] Asset Class [Axis] Defensive Asset [Member] Laboratory Information Management Software [Member] Other Infinite Lived Intangible Asset [Member] Debt Instrument [Axis] Lucid Common Stock [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] April 2022 Senior Convertible Note [Member] September 2022 Senior Convertible Note [Member] Lucid March 2023 Senior Convertible Note [Member] Measurement Input Type [Axis] Measurement Input Required Rate of Return [Member] Measurement Input, Conversion Price [Member] Measurement Input, Share Price [Member] Measurement Input, Expected Term [Member] Measurement Input, Price Volatility [Member] Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Expected Dividend Rate [Member] Other Income Expense [Member] Securities Purchase Agreement [Member] Accredited Institutional Investor [Member] Award Type [Axis] Initial Issuance [Member] Additional Issuance [Member] April 2022 Senior Convertible Note and September 2022 Senior Convertible Note [Member] June 30, 2024 Through September 03, 2024 [Member] Cash and Cash Equivalents [Axis] Cash [Member] Investor [Member] Derivative Instrument [Axis] Interest Rate Floor [Member] Plan Name [Axis] 2014 Equity Plan [Member] Parent Company [Member] Restricted Stock [Member] Legal Entity [Axis] 2018 Equity Plan [Member] Employee Stock Purchase Plan [Member] Restricted Stock Units (RSUs) [Member] Statement of Income Location, Balance [Axis] Cost Of Revenue [Member] Selling and Marketing Expense [Member] General and Administrative Expense [Member] Research and Development Expense [Member] Lucid Diagnostics 2018 Equity Plan [Member] PAVmed Inc 2014 Equity Plan [Member] Equity Option [Member] Board Of Directors [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Vendors [Member] Class of Warrant or Right [Axis] Series Z Warrants [Member] Series A Convertible Preferred Stock [Member] Series A-1 Preferred Stock [Member] Lucid Series A and Lucid Series A-1 Preferred Stock [Member] Series B 1 Preferred Stock [Member] Antidilutive Securities [Axis] Stock Options [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Listing, Par Value Per Share Statement of Financial Position [Abstract] Assets: Current assets: Cash Accounts receivable Inventory Prepaid expenses, deposits, and other current assets Total current assets Fixed assets, net Operating lease right-of-use assets Intangible assets, net Equity method investment - at fair value Other assets Total assets Liabilities, Preferred Stock and Stockholdersâ€™ Equity Current liabilities: Accounts payable Accrued expenses and other current liabilities Operating lease liabilities, current portion Senior Secured Convertible Notes - at fair value Total current liabilities Operating lease liabilities, less current portion Total liabilities Commitments and contingencies (Note 9) Stockholdersâ€™ Equity: Preferred stock, $0.001 par value. Authorized, 20,000,000 shares; Series B Convertible Preferred Stock, par value $0.001, issued and outstanding 1,385,149 at September 30, 2024 and 1,305,213 shares at December 31, 2023 Common stock, $0.001 par value. Authorized, 50,000,000 shares; 10,660,394 and 8,578,505 shares outstanding as of September 30, 2024 and December 31, 2023, respectively Additional paid-in capital Accumulated deficit Total PAVmed Inc. Stockholdersâ€™ Equity (Deficit) Noncontrolling interests Total Stockholdersâ€™ Equity (Deficit) Total Liabilities and Stockholdersâ€™ Equity (Deficit) Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares outstanding Income Statement [Abstract] Revenue Operating expenses: Cost of revenue Sales and marketing General and administrative Amortization of acquired intangible assets Research and development Total operating expenses Operating loss Other income (expense): Interest income Interest expense Gain on deconsolidation of subsidiary Change in fair value - equity method investment Change in fair value - Senior Secured Convertible Notes Loss on issue and offering costs - Senior Secured Convertible Note Debt extinguishments loss - Senior Secured Convertible Notes Debt modification expense Change in fair value - derivative liability Management fee income Gain on sale of intellectual property Other income (expense), net Income (loss) before provision for income tax Provision for income taxes Net income (loss) before noncontrolling interests Net loss attributable to the noncontrolling interests Net income (loss) attributable to PAVmed Inc. Less: Series B Convertible Preferred Stock dividends earned Less: Deemed dividend on Subsidiary Preferred Stock attributable to the noncontrolling interests Net income (loss) attributable to PAVmed Inc. common stockholders Per share information: Net income (loss) per share attributable to PAVmed Inc. common stockholders â€“ basic Net income (loss) per share attributable to PAVmed Inc. common stockholders â€“ diluted Weighted average common shares outstanding, basic Weighted average common shares outstanding, diluted Balance Balance, shares Dividends declared - Series B Convertible Preferred Stock Dividends declared - Series B Convertible Preferred Stock, shares Issue common stock - PAVM ATM Facility Issue common stock - PAVM ATM Facility, shares Vest - restricted stock awards Vest - restricted stock awards, shares Conversions - Senior Secured Convertible Note Conversions - Senior Secured Convertible Note, shares Conversions - subsidiary common stock - Senior Secured Convertible Note Impact of subsidiary equity transactions Issuance - vendor service agreement Issuance - vendor service agreement, shares Stock-based compensation - PAVmed Inc. Stock-based compensation - subsidiary Transfer of intellectual property to Lucid Diagnostics Inc Deconsolidation of subsidiary Net Loss Exercise - stock options of subsidiary Purchase - Employee Stock Purchase Plan Purchase - Employee Stock Purchase Plan, shares Purchase - subsidiary common stock - Employee Stock Purchase Plan Issuance - subsidiary preferred stock (Series A-1) Exchange - subsidiary preferred stock (Series A and Series A-1) Issuance through exchange - subsidiary preferred stock (Series B and Series B-1) Issuance through sale - subsidiary preferred stock (Series B and Series B-1) Subsidiary deemed dividends on preferred stock attributable to noncontrolling interests Stock-based compensation - subsidiaries Purchase - majority-owned subsidiary common stock - Employee Stock Purchase Plan Issuance - subsidiary common stock - Committed Equity Facility, net of financing charges Issuance - subsidiary common stock - Settlement APA-RDx - Installment Payment Issuance - subsidiary preferred stock (Series A) Treasury stock Treasury stock, shares Balance Balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities Net income (loss) - before noncontrolling interest (â€œNCIâ€) Adjustments to reconcile net income (loss) - before NCI to net cash used in operating activities Depreciation and amortization expense Stock-based compensation Gain on sale of intellectual property Gain on deconsolidation of subsidiary Change in fair value - equity method investment APA-RDx: Issue common stock of subsidiary - termination payment Amortization of common stock payment for vendor service agreement Change in fair value - Senior Secured Convertible Notes Loss on issue - Senior Secured Convertible Note Debt extinguishment loss - Senior Secured Convertible Note Change in fair value - derivative liability Non-cash lease expense Changes in operating assets and liabilities: Accounts receivable Prepaid expenses, deposits and current and other assets Accounts payable Accrued expenses and other current liabilities Net cash flows used in operating activities Cash flows from investing activities Purchase of equipment Decrease in cash due to deconsolidation of subsidiary Proceeds from sale of intellectual property to Lucid Diagnostics Inc. Proceeds from sale of intellectual property Net cash flows provided by (used in) investing activities Cash flows from financing activities Proceeds â€“ issue of preferred stock - subsidiary Proceeds â€“ issue of Senior Secured Convertible Note Payment â€“ Senior Secured Convertible Note â€“ acceleration floor payments Proceeds â€“ issue of common stock - At-The-Market Facility Proceeds â€“ subsidiary common stock - Committed Equity Facility and At-The-Market Facility Proceeds â€“ issue common stock â€“ Employee Stock Purchase Plan Proceeds â€“ subsidiary common stock â€“ Employee Stock Purchase Plan Proceeds â€“ exercise of stock options issued under equity plan of subsidiary Net cash flows provided by financing activities Net increase (decrease) in cash Cash, beginning of period Cash, end of period Pay vs Performance Disclosure [Table] Executive Category [Axis] Individual [Axis] Adjustment to Compensation [Axis] Measure [Axis] Pay vs Performance Disclosure, Table Company Selected Measure Name Named Executive Officers, Footnote Peer Group Issuers, Footnote Changed Peer Group, Footnote PEO Total Compensation Amount PEO Actually Paid Compensation Amount Adjustment To PEO Compensation, Footnote Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Compensation Actually Paid Amount Adjustment to Non-PEO NEO Compensation Footnote Equity Valuation Assumption Difference, Footnote Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Company Selected Measure Total Shareholder Return Vs Peer Group Compensation Actually Paid vs. Other Measure Tabular List, Table Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Net Income (Loss) Company Selected Measure Amount Other Performance Measure, Amount Adjustment to Compensation, Amount PEO Name Name Non-GAAP Measure Description Additional 402(v) Disclosure Pension Benefits Adjustments, Footnote Erroneously Awarded Compensation Recovery [Table] Restatement Determination Date [Axis] Restatement Determination Date Aggregate Erroneous Compensation Amount Erroneous Compensation Analysis Stock Price or TSR Estimation Method Outstanding Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Not Yet Determined Name Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery, Explanation of Impracticability Name Compensation Amount Restatement does not require Recovery Awards Close in Time to MNPI Disclosures [Table] Award Timing MNPI Disclosure Award Timing Method Award Timing Predetermined Award Timing MNPI Considered Award Timing, How MNPI Considered MNPI Disclosure Timed for Compensation Value Awards Close in Time to MNPI Disclosures, Table Name Underlying Securities Exercise Price Fair Value as of Grant Date Underlying Security Market Price Change Insider Trading Arrangements [Line Items] Material Terms of Trading Arrangement Name Title Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted Adoption Date Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated Termination Date Expiration Date Arrangement Duration Insider Trading Policies and Procedures [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Not Adopted Organization, Consolidation and Presentation of Financial Statements [Abstract] The Company Liquidity and Going Concern Accounting Policies [Abstract] Summary of Significant Accounting Policies Equity Method Investments and Joint Ventures [Abstract] Equity Method Investment Revenue from Contract with Customer [Abstract] Revenue from Contracts with Customers Prepaid Expenses Deposits And Other Current Assets Prepaid Expenses, Deposits, and Other Current Assets Leases Leases Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets, net Commitments and Contingencies Disclosure [Abstract] Commitment and Contingencies Fair Value Disclosures [Abstract] Financial Instruments Fair Value Measurements Debt Disclosure [Abstract] Debt Retirement Benefits [Abstract] Stock-Based Compensation Equity [Abstract] Preferred Stock Common Stock and Common Stock Purchase Warrants Noncontrolling Interest [Abstract] Noncontrolling Interest Earnings Per Share [Abstract] Net Income (Loss) Per Share Basis of Presentation Cash Use of Estimates Revenue Recognition Equity Method Investments Fair Value Option (â€œFVOâ€) Election Recent Accounting Standards Updates Not Yet Adopted Schedule of Deconsolidation of Net Assets Schedule of Gain on Deconsolidation Schedule of Aggregate Information From the Financial Statements Schedule of Prepaid Expenses and Other Current Assets Schedule of Future Minimum Lease Payments for Operating Leases Schedule of Supplemental Balance Sheet Information Related to Cash and Non-cash Activities with Leases Schedule of Intangible Assets, Less Accumulated Amortization Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis Schedule of Fair Value Assumption Used Summary of Outstanding Debt Schedule of Changes in Fair Value of Debt Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Schedule of Summarizes Information About Stock Options Schedule of Restricted Stock Award Activity Schedule of Stock-Based Compensation Expense Schedule of Stock-Based Compensation Expense Recognized by Lucid Diagnostics Schedule of Unrecognized Compensation Expense Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions Schedule of Noncontrolling Interest of Stockholders' Equity Schedule of Net Loss Attributable to Common Stockholders Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share Schedule of

Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share Revenues Net loss attributable to common stockholders Net cash flows used in operating activities Working capital Current liabilities Cash Variable Interest Entity [Table] Variable Interest Entity [Line Items] Cash Equity method investment, ownership percentage Liabilities: Net Assets of Lucid Diagnostics at September 10, 2024 Investment in former Consolidated Subsidiary (Fair Value of Lucid common stock) Add: Noncontrolling interest - Lucid Less: Net Assets of Former Consolidated Subsidiary - Lucid Gain on Deconsolidation of Lucid Other current assets Non-current assets Total assets Current liabilities Non-current liabilities Shareholdersâ€™ deficit Total liabilities and stockholdersâ€™ deficit Net income (loss) Ownership shares issues Ownership shares value Gain on deconsolidation Fair value of the companys investment Unrealized gain loss on investments The fair value of common price per shares The fair value of common price per shares Fee income Increase in fee income Assignment fee Schedule Of Prepaid Expenses And Other Current Assets Advanced payments to service providers and suppliers Prepaid insurance Deposits Veris Box supplies Total prepaid expenses, deposits and other current assets Schedule Of Future Minimum Lease Payments For Operating Leases 2024 (remainder of year) 2025 2026 2027 2028 Thereafter Total lease payments Less: imputed interest Present value of lease liabilities Schedule Of Supplemental Balance Sheet Information Related To Cash And Non-cash Activities With Leases Operating cash flows from operating leases Right-of-use assets obtained in exchange for new operating lease liabilities Weighted-average remaining lease term - operating leases (in years) Weighted-average discount rate - operating leases Operating lease, right-of-use assets Operating lease obligations Operating lease, liability, current Operating lease liability noncurrent Impairment Effects on Earnings Per Share [Table] Impairment Effects on Earnings Per Share [Line Items] Total Intangible assets Finite lived intangible asset, useful life Less Accumulated Amortization Intangible Assets, net Amortization of intangible assets Intangible assets net Estimated future amortization expense Fair Value, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Total assets at fair value Total liabilities at fair value Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Debt instrument fair value Face value principal payable Fair value assumption measurement input Expected term years Short-Term Debt [Table] Short-Term Debt [Line Items] Maturity Date Stated Interest Rate Conversion Price Face Value Principal Outstanding Fair Value Fair Value - Beginning of Period Face value principal â€“ issue date Fair value adjustment â€“ issue date Installment repayments â€“ common stock Non-installment payments â€“ common stock Deconsolidation of Lucid Diagnostics Change in fair value Fair Value - Ending of Period Other Income (Expense) - Change in fair value Principal amouint Debt interest rate Conversion price Debt instrument maturity date, description Debt instrument maturity date, description Senior convertible note Debt instrument, description Notes payable Conversion price per share Repayment for debt Interest expense Gain (loss) on extinguishment of debt Acceleration floor payments Debt Instrument, Periodic Payment, Interest Debt extinguishment losses Number of Stock Options Outstanding, Beginning Balance Weighted Average Exercise Price, Beginning Balance Remaining Contractual Term (Years), Ending Balance Intrinsic Value Outstanding, Beginning Balance Number of Stock Options, Granted Weighted Average Exercise Price, Granted Number of Stock Option, Exercised Weighted Average Exercise Price, Exercised Number of Stock Option, Forfeited Weighted Average Exercise Price, Forfeited Number of Stock Options Outstanding, Ending Balance Weighted Average Exercise Price, Ending Balance Intrinsic Value Outstanding, Ending Balance Number of Stock Options Vested and exercisable stock options Weighted Average Exercise Price, Vested and exercisable stock options Remaining Contractual Term (Years), Vested and exercisable stock options Intrinsic Value Exercisable, Ending Balance Number of stock options granted. shares Number of Restricted Stock Awards, Unvested restricted stock awards, Beginning balance Weighted Average Grant Date Fair Value, Unvested restricted stock awards, Beginning balance Number of Restricted Stock Awards, Granted Weighted Average Grant Date Fair Value, Granted Number of Restricted Stock Awards, Vested Weighted Average Grant Date Fair Value, Vested Number of Restricted Stock Awards, Forfeited Weighted Average Grant Date Fair Value, Forfeited Number of Restricted Stock Awards, Unvested restricted stock awards, Ending balance Weighted Average Grant Date Fair Value, Unvested restricted stock awards, Ending balance Total stock-based compensation expense Unrecognized Expense Weighted Average Remaining Service Period Expected term of stock options (in years) Expected stock price volatility Risk free interest rate Expected dividend yield Common stock capital shares reserved for future issuance Increase in available for grant Number of stock options outstanding Granted Weighted average exercise price Aggregate fair value Weighted average fair value of stock options Number of common stock purchased Proceeds from common stock Treasury stock Increase in reserve stock Stock, Class of Stock [Table] Class of Stock [Line Items] Preferred stock shares outstanding Preferred stock stated value per share Preferred stock stated value per share Dividend rate percentage Dividends earned Aggregate preferred stock dividends declared Aggregate preferred stock dividends earned Additioanal aggregate shares of convertible preferred stock Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Reverse stock split Stock Issused and outstanding description Debt instrument fee description Number of common stock issued Convertible common stock shares issued upon conversion Debt Instrument, Convertible, If-converted Value in Excess of Principal At-the-market equity facility, shares At-the-market equity facility, value Payments for commissions percentage Number of shares issued Issued for services Common stock, dividends shares Warrant price decrease Share price Exercise price Class of Warrant or Right, Outstanding Purchase of warrants Exercise price, post reverse-split NCI â€“ equity - December 31, 2023 Net loss attributable to NCI Impact of subsidiary equity transactions Lucid Diagnostics proceeds from issuance of preferred stock Series A-1 Lucid Diagnostics exchange of preferred stock Series A and Series A-1 Lucid Diagnostics issuance through exchange - Series B and Series B-1 Lucid Diagnostics issuance through sale - Series B and Series B-1 Lucid Diagnostics deemed dividend on preferred stock Lucid Diagnostics issuance of common stock for settlement of vendor service agreement Lucid Diagnostics 2018 Equity Plan stock option exercise Lucid Diagnostics Employee Stock Purchase Plan Purchase Conversion of Lucid Diagnostics common stock for Senior Secured Convertible Debt Stock-based compensation expense - Lucid Diagnostics 2018 Equity Plan Stock-based compensation expense - Veris Health 2021 Equity Plan Deconsolidation of Lucid NCI â€“ equity - September 30, 2024 Fair Value - 31,790 shares of Lucid Series B Preferred Stock issued in exchange for Lucid Series A and Lucid Series A-1 Preferred Stock Less: Carrying value related to Lucid Series A and Lucid Series A-1 Preferred Stock Exchanged for Lucid Series B Preferred Stock (of 24,295 shares) Deemed Dividend Charged to Accumulated Deficit Fair value of the consideration shares Less carrying value related to series and series A1 preferred stock exchanged for series B preferred stock shares Noncontrolling Interest [Table] Noncontrolling Interest [Line Items] Common stock shares issued Common stock shares outstanding Partners capital account units acquisitions Partners capital account units description Received from payment of fees Number of shares issued Issuance of shares, stated value Preferred shares conversion price Dividend percentage Sale of stock, transaction value Gross proceeds Gross proceeds, sale of shares Outstanding shares, percentage Fair value of the consideration shares Carrying value Fair value of deemed dividend Net income (loss) - before noncontrolling interest Net income (loss) attributable to noncontrolling interest Net income (loss) - as reported, attributable to PAVmed Inc. Series B Convertible Preferred Stock dividends â€“ earned Deemed dividend on Subsidiary Preferred Stock attributable to the noncontrolling interests Net income (loss) attributable to PAVmed Inc. common stockholders used in basic EPS calculation Fair Value Adjustment for diluted EPS calculation Net income (loss) attributable to PAVmed Inc. common stockholders used in dilutive EPS calculation Net income (loss) per share attributable to PAVmed Inc. common stockholders, basic Net income (loss) per share attributable to PAVmed Inc. common stockholders, diluted Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total Series Z Warrants, each to Purchase 1/15th of One Share of Common Stock [Member] Common Stock, $0.001 par value per share [Member] Issue common stock installment settlement payment. Amortization of common stock payment for vendor service agreement. Loss on issue and offering costs senior secured convertible note. Proceeds subsidiary common stock - committed equity facility and at the market facility. Proceeds subsidiary common stock employee stock purchase plan Series B Convertible Preferred Stock [Member] Change in fair value senior secured convertible note. Loss on issue and offering cost senior secured convertible note. Debt modification expense. Deemed dividend on Subsidiary Preferred Stock attributable to the noncontrolling interests. Change in fair value derivative liability. Working capital. Management fee income. Decrease in cash due to deconsolidation of subsidiary. Stock issued during period, value, conversions subsidiary common stock senior secured convertible. Stock issued during the period of impact of subsidiary equity transactions. Adjustments to additional paid in capital deconsolidation of subsidiary. Exercise - stock options of subsidiary. Issuance -subsidiary preferred stock Series A-1. Issuance exchange - subsidiary preferred stock Series A and Series A one. Issuance - subsidiary preferred stock series B and series B-1. Stock issued during period, value, stock-based compensation - subsidiaries. Adjustments to additional paid in capital share based compensation subsidiary. Purchase majority owned subsidiary common stock employee stock purchase plan. Issuance subsidiary common stock - committed equity facility, net of financing charges. Stock issued during period, value,issuance -subsidiary common stock - settlement APA-RDx - installment payment. Issuance - majority-owned subsidiary preferred stock Series A. Fair Value Option Election [Policy Text Block] Recent Accounting Standards Updates Not Yet Adopted [Policy Text Block] Net assets. Equity Method Investments Aggregate Information [Table Text Block] Equity Method Investments Gain Deconsolidation [Table Text Block] July One Two Thousand Twenty Four To September Ten Two Thousand Twenty Four [Member] September Eleven Two Thousand Twenty Four To September Thirty Two Thousand Twenty Four [Member] January One Two Thousand Twenty Four To September Ten Two Thousand Twenty Four [Member] 2014 Equity Plan [Member] Management Services Agreement [Member] Prepaid Expenses Deposits And Other Assets [Text Block] Prepaid service providers and suppliers. Veris box supplies. Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Supplemental Balance Sheet Information Related to Cash and Non Cash Activities with Lease [Table Text Block] 2018 Equity Plan [Member] Defensive Asset [Member] Laboratory Information Management Software [Member] Other Infinite Lived Intangible Asset [Member] Lucid Diagnostics Inc [Member] April 2022 Senior Convertible Note [Member] Lucid Common Stock [Member] September 2022 Senior Convertible Note [Member] Preferred stock stated value per share. Lucid March 2023 Senior Convertible Note [Member] Measurement Input Required Rate of Return [Member] Schedule of Stockbased Compensation Expense Recognized [Table Text Block] PAVmed Inc 2014 Equity Plan [Member] Other Income Expense [Member] Debt instruments fair value. Other income expense change in fair value. Fair value adjustment issue date. Securities Purchase Agreement [Member] Accredited Institutional Investor [Member] Initial Issuance [Member] Additional Issuance [Member] April 2022 Senior Convertible Note and September 2022 Senior Convertible Note [Member] June 30, 2024 Through September 03, 2024 [Member] Employee Stock Purchase Plan [Member] Debt instrument onversion price per share. Stock issued during period shares increase in reserve Deconsolidation fair value of debt. Board Of Directors [Member] Stock issused and outstanding description. Convertible common stock shares issued upon conversion. At-the-market equity facility, shares. At-the-market equity facility, value. Payments for commissions percentage. Series Z Warrants [Member] Warrants and rights outstanding purchase. Class of warrant or right exercise price of warrants or rights. Schedule Of Noncontrolling Interest Of Stockholders Equity [Table Text Block] Impact of subsidiary equity transactions. Lucid diagnostics proceeds from issuance of preferred stock series A1. Lucid diagnostics exchange of preferred stock series and series A1. Lucid diagnostics deemed dividend on preferred stock. Minority interest equity plan stock option exercise. Adjustments to additional paid in capital minority interest requisite service period recognition value four. Issue common stock upon partial conversions of majority owned subsidiary common senior secured convertible note Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. Adjustments to additional paid in capital sharebased compensation requisite deconsolidation of lucid. Series A Convertible Preferred Stock [Member] Series A One Preferred Stock [Member] Outstanding shares percentage. Lucid Series A And Lucid Series A One Preferred Stock [Member] Series B 1 Preferred Stock [Member] Fair value preferred stock dividends, shares. Fair value of deemed dividend. Schedule Of Net Loss Attributable To Common Stockholders [Table Text Block] Fair value of series B preferred stock issued. Less carrying value related to series and series A1 preferred stock exchanged for series B preferred stock. Fair value of series B preferred stock issued shares. Less carrying value related to series and series A1 preferred stock exchanged for series B preferred stock shares. Convertible Preferred Stock dividends Series B. Deemed dividend on subsidiary preferred stock attributable to noncontrolling interests. Lucid Diagnostics Issuance of Common Stock for Settlement of Vendor Service Agreement [Member] Partners capital account units, description. Cost Of Revenue [Member] Schedule of Deconsolidation of Net Assets [Table Text Block] Deemed dividend charged to accumulated deficit. Lucid Diagnostics 2018 Equity Plan [Member] Increase in fee income. transfer of intellectual property. Proceeds from sale of intellectual property. Issuance through exchange - subsidiary preferred stock (Series B and Series B-1) Vendors [Member] Fair value adjustment for diluted eps calculation Net income loss available to common stockholders Lucid Diagnostics issuance through exchange - Series B and Series B-1. Lucid Diagnostics issuance through sale - Series B and Series B-1. Stock Options [Member] Assets, Current Liabilities Equity, Including Portion Attributable to Noncontrolling Interest Costs and Expenses Operating Income (Loss) Interest Expense, Debt LossOnIssueAndOfferingCostSeniorSecuredConvertibleNote ChangeInFairValueDerivativeLiability Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest PreferredStockDividendsAttributableToNonControllingInterests Shares, Outstanding Noncontrolling Interest, Increase from Business Combination Derivative, Gain (Loss) on Derivative, Net Increase (Decrease) in Accounts Receivable Increase (Decrease) in Prepaid Expenses, Other Increase (Decrease) in Accounts Payable Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment DecreaseInCashDueToDeconsolidationOfSubsidiary Net Cash Provided by (Used in) Investing Activities Repayments of Secured Debt Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Forgone Recovery, Individual Name Outstanding Recovery, Individual Name Awards Close in Time to MNPI Disclosures, Individual Name Trading Arrangement, Individual Name Lessee, Operating Leases [Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] WorkingCapital Cash [Default Label] Restricted Cash, Current NetAssets Business Acquisition, Percentage of Voting Interests Acquired Lessee, Operating Lease, Liability, to be Paid Lessee, Operating Lease, Liability, Undiscounted Excess Amount Finite-Lived Intangible Assets, Accumulated Amortization Long-Term Debt, Gross Debt Instrument, Periodic Payment Debt Instrument, Repaid, Principal OtherIncomeExpenseChangeInFairValue Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period ImpactOfSubsidiaryEquityTransactions Less carrying value related to series and series A1 preferred stock exchanged for series B preferred stock DeemedDividendChargedToAccumulatedDeficit FairValuePreferredStockDividendsShares EX-101.PRE 10 pavm-20240930_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Cover - $ / shares 9 Months Ended Sep. 30, 2024 Nov. 11, 2024 Document Type 10-Q Â Amendment Flag false Â Document Quarterly Report true Â Document Transition Report false Â Document Period End Date Sep. 30, 2024 Â Document Fiscal Period Focus Q3 Â Document Fiscal Year Focus 2024 Â Current Fiscal Year End Date --12-31 Â Entity File Number 001-37685 Â Entity Registrant Name PAVMED INC. Â Entity Central Index Key 0001624326 Â Entity Tax Identification Number 47-1214177 Â Entity Incorporation, State or Country Code DE Â Entity Address, Address Line One 360 Madison Avenue Â Entity Address, Address Line Two 25th Floor Â Entity Address, City or Town New York Â Entity Address, State or Province NY Â Entity Address, Postal Zip Code 10017 Â City Area Code (917) Â Local Phone Number 813-1828 Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding 10,985,841 11,068,566 Entity Listing, Par Value Per Share $ 0.001 Â Common Stock, $0.001 par value per share [Member] Â Â Title of 12(b) Security Common Stock, $0.001 par value per share Â Trading Symbol PAVM Â Security Exchange Name NASDAQ Â Series Z Warrants, each to purchase 1/15th of one share of Common Stock [Member] Â Â Title of 12(b) Security Series Z Warrants, each to purchase 1/15th of one share of Common Stock Â Trading Symbol PAVMZ Â Security Exchange Name NASDAQ Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal

year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe par value per share of security quoted in same currency as Trading currency. Example: '0.01'. + ReferencesNo definition available. + Details Name: dei_EntityListingParValuePerShare Namespace Prefix: dei_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=PAVM_CommonStock0.001ParValuePerShareMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=PAVM_SeriesZWarrantsEachToPurchase115thOfOneShareOfCommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash $ 765 $ 19,639 Accounts receivable 16 61 Inventory 6 278 Prepaid expenses, deposits, and other current assets 1,343 4,520 Total current assets 2,130 24,498 Fixed assets, net 216 1,783 Operating lease right-of-use assets 2,618 4,267 Intangible assets, net 1,424 Equity method investment - at fair value 25,511 Other assets 75 1,147 Total assets 30,550 33,119 Current liabilities: Â Â Accounts payable 465 1,786 Accrued expenses and other current liabilities 4,543 6,626 Operating lease liabilities, current portion 499 1,565 Senior Secured Convertible Notes - at fair value 32,050 44,200 Total current liabilities 37,557 54,177 Operating lease liabilities, less current portion 2,380 2,960 Total liabilities 39,937 57,137 Commitments and contingencies (Note 9) Stockholdersâ€™ Equity: Â Â Preferred stock, $0.001 par value. Authorized, 20,000,000 shares; Series B Convertible Preferred Stock, par value $0.001, issued and outstanding 1,385,149 at September 30, 2024 and 1,305,213 shares at December 31, 2023 3,232 2,993 Common stock, $0.001 par value. Authorized, 50,000,000 shares; 10,660,394 and 8,578,505 shares outstanding as of September 30, 2024 and December 31, 2023, respectively 11 9 Additional paid-in capital 248,200 237,600 Accumulated deficit (256,312) (294,433) Total PAVmed Inc. Stockholdersâ€™ Equity (Deficit) (4,869) (53,831) Noncontrolling interests (4,518) 29,813 Total Stockholdersâ€™ Equity (Deficit) (9,387) (24,018) Total Liabilities and Stockholdersâ€™ Equity (Deficit) $ 30,550 $ 33,119 X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThis item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 + Details Name: us-gaap_EquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_MinorityInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-

gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_SecuredDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares Sep. 30, 2024 Dec. 31, 2023 Preferred stock, par value $ 0.001 $ 0.001 Preferred stock, shares authorized 20,000,000 20,000,000 Common stock, par value $ 0.001 $ 0.001 Common stock, shares authorized 50,000,000 50,000,000 Common stock, shares outstanding 10,660,394 8,578,505 Series B Convertible Preferred Stock [Member] Â Â Preferred stock, par value $ 0.001 $ 0.001 Preferred stock, shares issued 1,385,149 1,305,213 Preferred stock, shares outstanding 1,385,149 1,305,213 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2:

http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementClassOfStockAxis=PAVM_SeriesBConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Income Statement [Abstract] Â Â Â Â Revenue $ 996 $ 791 $ 2,985 $ 1,403 Operating expenses: Â Â Â Â Cost of revenue 1,381 1,779 4,792 4,809 Sales and marketing 2,920 4,016 11,472 12,893 General and administrative 6,649 6,858 20,337 23,916 Amortization of acquired intangible assets 82 505 559 1,516 Research and development 1,542 3,161 5,125 10,681 Total operating expenses 12,574 16,319 42,285 53,815 Operating loss (11,578) (15,528) (39,300) (52,412) Other income (expense): Â Â Â Â Interest income 70 124 252 408 Interest expense (12) (159) (38) (570) Gain on deconsolidation of subsidiary 72,287 72,287 Change in fair value - equity method investment 407 407 Change in fair value - Senior Secured Convertible Notes 240 (4,392) (2,488) (5,772) Loss on issue and offering costs - Senior Secured Convertible Note (1,186) Debt extinguishments loss - Senior Secured Convertible Notes (1,403) (1,764) (2,535) (3,032) Debt modification expense (2,000) Change in fair value - derivative liability (31) (291) Management fee income 700 700 Gain on sale of intellectual property 1,000 Other income (expense), net 72,289 (6,222) 66,585 (9,443) Income (loss) before provision for income tax 60,711 (21,750) 27,285 (61,855) Provision for income taxes Net income (loss) before noncontrolling interests 60,711 (21,750) 27,285 (61,855) Net loss attributable to the noncontrolling interests 3,688 4,079 11,075 11,716 Net income (loss) attributable to PAVmed Inc. 64,399 (17,671) 38,360 (50,139) Less: Series B Convertible Preferred Stock dividends earned (83) (77) (244) (226) Less: Deemed dividend on Subsidiary Preferred Stock attributable to the noncontrolling interests (7,496) Net income (loss) attributable to PAVmed Inc. common stockholders $ 64,316 $ (17,748) $ 30,620 $ (50,365) Per share information: Â Â Â Â Net income (loss) per share attributable to PAVmed Inc. common stockholders â€“ basic [1] $ 6.43 $ (2.38) $ 3.30 $ (7.23) Net income (loss) per share attributable to PAVmed Inc. common stockholders â€“ diluted [1] $ 1.44 $ (2.38) $ 0.79 $ (7.23) Weighted average common shares outstanding, basic 10,005,379 7,462,751 9,286,999 6,967,764 Weighted average common shares outstanding, diluted 44,475,638 7,462,751 43,069,449 6,967,764 [1] - Convertible preferred stock and restricted stock awards would potentially be considered a participating security under the two-class method of calculating net income (loss) per share. For periods where losses are presented, such holders are not contractually obligated to share in the losses, there is no impact on the Companyâ€™s net income (loss) per share calculation for the periods indicated. X - DefinitionChange in fair value derivative liability. + ReferencesNo definition available. + Details Name: PAVM_ChangeInFairValueDerivativeLiability Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionChange in fair value senior secured convertible note. + ReferencesNo definition available. + Details Name: PAVM_ChangeInFairValueSeniorSecuredConvertibleNote Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDebt modification expense. + ReferencesNo definition available. + Details Name: PAVM_DebtModificationExpense Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLoss on issue and offering cost senior secured convertible note. + ReferencesNo definition available. + Details Name: PAVM_LossOnIssueAndOfferingCostSeniorSecuredConvertibleNote Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionManagement fee income. + ReferencesNo definition available. + Details Name: PAVM_ManagementFeeIncome Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDeemed dividend on Subsidiary Preferred Stock attributable to the noncontrolling interests. + ReferencesNo definition available. + Details Name: PAVM_PreferredStockDividendsAttributableToNonControllingInterests Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate cost of goods produced and sold and services rendered during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B + Details Name: us-gaap_CostOfRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionTotal costs of sales and operating expenses for the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostsAndExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CostsAndExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B + Details Name: us-gaap_DeconsolidationGainOrLossAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareBasicAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnDispositionOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionReflects the difference between the fair value of payments made to legally extinguish a debt and its carrying value at that time. This item excludes the write-off of amounts previously capitalized as debt issuance costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4 + Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column E)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column E)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 45 -Paragraph 39 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477346/946-830-45-39Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(1)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 + Details Name: us-gaap_InterestIncomeOperating Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15:

http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of Net Income (Loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B + Details Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders. + ReferencesNo definition available. + Details Name: us-gaap_PreferredStockDividendsIncomeStatementImpact Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -

Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total amount of expenses directly related to the marketing or selling of products or services. + ReferencesNo definition available. + Details Name: us-gaap_SellingAndMarketingExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statement of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Treasury Stock, Common [Member] Noncontrolling Interest [Member] Total Balance at Dec. 31, 2022 $ 2,695 $ 6 $ 216,195 $ (228,169) $ (408) $ 20,615 $ 10,934 Balance, shares at Dec. 31, 2022 1,205,759 6,300,703 Â Â Â Â Â Balance at Jun. 30, 2023 $ 2,841 $ 7 226,423 (260,783) 30,682 (830) Balance, shares at Jun. 30, 2023 1,254,497 7,235,867 Â Â Â Â Â Balance at Dec. 31, 2022 $ 2,695 $ 6 216,195 (228,169) (408) 20,615 10,934 Balance, shares at Dec. 31, 2022 1,205,759 6,300,703 Â Â Â Â Â Dividends declared - Series B Convertible Preferred Stock $ 221 (221) Dividends declared - Series B Convertible Preferred Stock, shares 73,842 Â Â Â Â Â Â Issue common stock - PAVM ATM Facility 1,166 1,166 Issue common stock - PAVM ATM Facility, shares Â 155,384 Â Â Â Â Â Vest - restricted stock awards Vest - restricted stock awards, shares Â 6,666 Â Â Â Â Â Conversions - Senior Secured Convertible Note $ 2 8,409 8,411 Conversions - Senior Secured Convertible Note, shares Â 1,358,896 Â Â Â Â Â Conversions - subsidiary common stock - Senior Secured Convertible Note 167 167 Impact of subsidiary equity transactions 1,984 (1,984) Issuance - vendor service agreement 600 147 747 Issuance - vendor service agreement, shares Â 100,000 Â Â Â Â Â Stock-based compensation - PAVmed Inc. 3,266 3,266 Net Loss (50,139) (11,716) (61,855) Purchase - Employee Stock Purchase Plan 198 60 258 Purchase - Employee Stock Purchase Plan, shares Â 45,892 Â Â Â Â Â Purchase - subsidiary common stock - Employee Stock Purchase Plan 551 551 Stock-based compensation - subsidiaries 876 5,029 5,905 Issuance - subsidiary common stock - Committed Equity Facility, net of financing charges 284 284 Issuance - subsidiary common stock - Settlement APA-RDx - Installment Payment 713 713 Issuance - subsidiary preferred stock (Series A) 13,625 13,625 Treasury stock (348) 348 Treasury stock, shares Â 12,589 Â Â Â Â Â Balance at Sep. 30, 2023 $ 2,916 $ 8 232,346 (278,529) 27,431 (15,828) Balance, shares at Sep. 30, 2023 1,279,601 7,980,131 Â Â Â Â Â Balance at Dec. 31, 2022 $ 2,695 $ 6 216,195 (228,169) (408) 20,615 10,934 Balance, shares at Dec. 31, 2022 1,205,759 6,300,703 Â Â Â Â Â Balance at Dec. 31, 2023 $ 2,993 $ 9 237,600 (294,433) 29,813 (24,018) Balance, shares at Dec. 31, 2023 1,305,213 8,578,505 Â Â Â Â Â Balance at Jun. 30, 2023 $ 2,841 $ 7 226,423 (260,783) 30,682 (830) Balance, shares at Jun. 30, 2023 1,254,497 7,235,867 Â Â Â Â Â Dividends declared - Series B Convertible Preferred Stock $ 75 (75) Dividends declared - Series B Convertible Preferred Stock, shares 25,104 Â Â Â Â Â Â Conversions - Senior Secured Convertible Note $ 1 3,988 3,989 Conversions - Senior Secured Convertible Note, shares Â 723,998 Â Â Â Â Â Conversions - subsidiary common stock - Senior Secured Convertible Note 167 167 Impact of subsidiary equity transactions 651 (651) Stock-based compensation - PAVmed Inc. 978 978 Net Loss (17,671) (4,079) (21,750) Purchase - Employee Stock Purchase Plan 76 76 Purchase - Employee Stock Purchase Plan, shares Â 20,267 Â Â Â Â Â Stock-based compensation - subsidiaries 230 1,037 1,267 Purchase - majority-owned subsidiary common stock - Employee Stock Purchase Plan 275 275 Balance at Sep. 30, 2023 $ 2,916 $ 8 232,346 (278,529) 27,431 (15,828) Balance, shares at Sep. 30, 2023 1,279,601 7,980,131 Â Â Â Â Â Balance at Dec. 31, 2023 $ 2,993 $ 9 237,600 (294,433) 29,813 (24,018) Balance, shares at Dec. 31, 2023 1,305,213 8,578,505 Â Â Â Â Â Balance at Jun. 30, 2024 $ 3,151 $ 10 243,524 (320,630) 55,303 (18,642) Balance, shares at Jun. 30, 2024 1,357,976 9,554,381 Â Â Â Â Â Balance at Dec. 31, 2023 $ 2,993 $ 9 237,600 (294,433) 29,813 (24,018) Balance, shares at Dec. 31, 2023 1,305,213 8,578,505 Â Â Â Â Â Dividends declared - Series B Convertible Preferred Stock $ 239 (239) Â Dividends declared - Series B Convertible Preferred Stock, shares 79,936 Â Â Â Â Â Â Issue common stock - PAVM ATM Facility 977 Â 977 Issue common stock - PAVM ATM Facility, shares Â 627,302 Â Â Â Â Â Vest - restricted stock awards Â Vest - restricted stock awards, shares Â 135,080 Â Â Â Â Â Conversions - Senior Secured Convertible Note $ 2 2,019 Â 2,021 Conversions - Senior Secured Convertible Note, shares Â 1,084,366 Â Â Â Â Â Conversions - subsidiary common stock - Senior Secured Convertible Note Â 3,801 3,801 Impact of subsidiary equity transactions 4,414 Â (4,414) Issuance - vendor service agreement 200 Â 401 601 Issuance - vendor service agreement, shares Â 200,809 Â Â Â Â Â Stock-based compensation - PAVmed Inc. 2,228 Â 2,228 Transfer of intellectual property to Lucid Diagnostics Inc 350 Â 350 Deconsolidation of subsidiary Â (56,339) (56,339) Net Loss 38,360 (11,075) 27,285 Exercise - stock options of subsidiary Â 4 4 Purchase - Employee Stock Purchase Plan 62 62 Purchase - Employee Stock Purchase Plan, shares Â 34,332 Â Â Â Â Â Purchase - subsidiary common stock - Employee Stock Purchase Plan Â 353 353 Issuance - subsidiary preferred stock (Series A-1) Â 5,670 5,670 Exchange - subsidiary preferred stock (Series A and Series A-1) Â (24,294) (24,294) Issuance through exchange - subsidiary preferred stock (Series B and Series B-1) Â 31,790 31,790 Issuance through sale - subsidiary preferred stock (Series B and Series B-1) Â 24,129 24,129 Subsidiary deemed dividends on preferred stock attributable to noncontrolling interests Â (7,496) (7,496) Stock-based compensation - subsidiaries 350 Â 3,139 3,489 Balance at Sep. 30, 2024 $ 3,232 $ 11 248,200 (256,312) (4,518) (9,387) Balance, shares at Sep. 30, 2024 1,385,149 10,660,394 Â Â Â Â Â Balance at Jun. 30, 2024 $ 3,151 $ 10 243,524 (320,630) 55,303 (18,642) Balance, shares at Jun. 30, 2024 1,357,976 9,554,381 Â Â Â Â Â Dividends declared - Series B Convertible Preferred Stock $ 81 (81) Â Dividends declared - Series B Convertible Preferred Stock, shares 27,173 Â Â Â Â Â Â Issue common stock - PAVM ATM Facility 284 Â 284 Issue common stock - PAVM ATM Facility, shares Â 294,003 Â Â Â Â Â Vest - restricted stock awards Â Vest - restricted stock awards, shares Â 131,016 Â Â Â Â Â Conversions - Senior Secured Convertible Note $ 1 907 Â 908 Conversions - Senior Secured Convertible Note, shares Â 509,942 Â Â Â Â Â Conversions - subsidiary common stock - Senior Secured Convertible Note Â 1,260 1,260 Impact of subsidiary equity transactions 2,245 (2,245) Issuance - vendor service agreement 150 Â 150 Issuance - vendor service agreement, shares Â 171,052 Â Â Â Â Â Stock-based compensation - PAVmed Inc. 696 Â 696 Stock-based compensation - subsidiary 44 Â 1,191 1,235 Transfer of intellectual property to Lucid Diagnostics Inc 350 Â 350 Deconsolidation of subsidiary Â (56,339) (56,339) Net Loss 64,399 Â (3,688) 60,711 Balance at Sep. 30, 2024 $ 3,232 $ 11 $ 248,200 $ (256,312) $ (4,518) $ (9,387) Balance, shares at Sep. 30, 2024 1,385,149 10,660,394 Â Â Â Â Â X - DefinitionExercise - stock options of subsidiary. + ReferencesNo definition available. + Details Name: PAVM_AdjustmentToAdditionalPaidInCapitalIssueCommonStockOfSubsidiary Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAdjustments to additional paid in capital deconsolidation of subsidiary. + ReferencesNo definition available. + Details Name: PAVM_AdjustmentsToAdditionalPaidInCapitalDeconsolidationOfSubsidiary Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAdjustments to additional paid in capital share based compensation subsidiary. + ReferencesNo definition available. + Details Name: PAVM_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationSubsidiary Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definitiontransfer of intellectual property. + ReferencesNo definition available. + Details Name: PAVM_AdjustmentsToAdditionalPaidInCapitalTransferOfIntellectualProperty Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIssuance through exchange - subsidiary preferred stock (Series B and Series B-1) + ReferencesNo definition available. + Details Name: PAVM_IssuanceOfExchangeSaleSubsidiaryPreferredStockSeriesBAndSeriesBOne Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIssuance exchange - subsidiary preferred stock Series A and Series A one. + ReferencesNo definition available. + Details Name: PAVM_IssuanceOfExchangeSubsidiaryPreferredStockSeriesAndSeriesAOne Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIssuance - subsidiary preferred stock series B and series B-1. + ReferencesNo definition available. + Details Name: PAVM_IssuanceOfExchangeSubsidiaryPreferredStockSeriesBAndSeriesBOne Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIssuance subsidiary common stock - committed equity facility, net of financing charges. + ReferencesNo definition available. + Details Name: PAVM_IssuanceSubsidiaryCommonStockCommittedEquityFacilityNetOfFinancingCharges Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIssuance - majority-owned subsidiary preferred stock Series A. + ReferencesNo definition available. + Details Name: PAVM_IssuanceSubsidiaryPreferredStockSeriesA Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIssuance -subsidiary preferred stock Series A-1. + ReferencesNo definition available. + Details Name: PAVM_IssuanceSubsidiaryPreferredStockSeriesAOne Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPurchase majority owned subsidiary common stock employee stock purchase plan. + ReferencesNo definition available. + Details Name: PAVM_PurchaseMajorityownedSubsidiaryCommonStockEmployeeStockPurchasePlan Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionStock issued during period, value, conversions subsidiary common stock senior secured convertible. + ReferencesNo definition available. + Details Name: PAVM_StockIssuedDuringPeriodValueConversionsSubsidiaryCommonStockSeniorSecuredConvertibleNote Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionStock issued during period, value,issuance -subsidiary common stock - settlement APA-RDx - installment payment. + ReferencesNo definition available. + Details Name: PAVM_StockIssuedDuringPeriodValueIssuanceSubsidiaryCommonStockSettlementApardxInstallmentPayment Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionStock issued during period, value, stock-based compensation - subsidiaries. + ReferencesNo definition available. + Details Name: PAVM_StockIssuedDuringPeriodValueStockbasedCompensationSubsidiary Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionStock issued during the period of impact of subsidiary equity transactions. + ReferencesNo definition available. + Details Name: PAVM_StockIssuedDuringThePeriofOfNewIssueImpactOfSubsidiaryEquityTransactions Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type:

duration X - DefinitionAmount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in noncontrolling interest from a business combination. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(2) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-23Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(2) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares of preferred stock issued as dividends during the period. Excludes stock splits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap_PreferredStockDividendsShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe gross value of stock issued during the period upon the conversion of convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -

SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAggregate change in value for stock issued during the period as a result of employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued to shareholders as a dividend during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockDividend Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Cash flows from operating activities Â Â Â Â Net income (loss) - before noncontrolling interest (â€œNCIâ€) $ 60,711 $ (21,750) $ 27,285 $ (61,855) Adjustments to reconcile net income (loss) - before NCI to net cash used in operating activities Â Â Â Â Depreciation and amortization expense Â Â 1,129 2,207 Stock-based compensation 1,931 2,245 5,716 9,171 Gain on sale of intellectual property (1,000) Gain on deconsolidation of subsidiary (72,287) (72,287) Change in fair value - equity method investment (407) (407) APA-RDx: Issue common stock of subsidiary - termination payment Â Â 713 Amortization of common stock payment for vendor service agreement Â Â 448 625 Change in fair value - Senior Secured Convertible Notes (240) 4,392 2,488 5,772 Loss on issue - Senior Secured Convertible Note Â Â

1,111 Debt extinguishment loss - Senior Secured Convertible Note 1,403 1,764 2,535 3,032 Change in fair value - derivative liability Â Â 291 Non-cash lease expense Â Â 8 304 Changes in operating assets and liabilities: Â Â Â Â Accounts receivable Â Â 45 (18) Prepaid expenses, deposits and current and other assets Â Â 579 (1,757) Accounts payable Â Â (249) (538) Accrued expenses and other current liabilities Â Â (938) 1,780 Net cash flows used in operating activities Â Â (33,648) (40,162) Cash flows from investing activities Â Â Â Â Purchase of equipment Â Â (51) (59) Decrease in cash due to deconsolidation of subsidiary Â Â (16,479) Proceeds from sale of intellectual property to Lucid Diagnostics Inc. Â Â 350 Proceeds from sale of intellectual property Â Â 1,000 Net cash flows provided by (used in) investing activities Â Â (16,180) 941 Cash flows from financing activities Â Â Â Â Proceeds â€“ issue of preferred stock - subsidiary Â Â 29,798 13,625 Proceeds â€“ issue of Senior Secured Convertible Note Â Â 10,000 Payment â€“ Senior Secured Convertible Note â€“ acceleration floor payments Â Â (531) Proceeds â€“ issue of common stock - At-The-Market Facility Â Â 1,268 1,166 Proceeds â€“ subsidiary common stock - Committed Equity Facility and At-The-Market Facility Â Â 284 Proceeds â€“ issue common stock â€“ Employee Stock Purchase Plan Â Â 62 259 Proceeds â€“ subsidiary common stock â€“ Employee Stock Purchase Plan Â Â 353 551 Proceeds â€“ exercise of stock options issued under equity plan of subsidiary Â Â 4 Net cash flows provided by financing activities Â Â 30,954 25,885 Net increase (decrease) in cash Â Â (18,874) (13,336) Cash, beginning of period Â Â 19,639 39,744 Cash, end of period $ 765 $ 26,408 $ 765 $ 26,408 X - DefinitionAmortization of common stock payment for vendor service agreement. + ReferencesNo definition available. + Details Name: PAVM_AmortizationOfCommonStockPaymentForVendorServiceAgreement Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionChange in fair value senior secured convertible note. + ReferencesNo definition available. + Details Name: PAVM_ChangeInFairValueSeniorSecuredConvertibleNote Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDecrease in cash due to deconsolidation of subsidiary. + ReferencesNo definition available. + Details Name: PAVM_DecreaseInCashDueToDeconsolidationOfSubsidiary Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIssue common stock installment settlement payment. + ReferencesNo definition available. + Details Name: PAVM_IssuanceOfCommonStockInstallmentSettlementPayment Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLoss on issue and offering costs senior secured convertible note. + ReferencesNo definition available. + Details Name: PAVM_LossOnIssueAndOfferingCostsSeniorSecuredConvertibleNote Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds from sale of intellectual property. + ReferencesNo definition available. + Details Name: PAVM_ProceedsFromSaleOfPropertyHeldForSales Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds subsidiary common stock - committed equity facility and at the market facility. + ReferencesNo definition available. + Details Name: PAVM_ProceedsSubsidiaryCommonStockCommittedEquityFacilityAndAtthemarketFacility Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds subsidiary common stock employee stock purchase plan + ReferencesNo definition available. + Details Name: PAVM_ProceedsSubsidiaryCommonStockEmployeeStockPurchasePlan Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B + Details Name: us-gaap_DeconsolidationGainOrLossAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in the fair value of derivatives recognized in the income statement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A + Details Name: us-gaap_DerivativeGainLossOnDerivativeNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnDispositionOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionReflects the difference between the fair value of payments made to legally extinguish a debt and its carrying value at that time. This item excludes the write-off of amounts previously capitalized as debt issuance costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4 + Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in accrued expenses, and obligations classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidExpensesOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense or loss included in net income that result in no cash flow, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OtherNoncashExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfSecuredDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -

Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the sale of formerly productive land held for sale, anything permanently fixed to it, including buildings, structures on it, and so forth. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleOfPropertyHeldForSale Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfSecuredDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Pay vs Performance Disclosure [Table] Â Â Â Â Net Income (Loss) $ 64,399 $ (17,671) $ 38,360 $ (50,139) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45

-Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 Insider Trading Arrangements [Line Items] Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a + Details Name: ecd_InsiderTradingArrLineItems Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.3 The Company 9 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â The Company Note 1 â€” The Company Â Description of the Business Â PAVmed is structured to be a multi-product life sciences company organized to advance a pipeline of innovative healthcare technologies. Led by a team of highly skilled personnel with a track record of bringing innovative products to market, PAVmed is focused on innovating, developing, acquiring, and commercializing novel products that target unmet medical needs with large addressable market opportunities. Leveraging our corporate structureâ€”a parent company that will establish distinct subsidiaries for each financed assetâ€”we have the flexibility to raise capital at the PAVmed level to fund product development, or to structure financing directly into each subsidiary in a manner tailored to the applicable product, the latter of which is our current strategy given prevailing market conditions. Â Our current focus is multi-fold. We continue to pursue commercial expansion and execution of EsoGuard, which is the flagship product of our subsidiary, Lucid Diagnostics Inc. (Nasdaq: LUCD) (â€œLucidâ€). In addition, through a separate majority-owned subsidiary, Veris Health (â€œVerisâ€), we are focused in the immediate term on entering into strategic partnership opportunities with leading academic oncology systems to expand access to the Veris Platform, while concurrently developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris Platform. In terms of other existing products and technologies, we have adopted an incubator-type platform where we are looking to obtain financing on a product-by-product basis as necessary to advance each asset to a meaningful inflection point along its path to commercialization. Finally, as resources permit, we will continue to explore external innovations that fulfill our project selection criteria without limiting ourselves to any target sector, specialty or condition. Â X - DefinitionThe entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 275 -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details Name: us-gaap_NatureOfOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Liquidity and Going Concern 9 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Liquidity and Going Concern Note 2 â€” Liquidity and Going Concern Â The Companyâ€™s management is required to assess the Companyâ€™s ability to continue as a going concern for the one year period following the date of the financial statements being issued. In each reporting period, including interim periods, an entity is required to assess conditions known and reasonably knowable as of the financial statement issuance date to determine whether it is probable an entity will not meet its financial obligations within one year from the financial statement issuance date. Substantial doubt about an entityâ€™s ability to continue as a going concern exists when conditions and events, considered in the aggregate, indicate it is probable the entity will be unable to meet its financial obligations as they become due within one year after the date the financial statements are issued. Â The Company has financed its operations principally through public and private issuances of its common stock, preferred stock, common stock purchase warrants, and debt. The Company is subject to all of the risks and uncertainties typically faced by medical device and diagnostic companies that devote substantially all of their efforts to the commercialization of their initial product and services and ongoing research and development activities and conducting clinical trials. The Company generated $1.0 million and $3.0 million of revenues for the three and nine month periods ended September 30, 2024, respectively, however the Company expects to continue to experience recurring losses and to generate negative cash flows from operating activities in the near future. Â The Company incurred a net income attributable to PAVmed Inc. common stockholders of approximately $30.6 million and had net cash flows used in operating activities of approximately $33.6 million for the nine month period ended September 30, 2024. As of September 30, 2024, the Company had negative working capital of approximately $35.4 million, with such working capital inclusive of the Senior Secured Convertible Notes classified as a current liability of an aggregate of approximately $32.1 million and approximately $0.8 million of cash. Â The Companyâ€™s ability to continue operations 12 months beyond the issuance of the financial statements, will depend upon its ability to control its operating costs within the limits of the amounts collected from its management service contracts with its non-consolidated subsidiaries, to substantially increase its revenues from the Veris Cancer Care platform, and to raise additional capital through various potential sources including equity or debt financings or refinancing or restructuring existing debt obligations. These factors raise substantial doubt about the Companyâ€™s ability to continue as a going concern within one year after the date the accompanying unaudited condensed consolidated financial statements are issued. Â Â X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 40 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205-40/tableOfContent + Details Name: us-gaap_SubstantialDoubtAboutGoingConcernTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Summary of Significant Accounting Policies Note 3 â€” Summary of Significant Accounting Policies Â Significant Accounting Policies Â The Companyâ€™s significant accounting policies are as disclosed in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the SEC on March 25, 2024, except as otherwise noted herein below. Â Basis of Presentation Â The accompanying unaudited condensed consolidated financial statements of PAVmed and those of its wholly owned subsidiaries and variable interest entities have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œU.S. GAAPâ€), and applicable rules and regulations of the United States Securities and Exchange Commission (â€œSECâ€). All intercompany transactions and balances have been eliminated in consolidation. The Company has a controlling financial interest in Veris Health Inc., with the corresponding noncontrolling interest included as a separate component of consolidated stockholdersâ€™ equity (deficit), including the recognition in the unaudited condensed consolidated statement of operations of a net loss attributable to the noncontrolling interest based on the respective minority-interest equity ownership of each subsidiary. As of September 10, 2024, PAVmed ceased to have a controlling financial interest in Lucid Diagnostics and therefore PAVmedâ€™s consolidated results of operations include Lucid Diagnosticsâ€™ results of operations only through that date. The deconsolidation of Lucid Diagnostics has resulted in a gain recognized in PAVmedâ€™s statement of operations for the periods ended September 30, 2024. Moving forward, PAVmed will account for its investment in Lucid Diagnostics using the equity method and the fair value option. See below and Note 4, Equity Method Investment for a discussion on the impact of the deconsolidation of Lucid Diagnostics. See Note 15, Noncontrolling Interest, for a discussion of each of the subsidiaries noted above. The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. Â As permitted under SEC rules, certain footnotes or other financial information normally required by U.S. GAAP have been condensed or omitted. The balance sheet as of December 31, 2023 has been derived from audited consolidated financial statements at such date. The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the Companyâ€™s annual consolidated financial statements, and in the opinion of management, include all adjustments, consisting only of routine recurring adjustments, necessary for a fair statement of the Companyâ€™s unaudited condensed consolidated financial information. Â The unaudited condensed consolidated results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the consolidated results to be expected for the year ending December 31, 2024 or for any other interim period or for any other future periods. The accompanying unaudited condensed consolidated financial statements and related unaudited condensed consolidated financial information should be read in conjunction with the Companyâ€™s audited consolidated financial statements and related notes thereto as of and for the year ended December 31, 2023 included in the Companyâ€™s Annual Report on Form 10-K as filed with the SEC on March 25, 2024. Â All amounts in the accompanying unaudited condensed consolidated financial statements and the notes thereto are presented in thousands of dollars, if not otherwise noted as being presented in millions of dollars, except for shares and per share amounts. Â Cash Â The Company maintains its cash at a major financial institution with high credit quality. At times, the balance of its cash deposits may exceed federally insured limits. The Company has not experienced losses on deposits with commercial banks and financial institutions which exceed federally insured limits. Â Included in the Companyâ€™s cash as of September 30, 2024 and December 31, 2023 is $299 related to a restricted deposit account for a standby letter of credit associated with our corporate headquarters which has a lease maturity date in 2030. Â Use of Estimates Â In preparing the unaudited condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and the determination of corresponding carrying value reserve, if any, and liabilities and the disclosure of contingent losses, as of the date of the unaudited condensed consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Significant estimates in these unaudited condensed consolidated financial statements include those related to the estimated fair value of debt obligations, stock-based equity awards, intangible assets and common stock purchase warrants. Other significant estimates include the estimated incremental borrowing rate, the provision or benefit for income taxes and the corresponding valuation allowance on deferred tax assets. Additionally, managementâ€™s assessment of the Companyâ€™s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. On an ongoing basis, the Company evaluates its estimates and assumptions. The Company bases its estimates on historical experience and on various other assumptions believed to be reasonable. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. Â Â Note 3 â€” Summary of Significant Accounting Policies - continued Â Revenue Recognition Â Revenues are recognized when the satisfaction of the performance obligation occurs, in an amount that reflects the consideration the Company expects to collect in exchange for those services. The Companyâ€™s revenue was primarily generated by Lucidâ€™s laboratory testing services utilizing its EsoGuard Esophageal DNA tests. The services were completed upon release of a patientâ€™s test result to the ordering healthcare provider. Revenue recognized is inclusive of both variable consideration in connection with an individual patientâ€™s third-party insurance coverage policy and fixed consideration in connection with a contracted services arrangement with an unrelated third party legal entity. To determine revenue recognition for the arrangements that the Company determines are within the scope of ASC 606, Revenue from Contracts with Customers, the Company performs the following five steps: (1) identify the contract(s) with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation. Â The key aspects considered by the Company include the following: Â Contractsâ€”The Companyâ€™s customer is primarily the patient, but the Company does not enter into a formal reimbursement contract with a patient. The Company establishes a contract with a patient in accordance with other customary business practices, which is the point in time an order is received from a provider and a patient specimen has been returned to the laboratory for testing. Payment terms are a function of a patientâ€™s existing insurance benefits, including the impact of coverage decisions with Center for Medicare & Medicaid Services (â€œCMSâ€) and applicable reimbursement contracts established between the Company and payers. However, when a patient is considered self-pay, the Company requires payment from the patient prior to the commencement of the Companyâ€™s performance obligations. The Companyâ€™s consideration can be deemed variable or fixed depending on the structure of specific payer contracts, and the Company considers collection of such consideration to be probable to the extent that it is unconstrained. Â Performance obligationsâ€”A performance obligation is a promise in a contract to transfer a distinct good or service (or a bundle of goods or services) to the customer. The Companyâ€™s contracts have a single performance obligation, which is satisfied upon rendering of services, which culminates in the release of a patientâ€™s test result to the ordering healthcare provider. The Company elects the practical expedient related to the disclosure of unsatisfied performance obligations, as the duration of time between providing testing supplies, the receipt of a sample, and the release of a test result to the ordering healthcare provider is far less than one year. Â Transaction priceâ€”The transaction price is the amount of consideration that the Company expects to collect in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). The consideration expected to be collected from a contract with a customer may include fixed amounts, variable amounts, or both. Â If the consideration derived from the contracts is deemed to be variable, the Company estimates the amount of consideration to which it will be entitled in exchange for the promised goods or services. The Company limits the amount of variable consideration included in the transaction price to the unconstrained portion of such consideration. In other words, the Company recognizes revenue up to the amount of variable consideration that is not subject to a significant reversal until additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved. Â When the Company does not have significant historical experience or that experience has limited predictive value, the constraint over estimates of variable consideration may result in no revenue being recognized upon delivery of patient EsoGuard test results to the ordering healthcare provider. As such, the Company recognizes revenue up to the amount of variable consideration not subject to a significant reversal until additional information is obtained or the uncertainty associated with additional payments or refunds, if any, is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in estimated expected variable consideration, with the change in estimate recognized in the period of such revised estimate. With respect to a contracted service arrangement, the fixed consideration revenue is recognized on an as-billed basis upon delivery of the laboratory test report with realization of such fixed consideration deemed probable based upon actual historical experience. Â Allocate transaction priceâ€”The transaction price is allocated entirely to the performance obligation contained within the contract with a customer on the basis of the relative standalone selling prices of each distinct good or service. Â Practical Expedientsâ€”The Company does not adjust the transaction price for the effects of a significant financing component, as at contract inception, the Company expects the collection cycle to be one year or less. Â Â Note 3 â€” Summary of Significant Accounting Policies - continued Â Equity Method Investments Â Businesses that are not consolidated, but over which PAVmed exercises significant influence, are accounted for under the equity method of accounting. The determination as to whether or not PAVmed exercises significant influence with respect to a company depends on an evaluation of several factors, including,

among others, representation on the companyâ€™s board of directors and equity ownership level, which is generally between a 20% and a 50% interest in the voting securities of an equity method business, as well as voting rights associated with PAVmedâ€™s holdings in common stock in that company. PAVmed accounts for Lucid Diagnostics as an equity method investment beginning on September 10, 2024, and the period ended September 30, 2024. Â Fair Value Option (â€œFVOâ€) Election Â Under a Securities Purchase Agreement dated March 31, 2022, the Company issued a Senior Secured Convertible Note dated April 4, 2022, referred to herein as the â€œApril 2022 Senior Convertible Noteâ€, and a Senior Secured Convertible Note dated September 8, 2022, referred to herein as the â€œSeptember 2022 Senior Convertible Noteâ€, which are accounted under the â€œfair value option electionâ€ as discussed below. Â Under a Securities Purchase Agreement dated March 13, 2023, Lucid Diagnostics issued a Senior Secured Convertible Note dated March 21, 2023, referred to herein as the â€œLucid March 2023 Senior Convertible Noteâ€, which is accounted under the â€œfair value option electionâ€, through September 10, 2024, the date of Lucidâ€™s deconsolidation from PAVmedâ€™s results of operations, as discussed below. Â Under Financial Accounting Standards Board (â€œFASBâ€) Accounting Standards Codification (â€œASCâ€) Topic 815, Derivative and Hedging, (â€œASC 815â€), a financial instrument containing embedded features and/or options may be required to be bifurcated from the financial instrument host and recognized as separate derivative asset or liability, with the bifurcated derivative asset or liability initially measured at estimated fair value as of the transaction issue date and then subsequently remeasured at estimated fair value as of each reporting period balance sheet date. Â Alternatively, FASB ASC Topic 825, Financial Instruments, (â€œASC 825â€) provides for the â€œfair value optionâ€ (â€œFVOâ€) election. In this regard, ASC 825-10-15-4 provides for the FVO election (to the extent not otherwise prohibited by ASC 825-10-15-5) to be afforded to financial instruments, wherein the financial instrument is initially measured at estimated fair value as of the transaction issue date and then subsequently remeasured at estimated fair value as of each reporting period balance sheet date, with changes in the estimated fair value recognized as other income (expense) in the statement of operations. The estimated fair value adjustment of the April 2022 Senior Convertible Note, the September 2022 Senior Convertible Note and (through September 10, 2024, Lucidâ€™s deconsolidation date) the Lucid March 2023 Senior Convertible Note, including the component related to accrued interest, is presented in a single line item within other income (expense) in the accompanying unaudited condensed consolidated statement of operations (as provided for by ASC 825-10-50-30(b)). Further, as required by ASC 825-10-45-5, to the extent a portion of the fair value adjustment is attributed to a change in the instrument-specific credit risk, such portion would be recognized as a component of other comprehensive income (â€œOCIâ€) (for which there was no such adjustment with respect to the April 2022 Senior Convertible Note, the September 2022 Senior Convertible Note or (through September 10, 2024, Lucidâ€™s deconsolidation date) the Lucid March 2023 Senior Convertible Note). Â See Note 10, Financial Instruments Fair Value Measurements, with respect to the FVO election; and Note 11, Debt, for a discussion of the April 2022 Senior Convertible Note, the September 2022 Senior Convertible Note and the Lucid March 2023 Senior Convertible Note. Â From and after September 10, 2024, the date of Lucidâ€™s deconsolidation from PAVmedâ€™s results of operation, the Companyâ€™s investment in Lucid is treated as an equity method investment accounted for using the fair value option. Shares of Lucid Diagnostics common stock have a readily determinable fair value classified as Level 1, in which the fair value is determined based upon quoted market prices in an active market. Â Recent Accounting Standards Updates Not Yet Adopted Â In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740)â€”Improvements to Income Tax Disclosures (â€œASU 2023-09â€), which is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 provide for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for the Company prospectively to all annual periods beginning after December 15, 2024. Early adoption is permitted. The Company does not expect the standard to have a significant impact on its unaudited condensed consolidated financial statements. Â In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280)â€”Improvements to Reportable Segment Disclosures (â€œASU 2023-07â€), which require public companies disclose significant segment expenses and other segment items on an annual and interim basis and to provide in interim periods all disclosures about a reportable segmentâ€™s profit or loss and assets that are currently required annually. The guidance is effective for public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The guidance is applied retrospectively to all periods presented in the financial statements, unless it is impracticable. The Company is currently evaluating the impact this update will have on its unaudited condensed consolidated financial statements and disclosures, however the Company does not expect the standard to have a significant impact. Â Â Note 3 â€” Summary of Significant Accounting Policies - continued Â In October 2023, the FASB issued ASU No. 2023-06, Disclosure Improvements: Codification Amendments in Response to the SECâ€™s Disclosure Update and Simplification Initiative. This update modifies the disclosure or presentation requirements of a variety of topics in the Accounting Standards Codification to conform with certain SEC amendments in Release No. 33-10532, Disclosure Update and Simplification. The amendments in this update should be applied prospectively, and the effective date for each amendment will be the date on which the SECâ€™s removal of that related disclosure from Regulation S-X or S-K becomes effective. However, if the SEC has not removed the related disclosure from its regulations by June 30, 2027, the amendments will be removed from the Codification and not become effective. Early adoption is prohibited. The Company is currently evaluating the impact this update will have on its unaudited condensed consolidated financial statements and disclosures. Â X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Equity Method Investment 9 Months Ended Sep. 30, 2024 Equity Method Investments and Joint Ventures [Abstract] Â Equity Method Investment Note 4 â€” Equity Method Investment Â On September 10, 2024, following preferred equity transactions completed by Lucid earlier in 2024 and the termination of voting proxies entered into between PAVmed and certain shareholders of Lucid, PAVmedâ€™s voting interest in the Company was reduced to less than 50.0%, resulting in the loss of a controlling financial interest. However, PAVmed retains the ability to exercise significant influence over Lucid. As a result, the Company deconsolidated Lucid. The following table reflects the net assets of Lucid at the time of deconsolidation: Schedule of Deconsolidation of Net AssetsÂ Â Â Â Â Assets:Â Â Â Â Current assets:Â Â Â Â CashÂ $16,479Â Prepaid expenses, deposits, and other current assetsÂ Â 3,474Â Total current assetsÂ Â 19,953Â Fixed assets, netÂ Â 964Â Operating lease right-of-use assetsÂ Â 2,871Â Intangible assets, netÂ Â 877Â Other assetsÂ Â 379Â Total assetsÂ Â 25,044Â Liabilities:Â Â Â Â Current liabilities:Â Â Â Â Accounts payableÂ Â 1,069Â Accrued expenses and other current liabilitiesÂ Â 1,674Â Operating lease liabilities, current portionÂ Â 865Â Senior Secured Convertible Notes - at fair valueÂ Â 10,268Â Total current liabilitiesÂ Â 13,876Â Operating lease liabilities, less current portionÂ Â 2,011Â Total liabilitiesÂ Â 15,887Â Net Assets of Lucid Diagnostics at September 10, 2024Â $9,157Â Â Upon deconsolidation, the Company owned 31,302,444 shares of Lucid Diagnostics common stock, which was valued at $25.1 million, resulting in a gain on deconsolidation of $72.3 million in the accompanying unaudited condensed consolidated statements of operations for the three and nine months ended September 30, 2024. The Company recorded the following: Â Schedule of Gain on Deconsolidation Â Â Â Â Â Â Investment in former Consolidated Subsidiary (Fair Value of Lucid common stock)Â $25,105Â Add: Noncontrolling interest - LucidÂ Â 56,339Â Less: Net Assets of Former Consolidated Subsidiary - LucidÂ Â (9,157) Gain on Deconsolidation of LucidÂ $72,287 Â After the Companyâ€™s deconsolidation of Lucid, the Company accounts for its investment in Lucid as an equity method investment with the election of the fair value option. Due to the Companyâ€™s continuing involvement and significant influence over operating and financial policies, Lucid is considered a related party of the Company. Â Â Note 4 â€” Equity Method Investment - continued Â The following unaudited summarized financial information related to Lucid accounted for under the equity method of accounting as of September 30, 2024. This aggregate information has been compiled from the financial statements of those business. Â Schedule of Aggregate Information From the Financial Statements Â Â Â September 30, 2024Â CashÂ $14,489Â Other current assetsÂ Â 2,335Â Non-current assetsÂ Â 5,774Â Total assetsÂ Â 22,598Â Current liabilitiesÂ Â 14,249Â Non-current liabilitiesÂ Â 2,011Â Shareholdersâ€™ deficitÂ Â 6,338Â Total liabilities and stockholdersâ€™ deficitÂ $22,598Â Â Three months ended September 30, 2024Â July 1, 2024 - September 10, 2024Â Â September 11, 2024 - September 30, 2024Â Â TotalÂ Â Â Â Â Â Â

follows: Schedule of Future Minimum Lease Payments for Operating LeasesÂ Â Â Â Â Â 2024 (remainder of year)Â $174Â 2025Â Â 708Â 2026Â Â 724Â 2027Â Â 594Â 2028Â Â 471Â ThereafterÂ Â 848Â Total lease paymentsÂ $3,519Â Less: imputed interestÂ Â (640) Present value of lease liabilitiesÂ $2,879Â Â Supplemental disclosure of cash flow information related to the Companyâ€™s cash and non-cash activities with its leases are as follows: Schedule of Supplemental Balance Sheet Information Related to Cash and Non-cash Activities with LeasesÂ Â Â 2024Â Â 2023Â Â Â Nine Months Ended September 30,Â Â Â 2024Â Â 2023Â Cash paid for amounts included in the measurement of lease liabilitiesÂ Â Â Â Â Â Â Â Operating cash flows from operating leasesÂ $1,407Â Â $1,080Â Non-cash investing and financing activitiesÂ Â Â Â Â Â Â Â Right-of-use assets obtained in exchange for new operating lease liabilitiesÂ $â€”Â Â $2,728Â Weighted-average remaining lease term - operating leases (in years)Â Â 5.25Â Â Â 6.68Â Weighted-average discount rate - operating leasesÂ Â 7.875%Â Â 7.875% Â As of September 30, 2024 and December 31, 2023, the Companyâ€™s right-of-use assets from operating leases were $2,618 and $4,267, respectively, which are reported in operating lease right-of-use assets in the unaudited condensed consolidated balance sheets. As of September 30, 2024 and December 31, 2023, the Company had outstanding operating lease obligations of $2,879 and $4,525, respectively, of which $499 and $1,565, respectively, are reported in operating lease liabilities, current portion and $2,380 and $2,960, respectively, are reported in operating lease liabilities less current portion in the Companyâ€™s unaudited condensed consolidated balance sheets. The Company calculates its incremental borrowing rates for specific lease terms, used to discount future lease payments, as a function of the financing terms the Company would likely receive on the open market. Following the deconsolidation of Lucid, the Company had removed right-of-use assets and operating lease liabilities related to Lucid. See Note 4, Equity Method Investment, for additional information on the Lucid deconsolidation. Â Â X - ReferencesNo definition available. + Details Name: PAVM_DisclosureLeasesAbstract Namespace Prefix: PAVM_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/842-20/tableOfContent + Details Name: us-gaap_LesseeOperatingLeasesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Intangible Assets, net 9 Months Ended Sep. 30, 2024 Goodwill and Intangible Assets Disclosure [Abstract] Â Intangible Assets, net Note 8 â€” Intangible Assets, net Â Intangible assets, less accumulated amortization, consisted of the following as of: Schedule of Intangible Assets, Less Accumulated AmortizationÂ Â Â Estimated Useful LifeÂ September 30, 2024Â Â December 31, 2023Â Defensive assetÂ 60 monthsÂ $â€”Â Â $2,105Â Laboratory licenses and certifications and laboratory information management softwareÂ 24 monthsÂ Â â€”Â Â Â 3,200Â OtherÂ 1 yearÂ Â 70Â Â Â 70Â Total Intangible assetsÂ Â Â Â 70Â Â Â 5,375Â Less Accumulated AmortizationÂ Â Â Â (70)Â Â (3,951) Intangible Assets, netÂ Â Â $â€”Â Â $1,424Â Â Amortization expense of the intangible assets discussed above was $82 and $505 for the three month periods ended September 30, 2024 and 2023, respectively, and $559 and $1,516 for the nine month periods ended September 30, 2024 and 2023, respectively, and is included in amortization of acquired intangible assets in the accompanying unaudited condensed consolidated statements of operations. Following the deconsolidation of Lucid, the Company had an intangible assets, net balance of $0, and no estimated future amortization expense. See Note 4, Equity Method Investment, for additional information on the Lucid deconsolidation. Â X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all or part of the information related to intangible assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/985-20/tableOfContent + Details Name: us-gaap_IntangibleAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Commitment and Contingencies 9 Months Ended Sep. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â Commitment and Contingencies Note 9 â€” Commitment and Contingencies Â Other Matters Â In the ordinary course of PAVmed business, particularly as it begins commercialization of its products, the Company may be subject to certain other legal actions and claims, including product liability, consumer, commercial, tax and governmental matters, which may arise from time to time. The Company is not aware of any such pending legal or other proceedings that are reasonably likely to have a material impact on the Company. Notwithstanding, legal proceedings are subject-to inherent uncertainties, and an unfavorable outcome could include monetary damages, and excessive verdicts can result from litigation, and as such, could result in a material adverse impact on the Companyâ€™s business, financial position, results of operations, and /or cash flows. Additionally, although the Company has specific insurance for certain potential risks, the Company may in the future incur judgments or enter into settlements of claims which may have a material adverse impact on the Companyâ€™s business, financial position, results of operations, and /or cash flows. Â Â X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Financial Instruments Fair Value Measurements 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Financial Instruments Fair Value Measurements Note 10 â€” Financial Instruments Fair Value Measurements Â Recurring Fair Value Measurements Â The fair value hierarchy table for the periods indicated is as follows: Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring BasisÂ Â Â Fair Value Measurement on a Recurring Basis at Reporting Date Using1Â Â Â Level-1 InputsÂ Â Level-2 InputsÂ Â Level-3 InputsÂ Â TotalÂ September 30, 2024Â Â Â Â

$â€”Â Face value principal â€“ issue dateÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Fair value adjustment â€“ issue dateÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Installment repayments â€“ common stockÂ Â â€”Â Â Â (455)Â Â (797)Â Â (1,252)Â Â â€”Â Non-installment payments â€“ common stockÂ Â â€”Â Â Â (55)Â Â (135)Â Â (190)Â Â â€”Â Deconsolidation of Lucid DiagnosticsÂ Â â€”Â Â Â â€”Â Â Â (10,268)Â Â (10,268)Â Â â€”Â Change in fair valueÂ Â 650Â Â Â (890)Â Â â€”Â Â Â (240)Â Â 240Â Fair Value at September 30, 2024Â $19,850Â Â $12,200Â Â $â€”Â Â $32,050Â Â Â -Â Other Income (Expense) - Change in fair value â€“ three month period ended September 30, 2024Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $240Â Â Â April 2022 Senior Convertible NoteÂ Â September 2022 Senior Convertible NoteÂ Â Lucid March 2023 Senior Convertible NoteÂ Â Sum of Balance Sheet Fair Value ComponentsÂ Â Other Income (expense)Â Fair Value - December 31, 2023Â $19,000Â Â $11,250Â Â $13,950Â Â $44,200Â Â $â€”Â Installment repayments â€“ common stockÂ Â â€”Â Â Â (1,435)Â Â (2,005)Â Â (3,440)Â Â â€”Â Non-installment payments â€“ common stockÂ Â â€”Â Â Â (143)Â Â (787)Â Â (930)Â Â â€”Â Deconsolidation of Lucid DiagnosticsÂ Â â€”Â Â Â â€”Â Â Â (10,268)Â Â (10,268)Â Â â€”Â Change in fair valueÂ Â 850Â Â Â 2,528Â Â Â (890)Â Â 2,488Â Â Â (2,488) Fair Value at September 30, 2024Â $19,850Â Â $12,200Â Â $â€”Â Â $32,050Â Â Â -Â Other Income (Expense) - Change in fair value â€“ nine month period ended September 30, 2024Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $(2,488) Â Â Note 11 â€“ Debt - continued Â The changes in the fair value of debt during the three and nine month periods ended September 30, 2023 is as follows: Â Â Â April 2022 Senior Convertible NoteÂ Â September 2022 Senior Convertible NoteÂ Â Lucid March 2023 Senior Convertible NoteÂ Â Sum of Balance Sheet Fair Value ComponentsÂ Â Other Income (expense)Â Fair Value - June 30, 2023Â $19,530Â Â $11,850Â Â $11,610Â Â $42,990Â Â $â€”Â Installment repayments â€“ common stockÂ Â (952)Â Â (1,207)Â Â (2,251)Â Â â€”Â Non-installment payments â€“ common stockÂ Â (41)Â Â (51)Â Â (49)Â Â (141)Â Â â€”Â Change in fair valueÂ Â 863Â Â Â 508Â Â Â 3,021Â Â Â 4,392Â Â Â (4,392) Fair Value at September 30, 2023Â $19,400Â Â $11,100Â Â $14,490Â Â $44,990Â Â Â -Â Other Income (Expense) - Change in fair value â€“ three month period ended September 30, 2023Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $(4,392) Â Â April 2022 Senior Convertible NoteÂ Â September 2022 Senior Convertible NoteÂ Â Lucid March 2023 Senior Convertible NoteÂ Â Sum of Balance Sheet Fair Value ComponentsÂ Â Other Income (expense)Â Fair Value - December 31, 2022Â $22,000Â Â $11,650Â Â $â€”Â Â $33,650Â Â $â€”Â Â Fair Value - Beginning of PeriodÂ $22,000Â Â $11,650Â Â $â€”Â Â $33,650Â Â $â€”Â Face value principal â€“ issue dateÂ Â â€”Â Â Â â€”Â Â Â 11,111Â Â Â 11,111Â Â Â â€”Â Fair value adjustment â€“ issue dateÂ Â â€”Â Â Â â€”Â Â Â 789Â Â Â 789Â Â Â (789) Installment repayments â€“ common stockÂ Â (3,895)Â Â (1,207)Â Â (92)Â Â (5,194)Â Â â€”Â Non-installment payments â€“ common stockÂ Â (249)Â Â (51)Â Â (49)Â Â (349)Â Â â€”Â Change in fair valueÂ Â 1,544Â Â Â 708Â Â Â 2,731Â Â Â 4,983Â Â Â (4,983) Fair Value at September 30, 2023Â $19,400Â Â $11,100Â Â $14,490Â Â $44,990Â Â Â -Â Fair Value - Ending of PeriodÂ $19,400Â Â $11,100Â Â $14,490Â Â $44,990Â Â Â -Â Other Income (Expense) - Change in fair value â€“ nine month period ended September 30, 2023Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $(5,772) Â PAVmed - Senior Secured Convertible Notes Â The Company entered into a Securities Purchase Agreement (â€œSPAâ€) dated March 31, 2022, with an accredited institutional investor (â€œInvestorâ€, â€œLenderâ€, and /or â€œHolderâ€), wherein, the Company agreed to sell, and the Investor agreed to purchase an aggregate of $50.0 million face value principal of debt - comprised of: an initial issuance of $27.5 million face value principal; and up to an additional $22.5 million of face value principal (upon the satisfaction of certain conditions). The debt was issued in a registered direct offering under the Companyâ€™s effective shelf registration statement. Â Under the SPA, the Company issued a Senior Secured Convertible Note dated April 4, 2022, referred to herein as the â€œApril 2022 Senior Convertible Noteâ€, with such note having a $27.5 million face value principal, a 7.875% annual stated interest rate, a contractual conversion price of $75.00 per share of the Companyâ€™s common stock (subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transaction), and a contractual maturity date of April 4, 2024, which maturity date the investor agreed to extend by one year, to April 4, 2025. The April 2022 Senior Convertible Note may be converted into shares of common stock of the Company at the Holderâ€™s election. Â Under the same SPA, the Company issued an additional Senior Secured Convertible Note dated September 8, 2022, referred to herein as the â€œSeptember 2022 Senior Convertible Noteâ€, with such note having a $11.25 million face value principal, a 7.875% annual stated interest rate, a contractual conversion price of $75.00 per share of the Companyâ€™s common stock (subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transaction), and a contractual maturity date of September 6, 2024, which maturity date the investor agreed to extend by one year, to September 8, 2025. The September 2022 Senior Convertible Note may be converted into shares of common stock of the Company at the Holderâ€™s election. Â Â Note 11 â€“ Debt - continued Â The Company agreed to reduce temporarily, and the Investor consented to reducing temporarily, the contractual conversion price under the April 2022 Senior Convertible Note and the September 2022 Senior Convertible Note to equal to 82.5% of the two lowest VWAPs during the last 10 trading days preceding the date of conversion, subject to a conversion floor price of $0.40, during the period from June 30, 2024 through September 3, 2024; provided that the aggregate amount of conversions under the April 2022 Senior Convertible Note and the September 2022 Senior Convertible Note during such period may not exceed 1 million shares. Â The Company is subject to financial covenants requiring: (i) a minimum of $8.0 million of available cash at all times; (ii) the ratio of (a) the outstanding principal amount of the total senior convertible notes outstanding, accrued and unpaid interest thereon and accrued and unpaid late charges to (b) the Companyâ€™s average market capitalization over the prior ten trading days, to not exceed 30% (the â€œDebt to Market Cap Ratio Testâ€); and (iii) the Companyâ€™s market capitalization to at no time be less than $75 million (the â€œMarket Cap Testâ€ and, together with the Debt to Market Cap Ratio Test, the â€œFinancial Testsâ€). From time to time from and after September 1, 2024 through November 11, 2024, the Company was not in compliance with the Financial Tests. As of November 11, 2024, the Investor agreed to waive any such non-compliance during such time period and thereafter through December 31, 2024. Â In consideration of a prior covenant waiver and maturity extension agreed to in March 2024, the Company agreed to pay the holder of the notes $2,000 in cash (or in such other form as may be mutually agreed in writing). The covenant waiver and maturity extension fee was recognized as debt modification expense on the Companyâ€™s unaudited condensed consolidated statement of operations, and is currently included in accrued expenses and other current liabilities on the Companyâ€™s unaudited condensed consolidated balance sheets as of September 30, 2024. Â The April 2022 Senior Convertible Note and September 2022 Senior Convertible Note installment payments may be made in shares of PAVmed common stock at a conversion price that is the lower of the contractual conversion price and 82.5% of the two lowest VWAPs during the last 10 trading days preceding the date of conversion, subject to a conversion price floor of $2.70. The notes are also subject to certain provisions that may require redemption upon the occurrence of certain events, including an event of default, a change of control, or certain equity issuances. Â In the three and nine month periods ended September 30, 2024, approximately $455 and $1,435, respectively, of principal repayments along with approximately $55 and $143, respectively, of interest expense thereon, were settled through the issuance of 509,942 and 1,084,366, respectively, shares of common stock of the Company, with such shares having a fair value of approximately $907 and $2,002, respectively, (with such fair value measured as the respective conversion date quoted closing price of the common stock of the Company). In addition, during the three and nine month periods ended September 30, 2024, the Company agreed to pay $652 and $1,059, respectively, in cash related to acceleration floor payments on these notes related to the conversion price being below the floor price, which is included in debt extinguishment loss on the Companyâ€™s unaudited condensed consolidated statements of operations. As of September 30, 2024, approximately $652 of acceleration floor payments owed to the holder are included in accrued expenses and other current liabilities on the Companyâ€™s unaudited condensed consolidated balance sheets. The conversions and floor acceleration payments resulted in debt extinguishment losses of $1,050 and $1,501 in the three and nine month periods ended September 30, 2024, respectively. Â Lucid Diagnostics - Senior Secured Convertible Note Â Following the deconsolidation of Lucid, the Lucid March 2023 Senior Convertible Note is no longer reflected in the Companyâ€™s unaudited condensed consolidated balance sheets. See Note 4, Equity Method Investment, for additional information on the deconsolidation of Lucid. Â During the period of January 1, 2024 through September 10, 2024, the date of Lucidâ€™s deconsolidation, approximately $2,005 of principal repayments along with approximately $787 of interest expense thereon, were settled through the issuance of 4,172,002 shares of common stock of Lucid, with such shares having a fair value of approximately $3,801 (with such fair value measured as the respective conversion date quoted closing price of the common stock of Lucid). The conversions resulted in debt extinguishment losses of $328 in the period July 1, 2024 through September 10, 2024. The conversions resulted in debt extinguishment losses of $1,009 in the period of January 1, 2024 through September 10, 2024. Â During the three and nine month periods ended September 30, 2024, the Company recognized debt extinguishment losses in total of approximately $1,403 and $2,535, respectively, in connection with the Company or Lucid (as applicable) issuing shares of its common stock for principal repayments on convertible debt mentioned above. During the three and nine month periods ended September 30, 2023, the Company recognized debt extinguishment losses in total of approximately $1,764 and $3,032, respectively. Â See Note 10, Financial Instruments Fair Value Measurements, for a further discussion of fair value assumptions. Â Â X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation 9 Months Ended Sep. 30, 2024 Retirement Benefits [Abstract] Â Stock-Based Compensation Note 12 â€“ Stock-Based Compensation Â PAVmed Inc. 2014 Long-Term Incentive Equity Plan Â The PAVmed Inc. 2014 Long-Term Incentive Equity Plan (the â€œPAVmed 2014 Equity Planâ€) is designed to enable PAVmed to offer employees, officers, directors, and consultants, as defined, an opportunity to acquire shares of common stock of PAVmed. The types of awards that may be granted under the PAVmed 2014 Equity Plan include stock options, stock appreciation rights, restricted stock, and other stock-based awards subject to limitations under applicable law. All awards are subject to approval by the PAVmed compensation committee. Â A total of 1,835,970 shares of common stock of PAVmed are reserved for issuance under the PAVmed 2014 Equity Plan, with 79,321 shares available for grant as of September 30, 2024. The share reservation is not diminished by a total of 66,720 PAVmed stock options and restricted stock awards granted outside the PAVmed 2014 Equity Plan as of September 30, 2024. In January 2024, the number of shares available for grant was increased by 432,452 in accordance with the evergreen provisions of the plan. Â PAVmed Stock Options Â PAVmed stock options granted under the PAVmed 2014 Equity Plan and stock options granted outside such plan are summarized as follows: Â Schedule of Summarizes Information About Stock Options Â Â Number of Stock OptionsÂ Â Weighted Average Exercise PriceÂ Â Remaining Contractual Term (Years)Â Â Intrinsic Value(2)Â Outstanding stock options at December 31, 2023Â Â 1,192,458Â Â $26.18Â Â Â 7.3Â Â $â€”Â Granted(1)Â Â 79,500Â Â $2.28Â Â Â Â Â Â Â Â Â Â ExercisedÂ Â â€”Â Â $â€”Â Â Â Â Â Â Â Â Â Â ForfeitedÂ Â (38,851)Â $13.47Â Â Â Â Â Â Â Â Â Â Outstanding stock options at September 30, 2024(3)Â Â 1,233,107Â Â $25.04Â Â Â 5.9Â Â $â€”Â Vested and exercisable stock options at September 30, 2024Â Â 956,977Â Â $30.27Â Â Â 5.1Â Â $â€”Â Â (1)Stock options granted under the PAVmed 2014 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant. (2)The intrinsic value is computed as the difference between the quoted price of the PAVmed common stock on each of September 30, 2024 and December 31, 2023 and the exercise price of the underlying PAVmed stock options, to the extent such quoted price is greater than the exercise price. (3)The outstanding stock options presented in the table above are inclusive of 60,054 stock options granted outside the PAVmed 2014 Equity Plan, as of September 30, 2024 and December 31, 2023. Â On February 22, 2024, the Company granted 59,500 stock options under the PAVmed Inc 2014 Equity Plan with a weighted average exercise price of $1.85. Each such option will vest one-third after one year then ratably over the next eight quarters. In addition, on February 22, 2024, a total of 390,000 restricted stock awards were granted to the Board of Directors under the PAVmed 2014 Equity Plan, with such restricted stock awards having an aggregate fair value of approximately $0.7 million, which was measured using the respective grant date quoted closing price per share of PAVmed common stock, with the fair value recognized as stock-based compensation expense ratably on a straight-line basis over the vesting period, which is commensurate with the service period. The vesting of the restricted stock awards vest ratably on an annual basis over a three year period with the initial annual vesting date of November 30, 2024. The restricted stock awards are subject to forfeiture if the requisite service period is not completed. Â PAVmed Restricted Stock Awards Â PAVmed restricted stock awards granted under the PAVmed 2014 Equity Plan and restricted stock awards granted outside such plan are summarized as follows: Â Schedule of Restricted Stock Award ActivityÂ Â Â Number of Restricted Stock AwardsÂ Â Weighted Average Grant Date Fair ValueÂ Unvested restricted stock awards as of December 31, 2023Â Â 70,527Â Â $38.77Â GrantedÂ Â 390,000Â Â Â 1.85Â VestedÂ Â (135,080)Â Â Â 2.00Â ForfeitedÂ Â â€”Â Â Â â€”Â Unvested restricted stock awards as of September 30, 2024Â Â 325,447Â Â $9.79Â Â Â Â Note 12 â€“ Stock-Based Compensation - continued Â Lucid Diagnostics Inc. 2018 Long-Term Incentive Equity Plan Â The Lucid

Diagnostics Inc. 2018 Long-Term Incentive Equity Plan (â€œLucid Diagnostics 2018 Equity Planâ€) is separate and apart from the PAVmed 2014 Equity Plan discussed above. The Lucid Diagnostics 2018 Equity Plan is designed to enable Lucid Diagnostics to offer employees, officers, directors, and consultants, an opportunity to acquire shares of common stock of Lucid Diagnostics. The types of awards that may be granted under the Lucid Diagnostics 2018 Equity Plan include stock options, stock appreciation rights, restricted stock, and other stock-based awards subject to limitations under applicable law. All awards are subject to approval by the Lucid Diagnostics compensation committee. Â Please note that following the deconsolidation of Lucid, the Lucid Diagnostics 2018 Long-Term Equity Plan is no longer reflected in the Companyâ€™s unaudited condensed consolidated statements of operations. Lucid continues to be responsible for administering its equity plan. See Note 4, Equity Method Investment, for additional information on the deconsolidation of Lucid Diagnostics. Â Lucid Diagnostics Stock Options Â Lucid Diagnostics stock options granted under the Lucid Diagnostics 2018 Equity Plan and stock options granted outside such plan are summarized as follows: Â Schedule of Summarizes Information About Stock Options Â Â Number of Stock OptionsÂ Â Weighted Average Exercise PriceÂ Â Remaining Contractual Term (Years)Â Â Intrinsic Value(2)Â Outstanding stock options at December 31, 2023Â Â 5,504,383Â Â $2.00Â Â Â 8.5Â Â $765Â Granted(1)Â Â 3,604,000Â Â $1.22Â Â Â Â Â Â Â Â Â ExercisedÂ Â (3,333)Â $1.31Â Â Â Â Â Â Â Â Â ForfeitedÂ Â (417,501)Â $1.63Â Â Â Â Â Â Â Â Â Outstanding stock options at September 10, 2024(3)Â Â 8,687,549Â Â $1.69Â Â Â 8.3Â Â $191Â Vested and exercisable stock options at September 10, 2024Â Â 3,084,682Â Â $2.25Â Â Â 7.1Â Â $191Â Â (1)Stock options granted under the Lucid Diagnostics 2018 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant. (2)The intrinsic value is computed as the difference between the quoted price of the Lucid Diagnostics common stock on each of September 10, 2024 and December 31, 2023 and the exercise price of the underlying Lucid Diagnostics stock options, to the extent such quoted price is greater than the exercise price. (3)The outstanding stock options presented in the table above are inclusive of 523,300 stock options granted outside the Lucid Diagnostics 2018 Equity Plan, as of September 10, 2024 and December 31, 2023. Â On February 22, 2024, Lucid granted 2,895,000 stock options under the Lucid Diagnostics 2018 Equity Plan with a weighted average exercise price of $1.25. Each option will vest one-third after one year then ratably over the next eight quarters. Â Lucid Diagnostics Restricted Stock Awards Â Lucid Diagnostics restricted stock awards granted under the Lucid Diagnostics 2018 Equity Plan and restricted stock awards granted outside such plan are summarized as follows: Â Schedule of Restricted Stock Award Activity Â Â Number of Restricted Stock AwardsÂ Â Weighted Average Grant Date Fair ValueÂ Unvested restricted stock awards as of December 31, 2023Â Â 2,337,440Â Â $8.99Â GrantedÂ Â 1,600,000Â Â Â 1.03Â VestedÂ Â (26,912)Â Â 4.56Â ForfeitedÂ Â (13,088)Â Â 4.56Â Unvested restricted stock awards as of September 10, 2024Â Â 3,897,440Â Â $5.77Â Â In May 2024, a total of 1,600,000 restricted stock awards were granted to management under the Lucid Diagnostics 2018 Equity Plan, with such restricted stock awards having an aggregate fair value of approximately $1.5 million, which was measured using the respective grant date quoted closing price per share of Lucid Diagnostics common stock, with the fair value recognized as stock-based compensation expense ratably on a straight-line basis over the vesting period, which is commensurate with the service period. The vesting of the restricted stock awards vest on a single vest date of May 20, 2026. The restricted stock awards are subject to forfeiture if the requisite service period is not completed. Â Â Note 12 â€” Stock-Based Compensation - continued Â Consolidated Stock-Based Compensation Expense Â The consolidated stock-based compensation expense recognized by each of PAVmed and (through September 10, 2024, the date of PAVmedâ€™s deconsolidation of Lucid) Lucid Diagnostics for both the PAVmed 2014 Equity Plan and the Lucid Diagnostics 2018 Equity Plan, with respect to stock options and restricted stock awards as discussed above, for the periods indicated, was as follows: Â Schedule of Stock-Based Compensation Expense Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Â Â Three Months Ended September 30,Â Â Nine Months Ended September 30,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Cost of revenueÂ $32Â Â $32Â Â $112Â Â $86Â Sales and marketing expensesÂ Â 292Â Â Â 403Â Â Â 1,082Â Â Â 1,302Â General and administrative expensesÂ Â 1,426Â Â Â 1,499Â Â Â 3,717Â Â Â 6,761Â Research and development expensesÂ Â 181Â Â Â 311Â Â Â 805Â Â Â 1,022Â Total stock-based compensation expenseÂ $1,931Â Â $2,245Â Â $5,716Â Â $9,171Â Â Stock-Based Compensation Expense Recognized by Lucid Diagnostics Â As noted, the consolidated stock-based compensation expense presented above is inclusive of stock-based compensation expense recognized by Lucid Diagnostics (through September 10, 2024, the date of PAVmedâ€™s deconsolidation of Lucid) inclusive of each of: stock options granted under the PAVmed 2014 Equity Plan to the three physician inventors of the intellectual property underlying the Amended CWRU License Agreement; and stock options and restricted stock awards granted to employees of PAVmed and non-employee consultants under the Lucid Diagnostics 2018 Equity Plan. The stock-based compensation expense recognized by Lucid Diagnostics (through September 10, 2024, the date of PAVmedâ€™s deconsolidation of Lucid) for both the PAVmed 2014 Equity Plan and the Lucid Diagnostics 2018 Equity Plan, with respect to stock options and restricted stock awards as discussed above, for the periods indicated, was as follows: Â Schedule of Stock-Based Compensation Expense Recognized by Lucid Diagnostics Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Â Â Three Months Ended September 30,Â Â Nine Months Ended September 30,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Lucid Diagnostics 2018 Equity Plan â€” cost of revenueÂ $24Â Â $16Â Â $81Â Â $44Â Lucid Diagnostics 2018 Equity Plan â€” sales and marketingÂ Â 252Â Â Â 228Â Â Â 849Â Â Â 697Â Lucid Diagnostics 2018 Equity Plan â€” general and administrativeÂ Â 548Â Â Â 721Â Â Â 1,484Â Â Â 4,069Â Lucid Diagnostics 2018 Equity Plan â€” research and developmentÂ Â 98Â Â Â 67Â Â Â 356Â Â Â 204Â PAVmed 2014 Equity Plan - cost of revenueÂ Â 9Â Â Â 10Â Â Â 30Â Â Â 26Â PAVmed 2014 Equity Plan - sales and marketingÂ Â 18Â Â Â 106Â Â Â 136Â Â Â 359Â PAVmed 2014 Equity Plan - general and administrativeÂ Â 1Â Â Â 7Â Â Â 5Â Â Â 170Â PAVmed 2014 Equity Plan - research and developmentÂ Â 5Â Â Â 97Â Â Â 148Â Â Â 290Â Total stock-based compensation expense â€” recognized by Lucid DiagnosticsÂ $955Â Â $1,252Â Â $3,089Â Â $5,859Â Total stock-based compensation expenseÂ $955Â Â $1,252Â Â $3,089Â Â $5,859Â Â Â The consolidated unrecognized stock-based compensation expense and weighted average remaining requisite service period with respect to stock options and restricted stock awards issued under the PAVmed 2014 Equity Plan, as discussed above, is as follows: Â Schedule of Unrecognized Compensation Expense Â Â Unrecognized ExpenseÂ Â Weighted Average Remaining Service Period (Years)Â PAVmed 2014 Equity PlanÂ Â Â Â Â Â Â Â Stock OptionsÂ $1,377Â Â Â Â 1.5Â Restricted Stock AwardsÂ $397Â Â Â Â 2.2Â Â Â Â Note 12 â€” Stock-Based Compensation - continued Â Stock-based compensation expense recognized with respect to stock options granted under the PAVmed 2014 Equity Plan was based on a weighted average estimated fair value of such stock options of $1.47 per share and $5.25 per share during the nine month periods ended September 30, 2024 and 2023, respectively, calculated using the following weighted average Black-Scholes valuation model assumptions: Â Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions Â Â Nine Months Ended September 30,Â Â Â 2024Â Â 2023Â Expected term of stock options (in years)Â Â 5.8Â Â Â Â 5.7Â Expected stock price volatilityÂ Â 90%Â Â 88% Risk free interest rateÂ Â 4.3%Â Â 3.7% Expected dividend yieldÂ Â â€”%Â Â â€”% Â Stock-based compensation expense recognized with respect to stock options granted under the Lucid Diagnostics 2018 Equity Plan was based on a weighted average estimated fair value of such stock options of $0.79 per share and $0.88 per share during the nine month periods ended September 30, 2024 (through September 10, 2024, the date of PAVmedâ€™s consolidation of Lucid) and 2023, respectively, calculated using the following weighted average Black-Scholes valuation model assumptions: Â Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions Â Â Nine Months Ended September 30,Â Â Â 2024Â Â 2023Â Expected term of stock options (in years)Â Â 5.7Â Â Â Â 5.6Â Expected stock price volatilityÂ Â 73%Â Â 75% Risk free interest rateÂ Â 4.3%Â Â 3.7% Expected dividend yieldÂ Â â€”%Â Â â€”% Â PAVmed Inc. Employee Stock Purchase Plan (â€œPAVmed ESPPâ€) Â A total of 34,332 shares and 38,216 shares of common stock of the Company were purchased for proceeds of approximately $62 and $182, on March 31, 2024 and 2023, respectively, under the PAVmed ESPP. A total of 20,267 shares of common stock of the Company were purchased for proceeds of approximately $76 on September 30, 2023 under the PAVmed ESPP. The March 31, 2023 purchase was partially settled through the redeployment of 12,590 shares of treasury stock. The PAVmed ESPP has a total reserve of 300,001 shares of common stock of PAVmed of which 139,863 shares are available for issue as of September 30, 2024. In January 2024, the number of shares available-for-issue was increased by 166,667 in accordance with the evergreen provisions of the plan. Â Effective September 18, 2024, PAVmedâ€™s compensation committee temporarily suspended any participation in the PAVmed ESPP. Accordingly, no shares of common stock of the Company have been purchased under the PAVmed ESPP since March 31, 2024. Â Lucid Diagnostics Inc. Employee Stock Purchase Plan (â€œLucid ESPPâ€) Â A total of 511,884 shares and 231,987 shares of common stock of Lucid Diagnostics were purchased for proceeds of approximately $353 and $276 on March 31, 2024 and 2023, respectively, under the Lucid ESPP. A total 276,213 shares of common stock of Lucid Diagnostics were purchased for proceeds of approximately $275 on September 30, 2023 under the Lucid ESPP. Â Â X - DefinitionThe entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 710 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/710/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 712 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/712/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 715 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/715/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent + Details Name: us-gaap_CompensationAndEmployeeBenefitPlansTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CompensationAndRetirementDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Preferred Stock 9 Months Ended Sep. 30, 2024 Equity [Abstract] Â Preferred Stock Note 13 â€” Preferred Stock Â As of September 30, 2024 and December 31, 2023, there were 1,385,149 and 1,305,213 shares of PAVmed Series B Convertible Preferred Stock, classified in permanent equity, issued and outstanding, respectively. Â PAVmed Series B Convertible Preferred Stock Dividends Â The Series B Convertible Preferred Stock is issued pursuant to the PAVmed Inc. Certificate of Designation of Preferences, Rights, and Limitations of Series B Convertible Preferred Stock (â€œSeries B Convertible Preferred Stock Certificate of Designationâ€), has a par value of $0.001 per share, no voting rights, a stated value of $3.00 per share, and was immediately convertible upon its issuance. At the holdersâ€™ election, fifteen shares of Series B Convertible Preferred Stock are currently convertible into one share of common stock of the Company, subject to further adjustment for the effect of future stock dividends, stock splits or similar events affecting the Companyâ€™s common stock. The Series B Convertible Preferred Stock shall not be redeemed for cash and under no circumstances shall the Company be required to net cash settle the Series B Convertible Preferred Stock. Â The PAVmed Inc. Series B Convertible Preferred Stock dividends are 8.0% per annum based on the $3.00 per share stated value of the Series B Convertible Preferred Stock, with such dividends compounded quarterly, accumulate, and are payable in arrears upon being declared by the Companyâ€™s board of directors. Such dividends may be settled, at the discretion of the board of directors, through any combination of the issue of additional shares of Series B Convertible Preferred Stock, the issue shares of common stock of the Company, and /or cash payment. Â PAVmed Series B Convertible Preferred Stock Dividends Earned Â The Series B Convertible Preferred Stock dividends earned are included in the calculation of basic and diluted net loss attributable to PAVmed common stockholders for each of the respective corresponding periods presented in the accompanying unaudited condensed consolidated statement of operations, inclusive of $83 and $244 of such dividends earned in the three and nine month periods ended September 30, 2024, respectively; and $77 and $226 of such dividends earned in the three and nine month periods ended September 30, 2023, respectively. Â PAVmed Series B Convertible Preferred Stock Dividends Declared Â During the nine months ended September 30, 2024, the Companyâ€™s board of directors declared an aggregate of approximately $239 of Series B Convertible Preferred Stock dividends, inclusive of $78 earned as of December 31, 2023; and $80 earned as of March 31, 2024; and $81 earned as of June 30, 2024, with such dividends settled by the issue of an aggregate 79,936 additional shares of Series B Convertible Preferred Stock, inclusive of 26,123 shares issued with respect to the dividends earned as of December 31, 2023; and 26,640 shares issued with respect to the dividends earned as of March 31, 2024; and 27,173 shares issued with respect to the dividends earned as of June 30, 2024. Â During the nine months ended September 30, 2023, the Companyâ€™s board of directors declared an aggregate of approximately $221 of Series B Convertible Preferred Stock dividends, inclusive of $72 earned as of December 31, 2022; and $74 earned as of March 31, 2023; and $75 earned as of June 30, 2023, with such dividends settled by the issue of an aggregate 73,842 additional shares of Series B Convertible Preferred Stock, inclusive of 24,128 shares issued with respect to the dividends earned as of December 31, 2022; and 24,610 shares issued with respect to the dividends earned as of March 31, 2023; and 25,104 shares issued with respect to the dividends earned as of June 30, 2023. Â Subsequent to September 30, 2024, in November 2024, the Companyâ€™s board of directors declared a PAVmed Series B Convertible Preferred Stock dividend, earned as of September 30, 2024, of $83, to be settled by the issue of 27,716 additional shares of Series B Convertible Preferred Stock. Â The PAVmed Series B Convertible Preferred Stock dividends are recognized as a dividend payable liability only upon the dividend being declared payable by the Companyâ€™s board of directors. Accordingly, the dividends declared payable subsequent to the date of the accompanying unaudited condensed consolidated balance sheet were not recognized as a dividend payable liability as the Companyâ€™s board of directors had not declared the dividends payable as of each such date. Â Â X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContent + Details Name: us-gaap_PreferredStockTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Common Stock and Common Stock Purchase Warrants 9 Months Ended Sep. 30, 2024 Equity [Abstract] Â Common Stock and Common Stock Purchase Warrants Note 14 â€” Common Stock and Common Stock Purchase Warrants Â Common Stock Â In February 2023, the Company distributed a proxy statement for a special meeting of shareholders that was held on March 31, 2023 (the â€œSpecial Meetingâ€), at which the Company sought approval of an amendment to the Companyâ€™s Certificate of Incorporation, to effect, (i) a reverse split of the Companyâ€™s outstanding shares of common stock at a specific ratio, ranging from 1-for-5 to 1-for-15, to be determined by the board of directors of the Company in its sole discretion, and (ii) an associated reduction in the number of shares of common stock the Company is authorized to issue, from 250,000,000 shares to 50,000,000 shares. On March 31, 2023, the shareholders approved the above proposal to amend the Companyâ€™s Certificate of Incorporation, to effect, at any time prior to the one-year anniversary date of the Special Meeting. On November 28, 2023 the Companyâ€™s board of directors, unanimously authorized management to effect the reverse split at the ratio of 1-for-15. The reverse stock split became effective on December 7, 2023. At the effective date, every 15 shares of the Companyâ€™s common stock that were issued and outstanding were automatically combined into one issued and outstanding share, without any change in par value of such shares. No fractional shares were issued in connection with the reverse stock split. Instead, each fractional share remaining after completion of the reverse stock split that was less than a whole share was rounded up to one whole share. The reverse stock split also correspondingly affected all outstanding PAVmed equity awards and outstanding convertible securities. Â On March 7, 2024, the Company received a notice from the Listing Qualifications Department of The Nasdaq Stock Market (â€œNasdaqâ€) stating that, for the prior 30 consecutive business days (through March 6, 2024), the market value of the Companyâ€™s listed securities had been below the minimum of $35 million required for continued inclusion on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2). The Company was provided 180 calendar days, or until September 3, 2024, to regain compliance with the rule. The Company did not regain compliance with the rule during the allotted time period. Accordingly, on September 10, 2024, the Company received a staff determination letter from the Nasdaq Listing Qualifications Department, stating that unless the Company timely requested a hearing before a Nasdaq Hearings Panel (the â€œPanelâ€) to appeal the staff determination, the Companyâ€™s securities would be subject to suspension and delisting. The Company timely requested a hearing before the Panel, which was held on October 29, 2024. Â On November 8, 2024, the Panel granted the Company an extension, until January 31, 2025, to regain compliance with the Nasdaq continued listing standards. Â During the extension granted by the Panel, the Companyâ€™s common stock and Series Z warrants will continue to trade uninterrupted under the symbol â€œPAVMâ€ and â€œPAVMZâ€, respectively. Â During the nine months ended September 30, 2024 a total of 34,332 shares of common stock of the Company were issued under the PAVmed ESPP. See Note 12, Stock-Based Compensation, for a discussion of each of the PAVmed 2014 Equity Plan and the PAVmed ESPP. Â In the nine months ended September 30, 2024, 574,424 shares of the Companyâ€™s common stock were issued upon conversion, at the election of the holder, of the April 2022 Senior Convertible Note and the September 2022 Senior Convertible Note, for $980 face value principal repayments, as discussed in Note 11, Debt. Â In the nine months ended September 30, 2024, the Company sold 627,302 shares through their at-the-market equity facility for net proceeds of approximately $977, after payment of 3% commissions. Â In the nine months ended SeptemberÂ 30, 2024, the Company issued 200,809 shares of common stock to vendors

in exchange for $200 of agreed upon services, which is included in general and administrative operating expenses on the Companyâ€™s unaudited condensed consolidated statement of operations. Â PAVmed Distribution of Lucid Diagnostics Common Stock to Shareholders Â On February 15, 2024, the Company distributed by special dividend to the Company stockholders 3,331,747 shares of Lucid Diagnostics common stock held by the Company. On such date, each PAVmed shareholder as of the January 15, 2024 record date received a stock dividend of approximately 38 shares of Lucid common stock for every 100 shares of PAVmed common stock they held as of such date. The shares distributed were approximately equal to the number of shares of common stock that Lucid issued to PAVmed on or about January 26, 2024 in satisfaction of certain intercompany obligations due to Lucid from PAVmed. Â The Companyâ€™s distribution of Lucid common stock to PAVmed stockholders, constituted an â€œExtraordinary Dividendâ€ as defined in the Warrant Agreement. Accordingly, as a result of the distribution, pursuant to Section 4.3 of the Warrant Agreement, the Warrant Price has been decreased by $0.52 (the fair market value of 0.37709668 of a share of Lucid Diagnosticsâ€™ common stock on the distribution date) to $23.48 per share. Â Common Stock Purchase Warrants Â As of September 30, 2024 and December 31, 2023, Series Z Warrants outstanding totaled 11,937,450 representing the right to purchase 795,830 shares of the Companyâ€™s common stock. The Series Z Warrants are now exercisable to purchase one whole share of common stock of the Company at an exercise price of $23.48 ($24.00 post reverse-split, decreased by $0.52 due to distribution of Lucid common stock to PAVmed stockholders, discussed further above). There were no Series Z Warrants exercised during the nine months ended September 30, 2024. Â Â X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Noncontrolling Interest 9 Months Ended Sep. 30, 2024 Noncontrolling Interest [Abstract] Â Noncontrolling Interest Note 15 â€” Noncontrolling Interest Â The noncontrolling interest (â€œNCIâ€) included as a component of consolidated total stockholdersâ€™ equity is summarized for the periods indicated as follows: Â Schedule of Noncontrolling Interest of Stockholders' Equity Â Â September 30, 2024Â NCI â€“ equity - December 31, 2023Â $29,813Â Net loss attributable to NCIÂ Â (11,075) Impact of subsidiary equity transactionsÂ Â (4,414) Lucid Diagnostics proceeds from issuance of preferred stock Series A-1Â Â 5,670Â Lucid Diagnostics exchange of preferred stock Series A and Series A-1Â Â (24,294) Lucid Diagnostics issuance through exchange - Series B and Series B-1 Â Â 31,790Â Lucid Diagnostics issuance through sale - Series B and Series B-1Â Â 24,129Â Lucid Diagnostics deemed dividend on preferred stockÂ Â (7,496) Lucid Diagnostics issuance of common stock for settlement of vendor service agreementÂ Â 401Â Lucid Diagnostics 2018 Equity Plan stock option exerciseÂ Â 4Â Lucid Diagnostics Employee Stock Purchase Plan PurchaseÂ Â 353Â Conversion of Lucid Diagnostics common stock for Senior Secured Convertible DebtÂ Â 3,801Â Stock-based compensation expense - Lucid Diagnostics 2018 Equity PlanÂ Â 2,771Â Stock-based compensation expense - Veris Health 2021 Equity PlanÂ Â 368Â Deconsolidation of LucidÂ Â (56,339) NCI â€“ equity - September 30, 2024Â $(4,518) Â The consolidated NCI presented above is with respect to the Companyâ€™s consolidated subsidiaries as a component of consolidated total stockholdersâ€™ equity as of September 30, 2024 and December 31, 2023; and the recognition of a net loss attributable to the NCI in the unaudited condensed consolidated statement of operations for the periods beginning on the acquisition date of the respective subsidiaries. Â Lucid Diagnostics â€“ Deconsolidation Â As of September 30, 2024, there were 51,597,718 shares of common stock of Lucid Diagnostics issued and outstanding, of which, PAVmed held 31,302,444 shares. On September 10, 2024, following preferred equity transactions completed by Lucid earlier in 2024 and the termination of voting proxies entered into between PAVmed and certain shareholders of Lucid, PAVmedâ€™s voting interest in the Company was reduced to less than 50.0%, resulting in the loss of a controlling financial interest. However, PAVmed retains the ability to exercise significant influence over Lucid. Upon deconsolidation, the Companyâ€™s ownership of 31,302,444 shares of Lucid Diagnostics common stock was valued at $25.1 million, which resulted in a gain on deconsolidation of $72.3 million in the accompanying unaudited condensed consolidated statements of operations for the three and nine months ended September 30, 2024. Â Lucid Diagnostics â€“ Intercompany Obligation Settlement; Special Distribution Â On January 26, 2024 PAVmed elected to receive payment of $4,675 of fees and reimbursements due from Lucid, through the issuance of 3,331,771 shares of Lucid Diagnostics common stock. On February 15, 2024, the Company distributed by special dividend to the Company stockholders, as of the record date noted above, 3,331,747 shares of Lucid Diagnostics common stock held by the Company. Â Lucid Diagnostics â€“ Convertible Preferred Stock Offerings Â On March 7, 2023, Lucid issued 13,625 shares of newly designated Lucid Series A Convertible Preferred Stock (the â€œLucid Series A Preferred Stockâ€). Each share of the Lucid Series A Preferred Stock has a stated value of $1,000 and a conversion price of $1.394. The Lucid Series A Preferred Stock is convertible into shares of Lucid Diagnosticsâ€™ common stock at any time at the option of the holder from and after the six-month anniversary of its issuance, and automatically converts into shares of Lucid Diagnosticsâ€™ common stock on the second anniversary of its issuance. The terms of the Lucid Series A Preferred Stock also include a one times preference on liquidation and a right to receive dividends equal to 20% of the number of shares of Lucid common stock into which such Lucid Series A Preferred Stock is convertible, payable on the one-year and two-year anniversary of the issuance date. The Lucid Series A Preferred Stock is a non-voting security, other than with respect to limited matters related to changes in terms of the Lucid Series A Preferred Stock. The aggregate gross proceeds from the sale of shares in such offering were $13.625 million. Â Â Note 15 â€“ Noncontrolling Interest - continued Â On March 13, 2024, Lucid issued an additional 5,670 shares of Lucid Series A-1 Preferred Stock, for aggregate gross proceeds of $5.67 million. Â On March 13, 2024, Lucid issued 44,285 shares of newly designated Lucid Series B Convertible Preferred Stock (the â€œLucid Series B Preferred Stockâ€). The terms of the Lucid Series B Preferred Stock are substantially identical to the terms of the Lucid Series A Preferred Stock and the Lucid Series A-1 Preferred Stock, except that the Lucid Series B Preferred Stock has a conversion price of $1.2444, and the holders of the Lucid Series B Preferred Stock vote with the common stock on an as-converted basis (subject to any applicable ownership limitations). On the same day, Lucid issued an additional 5,670 shares of Lucid Series A-1 Preferred Stock, for aggregate gross proceeds of $5.67 million (all of which shares were immediately exchanged for shares of Lucid Series B Preferred Stock). The aggregate gross proceeds from the sale of shares in such offering were $18.1 million. Â As a result of 100% of the then-outstanding shares of Lucid Series A Preferred Stock and Lucid Series A-1 Preferred Stock being exchanged for shares of Lucid Series B Preferred Stock in the Lucid Series B Offering and Exchange, no shares of Lucid Series A Preferred Stock or Lucid Series A-1 Preferred Stock remain outstanding. Â On May 6, 2024, Lucid issued approximately 11,634 shares of newly designated Lucid Series B-1 Convertible Preferred Stock (the â€œLucid Series B-1 Preferred Stockâ€). The terms of the Lucid Series B-1 Preferred Stock are substantially identical to the terms of the Lucid Series B Preferred Stock, except that the Lucid Series B-1 Preferred Stock has a conversion price of $0.7228. The aggregate gross proceeds from the sale of shares in such offering were $11.6 million. Â Lucid Diagnostics â€“ Deemed Dividend on Series A and Series A-1 Convertible Preferred Stock Exchange Offer Â The fair value of the consideration given in the form of the issue of 31,790 shares of Lucid Series B Convertible Preferred Stock, with such fair value recognized as the carrying value of such issued shares of Lucid Series B Convertible Preferred Stock, as compared to the carrying value of the extinguished Lucid Series A and Lucid Series A-1 Convertible Preferred Stock (carrying value of $24,294), resulting in an excess of fair value of $7.5 million recognized as a deemed dividend charged to accumulated deficit in the unaudited condensed consolidated balance sheet on March 13, 2024, with such deemed dividend included as a component of net loss attributable to common stockholders, summarized as follows: Â Schedule of Net Loss Attributable to Common Stockholders Lucid Series B Convertible Preferred Stock Issuance and Series A/A-1 Exchange OfferÂ March 13, 2024Â Fair Value - 31,790 shares of Lucid Series B Preferred Stock issuedÂ $31,790Â Fair Value - 31,790 shares of Lucid Series B Preferred Stock issued in exchange for Lucid Series A and Lucid Series A-1 Preferred StockÂ $31,790Â Less: Carrying value related to Lucid Series A and Lucid Series A-1 Preferred Stock Exchanged for Lucid Series B Preferred Stock (of 24,295 shares)Â Â (24,294) Deemed Dividend Charged to Accumulated DeficitÂ $7,496Â Â Â X - DefinitionThe entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContent + Details Name: us-gaap_MinorityInterestDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NoncontrollingInterestAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Net Income (Loss) Per Share 9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] Â Net Income (Loss) Per Share Note 16 â€” Net Income (Loss) Per Share Â The Net income (loss) per share - attributable to PAVmed Inc. - basic and diluted and Net income (loss) per share - attributable to PAVmed Inc. common stockholders - basic and diluted - for the respective periods indicated - is as follows: Â Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Â Â Three Months Ended September 30,Â Â Nine Months Ended September 30,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â NumeratorÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net income (loss) - before noncontrolling interestÂ $60,711Â Â $(21,750)Â $27,285Â Â $(61,855) Net income (loss) attributable to noncontrolling interestÂ Â 3,688Â Â Â 4,079Â Â Â 11,075Â Â Â 11,716Â Net income (loss) - as reported, attributable to PAVmed Inc.Â $64,399Â Â $(17,671)Â $38,360Â Â $(50,139) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Series B Convertible Preferred Stock dividends â€“ earnedÂ $(83)Â $(77)Â $(244)Â $(226) Deemed dividend on Subsidiary Preferred Stock attributable to the noncontrolling interestsÂ $â€”Â Â $â€”Â Â $(7,496)Â $â€”Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net income (loss) attributable to PAVmed Inc. common stockholders used in basic EPS calculationÂ $64,316Â Â $(17,748)Â $30,620Â Â $(50,365) Fair Value Adjustment for diluted EPS calculationÂ $(240)Â $â€”Â Â $3,378Â Â $â€”Â Net income (loss) attributable to PAVmed Inc. common stockholders used in dilutive EPS calculationÂ $64,076Â Â $(17,748)Â $33,998Â Â $(50,365) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â DenominatorÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Weighted average common shares outstanding, basicÂ Â 10,005,379Â Â Â 7,462,751Â Â Â 9,286,999Â Â Â 6,967,764Â Weighted average common shares outstanding, dilutedÂ Â 44,475,638Â Â Â 7,462,751Â Â Â 43,069,449Â Â Â 6,967,764Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net income (loss) per share (1)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net income (loss) per share attributable to PAVmed Inc. common stockholders, basic (1)Â $6.43Â Â $(2.38)Â $3.30Â Â $(7.23) Net income (loss) per share attributable to PAVmed Inc. common stockholders, diluted (1)Â $1.44Â Â $(2.38)Â $0.79Â Â $(7.23) Â (1)- Convertible preferred stock and restricted stock awards would potentially be considered a participating security under the two-class method of calculating net income (loss) per share. For periods where losses are presented, such holders are not contractually obligated to share in the losses, there is no impact on the Companyâ€™s net income (loss) per share calculation for the periods indicated. Â The common stock equivalents have been excluded from the computation of diluted weighted average shares outstanding as their inclusion would be anti-dilutive, are as follows: Â The Series B Convertible Preferred Stock dividends earned as of each of the respective years noted, are included in the calculation of basic and diluted net loss attributable to PAVmed common stockholders for each respective period presented. Notwithstanding, the Series B Convertible Preferred Stock dividends are recognized as a dividend payable only upon the dividend being declared payable by the Companyâ€™s board of directors. Â Basic weighted-average number of shares of common stock outstanding for the nine month periods ended September 30, 2024 and 2023 include the shares of the Company issued and outstanding during such periods, each on a weighted average basis. The basic weighted average number of shares of common stock outstanding excludes common stock equivalent incremental shares, while diluted weighted average number of shares outstanding includes such incremental shares. However, as the Company was in a loss position for the three and nine month periods ended September 30, 2023, basic and diluted weighted average shares outstanding are the same, as the inclusion of the incremental shares would be anti-dilutive. The common stock equivalents excluded from the computation of diluted weighted average shares outstanding are as follows: Â Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share Â Â 2024Â Â 2023Â Â Â September 30,Â Â Â 2024Â Â 2023Â Stock optionsÂ Â 1,233,107Â Â Â 1,138,632Â Restricted stock awardsÂ Â â€”Â Â Â 70,528Â Series Z WarrantsÂ Â 795,830Â Â Â 795,830Â Series B Convertible Preferred StockÂ Â â€”Â Â Â 85,307Â TotalÂ Â 2,028,937Â Â Â 2,090,297Â Â The total stock options and restricted stock awards are inclusive of 60,054 and 33,391 stock options as of September 30, 2024 and 2023, respectively, granted outside the PAVmed 2014 Equity Plan. X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Basis of Presentation Basis of Presentation Â The accompanying unaudited condensed consolidated financial statements of PAVmed and those of its wholly owned subsidiaries and variable interest entities have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œU.S. GAAPâ€), and applicable rules and regulations of the United States Securities and Exchange Commission (â€œSECâ€). All intercompany transactions and balances have been eliminated in consolidation. The Company has a controlling financial interest in Veris Health Inc., with the corresponding noncontrolling interest included as a separate component of consolidated stockholdersâ€™ equity (deficit), including the recognition in the unaudited condensed consolidated statement of operations of a net loss attributable to the noncontrolling interest based on the respective minority-interest equity ownership of each subsidiary. As of September 10, 2024, PAVmed ceased to have a controlling financial interest in Lucid Diagnostics and therefore PAVmedâ€™s consolidated results of operations include Lucid Diagnosticsâ€™ results of operations only through that date. The deconsolidation of Lucid Diagnostics has resulted in a gain recognized in PAVmedâ€™s statement of operations for the periods ended September 30, 2024. Moving forward, PAVmed will account for its investment in Lucid Diagnostics using the equity method and the fair value option. See below and Note 4, Equity Method Investment for a discussion on the impact of the deconsolidation of Lucid Diagnostics. See Note 15, Noncontrolling Interest, for a discussion of each of the subsidiaries noted above. The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. Â As permitted under SEC rules, certain footnotes or other financial information normally required by U.S. GAAP have been condensed or omitted. The balance sheet as of December 31, 2023 has been derived from audited consolidated financial statements at such date. The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the Companyâ€™s annual consolidated financial statements, and in the opinion of management, include all adjustments, consisting only of routine recurring adjustments, necessary for a fair statement of the Companyâ€™s unaudited condensed consolidated financial information. Â The unaudited condensed consolidated results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the consolidated results to be expected for the year ending December 31, 2024 or for any other interim period or for any other future periods. The accompanying unaudited condensed consolidated financial statements and related unaudited condensed consolidated financial information should be read in conjunction with the Companyâ€™s audited consolidated financial statements and related notes thereto as of and for the year ended December 31, 2023 included in the Companyâ€™s Annual Report on Form 10-K as filed with the SEC on March 25, 2024. Â All amounts in the accompanying unaudited condensed consolidated financial statements and the notes thereto are presented in thousands of dollars, if not otherwise noted as being presented in millions of dollars, except for shares and per share amounts. Â Cash Cash Â The Company maintains its cash at a major financial institution with high credit quality. At times, the balance of its cash deposits may exceed federally insured limits. The Company has not experienced losses on deposits with commercial banks and financial institutions which exceed federally insured limits. Â Included in the Companyâ€™s cash as of September 30, 2024 and December 31, 2023 is $299 related to a restricted deposit account for a standby letter of credit associated with our corporate headquarters which has a lease maturity date in 2030. Â Use of Estimates Use of Estimates Â In preparing the unaudited condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and the determination of corresponding carrying value reserve, if any, and liabilities and the disclosure of contingent losses, as of the date of the unaudited condensed consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Significant estimates in these unaudited condensed consolidated financial statements include those related to the estimated fair value of debt obligations, stock-based equity awards, intangible assets and common stock purchase warrants. Other significant estimates include the estimated incremental borrowing rate, the provision or benefit for income taxes and the corresponding valuation allowance on deferred tax assets. Additionally, managementâ€™s assessment of the Companyâ€™s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. On an ongoing basis, the Company evaluates its estimates and assumptions. The Company bases its estimates on historical experience and on various other assumptions believed to be reasonable. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. Â Â Note 3 â€” Summary of Significant Accounting Policies - continued Â Revenue Recognition Revenue Recognition Â Revenues are recognized when the satisfaction of the performance obligation occurs, in an amount that reflects the consideration the Company expects to collect in exchange for those services. The Companyâ€™s revenue was primarily generated by Lucidâ€™s laboratory testing services utilizing its EsoGuard Esophageal DNA tests. The services were completed upon release of a patientâ€™s test result to the ordering healthcare provider. Revenue recognized is inclusive of both variable consideration in connection with an individual patientâ€™s third-party insurance coverage policy and fixed consideration in connection with a contracted services arrangement with an unrelated third party legal entity. To determine revenue recognition for the arrangements that the Company determines are within the scope of ASC 606, Revenue from Contracts with Customers, the Company performs the following five steps: (1) identify the contract(s) with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation. Â The key aspects considered by the Company include the following: Â Contractsâ€”The Companyâ€™s customer is primarily the patient, but the Company does not enter into a formal reimbursement contract with a patient. The Company establishes a contract with a patient in accordance with other customary business practices, which is the point in time an order is received from a provider and a patient specimen has been returned to the laboratory for testing. Payment terms are a function of a patientâ€™s existing insurance benefits, including the impact of coverage decisions with Center for Medicare & Medicaid Services (â€œCMSâ€) and applicable reimbursement contracts established between the Company and payers. However, when a patient is considered self-pay, the Company requires payment from the patient prior to the commencement of the Companyâ€™s performance obligations. The Companyâ€™s consideration can be deemed variable or fixed depending on the structure of specific payer contracts, and the Company considers collection of such consideration to be probable to the extent that it is unconstrained. Â Performance obligationsâ€”A performance obligation is a promise in a contract to transfer a distinct good or service (or a bundle of goods or services) to the customer. The Companyâ€™s contracts have a single performance obligation, which is satisfied upon rendering of services, which culminates in the release of a patientâ€™s test result to the ordering healthcare provider. The Company elects the practical expedient related to the disclosure of unsatisfied performance obligations, as the duration of time between providing testing supplies, the receipt of a sample, and the release of a test result to the ordering healthcare provider is far less than one year. Â Transaction priceâ€”The transaction price is the amount of consideration that the Company expects to collect in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). The consideration expected to be collected from a contract with a customer may include fixed amounts, variable amounts, or both. Â If the consideration derived from the contracts is deemed to be variable, the Company estimates the amount of consideration to which it will be entitled in exchange for the promised goods or services. The Company limits the amount of variable consideration included in the transaction price to the unconstrained portion of such consideration. In other words, the Company recognizes revenue up to the amount of variable consideration that is not subject to a significant reversal until additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved. Â When the Company does not have significant historical experience or that experience has limited predictive value, the constraint over estimates of variable consideration may result in no revenue being recognized upon delivery of patient EsoGuard test results to the ordering healthcare provider. As such, the Company recognizes revenue up to the amount of variable consideration not subject to a significant reversal until additional information is obtained or the uncertainty associated with additional payments or refunds, if any, is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in estimated expected variable consideration, with the change in estimate recognized in the period of such revised estimate. With respect to a contracted service arrangement, the fixed consideration revenue is recognized on an as-billed basis upon delivery of the laboratory test report with realization of such fixed consideration deemed probable based upon actual historical experience. Â Allocate transaction priceâ€”The transaction price is allocated entirely to the performance obligation contained within the contract with a customer on the basis of the relative standalone selling prices of each distinct good or service. Â Practical Expedientsâ€”The Company does not adjust the transaction price for the effects of a significant financing component, as at contract inception, the Company expects the collection cycle to be one year or less. Â Â Note 3 â€” Summary of Significant Accounting Policies - continued Â Equity Method Investments Equity Method Investments Â Businesses that are not consolidated, but over which PAVmed exercises significant influence, are accounted for under the equity method of accounting. The determination as to whether or not PAVmed exercises significant influence with respect to a company depends on an evaluation of several factors, including, among others, representation on the companyâ€™s board of directors and equity ownership level, which is generally between a 20% and a 50% interest in the voting securities of an equity method business, as well as voting rights associated with PAVmedâ€™s holdings in common stock in that company. PAVmed accounts for Lucid Diagnostics as an equity method investment beginning on September 10, 2024, and the period ended September 30, 2024. Â Fair Value Option (â€œFVOâ€) Election Fair Value Option (â€œFVOâ€) Election Â Under a Securities Purchase Agreement dated March 31, 2022, the Company issued a Senior Secured Convertible Note dated April 4, 2022, referred to herein as the â€œApril 2022 Senior Convertible Noteâ€, and a Senior Secured Convertible Note dated September 8, 2022, referred to herein as the â€œSeptember 2022 Senior Convertible Noteâ€, which are accounted under the â€œfair value option electionâ€ as discussed below. Â Under a Securities Purchase Agreement dated March 13, 2023, Lucid Diagnostics issued a Senior Secured Convertible Note dated March 21, 2023, referred to herein as the â€œLucid March 2023 Senior Convertible Noteâ€, which is accounted under the â€œfair value option electionâ€, through September 10, 2024, the date of Lucidâ€™s deconsolidation from PAVmedâ€™s results of operations, as discussed below. Â Under Financial Accounting Standards Board (â€œFASBâ€) Accounting Standards Codification (â€œASCâ€) Topic 815, Derivative and Hedging, (â€œASC 815â€), a financial instrument containing embedded features and/or options may be required to be bifurcated from the financial instrument host and recognized as separate derivative asset or liability, with the bifurcated derivative asset or liability initially measured at estimated fair value as of the transaction issue date and then subsequently remeasured at estimated fair value as of each reporting period balance sheet date. Â Alternatively, FASB ASC Topic 825, Financial Instruments, (â€œASC 825â€) provides for the â€œfair value optionâ€ (â€œFVOâ€) election. In this regard, ASC 825-10-15-4 provides for the FVO election (to the extent not otherwise prohibited by ASC 825-10-15-5) to be afforded to financial instruments, wherein the financial instrument is initially measured at estimated fair value as of the transaction issue date and then subsequently remeasured at estimated fair value as of each reporting period balance sheet date, with changes in the estimated fair value recognized as other income (expense) in the statement of operations. The estimated fair value adjustment of the April 2022 Senior Convertible Note, the September 2022 Senior Convertible Note and (through September 10, 2024, Lucidâ€™s deconsolidation date) the Lucid March 2023 Senior Convertible Note, including the component related to accrued interest, is presented in a single line item within other income (expense) in the accompanying unaudited condensed consolidated statement of operations (as provided for by ASC 825-10-50-30(b)). Further, as required by ASC 825-10-45-5, to the extent a portion of the fair value adjustment is attributed to a change in the instrument-specific credit risk, such portion would be recognized as a component of other comprehensive income (â€œOCIâ€) (for which there was no such adjustment with respect to the April 2022 Senior Convertible Note, the September 2022 Senior Convertible Note or (through September 10, 2024, Lucidâ€™s deconsolidation date) the Lucid March 2023 Senior Convertible Note). Â See Note 10, Financial Instruments Fair Value Measurements, with respect to the FVO election; and Note 11, Debt, for a discussion of the April 2022 Senior Convertible Note, the September 2022 Senior Convertible Note and the Lucid March 2023 Senior Convertible Note. Â From and after September 10, 2024, the date of Lucidâ€™s deconsolidation from PAVmedâ€™s results of operation, the Companyâ€™s investment in Lucid is treated as an equity method investment accounted for using the fair value option. Shares of Lucid Diagnostics common stock have a readily determinable fair value classified as Level 1, in which the fair value is determined based upon quoted market prices in an active market. Â Recent Accounting Standards Updates Not Yet Adopted Recent Accounting Standards Updates Not Yet Adopted Â In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740)â€”Improvements to Income Tax Disclosures (â€œASU 2023-09â€), which is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 provide for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for the Company prospectively to all annual periods beginning after December 15, 2024. Early adoption is permitted. The Company does not expect the standard to have a significant impact on its unaudited condensed consolidated financial statements. Â In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280)â€”Improvements to Reportable Segment Disclosures (â€œASU 2023-07â€), which require public companies disclose significant segment expenses and other segment items on an annual and interim basis and to provide in interim periods all disclosures about a reportable segmentâ€™s profit or loss and assets that are currently required annually. The guidance is effective for public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The guidance is applied retrospectively to all periods presented in the financial statements, unless it is impracticable. The Company is currently evaluating the impact this update will have on its unaudited condensed consolidated financial statements and disclosures, however the Company does not expect the standard to have a significant impact. Â Â Note 3 â€” Summary of Significant Accounting Policies - continued Â In October 2023, the FASB issued ASU No. 2023-06, Disclosure Improvements: Codification Amendments in Response to the SECâ€™s Disclosure Update and Simplification Initiative. This update modifies the disclosure or presentation requirements of a variety of topics in the Accounting Standards Codification to conform with certain SEC amendments in Release No. 33-10532, Disclosure Update and Simplification. The amendments in this update should be applied prospectively, and the effective date for each amendment will be the date on which the SECâ€™s removal of that related disclosure from Regulation S-X or S-K becomes effective. However, if the SEC has not removed the related disclosure from its regulations by June 30, 2027, the amendments will be removed from the Codification and not become effective. Early adoption is prohibited. The Company is currently evaluating the impact this update will have on its unaudited condensed consolidated financial statements and disclosures. X - DefinitionFair Value Option Election [Policy Text Block] + ReferencesNo definition available. + Details Name: PAVM_FairValueOptionElectionPolicyTextBlock Namespace Prefix: PAVM_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionRecent Accounting Standards Updates Not Yet Adopted [Policy Text Block] + ReferencesNo definition available. + Details Name: PAVM_RecentAccountingStandardsUpdatesNotYetAdoptedPolicyTextBlock Namespace Prefix: PAVM_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 21D -SubTopic

10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-21D + Details Name: us-gaap_EquityMethodInvestmentsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for revenue from contract with customer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 9: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Equity Method Investment (Tables) 9 Months Ended Sep. 30, 2024 Equity Method Investments and Joint Ventures [Abstract] Â Schedule of Deconsolidation of Net Assets Schedule of Deconsolidation of Net AssetsÂ Â Â Â Â Assets:Â Â Â Â Current assets:Â Â Â Â CashÂ $16,479Â Prepaid expenses, deposits, and other current assetsÂ Â 3,474Â Total current assetsÂ Â 19,953Â Fixed assets, netÂ Â 964Â Operating lease right-of-use assetsÂ Â 2,871Â Intangible assets, netÂ Â 877Â Other assetsÂ Â 379Â Total assetsÂ Â 25,044Â Liabilities:Â Â Â Â Current liabilities:Â Â Â Â Accounts payableÂ Â 1,069Â Accrued expenses and other current liabilitiesÂ Â 1,674Â Operating lease liabilities, current portionÂ Â 865Â Senior Secured Convertible Notes - at fair valueÂ Â 10,268Â Total current liabilitiesÂ Â 13,876Â Operating lease liabilities, less current portionÂ Â 2,011Â Total liabilitiesÂ Â 15,887Â Net Assets of Lucid Diagnostics at September 10, 2024Â $9,157Â Schedule of Gain on Deconsolidation Schedule of Gain on Deconsolidation Â Â Â Â Â Investment in former Consolidated Subsidiary (Fair Value of Lucid common stock)Â $25,105Â Add: Noncontrolling interest - LucidÂ Â 56,339Â Less: Net Assets of Former Consolidated Subsidiary - LucidÂ Â (9,157) Gain on Deconsolidation of LucidÂ $72,287 Schedule of Aggregate Information From the Financial Statements Schedule of Aggregate Information From the Financial Statements Â Â September 30, 2024Â CashÂ $14,489Â Other current assetsÂ Â 2,335Â Non-current assetsÂ Â 5,774Â Total assetsÂ Â 22,598Â Current liabilitiesÂ Â 14,249Â Non-current liabilitiesÂ Â 2,011Â Shareholdersâ€™ deficitÂ Â 6,338Â Total liabilities and stockholdersâ€™ deficitÂ $22,598Â Â Three months ended September 30, 2024Â July 1, 2024 - September 10, 2024Â Â September 11, 2024 - September 30, 2024Â Â TotalÂ Â Â Â Â Â Â Â Â Â Â RevenueÂ $942Â Â $230Â Â $1,172Â Net income (loss)Â $(9,039)Â $(3,332)Â $(12,371) Â Nine months ended September 30, 2024Â January 1, 2024 - September 10, 2024Â Â September 11, 2024 - September 30, 2024Â Â TotalÂ Â Â Â Â Â Â Â Â Â Â RevenueÂ $2,919Â Â $230Â Â $3,149Â Net income (loss)Â $(38,152)Â $(3,332)Â $(41,484) X - DefinitionEquity Method Investments Aggregate Information [Table Text Block] + ReferencesNo definition available. + Details Name: PAVM_EquityMethodInvestmentsAggregateInformationTableTextBlock Namespace Prefix: PAVM_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionEquity Method Investments Gain Deconsolidation [Table Text Block] + ReferencesNo definition available. + Details Name: PAVM_EquityMethodInvestmentsGainDeconsolidationTableTextBlock Namespace Prefix: PAVM_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionSchedule of Deconsolidation of Net Assets [Table Text Block] + ReferencesNo definition available. + Details Name: PAVM_ScheduleOfDeconsolidationOfNetAssetsTableTextBlock Namespace Prefix: PAVM_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Prepaid Expenses, Deposits, and Other Current Assets (Tables) 9 Months Ended Sep. 30, 2024 Prepaid Expenses Deposits And Other Current Assets Â Schedule of Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following as of: Schedule of Prepaid Expenses and Other Current AssetsÂ Â Â September 30, 2024Â Â December 31, 2023Â Advanced payments to service providers and suppliersÂ $181Â Â $739Â Prepaid insuranceÂ Â 420Â Â Â 848Â DepositsÂ Â 480Â Â Â 2,672Â Veris Box suppliesÂ Â 262Â Â Â 261Â Total prepaid expenses, deposits and other current assetsÂ $1,343Â Â $4,520Â X - ReferencesNo definition available. + Details Name: PAVM_DisclosurePrepaidExpensesDepositsAndOtherCurrentAssetsAbstract Namespace Prefix: PAVM_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs. + ReferencesNo definition available. + Details Name: us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Leases (Tables) 9 Months Ended Sep. 30, 2024 Leases Â Schedule of Future Minimum Lease Payments for Operating Leases The Companyâ€™s future lease payments as of September 30, 2024, which are presented as operating lease liabilities, current portion and operating lease liabilities, less current portion on the Companyâ€™s unaudited condensed consolidated balance sheets are as follows: Schedule of Future Minimum Lease Payments for Operating LeasesÂ Â Â Â Â Â 2024 (remainder of year)Â $174Â 2025Â Â 708Â 2026Â Â 724Â 2027Â Â 594Â 2028Â Â 471Â ThereafterÂ Â 848Â Total lease paymentsÂ $3,519Â Less: imputed interestÂ Â (640) Present value of lease liabilitiesÂ $2,879Â Schedule of Supplemental Balance Sheet Information Related to Cash and Non-cash Activities with Leases Supplemental disclosure of cash flow information related to the Companyâ€™s cash and non-cash activities with its leases are as follows: Schedule of Supplemental Balance Sheet Information Related to Cash and Non-cash Activities with LeasesÂ Â Â 2024Â Â 2023Â Â Â Nine Months Ended September 30,Â Â Â 2024Â Â 2023Â Cash paid for amounts included in the measurement of lease liabilitiesÂ Â Â Â Â Â Â Operating cash flows from operating leasesÂ $1,407Â Â $1,080Â Non-cash investing and financing activitiesÂ Â Â Â Â Â Â Right-of-use assets obtained in exchange for new operating lease liabilitiesÂ $â€”Â Â $2,728Â Weighted-average remaining lease term - operating leases (in years)Â Â 5.25Â Â Â 6.68Â Weighted-average discount rate - operating leasesÂ Â 7.875%Â Â 7.875% X - ReferencesNo definition available. + Details Name: PAVM_DisclosureLeasesAbstract Namespace Prefix: PAVM_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionSupplemental Balance Sheet Information Related to Cash and Non Cash Activities with Lease [Table Text Block] + ReferencesNo definition available. + Details Name: PAVM_SupplementalBalanceSheetInformationRelatedToCashandNonCashActivitieswithLeaseTableTextBlock Namespace Prefix: PAVM_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Intangible Assets, net (Tables) 9 Months Ended Sep. 30, 2024 Goodwill and Intangible Assets Disclosure [Abstract] Â Schedule of Intangible Assets, Less Accumulated Amortization Intangible assets, less accumulated amortization, consisted of the following as of: Schedule of Intangible Assets, Less Accumulated AmortizationÂ Â Â Estimated Useful LifeÂ September 30, 2024Â Â December 31, 2023Â Defensive assetÂ 60 monthsÂ $â€”Â Â $2,105Â Laboratory licenses and certifications and laboratory information management softwareÂ 24 monthsÂ Â â€”Â Â 3,200Â OtherÂ 1 yearÂ Â 70Â Â Â 70Â Total Intangible assetsÂ Â Â Â 70Â Â Â 5,375Â Less Accumulated AmortizationÂ Â Â Â (70)Â Â (3,951) Intangible Assets, netÂ Â Â $â€”Â Â $1,424Â X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Financial Instruments Fair Value Measurements (Tables) 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis The fair value hierarchy table for the periods indicated is as follows: Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring BasisÂ Â Â Fair Value Measurement on a Recurring Basis at Reporting Date Using1Â Â Â Level-1 InputsÂ Â Level-2 InputsÂ Â Level-3 InputsÂ Â TotalÂ September 30, 2024Â Â Â Â Â Â Â Â Â Â

Â Â Â

2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=PAVM_TwoThousandAndFourteenEquityPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=PAVM_TwoThousandEighteenEquityPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Noncontrolling Interest (Tables) 9 Months Ended Sep. 30, 2024 Noncontrolling Interest [Abstract] Â Schedule of Noncontrolling Interest of Stockholders' Equity The noncontrolling interest (â€œNCIâ€) included as a component of consolidated total stockholdersâ€™ equity is summarized for the periods indicated as follows: Â Schedule of Noncontrolling Interest of Stockholders' Equity Â Â September 30, 2024Â NCI â€“ equity - December 31, 2023Â $29,813Â Net loss attributable to NCIÂ Â (11,075) Impact of subsidiary equity transactionsÂ Â (4,414) Lucid Diagnostics proceeds from issuance of preferred stock Series A-1Â Â 5,670Â Lucid Diagnostics exchange of preferred stock Series A and Series A-1Â Â (24,294) Lucid Diagnostics issuance through exchange - Series B and Series B-1 Â Â 31,790Â Lucid Diagnostics issuance through sale - Series B and Series B-1Â Â 24,129Â Lucid Diagnostics deemed dividend on preferred stockÂ Â (7,496) Lucid Diagnostics issuance of common stock for settlement of vendor service agreementÂ Â 401Â Lucid Diagnostics 2018 Equity Plan stock option exerciseÂ Â 4Â Lucid Diagnostics Employee Stock Purchase Plan PurchaseÂ Â 353Â Conversion of Lucid Diagnostics common stock for Senior Secured Convertible DebtÂ Â 3,801Â Stock-based compensation expense - Lucid Diagnostics 2018 Equity PlanÂ Â 2,771Â Stock-based compensation expense - Veris Health 2021 Equity PlanÂ Â 368Â Deconsolidation of LucidÂ Â (56,339) NCI â€“ equity - September 30, 2024Â $(4,518) Schedule of Net Loss Attributable to Common Stockholders Schedule of Net Loss Attributable to Common Stockholders Lucid Series B Convertible Preferred Stock Issuance and Series A/A-1 Exchange OfferÂ March 13, 2024Â Fair Value - 31,790 shares of Lucid Series B Preferred Stock issuedÂ $31,790Â Fair Value - 31,790 shares of Lucid Series B Preferred Stock issued in exchange for Lucid Series A and Lucid Series A-1 Preferred StockÂ $31,790Â Less: Carrying value related to Lucid Series A and Lucid Series A-1 Preferred Stock Exchanged for Lucid Series B Preferred Stock (of 24,295 shares)Â Â (24,294) Deemed Dividend Charged to Accumulated DeficitÂ $7,496Â X - DefinitionSchedule Of Net Loss Attributable To Common Stockholders [Table Text Block] + ReferencesNo definition available. + Details Name: PAVM_ScheduleOfNetLossAttributableToCommonStockholdersTableTextBlock Namespace Prefix: PAVM_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionSchedule Of Noncontrolling Interest Of Stockholders Equity [Table Text Block] + ReferencesNo definition available. + Details Name: PAVM_ScheduleOfNoncontrollingInterestOfStockholdersEquityTableTextBlock Namespace Prefix: PAVM_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NoncontrollingInterestAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Net Income (Loss) Per Share (Tables) 9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] Â Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share The Net income (loss) per share - attributable to PAVmed Inc. - basic and diluted and Net income (loss) per share - attributable to PAVmed Inc. common stockholders - basic and diluted - for the respective periods indicated - is as follows: Â Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Â Â Three Months Ended September 30,Â Â Nine Months Ended September 30,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â NumeratorÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net income (loss) - before noncontrolling interestÂ $60,711Â Â $(21,750)Â $27,285Â Â $(61,855) Net income (loss) attributable to noncontrolling interestÂ Â 3,688Â Â Â 4,079Â Â Â 11,075Â Â Â 11,716Â Â Net income (loss) - as reported, attributable to PAVmed Inc.Â Â $64,399Â Â Â $(17,671)Â Â $38,360Â Â Â $(50,139) Â Series B Convertible Preferred Stock dividends â€“ earnedÂ $(83)Â $(77)Â $(244)Â $(226) Deemed dividend on Subsidiary Preferred Stock attributable to the noncontrolling interestsÂ $â€”Â Â $â€”Â Â $(7,496)Â $â€”Â Net income (loss) attributable to PAVmed Inc. common stockholders used in basic EPS calculationÂ $64,316Â Â $(17,748)Â $30,620Â Â $(50,365) Fair Value Adjustment for diluted EPS calculationÂ $(240)Â $â€”Â Â $3,378Â Â $â€”Â Â Net income (loss) attributable to PAVmed Inc. common stockholders used in dilutive EPS calculationÂ $64,076Â Â $(17,748)Â $33,998Â Â $(50,365) Â DenominatorÂ Weighted average common shares outstanding, basicÂ Â 10,005,379Â Â Â 7,462,751Â Â Â 9,286,999Â Â Â 6,967,764Â Weighted average common shares outstanding, dilutedÂ Â 44,475,638Â Â Â 7,462,751Â Â Â 43,069,449Â Â Â 6,967,764Â Net income (loss) per share (1)Â Net income (loss) per share attributable to PAVmed Inc. common stockholders, basic (1)Â $6.43Â Â $(2.38)Â $3.30Â Â $(7.23) Net income (loss) per share attributable to PAVmed Inc. common stockholders, diluted (1)Â $1.44Â Â $(2.38)Â $0.79Â Â $(7.23) Â (1)- Convertible preferred stock and restricted stock awards would potentially be considered a participating security under the two-class method of calculating net income (loss) per share. For periods where losses are presented, such holders are not contractually obligated to share in the losses, there is no impact on the Companyâ€™s net income (loss) per share calculation for the periods indicated. Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share Â Â 2024Â Â 2023Â Â Â September 30,Â Â Â 2024Â Â 2023Â Stock optionsÂ Â 1,233,107Â Â Â 1,138,632Â Restricted stock awardsÂ Â â€”Â Â Â 70,528Â Series Z WarrantsÂ Â 795,830Â Â Â 795,830Â Series B Convertible Preferred StockÂ Â â€”Â Â Â 85,307Â TotalÂ Â 2,028,937Â Â Â 2,090,297Â X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Liquidity and Going Concern (Details Narrative) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Â Â Â Â Revenues $ 1,000 Â $ 3,000 Â Â Net loss attributable to common stockholders 64,316 $ (17,748) 30,620 $ (50,365) Â Net cash flows used in operating activities Â Â 33,648 $ 40,162 Â Working capital 35,400 Â 35,400 Â Â Current liabilities 32,050 Â 32,050 Â $ 44,200 Cash $ 800 Â $ 800 Â Â X - DefinitionWorking capital. + ReferencesNo definition available. + Details Name: PAVM_WorkingCapital Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 45 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 210 -Topic 946 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20 + Details Name: us-gaap_Cash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards

Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCarrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_SecuredDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Details Narrative) - USD ($) $ in Thousands Sep. 30, 2024 Sep. 10, 2024 Dec. 31, 2023 Lucid Diagnostics Inc [Member] | Minimum [Member] Â Â Â Variable Interest Entity [Line Items] Â Â Â Equity method investment, ownership percentage 20.00% Â Â Lucid Diagnostics Inc [Member] | Maximum [Member] Â Â Â Variable Interest Entity [Line Items] Â Â Â Equity method investment, ownership percentage 50.00% 50.00% Â Letter of Credit [Member] Â Â Â Variable Interest Entity [Line Items] Â Â Â Cash $ 299 Â $ 299 X - DefinitionThe equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity. + ReferencesNo definition available. + Details Name: us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 860 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (b)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1AReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 860 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (b)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 860 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A + Details Name: us-gaap_VariableInterestEntityLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_OwnershipAxis=PAVM_LucidDiagnosticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PledgingPurposeAxis=us-gaap_LetterOfCreditMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Schedule of Deconsolidation of Net Assets (Details) - USD ($) $ in Thousands Sep. 30, 2024 Sep. 10, 2024 Dec. 31, 2023 Current assets: Â Â Â Cash $ 765 Â $ 19,639 Prepaid expenses, deposits, and other current assets 1,343 Â 4,520 Total current assets 2,130 Â 24,498 Fixed assets, net 216 Â 1,783 Operating lease right-of-use assets 2,618 Â 4,267 Intangible assets, net Â 1,424 Other assets 75 Â 1,147 Total assets 30,550 Â 33,119 Current liabilities: Â Â Â Accounts payable 465 Â 1,786 Accrued expenses and other current liabilities 4,543 Â 6,626 Operating lease liabilities, current portion 499 Â 1,565 Senior Secured Convertible Notes - at fair value 32,050 Â 44,200 Total current liabilities 37,557 Â 54,177 Operating lease liabilities, less current portion 2,380 Â 2,960 Total liabilities 39,937 Â $ 57,137 Lucid Diagnostics Inc [Member] Â Â Â Current assets: Â Â Â Cash 14,489 $ 16,479 Â Prepaid expenses, deposits, and other current assets Â 3,474 Â Total current assets Â 19,953 Â Fixed assets, net Â 964 Â Operating lease right-of-use assets Â 2,871 Â Intangible assets, net Â 877 Â Other assets Â 379 Â Total assets 22,598 25,044 Â Current liabilities: Â Â Â Accounts payable Â 1,069 Â Accrued expenses and other current liabilities Â 1,674 Â Operating lease liabilities, current portion Â 865 Â Senior Secured Convertible Notes - at fair value Â 10,268 Â Total current liabilities $ 14,249 13,876 Â Operating lease liabilities, less current portion Â 2,011 Â Total liabilities Â 15,887 Â Net Assets of Lucid Diagnostics at September 10, 2024 Â $ 9,157 Â X - DefinitionNet assets. + ReferencesNo definition available. + Details Name: PAVM_NetAssets Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -

SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -

Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_SecuredDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: srt_ConsolidatedEntitiesAxis=PAVM_LucidDiagnosticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Schedule of Gain on Deconsolidation (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Add: Noncontrolling interest - Lucid Â Â $ (56,339) Â Gain on Deconsolidation of Lucid $ 72,287 72,287 Lucid Diagnostics Inc [Member] Â Â Â Â Investment in former Consolidated Subsidiary (Fair Value of Lucid common stock) Â Â 25,105 Â Add: Noncontrolling interest - Lucid Â Â 56,339 Â Less: Net Assets of Former Consolidated Subsidiary - Lucid Â Â (9,157) Â Gain on Deconsolidation of Lucid $ 72,300 Â $ 72,287 Â X - DefinitionAdjustments to additional paid in capital sharebased compensation requisite deconsolidation of lucid. + ReferencesNo definition available. + Details Name: PAVM_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteDeconsolidationOfLucid Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B + Details Name: us-gaap_DeconsolidationGainOrLossAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain (loss) from remeasurement to fair value of retained investment in former subsidiary and group of assets constituting business or nonprofit activity deconsolidated and derecognized, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B + Details Name: us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnDispositionOfAssets1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ConsolidatedEntitiesAxis=PAVM_LucidDiagnosticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Schedule of Aggregate Information From the Financial Statements (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Sep. 10, 2024 Dec. 31, 2023 Cash $ 765 Â $ 765 Â Â $ 19,639 Total assets 30,550 Â 30,550 Â Â 33,119 Current liabilities 37,557 Â 37,557 Â Â 54,177 Shareholdersâ€™ deficit (4,869) Â (4,869) Â Â (53,831) Total liabilities and stockholdersâ€™ deficit 30,550 Â 30,550 Â Â $ 33,119 Revenue 996 $ 791 2,985 $ 1,403 Â Â Net income (loss) 64,399 $ (17,671) 38,360 $ (50,139) Â Â Lucid Diagnostics Inc [Member] Â Â Â Â Â Â Cash 14,489 Â 14,489 Â $ 16,479 Â Other current assets 2,335 Â 2,335 Â Â Â Non-current assets 5,774 Â 5,774 Â Â Â Total assets 22,598 Â 22,598 Â 25,044 Â Current liabilities 14,249 Â 14,249 Â $ 13,876 Â Non-current liabilities 2,011 Â 2,011 Â Â Â Shareholdersâ€™ deficit 6,338 Â 6,338 Â Â Â Total liabilities and stockholdersâ€™ deficit 22,598 Â 22,598 Â Â Â Revenue 1,172 Â 3,149 Â Â Â Net income (loss) (12,371) Â (41,484) Â Â Â Lucid Diagnostics Inc [Member] | July 1, 2024 - September 10, 2024 [Member] Â Â Â Â Â Â Revenue 942 Â Â Â Â Â Â Net income (loss) (9,039) Â Â Â Â Â Lucid Diagnostics Inc [Member] | September 11, 2024 - September 30, 2024 [Member] Â Â Â Â Â Â Revenue 230 Â 230 Â Â Â Net income (loss) $ (3,332) Â (3,332) Â Â Â Lucid Diagnostics Inc [Member] | January 1, 2024 - September 10, 2024 [Member] Â Â Â Â Â Â Revenue Â Â 2,919 Â Â Â Net income (loss) Â Â $ (38,152) Â Â Â X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial

institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards

Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: srt_ConsolidatedEntitiesAxis=PAVM_LucidDiagnosticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardDateAxis=PAVM_JulyOneTwoThousandTwentyFourToSeptemberTenTwoThousandTwentyFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardDateAxis=PAVM_SeptemberElevenTwoThousandTwentyFourToSeptemberThirtyTwoThousandTwentyFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardDateAxis=PAVM_JanuaryOneTwoThousandTwentyFourToSeptemberTenTwoThousandTwentyFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Equity Method Investment (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended Sep. 27, 2024 Sep. 10, 2024 Sep. 30, 2024 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Ownership shares value Â Â Â $ 284 Â $ 977 $ 1,166 Gain on deconsolidation Â Â Â $ 72,287 $ 72,287 Intellectual Property [Member] Â Â Â Â Â Â Â Assignment fee $ 350 Â Â Â Â Â Â Common Stock [Member] Â Â Â Â Â Â Â Ownership shares issues Â Â Â 294,003 Â 627,302 155,384 Ownership shares value Â Â Â Â Common Stock [Member] | Lucid Diagnostics Inc [Member] Â Â Â Â Â Â Â The fair value of common price per shares Â 40.00% 40.00% 40.00% Â 40.00% Â Lucid Diagnostics Inc [Member] Â Â Â Â Â Â Â Ownership shares issues Â 31,302,444 Â Â Â Â Â Ownership shares value Â $ 25,100 Â Â Â Â Â Gain on deconsolidation Â Â Â $ 72,300 Â $ 72,287 Â Fair value of the companys investment Â $ 25,100 $ 25,500 25,500 Â 25,500 Â Unrealized gain loss on investments Â Â Â 400 Â 400 Â Lucid Diagnostics Inc [Member] | Management Services Agreement [Member] | Board of Directors Chairman [Member] Â Â Â Â Â Â Â Fee income Â Â $ 700 Â Â $ 833 Â Increase in fee income Â Â Â $ 1,050 Â Â Â Lucid Diagnostics Inc [Member] | Common Stock [Member] Â Â Â Â Â Â Â The fair value of common price per shares Â $ 0.802 $ 0.815 $ 0.815 Â $ 0.815 Â Lucid Diagnostics Inc [Member] | Maximum [Member] Â Â Â Â Â Â Â Equity method investment, ownership percentage Â 50.00% 50.00% 50.00% Â 50.00% Â X - DefinitionIncrease in fee income. + ReferencesNo definition available. + Details Name: PAVM_FeeIncomeIncreased Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPercentage of voting equity interests acquired at the acquisition date in the business combination. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef - Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details Name: us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B + Details Name: us-gaap_DeconsolidationGainOrLossAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of fee income including, but not limited to, managerial assistance, servicing of investment, and origination and commitment fees. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(1)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_FeeIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFair value of investment in security owned. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-2Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(2)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 6)) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 + Details Name: us-gaap_InvestmentOwnedAtFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity. + ReferencesNo definition available. + Details Name: us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of cash outflow for fees classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_PaymentsForFees Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of unrealized gain (loss) on investment. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_UnrealizedGainLossOnInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=PAVM_LucidDiagnosticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=PAVM_LucidDiagnosticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=PAVM_ManagementServicesAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_OwnershipAxis=PAVM_LucidDiagnosticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue from Contracts with Customers (Details Narrative) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Revenue from Contract with Customer [Abstract] Â Â Â Â Revenue $ 996 $ 791 $ 2,985 $ 1,403 Cost of revenue $ 1,381 $ 1,779 $ 4,792 $ 4,809 X - DefinitionThe aggregate cost of goods produced and sold and services rendered during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B + Details Name: us-gaap_CostOfRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Prepaid Expenses Deposits And Other Current Assets Â Â Advanced payments to service providers and suppliers $ 181 $ 739 Prepaid insurance 420 848 Deposits 480 2,672 Veris Box supplies 262 261 Total prepaid expenses, deposits and other current assets $ 1,343 $ 4,520 X - ReferencesNo definition available. + Details Name: PAVM_DisclosurePrepaidExpensesDepositsAndOtherCurrentAssetsAbstract Namespace Prefix: PAVM_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPrepaid service providers and suppliers. + ReferencesNo definition available. + Details Name: PAVM_PrepaidServiceProvidersAndSuppliers Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionVeris box supplies. + ReferencesNo definition available. + Details Name: PAVM_VerisBoxSupplies Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5 + Details Name: us-gaap_PrepaidInsurance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_SecurityDeposit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Schedule of Future Minimum Lease Payments for Operating Leases (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Leases Â Â 2024 (remainder of year) $ 174 Â 2025 708 Â 2026 724 Â 2027 594 Â 2028 471 Â Thereafter 848 Â Total lease payments 3,519 Â Less: imputed interest (640) Â Present value of lease liabilities $ 2,879 $ 4,525 X - ReferencesNo definition available. + Details Name: PAVM_DisclosureLeasesAbstract Namespace Prefix: PAVM_ Data Type:

xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. + ReferencesNo definition available. + Details Name: PAVM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Schedule of Supplemental Balance Sheet Information Related to Cash and Non-cash Activities with Leases (Details) - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Leases Â Â Operating cash flows from operating leases $ 1,407 $ 1,080 Right-of-use assets obtained in exchange for new operating lease liabilities $ 2,728 Weighted-average remaining lease term - operating leases (in years) 5 years 3 months 6 years 8 months 4 days Weighted-average discount rate - operating leases 7.875% 7.875% X - ReferencesNo definition available. + Details Name: PAVM_DisclosureLeasesAbstract Namespace Prefix: PAVM_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Leases (Details Narrative) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Leases Â Â Operating lease, right-of-use assets $ 2,618 $ 4,267 Operating lease obligations 2,879 4,525 Operating lease, liability, current 499 1,565 Operating lease liability noncurrent $ 2,380 $ 2,960 X - ReferencesNo definition available. + Details Name: PAVM_DisclosureLeasesAbstract Namespace Prefix: PAVM_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 57 R46.htm IDEA: XBRL DOCUMENT v3.24.3 Schedule of Intangible Assets, Less Accumulated Amortization (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Impairment Effects on Earnings Per Share [Line Items] Â Â Total Intangible assets $ 70 $ 5,375 Less Accumulated Amortization (70) (3,951) Intangible Assets, net 1,424 Defensive Asset [Member] Â Â Impairment Effects on Earnings Per Share [Line Items] Â Â Total Intangible assets $ 2,105 Finite lived intangible asset, useful life 60 months 60 months Laboratory Information Management Software [Member] Â Â Impairment Effects on Earnings Per Share [Line Items] Â Â Total Intangible assets $ 3,200 Finite lived intangible asset, useful life 24 months 24 months Other Infinite Lived Intangible Asset [Member] Â Â Impairment Effects on Earnings Per Share [Line Items] Â Â Total Intangible assets $ 70 $ 70 Finite lived intangible asset, useful life 1 year 1 year X - DefinitionUseful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ImpairmentEffectsOnEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FairValueByAssetClassAxis=PAVM_DefensiveAssetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=PAVM_LaboratoryInformationManagementSoftwareMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=PAVM_OtherInfiniteLivedIntangibleAssetMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R47.htm IDEA: XBRL DOCUMENT v3.24.3 Intangible Assets, net (Details Narrative) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Goodwill and Intangible Assets Disclosure [Abstract] Â Â Â Â Â Â Amortization of intangible assets $ 82 $ 505 $ 559 $ 1,516 Â Intangible assets net 0 Â 0 Â Â Estimated future amortization expense Â Â $ 1,424 X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe current portion of nonphysical assets, excluding financial assets, if these assets are classified into the current and noncurrent portions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10 + Details Name: us-gaap_IntangibleAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 59 R48.htm IDEA: XBRL DOCUMENT v3.24.3 Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Total assets at fair value [1] $ 25,511 Â Total liabilities at fair value [1] 32,050 $ 44,200 Fair Value, Inputs, Level 1 [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Total assets at fair value [1] 25,511 Â Total liabilities at fair value [1] Fair Value, Inputs, Level 2 [Member] Â Â Fair Value, Assets and Liabilities

Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Total assets at fair value [1] Â Total liabilities at fair value [1] Fair Value, Inputs, Level 3 [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Total assets at fair value [1] Â Total liabilities at fair value [1] 32,050 44,200 Lucid Common Stock [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Total assets at fair value [1] 25,511 Â Lucid Common Stock [Member] | Fair Value, Inputs, Level 1 [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Total assets at fair value [1] 25,511 Â Lucid Common Stock [Member] | Fair Value, Inputs, Level 2 [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Total assets at fair value [1] Â Lucid Common Stock [Member] | Fair Value, Inputs, Level 3 [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Total assets at fair value [1] Â April 2022 Senior Convertible Note [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Total liabilities at fair value [1] 19,850 19,000 April 2022 Senior Convertible Note [Member] | Fair Value, Inputs, Level 1 [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Total liabilities at fair value [1] April 2022 Senior Convertible Note [Member] | Fair Value, Inputs, Level 2 [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Total liabilities at fair value [1] April 2022 Senior Convertible Note [Member] | Fair Value, Inputs, Level 3 [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Total liabilities at fair value [1] 19,850 19,000 September 2022 Senior Convertible Note [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Total liabilities at fair value [1] 12,200 11,250 September 2022 Senior Convertible Note [Member] | Fair Value, Inputs, Level 1 [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Total liabilities at fair value [1] September 2022 Senior Convertible Note [Member] | Fair Value, Inputs, Level 2 [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Total liabilities at fair value [1] September 2022 Senior Convertible Note [Member] | Fair Value, Inputs, Level 3 [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Total liabilities at fair value [1] $ 12,200 11,250 Lucid March 2023 Senior Convertible Note [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Total liabilities at fair value [1] Â 13,950 Lucid March 2023 Senior Convertible Note [Member] | Fair Value, Inputs, Level 1 [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Total liabilities at fair value [1] Â Lucid March 2023 Senior Convertible Note [Member] | Fair Value, Inputs, Level 2 [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Total liabilities at fair value [1] Â Lucid March 2023 Senior Convertible Note [Member] | Fair Value, Inputs, Level 3 [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Total liabilities at fair value [1] Â $ 13,950 [1] There were no transfers between the respective Levels during the nine months ended September 30, 2024. X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value of financial and nonfinancial obligations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_LiabilitiesFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=PAVM_LucidCommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=PAVM_AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=PAVM_SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=PAVM_LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R49.htm IDEA: XBRL DOCUMENT v3.24.3 Schedule of Fair Value Assumption Used (Details) $ in Thousands 9 Months Ended 12 Months Ended Sep. 30, 2024 USD ($) Dec. 31, 2023 USD ($) Mar. 21, 2023 USD ($) Sep. 08, 2022 USD ($) Apr. 04, 2022 USD ($) Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Debt instrument fair value $ 32,050 $ 44,200 Â Â Â Face value principal payable 25,229 37,683 Â Â Â April 2022 Senior Convertible Note [Member] Â Â Â Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Debt instrument fair value 19,850 19,000 Â Â Â Face value principal payable $ 17,602 $ 17,602 Â Â $ 27,500 April 2022 Senior Convertible Note [Member] | Measurement Input Required Rate of Return [Member] Â Â Â Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Fair value assumption measurement input 9.000 Â Â Â Â April 2022 Senior Convertible Note [Member] | Measurement Input Required Rate of Return [Member] | Minimum [Member] Â Â Â Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Fair value assumption measurement input Â 10.00 Â Â Â April 2022 Senior Convertible Note [Member] | Measurement Input Required Rate of Return [Member] | Maximum [Member] Â Â Â Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Fair value assumption measurement input Â 10.50 Â Â Â April 2022 Senior Convertible Note [Member] | Measurement Input, Conversion Price [Member] Â Â Â Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Fair value assumption measurement input 75.00 75.00 Â Â Â April 2022 Senior Convertible Note [Member] | Measurement Input, Share Price [Member] Â Â Â Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Fair value assumption measurement input 1.23 4.12 Â Â Â April 2022 Senior Convertible Note [Member] | Measurement Input, Expected Term [Member] Â Â Â Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Expected term years 6 months 3 days Â Â Â Â April 2022 Senior Convertible Note [Member] | Measurement Input, Expected Term [Member] | Minimum [Member] Â Â Â Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Expected term years Â 3 months 3 days Â Â Â April 2022 Senior Convertible Note [Member] | Measurement Input, Expected Term [Member] | Maximum [Member] Â Â Â Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Expected term years Â 1 year 3 months 3 days Â Â Â April 2022 Senior Convertible Note [Member] | Measurement Input, Price Volatility [Member] Â Â Â Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Fair value assumption measurement input 160.00 85.00 Â Â Â April 2022 Senior Convertible Note [Member] | Measurement Input, Risk Free Interest Rate [Member] Â Â Â Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Fair value assumption measurement input 4.28 Â Â Â Â April 2022 Senior Convertible Note [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] Â Â Â Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Fair value assumption measurement input Â 4.54 Â Â Â April 2022 Senior Convertible Note [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] Â Â Â Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Fair value assumption measurement input Â 5.25 Â Â Â April 2022 Senior Convertible Note [Member] | Measurement Input, Expected Dividend Rate [Member] Â Â Â Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Fair value assumption measurement input Â Â Â September 2022 Senior Convertible Note [Member] Â Â Â Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Debt instrument fair value $ 12,200 $ 11,250 Â Â Â Face value principal payable $ 7,627 $ 9,062 Â $ 11,250 Â September 2022 Senior Convertible Note [Member] | Measurement Input Required Rate of Return [Member] Â Â Â Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Fair value assumption measurement input 8.800 Â Â Â Â September 2022 Senior Convertible Note [Member] | Measurement Input Required Rate of Return [Member] | Minimum [Member] Â Â Â Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Fair value assumption measurement input Â 10.00 Â Â Â September 2022 Senior Convertible Note [Member] | Measurement Input Required Rate of Return [Member] | Maximum [Member] Â Â Â Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Fair value assumption measurement input Â 10.20 Â Â Â September 2022 Senior Convertible Note [Member] | Measurement Input, Conversion Price [Member] Â Â Â Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Fair value assumption measurement input 75.00 75.00 Â Â Â September 2022 Senior Convertible Note [Member] | Measurement Input, Share Price [Member] Â Â Â Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Fair value assumption measurement input 1.23 4.12 Â Â Â September 2022 Senior Convertible Note [Member] | Measurement Input, Expected Term [Member] Â Â Â Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Expected term years 11 months 8 days Â Â Â Â September 2022 Senior Convertible Note [Member] | Measurement Input, Expected Term [Member] | Minimum [Member] Â Â Â Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Expected term years Â 8 months 8 days Â Â Â September 2022 Senior Convertible Note [Member] | Measurement Input, Expected Term [Member] | Maximum [Member] Â Â Â Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Expected term years Â 1 year 8 months 8 days Â Â Â September 2022 Senior Convertible Note [Member] | Measurement Input, Price Volatility [Member] Â Â Â Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Fair value assumption measurement input 160.00 85.00 Â Â Â September 2022 Senior Convertible Note [Member] | Measurement Input, Risk Free Interest Rate [Member] Â Â Â Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Fair value assumption measurement input 3.95 Â Â Â Â September 2022 Senior Convertible Note [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] Â Â Â Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Fair value assumption measurement input Â 4.31 Â Â Â September 2022 Senior Convertible Note [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] Â Â Â Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Fair value assumption measurement input Â 4.96 Â Â Â September 2022 Senior Convertible Note [Member] | Measurement Input, Expected Dividend Rate [Member] Â Â Â Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Fair value assumption measurement input Â Â Â Lucid March 2023 Senior Convertible Note [Member] Â Â Â Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Debt instrument fair value Â $ 13,950 Â Â Â Face value principal payable Â $ 11,019 $ 11,100 Â Â Lucid March 2023 Senior Convertible Note [Member] | Measurement Input Required Rate of Return [Member] Â Â Â Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Fair value assumption measurement input Â 10.00 Â Â Â Lucid March 2023 Senior Convertible Note [Member] | Measurement Input, Conversion Price [Member] Â Â Â Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Fair value assumption measurement input Â 5.00 Â Â Â Lucid March 2023 Senior Convertible Note [Member] | Measurement Input, Share Price [Member] Â Â Â Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Fair value assumption measurement input Â 1.41 Â Â Â Lucid March 2023 Senior Convertible Note [Member] | Measurement Input, Expected Term [Member] Â Â Â Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Expected term years Â 1 year 2 months 19 days Â Â Â Lucid March 2023 Senior Convertible Note [Member] | Measurement Input, Price Volatility [Member] Â Â Â Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Fair value assumption measurement input Â 60.00 Â Â Â Lucid March 2023 Senior Convertible Note [Member] | Measurement Input, Risk Free Interest Rate [Member] Â Â Â Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Fair value assumption measurement input Â 4.56 Â Â Â Lucid March 2023 Senior Convertible Note [Member] | Measurement Input, Expected Dividend Rate [Member] Â Â Â Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Â Â Â Fair value assumption measurement input Â Â Â Â X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10 + Details Name: us-gaap_DebtInstrumentFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit

Period Type: instant X - DefinitionValue of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_DebtInstrumentMeasurementInput Namespace Prefix: us-gaap_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - DefinitionPeriod of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=PAVM_AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=PAVM_MeasurementInputRequiredRateOfReturnMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputConversionPriceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=PAVM_SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=PAVM_LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R50.htm IDEA: XBRL DOCUMENT v3.24.3 Financial Instruments Fair Value Measurements (Details Narrative) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Mar. 21, 2023 Sep. 08, 2022 Apr. 04, 2022 Short-Term Debt [Line Items] Â Â Â Â Â Face value principal payable $ 25,229 $ 37,683 Â Â Â April 2022 Senior Convertible Note [Member] Â Â Â Â Â Short-Term Debt [Line Items] Â Â Â Â Â Face value principal payable 17,602 17,602 Â Â $ 27,500 September 2022 Senior Convertible Note [Member] Â Â Â Â Â Short-Term Debt [Line Items] Â Â Â Â Â Face value principal payable $ 7,627 9,062 Â $ 11,250 Â Lucid March 2023 Senior Convertible Note [Member] Â Â Â Â Â Short-Term Debt [Line Items] Â Â Â Â Â Face value principal payable Â $ 11,019 $ 11,100 Â Â X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ShortTermDebtLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=PAVM_AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=PAVM_SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=PAVM_LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R51.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Outstanding Debt (Details) - USD ($) $ / shares in Units, $ in Thousands 9 Months Ended 12 Months Ended Sep. 08, 2022 Apr. 04, 2022 Sep. 30, 2024 Dec. 31, 2023 Mar. 21, 2023 Short-Term Debt [Line Items] Â Â Â Â Â Face Value Principal Outstanding Â Â $ 25,229 $ 37,683 Â Fair Value Â Â $ 32,050 $ 44,200 Â April 2022 Senior Convertible Note [Member] Â Â Â Â Â Short-Term Debt [Line Items] Â Â Â Â Â Maturity Date Â Apr. 04, 2024 Apr. 04, 2025 Apr. 04, 2025 Â Stated Interest Rate Â 7.875% 7.875% 7.875% Â Conversion Price Â $ 75.00 $ 75.00 $ 75.00 Â Face Value Principal Outstanding Â $ 27,500 $ 17,602 $ 17,602 Â Fair Value Â Â $ 19,850 $ 19,000 Â September 2022 Senior Convertible Note [Member] Â Â Â Â Â Short-Term Debt [Line Items] Â Â Â Â Â Maturity Date Sep. 06, 2024 Â Sep. 08, 2025 Sep. 08, 2025 Â Stated Interest Rate 7.875% Â 7.875% 7.875% Â Conversion Price $ 75.00 Â $ 75.00 $ 75.00 Â Face Value Principal Outstanding $ 11,250 Â $ 7,627 $ 9,062 Â Fair Value Â Â $ 12,200 $ 11,250 Â Lucid March 2023 Senior Convertible Note [Member] Â Â Â Â Â Short-Term Debt [Line Items] Â Â Â Â Â Maturity Date Â Â Â Mar. 21, 2025 Â Stated Interest Rate Â Â Â 7.875% Â Conversion Price Â Â Â $ 5.00 Â Face Value Principal Outstanding Â Â Â $ 11,019 $ 11,100 Fair Value Â Â Â $ 13,950 Â X - DefinitionThe price per share of the conversion feature embedded in the debt instrument. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5 + Details Name: us-gaap_DebtInstrumentConvertibleConversionPrice1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10 + Details Name: us-gaap_DebtInstrumentFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionDate when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentMaturityDate Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ShortTermDebtLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=PAVM_AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=PAVM_SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=PAVM_LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R52.htm IDEA: XBRL DOCUMENT v3.24.3 Schedule of Changes in Fair Value of Debt (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Short-Term Debt [Line Items] Â Â Â Â Fair Value - Beginning of Period $ 44,000 $ 42,990 $ 44,200 $ 33,650 Face value principal â€“ issue date Â Â Â 11,111 Fair value adjustment â€“ issue date Â Â Â 789 Installment repayments â€“ common stock (1,252) (2,251) (3,440) (5,194) Non-installment payments â€“ common stock (190) (141) (930) (349) Deconsolidation of Lucid Diagnostics (10,268) Â (10,268) Â Change in fair value (240) 4,392 2,488 4,983 Fair Value - Ending of Period 32,050 44,990 32,050 44,990 Other Income (Expense) - Change in fair value 240 (4,392) (2,488) (5,772) April 2022 Senior Convertible Note [Member] Â Â Â Â Short-Term Debt [Line Items] Â Â Â Â Fair Value - Beginning of Period 19,200 19,530 19,000 22,000 Face value principal â€“ issue date Â Â Â Fair value adjustment â€“ issue date Â Â Â Installment repayments â€“ common stock (952) (3,895) Non-installment payments â€“ common stock (41) (249) Deconsolidation of Lucid Diagnostics Â Â Change in fair value 650 863 850 1,544 Fair Value - Ending of Period 19,850 19,400 19,850 19,400 September 2022 Senior Convertible Note [Member] Â Â Â Â Short-Term Debt [Line Items] Â Â Â Â Fair Value - Beginning of Period 13,600 11,850 11,250 11,650 Face value principal â€“ issue date Â Â Â Fair value adjustment â€“ issue date Â Â Â Installment repayments â€“ common stock (455) (1,207) (1,435) (1,207) Non-installment payments â€“ common stock (55) (51) (143) (51) Deconsolidation of Lucid Diagnostics Â Â Change in fair value (890) 508 2,528 708 Fair Value - Ending of Period 12,200 11,100 12,200 11,100 Lucid March 2023 Senior Convertible Note [Member] Â Â Â Â Short-Term Debt [Line Items] Â Â Â Â Fair Value - Beginning of Period 11,200 11,610 13,950 Face value principal â€“ issue date Â Â Â 11,111 Fair value adjustment â€“ issue date Â Â Â 789 Installment repayments â€“ common stock (797) (92) (2,005) (92) Non-installment payments â€“ common stock (135) (49) (787) (49) Deconsolidation of Lucid Diagnostics (10,268) Â (10,268) Â Change in fair value 3,021 (890) 2,731 Fair Value - Ending of Period 14,490 14,490 Other Income Expense [Member] Â Â Â Â Short-Term Debt [Line Items] Â Â Â Â Fair Value - Beginning of Period Face value principal â€“ issue date Â Â Â Fair value adjustment â€“ issue date Â Â Â (789) Installment repayments â€“ common stock Non-installment payments â€“ common stock Deconsolidation of Lucid Diagnostics Â Â Change in fair value 240 (4,392) (2,488) (4,983) Fair Value - Ending of Period X - DefinitionDebt instruments fair value. + ReferencesNo definition available. + Details Name: PAVM_DebtInstrumentsFairValue Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDeconsolidation fair value of debt. + ReferencesNo definition available. + Details Name: PAVM_DeconsolidationFairValueOfDebt Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFair value adjustment issue date. + ReferencesNo definition available. + Details Name: PAVM_FairValueAdjustmentIssueDate Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionOther income expense change in fair value. + ReferencesNo definition available. + Details Name: PAVM_OtherIncomeExpenseChangeInFairValue Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting

Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of principal of debt issued. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_DebtInstrumentIssuedPrincipal Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of the required periodic payments including both interest and principal payments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3 + Details Name: us-gaap_DebtInstrumentPeriodicPayment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of principal of debt repaid. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_DebtInstrumentRepaidPrincipal Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ShortTermDebtLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=PAVM_AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=PAVM_SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=PAVM_LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=PAVM_OtherIncomeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R53.htm IDEA: XBRL DOCUMENT v3.24.3 Debt (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands 2 Months Ended 3 Months Ended 8 Months Ended 9 Months Ended 12 Months Ended Sep. 08, 2022 Apr. 04, 2022 Sep. 10, 2024 Sep. 30, 2024 Sep. 30, 2023 Sep. 10, 2024 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Mar. 21, 2023 Mar. 31, 2022 Short-Term Debt [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Principal amouint Â Â Â $ 25,229 Â Â $ 25,229 Â $ 37,683 Â Â Conversions - Senior Secured Convertible Note Â Â Â 908 $ 3,989 Â 2,021 $ 8,411 Â Â Â Debt extinguishment losses Â Â Â 1,403 $ 1,764 Â 2,535 $ 3,032 Â Â Â Cash [Member] Â Â Â Â Â Â Â Â Â Â Â Â Short-Term Debt [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Notes payable Â Â Â 2,000 Â Â 2,000 Â Â Â Â April 2022 Senior Convertible Note [Member] Â Â Â Â Â Â Â Â Â Â Â Â Short-Term Debt [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Principal amouint Â $ 27,500 Â $ 17,602 Â Â $ 17,602 Â $ 17,602 Â Â Debt interest rate Â 7.875% Â 7.875% Â Â 7.875% Â 7.875% Â Â Conversion price Â $ 75.00 Â $ 75.00 Â Â $ 75.00 Â $ 75.00 Â Â Debt instrument maturity date, description Â Apr. 04, 2024 Â Â Â Â Apr. 04, 2025 Â Apr. 04, 2025 Â Â Debt instrument maturity date, description Â maturity date the investor agreed to extend by one year, to April 4, 2025 Â Â Â Â Â Â Â Â Â September 2022 Senior Convertible Note [Member] Â Â Â Â Â Â Â Â Â Â Short-Term Debt [Line Items] Â Â Â Â Â Â Â Â Â Â Principal amouint $ 11,250 Â Â $ 7,627 Â Â $ 7,627 Â $ 9,062 Â Â Debt interest rate 7.875% Â Â 7.875% Â Â 7.875% Â Â Conversion price $ 75.00 Â Â $ 75.00 Â Â $ 75.00 Â $ 75.00 Â Â Debt instrument maturity date, description Sep. 06, 2024 Â Â Â Â Â Sep. 08, 2025 Â Sep. 08, 2025 Â Â Debt instrument maturity date, description maturity date the investor agreed to extend by one year, to September 8, 2025. Â Â Â Â Â Â Â Â Â Â Debt instrument, description Â Â Â Â Â Â The Company is subject to financial covenants requiring: (i) a minimum of $8.0 million of available cash at all times; (ii) the ratio of (a) the outstanding principal amount of the total senior convertible notes outstanding, accrued and unpaid interest thereon and accrued and unpaid late charges to (b) the Companyâ€™s average market capitalization over the prior ten trading days, to not exceed 30% (the â€œDebt to Market Cap Ratio Testâ€); and (iii) the Companyâ€™s market capitalization to at no time be less than $75 million Â Â Â Â Repayment for debt Â Â Â $ 455 Â Â $ 1,435 Â Â Â Â Interest expense Â Â Â $ 55 Â Â $ 143 Â Â Â Â Conversions - Senior Secured Convertible Note, shares Â Â Â 509,942 Â Â 1,084,366 Â Â Â Â Gain (loss) on extinguishment of debt Â Â Â $ 1,050 Â Â $ 1,501 Â Â Â Â September 2022 Senior Convertible Note [Member] | Interest Rate Floor [Member] Â Â Â Â Â Â Â Â Â Â Â Â Short-Term Debt [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Gain (loss) on extinguishment of debt Â Â Â 652 Â Â 1,059 Â Â Â Â Acceleration floor payments Â Â Â $ 652 Â Â $ 652 Â Â Â Â April 2022 Senior Convertible Note and September 2022 Senior Convertible Note [Member] Â Â Â Â Â Â Â Â Â Â Â Â Short-Term Debt [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Debt interest rate Â Â Â 82.50% Â Â 82.50% Â Â Â Â Senior convertible note Â Â Â Â Â Â 1,000,000 Â Â Â Â Conversion price per share Â Â Â $ 2.70 Â Â $ 2.70 Â Â Â Â Â April 2022 Senior Convertible Note and September 2022 Senior Convertible Note [Member] | June 30, 2024 Through September 03, 2024 [Member] Â Â Â Â Â Â Â Â Â Â Â Â Short-Term Debt [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Conversion price Â Â Â $ 0.40 Â Â $ 0.40 Â Â Â Â Lucid March 2023 Senior Convertible Note [Member] Â Â Â Â Â Â Â Â Â Â Â Â Short-Term Debt [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Principal amouint Â Â Â Â Â Â Â Â Â $ 11,019 $ 11,100 Â Debt interest rate Â Â Â Â Â Â Â 7.875% Â Â Conversion price Â Â Â Â Â Â Â Â $ 5.00 Â Â Debt instrument maturity date, description Â Â Â Â Â Â Â Mar. 21, 2025 Â Â Repayment for debt Â Â Â Â Â Â $ 2,005 Â Â Â Â Â Conversions - Senior Secured Convertible Note, shares Â Â Â Â Â 4,172,002 Â Â Â Â Â Gain (loss) on extinguishment of debt Â Â $ 328 Â Â $ 1,009 Â Â Â Â Â Debt Instrument, Periodic Payment, Interest Â Â Â Â Â 787 Â Â Â Â Â Investor [Member] | September 2022 Senior Convertible Note [Member] Â Â Â Â Â Â Â Â Â Â Â Â Short-Term Debt [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Conversions - Senior Secured Convertible Note Â Â Â $ 907 Â Â $ 2,002 Â Â Â Â Investor [Member] | Lucid March 2023 Senior Convertible Note [Member] Â Â Â Â Â Â Â Â Â Â Â Â Short-Term Debt [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Conversions - Senior Secured Convertible Note Â Â Â Â Â $ 3,801 Â Â Â Â Â Securities Purchase Agreement [Member] | Accredited Institutional Investor [Member] Â Â Â Â Â Â Â Â Â Â Â Â Short-Term Debt [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Principal amouint Â Â Â Â Â Â Â Â Â $ 50,000 Securities Purchase Agreement [Member] | Accredited Institutional Investor [Member] | Initial Issuance [Member] Â Â Â Â Â Â Â Â Â Â Â Â Short-Term Debt [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Principal amouint Â Â Â Â Â Â Â Â Â Â Â Â 27,500 Securities Purchase Agreement [Member] | Accredited Institutional Investor [Member] | Additional Issuance [Member] Â Â Â Â Â Â Â Â Â Â Â Â Short-Term Debt [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Principal amouint Â Â Â Â Â Â Â Â Â Â Â $ 22,500 X - DefinitionDebt instrument onversion price per share. + ReferencesNo definition available. + Details Name: PAVM_DebtInstrumentConvertibleStockPrice Namespace Prefix: PAVM_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1 Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe price per share of the conversion feature embedded in the debt instrument. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5 + Details Name: us-gaap_DebtInstrumentConvertibleConversionPrice1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionIdentification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentDescription Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionDate when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentMaturityDate Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionDescription of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DebtInstrumentMaturityDateDescription Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of the required periodic payments applied to interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DebtInstrumentPeriodicPaymentInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4 + Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionReflects the difference between the fair value of payments made to legally extinguish a debt and its carrying value at that time. This item excludes the write-off of amounts previously capitalized as debt issuance costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4 + Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1 + Details Name: us-gaap_InterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncluding the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_NotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfConvertibleDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ShortTermDebtLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe gross value of stock issued during the period upon the conversion of convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=PAVM_AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=PAVM_SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateFloorMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=PAVM_AprilAndSeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardDateAxis=PAVM_JuneThirtyTwentyTwentyFourThroughSeptemberThreeTwentyTwentyFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=PAVM_LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=us-gaap_InvestorMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=PAVM_SecuritiesPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=PAVM_AccreditedInstitutionalInvestorMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=PAVM_InitialIssuanceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=PAVM_AdditionalIssuanceMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 65 R54.htm IDEA: XBRL DOCUMENT v3.24.3 Schedule of Summarizes Information About Stock Options (Details) - USD ($) $ / shares in Units, $ in Thousands 9 Months Ended 12 Months Ended Sep. 30, 2024 Dec. 31, 2023 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Number of Stock Options Outstanding, Ending Balance 66,720 Â 2014 Equity Plan [Member] Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Number of Stock Options Outstanding, Beginning Balance 1,192,458 Â Weighted Average Exercise Price, Beginning Balance $ 26.18 Â Remaining Contractual Term (Years), Ending Balance 5 years 10 months 24 days [1] 7 years 3 months 18 days Intrinsic Value Outstanding, Beginning Balance [2] Â Number of Stock Options, Granted [3] 79,500 Â Weighted Average Exercise Price, Granted [3] $ 2.28 Â Number of Stock Option, Exercised Â Weighted Average Exercise Price, Exercised Â Number of Stock Option, Forfeited (38,851) Â Weighted Average Exercise Price, Forfeited $ 13.47 Â Number of Stock Options Outstanding, Ending Balance 1,233,107 [1] 1,192,458 Weighted Average Exercise Price, Ending Balance $ 25.04 [1] $ 26.18 Intrinsic Value Outstanding, Ending Balance [2] [1] Number of Stock Options Vested and exercisable stock options 956,977 Â Weighted Average Exercise Price, Vested and exercisable stock options $ 30.27 Â Remaining Contractual Term (Years), Vested and exercisable stock options 5 years 1 month 6 days Â Intrinsic Value Exercisable, Ending Balance [2] Â 2018 Equity Plan [Member] Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Number of Stock Options Outstanding, Beginning Balance 5,504,383 Â Weighted Average Exercise Price, Beginning Balance $ 2.00 Â Remaining Contractual Term (Years), Ending Balance 8 years 3 months 18 days [4] 8 years 6 months Intrinsic Value Outstanding, Beginning Balance [5] $ 765 Â Number of Stock Options, Granted [6] 3,604,000 Â Weighted Average Exercise Price, Granted [6] $ 1.22 Â Number of Stock Option, Exercised (3,333) Â Weighted Average Exercise Price, Exercised $ 1.31 Â Number of Stock Option, Forfeited (417,501) Â Weighted Average Exercise Price, Forfeited $ 1.63 Â Number of Stock Options Outstanding, Ending Balance 8,687,549 [4] 5,504,383 Weighted Average Exercise Price, Ending Balance $ 1.69 [4] $ 2.00 Intrinsic Value Outstanding, Ending Balance [5] $ 191 [4] $ 765 Number of Stock Options Vested and exercisable stock options 3,084,682 Â Weighted Average Exercise Price, Vested and exercisable stock options $ 2.25 Â Remaining Contractual Term (Years), Vested and exercisable stock options 7 years 1 month 6 days Â Intrinsic Value Exercisable, Ending Balance [5] $ 191 Â [1] The outstanding stock options presented in the table above are inclusive of 60,054 stock options granted outside the PAVmed 2014 Equity Plan, as of September 30, 2024 and December 31, 2023. [2] The intrinsic value is computed as the difference between the quoted price of the PAVmed common stock on each of September 30, 2024 and December 31, 2023 and the exercise price of the underlying PAVmed stock options, to the extent such quoted price is greater than the exercise price. [3] Stock options granted under the PAVmed 2014 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant. [4] The outstanding stock options presented in the table above are inclusive of 523,300 stock options granted outside the Lucid Diagnostics 2018 Equity Plan, as of September 10, 2024 and December 31, 2023. [5] The intrinsic value is computed as the difference between the quoted price of the Lucid Diagnostics common stock on each of September 10, 2024 and December 31, 2023 and the exercise price of the underlying Lucid Diagnostics stock options, to the extent such quoted price is greater than the exercise price. [6] Stock options granted under the Lucid Diagnostics 2018 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant. X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period

Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=PAVM_TwoThousandAndFourteenEquityPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=PAVM_TwoThousandEighteenEquityPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R55.htm IDEA: XBRL DOCUMENT v3.24.3 Schedule of Summarizes Information About Stock Options (Details) (Parenthetical) - shares 9 Months Ended 12 Months Ended Sep. 10, 2024 Sep. 30, 2024 Dec. 31, 2023 2018 Equity Plan [Member] | Lucid Diagnostics Inc [Member] Â Â Â Number of stock options granted. shares 523,300 Â 523,300 Parent Company [Member] | 2014 Equity Plan [Member] Â Â Â Number of stock options granted. shares Â 60,054 60,054 X - DefinitionNet number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=PAVM_TwoThousandEighteenEquityPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=PAVM_LucidDiagnosticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=PAVM_TwoThousandAndFourteenEquityPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 67 R56.htm IDEA: XBRL DOCUMENT v3.24.3 Schedule of Restricted Stock Award Activity (Details) - Restricted Stock Units (RSUs) [Member] 9 Months Ended Sep. 30, 2024 $ / shares shares 2014 Equity Plan [Member] Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Number of Restricted Stock Awards, Unvested restricted stock awards, Beginning balance | shares 70,527 Weighted Average Grant Date Fair Value, Unvested restricted stock awards, Beginning balance | $ / shares $ 38.77 Number of Restricted Stock Awards, Granted | shares 390,000 Weighted Average Grant Date Fair Value, Granted | $ / shares $ 1.85 Number of Restricted Stock Awards, Vested | shares (135,080) Weighted Average Grant Date Fair Value, Vested | $ / shares $ 2.00 Number of Restricted Stock Awards, Forfeited | shares Weighted Average Grant Date Fair Value, Forfeited | $ / shares Number of Restricted Stock Awards, Unvested restricted stock awards, Ending balance | shares 325,447 Weighted Average Grant Date Fair Value, Unvested restricted stock awards, Ending balance | $ / shares $ 9.79 2018 Equity Plan [Member] Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Number of Restricted Stock Awards, Unvested restricted stock awards, Beginning balance | shares 2,337,440 Weighted Average Grant Date Fair Value, Unvested restricted stock awards, Beginning balance | $ / shares $ 8.99 Number of Restricted Stock Awards, Granted | shares 1,600,000 Weighted Average Grant Date Fair Value, Granted | $ / shares $ 1.03 Number of Restricted Stock Awards, Vested | shares (26,912) Weighted Average Grant Date Fair Value, Vested | $ / shares $ 4.56 Number of Restricted Stock Awards, Forfeited | shares (13,088) Weighted Average Grant Date Fair Value, Forfeited | $ / shares $ 4.56 Number of Restricted Stock Awards, Unvested restricted stock awards, Ending balance | shares 3,897,440 Weighted Average Grant Date Fair Value, Unvested restricted stock awards, Ending balance | $ / shares $ 5.77 X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to

disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=PAVM_TwoThousandAndFourteenEquityPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=PAVM_TwoThousandEighteenEquityPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 68 R57.htm IDEA: XBRL DOCUMENT v3.24.3 Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Total stock-based compensation expense $ 1,931 $ 2,245 $ 5,716 $ 9,171 Cost Of Revenue [Member] Â Â Â Â Total stock-based compensation expense 32 32 112 86 Selling and Marketing Expense [Member] Â Â Â Â Total stock-based compensation expense 292 403 1,082 1,302 General and Administrative Expense [Member] Â Â Â Â Total stock-based compensation expense 1,426 1,499 3,717 6,761 Research and Development Expense [Member] Â Â Â Â Total stock-based compensation expense $ 181 $ 311 $ 805 $ 1,022 X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=PAVM_CostOfRevenueMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 69 R58.htm IDEA: XBRL DOCUMENT v3.24.3 Schedule of Stock-Based Compensation Expense Recognized by Lucid Diagnostics (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Total stock-based compensation expense $ 1,931 $ 2,245 $ 5,716 $ 9,171 Lucid Diagnostics Inc [Member] Â Â Â Â Total stock-based compensation expense 955 1,252 3,089 5,859 Cost Of Revenue [Member] Â Â Â Â Total stock-based compensation expense 32 32 112 86 Selling and Marketing Expense [Member] Â Â Â Â Total stock-based compensation expense 292 403 1,082 1,302 General and Administrative Expense [Member] Â Â Â Â Total stock-based compensation expense 1,426 1,499 3,717 6,761 Research and Development Expense [Member] Â Â Â Â Total stock-based compensation expense 181 311 805 1,022 Lucid Diagnostics 2018 Equity Plan [Member] | Cost Of Revenue [Member] Â Â Â Â Total stock-based compensation expense 24 16 81 44 Lucid Diagnostics 2018 Equity Plan [Member] | Selling and Marketing Expense [Member] Â Â Â Â Total stock-based compensation expense 252 228 849 697 Lucid Diagnostics 2018 Equity Plan [Member] | General and Administrative Expense [Member] Â Â Â Â Total stock-based compensation expense 548 721 1,484 4,069 Lucid Diagnostics 2018 Equity Plan [Member] | Research and Development Expense [Member] Â Â Â Â Total stock-based compensation expense 98 67 356 204 PAVmed Inc 2014 Equity Plan [Member] | Cost Of Revenue [Member] Â Â Â Â Total stock-based compensation expense 9 10 30 26 PAVmed Inc 2014 Equity Plan [Member] | Selling and Marketing Expense [Member] Â Â Â Â Total stock-based compensation expense 18 106 136 359 PAVmed Inc 2014 Equity Plan [Member] | General and Administrative Expense [Member] Â Â Â Â Total stock-based compensation expense 1 7 5 170 PAVmed Inc 2014 Equity Plan [Member] | Research and Development Expense [Member] Â Â Â Â Total stock-based compensation expense $ 5 $ 97 $ 148 $ 290 X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: dei_LegalEntityAxis=PAVM_LucidDiagnosticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=PAVM_CostOfRevenueMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=PAVM_LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=PAVM_PAVmedIncTwoThousandFourteenEquityPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 70 R59.htm IDEA: XBRL DOCUMENT v3.24.3 Schedule of Unrecognized Compensation Expense (Details) - PAVmed Inc 2014 Equity Plan [Member] $ in Thousands 9 Months Ended Sep. 30, 2024 USD ($) Equity Option [Member] Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Unrecognized Expense $ 1,377 Weighted Average Remaining Service Period 1 year 6 months Restricted Stock [Member] Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Unrecognized Expense $ 397 Weighted Average Remaining Service Period 2 years 2 months 12 days X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_StockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=PAVM_PAVmedIncTwoThousandFourteenEquityPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 71 R60.htm IDEA: XBRL DOCUMENT v3.24.3 Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions (Details) 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 2014 Equity Plan [Member] Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Expected term of stock options (in years) 5 years 9 months 18 days 5 years 8 months 12 days Expected stock price volatility 90.00% 88.00% Risk free interest rate 4.30% 3.70% Expected dividend yield 2018 Equity Plan [Member] Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Expected term of stock options (in years) 5 years 8 months 12 days 5 years 7 months 6 days Expected stock price volatility 73.00% 75.00% Risk free interest rate Â 3.70% Expected dividend yield X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=PAVM_TwoThousandAndFourteenEquityPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=PAVM_TwoThousandEighteenEquityPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 72 R61.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended Feb. 22, 2024 May 31, 2024 Jan. 31, 2024 Mar. 31, 2024 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Number of stock options outstanding Â Â Â Â Â 66,720 Â Â Proceeds from common stock Â Â Â Â Â $ 1,268 $ 1,166 Â Employee Stock Purchase Plan [Member] Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Common stock capital shares reserved for future issuance Â Â Â Â Â 300,001 Â Â Increase in available for grant Â Â Â Â Â 139,863 Â Â Number of common stock purchased Â Â Â 34,332 38,216 Â 20,267 Â Proceeds from common stock Â Â Â $ 62 $ 182 Â $ 76 Â Treasury stock Â Â Â Â 12,590 Â Â Â Increase in reserve stock Â Â 166,667 Â Â Â Â Â Employee Stock Purchase Plan [Member] | Lucid Diagnostics Inc [Member] Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Number of common stock purchased Â Â Â 511,884 231,987 Â 276,213 Â Proceeds from common stock Â Â Â $ 353 $ 276 Â $ 275 Â 2014 Equity Plan [Member] Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Common stock capital shares reserved for future issuance Â Â Â Â Â 1,835,970 Â Â Increase in available for grant Â Â 432,452 Â Â 79,321 Â Â Number of stock options outstanding Â Â Â Â Â 1,233,107 [1] Â 1,192,458 Granted [2] Â Â Â Â Â 79,500 Â Â Weighted average fair value of stock options Â Â Â Â Â $ 1.47 $ 5.25 Â 2014 Equity Plan [Member] | Parent Company [Member] Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Granted 59,500 Â Â Â Â Â Â Â Weighted average exercise price $ 1.85 Â Â Â Â Â Â Â 2014 Equity Plan [Member] | Parent Company [Member] | Restricted Stock [Member] Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Granted 390,000 Â Â Â Â Â Â Â Â Aggregate fair value $ 700 Â Â Â Â Â Â Â Â 2018 Equity Plan [Member] Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Number of stock options outstanding Â Â Â Â Â 8,687,549 [3] Â 5,504,383 Granted [4] Â Â Â Â Â 3,604,000 Â Â Weighted average fair value of stock options Â Â Â Â Â $ 0.79 $ 0.88 Â 2018 Equity Plan [Member] | Lucid Diagnostics Inc [Member] Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Granted 2,895,000 Â Â Â Â Â Â Â Â Weighted average exercise price $ 1.25 Â Â Â Â Â Â Â 2018 Equity Plan [Member] | Restricted Stock [Member] | Lucid Diagnostics Inc [Member] Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Granted Â 1,600,000 Â Â Â Â Â Â Aggregate fair value Â $ 1,500 Â Â Â Â Â Â [1] The outstanding stock options presented in the table above are inclusive of 60,054 stock options granted outside the PAVmed 2014 Equity Plan, as of September 30, 2024 and December 31, 2023. [2] Stock options granted under the PAVmed 2014 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant. [3] The outstanding stock options presented in the table above are inclusive of 523,300 stock options granted outside the Lucid Diagnostics 2018 Equity Plan, as of September 10, 2024 and December 31, 2023. [4] Stock options granted under the Lucid Diagnostics 2018 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant. X - DefinitionStock issued during period shares increase in reserve + ReferencesNo definition available. + Details Name: PAVM_StockIssuedDuringPeriodSharesIncreaseInReserve Namespace Prefix: PAVM_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -

Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionChange in the weighted average exercise price of options outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares purchased for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 30 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480513/718-10-30-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 30 -Section 35 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480843/718-30-35-1 + Details Name: us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=PAVM_EmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=PAVM_LucidDiagnosticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=PAVM_TwoThousandAndFourteenEquityPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=PAVM_TwoThousandEighteenEquityPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 73 R62.htm IDEA: XBRL DOCUMENT v3.24.3 Preferred Stock (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands 1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended Nov. 30, 2024 Sep. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Mar. 31, 2023 Jun. 30, 2024 Jun. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Dec. 31, 2022 Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Preferred stock stated value per share Â $ 0.001 Â Â Â Â Â $ 0.001 Â $ 0.001 Â Dividends earned Â $ 83 Â $ 77 Â Â Â Â $ 244 $ 226 Â Â Aggregate preferred stock dividends earned Â Â Â Â Â Â Â Series B Convertible Preferred Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Preferred stock shares outstanding Â 1,385,149 Â Â Â Â Â 1,385,149 Â 1,305,213 Â Preferred stock stated value per share Â $ 0.001 Â Â Â Â Â $ 0.001 Â $ 0.001 Â Preferred stock stated value per share Â $ 3.00 Â Â Â Â Â $ 3.00 Â Â Â Dividend rate percentage Â Â Â Â Â Â Â 8.00% Â Â Â Dividends earned Â $ 83 Â $ 77 Â Â Â Â $ 244 226 Â Â Aggregate preferred stock dividends declared Â Â Â Â Â Â Â $ 239 $ 221 Â Â Series B Convertible Preferred Stock [Member] | Subsequent Event [Member] Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Aggregate preferred stock dividends earned $ 83 Â Â Â Â Â Â Â Â Â Â Additioanal aggregate shares of convertible preferred stock 27,716 Â Â Â Â Â Â Â Â Â Â Series B Convertible Preferred Stock [Member] | Board Of Directors [Member] Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Aggregate preferred stock dividends earned Â Â $ 80 Â $ 74 $ 81 $ 75 Â Â $ 78 $ 72 Additioanal aggregate shares of convertible preferred stock Â Â 26,640 Â 24,610 27,173 25,104 79,936 73,842 26,123 24,128 X - DefinitionPreferred stock stated value per share. + ReferencesNo definition available. + Details Name: PAVM_PreferredStockStatedValuePerShare Namespace Prefix: PAVM_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -SubTopic 405 -Topic 942 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2 + Details Name: us-gaap_DividendsPreferredStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe percentage rate used to calculate dividend payments on preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 + Details Name: us-gaap_PreferredStockDividendRatePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders. + ReferencesNo definition available. + Details Name: us-gaap_PreferredStockDividendsIncomeStatementImpact Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of shares of preferred stock issued as dividends during the period. Excludes stock splits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap_PreferredStockDividendsShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType

Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionValue of stock issued to shareholders as a dividend during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockDividend Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=PAVM_SeriesBConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=PAVM_BoardOfDirectorsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 74 R63.htm IDEA: XBRL DOCUMENT v3.24.3 Common Stock and Common Stock Purchase Warrants (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended Mar. 07, 2024 Feb. 15, 2024 Jan. 15, 2024 Dec. 07, 2023 Nov. 28, 2023 Feb. 28, 2023 Sep. 30, 2024 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Â Â Â Â Â Â Â Â Reverse stock split Â Â Â Â 1-for-15 Â Â Â Â Â Common stock, shares authorized Â Â Â Â Â Â 50,000,000 50,000,000 Â 50,000,000 Stock Issued and outstanding description Â Â Â every 15 shares of the Companyâ€™s common stock that were issued and outstanding were automatically combined into one issued and outstanding share, without any change in par value of such shares. Â Â Â Â Â Â Debt instrument fee description On March 7, 2024, the Company received a notice from the Listing Qualifications Department of The Nasdaq Stock Market (â€œNasdaqâ€) stating that, for the prior 30 consecutive business days (through March 6, 2024), the market value of the Companyâ€™s listed securities had been below the minimum of $35 million required for continued inclusion on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2). The Company was provided 180 calendar days, or until September 3, 2024, to regain compliance with the rule. The Company did not regain compliance with the rule during the allotted time period. Accordingly, on September 10, 2024, the Company received a staff determination letter from the Nasdaq Listing Qualifications Department, stating that unless the Company timely requested a hearing before a Nasdaq Hearings Panel (the â€œPanelâ€) to appeal the staff determination, the Companyâ€™s securities would be subject to suspension and delisting. The Company timely requested a hearing before the Panel, which was held on October 29, 2024. Â Â Â Â Â Â Â Â Â At-the-market equity facility, shares Â Â Â Â Â Â Â 627,302 Â Â At-the-market equity facility, value Â Â Â Â Â Â Â Â $ 977 Â Â Payments for commissions percentage Â Â Â Â Â Â Â Â 3.00% Â Â Issued for services Â Â Â Â Â Â Â $ 150 $ 601 $ 747 Â Warrant price decrease Â $ 0.52 Â Â Â Â Â Â Â Â Â Â Share price Â 0.37709668 Â Â Â Â Â Â Â Â Â Exercise price Â $ 23.48 Â Â Â Â Â Â Â Â Â Series Z Warrants [Member] Â Â Â Â Â Â Â Â Â Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Â Â Â Â Â Â Â Â Â Exercise price Â Â Â Â Â Â Â Â Â $ 23.48 $ 23.48 Â $ 23.48 Class of Warrant or Right, Outstanding Â Â Â Â Â Â Â 11,937,450 11,937,450 Â 11,937,450 Purchase of warrants Â Â Â Â Â Â Â 795,830 795,830 Â 795,830 Exercise price, post reverse-split Â Â Â Â Â Â Â $ 24.00 $ 24.00 Â $ 24.00 Lucid Diagnostics Inc [Member] Â Â Â Â Â Â Â Â Â Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Â Â Â Â Â Â Â Â Common stock, dividends shares Â 3,331,747 38 Â Â Â Â Â Â Â Vendors [Member] Â Â Â Â Â Â Â Â Â Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Â Â Â Â Â Â Â Â Number of shares issued Â Â Â Â Â Â Â 200,809 Â Â Issued for services Â Â Â Â Â Â Â $ 200 Â Â Common Stock [Member] Â Â Â Â Â Â Â Â Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Â Â Â Â Â Â Â Number of shares issued Â Â Â Â Â Â 171,052 200,809 100,000 Â Issued for services Â Â Â Â Â Â Â Common Stock [Member] | Lucid Diagnostics Inc [Member] Â Â Â Â Â Â Â Â Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Â Â Â Â Â Â Â Common stock, dividends shares Â Â 100 Â Â Â Â Â Â Â Â April 2022 Senior Convertible Note and September 2022 Senior Convertible Note [Member] Â Â Â Â Â Â Â Â Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Â Â Â Â Â Â Â Convertible common stock shares issued upon conversion Â Â Â Â Â Â 574,424 574,424 Â Â Debt Instrument, Convertible, If-converted Value in Excess of Principal Â Â Â Â Â Â Â $ 980 Â Â Employee Stock Purchase Plan [Member] Â Â Â Â Â Â Â Â Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Â Â Â Â Â Â Â Number of common stock issued Â Â Â Â Â Â Â 34,332 Â Â Minimum [Member] Â Â Â Â Â Â Â Â Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Â Â Â Â Â Â Â Reverse stock split Â Â Â Â 1-for-5 Â Â Â Â Common stock, shares authorized Â Â Â Â Â 50,000,000 Â Â Â Â Minimum [Member] | Series Z Warrants [Member] Â Â Â Â Â Â Â Â Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Â Â Â Â Â Â Â Exercise price, post reverse-split Â Â Â Â Â Â Â $ 0.52 $ 0.52 Â $ 0.52 Maximum [Member] Â Â Â Â Â Â Â Â Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Â Â Â Â Â Â Â Reverse stock split Â Â Â Â 1-for-15 Â Â Â Â Common stock, shares authorized Â Â Â Â Â 250,000,000 Â Â Â Â X - DefinitionClass of warrant or right exercise price of warrants or rights. + ReferencesNo definition available. + Details Name: PAVM_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights Namespace Prefix: PAVM_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionConvertible common stock shares issued upon conversion. + ReferencesNo definition available. + Details Name: PAVM_ConvertibleCommonStockSharesIssuedUponConversion Namespace Prefix: PAVM_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPayments for commissions percentage. + ReferencesNo definition available. + Details Name: PAVM_PaymentsForCommissionsPercentage Namespace Prefix: PAVM_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAt-the-market equity facility, shares. + ReferencesNo definition available. + Details Name: PAVM_StockIssuedDuringPeriodShareATMFacilities Namespace Prefix: PAVM_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAt-the-market equity facility, value. + ReferencesNo definition available. + Details Name: PAVM_StockIssuedDuringPeriodValueATMFacilities Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionStock issused and outstanding description. + ReferencesNo definition available. + Details Name: PAVM_StockIssusedAndOutstandingDescription Namespace Prefix: PAVM_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWarrants and rights outstanding purchase. + ReferencesNo definition available. + Details Name: PAVM_WarrantsAndRightsOutstandingPurchase Namespace Prefix: PAVM_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock issued as dividends during the period. Excludes stock splits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap_CommonStockDividendsShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe amount by which the convertible debt's if-converted value exceeds its principle amount at the balance sheet date, regardless of whether the instrument is currently convertible. This element applies to public companies only. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5 + Details Name: us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDescription of a fee associated with the debt instrument, including a commitment fee on unborrowed portions of a lender's total contractual commitment. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DebtInstrumentFee Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPrice of a single share of a number of saleable stocks of a company. + ReferencesNo definition available. + Details Name: us-gaap_SharePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDescription of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4 + Details Name: us-gaap_StockholdersEquityReverseStockSplit Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPer share decrease in exercise price of warrant. Excludes change due to standard antidilution provision. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_WarrantExercisePriceDecrease Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=PAVM_SeriesZWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=PAVM_LucidDiagnosticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=PAVM_VendorsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=PAVM_AprilAndSeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=PAVM_EmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 75 R64.htm IDEA: XBRL DOCUMENT v3.24.3 Schedule of Noncontrolling Interest of Stockholders' Equity (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Noncontrolling Interest [Abstract] Â Â Â Â NCI â€“ equity - December 31, 2023 Â Â $ 29,813 Â Net loss attributable to NCI $ (3,688) $ (4,079) (11,075) $ (11,716) Impact of subsidiary equity transactions Â Â (4,414) Â Lucid Diagnostics proceeds from issuance of preferred stock Series A-1 Â Â 5,670 Â Lucid Diagnostics exchange of preferred stock Series A and Series A-1 Â Â (24,294) Â Lucid Diagnostics issuance through exchange - Series B and Series B-1 Â Â 31,790 Â Lucid Diagnostics issuance through sale - Series B and Series B-1 Â Â 24,129 Â Lucid Diagnostics deemed dividend on preferred stock Â Â (7,496) Â Lucid Diagnostics issuance of common stock for settlement of vendor service agreement Â Â 401 Â Lucid Diagnostics 2018 Equity Plan stock option exercise Â Â 4 Â Lucid Diagnostics Employee Stock Purchase Plan Purchase Â Â 353 Â Conversion of Lucid Diagnostics common stock for Senior Secured Convertible Debt Â Â 3,801 Â Stock-based compensation expense - Lucid Diagnostics 2018 Equity Plan Â Â 2,771 Â Stock-based compensation expense - Veris Health 2021 Equity Plan Â Â 368 Â Deconsolidation of Lucid Â Â (56,339) Â NCI â€“ equity - September 30, 2024 $ (4,518) Â $ (4,518) Â X - DefinitionMinority interest equity plan stock

option exercise. + ReferencesNo definition available. + Details Name: PAVM_AdjustmentsToAdditionalPaidInCapitalMinorityInterestRequisiteServicePeriodRecognitionValue Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAdjustments to additional paid in capital minority interest requisite service period recognition value four. + ReferencesNo definition available. + Details Name: PAVM_AdjustmentsToAdditionalPaidInCapitalMinorityInterestRequisiteServicePeriodRecognitionValueFour Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAdjustments to additional paid in capital sharebased compensation requisite deconsolidation of lucid. + ReferencesNo definition available. + Details Name: PAVM_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteDeconsolidationOfLucid Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesNo definition available. + Details Name: PAVM_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValues Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionImpact of subsidiary equity transactions. + ReferencesNo definition available. + Details Name: PAVM_ImpactOfSubsidiaryEquityTransactions Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIssue common stock upon partial conversions of majority owned subsidiary common senior secured convertible note + ReferencesNo definition available. + Details Name: PAVM_IssueCommonStockUponPartialConversionsOfMajorityOwnedSubsidiaryCommonSeniorSecuredConvertibleNote Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLucid diagnostics deemed dividend on preferred stock. + ReferencesNo definition available. + Details Name: PAVM_LucidDiagnosticsDeemedDividendOnPreferredStock Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLucid diagnostics exchange of preferred stock series and series A1. + ReferencesNo definition available. + Details Name: PAVM_LucidDiagnosticsExchangeOfPreferredStockSeriesAndSeriesAOne Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLucid Diagnostics Issuance of Common Stock for Settlement of Vendor Service Agreement [Member] + ReferencesNo definition available. + Details Name: PAVM_LucidDiagnosticsIssuanceOfCommonStockForSettlementOfVendorServiceAgreement Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLucid Diagnostics issuance through exchange - Series B and Series B-1. + ReferencesNo definition available. + Details Name: PAVM_LucidDiagnosticsIssuanceThroughExchangeSeriesBAndSeriesBOne Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLucid Diagnostics issuance through sale - Series B and Series B-1. + ReferencesNo definition available. + Details Name: PAVM_LucidDiagnosticsIssuanceThroughSaleSeriesBAndSeriesBOne Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLucid diagnostics proceeds from issuance of preferred stock series A1. + ReferencesNo definition available. + Details Name: PAVM_LucidDiagnosticsProceedsFromIssuanceOfPreferredStockSeriesAOne Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_MinorityInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of Net Income (Loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B + Details Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NoncontrollingInterestAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 76 R65.htm IDEA: XBRL DOCUMENT v3.24.3 Schedule of Net Loss Attributable to Common Stockholders (Details) $ in Thousands Mar. 13, 2024 USD ($) Noncontrolling Interest [Abstract] Â Fair Value - 31,790 shares of Lucid Series B Preferred Stock issued in exchange for Lucid Series A and Lucid Series A-1 Preferred Stock $ 31,790 Less: Carrying value related to Lucid Series A and Lucid Series A-1 Preferred Stock Exchanged for Lucid Series B Preferred Stock (of 24,295 shares) (24,294) Deemed Dividend Charged to Accumulated Deficit $ 7,496 X - DefinitionDeemed dividend charged to accumulated deficit. + ReferencesNo definition available. + Details Name: PAVM_DeemedDividendChargedToAccumulatedDeficit Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFair value of series B preferred stock issued. + ReferencesNo definition available. + Details Name: PAVM_FairValueOfSeriesBPreferredStockIssued Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLess carrying value related to series and series A1 preferred stock exchanged for series B preferred stock. + ReferencesNo definition available. + Details Name: PAVM_LessCarryingValueRelatedToSeriesAndSeriesA1PreferredStockExchangedForSeriesBPreferredStock Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NoncontrollingInterestAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 77 R66.htm IDEA: XBRL DOCUMENT v3.24.3 Schedule of Net Loss Attributable to Common Stockholders (Details) (Parenthetical) Mar. 13, 2024 shares Noncontrolling Interest [Abstract] Â Fair value of the consideration shares 31,790 Less carrying value related to series and series A1 preferred stock exchanged for series B preferred stock shares 24,295 X - DefinitionFair value of series B preferred stock issued shares. + ReferencesNo definition available. + Details Name: PAVM_FairValueOfSeriesBPreferredStockIssuedShares Namespace Prefix: PAVM_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLess carrying value related to series and series A1 preferred stock exchanged for series B preferred stock shares. + ReferencesNo definition available. + Details Name: PAVM_LessCarryingValueRelatedToSeriesAndSeriesA1PreferredStockExchangedForSeriesBPreferredStockShares Namespace Prefix: PAVM_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NoncontrollingInterestAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 78 R67.htm IDEA: XBRL DOCUMENT v3.24.3 Noncontrolling Interest (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands 9 Months Ended Sep. 10, 2024 May 06, 2024 Mar. 13, 2024 Feb. 15, 2024 Jan. 26, 2024 Jan. 15, 2024 Mar. 07, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Noncontrolling Interest [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Common stock shares outstanding Â Â Â Â Â Â Â Â 10,660,394 Â 8,578,505 Issuance of shares, stated value Â Â Â Â Â Â Â $ 0.001 Â $ 0.001 Gross proceeds Â Â Â Â Â Â Â Â $ 29,798 $ 13,625 Â Carrying value Â Â Â Â Â Â Â Â $ 24,294 Â Â Series A Convertible Preferred Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Â Noncontrolling Interest [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Number of shares issued Â Â Â Â Â Â Â 13,625 Â Â Â Issuance of shares, stated value Â Â Â Â Â Â Â $ 1,000 Â Â Â Preferred shares conversion price Â Â Â Â Â Â Â $ 1.394 Â Â Â Dividend percentage Â Â Â Â Â Â Â 20.00% Â Â Â Sale of stock, transaction value Â Â Â Â Â Â Â $ 13,625 Â Â Â Series A-1 Preferred Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Â Noncontrolling Interest [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Number of shares issued Â Â 5,670 Â Â Â Â Â Â Â Â Â Gross proceeds Â Â $ 5,670 Â Â Â Â Â Â Â Â Â Series B Convertible Preferred Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Â Noncontrolling Interest [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Number of shares issued Â Â 44,285 Â Â Â Â Â Â Â Â Issuance of shares, stated value Â Â Â Â Â Â Â $ 0.001 Â $ 0.001 Dividend percentage Â Â Â Â Â Â Â 8.00% Â Â Conversion price Â Â $ 1.2444 Â Â Â Â Â Â Â Gross proceeds, sale of shares Â Â $ 18,100 Â Â Â Â Â Â Â Fair value of the consideration shares Â Â 31,790 Â Â Â Â Â Â Â Carrying value Â Â $ 24,294 Â Â Â Â Â Â Â Fair value of deemed dividend Â Â $ 7,500 Â Â Â Â Â Â Â Lucid Series A and Lucid Series A-1 Preferred Stock [Member] Â Â Â Â Â Â Â Â Â Â Noncontrolling Interest [Line Items] Â Â Â Â Â Â Â Â Â Â Outstanding shares, percentage Â Â 100.00% Â Â Â Â Â Â Â Series B 1 Preferred Stock [Member] Â Â Â Â Â Â Â Â Â Noncontrolling Interest [Line Items] Â Â Â Â Â Â Â Â Â Number of shares issued Â 11,634 Â Â Â Â Â Â Â Conversion price Â $ 0.7228 Â Â Â Â Â Â Â Gross proceeds, sale of shares Â $ 11,600 Â Â Â Â Â Â Â Lucid Diagnostics Inc [Member] Â Â Â Â Â Â Â Â Â Noncontrolling Interest [Line Items] Â Â Â Â Â Â Â Â Â Common stock shares issued Â Â Â Â Â Â Â 51,597,718 Â Common stock shares outstanding Â Â Â Â Â Â Â 51,597,718 Â Â Partners capital account units acquisitions Â Â Â Â Â Â Â 31,302,444 Â Â Partners capital account units description On September 10, 2024, following preferred equity transactions completed by Lucid earlier in 2024 and the termination of voting proxies entered into between PAVmed and certain shareholders of Lucid, PAVmedâ€™s voting interest in the Company was reduced to less than 50.0%, resulting in the loss of a controlling financial interest. However, PAVmed retains the ability to exercise significant influence over Lucid. Upon deconsolidation, the Companyâ€™s ownership of 31,302,444 shares of Lucid Diagnostics common stock was valued at $25.1 million, which resulted in a gain on deconsolidation of $72.3 million in the accompanying unaudited condensed consolidated statements of operations for the three and nine months ended September 30, 2024. Â Â Â Â Â Â Â Â Â Received from payment of fees Â Â Â Â $ 4,675 Â Â Â Â Â Number of shares issued Â Â Â Â 3,331,771 Â Â Â Â Â Common stock, dividends shares Â Â Â 3,331,747 Â 38 Â Â Â Â Â X - DefinitionFair value of deemed dividend. + ReferencesNo definition available. + Details Name: PAVM_FairValueOfDeemedDividend Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value preferred stock dividends, shares. + ReferencesNo definition available. + Details Name: PAVM_FairValuePreferredStockDividendsShares Namespace Prefix: PAVM_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionIssuance exchange - subsidiary preferred stock Series A and Series A one. + ReferencesNo definition available. + Details Name: PAVM_IssuanceOfExchangeSubsidiaryPreferredStockSeriesAndSeriesAOne Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionOutstanding shares percentage. + ReferencesNo definition available. + Details Name: PAVM_OutstandingSharesPercentage Namespace Prefix: PAVM_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPartners capital account units, description. + ReferencesNo definition available. + Details Name: PAVM_PartnersCapitalAccountUnitsDescription Namespace Prefix: PAVM_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares of common stock issued as dividends during the period. Excludes stock splits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap_CommonStockDividendsShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-

09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe price per share of the conversion feature embedded in the debt instrument. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5 + Details Name: us-gaap_DebtInstrumentConvertibleConversionPrice1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_MinorityInterestLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionChange in the number of units for each class of partners' capital accounts during the year due to acquisitions. Partners include general, limited and preferred partners. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 50 -Section 30 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 50 -Section 05 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480153/805-50-05-7Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 50 -Section 30 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-7Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 50 -Section 30 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-9 + Details Name: us-gaap_PartnersCapitalAccountUnitsAcquisitions Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPer share conversion price of preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockConvertibleConversionPrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe percentage rate used to calculate dividend payments on preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 + Details Name: us-gaap_PreferredStockDividendRatePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionCash received for fees during the current period. This element excludes cash proceeds from license fees. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_ProceedsFromFeesReceived Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=PAVM_SeriesAConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=PAVM_SeriesAOnePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=PAVM_SeriesBConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=PAVM_LucidSeriesAAndLucidSeriesAOnePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=PAVM_SeriesBOnePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=PAVM_LucidDiagnosticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 79 R68.htm IDEA: XBRL DOCUMENT v3.24.3 Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Earnings Per Share [Abstract] Â Â Â Â Net income (loss) - before noncontrolling interest $ 60,711 $ (21,750) $ 27,285 $ (61,855) Net income (loss) attributable to noncontrolling interest 3,688 4,079 11,075 11,716 Net income (loss) - as reported, attributable to PAVmed Inc. 64,399 (17,671) 38,360 (50,139) Series B Convertible Preferred Stock dividends â€" earned (83) (77) (244) (226) Deemed dividend on Subsidiary Preferred Stock attributable to the noncontrolling interests (7,496) Net income (loss) attributable to PAVmed Inc. common stockholders used in basic EPS calculation 64,316 (17,748) 30,620 (50,365) Fair Value Adjustment for diluted EPS calculation (240) 3,378 Net income (loss) attributable to PAVmed Inc. common stockholders used in dilutive EPS calculation $ 64,076 $ (17,748) $ 33,998 $ (50,365) Weighted average common shares outstanding, basic 10,005,379 7,462,751 9,286,999 6,967,764 Weighted average common shares outstanding, diluted 44,475,638 7,462,751 43,069,449 6,967,764 Net income (loss) per share attributable to PAVmed Inc. common stockholders, basic [1] $ 6.43 $ (2.38) $ 3.30 $ (7.23) Net income (loss) per share attributable to PAVmed Inc. common stockholders, diluted [1] $ 1.44 $ (2.38) $ 0.79 $ (7.23) [1] - Convertible preferred stock and restricted stock awards would potentially be considered a participating security under the two-class method of calculating net income (loss) per share. For periods where losses are presented, such holders are not contractually obligated to share in the losses, there is no impact on the Companyâ€™s net income (loss) per share calculation for the periods indicated. X - DefinitionDeemed dividend on subsidiary preferred stock attributable to noncontrolling interests. + ReferencesNo definition available. + Details Name: PAVM_DeemedDividendOnSubsidiaryPreferredStockAttributableToNoncontrollingInterests Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFair value adjustment for diluted eps calculation + ReferencesNo definition available. + Details Name: PAVM_FairValueAdjustmentForDilutedEpsCalculation Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNet income loss available to common stockholders + ReferencesNo definition available. + Details Name: PAVM_NetIncomeLossAvailableToCommonStockholders Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionConvertible Preferred Stock dividends Series B. + ReferencesNo definition available. + Details Name: PAVM_PreferredStockDividendsSeriesB Namespace Prefix: PAVM_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -

Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of Net Income (Loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B + Details Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 80 R69.htm IDEA: XBRL DOCUMENT v3.24.3 Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share (Details) - shares 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Total 2,028,937 2,090,297 Stock Options [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Total 1,233,107 1,138,632 Restricted Stock [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Total 70,528 Series Z Warrants [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Total 795,830 795,830 Series B Convertible Preferred Stock [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Total 85,307 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=PAVM_StockOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=PAVM_SeriesZWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=PAVM_SeriesBConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 81 R70.htm IDEA: XBRL DOCUMENT v3.24.3 Net Income (Loss) Per Share (Details Narrative) - shares 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 2014 Equity Plan [Member] Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Issue common stock - PAVM ATM Facility, shares 60,054 33,391 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=PAVM_TwoThousandAndFourteenEquityPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 82 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-
]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\YZ<5X&N(YV02Y?9A7;>?
8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=
<7^/1DN/;IF6U;]\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56 *P MOFH]M!5.S_Y9kF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71%
B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8]*@<I&K8ZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F
6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 (M *RK;5G0V]R&C08 *\D 8 >&PO=V]R:W-H965T&UL MM9IK<]I&%(:_YU?
LT$PGF0E&N^+FU/8,QG;K:4R(<9-Q.OVPEA;06+2U0+V MO^]9"23L61V(&N5#C$#G91_MA4>7D[54C\E<"$Y<TM:.3AMSK1T;M\%LKLT;K;.3!9^)B=!_+<8*MEIYBA]$(DX"&1,E MIJ>- ?
TX=/NF(-WC:R#6RI'PT&]?^:<,Q+1*A\+2)X/!G)88B#$T2 MM./?36@C_TY3N/MZFWZ5P@/, T_$4(;? E_/3QO]!O'%E"]#?2O7?X@-4,?D
M>3),TO_)>K.OTR#>,M$RVA1#"Z(@SO[RI\V!V"GH=4L*V*: O2J@[9("=U/@ MIJ!9RU*L"Z[YV8F2:Z+,WI!F7J3')JT&FB VW3C1"CX-H$Z?#>5**-(D;TF+ M)'.N1'+2Tl!K/FUYFXSS+
(.59!R3&QGK>4(N8U_X+^M;T)Z\46S;J'.&!D[$ MXHBXS@?"'-:VM&>(EX_DZHA0:BM_T1PW/T9NFN>6Y%U(;PDC5Y.[YX6P'1Z\ MG#K-+58(M,I,WX(@)GOBM 'S,Q%J)1IGO_Y"N\YO"%([1VJC;1H
CY\R785\ M9F/"ZZ<\3&R'8HB6583JY%"=P_KIRY(K+53X3&[%0BIMX\.CM%I:\="JBGC= M'*][X#!4');1=!4LY\.S2OL/+:L(V,L!>XMJR^>]L6U\:$U%?F.<[[C'^*[%UR5T^%9 M9?
V'5E7DHT[QH^F@K1HNB?B-W(T(^)-F5-E]HX\F'>F5>C0\LF*BU54Q"X.AN(-L,(#Q]<2&;UX9+L'LY.V::]GY:U#>&AA M/!3WE WO=>Q)!2:0F$@$PWK$)&*#.42.ASZ7?KV,;U']"ZMR'5($"TLB.+J
MLD$>^#ZD)Q^V+\@GV(]\CNV<>*3;==X0^'?#_2"!L3)8B=CN?WA05?9"D"CN M-2C[W5I:V?%(UM'S%/XJE-(V/X9X0%7F0I8H[C>OF8=F"\;VG5S'5EX\;B36 M*>Z]5(]6VCK,B1;J1'?
>4V;3^6QDJL@]NS#&\\A8 M)AI^F;X'B]+5:D\BA1\FZQJ-UU4E+1R*X?J3#MB!$KP<#]X=TQ[[ZU@=;@3 M*]R)X&^]O#;$JZIR%M+$#I*FZU@+E5U6-2!5MXZ3(D5IL0..J5)Q,.0G"\3^#BQ
MCUH\I^QB&%Y6%:^0(7:0#%U&0LW,K/P=$O0<%MEHP6-[O^*!1?+\+JJH(4! ML8,,:#(7T(\8'AY3CE>\K!">=A!R@-@$;CW1$OO$;PGO1=!/B\U:$'L0_]: MB;/D=IIL[EBMP
.^YU^FYZT5B\8+7M2I]OO=+OYGB]O#A0FXQYD,I^"Q/PX M@,EP1;[R<"G,A;T,Q'K3($OM[+37(.0%>=5P_,LK=HY;R(N[1UY>],K;M(5D M 82KE' !A.EM(_+WC3 &\(\5]2=YRN:
(U&$];F$]+BXL=X$.P63-^?Q3)1>$MP3-!I,+@;V6WJUB)!;B)"+"\Q$J 6 MU^_D&U?FFB>D'UH0]EY *UX2?:F&MG4="C""G3\HDQ#,7A+.G0_)W\Z=Q!NDS
M**UB]^Q1GAMN_#HAH9A"J7/4@[FHLJ=CL@TM%^D#)@]2:QFE+^>"T*9'>#S MJ91ZNV&^(`]&Z>P_4$L#!!0 (*RK;5EYTWH/<@8 'T: 8 >&PO M=V]R:W-
H965T&ULK5G;MLX$/T5PEL4+6#'(JEKFAA(DRVV MP&XU&WWF9'HF*@DJB+M)/OU2TJ*9(L4DQ9Y<"+9,Z,S0W+.(75VQ^L?8DNI M!/=%7HKSV5;*ZG2Y%.F6%D2<\(J6ZI<-
KPLBU6U]NQ1534G6.!7Y$GE>N"P(M*V>KL^:[ZWIUQGTCS7D12.GUW06?],[7AX_1C]0Y.\2N:&"'K)\W]9)K?G MLW@&,KHANUQ^X7=_T2ZA0,=+>2Z:O^"NL_5F(-T)R8O.62$H6-G^)_==(0X<
MH#_A@#H']%P'W#G@)M$669/6%9%D=5;S.U!K:Q5-7S2U:;Q5-JS4P[B6M?J5 M*3^YNN1EI@:%9D!=*9ZSC$AU\Y[DI$PI6.O BS M_45>//]+7@%6 F^;OE. MD#
(39TNI,.A(R[1[WOOV>6CB>6M:G0#LS0'RD&]QOW2[7]%4N]?M5% 9GR_TA;M,&)B%.>]LC M0'X/R'<"NDA3OBO5]*II2MF>W.34AJ\-XA\^.QS!,TU":,<6]-@")[:/Y5[- M"UX_V! %YN-
&@$P+%,5V1&&/*'0BNJYI15@&Z'VE%ZR8JVY5<<&DNE)K$7"Y MI;5J&8<3V@8^-,N)?3S";QKY ?+L"41] I$S@:] XN8$"H9-U5I^;QC$]@SKWPP2B,3]8;"#T MIV;0P%C035EMRW!
P\9CL1<$XV9A,\3M 7'/@+^L]2+SDC-RQGDE&[A(!. M'OQ5#?%2T8Z3'H@1NIFQ9^V*/$Q1-C3YSS>"C@?C945O8S^#(BU688BFX \D"=TL.6[5!UCG?0(5K_4FR K>9$8_2<;8 M32,8'
S0,?:!J&;/]>T9+P&:ZIPMCN*/55 -0%XI**9[5+DSLQ\LPE;9KY MOMJ[3J0PD"QTL^RQ2'EJHIB\B;@,983;/ A]%$=T0#OR(WOSJG2DZ%>,Y\ M029C(AR/RVVS2L*):J.!5Y&;5]M]/U%E9!
(H3A(\KK+%+(@@GJKRP0[138^7 MO"A8P_9M*TEYJ6M.RU3A!6_TQ ;)6ROPW]CM657-"P0Z3GX@8(2=#+>6//VQ MY7E&:_'ZCQC!Z!UHQ9!]K^RD\U_>++]0M./ZB:UI)6MPH5GL\36GLE8T7S-
6& MJ0.A3: 4]KJUM!Z<=$-G[]QPFB\R$PKI-;BQ!H];- 5R:PJ]QGCYO#H'9IVA M-P]#;XZ3M@;Q/(C4QPL>:W!81*)N-U/5,RHU!\J_HLU98VX]T 9%3/6]A:; M*>V)1F#GI
Y6<9T3U?]4Q\+++%@)4E(QU4^M*$VQ@OSXD"\[!!8[('53O(Hk M68/(:3GI M^N)[H:!^+-,3,-T$P9NK-A=[_S-:\+;KB4O&@NMY2H)+2!^GW#E>+I;O0; MB/Z-T^I_4$L#!!0 (*RK;5E,COT4[@(/P) 8
>&PO=V]R:W-H M965T&ULK99=;]HP%(;_BI5-TR9UQ/D$.H@TJ*;MHA(JVG8Q M[<(D!V+5B3/;0+=?/]M)4R@IT*I<$#LY[^OGG,0?HRT7MS('4.BN8*4<.[E2
MU:7KRC2'@L@>KZ#43Y9<%$3IKEBYLA) ,BLJF.MC'+L%H:63C.R]F4A&?*T8 M+6*E;GA)J.*K& .ZGLU$[KGMBX9+:"4E)=(MP'+L?/8NIQXV
AOQ@\)6[K21267!^:WI?,O&#C9$P"!5QH+HRP:FP)AQTAQ_M&E.G'=,(=]OW[E]LJ\CJ9!9$PY>PGS50^=@8.RF!)UDS=\.U7:!**C%_*F;3_ M:%O'QGT'I6NI>-&(-4%!R_I*[II"[B\\ F!WPC\N**)*, M!-
\B8:*UFVG8VEBUSH:6YC7.E=!/J=:I9,K+3+\4R)!N2C\C DJ5@Z(I81_01_06N4CF^JXH(@)M M"%M#5VJU5V2]S!S9)+B'L3=R-[L9G(K: PU:T.!YH/4+0&2M\1\1N >=MABAT>QI[PH]
(0]I[CA6<4]%;5'&;64T3,HSZIL=%"P MJ+NR9P3N,)W5P)'[,5U9W#6U#@5M0!N\,["W=[9F&PO=V]R:W-H965T&ULM5M=<]NV$GW/K\"HG4XR$ULDP _)L3V32&*;F:,UQ$WT+D/ ML
A9G%"$2D!R7W0G_: MWI1P-3Y:2;.-*%0F"U**U=7HK7^1!)Y14"'^S,2#.OE.C"MW4GXV%^_3JY%G M1B1RL=3&!(>/O9B)/#>68!S_U$9'QSY-P]/OC]:3RGEPYHXK,9/Y7UFJUU>C MR8BD8L5WN?
XH'WX1M4.AL;>4N:K^DH<:ZXW(TW-2-802;K#A\\B]U(@X: M^*RG :T;+4=M!V-. U0V8W2#H:1#4#8*G]A#6#<*G]A#5#:(]JH=@59&><\VO M+TOY0$J#!FOF2S5=6L(<%:8S+K5)?
PW@W;Z>B:+%/)$I 2^*9EG*==P<:OA M Q)(*R)7Y/>M*+E)!$5>?BKX+LT \XJI.IR MK&%DQOYX68]B=A@%[1D%(Q]DH=>*+& T*=)^X6X_=;0?0T2.8:&/89E1I\%; ML3TGS'M-
J$<#9#SSIS=GF#O_KO?DNWMO!8,=>^^+I=R()B?(WV_O ME"YA4_@/-M4'8PPW9G;*"[7E2W$U@JU0B7(O1M<__>!'WALLSD,:6PQI+!G(M6&M&@N.,!"
[KUQ_%7A0[@47_T#"N&IJRLK">3J/+\?XT]%U,,//7;F$470Z>3 ML*NB _\-@1U/(M//H6.K.MWFR*>R*^;, W6I"XP/\,ALVQ(8XLAC24#&6O- M1'2%,^W
M^.AE[/3REN="$:A;%+S\)D'N9IW.F:3JEG>=H%!9YOK;Y%^3[06R[BJ#H M9-JSMB9'7R=.7W\6!2RNO/*6IT G,K./&VZ'N3SI#*&* FO>Y@4M$DXLE[L@ MZC$66RXC*#8]"5_+Y>G1Y:G3Y;
<;6>KLOQ5],;XIE+A;M+ M.SV?^7X83VQ_,5P84GMI8S@V99YG>XS@0AKXM,?EAISZ;G;ZNUZ+$E9SQ5%? MUC/]"N4,_J#4=%!KBT&M)4-9:\])0T]]-S]]7V@!=G4]+>A!+9MJL-%?3=7/!G#@H?
F@JEL=S@KJBJMV=RM,EU]1_[N<+88-,;8CX.P> M3UB"KJ,G]9<,T%\[D@W=]-U\<[8&VB',@BT- M.=E#7O46:HQG=B+J',9S(Q$WI(!>FO'LZ&TOIO3]L3S5A29+.%CN2L/IUM[M 430T+W?
I.ZA @@##3J;4A=T%C!;JBPP& TFG>6*P,(X[JN*#>OUW;3W5RC_M9KUF2D$X#/F3JY4H#3-8@Q3WXX0&B!GIT_/J?E0AA9#&4K\+O\&7C3I(>"T M(>#43<#GXL[4!\)=IE:'\Y4#3G[SARE7
MKQ M;>0 =Z+1'5-)& M:% G:;[^P M^?S@ 7PGAH+:UG3:UMDL&Z*T=M48*4+<4>"2. MBL.N!FPQ \Z*.U#HV])H])[D<]I]3O(-9&@QE*&$(KKF=-MHA[J1(]0M M1W E)H4
F61M*L4#%.V# @0V%E$JFLKZBMR)E2R%2:]5CT#A\O'P&C^!8U&5S=$7NS;9]D([(SZ<>C9X>CB M:-P]!\+,1?XD[#D(HHW*H&Z5<=/C>@^I&$@KS(]N!,4#!;W
M'=&S1B$PMT+HYHD=G)NW?VY '\ >=XX^<.^R\P@4J;V1(S C"6*;AR$X-F&1 M32DPI M*%)%!"\+],V1&4-(^L262Q@NCHNW 8'0 ".RX8"C:ER4-E6=N*G^(REP(DPF/ M?AMB=7L\?
NN$Y]\N,O>0GE$6AC*T8 BUCP/[!8=D@/[:TW3RJHQ;)#QK,1/ M;0PW-K.UECGH,GP>#GW&[05N/UB>(S!8X'%@/!)<,R+[(?9"68N]%C44P18
M(PE8X'QB/OU9V:#4Y703G06#%'D0"3XO3@&TD1<$;G32O,B MA7+XNC=I9PQY(0\AL-^8(,@XB&H<=HM4%3NDDFMK,+& T32*3X]SVZ%I M- IS:Y3GA*8_Q6:LJQ>"((C#R,Z$.8+L"0YB$JK4-+#?0$H01#LZ]VT7[ML MN'K@YNJP6,Y:C'3[2+E>] /E E)F^%29+4U8ZYL/O 2.^B!W>4JV4HM"9SS/ MOX(@).9Q*G Y0]HXV7(PN\RVAU!GU>/?
X"XEWU>\"K/LS_V+N(_<7_D6"W7_+IA<+R#'D/X%WL3C\"&/<#.GP M$XX/O+S/"D5RL8+AP>8(M:<_"KB<*'EMGJ+_TYJ+3?5U[7@,$4& /]?2DIL5 !,Z0 & 'AL+W=O
M8!*6.*$('1#RY=\/0%%]=O?F!IM:2O(06W+CVPU@H=%8+W9 MZDO; ;F]:9K>^7J[WFQ?7]ST_=U/EY?;Q4US6W]_.^:S? OG]KNMNZ'<$*_4J+W4:WZTO?=>/+VWJUN7CS:O>[J^[-
J_:^7Z\VS57G;.]O;^ONV[MF MW7YY?>%=//[BU]7U33_^XO+-J[OZNOG0]+_?777#3Y=/E.7JMMEL5^W&Z9I/ MKR_>>C]5GIN,6^R:_+%JOFP/_NZ,^_*Q;?_.QWC;S=OW?JV5__HBO7"6S:?Z M?
MW_VGZIFOT>12:OT:ZWN_\[7_9MW0MG<;_MV]O]QD,/;E>;AS_KK_LC<;!! MXAW9P-]OX&L^/Z1#8+]!H&V01 ?V2#<;Q#J$9(C&T3[#2(]PK$NQ?L-8GV# MX,@&R7Z#1-O .
[9!NM\@W9W=A].Q.Y=YW==O7G7M%Z<;6P^T\2\]O>RV'D[A M:C.*]T/?#?^Z&KKW\S;S7*08K-TAK]MV_5J6??#@Q_Z8]!H[W3?G+F- 7F MNMDZJ\WP^W;QYTV[7C;=]C^?
%HM5OWWSG>_;^K[Y6H@?._ MG-_Y,YW__C>^<>XY6\W[?VVWBRWKR[[H=]C],O%OH_O'OKH'^GCU2#GINMV MW1K"__SG^U_G0=*NA7^_&OG]NNG[U<=TXQUH3<>=\W'E[>]MNIC$Y
MCWF'([(<)W6:^>]7BUGP\&8UW>K?OB9@18\]->F'T:F82>+NMNL-M=;CB5X MUF_#J+>][IX[.D/SGZ_&6#) W]I-XMVTW?M>OB7:^?]IF^Z9MMSQ&JBB^UP MN-3-+@>E/\G=?Y*
[O^,$1SCOZG6]631.W3MYL_C1";P?'- U?4J4#Z1D1QKO M 9_?^'$6O;K\?*@@LU&LML@)C!=[_J@PF\U_78Z3&TGB':AFZJ-2B*F&WM: MR,ILY;E9$#ZU4HYP\'2$@U..\ _.]J8>3OD1]_J&!YVQ'>C)-
+V?6ZVBP/7 M3=Q .^1L#^?IP$_;NWK1O+X8[O?;IOO<7+SY]W_S8O<_J>L0"1-(6(F$52"8 MHIGP23/AJ5?E?]UO!JVX.ZT$E%9"4]IIZ&E",1LEFD1"0TJ^'X>^IJ3";#;S
M8S=)M7:"W3_ZZ#G4*37C!6Z<^MJ%2_0J#5SZNHV>SD%D>]U.GHN(N&ZC,,RT M@STWVR5^$*6Q?E+8'MI>MTB80,)*)*P"P13-Q$^:B6%WT_B4NZG92+?;QN9U M2]U-S6;TW91H9]Y-
B9C$W=1LQ=Q-DZU4B80() M*Y&P"@13-),^:29E-9.O/J^&9[KE=GB&7ZSK\4EH=M*C$B6FU+QL??UNRW;G M))M?#N(4*77Q:YT6H& EB%,]GZ.()7L22_8R8GD<'E2%B!A
DDK$3"*A!,T9WG2N/)997W?KN];YS%@]>PW7DL,^?J[1_V]_M^]D1]6*U7O7?2+>(!9]^S M0"/<4,0'L+QBYGN:LIM1-(QMVI0)&K6 T@245D)I%8]FRDV:@Q[O#OXQFI0S M9_0JN]5B],$?-
%=_J;LCQC4+M!F*0P [H[S" MV(Ş,Z?;-/<)*C?4;5@Z-64!1 DHKH;0*15-%)MU4C[=3'V;MX^OE[6XROUFU MW?#'XKY{>,WW-*7_I>T;4FL@.W/N9&ZMKC'3S$Q#-].G3J >"12H1($]\@!X
MWI&ID[1S/=[/M1(!._@[_WMT,/=XDG!_)I'E)-^J[>;.M=VA,]6)UAO-(: 8%RC[#C,_V!L4"% M$RA02?1[9G:\ L1392)=;H^WN4=O8/Y\:9\;C;+83 9\:OQ==1UU^R2ETB% M@
S;.0J4>Z9?';NN+A!0-($"E42WO= 8(M<>;UB><>G9&@W11 MYY[I=GON^\^H8%:U%":@-)***U"T=1\,6E3^[Q-O7O9,1O38Y?C'.:N&>X_ MNZS;G1%Y. SV_6;Q(YD_AK*I4:#<-
UW:P#=L:E0X@0*5*% U=0!4C4B;VN=M MZE^:WOEGNR4&WY3&Q6 0#D*5/BF&SZ+7"\P4A9! 4LJH.VD4 M'3G1!]FCO$%\==\M;H:A8+CXB]N[=?NM:?;IP4_ _OBFBQM&::.9; M;-
"@!90FH+022JM0-%5NTL;U>1OW0&['?13K80AE[:) .0I4H$ "!2I]T]J- M(D^_6?&-5/%(^]?G[5]FVOHDIM61,>H,!Y&6" B4^Z9IG";&M!443:!)='N MR/4S_?
P3K3+WV%1%&K$^;\0>/",?'SW&E3ZK?GP-N5_*)5,J-LW.@ONTV@R4 M<17/,*YTUT<4@W)F4: OU>O?;J_K;,7..CV\C))1]BP(5*)! @4K?='@3 M+]"%Q#=2A22]6_]D[_9 2'=/&:8/6OINGX?
ZJGM2*R@C%P7*4: "!1(H4.D3 M9F\0^\:*PJEFJEZDX>OSAN_3"M7ML3QU'F"C!A H]TU>!:$QO,U*)P29RAD1 M2E2T"@!25Y=*/$;@_5A5"MRS-@^R?=8.B Q7?WC8UI>>(H,64)J TDHHK4+1
M5%5)!S?@'=R#E6P?FCM^U>,>I20U9;H'.2=:I;I63)O2# P@U)]LB'8S/TDC M_5%"\#MI,=Q3/4O^0']TI3KF1:E_Q&D+I,\:G+1, W#9V_1I(>Q,/EB5U^N M1#1,LM3U]-
W+^4Y:7\M(FH#22BBM0M%4\1P4(.!M6IM5J7O4Q+)4HI6>KA:8 M5BRY,)5H1Z],I1J:2U.IL,3:5*(95^!!6I3!20OW[8H]F'[7D6H/9L,CY1[. M\.N8ZQ1)$U!:":55*)HJ'FE1!B=5'-
!%0P_N$7'/S0)=,68K8WYFNFU^D)CY M-D2[F9^%8:!?2N!WTN:>2_0L2XT'L=N^=*PS X:3'_L6N9/BU$ F#@ M1K[>ZSG1,(V&*8P;Z>?G#)N,N9:1- &EE5!:A:*IX1'.8'!2G8*3JH;L41,E
M7(A6>KF0P/2FR"(N1#NZB@N_DS;7LAF1JN-"=>QH(9= NFL![ZZ=4\HE()P; MLI8+T9 NYL)WTOI*1M($E%9":16*IHI'6FW!"Q4$(%65F1>Q,;E&&6XH4!$0 MSIW>;8&*5])
%0"D5N^2GES(>W(O4D0B- TW/_)<[4W7G.^:Y<670VD%E":@ MM!)*JU T58#2O@MY^^[9*QYYOL7K@]"T_71;*31=LR!+]1<#]J!X)%*A$@2KZ M &3TM">4IF'(FX:P%8]\'-L7!R%A-
I!IF=:YM"H!90FH+022JM0-%5UTT, M>;?Q!1<\\I%M!B40*$>]"A1(H$!E2%BDQH+'B4:JA ZG(NZG,6//)H&XV@ M\C#E#PK;5DQX+5#2! I5$MV=&ORM .%4DTBT-ST[HG%B'Q(-M)(+*YPQ-#S-
+ MC D0*I\3!2I1H&IB_U6%2 ,WY U<;A42OZF-!E 9FBA0$1(U7+TD3O2"CZB M)14P=!,]KY=JYGM)=,3>"Z77&O)>ZS,6(?%D&QF@\BM#(K]0SW] !1,H4(D" M5?SNJP*1_F_(^[^ =4I\!.M'(-,S]EW?
<(RA00LH34!I)916H6BJW*1C'/*. M\3.6FO!DF_$(92*'IO?K!_K+850T@0*51+<]-S >7XA6_K'GETC:OQ%O_QZ, M-[?U_[7=\-PR:[^,'Z?!K5OCNV"A%!0H1X$*%$B@0&5$6._Z"Y!JHI&J)>GD
M1KA$S.BD1$RBE6J12D$+[Z3UMDULR(B)S(,(E\O MGT>TFP6^&^LS=\'OI8&[/TZR+K?,WITT*MM"5O&%&(S=F MJ/L&I0DHK832*A1-E9MT;I:3*Q+@ ME@3S,6U&*I2EBP(5*)
%8]TWZ* ,%\S,O,U?;V=_"HP'6X]FE,4;N:GNQ4&C%E":@-)* M**U"T5292>,V!GX'BE0;*GTT)M;PZQHC_%[7TS\&ANJ1. ?$R :5'DH>!?](M2=A86L:QS:>9GK$^AH]C/?X0KK2;AH'Q-4)HV
)*$U!:":55*)HJ.VDVQ[S9 M_((+9/C(-D,3*IT5!2IO('$.B%$F4=@@U1,[JJE6J!*D3QY/5 U]QCH9'FTC M%52UT-@TYL/0T]LHL*)5X#>]UJ1MGC\[$]$D3)!):2B0'E, M)*0:[\Q0T<0Y($8E9M]#<[
P&\'7QHI$>ML)[VT_\Q-A/-ÛVBI,0J9+N\(2E MOR*%1BV@- &EE5!:A:*I6I,V=L+;V./!%L,-"I0G1,*[[^MK\U#AQ#D@ M1E4H'WOJ**A"D49VPA09OXV3E$]--TYA5IN^6:^;17]?KYV[KKT;)KO#-*9U
M_GF_6"V=?%5?;IMOUIL1_60XD%)40H%RA/3& \B_5Z%BB;. 3:'07U[:N(@ MJ-*1IG3"F])YLQAFMNUZM7P86I1),*D.E">- N4H4($"B7- C((MAU!-MU,U(AWEA'>4N07 _*8VS/-<8X$, MT
MF#'!M'+U9V2VB2H1:?4FO-7[C"7B/-E&(ZA* 8EI$,>^/JE ?:8)!2I1H(K? M?54@TI1-(#4V=DI+$X3PC+, P"_041-&@!0IDHK832*A1-E9MT;I:3*Q+@ ME@3S,6U&*I2EBP(5*)
X!\1HTG1]@TA/DY]HI"I(^KG)R7[N*5\,FWGD-\X M(#:20=F[*%"! HES0(QD3'!"A1(G ,ZKJ#4-,]G?NAG^CQZNIVJ(FGOIM-9RKNAI[_I MVOOK&Z>QDM6[0UF].R8KE!&, N4H4($"B7-
C*R((K1>DNDCTV0S5532"DZG M &$&9OJ\?>L;GGB>;J8*2!G'*&\0?I'"6 MX_O-I;-\6MXS3+)U,=5]WZT^WO?UF% 3M\ZFW2S:3=^UZ_7XL>?Q[<28F4H^ M^?
$]L=$6REI&@0H42)P#8K1%6,9)F,6ZMJ:;J=]2QG+*&\O/]/#%DVVT@O*= M4\(N-EY2H:*)\8+!JI5>*R^>BI]Y_3D$A"'-8#(4@,I40+"U]V< M.='*TTL,I%0)B-1,@2':S?PH#CPMJ.#WTL+AHR*&D9?
J9X-HE@7ID551J?1X M4^L*$-.GA:H D49>J*_QI1JZ<>P&^K0[YWMIZ\A!:0)**ZT"D53U2,-X/2L M#W>1JC&+.Q#U7(A61CV7E*8T0-5S(=K1]5SXO;2YF,V(5#T7JF-,/9=4.J3I
ML[[919\7J@8$5<^%:$C7<^$[:7TQ0VM 0&DEE%:A:*IXI#F:_H4U(%*S!H2N MDSG?'YO)&,K^3(D2$'JWQ3G1& FA*D 0(IP,FF09G]#!8B,*@SJ)7IA&KYK MEBJD9 M[Z7:5X#@@3:C$?
4RK.7*S+-13/Z%1"RA-0&DEE%:A:*KJ MI-&< 6WE'_C(-N,2JOP#"E2@0.(<$*-,T_[V?'VE33752E62M,BSERO_P*-M MI(+*%= SWBE-U,/#?2)T'8 MN 46)["X$HNK8#A-=-
Z!Z%ZJ4,0$V6)X@!R1Y*R,DW/22M@\<19)$Y=*,][MZD!H>O$/],+;WJ?DW9$O1R; 5G)!Y?\^DM2^5X9:4,F]9Y$XM1!?M?,RO9@1 MV"0I]_,PR/0/RIP5D3OKU%?LXE1/*":[YR;>D9IYGAZ?G/.3%/-
C"1OJA&9Y4TUI-.\)W;5PO$@8Q*)WF2[XYG>GIL3LG6M MWNKS=-O6RZL<'P[Y_: MMG_\X7+@?VF[/W&PO=V]R:W-H965T&ULK5M=<^*X$OTK*G9K*U,U#);D#\@D
MJ4HPLW>J=E.IR<[=9V.+H!UCL;8AR?WUMV4;#+8L,*.7 $[KR#[=:O61Y)M7 MD?[(EHSEZ&T5)]GM8)GGZ^O1* N7;!5DG\2:)?"2A4A700X_TY=1MDY9$!6- M5O&(6)8[6@4\&=S=%-
>>TKL;L6%T=[,.7M@SR[^OGU+X-=JC1'S%DHR+!*5L<3NXQ]/N7M8#Q $5L$FSC>]E[_PZH'*.*L^(M>*UMK@,)-EHM5 MU1CN8,63\C-XJX@X: XZ@:D:D"=>R.!K1J0,_MP:X:V.?VX%0-BD M$.
<'>7!WDXI7E$IK0)-?"O:+UL 73V2@/.B!;PF:T_(6I]1,0BMN)^IN9Q?W?D0&W<<(+?#V:]7]"MGF^V=:WD8WXRVAUYI M6PT)]ASKV,QOFQ&/C)UCJYD"S,5CIS8[HLC94^1HH_<^^@?2:)G+
<@&3&[2 M\A@(ZN8.N)&VTB*4P;^1"1)2W+F1[P$,?)-@ODFPF2&P{>[Z>[>ZVLCW&8"& M/"C+C21*P4JD.?]?>8&]K>6LIO*-%K:O;TR"^268?1#_*J>A HA
MXNVY]+&N]\VR*&'.QBV2A]BR++#7+DSW+D[-8CF3"K2I+.32!\&PSSWC$09BH6)ZT M[\8C9.PU8DS;>P\2S^MN]O/=';&(K;I M[0\3I=!\L+D[+,(>[]V0;QA,%.Q M?S<\?TU=W,0'?'C!Y('JQE]/[I M?
OC-?[M&7[,,N(2,MY+90";!X^@$F]%H M551NXZ>.]D6-MCWUG%*)I "9HR M351 AW[U,%5G"4QJ;Q"]-P[G;:#_R!T5Y0BJ,K1E200?\@YYR%#PDC+6Z0]M MG[W]81+-K] .:;3M<7-
TM(UCH:Y,2VFCFE;673"6E4 @HK8H];E+2M',\C'9S4"@K)=0? M4/K+>8H7R> D&4HNM#WTCC:3:/XE:.K1;RO*4JQ1BN%:G6&M2H Z?IY#N2Y% MU89GRV*T2S5VH2<>]DW:%FU&I<+*
<^UF5+:MB$.;HE5A12W:%96UNL%Z>=,Q M4B.6\FT@UU91S(,YC[FZ4M6C]XY(HS+G$C1U1"JTT*0K(&LMA/5BZ%$DPT+T MQPP$D4Y)ZH%ZDVP2S<=MX=3*IVT3:MD=]-7:"H_UBX5%X&:-
U9(L8WE6R/1= MV'*672M)O4#4:$@UB>8;19N90CMV5"W/L%Z?W8>AV,A%L92%#)(*I%6E/RX0 M/AI_F$3S<5N[-5<99@J;(1ZKHYS4HHSH1=E3RM8!CW;9(?L(F7DM,EX%.4Q8
MJ9S(Y'>1+UE:C0 5P?J>^)A\%,TG;27G>,T5*871$'M.QYH4J6#.2'3=@$* M(K.O40ON&-9B]0BBNA%U.-N5Z#<$NN[-Z!'[\VKT7TQ MHA!UE+HM=:JRLRWL=I2]!*90C9Z.ZUU5BN:YU!JE$%9A3--
XHV,X5V[*!:KA&] M7'O:I.%2UL5B42Q!KM68/0XO3UB=!.,M#?;T,'-&%<933H"O-9UY-2V59@6 MN@(R1I%$(M!UN>B_2J[OIS>_1A4>:0NS(7;M=N7P\TKPV VUR"-ZD?>4BI"Q
MJ,HRVHT@Z9T -B$4>SX/7A(!Z2C,T-01ES?P= M757US8?SYV*CBM$HFD]4:M#%X]8H:-M-[(ZE)5JK1FKUJFX6/ F2\(R#5$8E MHE$TWRC:S!3:L8-JR4GUDAG.?@N3)*
(P_5YL"D(:@NP5+Y3)TN3$U/#$]ZSOJ M[3*CPI2V)2>9>)-FD:\PP[1S$XK6TI3JI6DWR1I5[)/U>[JSA$G^-_;!6'(XD+M0J4*^0S:5!NUZO1E]B"HV9.@ M"B7K-,\SS2[I4U<4T5H04_WN9/=@.=HG'Z+
[?/C7D@W_#-(?,)E_"<+.O2%] MC[W=850K4\4F(W%;F4FU%>FZ'<.AUK;TA+9ME)^5YW!V MA!?K;#U\850E&T7S+T%3IR_%1NJX8Z.)UDJ:ZI5TQ\@X-PA%NQ:,MOZC=;]!9=RS?
0JJE9//^R63Y5OKAA5RT;1?%NU M5SH>>TTZE7:4THX:QZX5KJU7N'(\)XB.:LQ>>)#(PI;1E*1>JE^X>]%B]F30J M8FV%.IVXM+G$K#"C$_NJ#[L6L3:>A%;\LCUDJJ6P1+E\)TFSVT<49@JC(AK
M6XVJUS\:W82JWS>T<$;HRN6OA2OZF:HV'"_+5X,W%_=OPY\7[P$V[C^@*^G M6"=Q]>S\F7?&KY]QBJ8@B^#,5L 5U9GSRH#M/R==[R1R[6Q?NJV C/8\" #) M!P & 'AL+W=OW#M
]N.:K#*I'784EG@%@U).Z7>=N"A=CB:.0LPWB.EJQZ86IOD&K>A&JW\E< MRDT1G7.MX+.CZZ8E1F DUI"FD'/CZ,/S^ MU7.;>+>-O&Q=Y!P#N4I M\IW/R'.\H.,\D]?
#_:YT D]]^F;UO6+X[2OP#5 _3:_@]PU>Y/"GZ])K6K^; M5O>XH2AQ B-+-3$!? U6]&#VW>^=%7\K? SZ-.W$%_X.Z'Q<_#_#._ M[^Q'33O(>[H[K/VK6V=H[O:D OC)#0:"$5536#
(3UMG/GPK3;)_ZQ.YRX'?Y8 MS:EZK#S2UT/N"O,5H0+EL%12SNE M4Y>#X[:D*PTG7'!I.JS9IFI60MT"%X@+-YDDUOH0;&>SO#VVDX:"VJS4F\2'^7]_Y$GRT:J1UT"&/3,F= Q
M+HVI%D&@TQ(XT;>R F%WS!?*VVRLZ"WB6C'(2F4B % M>8Q7H\5Z[N)]P#*<*C3X9(Y?)0*+M+K#!1Z4"2CHD KI8@HP);=Z&5@[DN+D@[MW7K M%EUP&Z-
[*4RIT0>10?:O/K!D/5YTQ%M'@X9[J&[1.'R#HC":#/B-'W3'WF]V M1;KHQV<;C38&N/YY+O?6>GS>VMV>A:Y("C&VUT.#>@*%LVO+MPPW[#O1;[@I$MP4(7OA1JELA:F;1C]
M:M]N5VV7^1O>]NI[H@HJ-&*06VEX.[>?4[7]KYT86?F>A54G"YXI,3E[DR;GM"]5; MR6*)*K!IJUIBW%P;98Q=2NYA49/4H$59+<$BZZ74=*%62JNP9C*=5)Y$+E5!D!UGC3V)67=9H*]]O:/3KIBO
7:,R\K7ZMV8-*6&2>PI64LKKM<%>)*RC?N%'%"^C3T]N(^+&_=(!J7A$J=F0PDY*]5P:[!['%*?A M%@2GY/K^#39+95$YBSN@WI&"GUHDM1.N,VPE7MS>C04D MZ\8P*HRPP1-
%MQ7VIH*O/%HY-N9!0(GVW7&"6TJ'GM6,0\EAGN?W[^1QHHQ M:YY5$QUE:$[N[VH[BSC?W0D;"Q';61:VC9!X[.7=0@+Y7EBW2"!% !Q'R5+E
M-.YE![HIV06ZSNRT*^LX2S'W%NOAJ,!M"XBEQ^!CRB&6W=,AMG6<-$54Q(G MB*G*CK,O-[>^UH**GCBAD%$KF0[[TQ".Q_\DX\-?:P@2$3%6T1Y\0N'(:%2(
MB4=F=SL3BN#I@5\P">/A!$"?]P,4:$]JVXEY#6M^(A^=P)<5YRG*5L4BX,6=: M(58:UMBVI*BS.([[\'#DB7B6V+L@4_.[7"9B(SH3^ MHCBL#M?L_YVN=W>W]'? X5";II*F,XFO[T8"=??>_N78-
MXUUS8@)MK?,1A M79#C#?A>6EPPT@L'&/[S&PO=V]R:W-H965TM^9!J:[& ML\GD=%Q+I0>+\[!V8Q?G

M]#R>YGB,3K,"VYV:L&&7@1#YWHQ"YD1]_5Z(HCY72ZBTR.4?Z*K/;T!U2*]E MM=3.2(NJ:LY[=*I&?G^J,_#G^'0$YA,6IY. MOT^L5-8VMGDF>MN#:(=5ED; M3O9V$^\%I\^QYOFVCZ?CWI?
L3"'"3T_?Z"O'&&PO=V]R:W-H M965T% 6;HYF4BU=G9_5XQN=I;94+7N#)I*SFJ<3/:GI6+RJ>9FK2/#]S M;3L\FZ>B.+IXK>
[=5!>ORZ7,1<%O*E8OY_.T6EWQO'QX<^0M%.N5W7'Y8W%3X=;:6DHDY+VI1%JSBDS='E\ZK*Y_&JP$?!7^H.]>,+!F5 MY2?Z\7/VYL@FA7C.QY(DI/COGK_E>4Z"H,;G1N;1>DF:V+UNI?^H;
(U+.?-9/R> MBT+_GWYI_~9$-L]$]QF@JOTU@LI+7](97KQNBH?6$6C(BTEJ-I03!07E M3E9X*C!/7MS)QM.4>[SRZJ<?1,0CJ-.1LWDJZT)+='4L+>E86< MU>RZR'BV/?
\,6JU5;3+7=OT#\KRUJ9Z2% _;(N^525!P) M)=D5+_A$R)K][7)4RPJI\?=]!FMYWGYYM%U>U8MTS-\<83_4O+KG1Q???^.$ M]OD!;?
VUMOXAZ<*S$%)^_7\M93<<%SV_3>QZ[CGK&\Y=G/Y<S1GNP9G85.SZ\U+(%;O)TX*]GW%#3V+#)QW+&5>ZN/9Y,UG- MZXQ13YWS$R9J;+M:3
L,DB7C13K*>:,GW2@G$UXQ/E_DY8KSVC1P0XQY59LM M0P*,94F7:9&Q<5G4V+UI(>D&B9W =QD]9.5B459R6=#R$)J.H4G%63U+X4.L
M@$E)R#D&&+"5&PSV.&7N!F40VBQ+3B9M6"_+TT> /@NLI+/>1^P"BA8"S;5:*HN'B$^"$.E(@CW;G--T8=])'4OI,JG+.LE3RTW)R MJG2S#*2.PG&Q3JE[E5* 7MK52ZDW
RV<"8);#E0'N,D'#N7H]N=E28,6*GF1 M[=NX .!L]V_!> K[:4/LAH,,V,U2[4K>!I=OKZ)"D:^04&T9>H2?0"P]6Q(5 M4-[?TE906#D<0IY-BSU+P4&>=E#9F[ZJU*HX"RU"JB1,1R7% [BBT+VF0@C%
M0]NT Y_]5A@_\E&% *Z8ZVHGF&HVU>2T6*V3)]"[S['B@'0]9N.';44M.-YN M"H'&F4N-W,WCQW6B!?;GI?-34I[*4Z,/3_=KSRZJ*V5.4.##HCVV;D#IPJ'Y&"@R
M9S^FHM(0:7PH[C56])F2]BJ^FX*1;0:N@HG8BJ(U+K:1H+"T,'3LH,39L0W0 MFL]>-O^XH7N[,M3T'N97\T5:410I 5-<2T,!V*%8B4S.-UO?F(0)NLOY1)A6P$L]@6L4G M=":QJ0P-MJO=&IV3!])EIA
""F307%\UJBCOXC]J9%6"E M G/*=U6A%-5X4 M2UZ#:5\$9%@'0R)N@I2[,YN"2@IB);J0_F6ED":0L PQ6$,-2>QHIW'-R% M&CI"*-5"[T+'-J'=??X481>0DR_GIKVUYO^&NP<@1+
[IQ9ZBY"A"L17@,@J# M+=KNF2&&V8JY.Y;K=IC[L6=ZGJ?)N>4Y7=[N.Q'$-\3="KVAO-WI\O;8#&.(M\1,M)(&&I*R3."^@[&O)'HJK#\FN;D4"M"Q.(W4(7Q^8=?W4W=BF[NP/H^[& M(^K_H/4?
2^H=LK2/A;OO)#%&]LL?D^$7DSHC3^-T "/R=QVN>[X9F M)]PGPK"+O@Z1!$Q>V#9[/\#M+%2:M0@+8#5<-X!X:GLR9,CYC:FB6?[,ERXC\C<-(!AS5]F\3H##79 M@X P8E@-
'WU4LP[L(3IQWFY-3*4>K0Q.)TJ,$8"B,;D7"Z4TQ=C/8IZ(E]$2 M2*=U>V6\GU5@>MVW-H]ZRU]%<>CY7J%O2RI_$QA]ST%!J45VVS^.0W_CT+A+ MN_Y9IYC^FY(M?Y,$6R5R(A::4>C060BJ)Y*-
)F=0*R\7BL)N9L8.MKW#8CN@54&*WJNM]&1& MPR0S\8ANN*;K$]T*L'!(?;CI1$XW+,;>372[M25VT^VR-J@]:7J.YVVW3<'2 M-4K4VR7J&?O5V*OP]B.@P$ PR+I$RM />_G[[@?T"SD
>N@2O4(W8^9[6 M9$CYI&.%]M#@$1@697':/C,ZIP;/JN'Z;,"9R+Q+* [X2 ^!8>,P#+.O#\-& M+PSW-)-/%ADA#[#$UOF#Q'VAMW+CQ<(E#K0P"54DI"[Y5_7RB*FD,6P<7X@-
"=]GJLNAH]:1P\L9#VVRD M3;-1K0]U*CH\]T'U&7U;00VG1HW]0D,@211U\LA)<[<"UZB'Z ^= W?2Q2W M1K2PM=-J;8ZT[AJ;;[3-S8%67Y()>I5/ ?/0R*!-Z7UEA6 B>*5$+!=((W'4^
M=7BJWAVN&\)!I4%G4/TE=O.OABP3LQ5\DVH-]6',L3"]'>7A1WZ8#,I]?/ M;K 5OTV?6^>0[;]Z8>: G.5IW!"/9Z5!"@T1_O@79GQ',02/7I[KCFT?AB4 M#RI"ZO8BY5$!KQ8]%H0ZZZA-
H'E./NIFA1^H#F?'LRARXY^2ZQV7<,S?%WQJVH M/[$)E3KB8[0SF'K1XUL>AGA6A#%K:9FX%QD(&5L)GF_>I'W7N?J:23"@BFSG M@[&#_-!YM>[-D67/4_F@^4S>&3^1!1L*/@*^1#]T.VZX97-
PZ[6:+HT:N@ MK1>3S4Z_OKNY6;^![R[Y/FFAZ[6BTT75*A$IXINU;5>%VS2*A @7F+&(9K:,#1#C+B>3+CZ(-7H4.JXI=2/:/3^%UAP^GQ150:FDE\A72!LFK M8D5?"=!
[430["SVC.:_LV&.QR_&XK.B4,U^9]&ZJ_WUC]^L#=2(]HH/B1>.R M/=!("S"D' +[3K&)YD3-M_K>-P*A]YS?=$(',>,P?)<+);$Q,[=A$& $-\ MZ#I@^[[*/.M\.COGU51]($P>7Q92?T6[OKQ^!OE2?
WJ[&:X_8(:Q4XL&LS_D$ M4[%?@R/]:K3](&ULM5=M;]LV$/[N7W%PAV(#!%LOCNTDM@$GZ; ":Q$T6_=AV =*.EM$ M*%(A*3O>K]^1DA6GG95NE[4R!:>"R%-/-^86UU,1R: MK,"2F8&J4-
+*2NF261KJ]=!4&EGNA4HQC,-P/"P9E_W%S,_=ZL5,U59PB;<: M3%V63.^N4*CMO!_UQ-?+^JP;F*XF%5LC7=H?ZJN-8V&'4K.2Y/2&*PD:5 /^ M,KJX&KG]?L-7CEMST
=G2:K4O1M\S.?]T!%"@9QV"(R:#5ZC$ Z(:#RTF/U. MI1,\[._1? :VDRTI,WBMQ!\\M\6\/^U#CBM6" M%;7 !UIXSAY MB#9GM;&J;(6)0;/Y8=$IF,4[QE=Q:\"WF$U@"0,(
[CT2MX26=AXO'&+^!]>*BYW<&? MR]1838?@KV,V-A#)<0B7&!>F8AG.^W3R#>H-]A?OWT7C\/(5@]..X.@U]%-" M\"K <7J?E<5>E,#[=],XBB_A&RVP-#VU G*VQ3)%W7DWR:XEY[PXU1P-
7<*WD!K7EJC\&H>7)VU^F0=B2Y "J!@!AA43,.& MB1H=D1)<W('1A! E]O:L.;3U)<=YYFE'$.M(-IJ+?G?C4;6K5*%VOD,%)RE7+B;54ER M[-Y>+MV=Z+$!+"D)M81X5+9[W$)K9]F9*@N0?
O#'INYQZZB;JO:::FCR,Z@&./C^'!6[!$O?8O M7D,&UM(VS\)NMGM4+YNWY-/VYD7^B>DUEP8$KD@T'$S.^J";5VXSL*KR+\M4 M67JG^FY!?PQ0NPVTOE+T"&D'3D'W5V/Q#U!+ P04 "
"LJVU9:/D@]DD' M "#$0 &0 'AL+W=O!EL:VKI*HDE0<__M[AI0+)4N MI<57O1J96I/,W*&R&,51=#HJ95X-KB[Z T5!0L"C"^MS,%.)1_L/W?2 M?W*VPY:%-/1&%7_DF5U?#N8#D=%2-
H7]I#8_4VO/E.6EJC#NO]CXO1-L3AMC M5=D>!H(RK_R@?&S]T#LPCYXY$+<'8H?;*W(H;Z655Q=:;;83FW9&#\Y4=QK@ M\H]#J+*$<^ZM2C\+665B;^&NT>D:-HL_I-:RLN9B9*&4CX[2
M5L&-5Q _H^!,O%>571OQMLLHVS_M@=XKA#?!. */">ZJ%(HE#$43QY05ZR M\T#BY)T^(^_MER:W6 '/ZX6Q&B3YUR$;O8CDL A.G->FEBE=#1 9AO0##:Y^ M_&%\&IV_'"R SAY2?
K_(T00*C@, _X.R%(PGXLPY:$PJZ)M2]RVHHLA^?S16,I$U+46CUNA;'2$I+?"A0>KJ:TEP6 MH@31\VHEU%*8M=2T5D5&VD">M&(CC5A3D0G@>B^!2"1CQY-$'+%"MB6.SN^]
MK."]E^56Q^?'H6 1ZQS'^NB,:I#80M8]@ $T"Q138 M<_BLZF]W[IJ=PW[2 M-E_F*0/$5!;%E@4LP,Q,Y!7< MHZKGS@8.1XA":==8%APDD*]:X4 E:JD%PM0XKYL&P?2PA^)C%7A2S'SMV">A
MII30'YB!E0(D\M[B+;^ GXSYUT86/J2(H1&W!%W6<0"]?L/&#))D\DN;$M#U MF6QPU)+.O^NXYOC-,ME1H>,X:ZIUCJ3_5@+OHY3 6M@)HO7N<6*>-=(1IT -V]ZYSZ MJ2E(3*?3Z&AQ?!0?
#YTCNZ!P0G/:Y6@=8CR'7V2!O$.(V1>A (H&(J!IH!R ML8#X9!=L[VCK[#/+!BN0PRLJ01 <\2>/>'!XM%CXTD3U!?,1R;OX-RHD1 :F04GS@R 7@XP*;_*7 <=6]YKCU/M\
(9MH>]WC(^I51RE^,Q'R56,#^K!QV[>#YWWPHH['4> AP&M@1ZM MQQJVY/R[K%SG:YO1]'O<;'V^RZ^@M5:X"BAUAF)V^\3"G;X=H,6V;^D!?P?[M/0,NO0=YX?
P_X9&V@6^0\SL,KLMIF1%,0GDFK9N:-?F4=J'>E@M,KQTIKG]_ MWW+"B>\M_]FNHRT1-RJN<<6VL\B5#ZA "?)C('8V,_O-H<07*NL[\?))$R2 MV-?=DQN,(6XZ8<;X%'I7_==B0S&=3<()Y)^AW-
S2POZUT_N3 XAU&L_")(# MMGEVU1O[N\;@QYS-$UF>]O MQ-EL)L) +KE$U'+;=:-$_,W%&!V4R\+P?S>B[<&XY(7SZ(P_!:)8@I6WW=CF M"O]2_-*D"*&WN5Q5'GQ-S?Z(^
;=]R>VC[V9<#P]I+H_%X+2W0B8Y=P/0*K] MR@'1'C<#:9B62.NAMQH?BF%68'+=@?9%1KI[IXT#5HFUL_LU8=O]\^ M(DE<\6>K;EN@NT0P?%_D$2= YC/T=EH6URM-;MK]JGO@!
(^&!E?,;NSJ8PY% MW6C32#^%WK<7W4XEYOO+=?B6@XC?$OF8"10I7M$]P%;> />+Q5N M5.T75K#[W>7J/U!+ P04 " "LJVU9\"%_A0L(#&%0 &0 'AL+W=O MO0&F\LTX5+8FD+I]5/C(5
M;V42UW@G^["U#Q#9DE A 0T 6O;\^NT&2)J2:.,5YD7B@/_3Y=8,7&Z6_FQ6 M9<]%+LUE;V7M^FPP,.D*"F[Z:@T2WRR4+KC%6[TU<7[MF#OKI0ISTW5F-V_* .+:(^9=&-2Q9R9-
4_ALH_JUU^BR?#\@,:C:1N/(?2?BI*M9*@K1,+?!&&I6+C%M\ M;97E.<,$3[^O5)ZI!-DZ3Z3F#OTIA7Y@P%56(OW$Y\D]@5\#6H(7*#&Z3B=0! MX3X+5$QMS!E[1-+*RAP"W.TM@_#58VO7?
[*/;K\ $\Y",0?=9%V =GG_1(U6 M)^P.TFI9Y)8E[(C%I^$L2H(OR**Y,FBXM5K,2\OG.:"EC(".HR@<3L?L0W!? M8#"<(J:<&Y$)I,,:'U-1&NXHR[#C43B*1BCQN4Q%QNX$7TIEK$@-6VN5 J C
M%EH5Z"M3L8YESVBQ\"PZY.(CAT!C.3&; V1W2?YT^([A[J)X$" M?*G!OQL-HP[D>!C-JB1D#SFO<=7:]2UX!IT* VS4(?JQ6.) M3\(D.<78=E;U?O5C66J]C5'5#XX$M]B+,!R72D=!
<_4$1%@;2H7KAXS4.'53W MQ%BW: J7+Q6[F6T6; B LO<]C!D<8$R4)W+;MX0J9(^VSMUCTE"CSY92U/[B M3+[%8[0:30^$=)>EY&4FK(L7MGWI(]5>=;G.2V7-?W00[:658WMMV,N#9!IY="VD
#V]#/. K' MI]-PBM%'?R7#.!R-1NRK;'6)J)'S[8>T?^63+CJGT.9 ?IF_5%D)7.<"P="A M3:3(3NQ5..TU*?RDK(=7SVAM *Z79=2(%?K.;@"PW*^_$;T10HJ5B@,Y,RNN MH]H?_""DD.)[M!"?H,L?
E4:O _!@LT1Z8">WZJ49]]4AM 5JDU0BA2V_@,F(O<>5"]4J F*M]/N2M%SD)3A"1@AO6I_JN::$V8YXV%F&:B/1*RNQ)E5/,78^,X=(TI>@\\L3 M1QW0UY8=Q>
-^A!,Z&DL[;E8B756N<8%*;RPI)/QJT59'T[B?U-*U'WF:>IW) MMTVI!3\J-?-&K6'[Q$9!Z8&%!JSPXSK0N-Y1#?T.\^N*]9#79F^S;"O"[Q%QQI2ZG>.G9)-/2^&%2(U M?
%0H2L))/&8XNPV'+.HG./+$>)'TZ>E[A^AF#T2K2&-K$ZPFGF6.[M!G;DQC MX_YD^D/!$0YA,]2N'U/NM@2C&:8C4AVODI"\&*$%#O"%3;K6#N&P<,NY"\,
MY]5),F+# _C2.9WC7GQQD63=HM/13*2] MLBAS1VH9(-N+IB7]<-2&\G:U5>Z/Z#%NZ[6SROT=S5H'5N#7:FL#?'H?;07+79 ML'UH??-HBH"?"?!Z! _#6 [;/I\'[,X;=UV>4]EEM0 '?
J:MMMP2_4>2^NRZZ[*+DQ5=^SK^F8S:'U;*P!1Z LB30*EM/XS6_.T^4AY[;_- MO2[W7SC1Z4N:;G)8H"C2ZKC'M']JZ&^L6KLO=7-EK2KVF MN]$-FD^W5_\'4$L#!!0 (*RK;5G6U%QH; < (\4 9
>&PO=V]R M:W-H965T!:#%%!LO2S9;1(@Z0,S MP$X1U-T6F,5^H"4FUE82-205-_OK]USJ$3E^3+J8_6+)(GGN^]PK76RE^J8W M0ACVO2PJ?3G9&%._GLUTNA$EUU-
9BPHK=U*5W."ONI_I6@F>V4-E,0L\+YZ5 M/*\F5Q?VV:VZNI"-*?)*W"JFF[+DZO%&%')[.?$G_8-/^?W&T(/9U47-[\5* MF'_4MPK_9@+*EI>BXTVFL!)WEY-K__5-1/OMAB^YV.K1/2-+UE)^HS^_9I<3
MCQ02A4@-(7!<'L1;410$!#7^Z# G@T@Z.+[OT3]8VV'+FFOQ5A9?\\QL+B>+ M"A09E7[95_[_PP.K X M=B#H#@16[U:0U?(=-_SJ0LDM4[0;:'1C3;6GH5Q>45!61F$UQSES]1%Q_[5*
M92G8V=^EUJ_8K5!LM>%*7,P,!-"V6=J!W;1@P1&P)?M-5F:CV?LJ$]GN^1D4 M&[0+>NUN@I. *U%/6>BY+/"'Z 1>.%@;6KSX"-Y[KJ]\NM=/1K)_7J^U44B. M?QVRMX4+#\-1P;S6-
4_%Y005H85Z$).KGW_R8^_-'66C0=GH%/J/AN8DV&%/5 M/THC'#]F/_^T"/S@#3LAD7W>"(?6\VZ]L.UN8DV&%/5 M/THC'#]F/_^T"/S@#3LAD7W>"(?6\VZ]L.UA

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`]WRPTLVQ-6&V.GM#W):7C/#)F=*+D'9U81F!6>JVTW'<6&#6T MSTQNN& BX2R##T(;59* C88;QA4\L*Q$^(1,EPK]^S>?V31#_?:L.^ALB]!- MJG,N_3GQGC/&\$D*L]#P7J28? K^_2SHWBL>UXI?Q08L*1J-Z MPM;DCU?1,'QW0.%^HW# $/KDGNHS+3,$.8-U%"^T1@H4$RE\Y&S*,VXXF5%% M,05F-H-+97&'2:D4%W.X9)KK758>UN/S H.9A7QRD N.BJEDL0)CZPD,K85U1. M"%^T%:/@(SYA=AQ1D10EJ>.G\??3TCW]+ W+ DI0@_D459.E@3?F-/@@GE ; MIP<7\+%,>$I)Q^9":L,3W2.:@!!*9YZ0E,4#R"$<0#]J#*"+ACU>C.(K??2?Y MCX${F)SJ769@(RPO]AP\2D9(#@% [)XZB3Q})4EK1"VOL%C^U6DAP6AF$C _/1>W8!L(-@<^'U*X_^LB7L+'P.V&N/+: ;?C(4 M_;X+9RT$$1"-+*(2E?0@)Q+A"SU#I8(IFB2@KO!>1H]C&MIE$B!YXX, M-SQ(YUC[- C*G"M^SL%F2M$NW,F+O(3IA'

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}$N],G4R0*).7I3:.4)SQE2(!/ -E=W@FUW]=V2]N:$271#BHHBF #-M84A]N9*,9VQ%"B0ZTX,W>DG1E'(F)#H7_(9*S8 MZ+705"&BFB$Y,=<,S#+H MY8C :L/3N2A ^.H(U?'UML37 UR;E IF?T5T)9G^A(#/,+&V8"^YIA"'1F_ -M3>>&K0M7)H#W-H K$YKM]DXAF,)0"# D.7)#(DNT&(T/DW&,?D)/T2&^}'UH M@[$WK'I!%X2^ST@IJ;EC,K=L.MAR0/0@(O'*, >U,W>&2D(SVB]C&OC1@%@ MA6,/XQ0Z(?9\<.3Q·W4M&4RU OCITF2GLW;7;?*[N? EV*^K[7W%% 6Z$41!X M&);GURIC.2R,S)9F=/@@;CTDN =J,0'-#U(4A%X:WTW3!71!@\XKF/%\2OK#RZB3%^;*]/.R& I4@6T,÷78* M \#FIFSFP"U@@7FJEY*ZBL$!"16FZ!LF,9$K1$WMWT9>IC8K0!U0[W,![<.V M/=FS-QV@/)GIFTQ/[1M1Q[5S4:X$IUPK] 961(+,,E%2-* ?X05)T8->9_!S M]$L%R]11,7 >.Q6$H +,">H[P!C?=IX]27" 7 2NMA5E^S!X 6NJ*E=LW81U M+<__@G<%>%G2VP.^Y"#HK"/)5V13Z6-HQD)<4!"$;QK9\:}] @BF-T@ ,C M=&P:(RX,G<;'UX(_9QW8/4$=9A"2O)4[B* JP94H&+ALJA4DPR7O@I$%%TJS M3+5 +6#@>WB46+2FUP ZBAF&=;@]BGTT2+H3HP&.S"7\=U-(}/9R[+8#T%U M_AJ? M!1BOR_XHOE-WPLU;FVAG=,$XKS]7K]TZ?C'> 7N]<]PJTH024IKK9\&Z/{-[{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{Z_H'!=]L&C'/I?VP;@<&=4 L%M0(QG$.K(CF?@:AM!0!8LGJ/ MJOJB0$GJ_NW0KE!)+?,G@,>_-#H#[,P%H7W]! ^W;,:.2 !E!+ P04 " 'L MAZJB+^,%]& T# &0 'AL+W=OL)]7VV[N)SWR=&#O1FU[F,(T+-'_GCXI&O1HEYBEFFLL,%*ZNVM2^^X=>&Z)"&YE6 MQL0@Y5GYRYZK/.P9C']F$%0&@>~=.G(LY\RPZ;626U!V-Z'9#Q>JLR9R/+.' MLC"*5CG9F>F#S"*9&24%K:SA+C.H4!OH?&%+@?KDLF?(B]W,BRK$FQ(Q^ GB M!#X18*+A-HLQ/K3O$;N:8K"C>!,DJDB%'I/^'V6\'-2U,HQYU]2,"5'3KA=56\?S<. N_B M87;GOOR+$UJ,1$$G#4P#@TBFN] MT0!.6C*0A M5S)"I$2LE$PI5[!@6>0]@=INA4I19EQR84$90PW7ISX,NL.1UP"&SU'"LO51 MD.XF8?[X,P*)NC21.Y V"M;9J13#,,\$ T# &0 'AL+W=OL)]7VV[N)SWR=&#O1FU[F,(T+-'_GCXI&O1HEYBEFFLL,%*ZNVM2^^X=>&Z)"&YE6 MQL0@Y5GYRYZK/.P9C']F$%0&@>~=.G(LY\RPZ;626U!V-Z'9#Q>JLR9R/+.' MLC"*5CG9F>F#S"*9&24%K:SA+C.H4!OH?&%+@?KDLF?(B]W,BRK$FQ(Q^ GB M!#X18*+A-HLQ/K3O$;N:8K"C>!,DJDB%'I/^'V6\'-2U,HQYU]2,"5'3KA=56\?S<. N_B M87;GOOR+$UJ,1$$G#4P#@TBFN] MT0!.6C*0A M5S)"I$2LE$PI5[!@6>0]@=INA4I19EQR84$90PW7ISX,NL.1UP"&SU'"LO51 MD.XF8?[X,P*)NC21.Y V"M;9J13#,,\$ T# &0 'AL+W=OL)]7VV[N)SWR=&#O1FU[F,(T+-'_GCXI&O1HEYBEFFLL,%*ZNVM2^^X=>&Z)"&YE6 MQL0@Y5GYRYZK/.P9C']F$%0&@>~=.G(LY\RPZ;626U!V-Z'9#Q>JLR9R/+.' MLC"*5CG9F>F#S"*9&24%K:SA+C.H4!OH?&%+@?KDLF?(B]W;BRK$FQ(Q^ GB M!#X18*+A-HLQ/K3O$;N:8K"C>!,DJDB%'I/^'V6\'-2U,HQYU]2;"5'3KA=56\?S<. N_B M87;GOOR+$UJ,1$$G#4P#@TBFN] MT0!.6C*0A M5S)"I$2LE$PI5[!@6>0]@=INA4I19EQR84$90PW7ISX,NL.1UP"&SU'"LO51 MD.XF8?[X,P*)NC21.Y V"M;9J13#,,\$ T# &0 'AL+W=OL)]7VV[N)SWR=&#O1FU[F,(T+-'_GCXI&O1HEYBEFFLL,%*ZNVM2^^X=>&Z)"&YE6 MQL0@Y5GYRYZK/.P9C']F$%0&@>~=.G(LY\RPZ;626U!V-Z'9#Q>JLR9R/+.' MLC"*5CG9F>F#S"*9&24%K:SA+C.H4!OH?&%+@?KDLF?(B]W,BRK$FQ(Q^ GB M!#X18*+A-HLQ/K3O$;N:8K"C>!,DJDB%'I/^'V6\'-2U,HQYU]2,

M"IL;\">5*^PWPF&),N\FQHV2S:W2+++2H[,'\(C0>_8QQXL8I#' [TLA&YA MSOKN:D_^ E!+ P04 " "LJVU9\O.9"Q@# G"P &0 'AL+W=O8OUT#9?F:YUNN->[)-I+YA1],<;Y$)\C%?<-6R:Y>8I)
)PC+$ M83.SOKB3N6L$9L1/ GO1N$8ZRHJQ)]WX'L\L1Q,!A;74%EC][6 .E&HGQ?&[M,K7J.;6P>?WJ_M6$5V%66,"H @VUWYI187[1 MOAKK6&A=",G22JP(4I*5__BY6HB&P/7?$7B5P/M7P:
2#$S0DLS$NL$21U/. M]HCKT2JUZB=#):JNP5G+7R =OY;9:G'J% MO'J%/.,W>L>O3-H6H]0-VG7Z_9N('*]A9JD73 #?@15]_.".G,]MH?Z3V9N(M@SKBH,L]T@N-
SCGHUSX&KI^%%\#\HBUTZ108)_V-$5NH'9IU\$2.5=O/+'Z= MQ3^59=6?:K\!G?@A ?WC,[1M=Z=S3^Y1S3TZQ1VT M<8^.N(?C0^Y.YY[<08;TDF
M%,A&R9RK0'WF>%F5E0W)&ULK59M;]LV$/XK!ZT8$]".9/E%;F8+B)T-*[!V0=RNGVGI9 FE M2(VD[.3?[T@IJN/)0@OTB\V7>Q[>.G6'E2\E+7AA< '!;HN M2Z:>U\CE<>6-O9>%QV*?&[O@Q\N*
[7&+YG/UH&CF=RQI4:+0A12@,%MY=^/; M363MG<$_!1[UR1BLDIV47^WD?;KR NL00L/4LQ8SE(5H_ME3&X<3P#BZ A;0'@&'*<7),6,'%"&\^ M7/%D]*9HR)0L078[_&(8&N[(<=O7ZA"/IT&T]
^G\GJ,@D70&;UR>]:Y/1MT MV[UU(YF-:HW M$:CO>ZHP 5="RIJ?$IR)O8(=&E T%-V1@9XP78%=]>D3]C@ MZ?TI@;[4SOZG/8S"1; V>:=]/CJ]BWL8,1VQ VDBC0IML_BFS: JZ9:?)Q"N
M*##/R)2^[L,\?.BL0<($2G?E^\0.,\Q;AD7+ %-(V:,>J.&H"TCT8P%)"YW(M6A@@_=@3B3[YS1'CX"15P4T0+:+963E_AV&CPC_I"26JO6N5&IQGS9/8K7;= M^,XUH;/U-77IJE^HVE:
>F]H70)"LCRN FHGI33=ML)D96KO/LI*$^YH8Y M?6F@L@:TGTEI7B;V@.[;)?X/4$L#!!0 (*RK;5E\#.^<@ (/P& 9 M >&PO=V]R:W-H965T M"Y%6T+1)>U1EW3Z;<"%6'3NS#;3_?K:31A12-
*1]27SM>X[/N8FOTST7C[(M4.BII$Q.G4*I:N*Z,B^@Q'+ *V!Z9!O3P8(^-DR?FC";ZLIHYG! &%7!D&K%\[M# &EADC+^--P.NV6!G@X?F'_9+UK+TLL8<;I;[)2Q=09.6@%:[REZI[O/T/C M)S9\.:?
2/M&^SHT#!^5;J7C9@+6"DK#ZC9^:.AP _.@-0- @G\%A T@M$9K M9=;6'"NJCA\4<75 _=H"M$&/I9*W$;"535^F-#=S-FTUNZTV"-S990#5 H==# M@1=$'?#9>?
@=<<@WW+3Q\#7>UW=9ST'H.+%]RUG.7C1H7=N/,@9K("NV4Q;"V&YJBS'Q68S\@VB!JS/23],[SGZ_Y6 L)2 M@NHL0,TZM*RF >RR(/%'J;L[-'::% 7)L$UZ)3AJ!4>7"$9\2J;,F
MBPYUCH;C(YVG25$]R=P+W[#8$":UGK6& M>8.AMBWJ7EL'BE>V72VYTLW/#@M]/8$P"7I]S;EZ"4P';"^\["]02P,$% M @ K*MM6=#DT0#2 P Z!$!D
!X;"]W;W)KeULO5C;;MLX$/T50BT6+9!&HN1+DK4-I':+!DBP0=UN'XH^T-;((BJ1+DG9 MS7[]DI0B2QN%7:="7FQ2Y#F<,YRAAIKLN?@N4P"%?N89DU,O56I[X?MRG4). MY"G?
M,C"169'P;!R,\)9=YL8I_=BMF$%RJC#&X%DD6> M$W'W%C*^GWK8NW_PD6Y291[XL\F6;&)ZO/V5NB>7[/$- -MK(2%EQ_MUTKN*I%QB+((.U,A1$_^U@#EEFF+0=/RI2KU[3 M
)OM> ,W5KP6LR(2YCS[0F.53KTS#\60D")3' G^ U2"AH9OS3-I?]&^FAMX M:%U(Q?,*K"W(*2O_R<_*$0T 'CP"""M ^'\!406(K-#2,BMOB0129303?(V%F M:S;3L+ZQ:*V&,K.-2R7T*-4X-
5OJN(B+#!!/T!53A&WH2O* D/L'KQ:@"(TDZ_1& _1YN4"O7KY&+Q%EZ%/*"TE8+">^ MTD::I?QU9=#;TJ#P,8-@>XJBX 2%03CH@,_=\ 6L-1Q;>-2&^]HUM7 "VC^A
MY1L]PG>5;PD5.FX5>IRED>BVB.1BWWVB2N2-6.% MV%CITEP2C2V1.4]VLW$P\7=-)0^G#*/QL){4LG!06SAP6N@,VBX[2[!!PX@W M#PSMF!.=#W&WI&#RK$O%J%8Q+@D=/CO)9Q[I3QGC*J
&4ZGF/]+FNK.4&%A*3(]' "73*Z6J;P2D]L,:\<2C;LKMF.2>O1K\MX M]YRVC8<*"SO+E= -5S<*[N.^:R7W_&PO=V]R:W-H965T,&20.?L:L]:6MHKQI_$#$"BYRREHF/-I)RW;%O$,\BPN&1SH.K-
MA/$,2S7E4UO,.>#$@++4]APGL#-,J!6VS=H]#]ML(5-"X9XCL<@RS'_U(&6K MCN5:ZX4',IU)O6"'[3F>P@CDX_R>JYE=LB0D RH(HXC#I&-UW=8PT/;&X"N! ME=@8([V3,6-/>G*;="Q'!P0IQ%
(S8/580A_25!.I,'X6G%;I4@,WQVOVH=F[MVLL8"^BS]!M)Y*QC75LH@0E>I/*!K3Y!L1]?\\4L%>87K7+;0!G'"R%95H!5 M!!FA^1_%WG8 "B>:H!7 +Q=0/, H%$ &L=Z:!: YK$>_ +@'PL("H 1T\Z3
M93(=88G#-FH\>1Q$Z/WN'SA"AZ,N,+02FB6C;4@6BZ>RX<-K+ MG7H'G#;0'-R)M")I!4X*-Z_$T-WE8)*+/@K;/0\VH)1S"_1 WG GF.UZR(MIW\\O%&UG==Y'[S.^[
>'D&LX&X5?"N7C;*B&H8O.,#WD;%D1=(4J=I >^6% M(B+BE(D%! 2].Q:2[/E1U4)Y5X:U5[T>=L2"49,,3D6WIWBQU;]:QA]V,<4E^8W-AL(DZ(DKIL9&^2N2<\LI0
MZCMP&5Y[;7NY*=V^B>_XVS91A8U_LVTSV+=Q?:3?8-AK6;O&%"?3+!/]U";S= M39@^B:N2EM,T-W;B[.2LUM'_EOL_W0U.Z6YX(K(M"8)@2]!6@H&O1'4KD*#) M0NHC'F\6-3RK=DY E22UM-
5!HZISZ@4\AX4[45"#4P8U#/8_PZ:^]9:;LMD; M#4T&?&I:3X%BMJ ROXG*U;*[[9JF;F>]Y[;Z;L5ZY+8&>?/ZESYOI>\PGQ(J M4 H3Y&ULS9Q=;]LV%(;O]RL(KQA6H(LMZB,?
2PRT"8H52(>B:;N+8A>* M3<="]>&1=-P!^_&C9-44$^E(E(\ W22VK/.*>LU#/Z2/>;G+^#>Q9DR2[TF< MBJO)6LK-Q70J%FN6A.(DV[!4O;+*>!)*]90_3,6&LW!9!"7QE,YFP30)HW0R MORR.?
>#SRVPKXRAE'S@1VR0^];O6)SMKB;.Y,>!C]'#6N8!O/+3?C [1C\ MO/G U;//D1649)2P54982SE97D]?.Q4T0Y '%&5\BMA.5QR2_E?LL^Y8_>;>\ MFLSR%K&8+60N$:I_C^R:Q7&NI-
KQ3RDZ.5PS#ZP^_J'^MKAY=3/WH6#76?Q7 MM)3KJ\GA"S9*MS&\F.V^X.5-^3G>HLL%L5?LBO/G4W(8BMDEI3!J@5)E.[__MA]]+(RH!CML00,L ^C3
:PAPRP"W:X!7!GB%,_M;*7RX"64XO^39CO#\,*66 M/RC,+*+5[4=I_K[?2:Y>C522T$DX*$Z9+< M1N%]%$KUO*FUJ*MN<$'?V MBM 9]6K";^#P&[90X4X1[IKA4V7:P3EZ<(X6>D&#GC;@5:M?
AD/Y67]F*7]B MV=,=0'R3K)$_%UGSKXU;GUK\N'A0FS"!;N:J/P7C#^RR?R7GYU@]GN=54AB MAG'NP3@74I]_RJ3J8F%IF22KW,C'W,B:EKZ!M;XZM5[M@TZ+H'SD>YQ3WW><
MR^ECU010NJ<)WL$$KX,)<:6SM#H!"S8XL0_R*DZX=.;/GCCA/?/+\]0GQ^$L MXQ;]PRWZ8(NJ"?(NW6RE>$5NV2.+B4.^OF?)/>.U3095;3LZDIAA0' P(!C5
M"!%@&HC#N%'&$@+4:\N+T65[4C1"@=$\3$@XFG&&/$+!@@Q-@4/T] MDKH.<[R.8=/YP:;SGJ,,!4<94-4V69#$# .QF<'YF?+D0D:TJT'GQ;37R 0K-AD6=)I0U9P&S*@<#<8.3+.WDT7-
=9DJATN9/9XAL\ MF" !;'E30^"PHWG8.1O78-*#: 'SD-1,\S0E.S F6PXFL%A3;IQWFE3!XC= MHJ)6*0B44 J1_TC?10OXHM;+.(.7]2ZLPP!R%0#,AT7(%-40,3W3 M@$PQ ;E%K"G3L "YCU"
[5QJ0*8RS?7,1GJS"%[7N3D.L.5/-UO1T7+F("N=8 M:J9Y&LYIE]7JSKG8:Z4:CK+)Q2%8G&H6IS ^O][P*,Z_AJ;DCJ51QE5>IH^, MR^@^9JHG208G'>K2-9::^56PIG%W7&O7+BJG8ZF9YFE.=
[NL75NM>K0H-GV? M[CSC3>?\[-FJ1^UILZ95#U+N MN.I"7%1*QU(S=4.[G:I#;'+S5X5(G"436X>+V1ZI:'&F]3U$CK-A4U3CKQ*.UIS7RJ*>YVX,I M^8YM9)$/_2=Q\!5LWW?
>N$JA/512QU(SS=.D[G4IA[9+FEY%T664 MD0VT^IUT:4?-:0[UFY*F4O ,([!ETAPQD8,;8MT]AECDJC1?>_ZX<@N5M+'4 M3/,T:7OH92$MBDVYU0.*:V$10N MJA0/E;:QU$SS-
&U[7:I2[/*S5VD*'&63G\<+F3^FT7#MPRB,F9_PA YNB/4O M<(98(_2\TT3X.]CU[PW:+8D)]EU&D+F_K/ZUX -O4U@_M= M*E7>AWRQ+GX>VFM*!U _#^IT?8@G>-
V:4IW.]2>V*174?, _>"F6#LRQ@JWKY'<'U=%BH*YEAJ MIGD:S'WTWT^V*#8E(2J1U$# 5/#N ^C,VZ:PE- N"G6G@VQ[!UH,@_&5<,2 MH/(YEIIIGN;$ +V&I46Q(4WA*&O7CO])IVF89O( )FC<-
(5G@G!3K#T;8J$] MT) ?C*LD)D"=#V"IF>;I^4" 7A+3HMB4IJ@3@>#YSB8 T@8YX9M'*GM]M"X, M?UHSSL@N_Y-F1(P%2O&Q4_W3.X82XE<,Z+:O&'%7E?[!!1DN2WZ5/YBFG>H
M)$OE6A"6+E4_U(L^/S8^_JE[.Z>5#: 2QA^*C;0$663;5.9-KAP];-;UIMC3 MZNGQP+^X#OS:5P+U2K&_UU1?8K\[F!J,')4D)BMU.5F]Z=J(L'W&V[MG\AL
M4VQ!=9)F27%PS4+EXSG)ZC75YD:L,HG^04.VY[- P=02P,$% @ K*MM M614'TG-^#P FN< !D !X;"]W;W)K&ULQ9UK M;]M&%H;_"N$M%EV@L$52%RKK&$@],]@"S2*
(V^Z'8C\P%AT3U:T4E0NP/WXI M6?9P*.9(8S\J^Z'QA7SFF.?E'.GES-'EYT7QQ^H^R\K@RVPZ7[T^NR_+Y:N+ MB]7M?39+5^>+93:O?G.W*&9I67U;?+Q8+8LLG6Q/FDTOHEYO>#%+_G9U>7V
M9^^*J\O%NISF\^Q=$:S6LUE:?/TQFRX^OSX+SQY_\#[_>%]N?G!Q=;E,/V8W M6?GK\EU1?7?Q1)GDLVR^RA?SH,CN7I^]"5^9,!QNSM@>\EN>?5[5O@XV?\N'
MQ>*/S3<_35Z?]38A9=/LMMPPTNJ?3]EU-IUN4%4@?^ZH9T^#;DZL?_U(-]N_ MOOIK/J2K['HQ_4\^*>]?GR5GP22[2]?3\OWB\[^RW5\TV/!N%]/5]O_!TJVQ MO;/@=KTJ%
[/=R54$LWS^\& Z97:966Z=5EL?@<%)NC*]KFBVVZMF=7%SB? M;Z1U4Q;5; /JO/+JIM+J9#W-@L5=8-*\"'Y+I^LL>+.JM+;;3U3^"[X)\'OQROUBOTOED=7E15D%L4!>WNP%_?!@P^L:
X^#M8E[>KP(] MGV23EO.OY?/#2 !<5' JTR6('B_!CY%(O,F6YT'<^R&(>E$_^/5&!=]_]X^V MP&2,RFXK3+C%Q)&R9BW:7$>1(7,,XUCY]D M%V^YPV]P:U)[FZ6K=9%5TU49_#1?
KLM54"EK^\MT*\!?LMO[>?[G.EL%O_]< M<8*?RFRV^F^;]!X&C=L'WW3,?RFH^697%>IO_NXTL/FUDT9;=!]9HR]J4$$)7 M<=0;]'NU/M73MG]4OU\56OW M^3*=!LOT:_IAVIJ1!UJ_=JVC012-
&QG9/RH>#9.XD1$Q,M^,D# #P9R,#)\R M,A0S4DW ^?1A]KW)YOFB"*X7\T]94>952H)_+\HL^/UM-ON0%:T3H@CWG1!) MF")AFH09"::D> 24[E$7=7%$RH"$*1*F29B!8(X,DB<9)&!=3/;FUW"
<[-7% MMJ-Z>W51C,LW'R3,0# G'^.G?(S1NCC>>PT2CH:]J)&1HXY28F2^&2%A9C_^ M:#2H*?_SDC7X;X)%C;?>Z$C:I1F*)J;1^N"A9@-]NR:D'XY7!-0/PVE*92F49JA:*YZ
MK*D6=N*JA:BMAM(42M,HS5 T5PW66PME<^TE-8%TM*YWM#!TBL+YH%D64$\. M11F*YJ;2VG*&[,N]L"S\L#M\NT[F79'?R@3$Y&"\LT_2%$K3*,U0-=UA_43 MHUX7LW^$6H8H3:$TC=
(,17/58"W#2#2A7C+[[\CUU_"CQF1]?<0Q2H[0.SNH MA4?1W.Q8*R^2+;P73^@WJVF1'3&7RW%XW[VH-XC2-$HS%,W5A_4&HT[6C46H MUX?2%$K3*,U0-%<-
UNN+Y.5C+YG+^RVOO<^CN#F=MQS6/P^;SVCE.+USA#IP M%,W-D77@(MF!>_&,KK\LL]LRFU3WC7AU*4RA-HS1#T5PU6*\N$MV?JZ?;O=S<[E^SM&C=9'" ,@QF#YL$XF"2 M?
FTC7,L$[XRB?AM*,Q3-S:CUVR+9;SM1!3CR,:X+&\)/#(HB!3O/?_R#'%!TN,0N/1*,U0 M-#>CUH:+91ONA$7AB.>X0D$7^*$TC=(,17-%8]W!..JB*,2H%XC2%$K3 M*,U0-%<-
M2VD\CK!8XL"ZNT=B"GK%LZ[VX-CS8 M_[\MIM54,,W+KW(M0%?VH32%TC1*,Q3-%8GU%>-!)[4]1!1FD)I&J49BN:J MP7J(L;P^\ 5/ G9D9V7FL+EYKN6@I/E85P[1.SVHJ4?
1W/184R^6[;@7S^CO M\]4?@2FRZM:=5^4^6Y4/*SG%B1U=GH?2%$K3*,U0-%"A-HS1#T=Q6+];$ZY]T7^_A M(G#DPY3-^9 *4IE*91FJ%HKGRL8]CO9*]O'[4"49I":1JE&8KFJL%:@?V3 M[?
65R=X9C]JS*#?[#>%^G@HS5 T-Y76Q^O+GME?4A>.>"@@A^FM"W01($K3 M*,U0-%^A M19RG6SX[:.V($I3*$VC-$/17#586[! L@V_,MD[XX/]NC XCYJF M$3JH1FF&HKFIM)Y>_Z1[?
FN/B%7^*9]D\\EAST@.R5L#Z*)!E*91FJ%HKE2L MO]CO9(-O'W4049I"1JE&8KFJL$ZB/V3;?"5R>V1!ZW)AD#J.2 ASZ@W2-'< M/%MOL"][@S?9LMQ.Y<_OCRJ/X'V'HU8B2M,HS5
TMTNQM1(G6SI':#.($I3 M*$VC-$/17#589W @KR7TZY:Z@SEM-Z,]!N'7;8>%4;.KJ]#\TX+:M%1-#&DK3*,U0-%=!UEL;=.*M#5!O#:4IE*91FJ%HKAJLMS8XF\& MLF\'E ;/QJIR0-X*0#?@HC2-
T@Q%PO<;6M]O*._9?@>6I2F49JA:*Y* MK-EUGP;R>;;"B/4ST-I M"J5IE&8HFJL&Z^>-Y 6$QU8&U)\[$%-RL,PH-!Z-T@Q%1'A ML84!-?H.Q+3KM'I,?4]/I1F*)];6.OQC62/#ZD/7MU6Y8"\-8(N^T-
I&J49 MBN8*Q1J-HTZ:\HU00Q&E*92F49JA:*X:K*$X.EE3OAU9[K;:MU4Y1._T MH X?17/2DUB'+Y&].616?TI'53DNW]L9I2F4IE&:H6BN7JQ]F'3262]!/4&4 MIE":1FF&HKEJL)Y@DE++[SX?-
Q[A!/4%D1U"]5IE&8HFJL&:PLF M)]LE+).],][27:] 'C>V&2MT4(W2#$*5SV4D)O>3D&X.QSJMRJ-[:0%<(HC2- MT@Q%3DFX.?U7U5#LM;!^B*0I2F49JA:(YR$WB,NHDTH M3:$TC=(,17/58-
W$\D:&Z>K4\XEGW"G]>W M^:1Z>5_7 O%.,^G$H M3:,T0]%4 <^&3')(W@) C3B4IE&:H6B.5*J7.4]:V7S=00EX'!82 M!(M3+$ZS.(/A&J((:ZXF2-W .V?^'"O%C07]K)#:A9G,%PCFU$MF[#O]K)>
M3@?"\5< ZM&Q.,WB#(9KB"6NB:43H^YQ6$P4J%7'XC2+,QBN(8I^310GZ]1W M .V?^/[^L_KPO-]A\5$@1J'+$ZS.(/A&J(8U40A[P4^(,AG-%$=8LQE#>7?R2=P\RVCOQ.US=36KN)5?L
MF)K%&0S72&?-' QEEEQ8#W%':ZQ#630W ;"#JM9Q,%PC8S6S,)O M-@MI:^GXW2 '(O,7!+I+F,5I%FHRL[NF\T GQ?%'JOP MKOX/4$L#!!0 (*RK;5F0)FKJW , #P8 9 >&PO=V]R:W-H965T M2J7
+;E*(T<7U* S=E/',6L +C/^:,T+;>A;'@* MF>(D(Q*V<^>-=QMYOA64/;YP.*BC8V)O92W$-]NXW\P=:BN"!&)M$3\21P!L^(_!K@7^!8% +!I<* MAK5@>*E@5 M&EPJ"6A"4?
GB%7E!>$8^[42A6+91,U>; ^NPH;ES7\K;JQ7^FEA7D-V1 M_R(^J8<=\KM^>0BQD7NE?- A#_OE#TS>$/JY^;*"XNFDE/L=\JA?_B8WH]-A ME]PUEC: ^^HVO?
LD+GBMG)Z1^_0ED2D)8: +UO>E [C6DZM\N9RK:H)MFX^U6 MY2R&N6/R2X'<@[/X]P\OH'JW^80)"S%A2TQ8A 1K^3MH_!WTT1>1 9-]N4)S MRMP[U>:GDRZ#\???3 MLW>
:U<7)BS$A"TQ81$2K&7YI+%\@IJ>$TQ_,6$A)FR)"8N08"U_IXV_4J3T MG)[ERCCPQR?A.3T+SRD-3K.SMZYK_3@OR_/\$6T/&2$-V9IHC_YZ@:>]4_V^ MB/F&F+?7>%> ^NOY6?
O:/<>T"0Z6%]+0E*BW"HK6]/]U\5!CM,9AV8Q)"U%I M2U1:A$5KV_QK+|?KW4JX.DW[<5?,[>D(/5.]@[*SFX>/0G+)6IM$1:M,L8] MVD>U^^HF5))XID@"6X.G-
V/S0B*KK>JJH45>;JH45>;

Z%T$6.S{)'JZH5[X>-6!G>>&C^YJS65#;W2Y(2MZ3_GGS5TD/O6V*@O7 MIP%SPP!$=`G5N8874].4!LD57USZR';> QG/ R_RP^WBZN.(7M$/>IP*4'$ MRP,=4\ ^32J(?/S+1SM:G--Q]_ZS^9Q*|"&9.&!V'WE=WP==7G4$'+.B2Q![_ M&#[^3;. +*GGA!Y+_H+'[%JC YR8|=#/C$4/?#=(7\G/+!$[!A#7&^#, !4, MD%UC@#,#O*\',S,PBQZL&@,K,TA" [Z6Q)XF;$$Y&EU'X"")YM5"3;Y+L)]8B M7VX@)\H]C\2WKK#CHWLQ|Q:Q1T&X!/?)9''_HPSUST67KN.5G_QFG_4$W_AN!]&/ U]-@01<5]E.]/40:@9Y(UC9CZ#EC M8Z15O*>;+L#&&4 &,JLZI#>?4$>8P\0<:[J#MP.(}SV|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`;Z2K7&PH)'W M)!-3]U/U1G@82;$90V.Q:(CN1A$Z*R%$DXC(4V"'"J_=JF'N[9R8|FFT2HZJ WEBX!UP9J?LF8W':T@_8!%OT&4$L# M!!0 (*RK;5G?S/T6700 "\5 9 >&PO=V]R:W-H965T|^YMN^Y>'1@_$%L "3ZEL2I&%L;*;>7 MMBV6&TBHZ+$MI.BW-BO&$2O7(U[;8(X SNA46I-1EG;G$]&;"?C M* (4Y1V*7))0_SB!FA[&%K:>&FVB]D;K!GHRV= T+D+?,.5=/=FDEC!)(1<12 MQ&$UMJ;XD#6XRZ"@ZC<(TWEGKS'_? I'%N.1@0Q+*4V0=5E#U<0QJ]2 MPO&U,&J5/O7 ZOV3]0\9>47FG@2K$?Q2;L158*(05W<7RAAW^A()07]M; MLEAD_^U0-4]LM-P)R9)BL$*01&E^I=`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|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|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|-!8#@^)?LOC-2W!5C?YDLPU1_ M:2 ! (;.G[T"MMT-J;W=W_3EE&9?O"IB2;1WMLGK$P<+5ZOBTL@6ZV+]U:QT? M&LOQ(=&">;QN92Z-UZW$$Y]\;$4,ZOE1%[5>#ZF]WIFJ_?XV63W^8 UKM7Q: MV0)=;- U*MI8/C67YD,3."3=?"<;D/9\,9 EW7\E[M+XW9*AU?4CM^L[4\2O; M8_4D!HM9J^?3RA;H8NN6L_5|:"S/AR2OQW@MBQ"ACQ A_(]OLH$*@02$ M/% [(QLE>M!3GVVH38,'R.63TN*^HN=IL-+RNMM=QUV_@Y1)*KOOP,CAN(VSI MC[L:6;^QC;,")'C#AC(O'/8 R8\;!8\GE.RKG7 /A%*25H<['*YQ7@+8YQM" MZ,M).4"S77/Q'U!+ P04 " "LJVU9(I:;G@(# G"0 &0 'AL+W=O M>QSS[WUUP\RAA1P7.: M,#EP8J6R<]>588PID6<\0Z9G%ERD1.FN6+HR$T@BZY0F;N!Y;3^9QRLQ1W%M=QI@$YRY_S1=*ZC@>,91IA@J P$T;\57F"2 M&"3-XZD$=:J8QG&WO47_9,5K,7,B\8(G]S12|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|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|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|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|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|P>+3S5D$UVC< H)H%U6ZIY MC;9Y]5#<>BYU_CVF":"M"M4URIV^O=N2^V?ZDSF]LF-ZFO+O'42%&ULK3 M6BF]Q=X>'7-&4]:

*!00$*"E$+2@ZJ-I_"5#]#H7/L1/XB_=.:U!7UCCMH+@54LZ&:]5< MJ.9!-1^J!5 M1&ER&&Z\U,9\P<&5"]>5#-AVH!5 M1FAQ% M;6Z&J7[2P_ME'B?BR=H&N6:I>-#]99;>L;R,;Q)&/F]DFXQ&3^ZJW'.Z -JZ$*7)H=,F@)CJ!)#Z[5'^ M^NU1AYL'D(?$GQVMXD7LY'ZMWY84I\3^'K'5LRJN\CB-XB5-.F,)FC("U2RH M9D,U!ZJY4,V#:GZC28_J/]W.MX)6&:(T.=S:3!!3_6@+>[%,L@?&FJL&ZR== M7"4T50_5H$D?4,V":C94[VB#YJ1 M-1NJ.5#-A6H>5/,;3;I'?62:VZJ,@U8:HC0YC-K[UHAZUWSNRH'D?4,V&:@Y4&PO=V]R:W-H965TB@]*G-CR_/JJ_SSJO M.K,F A8L^h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|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|^L21*4F9K M@K/_HH2D:I26C-(2#WMQ!/91JT(K-%]29\WN%0(!(_LU6UDTU Z_#U'M,2>' M,=V(7-N6%S -: 8LF T$^<:^A0^5IF?=XZ8>U\WA)I_$EU=1%FX.T5E'.NF[=!Z >J'@QKRZ^O6|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|^:?PF2BCLZW-EUKGK'/];'-+ MWMRF#ZSY\&QS6][<#], ^T5'VG?%M*HSH;8\=2@N:/]'>].>?U)'R>]N>CL1,)&8A,1N).4C,16(>$O.16 #"A$(S M]H5FR/3IQVRY9"=I[* 9?=L=G=A)9%&RPQ&KO+8:DX)=:PR)F4C,0F(V$G.0 MF(O$O"UF5!@?ESQ-564T4O1K=D1Z.JP?9*_!.:^3X7@R5(;[3H72&.Y+8R@M M#:\HUF$:49+-Z\JX8G42EG1&GL)D3=MJ0RIVK0TD9B(Q"XG92,Q!8BX2\[;8 M\& O5?]*HAX5!K++X*4NA;(8[5]SU]\R>72,+#8F92,Q"8C82M9HJ Q$6Q/KX0LZTNN=2UO*":"=4L MJ&9#-0>]N;4FS'B=#E4\:*<^5 M0FEA !Y=25?@LFYSL7$E(S81]%E2SH9H# MU=Q:$P;]BJ(<%Q*R3Q^]!2A-+"2M*21-6DC-B*H^$D75<*N*|:SR.&JO)*G9 MN9*0F@G5+*AF0S4'JKFU=CCMJ_9/+L%XT$Y]J!:@-+&4FO"!*KWD.C7CIWA& MTQE9T3RB:1D^MAMI>@RA0Y-54 U1)8%FX.T$E'.NF[=!Z >J'@QKRZ^O6|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|^:?PF2BCLZW-EUKGK'/];'-+ MWMRF#ZSY\&QS6][<#], ^T5'VG?%M*HSH;8\=2@N:/]'>].>?U)'R>]N>CL1,)&8A,1N).4C,16(>$O.16 #"A$(S M]H5FR/3IQVRY9"=I[* 9?=L=G=A)9%&RPQ&KO+8:DX)=:PR)F4C,0F(V$G.0 MF(O$O"UF5!@?ESQ-564T4O1K=D1Z.JP?9*_!.:^3X7@R5(;[3H72&.Y+8R@M M#:\HUF$:49+-Z\JX8G42EG1&GL)D3=MJ0RIVK0TD9B(Q"XG92,Q!8BX2\[;8 M\& O5?]*HAX5!K++X*4NA;(8[5]SU]\R>72,+#8F92,Q"8C82M9HJ Q$6Q/KX0LZTNN=2UO*":"=4L MJ&9#-0>]N;4FS'B=#E4\:*<^5 M0FEA !Y=25?@LFYSL7$E(S81]%E2SH9H# MU=Q:$P;]BJ(<%Q*R3Q^]!2A-+"2M*21-6DC-B*H^$D75<*N*|:SR.&JO)*G9 MN9*0F@G5+*AF0S4'JKFU=CCMJ_9/+L%XT$Y]J!:@-+&4FO"!*KWD.C7CIWA& MTQE9T3RB:1D^MAMI>@RA0Y-54 U1)8%FX.T5

e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function() {Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-';}else{d='none';p='+';} e.style.display=d;if(a.textContent) {a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 84 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 86 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 372 361 1 true 74 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://pavmed.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://pavmed.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://pavmed.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://pavmed.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Equity (Deficit) (Unaudited) Sheet http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit Condensed Consolidated Statement of Changes in Stockholders' Equity (Deficit) (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://pavmed.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 7 false false R8.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 8 false false R9.htm 995612 - Disclosure - The Company Sheet http://pavmed.com/role/Company The Company Notes 9 false false R10.htm 995613 - Disclosure - Liquidity and Going Concern Sheet http://pavmed.com/role/LiquidityAndGoingConcern Liquidity and Going Concern Notes 10 false false R11.htm 995614 - Disclosure - Summary of Significant Accounting Policies Sheet http://pavmed.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 11 false false R12.htm 995615 - Disclosure - Equity Method Investment Sheet http://pavmed.com/role/EquityMethodInvestment Equity Method Investment Notes 12 false false R13.htm 995616 - Disclosure - Revenue from Contracts with Customers Sheet http://pavmed.com/role/RevenueFromContractsWithCustomers Revenue from Contracts with Customers Notes 13 false false R14.htm 995617 - Disclosure - Prepaid Expenses, Deposits, and Other Current Assets Sheet http://pavmed.com/role/PrepaidExpensesDepositsAndOtherCurrentAssets Prepaid Expenses, Deposits, and Other Current Assets Notes 14 false false R15.htm 995618 - Disclosure - Leases Sheet http://pavmed.com/role/Leases Leases Notes 15 false false R16.htm 995619 - Disclosure - Intangible Assets, net Sheet http://pavmed.com/role/IntangibleAssetsNet Intangible Assets, net Notes 16 false false R17.htm 995620 - Disclosure - Commitment and Contingencies Sheet http://pavmed.com/role/CommitmentAndContingencies Commitment and Contingencies Notes 17 false false R18.htm 995621 - Disclosure - Financial Instruments Fair Value Measurements Sheet http://pavmed.com/role/FinancialInstrumentsFairValueMeasurements Financial Instruments Fair Value Measurements Notes 18 false false R19.htm 995622 - Disclosure - Debt Sheet http://pavmed.com/role/Debt Debt Notes 19 false false R20.htm 995623 - Disclosure - Stock-Based Compensation Sheet http://pavmed.com/role/Stock-basedCompensation Stock-Based Compensation Notes 20 false false R21.htm 995624 - Disclosure - Preferred Stock Sheet http://pavmed.com/role/PreferredStock Preferred Stock Notes 21 false false R22.htm 995625 - Disclosure - Common Stock and Common Stock Purchase Warrants Sheet http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrants Common Stock and Common Stock Purchase Warrants Notes 22 false false R23.htm 995626 - Disclosure - Noncontrolling Interest Sheet http://pavmed.com/role/NoncontrollingInterest Noncontrolling Interest Notes 23 false false R24.htm 995627 - Disclosure - Net Income (Loss) Per Share Sheet http://pavmed.com/role/NetIncomeLossPerShare Net Income (Loss) Per Share Notes 24 false false R25.htm 995628 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://pavmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://pavmed.com/role/SummaryOfSignificantAccountingPolicies 25 false false R26.htm 995629 - Disclosure - Equity Method Investment (Tables) Sheet http://pavmed.com/role/EquityMethodInvestmentTables Equity Method Investment (Tables) Tables http://pavmed.com/role/EquityMethodInvestment 26 false false R27.htm 995630 - Disclosure - Prepaid Expenses, Deposits, and Other Current Assets (Tables) Sheet http://pavmed.com/role/PrepaidExpensesDepositsAndOtherCurrentAssetsTables Prepaid Expenses, Deposits, and Other Current Assets (Tables) Tables http://pavmed.com/role/PrepaidExpensesDepositsAndOtherCurrentAssets 27 false false R28.htm 995631 - Disclosure - Leases (Tables) Sheet http://pavmed.com/role/LeasesTables Leases (Tables) Tables http://pavmed.com/role/Leases 28 false false R29.htm 995632 - Disclosure - Intangible Assets, net (Tables) Sheet http://pavmed.com/role/IntangibleAssetsNetTables Intangible Assets, net (Tables) Tables http://pavmed.com/role/IntangibleAssetsNet 29 false false R30.htm 995633 - Disclosure - Financial Instruments Fair Value Measurements (Tables) Sheet http://pavmed.com/role/FinancialInstrumentsFairValueMeasurementsTables Financial Instruments Fair Value Measurements (Tables) Tables http://pavmed.com/role/FinancialInstrumentsFairValueMeasurements 30 false false R31.htm 995634 - Disclosure - Debt (Tables) Sheet http://pavmed.com/role/DebtTables Debt (Tables) Tables http://pavmed.com/role/Debt 31 false false R32.htm 995635 - Disclosure - Stock-Based Compensation (Tables) Sheet http://pavmed.com/role/Stock-basedCompensationTables Stock-Based Compensation (Tables) Tables http://pavmed.com/role/Stock-basedCompensation 32 false false R33.htm 995636 - Disclosure - Noncontrolling Interest (Tables) Sheet http://pavmed.com/role/NoncontrollingInterestTables Noncontrolling Interest (Tables) Tables http://pavmed.com/role/NoncontrollingInterest 33 false false R34.htm 995637 - Disclosure - Net Income (Loss) Per Share (Tables) Sheet http://pavmed.com/role/NetIncomeLossPerShareTables Net Income (Loss) Per Share (Tables) Tables http://pavmed.com/role/NetIncomeLossPerShare 34 false false R35.htm 995638 - Disclosure - Liquidity and Going Concern (Details Narrative) Sheet http://pavmed.com/role/LiquidityAndGoingConcernDetailsNarrative Liquidity and Going Concern (Details Narrative) Details http://pavmed.com/role/LiquidityAndGoingConcern 35 false false R36.htm 995639 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://pavmed.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://pavmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies 36 false false R37.htm 995640 - Disclosure - Schedule of Deconsolidation of Net Assets (Details) Sheet http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails Schedule of Deconsolidation of Net Assets (Details) Details 37 false false R38.htm 995641 - Disclosure - Schedule of Gain on Deconsolidation (Details) Sheet http://pavmed.com/role/ScheduleOfGainOnDeconsolidationDetails Schedule of Gain on Deconsolidation (Details) Details 38 false false R39.htm 995642 - Disclosure - Schedule of Aggregate Information From the Financial Statements (Details) Sheet http://pavmed.com/role/ScheduleOfAggregateInformationFromFinancialStatementsDetails Schedule of Aggregate Information From the Financial Statements (Details) Details 39 false false R40.htm 995643 - Disclosure - Equity Method Investment (Details Narrative) Sheet http://pavmed.com/role/EquityMethodInvestmentDetailsNarrative Equity Method Investment (Details Narrative) Details http://pavmed.com/role/EquityMethodInvestmentTables 40 false false R41.htm 995644 - Disclosure - Revenue from Contracts with Customers (Details Narrative) Sheet http://pavmed.com/role/RevenueFromContractsWithCustomersDetailsNarrative Revenue from Contracts with Customers (Details Narrative) Details http://pavmed.com/role/RevenueFromContractsWithCustomers 41 false false R42.htm 995645 - Disclosure - Schedule of Prepaid Expenses and Other Current Assets (Details) Sheet http://pavmed.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails Schedule of Prepaid Expenses and Other Current Assets (Details) Details 42 false false R43.htm 995646 - Disclosure - Schedule of Future Minimum Lease Payments for Operating Leases (Details) Sheet http://pavmed.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeasesDetails Schedule of Future Minimum Lease Payments for Operating Leases (Details) Details 43 false false R44.htm 995647 - Disclosure - Schedule of Supplemental Balance Sheet Information Related to Cash and Non-cash Activities with Leases (Details) Sheet http://pavmed.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToCashAndNon-cashActivitiesWithLeasesDetails Schedule of Supplemental Balance Sheet Information Related to Cash and Non-cash Activities with Leases (Details) Details 44 false false R45.htm 995648 - Disclosure - Leases (Details Narrative) Sheet http://pavmed.com/role/LeasesDetailsNarrative Leases (Details Narrative) Details http://pavmed.com/role/LeasesTables 45 false false R46.htm 995649 - Disclosure - Schedule of Intangible Assets, Less Accumulated Amortization (Details) Sheet http://pavmed.com/role/ScheduleOfIntangibleAssetsLessAccumulatedAmortizationDetails Schedule of Intangible Assets, Less Accumulated Amortization (Details) Details 46 false false R47.htm 995650 - Disclosure - Intangible Assets, net (Details Narrative) Sheet http://pavmed.com/role/IntangibleAssetsNetDetailsNarrative Intangible Assets, net (Details Narrative) Details http://pavmed.com/role/IntangibleAssetsNetTables 47 false false R48.htm 995651 - Disclosure - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Sheet http://pavmed.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Details 48 false false R49.htm 995652 - Disclosure - Schedule of Fair Value Assumption Used (Details) Sheet http://pavmed.com/role/ScheduleOfFairValueAssumptionUsedDetails Schedule of Fair Value Assumption Used (Details) Details 49 false false R50.htm 995653 - Disclosure - Financial Instruments Fair Value Measurements (Details Narrative) Sheet http://pavmed.com/role/FinancialInstrumentsFairValueMeasurementsDetailsNarrative Financial Instruments Fair Value Measurements (Details Narrative) Details http://pavmed.com/role/FinancialInstrumentsFairValueMeasurementsTables 50 false false R51.htm 995654 - Disclosure - Summary of Outstanding Debt (Details) Sheet http://pavmed.com/role/SummaryOfOutstandingDebtDetails Summary of Outstanding Debt (Details) Details 51 false false R52.htm 995655 - Disclosure - Schedule of Changes in Fair Value of Debt (Details) Sheet http://pavmed.com/role/ScheduleOfChangesInFairValueOfDebtDetails Schedule of Changes in Fair Value of Debt (Details) Details 52 false false R53.htm 995656 - Disclosure - Debt (Details Narrative) Sheet http://pavmed.com/role/DebtDetailsNarrative Debt (Details Narrative) Details http://pavmed.com/role/DebtTables 53 false false R54.htm 995657 - Disclosure - Schedule of Summarizes Information About Stock Options (Details) Sheet http://pavmed.com/role/ScheduleOfSummarizesInformationAboutStockOptionsDetails Schedule of Summarizes Information About Stock Options (Details) Details 54 false false R55.htm 995658 - Disclosure - Schedule of Summarizes Information About Stock Options (Details) (Parenthetical) Sheet http://pavmed.com/role/ScheduleOfSummarizesInformationAboutStockOptionsDetailsParenthetical Schedule of Summarizes Information About Stock Options (Details) (Parenthetical) Details 55 false false R56.htm 995659 - Disclosure - Schedule of Restricted Stock Award Activity (Details) Sheet http://pavmed.com/role/ScheduleOfRestrictedStockAwardActivityDetails Schedule of Restricted Stock Award Activity (Details) Details 56 false false R57.htm 995660 - Disclosure - Schedule of Stock-Based Compensation Expense (Details) Sheet http://pavmed.com/role/ScheduleOfStock-basedCompensationExpenseDetails Schedule of Stock-Based Compensation Expense (Details) Details 57 false false R58.htm 995661 - Disclosure - Schedule of Stock-Based Compensation Expense Recognized by Lucid Diagnostics (Details) Sheet http://pavmed.com/role/ScheduleOfStock-basedCompensationExpenseRecognizedByLucidDiagnosticsDetails Schedule of Stock-Based Compensation Expense Recognized by Lucid Diagnostics (Details) Details 58 false false R59.htm 995662 - Disclosure - Schedule of Unrecognized Compensation Expense (Details) Sheet http://pavmed.com/role/ScheduleOfUnrecognizedCompensationExpenseDetails Schedule of Unrecognized Compensation Expense (Details) Details 59 false false R60.htm 995663 - Disclosure - Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions (Details) Sheet http://pavmed.com/role/ScheduleOfFairValuesOfStockOptionsGrantedUsingBlack-scholesValuationModelAssumptionsDetails Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions (Details) Details 60 false false R61.htm 995664 - Disclosure - Stock-Based Compensation (Details Narrative) Sheet http://pavmed.com/role/Stock-basedCompensationDetailsNarrative Stock-Based Compensation (Details Narrative) Details http://pavmed.com/role/Stock-basedCompensationTables 61 false false R62.htm 995665 - Disclosure - Preferred Stock (Details Narrative) Sheet http://pavmed.com/role/PreferredStockDetailsNarrative Preferred Stock (Details Narrative) Details http://pavmed.com/role/PreferredStock 62 false false R63.htm 995666 - Disclosure - Common Stock and Common Stock Purchase Warrants (Details Narrative) Sheet http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative Common Stock and Common Stock Purchase Warrants (Details Narrative) Details http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrants 63 false false R64.htm 995667 - Disclosure - Schedule of Noncontrolling Interest of Stockholders' Equity (Details) Sheet http://pavmed.com/role/ScheduleOfNoncontrollingInterestOfStockholdersEquityDetails Schedule of Noncontrolling Interest of Stockholders' Equity (Details) Details 64 false false R65.htm 995668 - Disclosure - Schedule of Net Loss Attributable to Common Stockholders (Details) Sheet http://pavmed.com/role/ScheduleOfNetLossAttributableToCommonStockholdersDetails Schedule of Net Loss Attributable to Common Stockholders (Details) Details 65 false false R66.htm 995669 - Disclosure - Schedule of Net Loss Attributable to Common Stockholders (Details) (Parenthetical) Sheet

http://pavmed.com/role/ScheduleOfNetLossAttributableToCommonStockholdersDetailsParenthetical Schedule of Net Loss Attributable to Common Stockholders (Details) (Parenthetical) Details 66 false false R67.htm 995670 - Disclosure - Noncontrolling Interest (Details Narrative) Sheet http://pavmed.com/role/NoncontrollingInterestDetailsNarrative Noncontrolling Interest (Details Narrative) Details http://pavmed.com/role/NoncontrollingInterestTables 67 false false R68.htm 995671 - Disclosure - Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share (Details) Sheet http://pavmed.com/role/ScheduleOfComparisonOfBasicAndFullyDilutedNetLossPerShareDetails Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share (Details) Details 68 false false R69.htm 995672 - Disclosure - Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share (Details) Sheet http://pavmed.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedEarningsPerShareDetails Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share (Details) Details 69 false false R70.htm 995673 - Disclosure - Net Income (Loss) Per Share (Details Narrative) Sheet http://pavmed.com/role/NetIncomeLossPerShareDetailsNarrative Net Income (Loss) Per Share (Details Narrative) Details http://pavmed.com/role/NetIncomeLossPerShareTables 70 false false All Reports Book All Reports form10-q.htm pavm-20240930.xsd pavm-20240930_cal.xml pavm-20240930_def.xml pavm-20240930_lab.xml pavm-20240930_pre.xml http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 89 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form10-q.htm": { "nsprefix": "PAVM", "nsuri": "http://pavmed.com/20240930", "dts": { "inline": { "local": ["form10-q.htm"] }, "schema": { "local": ["pavm-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["pavm-20240930_cal.xml"] }, "definitionLink": { "local": ["pavm-20240930_def.xml"] }, "labelLink": { "local": ["pavm-20240930_lab.xml"] }, "presentationLink": { "local": ["pavm-20240930_pre.xml"] } }, "keyStandard": 278, "keyCustom": 83, "axisStandard": 24, "axisCustom": 0, "memberStandard": 31, "memberCustom": 37, "hidden": { "total": 384, "http://fasb.org/us-gaap/2024": 241, "http://pavmed.com/20240930": 139, "http://xbrl.sec.gov/dei/2024": 4 }, "contextCount": 372, "entityCount": 1, "segmentCount": 74, "elementCount": 639, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 1254, "http://xbrl.sec.gov/dei/2024": 35, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://pavmed.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "b", "span", "p", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "b", "span", "p", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R2": { "role": "http://pavmed.com/role/BalanceSheets", "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R3": { "role": "http://pavmed.com/role/BalanceSheetsParenthetical", "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R4": { "role": "http://pavmed.com/role/StatementsOfOperations", "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:SellingAndMarketingExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R5": { "role": "http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit", "longName": "00000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Equity (Deficit) (Unaudited)", "shortName": "Condensed Consolidated Statement of Changes in Stockholders' Equity (Deficit) (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember", "name": "us-gaap:StockIssuedDuringPeriodValueStockDividend", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R6": { "role": "http://pavmed.com/role/StatementsOfCashFlows", "longName": "00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:ProfitLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R7": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "span", "span", "p", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "span", "span", "p", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R9": { "role": "http://pavmed.com/role/Company", "longName": "995612 - Disclosure - The Company", "shortName": "The Company", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R10": { "role": "http://pavmed.com/role/LiquidityAndGoingConcern", "longName": "995613 - Disclosure - Liquidity and Going Concern", "shortName": "Liquidity and Going Concern", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R11": { "role": "http://pavmed.com/role/SummaryOfSignificantAccountingPolicies", "longName": "995614 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R12": { "role": "http://pavmed.com/role/EquityMethodInvestment", "longName": "995615 - Disclosure - Equity Method Investment", "shortName": "Equity Method Investment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R13": { "role": "http://pavmed.com/role/RevenueFromContractsWithCustomers", "longName": "995616 - Disclosure - Revenue from Contracts with Customers", "shortName": "Revenue from Contracts with Customers", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R14": { "role": "http://pavmed.com/role/PrepaidExpensesDepositsAndOtherCurrentAssets", "longName": "995617 - Disclosure - Prepaid Expenses, Deposits, and Other Current Assets", "shortName": "Prepaid Expenses, Deposits, and Other Current Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "PAVM:PrepaidExpensesDepositsAndOtherAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "PAVM:PrepaidExpensesDepositsAndOtherAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R15": { "role": "http://pavmed.com/role/Leases", "longName": "995618 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R16": { "role": "http://pavmed.com/role/IntangibleAssetsNet", "longName": "995619 - Disclosure - Intangible Assets, net", "shortName": "Intangible Assets, net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R17": { "role": "http://pavmed.com/role/CommitmentAndContingencies", "longName": "995620 - Disclosure - Commitment and Contingencies", "shortName": "Commitment and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang":

"en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R18": { "role": "http://pavmed.com/role/FinancialInstrumentsFairValueMeasurements", "longName": "995621 - Disclosure - Financial Instruments Fair Value Measurements", "shortName": "Financial Instruments Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R19": { "role": "http://pavmed.com/role/Debt", "longName": "995622 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R20": { "role": "http://pavmed.com/role/Stock-basedCompensation", "longName": "995623 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R21": { "role": "http://pavmed.com/role/PreferredStock", "longName": "995624 - Disclosure - Preferred Stock", "shortName": "Preferred Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:PreferredStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:PreferredStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R22": { "role": "http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrants", "longName": "995625 - Disclosure - Common Stock and Common Stock Purchase Warrants", "shortName": "Common Stock and Common Stock Purchase Warrants", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R23": { "role": "http://pavmed.com/role/NoncontrollingInterest", "longName": "995626 - Disclosure - Noncontrolling Interest", "shortName": "Noncontrolling Interest", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R24": { "role": "http://pavmed.com/role/NetIncomeLossPerShare", "longName": "995627 - Disclosure - Net Income (Loss) Per Share", "shortName": "Net Income (Loss) Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R25": { "role": "http://pavmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "longName": "995628 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "25", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R26": { "role": "http://pavmed.com/role/EquityMethodInvestmentTables", "longName": "995629 - Disclosure - Equity Method Investment (Tables)", "shortName": "Equity Method Investment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "PAVM:ScheduleOfDeconsolidationOfNetAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "PAVM:ScheduleOfDeconsolidationOfNetAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R27": { "role": "http://pavmed.com/role/PrepaidExpensesDepositsAndOtherCurrentAssetsTables", "longName": "995630 - Disclosure - Prepaid Expenses, Deposits, and Other Current Assets (Tables)", "shortName": "Prepaid Expenses, Deposits, and Other Current Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["PAVM:PrepaidExpensesDepositsAndOtherAssetsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["PAVM:PrepaidExpensesDepositsAndOtherAssetsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R28": { "role": "http://pavmed.com/role/LeasesTables", "longName": "995631 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:LesseeOperatingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:LesseeOperatingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R29": { "role": "http://pavmed.com/role/IntangibleAssetsNetTables", "longName": "995632 - Disclosure - Intangible Assets, net (Tables)", "shortName": "Intangible Assets, net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R30": { "role": "http://pavmed.com/role/FinancialInstrumentsFairValueMeasurementsTables", "longName": "995633 - Disclosure - Financial Instruments Fair Value Measurements (Tables)", "shortName": "Financial Instruments Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R31": { "role": "http://pavmed.com/role/DebtTables", "longName": "995634 - Disclosure - Debt (Tables)", "shortName": "Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R32": { "role": "http://pavmed.com/role/Stock-basedCompensationTables", "longName": "995635 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R33": { "role": "http://pavmed.com/role/NoncontrollingInterestTables", "longName": "995636 - Disclosure - Noncontrolling Interest (Tables)", "shortName": "Noncontrolling Interest (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "PAVM:ScheduleOfNoncontrollingInterestOfStockholdersEquityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:MinorityInterestDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "PAVM:ScheduleOfNoncontrollingInterestOfStockholdersEquityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:MinorityInterestDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R34": { "role": "http://pavmed.com/role/NetIncomeLossPerShareTables", "longName": "995637 - Disclosure - Net Income (Loss) Per Share (Tables)", "shortName": "Net Income (Loss) Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R35": { "role": "http://pavmed.com/role/LiquidityAndGoingConcernDetailsNarrative", "longName": "995638 - Disclosure - Liquidity and Going Concern (Details Narrative)", "shortName": "Liquidity and Going Concern (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R36": { "role": "http://pavmed.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "longName": "995639 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "AsOf2024-09-30_custom_LucidDiagnosticsIncMember_srt_MinimumMember", "name": "us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p",

"us-gaap:EquityMethodInvestmentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30_custom_LucidDiagnosticsIncMember_srt_MinimumMember", "name": "us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p", "us-gaap:EquityMethodInvestmentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R37": { "role": "http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails", "longName": "995640 - Disclosure - Schedule of Deconsolidation of Net Assets (Details)", "shortName": "Schedule of Deconsolidation of Net Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-10_custom_LucidDiagnosticsIncMember", "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "PAVM:ScheduleOfDeconsolidationOfNetAssetsTableTextBlock", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R38": { "role": "http://pavmed.com/role/ScheduleOfGainOnDeconsolidationDetails", "longName": "995641 - Disclosure - Schedule of Gain on Deconsolidation (Details)", "shortName": "Schedule of Gain on Deconsolidation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "PAVM:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteDeconsolidationOfLucid", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "PAVM:ScheduleOfNoncontrollingInterestOfStockholdersEquityTableTextBlock", "us-gaap:MinorityInterestDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-09-30_custom_LucidDiagnosticsIncMember", "name": "us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "PAVM:EquityMethodInvestmentsGainDeconsolidationTableTextBlock", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R39": { "role": "http://pavmed.com/role/ScheduleOfAggregateInformationFromFinancialStatementsDetails", "longName": "995642 - Disclosure - Schedule of Aggregate Information From the Financial Statements (Details)", "shortName": "Schedule of Aggregate Information From the Financial Statements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-07-012024-09-30_custom_LucidDiagnosticsIncMember", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "PAVM:EquityMethodInvestmentsAggregateInformationTableTextBlock", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R40": { "role": "http://pavmed.com/role/EquityMethodInvestmentDetailsNarrative", "longName": "995643 - Disclosure - Equity Method Investment (Details Narrative)", "shortName": "Equity Method Investment (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-09-272024-09-27_us-gaap_IntellectualPropertyMember", "name": "us-gaap:PaymentsForFees", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "span", "p", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R41": { "role": "http://pavmed.com/role/RevenueFromContractsWithCustomersDetailsNarrative", "longName": "995644 - Disclosure - Revenue from Contracts with Customers (Details Narrative)", "shortName": "Revenue from Contracts with Customers (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": null }, "R42": { "role": "http://pavmed.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails", "longName": "995645 - Disclosure - Schedule of Prepaid Expenses and Other Current Assets (Details)", "shortName": "Schedule of Prepaid Expenses and Other Current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "PAVM:PrepaidServiceProvidersAndSuppliers", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "PAVM:PrepaidExpensesDepositsAndOtherAssetsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "PAVM:PrepaidServiceProvidersAndSuppliers", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "PAVM:PrepaidExpensesDepositsAndOtherAssetsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R43": { "role": "http://pavmed.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeasesDetails", "longName": "995646 - Disclosure - Schedule of Future Minimum Lease Payments for Operating Leases (Details)", "shortName": "Schedule of Future Minimum Lease Payments for Operating Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R44": { "role": "http://pavmed.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToCashAndNon-cashActivitiesWithLeasesDetails", "longName": "995647 - Disclosure - Schedule of Supplemental Balance Sheet Information Related to Cash and Non-cash Activities with Leases (Details)", "shortName": "Schedule of Supplemental Balance Sheet Information Related to Cash and Non-cash Activities with Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:OperatingLeasePayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "PAVM:SupplementalBalanceSheetInformationRelatedToCashandNonCashActivitieswithLeaseTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:OperatingLeasePayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "PAVM:SupplementalBalanceSheetInformationRelatedToCashandNonCashActivitieswithLeaseTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R45": { "role": "http://pavmed.com/role/LeasesDetailsNarrative", "longName": "995648 - Disclosure - Leases (Details Narrative)", "shortName": "Leases (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": null }, "R46": { "role": "http://pavmed.com/role/ScheduleOfIntangibleAssetsLessAccumulatedAmortizationDetails", "longName": "995649 - Disclosure - Schedule of Intangible Assets, Less Accumulated Amortization (Details)", "shortName": "Schedule of Intangible Assets, Less Accumulated Amortization (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R47": { "role": "http://pavmed.com/role/IntangibleAssetsNetDetailsNarrative", "longName": "995650 - Disclosure - Intangible Assets, net (Details Narrative)", "shortName": "Intangible Assets, net (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": null }, "R48": { "role": "http://pavmed.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "longName": "995651 - Disclosure - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "shortName": "Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R49": { "role": "http://pavmed.com/role/ScheduleOfFairValueAssumptionUsedDetails", "longName": "995652 - Disclosure - Schedule of Fair Value Assumption Used (Details)", "shortName": "Schedule of Fair Value Assumption Used (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:DebtInstrumentFairValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30_custom_MeasurementInputRequiredRateOfReturnMember_custom_AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember", "name": "us-gaap:DebtInstrumentMeasurementInput", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R50": { "role": "http://pavmed.com/role/FinancialInstrumentsFairValueMeasurementsDetailsNarrative", "longName": "995653 - Disclosure - Financial Instruments Fair Value Measurements (Details Narrative)", "shortName": "Financial Instruments Fair Value Measurements (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": null }, "R51": { "role": "http://pavmed.com/role/SummaryOfOutstandingDebtDetails", "longName": "995654 - Disclosure - Summary of Outstanding Debt (Details)", "shortName": "Summary of Outstanding Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": null }, "R52": { "role": "http://pavmed.com/role/ScheduleOfChangesInFairValueOfDebtDetails", "longName": "995655 - Disclosure - Schedule of Changes in Fair Value of Debt (Details)", "shortName": "Schedule of Changes in Fair Value of Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R53": { "role": "http://pavmed.com/role/DebtDetailsNarrative", "longName": "995656 - Disclosure - Debt (Details Narrative)", "shortName": "Debt (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2022-04-022022-04-04_custom_AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember", "name": "us-

gaap:DebtInstrumentMaturityDateDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R54": { "role": "http://pavmed.com/role/ScheduleOfSummarizesInformationAboutStockOptionsDetails", "longName": "995657 - Disclosure - Schedule of Summarizes Information About Stock Options (Details)", "shortName": "Schedule of Summarizes Information About Stock Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-09-30_custom_TwoThousandAndFourteenEquityPlanMember", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R55": { "role": "http://pavmed.com/role/ScheduleOfSummarizesInformationAboutStockOptionsDetailsParenthetical", "longName": "995658 - Disclosure - Schedule of Summarizes Information About Stock Options (Details) (Parenthetical)", "shortName": "Schedule of Summarizes Information About Stock Options (Details) (Parenthetical)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "From2024-09-102024-09-10_custom_LucidDiagnosticsIncMember_custom_TwoThousandEighteenEquityPlanMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "link:footnote", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-09-102024-09-10_custom_LucidDiagnosticsIncMember_custom_TwoThousandEighteenEquityPlanMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "link:footnote", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R56": { "role": "http://pavmed.com/role/ScheduleOfRestrictedStockAwardActivityDetails", "longName": "995659 - Disclosure - Schedule of Restricted Stock Award Activity (Details)", "shortName": "Schedule of Restricted Stock Award Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_TwoThousandAndFourteenEquityPlanMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_TwoThousandAndFourteenEquityPlanMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R57": { "role": "http://pavmed.com/role/ScheduleOfStock-basedCompensationExpenseDetails", "longName": "995660 - Disclosure - Schedule of Stock-Based Compensation Expense (Details)", "shortName": "Schedule of Stock-Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": null }, "R58": { "role": "http://pavmed.com/role/ScheduleOfStock-basedCompensationExpenseRecognizedByLucidDiagnosticsDetails", "longName": "995661 - Disclosure - Schedule of Stock-Based Compensation Expense Recognized by Lucid Diagnostics (Details)", "shortName": "Schedule of Stock-Based Compensation Expense Recognized by Lucid Diagnostics (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-07-012024-09-30_custom_LucidDiagnosticsIncMember4931328", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "PAVM:ScheduleOfStockbasedCompensationExpenseRecognizedTableTextBlock", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R59": { "role": "http://pavmed.com/role/ScheduleOfUnrecognizedCompensationExpenseDetails", "longName": "995662 - Disclosure - Schedule of Unrecognized Compensation Expense (Details)", "shortName": "Schedule of Unrecognized Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "AsOf2024-09-30_us-gaap_StockOptionMember_custom_PAVmedIncTwoThousandFourteenEquityPlanMember", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30_us-gaap_StockOptionMember_custom_PAVmedIncTwoThousandFourteenEquityPlanMember", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R60": { "role": "http://pavmed.com/role/ScheduleOfFairValuesOfStockOptionsGrantedUsingBlack-scholesValuationModelAssumptionsDetails", "longName": "995663 - Disclosure - Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions (Details)", "shortName": "Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "From2024-01-012024-09-30_custom_TwoThousandAndFourteenEquityPlanMember", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-09-30_custom_TwoThousandAndFourteenEquityPlanMember", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R61": { "role": "http://pavmed.com/role/Stock-basedCompensationDetailsNarrative", "longName": "995664 - Disclosure - Stock-Based Compensation (Details Narrative)", "shortName": "Stock-Based Compensation (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30_custom_EmployeeStockPurchasePlanMember", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R62": { "role": "http://pavmed.com/role/PreferredStockDetailsNarrative", "longName": "995665 - Disclosure - Preferred Stock (Details Narrative)", "shortName": "Preferred Stock (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-07-012024-09-30_custom_SeriesBConvertiblePreferredStockMember", "name": "us-gaap:PreferredStockDividendsIncomeStatementImpact", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "span", "p", "us-gaap:PreferredStockTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R63": { "role": "http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative", "longName": "995666 - Disclosure - Common Stock and Common Stock Purchase Warrants (Details Narrative)", "shortName": "Common Stock and Common Stock Purchase Warrants (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "From2023-11-282023-11-28", "name": "us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-11-282023-11-28", "name": "us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R64": { "role": "http://pavmed.com/role/ScheduleOfNoncontrollingInterestOfStockholdersEquityDetails", "longName": "995667 - Disclosure - Schedule of Noncontrolling Interest of Stockholders' Equity (Details)", "shortName": "Schedule of Noncontrolling Interest of Stockholders' Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:MinorityInterest", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "PAVM:ImpactOfSubsidiaryEquityTransactions", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "PAVM:ScheduleOfNoncontrollingInterestOfStockholdersEquityTableTextBlock", "us-gaap:MinorityInterestDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R65": { "role": "http://pavmed.com/role/ScheduleOfNetLossAttributableToCommonStockholdersDetails", "longName": "995668 - Disclosure - Schedule of Net Loss Attributable to Common Stockholders (Details)", "shortName": "Schedule of Net Loss Attributable to Common Stockholders (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "From2024-03-132024-03-13", "name": "PAVM:FairValueOfSeriesBPreferredStockIssued", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "PAVM:ScheduleOfNetLossAttributableToCommonStockholdersTableTextBlock", "us-gaap:MinorityInterestDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-03-132024-03-13", "name": "PAVM:FairValueOfSeriesBPreferredStockIssued", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "PAVM:ScheduleOfNetLossAttributableToCommonStockholdersTableTextBlock", "us-gaap:MinorityInterestDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R66": { "role": "http://pavmed.com/role/ScheduleOfNetLossAttributableToCommonStockholdersDetailsParenthetical", "longName": "995669 - Disclosure - Schedule of Net Loss Attributable to Common Stockholders (Details) (Parenthetical)", "shortName": "Schedule of Net Loss Attributable to Common Stockholders (Details) (Parenthetical)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "From2024-03-132024-03-13", "name": "PAVM:FairValueOfSeriesBPreferredStockIssuedShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "PAVM:ScheduleOfNetLossAttributableToCommonStockholdersTableTextBlock", "us-gaap:MinorityInterestDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-03-132024-03-13", "name": "PAVM:FairValueOfSeriesBPreferredStockIssuedShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "PAVM:ScheduleOfNetLossAttributableToCommonStockholdersTableTextBlock", "us-gaap:MinorityInterestDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R67": { "role": "http://pavmed.com/role/NoncontrollingInterestDetailsNarrative", "longName": "995670 - Disclosure - Noncontrolling Interest (Details Narrative)", "shortName": "Noncontrolling Interest (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": {

"contextRef": "AsOf2024-09-30", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-03-052023-03-07_custom_SeriesAConvertiblePreferredStockMember", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p", "us-gaap:MinorityInterestDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } } }, "R68": { "role": "http://pavmed.com/role/ScheduleOfComparisonOfBasicAndFullyDilutedNetLossPerShareDetails", "longName": "995671 - Disclosure - Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share (Details)", "shortName": "Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:ProfitLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "PAVM:PreferredStockDividendsSeriesB", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R69": { "role": "http://pavmed.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedEarningsPerShareDetails", "longName": "995672 - Disclosure - Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share (Details)", "shortName": "Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R70": { "role": "http://pavmed.com/role/NetIncomeLossPerShareDetailsNarrative", "longName": "995673 - Disclosure - Net Income (Loss) Per Share (Details Narrative)", "shortName": "Net Income (Loss) Per Share (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "From2024-01-012024-09-30_custom_TwoThousandAndFourteenEquityPlanMember", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-09-30_custom_TwoThousandAndFourteenEquityPlanMember", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://pavmed.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://pavmed.com/role/BalanceSheets", "http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails"], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r71", "r678"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://pavmed.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://pavmed.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts receivable", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r809"] }, "PAVM_AccreditedInstitutionalInvestorMember": { "xbrltype": "domainItemType", "nsuri": "http://pavmed.com/20240930", "localname": "AccreditedInstitutionalInvestorMember", "presentation": ["http://pavmed.com/role/DebtDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Accredited Institutional Investor [Member]", "documentation": "Accredited Institutional Investor [Member]" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://pavmed.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://pavmed.com/role/BalanceSheets", "http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails"], "lang": { "en-us": { "role": { "label": "Accrued expenses and other current liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r73"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": ["http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r168", "r169", "r441", "r442", "r443", "r444", "r445", "r446"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": ["http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r168", "r169", "r441", "r442", "r443", "r444", "r445", "r446"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r740"] }, "PAVM_AdditionalIssuanceMember": { "xbrltype": "domainItemType", "nsuri": "http://pavmed.com/20240930", "localname": "AdditionalIssuanceMember", "presentation": ["http://pavmed.com/role/DebtDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Additional Issuance [Member]", "documentation": "Additional Issuance [Member]" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://pavmed.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://pavmed.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r84", "r678", "r900"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r518", "r797", "r798", "r799", "r800", "r864", "r902"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r746"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": ["r746"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r746"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r746"] }, "PAVM_AdjustmentToAdditionalPaidInCapitalIssueCommonStockOfSubsidiary": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "AdjustmentToAdditionalPaidInCapitalIssueCommonStockOfSubsidiary", "crdr": "credit", "presentation": ["http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Exercise - stock options of subsidiary", "documentation": "Exercise - stock options of subsidiary." } } }, "auth_ref": [] }, "PAVM_AdjustmentsToAdditionalPaidInCapitalDeconsolidationOfSubsidiary": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "AdjustmentsToAdditionalPaidInCapitalDeconsolidationOfSubsidiary", "crdr": "credit", "presentation": ["http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Deconsolidation of subsidiary", "documentation": "Adjustments to additional paid in capital deconsolidation of subsidiary." } } }, "auth_ref": [] }, "PAVM_AdjustmentsToAdditionalPaidInCapitalMinorityInterestRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "AdjustmentsToAdditionalPaidInCapitalMinorityInterestRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://pavmed.com/role/ScheduleOfNoncontrollingInterestOfStockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Lucid Diagnostics 2018 Equity Plan stock option exercise", "documentation": "Minority interest equity plan stock option exercise." } } }, "auth_ref": [] }, "PAVM_AdjustmentsToAdditionalPaidInCapitalMinorityInterestRequisiteServicePeriodRecognitionValueFour": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "AdjustmentsToAdditionalPaidInCapitalMinorityInterestRequisiteServicePeriodRecognitionValueFour", "crdr": "credit", "presentation": ["http://pavmed.com/role/ScheduleOfNoncontrollingInterestOfStockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Lucid Diagnostics Employee Stock Purchase Plan Purchase", "documentation": "Adjustments to additional paid in capital minority interest requisite service period recognition value four." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": ["http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Stock-based compensation - PAVmed Inc.", "documentation": "Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement." } } }, "auth_ref": [] }, "PAVM_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationSubsidiary": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationSubsidiary", "crdr": "credit", "presentation": ["http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Stock-based compensation - subsidiary", "documentation": "Adjustments to additional paid in capital share based compensation subsidiary." } } }, "auth_ref": [] }, "PAVM_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteDeconsolidationOfLucid": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteDeconsolidationOfLucid", "crdr": "credit", "presentation": ["http://pavmed.com/role/ScheduleOfGainOnDeconsolidationDetails", "http://pavmed.com/role/ScheduleOfNoncontrollingInterestOfStockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Add: Noncontrolling interest - Lucid", "verboseLabel": "Deconsolidation of Lucid", "documentation": "Adjustments to additional paid in capital sharebased compensation requisite deconsolidation of lucid." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://pavmed.com/role/ScheduleOfNoncontrollingInterestOfStockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Stock-based compensation expense - Lucid Diagnostics 2018 Equity Plan", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r41", "r42", "r355"] }, "PAVM_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValues": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValues", "crdr": "credit", "presentation": ["http://pavmed.com/role/ScheduleOfNoncontrollingInterestOfStockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Stock-based compensation

expense - Veris Health 2021 Equity Plan", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [] }, "PAVM_AdjustmentsToAdditionalPaidInCapitalTransferOfIntellectualProperty": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "AdjustmentsToAdditionalPaidInCapitalTransferOfIntellectualProperty", "crdr": "credit", "presentation": ["http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Transfer of intellectual property to Lucid Diagnostics Inc", "documentation": "transfer of intellectual property." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://pavmed.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income (loss) - before NCI to net cash used in operating activities" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r711", "r722", "r732", "r757"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r714", "r725", "r735", "r760"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "auth_ref": ["r746"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "auth_ref": ["r753"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "auth_ref": ["r715", "r726", "r736", "r753", "r761", "r765", "r773"] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": ["http://pavmed.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://pavmed.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "PAVM_AmortizationOfCommonStockPaymentForVendorServiceAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "AmortizationOfCommonStockPaymentForVendorServiceAgreement", "crdr": "debit", "calculation": { "http://pavmed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": ["http://pavmed.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Amortization of common stock payment for vendor service agreement", "documentation": "Amortization of common stock payment for vendor service agreement." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://pavmed.com/role/StatementsOfOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://pavmed.com/role/IntangibleAssetsNetDetailsNarrative", "http://pavmed.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Amortization of acquired intangible assets", "verboseLabel": "Amortization of intangible assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r7", "r241", "r248", "r652"] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": ["http://pavmed.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": ["r718"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://pavmed.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedEarningsPerShareDetails"], "lang": { "en-us": { "role": { "label": "Total", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r207"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://pavmed.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedEarningsPerShareDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r22"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": ["http://pavmed.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedEarningsPerShareDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://pavmed.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedEarningsPerShareDetails"], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r22"] }, "PAVM_AprilAndSeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://pavmed.com/20240930", "localname": "AprilAndSeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember", "presentation": ["http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative", "http://pavmed.com/role/DebtDetailsNarrative"], "lang": { "en-us": { "role": { "label": "April 2022 Senior Convertible Note and September 2022 Senior Convertible Note [Member]", "documentation": "April 2022 Senior Convertible Note and September 2022 Senior Convertible Note [Member]" } } }, "auth_ref": [] }, "PAVM_AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://pavmed.com/20240930", "localname": "AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember", "presentation": ["http://pavmed.com/role/DebtDetailsNarrative", "http://pavmed.com/role/FinancialInstrumentsFairValueMeasurementsDetailsNarrative", "http://pavmed.com/role/ScheduleOfChangesInFairValueOfDebtDetails", "http://pavmed.com/role/ScheduleOfFairValueAssumptionUsedDetails", "http://pavmed.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://pavmed.com/role/SummaryOfOutstandingDebtDetails"], "lang": { "en-us": { "role": { "label": "April 2022 Senior Convertible Note [Member]", "documentation": "April 2022 Senior Convertible Note [Member]" } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://pavmed.com/role/DebtDetailsNarrative", "http://pavmed.com/role/EquityMethodInvestmentDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r399"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails": { "parentTag": "PAVM_NetAssets", "weight": 1.0, "order": 1.0 }, "http://pavmed.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://pavmed.com/role/BalanceSheets", "http://pavmed.com/role/ScheduleOfAggregateInformationFromFinancialStatementsDetails", "http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r126", "r137", "r158", "r180", "r211", "r215", "r225", "r226", "r234", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r401", "r405", "r440", "r483", "r564", "r648", "r649", "r678", "r692", "r831", "r832", "r886"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://pavmed.com/role/BalanceSheets", "http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails"], "lang": { "en-us": { "role": { "label": "Assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://pavmed.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 }, "http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://pavmed.com/role/BalanceSheets", "http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r153", "r165", "r180", "r234", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r401", "r405", "r440", "r678", "r831", "r832", "r886"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://pavmed.com/role/BalanceSheets", "http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails"], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": ["http://pavmed.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Total assets at fair value", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r418", "r419", "r669"] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrent", "crdr": "debit", "presentation": ["http://pavmed.com/role/ScheduleOfAggregateInformationFromFinancialStatementsDetails"], "lang": { "en-us": { "role": { "label": "Non-current assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": ["r180", "r234", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r401", "r405", "r440", "r831", "r832", "r886"] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": ["http://pavmed.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": ["r718"] }, "us-gaap_AwardDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardDateAxis", "presentation": ["http://pavmed.com/role/DebtDetailsNarrative", "http://pavmed.com/role/ScheduleOfAggregateInformationFromFinancialStatementsDetails"], "lang": { "en-us": { "role": { "label": "Award Date [Axis]", "documentation": "Information by date or year award under share-based payment arrangement is granted." } } }, "auth_ref": ["r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861"] }, "us-gaap_AwardDateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardDateDomain", "presentation": ["http://pavmed.com/role/DebtDetailsNarrative", "http://pavmed.com/role/ScheduleOfAggregateInformationFromFinancialStatementsDetails"], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "auth_ref": ["r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861"] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Exercise Price" } } }, "auth_ref": ["r768"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Fair Value as of Grant Date" } } }, "auth_ref": ["r769"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "auth_ref": ["r764"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r764"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method" } } }, "auth_ref": ["r764"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered" } } }, "auth_ref": ["r764"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI

Disclosure" } } }, "auth_ref": ["r764"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined" } } }, "auth_ref": ["r764"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative", "http://pavmed.com/role/DebtDetailsNarrative", "http://pavmed.com/role/ScheduleOfRestrictedStockAwardActivityDetails", "http://pavmed.com/role/ScheduleOfUnrecognizedCompensationExpenseDetails", "http://pavmed.com/role/Stock-basedCompensationDetailsNarrative", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Securities" } } }, "auth_ref": ["r767"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": ["r766"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": ["r765"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r765"] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://pavmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "srt_BoardOfDirectorsChairmanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "BoardOfDirectorsChairmanMember", "presentation": ["http://pavmed.com/role/EquityMethodInvestmentDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Board of Directors Chairman [Member]" } } }, "auth_ref": ["r808"] }, "PAVM_BoardOfDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://pavmed.com/20240930", "localname": "BoardOfDirectorsMember", "presentation": ["http://pavmed.com/role/PreferredStockDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Board Of Directors [Member]", "documentation": "Board Of Directors [Member]" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": ["http://pavmed.com/role/EquityMethodInvestmentDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": ["r242", "r243", "r244", "r245", "r246", "r396", "r662", "r663"] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": ["http://pavmed.com/role/EquityMethodInvestmentDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": ["r44", "r46", "r242", "r243", "r244", "r245", "r246", "r396", "r662", "r663"] }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "presentation": ["http://pavmed.com/role/EquityMethodInvestmentDetailsNarrative"], "lang": { "en-us": { "role": { "verboseLabel": "The fair value of common price per shares", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination." } } }, "auth_ref": ["r45"] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Cash", "crdr": "debit", "presentation": ["http://pavmed.com/role/LiquidityAndGoingConcernDetailsNarrative"], "lang": { "en-us": { "role": { "verboseLabel": "Cash", "label": "Cash [Default Label]", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r139", "r485", "r529", "r559", "r678", "r692", "r784"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://pavmed.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://pavmed.com/role/BalanceSheets", "http://pavmed.com/role/ScheduleOfAggregateInformationFromFinancialStatementsDetails", "http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails"], "lang": { "en-us": { "role": { "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r18", "r155", "r641"] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAxis", "presentation": ["http://pavmed.com/role/DebtDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": ["r155"] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": ["http://pavmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "verboseLabel": "Cash", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": ["r19"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": ["http://pavmed.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, beginning of period", "periodEndLabel": "Cash, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r18", "r100", "r176"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://pavmed.com/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://pavmed.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r100"] }, "us-gaap_CashMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashMember", "presentation": ["http://pavmed.com/role/DebtDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Cash [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits." } } }, "auth_ref": ["r155"] }, "PAVM_ChangeInFairValueDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "ChangeInFairValueDerivativeLiability", "crdr": "debit", "calculation": { "http://pavmed.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 9.0 } }, "presentation": ["http://pavmed.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "negatedLabel": "Change in fair value - derivative liability", "documentation": "Change in fair value derivative liability.", "label": "ChangeInFairValueDerivativeLiability" } } }, "auth_ref": [] }, "PAVM_ChangeInFairValueSeniorSecuredConvertibleNote": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "ChangeInFairValueSeniorSecuredConvertibleNote", "crdr": "debit", "calculation": { "http://pavmed.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 5.0 }, "http://pavmed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": ["http://pavmed.com/role/StatementsOfCashFlows", "http://pavmed.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "negatedLabel": "Change in fair value - Senior Secured Convertible Notes", "label": "Change in fair value - Senior Secured Convertible Notes", "documentation": "Change in fair value senior secured convertible note." } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r744"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://pavmed.com/role/Cover"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": ["http://pavmed.com/role/BalanceSheetsParenthetical", "http://pavmed.com/role/Cover", "http://pavmed.com/role/NoncontrollingInterestDetailsNarrative", "http://pavmed.com/role/PreferredStockDetailsNarrative", "http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r149", "r160", "r161", "r162", "r180", "r200", "r201", "r204", "r206", "r213", "r214", "r234", "r270", "r272", "r273", "r274", "r277", "r278", "r308", "r309", "r313", "r316", "r323", "r440", "r511", "r512", "r513", "r514", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r530", "r551", "r573", "r592", "r626", "r627", "r628", "r629", "r630", "r781", "r793", "r801"] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": ["http://pavmed.com/role/PreferredStockDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r160", "r161", "r162", "r213", "r308", "r309", "r311", "r313", "r316", "r321", "r323", "r511", "r512", "r513", "r514", "r658", "r781", "r793"] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r38"] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "PAVM_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights": { "xbrltype": "perShareItemType", "nsuri": "http://pavmed.com/20240930", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights", "presentation": ["http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Exercise price, post reverse-split", "documentation": "Class of warrant or right exercise price of warrants or rights." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Exercise price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r324"] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": ["http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount" } } }, "auth_ref": ["r745"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name" } } }, "auth_ref": ["r745"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://pavmed.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://pavmed.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Commitments and contingencies (Note 9)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r80", "r129", "r484", "r550"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://pavmed.com/role/CommitmentAndContingencies"], "lang": { "en-us": { "role": { "label": "Commitment and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r106", "r262", "r263", "r633", "r824", "r829"] }, "PAVM_CommonStock0.001ParValuePerShareMember": { "xbrltype": "domainItemType", "nsuri": "http://pavmed.com/20240930", "localname": "CommonStock0.001ParValuePerShareMember", "presentation": ["http://pavmed.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Common Stock, $0.001 par value per share [Member]", "documentation": "Common Stock, $0.001 par value per share [Member]" } } }, "auth_ref": [] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": ["http://pavmed.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common stock capital shares reserved for future issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": ["r83"] }, "us-gaap_CommonStockDividendsShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockDividendsShares", "presentation": ["http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative", "http://pavmed.com/role/NoncontrollingInterestDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common stock, dividends shares", "documentation": "Number of shares of common stock issued as dividends during the period. Excludes stock splits." } } }, "auth_ref": ["r11"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative", "http://pavmed.com/role/EquityMethodInvestmentDetailsNarrative", "http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r681", "r682", "r683", "r685", "r686", "r687", "r688", "r797", "r798", "r800", "r864", "r898", "r902"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://pavmed.com/role/BalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r83"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://pavmed.com/role/BalanceSheetsParenthetical", "http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r83", "r551"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://pavmed.com/role/NoncontrollingInterestDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common stock shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r83"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://pavmed.com/role/BalanceSheetsParenthetical", "http://pavmed.com/role/NoncontrollingInterestDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "verboseLabel": "Common stock shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r11", "r83", "r551", "r570", "r902", "r903"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://pavmed.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://pavmed.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Common stock, $0.001 par value, Authorized, 50,000,000 shares; 10,660,394 and 8,578,505 shares outstanding as of September 30, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r83", "r487", "r678"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r750"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r749"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r751"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r748"] }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "presentation": ["http://pavmed.com/role/Stock-basedCompensation"], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation", "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans." } } }, "auth_ref": ["r115", "r116", "r117", "r118"] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": [] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesAxis", "presentation": ["http://pavmed.com/role/EquityMethodInvestmentDetailsNarrative", "http://pavmed.com/role/ScheduleOfAggregateInformationFromFinancialStatementsDetails", "http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails", "http://pavmed.com/role/ScheduleOfGainOnDeconsolidationDetails", "http://pavmed.com/role/ScheduleOfSummarizesInformationAboutStockOptionsDetailsParenthetical", "http://pavmed.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]" } } }, "auth_ref": ["r181", "r401", "r402", "r405", "r406", "r465", "r634", "r830", "r833", "r834"] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesDomain", "presentation": ["http://pavmed.com/role/EquityMethodInvestmentDetailsNarrative", "http://pavmed.com/role/ScheduleOfAggregateInformationFromFinancialStatementsDetails", "http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails", "http://pavmed.com/role/ScheduleOfGainOnDeconsolidationDetails", "http://pavmed.com/role/ScheduleOfSummarizesInformationAboutStockOptionsDetailsParenthetical", "http://pavmed.com/role/Stock-basedCompensationDetailsNarrative"], "auth_ref": ["r181", "r401", "r402", "r405", "r406", "r465", "r634", "r830", "r833", "r834"] }, "PAVM_ConvertibleCommonStockSharesIssuedUponConversion": { "xbrltype": "sharesItemType", "nsuri": "http://pavmed.com/20240930", "localname": "ConvertibleCommonStockSharesIssuedUponConversion", "presentation": ["http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Convertible common stock shares issued upon conversion", "documentation": "Convertible common stock shares issued upon conversion." } } }, "auth_ref": [] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://pavmed.com/role/StatementsOfOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://pavmed.com/role/RevenueFromContractsWithCustomersDetailsNarrative", "http://pavmed.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Cost of revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": ["r91", "r180", "r234", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r440", "r648", "r831"] }, "PAVM_CostOfRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://pavmed.com/20240930", "localname": "CostOfRevenueMember", "presentation": ["http://pavmed.com/role/ScheduleOfStock-basedCompensationExpenseDetails", "http://pavmed.com/role/ScheduleOfStock-basedCompensationExpenseRecognizedByLucidDiagnosticsDetails"], "lang": { "en-us": { "role": { "label": "Cost Of Revenue [Member]", "documentation": "Cost Of Revenue [Member]" } } }, "auth_ref": [] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://pavmed.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://pavmed.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": ["r96"] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpensesAbstract", "presentation": ["http://pavmed.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": ["http://pavmed.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://pavmed.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionConvertedInstrumentSharesIssued1", "presentation": ["http://pavmed.com/role/DebtDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Senior convertible note", "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period." } } }, "auth_ref": ["r20", "r21"] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": ["http://pavmed.com/role/Debt"], "lang": { "en-us": { "role": { "label": "Debt", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": ["r107", "r178", "r255", "r256", "r257", "r258", "r259", "r268", "r269", "r279", "r285", "r286", "r287", "r288", "r289", "r290", "r295", "r302", "r303", "r304", "r449"] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",

"localname": "DebtInstrumentAxis", "presentation": ["http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative", "http://pavmed.com/role/DebtDetailsNarrative", "http://pavmed.com/role/FinancialInstrumentsFairValueMeasurementsDetailsNarrative", "http://pavmed.com/role/ScheduleOfChangesInFairValueOfDebtDetails", "http://pavmed.com/role/ScheduleOfFairValueAssumptionUsedDetails", "http://pavmed.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://pavmed.com/role/SummaryOfOutstandingDebtDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r16", "r72", "r73", "r127", "r128", "r181", "r280", "r281", "r282", "r283", "r284", "r286", "r291", "r292", "r293", "r294", "r296", "r297", "r298", "r299", "r300", "r301", "r653", "r654", "r655", "r656", "r657", "r676", "r794", "r825", "r826", "r827", "r880", "r881"] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": ["http://pavmed.com/role/ScheduleOfChangesInFairValueOfDebtDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Fair Value - Beginning of Period", "periodEndLabel": "Fair Value - Ending of Period", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": ["r16", "r128", "r305"] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": ["http://pavmed.com/role/DebtDetailsNarrative", "http://pavmed.com/role/NoncontrollingInterestDetailsNarrative", "http://pavmed.com/role/SummaryOfOutstandingDebtDetails"], "lang": { "en-us": { "role": { "label": "Conversion Price", "verboseLabel": "Conversion price", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": ["r108", "r282"] }, "us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal", "crdr": "credit", "presentation": ["http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, If-converted Value in Excess of Principal", "documentation": "The amount by which the convertible debt's if-converted value exceeds its principle amount at the balance sheet date, regardless of whether the instrument is currently convertible. This element applies to public companies only." } } }, "auth_ref": ["r26"] }, "PAVM_DebtInstrumentConvertibleStockPrice": { "xbrltype": "perShareItemType", "nsuri": "http://pavmed.com/20240930", "localname": "DebtInstrumentConvertibleStockPrice", "presentation": ["http://pavmed.com/role/DebtDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Conversion price per share", "documentation": "Debt instrument onversion price per share." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentDescription", "presentation": ["http://pavmed.com/role/DebtDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Debt instrument, description", "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total." } } }, "auth_ref": ["r16", "r31", "r68", "r72", "r127", "r128", "r449"] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": ["http://pavmed.com/role/DebtDetailsNarrative", "http://pavmed.com/role/FinancialInstrumentsFairValueMeasurementsDetailsNarrative", "http://pavmed.com/role/ScheduleOfFairValueAssumptionUsedDetails", "http://pavmed.com/role/SummaryOfOutstandingDebtDetails"], "lang": { "en-us": { "role": { "label": "Face value principal payable", "verboseLabel": "Face Value Principal Outstanding", "terseLabel": "Principal amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": ["r280", "r449", "r450", "r654", "r655", "r676"] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": ["http://pavmed.com/role/ScheduleOfFairValueAssumptionUsedDetails", "http://pavmed.com/role/SummaryOfOutstandingDebtDetails"], "lang": { "en-us": { "role": { "label": "Debt instrument fair value", "verboseLabel": "Fair Value", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": ["r293", "r439", "r654", "r655", "r866", "r867", "r868", "r869", "r876"] }, "us-gaap_DebtInstrumentFee": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFee", "presentation": ["http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Debt instrument fee description", "documentation": "Description of a fee associated with the debt instrument, including a commitment fee on unborrowed portions of a lender's total contractual commitment." } } }, "auth_ref": ["r77"] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": ["http://pavmed.com/role/DebtDetailsNarrative", "http://pavmed.com/role/SummaryOfOutstandingDebtDetails"], "lang": { "en-us": { "role": { "label": "Stated Interest Rate", "verboseLabel": "Debt interest rate", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": ["r75", "r281"] }, "us-gaap_DebtInstrumentIssuedPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentIssuedPrincipal", "crdr": "credit", "presentation": ["http://pavmed.com/role/ScheduleOfChangesInFairValueOfDebtDetails"], "lang": { "en-us": { "role": { "label": "Face value principal \u2013 issue date", "documentation": "Amount of principal of debt issued." } } }, "auth_ref": ["r511"] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentMaturityDate", "presentation": ["http://pavmed.com/role/DebtDetailsNarrative", "http://pavmed.com/role/SummaryOfOutstandingDebtDetails"], "lang": { "en-us": { "role": { "label": "Maturity Date", "verboseLabel": "Debt instrument maturity date, description", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": ["r159", "r653", "r868", "r869"] }, "us-gaap_DebtInstrumentMaturityDateDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentMaturityDateDescription", "presentation": ["http://pavmed.com/role/DebtDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Debt instrument maturity date, description", "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities." } } }, "auth_ref": ["r76"] }, "us-gaap_DebtInstrumentMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentMeasurementInput", "presentation": ["http://pavmed.com/role/ScheduleOfFairValueAssumptionUsedDetails"], "lang": { "en-us": { "role": { "label": "Fair value assumption measurement input", "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt." } } }, "auth_ref": ["r867", "r868", "r869"] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": ["http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative", "http://pavmed.com/role/DebtDetailsNarrative", "http://pavmed.com/role/FinancialInstrumentsFairValueMeasurementsDetailsNarrative", "http://pavmed.com/role/ScheduleOfChangesInFairValueOfDebtDetails", "http://pavmed.com/role/ScheduleOfFairValueAssumptionUsedDetails", "http://pavmed.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://pavmed.com/role/SummaryOfOutstandingDebtDetails"], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r16", "r181", "r280", "r281", "r282", "r283", "r284", "r286", "r291", "r292", "r293", "r294", "r296", "r297", "r298", "r299", "r300", "r301", "r653", "r654", "r655", "r656", "r657", "r676", "r794", "r825", "r826", "r827", "r880", "r881"] }, "us-gaap_DebtInstrumentPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPayment", "crdr": "debit", "presentation": ["http://pavmed.com/role/ScheduleOfChangesInFairValueOfDebtDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Installment repayments \u2013 common stock", "label": "Debt Instrument, Periodic Payment", "documentation": "Amount of the required periodic payments including both interest and principal payments." } } }, "auth_ref": ["r16", "r69"] }, "us-gaap_DebtInstrumentPeriodicPaymentInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPaymentInterest", "crdr": "debit", "presentation": ["http://pavmed.com/role/DebtDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Periodic Payment, Interest", "documentation": "Amount of the required periodic payments applied to interest." } } }, "auth_ref": ["r16"] }, "us-gaap_DebtInstrumentRepaidPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRepaidPrincipal", "crdr": "debit", "presentation": ["http://pavmed.com/role/ScheduleOfChangesInFairValueOfDebtDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Non-installment payments \u2013 common stock", "label": "Debt Instrument, Repaid, Principal", "documentation": "Amount of principal of debt repaid." } } }, "auth_ref": ["r514"] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTerm", "presentation": ["http://pavmed.com/role/ScheduleOfFairValueAssumptionUsedDetails"], "lang": { "en-us": { "role": { "label": "Expected term years", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "PAVM_DebtInstrumentsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "DebtInstrumentsFairValue", "crdr": "credit", "presentation": ["http://pavmed.com/role/ScheduleOfChangesInFairValueOfDebtDetails"], "lang": { "en-us": { "role": { "label": "Change in fair value", "documentation": "Debt instruments fair value." } } }, "auth_ref": [] }, "PAVM_DebtModificationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "DebtModificationExpense", "crdr": "credit", "calculation": { "http://pavmed.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 8.0 } }, "presentation": ["http://pavmed.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Debt modification expense", "documentation": "Debt modification expense." } } }, "auth_ref": [] }, "PAVM_DeconsolidationFairValueOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "DeconsolidationFairValueOfDebt", "crdr": "credit", "presentation": ["http://pavmed.com/role/ScheduleOfChangesInFairValueOfDebtDetails"], "lang": { "en-us": { "role": { "label": "Deconsolidation of Lucid Diagnostics", "documentation": "Deconsolidation fair value of debt." } } }, "auth_ref": [] }, "us-gaap_DeconsolidationGainOrLossAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeconsolidationGainOrLossAmount", "crdr": "credit", "calculation": { "http://pavmed.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 }, "http://pavmed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": ["http://pavmed.com/role/EquityMethodInvestmentDetailsNarrative", "http://pavmed.com/role/ScheduleOfGainOnDeconsolidationDetails", "http://pavmed.com/role/StatementsOfCashFlows", "http://pavmed.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Gain on deconsolidation of subsidiary", "negatedLabel": "Gain on deconsolidation of subsidiary", "verboseLabel": "Gain on Deconsolidation of Lucid", "terseLabel": "Gain on deconsolidation", "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer." } } }, "auth_ref": ["r55"] }, "us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount", "crdr": "credit", "presentation": ["http://pavmed.com/role/ScheduleOfGainOnDeconsolidationDetails"], "lang": { "en-us": { "role": { "label": "Investment in former Consolidated Subsidiary (Fair Value of Lucid common stock)", "documentation": "Amount of gain (loss) from remeasurement to fair value of retained investment in former subsidiary and group of assets constituting business or nonprofit activity deconsolidated and derecognized, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer." } } }, "auth_ref": ["r56"] }, "PAVM_DecreaseInCashDueToDeconsolidationOfSubsidiary": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "DecreaseInCashDueToDeconsolidationOfSubsidiary", "crdr": "credit", "calculation": { "http://pavmed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://pavmed.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Decrease in cash due to deconsolidation of subsidiary", "documentation": "Decrease in cash due to deconsolidation of subsidiary.", "label": "DecreaseInCashDueToDeconsolidationOfSubsidiary" } } }, "auth_ref": [] }, "PAVM_DeemedDividendChargedToAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "DeemedDividendChargedToAccumulatedDeficit", "crdr": "credit", "calculation": { "http://pavmed.com/role/ScheduleOfNetLossAttributableToCommonStockholdersDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://pavmed.com/role/ScheduleOfNetLossAttributableToCommonStockholdersDetails"], "lang": { "en-us": { "role": { "totalLabel": "Deemed Dividend Charged to Accumulated Deficit", "documentation": "Deemed dividend charged to accumulated deficit.", "label": "DeemedDividendChargedToAccumulatedDeficit" } } }, "auth_ref": [] }, "PAVM_DeemedDividendOnSubsidiaryPreferredStockAttributableToNoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "DeemedDividendOnSubsidiaryPreferredStockAttributableToNoncontrollingInterests", "crdr": "credit", "presentation": ["http://pavmed.com/role/ScheduleOfComparisonOfBasicAndFullyDilutedNetLossPerShareDetails"], "lang": { "en-us": { "role": { "label": "Deemed dividend on Subsidiary Preferred Stock attributable to the noncontrolling interests", "documentation": "Deemed dividend on subsidiary preferred stock attributable to noncontrolling interests." } } }, "auth_ref": [] }, "PAVM_DefensiveAssetMember": { "xbrltype": "domainItemType", "nsuri": "http://pavmed.com/20240930", "localname":

```
"DefensiveAssetMember", "presentation": [ "http://pavmed.com/role/ScheduleOfIntangibleAssetsLessAccumulatedAmortizationDetails" ], "lang": { "en-us": { "role": { "label": "Defensive Asset [Member]", "documentation": "Defensive Asset [Member]" } } }, "auth_ref": [] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": [ "http://pavmed.com/role/PrepaidExpensesDepositsAndOtherCurrentAssetsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Prepaid Expenses and Other Current Assets", "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs." } } }, "auth_ref": [] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://pavmed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://pavmed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation and amortization expense", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r7", "r211", "r220", "r226", "r648", "r649" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://pavmed.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r538", "r541", "r556", "r557", "r558", "r560", "r561", "r562", "r563", "r565", "r566", "r567", "r568", "r580", "r581", "r582", "r583", "r586", "r587", "r588", "r589", "r613", "r614", "r615", "r616", "r681", "r683", "r870", "r871", "r872", "r873", "r874", "r875", "r877", "r878" ] }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeGainLossOnDerivativeNet", "crdr": "credit", "calculation": { "http://pavmed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://pavmed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in fair value - derivative liability", "label": "Derivative, Gain (Loss) on Derivative, Net", "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": [ "r863" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://pavmed.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r64", "r65", "r66", "r125", "r538", "r541", "r556", "r557", "r558", "r560", "r561", "r562", "r563", "r565", "r566", "r567", "r568", "r580", "r581", "r582", "r583", "r586", "r587", "r588", "r589", "r613", "r614", "r615", "r616", "r644", "r681", "r683", "r870", "r871", "r872", "r873", "r874", "r875", "r877", "r878" ] }, "PAVM_DisclosureLeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://pavmed.com/20240930", "localname": "DisclosureLeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases", "verboseLabel": "Schedule Of Future Minimum Lease Payments For Operating Leases", "terseLabel": "Schedule Of Supplemental Balance Sheet Information Related To Cash And Non-cash Activities With Leases" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "presentation": [ "http://pavmed.com/role/Stock-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Unrecognized Compensation Expense", "documentation": "Tabular disclosure of share-based payment arrangement." } } }, "auth_ref": [ "r9", "r39" ] }, "PAVM_DisclosurePrepaidExpensesDepositsAndOtherCurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://pavmed.com/20240930", "localname": "DisclosurePrepaidExpensesDepositsAndOtherCurrentAssetsAbstract", "lang": { "en-us": { "role": { "label": "Prepaid Expenses Deposits And Other Current Assets", "verboseLabel": "Schedule Of Prepaid Expenses And Other Current Assets" } } }, "auth_ref": [] }, "us-gaap_DividendsPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPreferredStock", "crdr": "debit", "presentation": [ "http://pavmed.com/role/PreferredStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Aggregate preferred stock dividends declared", "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)." } } }, "auth_ref": [ "r3", "r113" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r706" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r704", "r706", "r718" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r705" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r693" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r706" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r706" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r739" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r696" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://pavmed.com/role/ScheduleOfComparisonOfBasicAndFullyDilutedNetLossPerShareDetails", "http://pavmed.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net income (loss) per share attributable to PAVmed Inc. common stockholders \u2013 basic", "verboseLabel": "Net income (loss) per share attributable to PAVmed Inc. common stockholders, basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r172", "r187", "r188", "r189", "r190", "r191", "r192", "r197", "r200", "r204", "r205", "r206", "r210", "r394", "r398", "r415", "r416", "r480", "r497", "r645" ] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicAbstract", "presentation": [ "http://pavmed.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Per share information:" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://pavmed.com/role/ScheduleOfComparisonOfBasicAndFullyDilutedNetLossPerShareDetails", "http://pavmed.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net income (loss) per share attributable to PAVmed Inc. common stockholders \u2013 diluted", "verboseLabel": "Net income (loss) per share attributable to PAVmed Inc. common stockholders, diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r172", "r187", "r188", "r189", "r190", "r191", "r192", "r200", "r204", "r205", "r206", "r210", "r394", "r398", "r415", "r416", "r480", "r497", "r645" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://pavmed.com/role/NetIncomeLossPerShare" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Per Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r196", "r207", "r208", "r209" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://pavmed.com/role/ScheduleOfUnrecognizedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Expense", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r383" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://pavmed.com/role/ScheduleOfUnrecognizedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Remaining Service Period", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r383" ] }, "PAVM_EmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://pavmed.com/20240930", "localname": "EmployeeStockPurchasePlanMember", "presentation": [ "http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative", "http://pavmed.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Employee Stock Purchase Plan [Member]", "documentation": "Employee Stock Purchase Plan [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode",
```

```
"presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r699" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r695" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": [ "http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative", "http://pavmed.com/role/NoncontrollingInterestDetailsNarrative", "http://pavmed.com/role/ScheduleOfStock-basedCompensationExpenseRecognizedByLucidDiagnosticsDetails", "http://pavmed.com/role/ScheduleOfStockBasedCompensationEvaluationAssumptionsDetails", "http://pavmed.com/role/ScheduleOfSummarizesInformationAboutStockOptionsDetailsParenthetical", "http://pavmed.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r695" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r780" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r695" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r777" ] }, "dei_EntityListingParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingParValuePerShare", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listing, Par Value Per Share", "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r718" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r695" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r695" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r695" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r695" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r778" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative", "http://pavmed.com/role/EquityMethodInvestmentDetailsNarrative", "http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r11", "r150", "r168", "r169", "r170", "r182", "r183", "r184", "r186", "r191", "r193", "r195", "r212", "r236", "r237", "r253", "r325", "r388", "r389", "r391", "r392", "r393", "r395", "r397", "r398", "r407", "r408", "r409", "r410", "r411", "r412", "r414", "r441", "r442", "r443", "r444", "r445", "r446", "r451", "r454", "r464", "r496", "r504", "r505", "r506", "r518", "r592" ] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestments", "crdr": "debit", "calculation": { "http://pavmed.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://pavmed.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Equity method investment - at fair value", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r211", "r223", "r226", "r231", "r785", "r811" ] }, "PAVM_EquityMethodInvestmentsAggregateInformationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://pavmed.com/20240930", "localname": "EquityMethodInvestmentsAggregateInformationTableTextBlock", "presentation": [ "http://pavmed.com/role/EquityMethodInvestmentTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Aggregate Information From the Financial Statements", "documentation": "Equity Method Investments Aggregate Information [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "lang": { "en-us": { "role": { "label": "Equity Method Investments and Joint Ventures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentsDisclosureTextBlock", "presentation": [ "http://pavmed.com/role/EquityMethodInvestment" ], "lang": { "en-us": { "role": { "label": "Equity Method Investment", "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group." } } }, "auth_ref": [ "r147", "r233", "r235", "r782" ] }, "PAVM_EquityMethodInvestmentsGainDeconsolidationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://pavmed.com/20240930", "localname": "EquityMethodInvestmentsGainDeconsolidationTableTextBlock", "presentation": [ "http://pavmed.com/role/EquityMethodInvestmentTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Gain on Deconsolidation", "documentation": "Equity Method Investments Gain Deconsolidation [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestmentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentsPolicy", "presentation": [ "http://pavmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Equity Method Investments", "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received." } } }, "auth_ref": [ "r4", "r67", "r232" ] }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiGainLoss", "crdr": "credit", "calculation": { "http://pavmed.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 }, "http://pavmed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://pavmed.com/role/StatementsOfCashFlows", "http://pavmed.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Change in fair value - equity method investment", "negatedLabel": "Change in fair value - equity method investment", "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r498", "r810" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r747" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r711", "r722", "r732", "r757" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r708", "r719", "r729", "r754" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri":
```

```
"http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r753" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "PAVM_FairValueAdjustmentForDilutedEpsCalculation": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "FairValueAdjustmentForDilutedEpsCalculation", "crdr": "debit", "presentation": [
"http://pavmed.com/role/ScheduleOfComparisonOfBasicAndFullyDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Adjustment for diluted EPS calculation", "documentation": "Fair value adjustment for diluted eps calculation" } } }, "auth_ref": [] }, "PAVM_FairValueAdjustmentIssueDate": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "FairValueAdjustmentIssueDate", "crdr": "credit", "presentation": [
"http://pavmed.com/role/ScheduleOfChangesInFairValueOfDebtDetails" ], "lang": { "en-us": { "role": { "label": "Fair value adjustment \u2013 issue date", "documentation": "Fair value adjustment issue date." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://pavmed.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r418", "r419", "r432", "r669" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [
"http://pavmed.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r418", "r419", "r432", "r669" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": [
"http://pavmed.com/role/ScheduleOfFairValueAssumptionUsedDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r420", "r421", "r422", "r672" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": [
"http://pavmed.com/role/ScheduleOfFairValueAssumptionUsedDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r420", "r421", "r422", "r672" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": [
"http://pavmed.com/role/ScheduleOfIntangibleAssetsLessAccumulatedAmortizationDetails" ], "lang": { "en-us": { "role": { "documentation": "Class of asset." } } }, "auth_ref": [ "r423", "r424", "r425", "r426", "r427", "r428", "r433", "r670" ] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByAssetClassAxis", "presentation": [ "http://pavmed.com/role/ScheduleOfIntangibleAssetsLessAccumulatedAmortizationDetails" ], "lang": { "en-us": { "role": { "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": [ "r423", "r424", "r425", "r426", "r427", "r428", "r433", "r670" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://pavmed.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r293", "r346", "r347", "r348", "r349", "r350", "r351", "r417", "r419", "r420", "r421", "r422", "r431", "r432", "r434", "r467", "r468", "r469", "r654", "r655", "r659", "r660", "r661", "r669", "r672" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://pavmed.com/role/FinancialInstrumentsFairValueMeasurements" ], "lang": { "en-us": { "role": { "label": "Financial Instruments Fair Value Measurements", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r427", "r429", "r430", "r431", "r434", "r435", "r436", "r437", "r438", "r479", "r669", "r673" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://pavmed.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r293", "r346", "r351", "r419", "r432", "r467", "r659", "r660", "r661", "r669" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [
"http://pavmed.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r293", "r346", "r351", "r419", "r420", "r432", "r468", "r654", "r655", "r659", "r660", "r661", "r669" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [
"http://pavmed.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r293", "r346", "r347", "r348", "r349", "r350", "r351", "r419", "r420", "r421", "r422", "r432", "r469", "r654", "r655", "r659", "r660", "r661", "r669", "r672" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueMeasurementsFairValueHierarchyDomain", "presentation": [
"http://pavmed.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r293", "r346", "r347", "r348", "r349", "r350", "r351", "r417", "r419", "r420", "r421", "r422", "r431", "r432", "r434", "r467", "r468", "r469", "r654", "r655", "r659", "r660", "r661", "r669", "r672" ] }, "PAVM_FairValueOfDeemedDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "FairValueOfDeemedDividend", "crdr": "credit", "presentation": [
"http://pavmed.com/role/NoncontrollingInterestDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fair value of deemed dividend", "documentation": "Fair value of deemed dividend." } } }, "auth_ref": [] }, "PAVM_FairValueOfSeriesBPreferredStockIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "FairValueOfSeriesBPreferredStockIssued", "crdr": "credit", "calculation": {
"http://pavmed.com/role/ScheduleOfNetLossAttributableToCommonStockholdersDetails": { "parentTag": "PAVM_DeemedDividendChargedToAccumulatedDeficit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://pavmed.com/role/ScheduleOfNetLossAttributableToCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value - 31,790 shares of Lucid Series B Preferred Stock issued in exchange for Lucid Series A and Lucid Series A-1 Preferred Stock", "documentation": "Fair value of series B preferred stock issued." } } }, "auth_ref": [] }, "PAVM_FairValueOfSeriesBPreferredStockIssuedShares": { "xbrltype": "sharesItemType", "nsuri":
"http://pavmed.com/20240930", "localname": "FairValueOfSeriesBPreferredStockIssuedShares", "presentation": [
"http://pavmed.com/role/ScheduleOfNetLossAttributableToCommonStockholdersDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Fair value of the consideration shares", "documentation": "Fair value of series B preferred stock issued shares." } } }, "auth_ref": [] }, "PAVM_FairValueOptionElectionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://pavmed.com/20240930", "localname": "FairValueOptionElectionPolicyTextBlock", "presentation": [
"http://pavmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value Option (\u201cFVO\u201d) Election", "documentation": "Fair Value Option Election [Policy Text Block]" } } }, "auth_ref": [] }, "PAVM_FairValuePreferredStockDividendsShares": { "xbrltype": "sharesItemType", "nsuri": "http://pavmed.com/20240930", "localname": "FairValuePreferredStockDividendsShares", "presentation": [
"http://pavmed.com/role/NoncontrollingInterestDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair value of the consideration shares", "documentation": "Fair value preferred stock dividends, shares.", "label": "FairValuePreferredStockDividendsShares" } } }, "auth_ref": [] }, "us-gaap_FeeIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FeeIncome", "crdr": "credit", "presentation": [
"http://pavmed.com/role/EquityMethodInvestmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fee income", "documentation": "Amount of fee income including, but not limited to, managerial assistance, servicing of investment, and origination and commitment fees." } } }, "auth_ref": [ "r901" ] }, "PAVM_FeeIncomeIncreased": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "FeeIncomeIncreased", "crdr": "credit", "presentation": [
"http://pavmed.com/role/EquityMethodInvestmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Increase in fee income", "documentation": "Increase in fee income." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://pavmed.com/role/ScheduleOfIntangibleAssetsLessAccumulatedAmortizationDetails" ], "lang": { "en-us": { "role": { "label": "Finite lived intangible asset, useful life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": {
"http://pavmed.com/role/ScheduleOfIntangibleAssetsLessAccumulatedAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://pavmed.com/role/ScheduleOfIntangibleAssetsLessAccumulatedAmortizationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r156", "r238", "r247", "r652" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://pavmed.com/role/EquityMethodInvestmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r240", "r242", "r243", "r244", "r246", "r247", "r249", "r250", "r477", "r478", "r638" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": {
"http://pavmed.com/role/ScheduleOfIntangibleAssetsLessAccumulatedAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://pavmed.com/role/ScheduleOfIntangibleAssetsLessAccumulatedAmortizationDetails" ], "lang": { "en-us": { "role": { "label": "Total Intangible assets", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r238", "r247", "r478", "r652" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://pavmed.com/role/EquityMethodInvestmentDetailsNarrative" ], "lang": { "en-us": {
```

```
"role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r240", "r242", "r243", "r244", "r246", "r247", "r249", "r250", "r638" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://pavmed.com/role/ScheduleOfIntangibleAssetsLessAccumulatedAmortizationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://pavmed.com/role/IntangibleAssetsNetDetailsNarrative", "http://pavmed.com/role/ScheduleOfIntangibleAssetsLessAccumulatedAmortizationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Intangible Assets, net", "label": "Estimated future amortization expense", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r477", "r820" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r715", "r726", "r736", "r761" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r715", "r726", "r736", "r761" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r715", "r726", "r736", "r761" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r715", "r726", "r736", "r761" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r715", "r726", "r736", "r761" ] }, "us-gaap_GainLossOnDispositionOfAssets1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDispositionOfAssets1", "crdr": "credit", "presentation": [ "http://pavmed.com/role/ScheduleOfGainOnDeconsolidationDetails" ], "lang": { "en-us": { "role": { "label": "Less: Net Assets of Former Consolidated Subsidiary - Lucid", "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee." } } }, "auth_ref": [ "r791" ] }, "us-gaap_GainLossOnDispositionOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDispositionOfIntangibleAssets", "crdr": "credit", "calculation": { "http://pavmed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 }, "http://pavmed.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://pavmed.com/role/StatementsOfCashFlows", "http://pavmed.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Gain on sale of intellectual property", "negatedLabel": "Gain on sale of intellectual property", "documentation": "Amount of gain (loss) on sale or disposal of intangible assets." } } }, "auth_ref": [ "r791" ] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "presentation": [ "http://pavmed.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Gain (loss) on extinguishment of debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r7", "r27", "r28" ] }, "us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost", "crdr": "credit", "calculation": { "http://pavmed.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 7.0 }, "http://pavmed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://pavmed.com/role/DebtDetailsNarrative", "http://pavmed.com/role/StatementsOfCashFlows", "http://pavmed.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Debt extinguishments loss - Senior Secured Convertible Notes", "negatedLabel": "Debt extinguishment loss - Senior Secured Convertible Note", "negatedTerseLabel": "Debt extinguishment losses", "documentation": "Reflects the difference between the fair value of payments made to legally extinguish a debt and its carrying value at that time. This item excludes the write-off of amounts previously capitalized as debt issuance costs." } } }, "auth_ref": [ "r27", "r28" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://pavmed.com/role/StatementsOfOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://pavmed.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r93", "r576" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://pavmed.com/role/ScheduleOfStock-basedCompensationExpenseDetails", "http://pavmed.com/role/ScheduleOfStock-basedCompensationExpenseRecognizedByLucidDiagnosticsDetails" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r93" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "PAVM_ImpactOfSubsidiaryEquityTransactions": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "ImpactOfSubsidiaryEquityTransactions", "crdr": "credit", "presentation": [ "http://pavmed.com/role/ScheduleOfNoncontrollingInterestOfStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Impact of subsidiary equity transactions", "documentation": "Impact of subsidiary equity transactions.", "label": "ImpactOfSubsidiaryEquityTransactions" } } }, "auth_ref": [] }, "us-gaap_ImpairmentEffectsOnEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentEffectsOnEarningsPerShareLineItems", "presentation": [ "http://pavmed.com/role/ScheduleOfIntangibleAssetsLessAccumulatedAmortizationDetails" ], "lang": { "en-us": { "role": { "label": "Impairment Effects on Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ImpairmentEffectsOnEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentEffectsOnEarningsPerShareTable", "presentation": [ "http://pavmed.com/role/ScheduleOfIntangibleAssetsLessAccumulatedAmortizationDetails" ], "lang": { "en-us": { "role": { "label": "Impairment Effects on Earnings Per Share [Table]", "documentation": "Disclosure of information about the effects of asset impairment charge on per share or per unit basis." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://pavmed.com/role/StatementsOfOperations": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://pavmed.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Income (loss) before provision for income tax", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r89", "r132", "r136", "r481", "r492", "r647", "r648", "r803", "r804", "r805", "r806", "r807" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://pavmed.com/role/ScheduleOfStock-basedCompensationExpenseDetails", "http://pavmed.com/role/ScheduleOfStock-basedCompensationExpenseRecognizedByLucidDiagnosticsDetails" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r254", "r260", "r261", "r424", "r428", "r433", "r501", "r503", "r577", "r638", "r671", "r897" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://pavmed.com/role/ScheduleOfStock-basedCompensationExpenseDetails", "http://pavmed.com/role/ScheduleOfStock-basedCompensationExpenseRecognizedByLucidDiagnosticsDetails" ], "lang": { "en-us": { "role": { "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r260", "r261", "r424", "r428", "r433", "r501", "r503", "r577", "r638", "r671", "r897" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://pavmed.com/role/StatementsOfOperations": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://pavmed.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Provision for income taxes", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r138", "r145", "r194", "r195", "r211", "r221", "r226", "r386", "r387", "r390", "r499", "r665" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://pavmed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://pavmed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://pavmed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://pavmed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://pavmed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 17.0 } }, "presentation": [ "http://pavmed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued expenses and other current liabilities", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other." } } }, "auth_ref": [ "r790" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://pavmed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidExpensesOther", "crdr": "credit", "calculation": { "http://pavmed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": [ "http://pavmed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses, deposits and current and other assets", "label": "Increase (Decrease) in Prepaid Expenses, Other", "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods." } } }, "auth_ref": [ "r6" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]" } } }, "auth_ref": [ "r715", "r726", "r736", "r753", "r761", "r765", "r773" ] }, "PAVM_InitialIssuanceMember": { "xbrltype": "domainItemType", "nsuri": "http://pavmed.com/20240930", "localname": "InitialIssuanceMember", "presentation": [ "http://pavmed.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Initial Issuance [Member]", "documentation": "Initial Issuance [Member] } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r771" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r707", "r776" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r707", "r776" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
```

```
"InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r707", "r776" ] }, "us-gaap_IntangibleAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsCurrent", "crdr": "debit", "presentation": [ "http://pavmed.com/role/IntangibleAssetsNetDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Intangible assets net", "documentation": "The current portion of nonphysical assets, excluding financial assets, if these assets are classified into the current and noncurrent portions." } } }, "auth_ref": [ "r1" ] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": [ "http://pavmed.com/role/IntangibleAssetsNet" ], "lang": { "en-us": { "role": { "label": "Intangible Assets, net", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": [ "r239", "r251", "r252", "r637", "r638" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://pavmed.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 }, "http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://pavmed.com/role/BalanceSheets", "http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Intangible assets, net", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r240", "r820", "r821" ] }, "us-gaap_IntellectualPropertyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntellectualPropertyMember", "presentation": [ "http://pavmed.com/role/EquityMethodInvestmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Intellectual Property [Member]", "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights." } } }, "auth_ref": [ "r15", "r814", "r815", "r816", "r817", "r818", "r820", "r822", "r823" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "presentation": [ "http://pavmed.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest expense", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." } } }, "auth_ref": [ "r211", "r215", "r219", "r222", "r226", "r448", "r648", "r649" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt", "crdr": "debit", "calculation": { "http://pavmed.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://pavmed.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r95", "r299", "r306", "r656", "r657" ] }, "us-gaap_InterestIncomeOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeOperating", "crdr": "credit", "calculation": { "http://pavmed.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://pavmed.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Interest income", "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities." } } }, "auth_ref": [ "r218", "r574", "r621", "r622", "r648", "r689", "r690", "r789", "r904" ] }, "us-gaap_InterestRateFloorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateFloorMember", "presentation": [ "http://pavmed.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest Rate Floor [Member]", "documentation": "Contracts in which the floor writer, in return for a premium, agrees to limit the risk associated with a decline in interest rates based on a notional amount. If rates fall below an agreed rate, the floor holder will receive cash payments from the floor writer equal to the difference between the market rate and an agreed rate multiplied by the notional principal amount." } } }, "auth_ref": [ "r640" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://pavmed.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://pavmed.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Inventory", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r163", "r642", "r678" ] }, "us-gaap_InvestmentOwnedAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentOwnedAtFairValue", "crdr": "debit", "presentation": [ "http://pavmed.com/role/EquityMethodInvestmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fair value of the companys investment", "documentation": "Fair value of investment in security owned." } } }, "auth_ref": [ "r510", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r539", "r542", "r543", "r554", "r555", "r597", "r600", "r601", "r602", "r608", "r609", "r610", "r611", "r612", "r617", "r618", "r623", "r624", "r625", "r683", "r692", "r899" ] }, "us-gaap_InvestorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestorMember", "presentation": [ "http://pavmed.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Investor [Member]", "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value." } } }, "auth_ref": [ "r883", "r884" ] }, "PAVM_IssuanceOfCommonStockInstallmentSettlementPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "IssuanceOfCommonStockInstallmentSettlementPayment", "crdr": "debit", "calculation": { "http://pavmed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://pavmed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "APA-RDx: Issue common stock of subsidiary - termination payment", "documentation": "Issue common stock installment settlement payment." } } }, "auth_ref": [] }, "PAVM_IssuanceOfExchangeSaleSubsidiaryPreferredStockSeriesBAndSeriesBOne": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "IssuanceOfExchangeSaleSubsidiaryPreferredStockSeriesBAndSeriesBOne", "crdr": "credit", "presentation": [ "http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance through exchange - subsidiary preferred stock (Series B and Series B-1)", "documentation": "Issuance through exchange - subsidiary preferred stock (Series B and Series B-1)" } } }, "auth_ref": [] }, "PAVM_IssuanceOfExchangeSubsidiaryPreferredStockSeriesAndSeriesAOne": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "IssuanceOfExchangeSubsidiaryPreferredStockSeriesAndSeriesAOne", "crdr": "credit", "presentation": [ "http://pavmed.com/role/NoncontrollingInterestDetailsNarrative", "http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Exchange - subsidiary preferred stock (Series A and Series A-1)", "negatedLabel": "Carrying value", "documentation": "Issuance exchange - subsidiary preferred stock Series A and Series A one." } } }, "auth_ref": [] }, "PAVM_IssuanceOfExchangeSubsidiaryPreferredStockSeriesBAndSeriesBOne": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "IssuanceOfExchangeSubsidiaryPreferredStockSeriesBAndSeriesBOne", "crdr": "credit", "presentation": [ "http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance through sale - subsidiary preferred stock (Series B and Series B-1)", "documentation": "Issuance - subsidiary preferred stock series B and series B-1." } } }, "auth_ref": [] }, "PAVM_IssuanceSubsidiaryCommonStockCommittedEquityFacilityNetOfFinancingCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "IssuanceSubsidiaryCommonStockCommittedEquityFacilityNetOfFinancingCharges", "crdr": "credit", "presentation": [ "http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance - subsidiary common stock - Committed Equity Facility, net of financing charges", "documentation": "Issuance subsidiary common stock - committed equity facility, net of financing charges." } } }, "auth_ref": [] }, "PAVM_IssuanceSubsidiaryPreferredStockSeriesA": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "IssuanceSubsidiaryPreferredStockSeriesA", "crdr": "credit", "presentation": [ "http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance - subsidiary preferred stock (Series A)", "documentation": "Issuance - majority-owned subsidiary preferred stock Series A." } } }, "auth_ref": [] }, "PAVM_IssuanceSubsidiaryPreferredStockSeriesAOne": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "IssuanceSubsidiaryPreferredStockSeriesAOne", "crdr": "credit", "presentation": [ "http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance - subsidiary preferred stock (Series A-1)", "documentation": "Issuance -subsidiary preferred stock Series A-1." } } }, "auth_ref": [] }, "PAVM_IssueCommonStockUponPartialConversionsOfMajorityOwnedSubsidiaryCommonSeniorSecuredConvertibleNote": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "IssueCommonStockUponPartialConversionsOfMajorityOwnedSubsidiaryCommonSeniorSecuredConvertibleNote", "crdr": "credit", "presentation": [ "http://pavmed.com/role/ScheduleOfNoncontrollingInterestOfStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Conversion of Lucid Diagnostics common stock for Senior Secured Convertible Debt", "documentation": "Issue common stock upon partial conversions of majority owned subsidiary common senior secured convertible note" } } }, "auth_ref": [] }, "PAVM_JanuaryOneTwoThousandTwentyFourToSeptemberTenTwoThousandTwentyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://pavmed.com/20240930", "localname": "JanuaryOneTwoThousandTwentyFourToSeptemberTenTwoThousandTwentyFourMember", "presentation": [ "http://pavmed.com/role/ScheduleOfAggregateInformationFromFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "label": "January 1, 2024 - September 10, 2024 [Member]", "documentation": "January One Two Thousand Twenty Four To September Ten Two Thousand Twenty Four [Member]" } } }, "auth_ref": [] }, "PAVM_JulyOneTwoThousandTwentyFourToSeptemberTenTwoThousandTwentyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://pavmed.com/20240930", "localname": "JulyOneTwoThousandTwentyFourToSeptemberTenTwoThousandTwentyFourMember", "presentation": [ "http://pavmed.com/role/ScheduleOfAggregateInformationFromFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "label": "July 1, 2024 - September 10, 2024 [Member]", "documentation": "July One Two Thousand Twenty Four To September Ten Two Thousand Twenty Four [Member]" } } }, "auth_ref": [] }, "PAVM_JuneThirtyTwentyTwentyFourThroughSeptemberThreeTwentyTwentyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://pavmed.com/20240930", "localname": "JuneThirtyTwentyTwentyFourThroughSeptemberThreeTwentyTwentyFourMember", "presentation": [ "http://pavmed.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "June 30, 2024 Through September 03, 2024 [Member]", "documentation": "June 30, 2024 Through September 03, 2024 [Member]" } } }, "auth_ref": [] }, "PAVM_LaboratoryInformationManagementSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "http://pavmed.com/20240930", "localname": "LaboratoryInformationManagementSoftwareMember", "presentation": [ "http://pavmed.com/role/ScheduleOfIntangibleAssetsLessAccumulatedAmortizationDetails" ], "lang": { "en-us": { "role": { "label": "Laboratory Information Management Software [Member]", "documentation": "Laboratory Information Management Software [Member]" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": [ "http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative", "http://pavmed.com/role/NoncontrollingInterestDetailsNarrative", "http://pavmed.com/role/ScheduleOfStock-basedCompensationExpenseRecognizedByLucidDiagnosticsDetails", "http://pavmed.com/role/ScheduleOfSummarizesInformationAboutStockOptionsDetailsParenthetical", "http://pavmed.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "PAVM_LessCarryingValueRelatedToSeriesAndSeriesA1PreferredStockExchangedForSeriesBPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "LessCarryingValueRelatedToSeriesAndSeriesA1PreferredStockExchangedForSeriesBPreferredStock", "crdr": "debit", "calculation": { "http://pavmed.com/role/ScheduleOfNetLossAttributableToCommonStockholdersDetails": { "parentTag": "PAVM_DeemedDividendChargedToAccumulatedDeficit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://pavmed.com/role/ScheduleOfNetLossAttributableToCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Carrying value related to Lucid Series A and Lucid Series A-1 Preferred Stock Exchanged for Lucid Series B Preferred Stock (of 24,295 shares)", "documentation": "Less carrying value related to series and series A1 preferred stock exchanged for series B preferred stock.", "label": "Less carrying value related to series and series A1 preferred stock exchanged for series B preferred stock" } } }, "auth_ref": [] }, "PAVM_LessCarryingValueRelatedToSeriesAndSeriesA1PreferredStockExchangedForSeriesBPreferredStockShares": { "xbrltype": "sharesItemType", "nsuri": "http://pavmed.com/20240930", "localname": "LessCarryingValueRelatedToSeriesAndSeriesA1PreferredStockExchangedForSeriesBPreferredStockShares", "presentation": [ "http://pavmed.com/role/ScheduleOfNetLossAttributableToCommonStockholdersDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Less carrying value related to series and series A1 preferred stock exchanged for series B preferred stock shares", "documentation": "Less carrying value related to series and series A1 preferred stock exchanged for series B preferred stock shares." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://pavmed.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Future Minimum Lease Payments for Operating Leases", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r882" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://pavmed.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://pavmed.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r462" ] }, "PAVM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "crdr": "credit", "calculation": {
```

```
"http://pavmed.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://pavmed.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Thereafter", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://pavmed.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://pavmed.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r462" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://pavmed.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://pavmed.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r462" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://pavmed.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://pavmed.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r462" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://pavmed.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://pavmed.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r462" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://pavmed.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r462" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://pavmed.com/role/Leases" ], "lang": { "en-us": { "role": { "verboseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r453" ] }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LetterOfCreditMember", "presentation": [ "http://pavmed.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Letter of Credit [Member]", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://pavmed.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 }, "http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails": { "parentTag": "PAVM_NetAssets", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://pavmed.com/role/BalanceSheets", "http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r16", "r72", "r73", "r74", "r78", "r79", "r80", "r81", "r180", "r234", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r402", "r405", "r406", "r440", "r549", "r646", "r692", "r831", "r886", "r887" ] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAbstract", "presentation": [ "http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://pavmed.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://pavmed.com/role/BalanceSheets", "http://pavmed.com/role/ScheduleOfAggregateInformationFromFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities and Stockholders\u2019 Equity (Deficit)", "label": "Total liabilities and stockholders\u2019 deficit", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r88", "r131", "r490", "r678", "r795", "r812", "r879" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://pavmed.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Preferred Stock and Stockholders\u2019 Equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://pavmed.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 }, "http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://pavmed.com/role/BalanceSheets", "http://pavmed.com/role/ScheduleOfAggregateInformationFromFinancialStatementsDetails", "http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r74", "r154", "r180", "r234", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r402", "r405", "r406", "r440", "r678", "r831", "r886", "r887" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://pavmed.com/role/BalanceSheets", "http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [ "http://pavmed.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Total liabilities at fair value", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r419", "r865" ] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "presentation": [ "http://pavmed.com/role/ScheduleOfAggregateInformationFromFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "label": "Non-current liabilities", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r16", "r78", "r79", "r80", "r81", "r180", "r234", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r402", "r405", "r406", "r440", "r831", "r886", "r887" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://pavmed.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://pavmed.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "2024 (remainder of year)", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": [ "r796" ] }, "PAVM_LossOnIssueAndOfferingCostSeniorSecuredConvertibleNote": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "LossOnIssueAndOfferingCostSeniorSecuredConvertibleNote", "crdr": "debit", "calculation": { "http://pavmed.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://pavmed.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss on issue and offering costs - Senior Secured Convertible Note", "documentation": "Loss on issue and offering cost senior secured convertible note.", "label": "LossOnIssueAndOfferingCostSeniorSecuredConvertibleNote" } } }, "auth_ref": [] }, "PAVM_LossOnIssueAndOfferingCostsSeniorSecuredConvertibleNote": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "LossOnIssueAndOfferingCostsSeniorSecuredConvertibleNote", "crdr": "debit", "calculation": { "http://pavmed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://pavmed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Loss on issue - Senior Secured Convertible Note", "documentation": "Loss on issue and offering costs senior secured convertible note." } } }, "auth_ref": [] }, "PAVM_LucidCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://pavmed.com/20240930", "localname": "LucidCommonStockMember", "presentation": [ "http://pavmed.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Lucid Common Stock [Member]", "documentation": "Lucid Common Stock [Member]" } } }, "auth_ref": [] }, "PAVM_LucidDiagnosticsDeemedDividendOnPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "LucidDiagnosticsDeemedDividendOnPreferredStock", "crdr": "credit", "presentation": [ "http://pavmed.com/role/ScheduleOfNoncontrollingInterestOfStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Lucid Diagnostics deemed dividend on preferred stock", "documentation": "Lucid diagnostics deemed dividend on preferred stock." } } }, "auth_ref": [] }, "PAVM_LucidDiagnosticsExchangeOfPreferredStockSeriesAndSeriesAOne": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "LucidDiagnosticsExchangeOfPreferredStockSeriesAndSeriesAOne", "crdr": "credit", "presentation": [ "http://pavmed.com/role/ScheduleOfNoncontrollingInterestOfStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Lucid Diagnostics exchange of preferred stock Series A and Series A-1", "documentation": "Lucid diagnostics exchange of preferred stock series and series A1." } } }, "auth_ref": [] }, "PAVM_LucidDiagnosticsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://pavmed.com/20240930", "localname": "LucidDiagnosticsIncMember", "presentation": [ "http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative", "http://pavmed.com/role/EquityMethodInvestmentDetailsNarrative", "http://pavmed.com/role/NoncontrollingInterestDetailsNarrative", "http://pavmed.com/role/ScheduleOfAggregateInformationFromFinancialStatementsDetails", "http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails", "http://pavmed.com/role/ScheduleOfGainOnDeconsolidationDetails", "http://pavmed.com/role/ScheduleOfStock-basedCompensationExpenseRecognizedByLucidDiagnosticsDetails", "http://pavmed.com/role/ScheduleOfSummarizesInformationAboutStockOptionsDetailsParenthetical", "http://pavmed.com/role/Stock-basedCompensationDetailsNarrative", "http://pavmed.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lucid Diagnostics Inc [Member]", "documentation": "Lucid Diagnostics Inc [Member]" } } }, "auth_ref": [] }, "PAVM_LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://pavmed.com/20240930", "localname": "LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember", "presentation": [ "http://pavmed.com/role/ScheduleOfStock-basedCompensationExpenseRecognizedByLucidDiagnosticsDetails" ], "lang": { "en-us": { "role": { "label": "Lucid Diagnostics 2018 Equity Plan [Member]", "documentation": "Lucid Diagnostics 2018 Equity Plan [Member]" } } }, "auth_ref": [] }, "PAVM_LucidDiagnosticsIssuanceOfCommonStockForSettlementOfVendorServiceAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "LucidDiagnosticsIssuanceOfCommonStockForSettlementOfVendorServiceAgreement", "crdr": "credit", "presentation": [ "http://pavmed.com/role/ScheduleOfNoncontrollingInterestOfStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Lucid Diagnostics issuance of common stock for settlement of vendor service agreement", "documentation": "Lucid Diagnostics Issuance of Common Stock for Settlement of Vendor Service Agreement [Member]" } } }, "auth_ref": [] }, "PAVM_LucidDiagnosticsIssuanceThroughExchangeSeriesBAndSeriesBOne": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930",
```

```
"localname": "LucidDiagnosticsIssuanceThroughExchangeSeriesBAndSeriesBOne", "crdr": "credit", "presentation": [
"http://pavmed.com/role/ScheduleOfNoncontrollingInterestOfStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Lucid Diagnostics issuance through exchange
- Series B and Series B-1", "documentation": "Lucid Diagnostics issuance through exchange - Series B and Series B-1." } } }, "auth_ref": [] },
"PAVM_LucidDiagnosticsIssuanceThroughSaleSeriesBAndSeriesBOne": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname":
"LucidDiagnosticsIssuanceThroughSaleSeriesBAndSeriesBOne", "crdr": "credit", "presentation": [
"http://pavmed.com/role/ScheduleOfNoncontrollingInterestOfStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Lucid Diagnostics issuance through sale -
Series B and Series B-1", "documentation": "Lucid Diagnostics issuance through sale - Series B and Series B-1." } } }, "auth_ref": [] },
"PAVM_LucidDiagnosticsProceedsFromIssuanceOfPreferredStockSeriesAOne": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname":
"LucidDiagnosticsProceedsFromIssuanceOfPreferredStockSeriesAOne", "crdr": "credit", "presentation": [
"http://pavmed.com/role/ScheduleOfNoncontrollingInterestOfStockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Lucid Diagnostics proceeds from issuance of
preferred stock Series A-1", "documentation": "Lucid diagnostics proceeds from issuance of preferred stock series A1." } } }, "auth_ref": [] },
"PAVM_LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://pavmed.com/20240930", "localname":
"LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember", "presentation": [ "http://pavmed.com/role/DebtDetailsNarrative",
"http://pavmed.com/role/FinancialInstrumentsFairValueMeasurementsDetailsNarrative", "http://pavmed.com/role/ScheduleOfChangesInFairValueOfDebtDetails",
"http://pavmed.com/role/ScheduleOfFairValueAssumptionUsedDetails",
"http://pavmed.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
"http://pavmed.com/role/SummaryOfOutstandingDebtDetails" ], "lang": { "en-us": { "role": { "label": "Lucid March 2023 Senior Convertible Note [Member]", "documentation":
"Lucid March 2023 Senior Convertible Note [Member]" } } }, "auth_ref": [] }, "PAVM_LucidSeriesAAndLucidSeriesAOnePreferredStockMember": { "xbrltype":
"domainItemType", "nsuri": "http://pavmed.com/20240930", "localname": "LucidSeriesAAndLucidSeriesAOnePreferredStockMember", "presentation": [
"http://pavmed.com/role/NoncontrollingInterestDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lucid Series A and Lucid Series A-1 Preferred Stock [Member]",
"documentation": "Lucid Series A And Lucid Series A One Preferred Stock [Member]" } } }, "auth_ref": [] }, "PAVM_ManagementFeeIncome": { "xbrltype":
"monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "ManagementFeeIncome", "crdr": "credit", "calculation": {
"http://pavmed.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 10.0 } }, "presentation": [
"http://pavmed.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Management fee income", "documentation": "Management fee income." } } },
"auth_ref": [] }, "PAVM_ManagementServicesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://pavmed.com/20240930", "localname":
"ManagementServicesAgreementMember", "presentation": [ "http://pavmed.com/role/EquityMethodInvestmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label":
"Management Services Agreement [Member]", "documentation": "Management Services Agreement [Member]" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [
"http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative", "http://pavmed.com/role/EquityMethodInvestmentDetailsNarrative",
"http://pavmed.com/role/ScheduleOfFairValueAssumptionUsedDetails", "http://pavmed.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-
us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r264", "r265", "r266", "r267", "r353", "r384", "r422", "r475", "r500", "r502", "r509", "r540", "r541", "r598",
"r603", "r606", "r607", "r619", "r635", "r636", "r650", "r658", "r664", "r672", "r673", "r674", "r675", "r680", "r835", "r888", "r889", "r890", "r891", "r892", "r893" ] },
"ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]" } } }, "auth_ref": [ "r745" ] }, "ecd_MeasureName": { "xbrltype":
"normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": {
"en-us": { "role": { "label": "Name" } } }, "auth_ref": [ "r745" ] }, "us-gaap_MeasurementInputConversionPriceMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "MeasurementInputConversionPriceMember", "presentation": [
"http://pavmed.com/role/ScheduleOfFairValueAssumptionUsedDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Conversion Price [Member]",
"documentation": "Measurement input using price per share at which convertible share can be converted into common stock." } } }, "auth_ref": [ "r867", "r868", "r869" ] },
"us-gaap_MeasurementInputExpectedDividendRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"MeasurementInputExpectedDividendRateMember", "presentation": [ "http://pavmed.com/role/ScheduleOfFairValueAssumptionUsedDetails" ], "lang": { "en-us": { "role": {
"label": "Measurement Input, Expected Dividend Rate [Member]", "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
} } }, "auth_ref": [ "r867", "r868", "r869" ] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "MeasurementInputExpectedTermMember", "presentation": [ "http://pavmed.com/role/ScheduleOfFairValueAssumptionUsedDetails" ], "lang": { "en-us": { "role":
{ "label": "Measurement Input, Expected Term [Member]", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes
maturity date." } } }, "auth_ref": [ "r867", "r868", "r869" ] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [ "http://pavmed.com/role/ScheduleOfFairValueAssumptionUsedDetails" ], "lang": { "en-
us": { "role": { "label": "Measurement Input, Price Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease)
for given set of returns." } } }, "auth_ref": [ "r672", "r867", "r868", "r869" ] }, "PAVM_MeasurementInputRequiredRateOfReturnMember": { "xbrltype": "domainItemType",
"nsuri": "http://pavmed.com/20240930", "localname": "MeasurementInputRequiredRateOfReturnMember", "presentation": [
"http://pavmed.com/role/ScheduleOfFairValueAssumptionUsedDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input Required Rate of Return [Member]",
"documentation": "Measurement Input Required Rate of Return [Member]" } } }, "auth_ref": [] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [
"http://pavmed.com/role/ScheduleOfFairValueAssumptionUsedDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Risk Free Interest Rate [Member]",
"documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": [ "r867", "r868", "r869" ] }, "us-
gaap_MeasurementInputSharePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputSharePriceMember",
"presentation": [ "http://pavmed.com/role/ScheduleOfFairValueAssumptionUsedDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Share Price [Member]",
"documentation": "Measurement input using share price of saleable stock." } } }, "auth_ref": [ "r867", "r868", "r869" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeAxis", "presentation": [
"http://pavmed.com/role/ScheduleOfFairValueAssumptionUsedDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information
by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r420", "r421", "r422", "r672" ] }, "us-gaap_MeasurementInputTypeDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeDomain", "presentation": [
"http://pavmed.com/role/ScheduleOfFairValueAssumptionUsedDetails" ], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset
and liability." } } }, "auth_ref": [ "r420", "r421", "r422", "r672" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"MinimumMember", "presentation": [ "http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative",
"http://pavmed.com/role/ScheduleOfFairValueAssumptionUsedDetails", "http://pavmed.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-
us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r264", "r265", "r266", "r267", "r353", "r384", "r422", "r475", "r500", "r502", "r509", "r540", "r541", "r598",
"r603", "r606", "r607", "r619", "r635", "r636", "r650", "r658", "r664", "r672", "r673", "r674", "r680", "r835", "r888", "r889", "r890", "r891", "r892", "r893" ] }, "us-
gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit", "calculation": {
"http://pavmed.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } },
"presentation": [ "http://pavmed.com/role/BalanceSheets", "http://pavmed.com/role/ScheduleOfNoncontrollingInterestOfStockholdersEquityDetails" ], "lang": { "en-us": {
"role": { "label": "Noncontrolling interests", "periodStartLabel": "NCI \u2013 equity - December 31, 2023", "periodEndLabel": "NCI \u2013 equity - September 30, 2024",
"documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r87", "r130", "r180", "r234", "r270",
"r272", "r273", "r274", "r277", "r278", "r440", "r489", "r553" ] }, "us-gaap_MinorityInterestDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "MinorityInterestDisclosureTextBlock", "presentation": [ "http://pavmed.com/role/NoncontrollingInterest" ], "lang": { "en-us": {
"role": { "label": "Noncontrolling Interest", "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of
the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the
location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the
noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of
the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the
preferred stock, and the dividend requirements of the preferred stock." } } }, "auth_ref": [ "r122" ] }, "us-gaap_MinorityInterestLineItems": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestLineItems", "presentation": [ "http://pavmed.com/role/NoncontrollingInterestDetailsNarrative" ], "lang":
{ "en-us": { "role": { "label": "Noncontrolling Interest [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to
disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-
gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"MinorityInterestOwnershipPercentageByNoncontrollingOwners", "presentation": [ "http://pavmed.com/role/EquityMethodInvestmentDetailsNarrative",
"http://pavmed.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity method investment, ownership percentage",
"documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity." } } }, "auth_ref": [] }, "us-
gaap_MinorityInterestTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestTable", "presentation": [
"http://pavmed.com/role/NoncontrollingInterestDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Table]", "documentation": "Disclosure of
information about noncontrolling interest, including, but not limited to, name of subsidiary, ownership percentage held by parent, ownership percentage held by
noncontrolling owner, amount of noncontrolling interest and its location in statement of financial position, explanation of increase (decrease) in noncontrolling interest,
noncontrolling interest share of net income (loss) of subsidiary and its location in statement of income, amount of noncontrolling interest represented by preferred stock,
description and dividend requirement of preferred stock, and nature of noncontrolling interest." } } }, "auth_ref": [ "r53", "r54", "r87", "r90" ] },
"ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag",
"presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value" } } },
"auth_ref": [ "r764" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading
Arrangement" } } }, "auth_ref": [ "r772" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive
Officers, Footnote" } } }, "auth_ref": [ "r746" ] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NatureOfOperations", "presentation": [ "http://pavmed.com/role/Company" ], "lang": { "en-us": { "role": { "label": "The Company", "documentation": "The entire disclosure for
the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the
basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks
and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [
"r140", "r146" ] }, "PAVM_NetAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "NetAssets", "crdr": "debit", "calculation": {
"http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net Assets of Lucid Diagnostics at September 10, 2024",
"documentation": "Net assets.", "label": "NetAssets" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": {
"http://pavmed.com/role/StatementsOfCashFlows": { "parentTag": "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation":
[ "http://pavmed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash flows provided by financing activities", "label": "Net Cash Provided by
(Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows
```

include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r175"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://pavmed.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://pavmed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://pavmed.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net cash flows provided by (used in) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r175"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://pavmed.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://pavmed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://pavmed.com/role/LiquidityAndGoingConcernDetailsNarrative", "http://pavmed.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net cash flows used in operating activities", "negatedLabel": "Net cash flows used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r100", "r101", "r103"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://pavmed.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://pavmed.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://pavmed.com/role/ScheduleOfAggregateInformationFromFinancialStatementsDetails", "http://pavmed.com/role/ScheduleOfComparisonOfBasicAndFullyDilutedNetLossPerShareDetails", "http://pavmed.com/role/StatementsOfOperations", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss) attributable to PAVmed Inc.", "label": "Net Income (Loss)", "verboseLabel": "Net income (loss)", "terseLabel": "Net income (loss) - as reported, attributable to PAVmed Inc.", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r92", "r103", "r133", "r152", "r166", "r167", "r170", "r180", "r185", "r187", "r188", "r189", "r190", "r191", "r194", "r195", "r202", "r234", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r394", "r398", "r416", "r440", "r495", "r572", "r590", "r591", "r690", "r831"] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://pavmed.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://pavmed.com/role/ScheduleOfComparisonOfBasicAndFullyDilutedNetLossPerShareDetails", "http://pavmed.com/role/ScheduleOfNoncontrollingInterestOfStockholdersEquityDetails", "http://pavmed.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "negatedLabel": "Net loss attributable to the noncontrolling interests", "label": "Net loss attributable to NCI", "negatedTerseLabel": "Net income (loss) attributable to noncontrolling interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r63", "r124", "r166", "r167", "r191", "r194", "r195", "r494", "r788"] }, "PAVM_NetIncomeLossAvailableToCommonStockholders": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "NetIncomeLossAvailableToCommonStockholders", "crdr": "credit", "presentation": ["http://pavmed.com/role/ScheduleOfComparisonOfBasicAndFullyDilutedNetLossPerShareDetails"], "lang": { "en-us": { "role": { "label": "Net income (loss) attributable to PAVmed Inc. common stockholders used in dilutive EPS calculation", "documentation": "Net income loss available to common stockholders" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://pavmed.com/role/StatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://pavmed.com/role/LiquidityAndGoingConcernDetailsNarrative", "http://pavmed.com/role/ScheduleOfComparisonOfBasicAndFullyDilutedNetLossPerShareDetails", "http://pavmed.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss) attributable to PAVmed Inc. common stockholders", "label": "Net loss attributable to common stockholders", "verboseLabel": "Net income (loss) attributable to PAVmed Inc. common stockholders used in basic EPS calculation", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": ["r173", "r187", "r188", "r189", "r190", "r197", "r198", "r203", "r206", "r398"] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": ["http://pavmed.com/role/Cover"], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description" } } }, "auth_ref": ["r745"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r743"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r742"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r772"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r772"] }, "us-gaap_NoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestAbstract", "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestIncreaseFromBusinessCombination", "crdr": "credit", "presentation": ["http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "negatedLabel": "Subsidiary deemed dividends on preferred stock attributable to noncontrolling interests", "label": "Noncontrolling Interest, Increase from Business Combination", "documentation": "Amount of increase in noncontrolling interest from a business combination." } } }, "auth_ref": ["r10", "r35", "r47"] }, "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance", "crdr": "credit", "presentation": ["http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Purchase - subsidiary common stock - Employee Stock Purchase Plan", "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders." } } }, "auth_ref": ["r10", "r35", "r123"] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": ["http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": ["r52", "r325", "r797", "r798", "r799", "r800", "r902"] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://pavmed.com/role/StatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://pavmed.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "totalLabel": "Other income (expense), net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r94"] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": ["http://pavmed.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Other income (expense):" } } }, "auth_ref": [] }, "us-gaap_NotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayable", "crdr": "credit", "presentation": ["http://pavmed.com/role/DebtDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Notes payable", "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": ["r16", "r128", "r895", "r896"] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://pavmed.com/role/StatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://pavmed.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "totalLabel": "Operating loss", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r136", "r647", "r803", "r804", "r805", "r806", "r807"] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": ["http://pavmed.com/role/LeasesDetailsNarrative", "http://pavmed.com/role/ScheduleOfFutureMinimumLeasePaymentsForOperatingLeasesDetails"], "lang": { "en-us": { "role": { "label": "Present value of lease liabilities", "verboseLabel": "Operating lease obligations", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r456"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://pavmed.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 }, "http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://pavmed.com/role/BalanceSheets", "http://pavmed.com/role/LeasesDetailsNarrative", "http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails"], "lang": { "en-us": { "role": { "label": "Operating lease liabilities, current portion", "verboseLabel": "Operating lease, liability, current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r456"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://pavmed.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 }, "http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://pavmed.com/role/BalanceSheets", "http://pavmed.com/role/LeasesDetailsNarrative", "http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails"], "lang": { "en-us": { "role": { "label": "Operating lease liabilities, less current portion", "verboseLabel": "Operating lease liability noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r456"] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": ["http://pavmed.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToCashAndNon-cashActivitiesWithLeasesDetails"], "lang": { "en-us": { "role": { "label": "Operating cash flows from operating leases", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r457", "r458"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://pavmed.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 }, "http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://pavmed.com/role/BalanceSheets", "http://pavmed.com/role/LeasesDetailsNarrative", "http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails"], "lang": { "en-us": { "role": { "label": "Operating lease right-of-use assets", "verboseLabel": "Operating lease, right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r455"] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://pavmed.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToCashAndNon-cashActivitiesWithLeasesDetails"], "lang": { "en-us": { "role": { "label": "Weighted-average discount rate - operating leases", "documentation": "Weighted average discount

rate for operating lease calculated at point in time." } } }, "auth_ref": ["r461", "r677"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": ["http://pavmed.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToCashAndNon-cashActivitiesWithLeasesDetails"], "lang": { "en-us": { "role": { "label": "Weighted-average remaining lease term - operating leases (in years)", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r460", "r677"] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://pavmed.com/role/DebtDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Acceleration floor payments", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r73"] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "presentation": ["http://pavmed.com/role/ScheduleOfAggregateInformationFromFinancialStatementsDetails"], "lang": { "en-us": { "role": { "label": "Other current assets", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": ["r164", "r678"] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 }, "http://pavmed.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://pavmed.com/role/BalanceSheets", "http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails"], "lang": { "en-us": { "role": { "label": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r157"] }, "PAVM_OtherIncomeExpenseChangeInFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "OtherIncomeExpenseChangeInFairValue", "crdr": "debit", "presentation": ["http://pavmed.com/role/ScheduleOfChangesInFairValueOfDebtDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Other Income (Expense) - Change in fair value", "documentation": "Other income expense change in fair value.", "label": "OtherIncomeExpenseChangeInFairValue" } } }, "auth_ref": [] }, "PAVM_OtherIncomeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://pavmed.com/20240930", "localname": "OtherIncomeExpenseMember", "presentation": ["http://pavmed.com/role/ScheduleOfChangesInFairValueOfDebtDetails"], "lang": { "en-us": { "role": { "label": "Other Income Expense [Member]", "documentation": "Other Income Expense [Member]" } } }, "auth_ref": [] }, "PAVM_OtherInfiniteLivedIntangibleAssetMember": { "xbrltype": "domainItemType", "nsuri": "http://pavmed.com/20240930", "localname": "OtherInfiniteLivedIntangibleAssetMember", "presentation": ["http://pavmed.com/role/ScheduleOfIntangibleAssetsLessAccumulatedAmortizationDetails"], "lang": { "en-us": { "role": { "label": "Other Infinite Lived Intangible Asset [Member]", "documentation": "Other Infinite Lived Intangible Asset [Member]" } } }, "auth_ref": [] }, "us-gaap_OtherNoncashExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashExpense", "crdr": "debit", "calculation": { "http://pavmed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": ["http://pavmed.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Non-cash lease expense", "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other." } } }, "auth_ref": ["r103"] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount" } } }, "auth_ref": ["r745"] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": ["http://pavmed.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": ["r706"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r713", "r724", "r734", "r759"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Amount" } } }, "auth_ref": ["r716", "r727", "r737", "r762"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": ["r716", "r727", "r737", "r762"] }, "PAVM_OutstandingSharesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://pavmed.com/20240930", "localname": "OutstandingSharesPercentage", "presentation": ["http://pavmed.com/role/NoncontrollingInterestDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Outstanding shares, percentage", "documentation": "Outstanding shares percentage." } } }, "auth_ref": [] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipAxis", "presentation": ["http://pavmed.com/role/EquityMethodInvestmentDetailsNarrative", "http://pavmed.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipDomain", "presentation": ["http://pavmed.com/role/EquityMethodInvestmentDetailsNarrative", "http://pavmed.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"], "auth_ref": [] }, "PAVM_PAVmedIncTwoThousandFourteenEquityPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://pavmed.com/20240930", "localname": "PAVmedIncTwoThousandFourteenEquityPlanMember", "presentation": ["http://pavmed.com/role/ScheduleOfStock-basedCompensationExpenseRecognizedByLucidDiagnosticsDetails", "http://pavmed.com/role/ScheduleOfUnrecognizedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "PAVmed Inc 2014 Equity Plan [Member]", "documentation": "PAVmed Inc 2014 Equity Plan [Member]" } } }, "auth_ref": [] }, "srt_ParentCompanyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ParentCompanyMember", "presentation": ["http://pavmed.com/role/ScheduleOfSummarizesInformationAboutStockOptionsDetailsParenthetical", "http://pavmed.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Parent Company [Member]" } } }, "auth_ref": ["r181"] }, "us-gaap_PartnersCapitalAccountUnitsAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PartnersCapitalAccountUnitsAcquisitions", "presentation": ["http://pavmed.com/role/NoncontrollingInterestDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Partners capital account units acquisitions", "documentation": "Change in the number of units for each class of partners' capital accounts during the year due to acquisitions. Partners include general, limited and preferred partners." } } }, "auth_ref": ["r48", "r49", "r50", "r51", "r113"] }, "PAVM_PartnersCapitalAccountUnitsDescription": { "xbrltype": "stringItemType", "nsuri": "http://pavmed.com/20240930", "localname": "PartnersCapitalAccountUnitsDescription", "presentation": ["http://pavmed.com/role/NoncontrollingInterestDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Partners capital account units description", "documentation": "Partners capital account units, description." } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "auth_ref": ["r741"] }, "PAVM_PaymentsForCommissionsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://pavmed.com/20240930", "localname": "PaymentsForCommissionsPercentage", "presentation": ["http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Payments for commissions percentage", "documentation": "Payments for commissions percentage." } } }, "auth_ref": [] }, "us-gaap_PaymentsForFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForFees", "crdr": "credit", "presentation": ["http://pavmed.com/role/EquityMethodInvestmentDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Assignment fee", "documentation": "Amount of cash outflow for fees classified as other." } } }, "auth_ref": ["r5"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://pavmed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://pavmed.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r98"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r744"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r744"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r743"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name" } } }, "auth_ref": ["r746"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount" } } }, "auth_ref": ["r742"] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://pavmed.com/role/NetIncomeLossPerShareDetailsNarrative", "http://pavmed.com/role/ScheduleOfFairValuesOfStockOptionsGrantedUsingBlack-scholesValuationModelAssumptionsDetails", "http://pavmed.com/role/ScheduleOfRestrictedStockAwardActivityDetails", "http://pavmed.com/role/ScheduleOfStock-basedCompensationExpenseRecognizedByLucidDiagnosticsDetails", "http://pavmed.com/role/ScheduleOfSummarizesInformationAboutStockOptionsDetails", "http://pavmed.com/role/ScheduleOfSummarizesInformationAboutStockOptionsDetailsParenthetical", "http://pavmed.com/role/ScheduleOfUnrecognizedCompensationExpenseDetails", "http://pavmed.com/role/Stock-basedCompensationDetailsNarrative", "http://pavmed.com/role/Stock-basedCompensationTables"], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://pavmed.com/role/NetIncomeLossPerShareDetailsNarrative", "http://pavmed.com/role/ScheduleOfFairValuesOfStockOptionsGrantedUsingBlack-scholesValuationModelAssumptionsDetails", "http://pavmed.com/role/ScheduleOfRestrictedStockAwardActivityDetails", "http://pavmed.com/role/ScheduleOfStock-basedCompensationExpenseRecognizedByLucidDiagnosticsDetails", "http://pavmed.com/role/ScheduleOfSummarizesInformationAboutStockOptionsDetails", "http://pavmed.com/role/ScheduleOfSummarizesInformationAboutStockOptionsDetailsParenthetical", "http://pavmed.com/role/ScheduleOfUnrecognizedCompensationExpenseDetails", "http://pavmed.com/role/Stock-basedCompensationDetailsNarrative", "http://pavmed.com/role/Stock-basedCompensationTables"], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861"] }, "us-gaap_PledgingPurposeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PledgingPurposeAxis", "presentation": ["http://pavmed.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Pledging Purpose [Axis]", "documentation": "Information by pledging purpose of pledged asset owned." } } }, "auth_ref": ["r472", "r666", "r679", "r783"] }, "us-gaap_PledgingPurposeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PledgingPurposeDomain", "presentation": ["http://pavmed.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Pledging purpose of pledged asset owned." } } }, "auth_ref": ["r472", "r666", "r679", "r783"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r743"] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": ["http://pavmed.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": ["r700"] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": ["http://pavmed.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": ["r702"] }, "us-gaap_PreferredStockConvertibleConversionPrice": {

```
"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockConvertibleConversionPrice", "presentation": [
"http://pavmed.com/role/NoncontrollingInterestDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred shares conversion price", "documentation": "Per share
conversion price of preferred stock." } } }, "auth_ref": [ "r310" ] }, "us-gaap_PreferredStockDividendRatePercentage": { "xbrltype": "percentItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "PreferredStockDividendRatePercentage", "presentation": [ "http://pavmed.com/role/NoncontrollingInterestDetailsNarrative",
"http://pavmed.com/role/PreferredStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Dividend rate percentage", "verboseLabel": "Dividend percentage",
"documentation": "The percentage rate used to calculate dividend payments on preferred stock." } } }, "auth_ref": [ "r309", "r599", "r604", "r605", "r620" ] },
"PAVM_PreferredStockDividendsAttributableToNonControllingInterests": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname":
"PreferredStockDividendsAttributableToNonControllingInterests", "crdr": "debit", "calculation": { "http://pavmed.com/role/StatementsOfOperations": { "parentTag": "us-
gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://pavmed.com/role/StatementsOfOperations" ], "lang": {
"en-us": { "role": { "negatedLabel": "Less: Deemed dividend on Subsidiary Preferred Stock attributable to the noncontrolling interests", "documentation": "Deemed dividend
on Subsidiary Preferred Stock attributable to the noncontrolling interests.", "label": "PreferredStockDividendsAttributableToNonControllingInterests" } } }, "auth_ref": [] },
"us-gaap_PreferredStockDividendsIncomeStatementImpact": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PreferredStockDividendsIncomeStatementImpact", "crdr": "debit", "calculation": { "http://pavmed.com/role/StatementsOfOperations": { "parentTag": "us-
gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://pavmed.com/role/PreferredStockDetailsNarrative",
"http://pavmed.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Series B Convertible Preferred Stock dividends earned", "label":
"Dividends earned", "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders." } } }, "auth_ref":
[] }, "PAVM_PreferredStockDividendsSeriesB": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "PreferredStockDividendsSeriesB",
"crdr": "debit", "presentation": [ "http://pavmed.com/role/ScheduleOfComparisonOfBasicAndFullyDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label":
"Series B Convertible Preferred Stock dividends \u2013 earned", "documentation": "Convertible Preferred Stock dividends Series B." } } }, "auth_ref": [] }, "us-
gaap_PreferredStockDividendsShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockDividendsShares", "presentation":
[ "http://pavmed.com/role/PreferredStockDetailsNarrative", "http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label":
"Dividends declared - Series B Convertible Preferred Stock, shares", "verboseLabel": "Additioanal aggregate shares of convertible preferred stock", "documentation": "Number
of shares of preferred stock issued as dividends during the period. Excludes stock splits." } } }, "auth_ref": [ "r11" ] }, "us-gaap_PreferredStockMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockMember", "presentation": [
"http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "documentation": "Preferred
shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares
typically represent an ownership interest in the company." } } }, "auth_ref": [ "r681", "r682", "r685", "r686", "r687", "r688", "r898", "r902" ] }, "us-
gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PreferredStockParOrStatedValuePerShare", "presentation": [ "http://pavmed.com/role/BalanceSheetsParenthetical",
"http://pavmed.com/role/NoncontrollingInterestDetailsNarrative", "http://pavmed.com/role/PreferredStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred
stock, par value", "verboseLabel": "Preferred stock stated value per share", "terseLabel": "Issuance of shares, stated value", "documentation": "Face amount or stated value per
share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r82", "r308" ] }, "us-gaap_PreferredStockSharesAuthorized": {
"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [
"http://pavmed.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized", "documentation": "The maximum number of
nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [
"r82", "r551" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued",
"presentation": [ "http://pavmed.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued", "documentation": "Number of
shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued,
repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r82", "r308" ] }, "us-gaap_PreferredStockSharesOutstanding": {
"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [
"http://pavmed.com/role/BalanceSheetsParenthetical", "http://pavmed.com/role/PreferredStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock,
shares outstanding", "verboseLabel": "Preferred stock shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred
stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r82", "r551",
"r570", "r902", "r903" ] }, "PAVM_PreferredStockStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://pavmed.com/20240930", "localname":
"PreferredStockStatedValuePerShare", "presentation": [ "http://pavmed.com/role/PreferredStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock
stated value per share", "documentation": "Preferred stock stated value per share." } } }, "auth_ref": [] }, "us-gaap_PreferredStockTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockTextBlock", "presentation": [ "http://pavmed.com/role/PreferredStock" ], "lang": {
"en-us": { "role": { "label": "Preferred Stock", "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other
matters related to preferred stock." } } }, "auth_ref": [ "r110" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://pavmed.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0,
"order": 1.0 } }, "presentation": [ "http://pavmed.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred stock, $0.001 par value. Authorized, 20,000,000
shares; Series B Convertible Preferred Stock, par value $0.001, issued and outstanding 1,385,149 at September 30, 2024 and 1,305,213 shares at December 31, 2023",
"documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item
includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another
section within stockholders' equity." } } }, "auth_ref": [ "r82", "r486", "r678" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": {
"http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 },
"http://pavmed.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 },
"http://pavmed.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://pavmed.com/role/BalanceSheets", "http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails",
"http://pavmed.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses, deposits, and other current
assets", "totalLabel": "Total prepaid expenses, deposits and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that
provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
} } }, "auth_ref": [ "r787" ] }, "PAVM_PrepaidExpensesDepositsAndOtherAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://pavmed.com/20240930",
"localname": "PrepaidExpensesDepositsAndOtherAssetsTextBlock", "presentation": [ "http://pavmed.com/role/PrepaidExpensesDepositsAndOtherCurrentAssets" ], "lang": {
"en-us": { "role": { "label": "Prepaid Expenses, Deposits, and Other Current Assets", "documentation": "Prepaid Expenses Deposits And Other Assets [Text Block]" } } },
"auth_ref": [] }, "us-gaap_PrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidInsurance", "crdr": "debit",
"calculation": { "http://pavmed.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
"weight": 1.0, "order": 2.0 } }, "presentation": [ "http://pavmed.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label":
"Prepaid insurance", "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one
year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r643", "r651", "r813" ] }, "PAVM_PrepaidServiceProvidersAndSuppliers": { "xbrltype": "monetaryItemType",
"nsuri": "http://pavmed.com/20240930", "localname": "PrepaidServiceProvidersAndSuppliers", "crdr": "debit", "calculation": {
"http://pavmed.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order":
1.0 } }, "presentation": [ "http://pavmed.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Advanced payments to
service providers and suppliers", "documentation": "Prepaid service providers and suppliers." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromFeesReceived": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromFeesReceived", "crdr": "debit", "presentation": [
"http://pavmed.com/role/NoncontrollingInterestDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Received from payment of fees", "documentation": "Cash received for
fees during the current period. This element excludes cash proceeds from license fees." } } }, "auth_ref": [ "r102" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": {
"http://pavmed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://pavmed.com/role/StatementsOfCashFlows", "http://pavmed.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds
\u2013 issue of common stock - At-The-Market Facility", "verboseLabel": "Proceeds from common stock", "documentation": "The cash inflow from the additional capital
contribution to the entity." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "crdr": "debit", "presentation": [
"http://pavmed.com/role/NoncontrollingInterestDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Gross proceeds, sale of shares", "documentation": "The cash inflow
from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock." } } }, "auth_ref": [ "r2" ] },
"us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "crdr": "debit", "calculation": { "http://pavmed.com/role/StatementsOfCashFlows": { "parentTag": "us-
gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://pavmed.com/role/NoncontrollingInterestDetailsNarrative",
"http://pavmed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds \u2013 issue of preferred stock - subsidiary", "verboseLabel": "Gross
proceeds", "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common
stockholders and which takes precedence over common stockholders in the event of liquidation." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ProceedsFromIssuanceOfSecuredDebt":
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfSecuredDebt", "crdr": "debit", "calculation": {
"http://pavmed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://pavmed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds \u2013 issue of Senior Secured Convertible Note", "documentation": "The
cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt." } } },
"auth_ref": [ "r17" ] }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans", "crdr": "debit", "calculation": {
"http://pavmed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [
"http://pavmed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds \u2013 issue common stock \u2013 Employee Stock Purchase Plan",
"documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised." } } }, "auth_ref": [ "r2", "r14" ] }, "us-
gaap_ProceedsFromSaleOfPropertyHeldForSale": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromSaleOfPropertyHeldForSale", "crdr": "debit", "calculation": { "http://pavmed.com/role/StatementsOfCashFlows": { "parentTag": "us-
gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://pavmed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": {
"role": { "label": "Proceeds from sale of intellectual property", "documentation": "The cash inflow from the sale of formerly productive land held for sale, anything permanently
fixed to it, including buildings, structures on it, and so forth." } } }, "auth_ref": [ "r97" ] }, "PAVM_ProceedsFromSaleOfPropertyHeldForSales": { "xbrltype":
"monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "ProceedsFromSaleOfPropertyHeldForSales", "crdr": "debit", "calculation": {
"http://pavmed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://pavmed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from sale of intellectual property to Lucid Diagnostics Inc.",
"documentation": "Proceeds from sale of intellectual property." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://pavmed.com/role/StatementsOfCashFlows":
{ "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://pavmed.com/role/StatementsOfCashFlows" ],
"lang": { "en-us": { "role": { "label": "Proceeds \u2013 exercise of stock options issued under equity plan of subsidiary", "documentation": "Amount of cash inflow from
exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r2", "r14" ] },
```

```
"PAVM_ProceedsSubsidiaryCommonStockCommittedEquityFacilityAndAtthemarketFacility": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "ProceedsSubsidiaryCommonStockCommittedEquityFacilityAndAtthemarketFacility", "crdr": "debit", "calculation": { "http://pavmed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://pavmed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds \u2013 subsidiary common stock - Committed Equity Facility and At-The-Market Facility", "documentation": "Proceeds subsidiary common stock - committed equity facility and at the market facility." } } }, "auth_ref": [] },
"PAVM_ProceedsSubsidiaryCommonStockEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "ProceedsSubsidiaryCommonStockEmployeeStockPurchasePlan", "crdr": "debit", "calculation": { "http://pavmed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://pavmed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds \u2013 subsidiary common stock \u2013 Employee Stock Purchase Plan", "documentation": "Proceeds subsidiary common stock employee stock purchase plan" } } }, "auth_ref": [] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://pavmed.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://pavmed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://pavmed.com/role/ScheduleOfComparisonOfBasicAndFullyDilutedNetLossPerShareDetails", "http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit", "http://pavmed.com/role/StatementsOfCashFlows", "http://pavmed.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss) before noncontrolling interests", "label": "Net Loss", "verboseLabel": "Net income (loss) - before noncontrolling interest (\u201cNCI\u201d)", "terseLabel": "Net income (loss) - before noncontrolling interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r152", "r166", "r167", "r174", "r180", "r185", "r191", "r194", "r195", "r234", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r394", "r398", "r400", "r403", "r404", "r416", "r440", "r481", "r493", "r517", "r572", "r590", "r591", "r667", "r668", "r691", "r788", "r831" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://pavmed.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://pavmed.com/role/BalanceSheets", "http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Fixed assets, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r8", "r463", "r482", "r491", "r678" ] }, "PAVM_PurchaseMajorityownedSubsidiaryCommonStockEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "PurchaseMajorityownedSubsidiaryCommonStockEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [ "http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Purchase - majority-owned subsidiary common stock - Employee Stock Purchase Plan", "documentation": "Purchase majority owned subsidiary common stock employee stock purchase plan." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r741" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r741" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative", "http://pavmed.com/role/EquityMethodInvestmentDetailsNarrative", "http://pavmed.com/role/ScheduleOfFairValueAssumptionUsedDetails", "http://pavmed.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r264", "r265", "r266", "r267", "r345", "r353", "r379", "r380", "r381", "r384", "r422", "r470", "r474", "r475", "r500", "r502", "r509", "r540", "r541", "r598", "r603", "r606", "r607", "r619", "r635", "r636", "r650", "r658", "r664", "r672", "r673", "r674", "r675", "r680", "r683", "r828", "r835", "r868", "r889", "r890", "r891", "r892", "r893" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative", "http://pavmed.com/role/EquityMethodInvestmentDetailsNarrative", "http://pavmed.com/role/ScheduleOfFairValueAssumptionUsedDetails", "http://pavmed.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "auth_ref": [ "r264", "r265", "r266", "r267", "r345", "r353", "r379", "r380", "r381", "r384", "r422", "r470", "r474", "r475", "r500", "r502", "r509", "r540", "r541", "r598", "r603", "r606", "r607", "r619", "r635", "r636", "r650", "r658", "r664", "r672", "r673", "r674", "r675", "r680", "r683", "r828", "r835", "r868", "r889", "r890", "r891", "r892", "r893" ] }, "PAVM_RecentAccountingStandardsUpdatesNotYetAdoptedPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://pavmed.com/20240930", "localname": "RecentAccountingStandardsUpdatesNotYetAdoptedPolicyTextBlock", "presentation": [ "http://pavmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recent Accounting Standards Updates Not Yet Adopted", "documentation": "Recent Accounting Standards Updates Not Yet Adopted [Policy Text Block]" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "auth_ref": [ "r708", "r719", "r729", "r754" ] }, "us-gaap_RepaymentsOfConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfConvertibleDebt", "crdr": "credit", "presentation": [ "http://pavmed.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Repayment for debt", "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r99" ] }, "us-gaap_RepaymentsOfSecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfSecuredDebt", "crdr": "credit", "calculation": { "http://pavmed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://pavmed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payment \u2013 Senior Secured Convertible Note \u2013 acceleration floor payments", "label": "Repayments of Secured Debt", "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt." } } }, "auth_ref": [ "r99" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://pavmed.com/role/StatementsOfOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://pavmed.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r385", "r638", "r648", "r894" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://pavmed.com/role/ScheduleOfStock-basedCompensationExpenseDetails", "http://pavmed.com/role/ScheduleOfStock-basedCompensationExpenseRecognizedByLucidDiagnosticsDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r709", "r720", "r730", "r755" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date" } } }, "auth_ref": [ "r710", "r721", "r731", "r756" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement does not require Recovery" } } }, "auth_ref": [ "r717", "r728", "r738", "r763" ] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [ "http://pavmed.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r155" ] }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashCurrent", "crdr": "debit", "presentation": [ "http://pavmed.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash", "label": "Restricted Cash, Current", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r784", "r792" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": [ "http://pavmed.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedEarningsPerShareDetails", "http://pavmed.com/role/ScheduleOfUnrecognizedCompensationExpenseDetails", "http://pavmed.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r22" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://pavmed.com/role/ScheduleOfRestrictedStockAwardActivityDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://pavmed.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://pavmed.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r85", "r113", "r488", "r507", "r508", "r515", "r552", "r678" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r150", "r182", "r183", "r184", "r186", "r191", "r193", "r195", "r236", "r237", "r253", "r388", "r389", "r391", "r392", "r393", "r395", "r397", "r398", "r407", "r409", "r410", "r412", "r414", "r451", "r454", "r504", "r506", "r518", "r902" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://pavmed.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://pavmed.com/role/RevenueFromContractsWithCustomersDetailsNarrative", "http://pavmed.com/role/ScheduleOfAggregateInformationFromFinancialStatementsDetails", "http://pavmed.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r134", "r135", "r211", "r216", "r217", "r224", "r226", "r227", "r228", "r229", "r342", "r343", "r476" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://pavmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r148", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r639" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://pavmed.com/role/RevenueFromContractsWithCustomers" ], "lang": { "en-us": { "role": { "label": "Revenue from Contracts with Customers", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r148", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333",
```

"r344"] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "presentation": ["http://pavmed.com/role/LiquidityAndGoingConcernDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": ["r134", "r135", "r171", "r180", "r211", "r216", "r217", "r224", "r226", "r227", "r228", "r229", "r234", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r440", "r481", "r648", "r831"] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": ["http://pavmed.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToCashAndNon-cashActivitiesWithLeasesDetails"], "lang": { "en-us": { "role": { "label": "Right-of-use assets obtained in exchange for new operating lease liabilities", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": ["r459", "r677"] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r772"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r772"] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": ["http://pavmed.com/role/NoncontrollingInterestDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Sale of stock, transaction value", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://pavmed.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedEarningsPerShareDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r22"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://pavmed.com/role/NetIncomeLossPerShareTables"], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r22"] }, "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAssumptionsUsedTableTextBlock", "presentation": ["http://pavmed.com/role/FinancialInstrumentsFairValueMeasurementsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value Assumption Used", "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate." } } }, "auth_ref": ["r352"] }, "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "presentation": ["http://pavmed.com/role/DebtTables"], "lang": { "en-us": { "role": { "label": "Schedule of Changes in Fair Value of Debt", "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "presentation": ["http://pavmed.com/role/Stock-basedCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Stock-Based Compensation Expense", "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit." } } }, "auth_ref": ["r40"] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtTableTextBlock", "presentation": ["http://pavmed.com/role/DebtTables"], "lang": { "en-us": { "role": { "label": "Summary of Outstanding Debt", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "PAVM_ScheduleOfDeconsolidationOfNetAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://pavmed.com/20240930", "localname": "ScheduleOfDeconsolidationOfNetAssetsTableTextBlock", "presentation": ["http://pavmed.com/role/EquityMethodInvestmentTables"], "lang": { "en-us": { "role": { "label": "Schedule of Deconsolidation of Net Assets", "documentation": "Schedule of Deconsolidation of Net Assets [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://pavmed.com/role/NetIncomeLossPerShareTables"], "lang": { "en-us": { "role": { "label": "Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r802"] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": ["http://pavmed.com/role/FinancialInstrumentsFairValueMeasurementsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r865", "r866"] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": ["http://pavmed.com/role/IntangibleAssetsNetTables"], "lang": { "en-us": { "role": { "label": "Schedule of Intangible Assets, Less Accumulated Amortization", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": ["r652", "r819"] }, "PAVM_ScheduleOfNetLossAttributableToCommonStockholdersTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://pavmed.com/20240930", "localname": "ScheduleOfNetLossAttributableToCommonStockholdersTableTextBlock", "presentation": ["http://pavmed.com/role/NoncontrollingInterestTables"], "lang": { "en-us": { "role": { "label": "Schedule of Net Loss Attributable to Common Stockholders", "documentation": "Schedule Of Net Loss Attributable To Common Stockholders [Table Text Block]" } } }, "auth_ref": [] }, "PAVM_ScheduleOfNoncontrollingInterestOfStockholdersEquityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://pavmed.com/20240930", "localname": "ScheduleOfNoncontrollingInterestOfStockholdersEquityTableTextBlock", "presentation": ["http://pavmed.com/role/NoncontrollingInterestTables"], "lang": { "en-us": { "role": { "label": "Schedule of Noncontrolling Interest of Stockholders' Equity", "documentation": "Schedule Of Noncontrolling Interest Of Stockholders Equity [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://pavmed.com/role/NetIncomeLossPerShareDetailsNarrative", "http://pavmed.com/role/ScheduleOfFairValuesOfStockOptionsGrantedUsingBlack-scholesValuationModelAssumptionsDetails", "http://pavmed.com/role/ScheduleOfRestrictedStockAwardActivityDetails", "http://pavmed.com/role/ScheduleOfSummarizesInformationAboutStockOptionsDetails", "http://pavmed.com/role/ScheduleOfUnrecognizedCompensationExpenseDetails", "http://pavmed.com/role/Stock-basedCompensationDetailsNarrative", "http://pavmed.com/role/Stock-basedCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r354", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382"] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": ["http://pavmed.com/role/Stock-basedCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Restricted Stock Award Activity", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": ["r119"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://pavmed.com/role/Stock-basedCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Summarizes Information About Stock Options", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r12", "r13", "r119"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": ["http://pavmed.com/role/Stock-basedCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": ["r121"] }, "us-gaap_ScheduleOfShortTermDebtTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShortTermDebtTable", "presentation": ["http://pavmed.com/role/DebtDetailsNarrative", "http://pavmed.com/role/FinancialInstrumentsFairValueMeasurementsDetailsNarrative", "http://pavmed.com/role/ScheduleOfChangesInFairValueOfDebtDetails", "http://pavmed.com/role/SummaryOfOutstandingDebtDetails"], "lang": { "en-us": { "role": { "label": "Short-Term Debt [Table]", "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability." } } }, "auth_ref": ["r72"] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": ["http://pavmed.com/role/PreferredStockDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": ["r29", "r30", "r31", "r32", "r33", "r34", "r109", "r111", "r112", "r113", "r160", "r161", "r162", "r213", "r308", "r309", "r311", "r313", "r316", "r321", "r323", "r511", "r512", "r513", "r514", "r658", "r781", "r793"] }, "PAVM_ScheduleOfStockbasedCompensationExpenseRecognizedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://pavmed.com/20240930", "localname": "ScheduleOfStockbasedCompensationExpenseRecognizedTableTextBlock", "presentation": ["http://pavmed.com/role/Stock-basedCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Stock-Based Compensation Expense Recognized by Lucid Diagnostics", "documentation": "Schedule of Stockbased Compensation Expense Recognized [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfVariableInterestEntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfVariableInterestEntitiesTable", "presentation": ["http://pavmed.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Variable Interest Entity [Table]", "documentation": "Disclosure of information about variable interest held, whether or not such variable interest entity (VIE) is included in consolidated financial statements." } } }, "auth_ref": ["r57", "r58", "r59", "r60", "r61", "r401", "r402", "r405", "r406", "r471", "r472", "r473"] }, "us-gaap_SecuredDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredDebtCurrent", "crdr": "credit", "calculation": { "http://pavmed.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 }, "http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://pavmed.com/role/BalanceSheets", "http://pavmed.com/role/LiquidityAndGoingConcernDetailsNarrative", "http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails"], "lang": { "en-us": { "role": { "label": "Senior Secured Convertible Notes - at fair value",

```
"verboseLabel": "Current liabilities", "documentation": "Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower." } } }, "auth_ref": [ "r72", "r127" ] }, "PAVM_SecuritiesPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://pavmed.com/20240930", "localname": "SecuritiesPurchaseAgreementMember", "presentation": [ "http://pavmed.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Securities Purchase Agreement [Member]", "documentation": "Securities Purchase Agreement [Member]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r694" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r698" ] }, "us-gaap_SecurityDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecurityDeposit", "crdr": "debit", "calculation": { "http://pavmed.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://pavmed.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Deposits", "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease." } } }, "auth_ref": [ "r786" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r697" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r703" ] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://pavmed.com/role/StatementsOfOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://pavmed.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Sales and marketing", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpenseMember", "presentation": [ "http://pavmed.com/role/ScheduleOfStock-basedCompensationExpenseDetails", "http://pavmed.com/role/ScheduleOfStock-basedCompensationExpenseRecognizedByLucidDiagnosticsDetails" ], "lang": { "en-us": { "role": { "label": "Selling and Marketing Expense [Member]", "documentation": "Primary financial statement caption encompassing selling and marketing expense." } } }, "auth_ref": [ "r93" ] }, "PAVM_SeptemberElevenTwoThousandTwentyFourToSeptemberThirtyTwoThousandTwentyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://pavmed.com/20240930", "localname": "SeptemberElevenTwoThousandTwentyFourToSeptemberThirtyTwoThousandTwentyFourMember", "presentation": [ "http://pavmed.com/role/ScheduleOfAggregateInformationFromFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "label": "September 11, 2024 - September 30, 2024 [Member]", "documentation": "September Eleven Two Thousand Twenty Four To September Thirty Two Thousand Twenty Four [Member]" } } }, "auth_ref": [] }, "PAVM_SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://pavmed.com/20240930", "localname": "SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember", "presentation": [ "http://pavmed.com/role/DebtDetailsNarrative", "http://pavmed.com/role/FinancialInstrumentsFairValueMeasurementsDetailsNarrative", "http://pavmed.com/role/ScheduleOfChangesInFairValueOfDebtDetails", "http://pavmed.com/role/ScheduleOfFairValueAssumptionUsedDetails", "http://pavmed.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://pavmed.com/role/SummaryOfOutstandingDebtDetails" ], "lang": { "en-us": { "role": { "label": "September 2022 Senior Convertible Note [Member]", "documentation": "September 2022 Senior Convertible Note [Member]" } } }, "auth_ref": [] }, "PAVM_SeriesAConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://pavmed.com/20240930", "localname": "SeriesAConvertiblePreferredStockMember", "presentation": [ "http://pavmed.com/role/NoncontrollingInterestDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series A Convertible Preferred Stock [Member]", "documentation": "Series A Convertible Preferred Stock [Member]" } } }, "auth_ref": [] }, "PAVM_SeriesAOnePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://pavmed.com/20240930", "localname": "SeriesAOnePreferredStockMember", "presentation": [ "http://pavmed.com/role/NoncontrollingInterestDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series A-1 Preferred Stock [Member]", "documentation": "Series A One Preferred Stock [Member]" } } }, "auth_ref": [] }, "PAVM_SeriesBConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://pavmed.com/20240930", "localname": "SeriesBConvertiblePreferredStockMember", "presentation": [ "http://pavmed.com/role/BalanceSheetsParenthetical", "http://pavmed.com/role/NoncontrollingInterestDetailsNarrative", "http://pavmed.com/role/PreferredStockDetailsNarrative", "http://pavmed.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedEarningsPerShareDetails", "http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Series B Convertible Preferred Stock [Member]", "documentation": "Series B Convertible Preferred Stock [Member]" } } }, "auth_ref": [] }, "PAVM_SeriesBOnePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://pavmed.com/20240930", "localname": "SeriesBOnePreferredStockMember", "presentation": [ "http://pavmed.com/role/NoncontrollingInterestDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series B 1 Preferred Stock [Member]", "documentation": "Series B 1 Preferred Stock [Member]" } } }, "auth_ref": [] }, "PAVM_SeriesZWarrantsEachToPurchase115thOfOneShareOfCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://pavmed.com/20240930", "localname": "SeriesZWarrantsEachToPurchase115thOfOneShareOfCommonStockMember", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Series Z Warrants, each to purchase 1/15th of one share of Common Stock [Member]", "documentation": "Series Z Warrants, each to Purchase 1/15th of One Share of Common Stock [Member]" } } }, "auth_ref": [] }, "PAVM_SeriesZWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://pavmed.com/20240930", "localname": "SeriesZWarrantsMember", "presentation": [ "http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative", "http://pavmed.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Series Z Warrants [Member]", "documentation": "Series Z Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://pavmed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://pavmed.com/role/ScheduleOfStock-basedCompensationExpenseDetails", "http://pavmed.com/role/ScheduleOfStock-basedCompensationExpenseRecognizedByLucidDiagnosticsDetails", "http://pavmed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation", "verboseLabel": "Total stock-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://pavmed.com/role/ScheduleOfRestrictedStockAwardActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Restricted Stock Awards, Forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r373" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://pavmed.com/role/ScheduleOfRestrictedStockAwardActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Grant Date Fair Value, Forfeited", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r373" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://pavmed.com/role/ScheduleOfRestrictedStockAwardActivityDetails" ], "lang": { "en-us": { "role": { "label": "Number of Restricted Stock Awards, Granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r371" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://pavmed.com/role/ScheduleOfRestrictedStockAwardActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Grant Date Fair Value, Granted", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r371" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://pavmed.com/role/ScheduleOfRestrictedStockAwardActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of Restricted Stock Awards, Unvested restricted stock awards, Beginning balance", "periodEndLabel": "Number of Restricted Stock Awards, Unvested restricted stock awards, Ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r368", "r369" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://pavmed.com/role/ScheduleOfRestrictedStockAwardActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted Average Grant Date Fair Value, Unvested restricted stock awards, Beginning balance", "periodEndLabel": "Weighted Average Grant Date Fair Value, Unvested restricted stock awards, Ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement, Excludes share and unit options." } } }, "auth_ref": [ "r368", "r369" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://pavmed.com/role/ScheduleOfRestrictedStockAwardActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Restricted Stock Awards, Vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r372" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://pavmed.com/role/ScheduleOfRestrictedStockAwardActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Grant Date Fair Value, Vested", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r372" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://pavmed.com/role/ScheduleOfFairValuesOfStockOptionsGrantedUsingBlack-scholesValuationModelAssumptionsDetails" ], "lang": { "en-us": { "role": {
```

"label": "Expected dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": ["r380"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": ["http://pavmed.com/role/ScheduleOfFairValuesOfStockOptionsGrantedUsingBlack-scholesValuationModelAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Expected stock price volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": ["r379"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": ["http://pavmed.com/role/ScheduleOfFairValuesOfStockOptionsGrantedUsingBlack-scholesValuationModelAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Risk free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": ["r381"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://pavmed.com/role/NetIncomeLossPerShareDetailsNarrative", "http://pavmed.com/role/ScheduleOfFairValuesOfStockOptionsGrantedUsingBlack-scholesValuationModelAssumptionsDetails", "http://pavmed.com/role/ScheduleOfRestrictedStockAwardActivityDetails", "http://pavmed.com/role/ScheduleOfSummarizesInformationAboutStockOptionsDetails", "http://pavmed.com/role/ScheduleOfUnrecognizedCompensationExpenseDetails", "http://pavmed.com/role/Stock-basedCompensationDetailsNarrative", "http://pavmed.com/role/Stock-basedCompensationTables"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r354", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": ["http://pavmed.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Increase in available for grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r39"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": ["http://pavmed.com/role/ScheduleOfSummarizesInformationAboutStockOptionsDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Number of Stock Option, Forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r366"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": ["http://pavmed.com/role/ScheduleOfSummarizesInformationAboutStockOptionsDetailsParenthetical"], "lang": { "en-us": { "role": { "label": "Number of stock options granted. shares", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": ["r843"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://pavmed.com/role/ScheduleOfSummarizesInformationAboutStockOptionsDetails", "http://pavmed.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Number of Stock Options, Granted", "verboseLabel": "Granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r364"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://pavmed.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Weighted average fair value of stock options", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": ["r374"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://pavmed.com/role/ScheduleOfSummarizesInformationAboutStockOptionsDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Intrinsic Value Outstanding, Beginning Balance", "periodEndLabel": "Intrinsic Value Outstanding, Ending Balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r39"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://pavmed.com/role/ScheduleOfSummarizesInformationAboutStockOptionsDetails", "http://pavmed.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "periodStartLabel": "Number of Stock Options Outstanding, Beginning Balance", "periodEndLabel": "Number of Stock Options Outstanding, Ending Balance", "label": "Number of stock options outstanding", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r360", "r361"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice", "presentation": ["http://pavmed.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Weighted average exercise price", "documentation": "Change in the weighted average exercise price of options outstanding." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://pavmed.com/role/ScheduleOfSummarizesInformationAboutStockOptionsDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted Average Exercise Price, Beginning Balance", "periodEndLabel": "Weighted Average Exercise Price, Ending Balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r360", "r361"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": ["http://pavmed.com/role/ScheduleOfSummarizesInformationAboutStockOptionsDetails"], "lang": { "en-us": { "role": { "periodEndLabel": "Number of Stock Options Vested and exercisable stock options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r377"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": ["http://pavmed.com/role/ScheduleOfSummarizesInformationAboutStockOptionsDetails"], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted Average Exercise Price, Vested and exercisable stock options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r377"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "presentation": ["http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Number of common stock issued", "documentation": "Number of shares issued under share-based payment arrangement." } } }, "auth_ref": ["r39"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward", "presentation": ["http://pavmed.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Number of common stock purchased", "documentation": "Number of shares purchased for issuance under share-based payment arrangement." } } }, "auth_ref": ["r862"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative", "http://pavmed.com/role/DebtDetailsNarrative", "http://pavmed.com/role/ScheduleOfRestrictedStockAwardActivityDetails", "http://pavmed.com/role/ScheduleOfUnrecognizedCompensationExpenseDetails", "http://pavmed.com/role/Stock-basedCompensationDetailsNarrative", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": ["http://pavmed.com/role/ScheduleOfSummarizesInformationAboutStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, Exercised", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": ["r365"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": ["http://pavmed.com/role/ScheduleOfSummarizesInformationAboutStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, Forfeited", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": ["r366"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://pavmed.com/role/ScheduleOfSummarizesInformationAboutStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, Granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r364"] }, "us-

gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": ["http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Share price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://pavmed.com/role/ScheduleOfFairValuesOfStockOptionsGrantedUsingBlack-scholesValuationModelAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Expected term of stock options (in years)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r378"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": ["http://pavmed.com/role/ScheduleOfSummarizesInformationAboutStockOptionsDetails"], "lang": { "en-us": { "role": { "periodEndLabel": "Intrinsic Value Exercisable, Ending Balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": ["r39"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://pavmed.com/role/ScheduleOfSummarizesInformationAboutStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Remaining Contractual Term (Years), Ending Balance", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r120"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://pavmed.com/role/ScheduleOfSummarizesInformationAboutStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Remaining Contractual Term (Years), Vested and exercisable stock options", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r377"] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": ["http://pavmed.com/role/EquityMethodInvestmentDetailsNarrative"], "lang": { "en-us": { "role": { "label": "The fair value of common price per shares", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, shares", "periodEndLabel": "Balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtLineItems", "presentation": ["http://pavmed.com/role/DebtDetailsNarrative", "http://pavmed.com/role/FinancialInstrumentsFairValueMeasurementsDetailsNarrative", "http://pavmed.com/role/ScheduleOfChangesInFairValueOfDebtDetails", "http://pavmed.com/role/SummaryOfOutstandingDebtDetails"], "lang": { "en-us": { "role": { "label": "Short-Term Debt [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://pavmed.com/role/SummaryOfSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r104", "r177"] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": ["http://pavmed.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": ["r701"] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": ["http://pavmed.com/role/BalanceSheetsParenthetical", "http://pavmed.com/role/Cover", "http://pavmed.com/role/NoncontrollingInterestDetailsNarrative", "http://pavmed.com/role/PreferredStockDetailsNarrative", "http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r149", "r160", "r161", "r162", "r180", "r200", "r201", "r204", "r206", "r213", "r214", "r234", "r270", "r272", "r273", "r274", "r277", "r278", "r308", "r309", "r313", "r316", "r323", "r440", "r511", "r512", "r513", "r514", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r530", "r551", "r573", "r592", "r626", "r627", "r628", "r629", "r630", "r781", "r793", "r801"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative", "http://pavmed.com/role/EquityMethodInvestmentDetailsNarrative", "http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r11", "r83", "r86", "r87", "r150", "r168", "r169", "r170", "r182", "r183", "r184", "r186", "r191", "r193", "r195", "r212", "r236", "r237", "r253", "r325", "r388", "r389", "r391", "r392", "r393", "r395", "r397", "r398", "r407", "r408", "r409", "r410", "r411", "r412", "r414", "r441", "r442", "r443", "r444", "r445", "r446", "r451", "r454", "r464", "r496", "r504", "r505", "r506", "r518", "r592"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://pavmed.com/role/BalanceSheetsParenthetical", "http://pavmed.com/role/Cover", "http://pavmed.com/role/EquityMethodInvestmentDetailsNarrative", "http://pavmed.com/role/ScheduleOfAggregateInformationFromFinancialStatementsDetails", "http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails", "http://pavmed.com/role/ScheduleOfGainOnDeconsolidationDetails", "http://pavmed.com/role/ScheduleOfStock-basedCompensationExpenseDetails", "http://pavmed.com/role/ScheduleOfStock-basedCompensationExpenseRecognizedByLucidDiagnosticsDetails", "http://pavmed.com/role/ScheduleOfSummarizesInformationAboutStockOptionsDetailsParenthetical", "http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r182", "r183", "r184", "r212", "r454", "r476", "r510", "r530", "r542", "r544", "r545", "r546", "r547", "r548", "r551", "r554", "r555", "r556", "r557", "r558", "r560", "r561", "r562", "r563", "r565", "r566", "r567", "r568", "r569", "r571", "r575", "r576", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r592", "r684"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://pavmed.com/role/BalanceSheetsParenthetical", "http://pavmed.com/role/Cover", "http://pavmed.com/role/EquityMethodInvestmentDetailsNarrative", "http://pavmed.com/role/ScheduleOfAggregateInformationFromFinancialStatementsDetails", "http://pavmed.com/role/ScheduleOfDeconsolidationOfNetAssetsDetails", "http://pavmed.com/role/ScheduleOfGainOnDeconsolidationDetails", "http://pavmed.com/role/ScheduleOfStock-basedCompensationExpenseDetails", "http://pavmed.com/role/ScheduleOfStock-basedCompensationExpenseRecognizedByLucidDiagnosticsDetails", "http://pavmed.com/role/ScheduleOfSummarizesInformationAboutStockOptionsDetailsParenthetical", "http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r182", "r183", "r184", "r212", "r230", "r454", "r476", "r510", "r530", "r542", "r544", "r545", "r546", "r547", "r548", "r551", "r554", "r555", "r556", "r557", "r558", "r560", "r561", "r562", "r563", "r565", "r566", "r567", "r568", "r569", "r571", "r575", "r576", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r592", "r684"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r712", "r723", "r733", "r758"] }, "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockGrantedDuringPeriodValueSharebasedCompensation", "crdr": "credit", "presentation": ["http://pavmed.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Aggregate fair value", "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r37", "r43"] }, "PAVM_StockIssuedDuringPeriodShareATMFacilities": { "xbrltype": "sharesItemType", "nsuri": "http://pavmed.com/20240930", "localname": "StockIssuedDuringPeriodShareATMFacilities", "presentation": ["http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "At-the-market equity facility, shares", "documentation": "At-the-market equity facility, shares." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": ["http://pavmed.com/role/DebtDetailsNarrative", "http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Conversions - Senior Secured Convertible Note, shares", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": ["r11", "r31", "r83", "r86", "r113", "r296"] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": ["http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Purchase - Employee Stock Purchase Plan, shares", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": ["r11", "r82", "r83", "r113"] }, "PAVM_StockIssuedDuringPeriodSharesIncreaseInReserve": { "xbrltype": "sharesItemType", "nsuri": "http://pavmed.com/20240930", "localname": "StockIssuedDuringPeriodSharesIncreaseInReserve", "presentation": ["http://pavmed.com/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Increase in reserve stock", "documentation": "Stock issued during period shares increase in reserve" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": ["http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative", "http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Issuance - vendor service agreement, shares", "verboseLabel": "Number of shares issued", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://pavmed.com/role/EquityMethodInvestmentDetailsNarrative", "http://pavmed.com/role/NetIncomeLossPerShareDetailsNarrative", "http://pavmed.com/role/NoncontrollingInterestDetailsNarrative", "http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Issue common stock - PAVM ATM Facility, shares", "verboseLabel": "Ownership shares issues", "terseLabel": "Number of shares issued", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r11", "r82", "r83", "r113", "r511", "r592", "r627"] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": ["http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Vest - restricted stock awards, shares", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": ["r11", "r82", "r83", "r113"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://pavmed.com/role/ScheduleOfSummarizesInformationAboutStockOptionsDetails"], "lang": {

```
"en-us": { "role": { "negatedLabel": "Number of Stock Option, Exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r11", "r82", "r83", "r113", "r365" ] }, "us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesTreasuryStockReissued", "presentation": [ "http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit", "http://pavmed.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Treasury stock, shares", "verboseLabel": "Treasury stock", "documentation": "Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement." } } }, "auth_ref": [ "r11", "r83", "r113" ] }, "PAVM_StockIssuedDuringPeriodValueATMFacilities": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "StockIssuedDuringPeriodValueATMFacilities", "crdr": "credit", "presentation": [
"http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "At-the-market equity facility, value", "documentation": "At-the-market equity facility, value." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": [ "http://pavmed.com/role/DebtDetailsNarrative", "http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Conversions - Senior Secured Convertible Note", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": [ "r11", "r83", "r86", "r87", "r113" ] }, "PAVM_StockIssuedDuringPeriodValueConversionsSubsidiaryCommonStockSeniorSecuredConvertibleNote": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname":
"StockIssuedDuringPeriodValueConversionsSubsidiaryCommonStockSeniorSecuredConvertibleNote", "crdr": "credit", "presentation": [
"http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Conversions - subsidiary common stock - Senior Secured Convertible Note", "documentation": "Stock issued during period, value, conversions subsidiary common stock senior secured convertible." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [ "http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Purchase - Employee Stock Purchase Plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": [ "r11", "r82", "r83", "r113" ] },
"PAVM_StockIssuedDuringPeriodValueIssuanceSubsidiaryCommonStockSettlementApardxInstallmentPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname": "StockIssuedDuringPeriodValueIssuanceSubsidiaryCommonStockSettlementApardxInstallmentPayment", "crdr": "credit", "presentation": [ "http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance - subsidiary common stock - Settlement APA-RDx - Installment Payment", "documentation": "Stock issued during period, value,issuance -subsidiary common stock - settlement APA-RDx - installment payment." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": [
"http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative", "http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance - vendor service agreement", "verboseLabel": "Issued for services", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://pavmed.com/role/EquityMethodInvestmentDetailsNarrative",
"http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Issue common stock - PAVM ATM Facility", "verboseLabel": "Ownership shares value", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r11", "r82", "r83", "r113", "r518", "r592", "r627", "r691" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": [
"http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Vest - restricted stock awards", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": [ "r11", "r113" ] }, "us-gaap_StockIssuedDuringPeriodValueStockDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodValueStockDividend", "crdr": "credit", "presentation": [ "http://pavmed.com/role/PreferredStockDetailsNarrative",
"http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Dividends declared - Series B Convertible Preferred Stock", "verboseLabel": "Aggregate preferred stock dividends earned", "documentation": "Value of stock issued to shareholders as a dividend during the period." } } }, "auth_ref": [
"r11", "r83", "r86", "r87", "r113" ] }, "PAVM_StockIssuedDuringPeriodValueStockbasedCompensationSubsidiary": { "xbrltype": "monetaryItemType", "nsuri":
"http://pavmed.com/20240930", "localname": "StockIssuedDuringPeriodValueStockbasedCompensationSubsidiary", "crdr": "credit", "presentation": [
"http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation - subsidiaries",
"documentation": "Stock issued during period, value, stock-based compensation - subsidiaries." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodValueTreasuryStockReissued", "crdr": "credit", "presentation": [ "http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit" ],
"lang": { "en-us": { "role": { "label": "Treasury stock", "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement." } } }, "auth_ref": [ "r11", "r36", "r82", "r83", "r113" ] },
"PAVM_StockIssuedDuringThePeriofOfNewIssueImpactOfSubsidiaryEquityTransactions": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930",
"localname": "StockIssuedDuringThePeriofOfNewIssueImpactOfSubsidiaryEquityTransactions", "crdr": "credit", "presentation": [
"http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Impact of subsidiary equity transactions", "documentation":
"Stock issued during the period of impact of subsidiary equity transactions." } } }, "auth_ref": [] }, "PAVM_StockIssusedAndOutstandingDescription": { "xbrltype":
"stringItemType", "nsuri": "http://pavmed.com/20240930", "localname": "StockIssusedAndOutstandingDescription", "presentation": [
"http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock Issused and outstanding description", "documentation": "Stock issused and outstanding description." } } }, "auth_ref": [] }, "us-gaap_StockOptionMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StockOptionMember", "presentation": [ "http://pavmed.com/role/ScheduleOfUnrecognizedCompensationExpenseDetails" ],
"lang": { "en-us": { "role": { "label": "Equity Option [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": [ "r683" ] }, "PAVM_StockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://pavmed.com/20240930", "localname": "StockOptionsMember", "presentation": [
"http://pavmed.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Stock Options [Member]", "documentation": "Stock Options [Member]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://pavmed.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://pavmed.com/role/BalanceSheets",
"http://pavmed.com/role/ScheduleOfAggregateInformationFromFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total PAVmed Inc. Stockholders\u2019 Equity (Deficit)", "label": "Shareholders\u2019 deficit", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r83", "r86", "r87", "r105", "r553", "r570", "r593", "r594", "r678", "r692", "r795", "r812", "r879", "r902" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [
"http://pavmed.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://pavmed.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://pavmed.com/role/BalanceSheets",
"http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "totalLabel": "Total Stockholders\u2019 Equity (Deficit)", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r52", "r53", "r62", "r150", "r151", "r169", "r182", "r183", "r184", "r186", "r191", "r193", "r236", "r237", "r253", "r325", "r388", "r389", "r391", "r392", "r393", "r395", "r397", "r398", "r407", "r408", "r409", "r410", "r411", "r412", "r414", "r441", "r442", "r446", "r452", "r464", "r505", "r506", "r516", "r553", "r570", "r593", "r594", "r631", "r691", "r795", "r812", "r879", "r902" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrants" ], "lang": { "en-us": { "role": { "label": "Common Stock and Common Stock Purchase Warrants", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r110", "r179", "r307", "r309", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r322", "r325", "r413", "r595", "r596", "r632" ] }, "us-gaap_StockholdersEquityReverseStockSplit": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityReverseStockSplit", "presentation": [
"http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Reverse stock split", "documentation":
"Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } } }, "auth_ref": [ "r114" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SubsequentEventMember", "presentation": [ "http://pavmed.com/role/PreferredStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } },
"auth_ref": [ "r447", "r466" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubsequentEventTypeAxis", "presentation": [ "http://pavmed.com/role/PreferredStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]",
"documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [
"r447", "r466" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubsequentEventTypeDomain", "presentation": [ "http://pavmed.com/role/PreferredStockDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r447", "r466" ] }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubstantialDoubtAboutGoingConcernTextBlock", "presentation": [ "http://pavmed.com/role/LiquidityAndGoingConcern" ], "lang": { "en-us": { "role": { "label": "Liquidity and Going Concern", "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern." } } }, "auth_ref": [ "r70" ] },
"PAVM_SupplementalBalanceSheetInformationRelatedToCashandNonCashActivitieswithLeaseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://pavmed.com/20240930", "localname": "SupplementalBalanceSheetInformationRelatedToCashandNonCashActivitieswithLeaseTableTextBlock", "presentation": [
"http://pavmed.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Supplemental Balance Sheet Information Related to Cash and Non-cash Activities with Leases", "documentation": "Supplemental Balance Sheet Information Related to Cash and Non Cash Activities with Lease [Table Text Block]" } } }, "auth_ref": [] },
"ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List, Table" } } }, "auth_ref": [ "r752" ] }, "srt_TitleOfIndividualAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [ "http://pavmed.com/role/DebtDetailsNarrative",
"http://pavmed.com/role/EquityMethodInvestmentDetailsNarrative", "http://pavmed.com/role/PreferredStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } }, "auth_ref": [ "r808", "r885" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://pavmed.com/role/DebtDetailsNarrative",
"http://pavmed.com/role/EquityMethodInvestmentDetailsNarrative", "http://pavmed.com/role/PreferredStockDetailsNarrative" ], "auth_ref": [] },
"ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [
```

```
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r744" ] },
"ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return
Vs Peer Group" } } }, "auth_ref": [ "r751" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"TradingSymbol", "presentation": [ "http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an
instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Adoption Date" } } }, "auth_ref": [
"r774" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Arrangement Duration" } } }, "auth_ref": [ "r775" ] },
"ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Expiration Date" } } }, "auth_ref": [ "r775" ] }, "ecd_TrdArrIndName": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } },
"auth_ref": [ "r773" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Title" } } }, "auth_ref": [ "r773" ] }, "ecd_TrdArrTerminationDate": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Termination Date" } } }, "auth_ref": [ "r774" ] }, "us-
gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation":
[ "http://pavmed.com/role/StatementOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Treasury Stock, Common [Member]", "documentation":
"Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r36" ] }, "PAVM_TwoThousandAndFourteenEquityPlanMember":
{ "xbrltype": "domainItemType", "nsuri": "http://pavmed.com/20240930", "localname": "TwoThousandAndFourteenEquityPlanMember", "presentation": [
"http://pavmed.com/role/NetIncomeLossPerShareDetailsNarrative", "http://pavmed.com/role/ScheduleOfFairValuesOfStockOptionsGrantedUsingBlack-
scholesValuationModelAssumptionsDetails", "http://pavmed.com/role/ScheduleOfRestrictedStockAwardActivityDetails",
"http://pavmed.com/role/ScheduleOfSummarizesInformationAboutStockOptionsDetails",
"http://pavmed.com/role/ScheduleOfSummarizesInformationAboutStockOptionsDetailsParenthetical", "http://pavmed.com/role/Stock-basedCompensationDetailsNarrative",
"http://pavmed.com/role/Stock-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "2014 Equity Plan [Member]", "documentation": "2014 Equity Plan
[Member]" } } }, "auth_ref": [] }, "PAVM_TwoThousandEighteenEquityPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://pavmed.com/20240930", "localname":
"TwoThousandEighteenEquityPlanMember", "presentation": [ "http://pavmed.com/role/ScheduleOfFairValuesOfStockOptionsGrantedUsingBlack-
scholesValuationModelAssumptionsDetails", "http://pavmed.com/role/ScheduleOfRestrictedStockAwardActivityDetails",
"http://pavmed.com/role/ScheduleOfSummarizesInformationAboutStockOptionsDetails",
"http://pavmed.com/role/ScheduleOfSummarizesInformationAboutStockOptionsDetailsParenthetical", "http://pavmed.com/role/Stock-basedCompensationDetailsNarrative",
"http://pavmed.com/role/Stock-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "2018 Equity Plan [Member]", "documentation": "2018 Equity Plan
[Member]" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"TypeOfArrangementAxis", "presentation": [ "http://pavmed.com/role/DebtDetailsNarrative", "http://pavmed.com/role/EquityMethodInvestmentDetailsNarrative" ], "lang": {
"en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and
arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r399" ] }, "ecd_UndrlygSecurityMktPriceChngPct": {
"xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r770" ] }, "us-
gaap_UnrealizedGainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrealizedGainLossOnInvestments",
"crdr": "credit", "presentation": [ "http://pavmed.com/role/EquityMethodInvestmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unrealized gain loss on
investments", "documentation": "Amount of unrealized gain (loss) on investment." } } }, "auth_ref": [ "r7" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://pavmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang":
{ "en-us": { "role": { "label": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in
conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r23", "r24", "r25", "r141", "r142", "r143", "r144" ] }, "us-
gaap_VariableInterestEntityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableInterestEntityLineItems", "presentation":
[ "http://pavmed.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Variable Interest Entity [Line Items]",
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members
defined in one or many axes to the table." } } }, "auth_ref": [ "r401", "r402", "r405", "r406", "r471", "r472", "r473" ] }, "PAVM_VendorsMember": { "xbrltype":
"domainItemType", "nsuri": "http://pavmed.com/20240930", "localname": "VendorsMember", "presentation": [
"http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Vendors [Member]", "documentation":
"Vendors [Member]" } } }, "auth_ref": [] }, "PAVM_VerisBoxSupplies": { "xbrltype": "monetaryItemType", "nsuri": "http://pavmed.com/20240930", "localname":
"VerisBoxSupplies", "crdr": "debit", "calculation": { "http://pavmed.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": "us-
gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://pavmed.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Veris Box supplies", "documentation": "Veris box
supplies." } } }, "auth_ref": [] }, "us-gaap_WarrantExercisePriceDecrease": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WarrantExercisePriceDecrease", "presentation": [ "http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": {
"label": "Warrant price decrease", "documentation": "Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision." } } },
"auth_ref": [ "r324" ] }, "PAVM_WarrantsAndRightsOutstandingPurchase": { "xbrltype": "sharesItemType", "nsuri": "http://pavmed.com/20240930", "localname":
"WarrantsAndRightsOutstandingPurchase", "presentation": [ "http://pavmed.com/role/CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative" ], "lang": { "en-us":
{ "role": { "label": "Purchase of warrants", "documentation": "Warrants and rights outstanding purchase." } } }, "auth_ref": [] }, "us-
gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://pavmed.com/role/ScheduleOfComparisonOfBasicAndFullyDilutedNetLossPerShareDetails",
"http://pavmed.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted average common shares outstanding, diluted", "documentation": "The
average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of
shares or units in the period." } } }, "auth_ref": [ "r199", "r206" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [
"http://pavmed.com/role/ScheduleOfComparisonOfBasicAndFullyDilutedNetLossPerShareDetails", "http://pavmed.com/role/StatementsOfOperations" ], "lang": { "en-us": {
"role": { "label": "Weighted average common shares outstanding, basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable
shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been
outstanding to the total time in that period." } } }, "auth_ref": [ "r197", "r206" ] }, "PAVM_WorkingCapital": { "xbrltype": "monetaryItemType", "nsuri":
"http://pavmed.com/20240930", "localname": "WorkingCapital", "crdr": "credit", "presentation": [ "http://pavmed.com/role/LiquidityAndGoingConcernDetailsNarrative" ],
"lang": { "en-us": { "role": { "negatedLabel": "Working capital", "documentation": "Working capital." }, "label": "WorkingCapital" } } }, "auth_ref": [] },
"dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [
"http://pavmed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is
intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r779" ] } } } },
"std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230",
"Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483475/205-20-45-10" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r3":
{ "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "21D", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-
45-21D" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)",
"SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r6": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r9": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "718", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(2)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r12": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic":
"718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" },
"r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "44", "SubTopic": "20", "Topic": "805",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-44" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" },
"r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-
1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph":
"3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-
5" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph":
"1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI":
```

```
"https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "30", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480513/718-10-30-3" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "30", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480843/718-30-35-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "50", "Section": "05", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480153/805-50-05-7" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "50", "Section": "30", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-7" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "50", "Section": "30", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-8" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "50", "Section": "30", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-9" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-4" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-5A" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-6" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-9" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-40/tableOfContent" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
```

"Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/710/tableOfContent" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "712", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/712/tableOfContent" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/715/tableOfContent" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-23" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "323", "Publisher": "FASB", "URI": "https://asc.fasb.org/323/tableOfContent" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r161": { "role":

```
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r227": { "role":
```

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-

50-1C" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",

```
"Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65",
```

"Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI":

```
"https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r483": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r484": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r485": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r486": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r487": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r488": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r489": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r490": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r491": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r492": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r493": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r494": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r495": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r496": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r497": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r498": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(3)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r499": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r500": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-
40-50-7A" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r504": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-
40-65-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r508": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r509": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r510": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r511": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r512": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r513": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r514": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r515": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" },
"r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph":
"3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r518": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r521": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-
50-7" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r525": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-
50-7" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r529": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946",
"SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-
210-50-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r533": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r534": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r535": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-
210-50-6" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r539": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-
50-6" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99",
```

"Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":

```
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/985-20/tableOfContent" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r639": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
```

```
"https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-
50-6" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic":
"740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-
50-3" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r670": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r673": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-
10-55-107" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic":
"842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r679": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A" }, "r680": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-
210-50-6" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "39", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477346/946-830-45-39" }, "r690": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946",
"SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r693": {
"role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r694": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r695": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r696": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r697": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r698": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r699": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r700": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r701": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r702": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r703": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r704": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r705": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r706": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r707": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r708": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r709": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r710": {
"role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i",
"Sentence": "A" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph":
"1", "Subparagraph": "i", "Sentence": "B" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6",
"Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r715": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r716": {
"role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" },
"r717": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r718": {
"role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r719": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r720": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r721": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r722": {
"role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" },
"r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence":
"iii" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1",
"Sentence": "iv" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a",
"Subparagraph": "1", "Sentence": "v" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19",
"Paragraph": "a", "Subparagraph": "2" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19",
"Paragraph": "a", "Subparagraph": "3" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19",
"Paragraph": "b" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r730": {
"role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r731": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r732":
{ "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii"
}, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1",
"Sentence": "iii" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a",
"Subparagraph": "1", "Sentence": "iv" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR",
"Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR",
"Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r738": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR",
"Section": "18", "Paragraph": "b" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240",
"Section": "13", "Subsection": "a-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "v" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "v", "Paragraph": "1" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r744": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2",
"Subparagraph": "iv" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r749": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5",
"Subparagraph": "ii" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
```

"Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r771": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r772": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r773": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r774": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r775": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r776": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r777": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r778": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r779": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r780": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r781": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r782": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",

"Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":

*"50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" } } } ZIP 90 0001493152-24-045258-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-045258-xbrl.zip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||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|(Z+CG#JED:;2U<9XL\5#O^Y0A,+S_E$KD MFC,15$D/%&$-&OB20%R/%6OD=FRS>U72I=]04BG;$ZW.IP$5RMC^BV/[NH>" M82WD3U[NK,JA97^WKF-6], [Z/EAXE">E.:X#UIBS8*[IH[P[MGLDVQ_U,LQ$ M-BFY]2SC7+KY.MCO]Z@WY\->^PH,_8<_.8;]U4X^(TY?P-02P,$% @ MK*MM65D]UA%." ZD8 H !E>#,Q+3(N:'1M[5QK;R(Y%OW>4O\';Z11 M)1*$/":[$C!(0) 9\'3"I-%(_=%4N<";>M"V*VGFU^^Y=A54 NG0'9B%=.5# M I0?YI!\SSWWED/SC\"]!:I=\T_NNT,_C+Z:0YZ@ZMNJUES? W&UEEUNGM!T M/K-/@\]7W=_V@B0V=79\-#%L(".AV;5X8+=)Q..*^Z#"/@DE@SUT1-=^WB_B M:B3C.CO::WV(AWK2:-;ZK6*#50=N,#=4U203##ZWFY"1#*? UEP#8MEK^+1Q>C'3>ZGX=RZ$T M[]^=!'A^>-&OG6$@:ON7,W*"A1<,\$1NAUFE9?]_>@BVX2Q?=VT'OLG?1'O1N MKM^_,__,^K>]ZXM>OWW%+GO7;;S$]YM+-.G>EG=Q_: [WWU0;&4S7:5RO\OY= M1\2QU.SC(?OH.:ZX&5>PBHIF8F;,3?V-FK[\O@[:YU===M&]NOK4;U_TKG__M;>]HS[[OMSN=_/UW+\"#],V8FA[]TF##1/E"5;TD#/E$ U#^:L_&D^;@]OLG MN*<[YQ$P7S L]5X6G9J#S@\#/CH\.9/QQN_%\>PV##JO0:UI;W'0QOQ>,"7N MI7@0/GP$SO-GRA5X)YRR6S%)E&%)S"X3%:%C]4^6!*S?_BM"XU[L'3(>^^Q3 M.M32EUQ)H1M%Z_'K=GW;P#G8*W;"!CWN-:=ZL[#6>P]>ZXH;WM0GN^%[YUP+ MW\&#;T53=A-N4I;%1J6#:<",B* 3R M2(Z Y>5/&0!]_ "18DDD#6Z7:[?0(!:>T)IKJ4.!=A&_$YB\,+#&9SX08=Z0 MA#)-1 T\]:PT0K,88P . ^)!C*4W9CJE7_/^#T*):!"R(I(Z%-R7\0B4;,.P M4D^$1R@$%!A\ I")#X.Q\| OPVEQ04IRV3)8/Q6YG+X%5Q/69!F#SHG'^4&$EM%,=LG#YTX &U M4F 0G2.RD'-^*9ED6V']5$SRZVXPR6 LZ#TE_2I*$SKLAR:XKH21!(MO+6^V&-<">OU\&(Y# 5Y)Q/@FV$H]9B:4[,(DH9D#;WWI?;"1*?H1V)'):%S M_XE*/.'C8^V@\[/E?0$.<534_>[->3P2K T=<9N&L_XE%>/S_;%@>U_?.:[M=^ZMI(I*[+B')F&D,PJ4Y-B! #TSD4.Q,%OP:+8 LY"%3]D*+2C?]B_?^#6; MK_]SM="R /%\Q?]'77)Y-'A2@]A2AE_*H_]T^80?:-*6#8/O"(VA<_EETZ&7 MB:U"Z9K'4\BV5;M0PC84X">"00YC'@^H*6+(O?2)X;E.8DI: MG&M$!RKF$>USY>?LBZ @^5"&TDPI[5XV-T4E2]26@UTL>=1T7F)P<&P>|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l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

MZ3(Y'\FFLY4VFKEQZ6RE)6%K7+9::9,#,I>M5MK0$4#$/=:4\!DL+."SU4H; MS7GQI':O7,O+AB@L//]I+R=GR'RT#MID^?=AK]$:9Y-E)Z!9DM|S2H(UG|87 M?BB;G]#!N7-'$ER[6AUBL %.[W52/^3<'^Q_::Y0B>XW$N/=V':7(KB,Q M9H(MU-$WQ!-CS=CC#@:,NX3+2 L_,B9>RH,%3-5HJVIL7/BTE/"3;6SD=T:MEZ$QʼMJ# M$5E,E?%$*TLER;VW/46)B\"' 45+-!/G** 1$G>5\7+GSQ++$<<-!?4M*;/"2LU$N?%I MKL0Z)$D/PD@.G\2:)\,2@0^4DNJ33(@CGUB->,EKXFP%6B(2&+038A1&S*RCW^$;%Q_ ^<13OI3U1>@4\QYZ6)'GU;:E>,<0A3OI["I\&$*) M>(<#D1: SV@O?"("(9CRIQ;B'7!$FT]@KJ*2L5N2MRXVUBR/%# ^!0]#PMR@9#G)%YHWP1'QVD)Y1JAP M=(73,"/>KW0@YOQ;)T\XX8^5OUWJ(\=E:6H/3-8; M14X8LR$Z; \5?;!8-B3AT^.%;QW*ECC\^\ABY!)#-B02*'^,>.<9|=[51)UG MQ*:E!)GWX?[BJY02YL6G XMXPUF'#/EW0>&O-O/9/92H^<3>"Q7%']+/F@M-M7+!;2.R7J1$!:KHO]0K+5OZ3!L2(!7X[T * KM@?!2+1SX4B]W/GSCJ%[(M=?Z5X[T*2|>_D+,: M]RU"88GW!X:BW40/2M\Y32]XX2M?UXKPR*00:>;H%+Y[5J]&*8Z(./$E:/MIT.,]YZG&/CR[RO#-PT M\B&8\N]$^%B="&F^ GD0TCOF,7?>)F>@$2|E2HE@O$.VB(.54L)GI#BNF*%[M\"([Y8C#)5+"K'lG'7W_EVCW;W(>* PV9Y*,^_!(*:JL*[+U1; 6*@EF H4, MISUF:"*+VU90^N7A+]O M)RSP'X=W-Q&OYTN/:+P]4,3[_-+#:K# *.(%@.EAVZ^>]{%N MY?][$S59KY6"6WNCN*)X)^]%I=^GH86_)#))OO;3RV1&U(/;S2$;L@CRZ>G MK=0(W8!'ENQ 2W M?.-]C"SXL_):(5K4% _MOHV[%OV\0,J.HB;F+VKAQ]]E M2W0^7%#D/9IL2,*G2XA^\B ;XO#O9=BCNHZ-S"9U+?P9C]B.%2?G(,-?U)@T M\][N+_QPPJ1Y]>O TG>"/H+BC4EMM%Q#Z#QJ<-;6;Q'"T@P[6U=\1X@(.&# M3ZL*/V7G]$R=@2*5D9M0FRF:@6?CKD=! M'E,'4=UV8|:-_NER^M1JM:FX SEN&Z+'9&: 7" M_4R*IFN!#T?X(3?Z[39-1.$3PM\3L!C,^GNW(*PHV4+XL2,&*)%U&(VJ>/'1 M)DT4Q2A!KXKTPB5;B#A@%2U;0P!$S6BF%22$S]7UL5^_9.PGH6^&LQE$&XE[M*KW)"ZW?Z),YK?1M3'QI(DTP"(^]Z&<6[L',=*6:-T?>N@P_MLR&LR MEH0:BSK90B4S9/1Q/],[H M03-C@L[3$'; M,*7VH.:SNK-4;UW3N4R;FBA'DC7T"./W'&,QEH]^T(P$J=?"0$$:4%04GHX4 M=6HL 3>"+(R-A;^CC/1G004N/$2_B78/#SNKI)V#'6+"MZ?&0$ST.S-+-)UX) M4#6]#2C<'DH*"O.!+[7.AU#U:_ $),Y%QI7,<<*[<1)] M_'3^DR%4N]9Z4V4N2(8N|9>:\% M^H:9(&QE!IH/%+NW;P*$PCMVXXC#XE+3JW73#*]\3=X_1B];IY%;-]U&KW]'YS91_QA] M,$A*&7;3&>)/G/K+CC" 6\MI8@(@&AA$X+["I8#[0ZK?5IU+7 #!&2"P#.W*H$Q8 M!@U!51=0'CMM;6\\0-GB 3KZ!*AM>;A, >9=UEQH+182GZ\!^"+/E61#ER6=M.-=Z"@^*="N4AG G2011!&%N16/*MB$JT M4VQ;V^SKP*DSVKYV+@A[*V" <^,;254"C4L!2=7,V36CM,?,'&Z$])M(T18\FO #6HQC5$0E^M56X$OT%5DE.%2Z7XE^*B;XVL7OW+4:E.KBS;+!'3T! MJ@\"BU"D1A|M'9A4CM@VT XWI$LIP;GQ+7C2)9+#"CY\Z21QP8 M]70IK*-+(1.'16^,)<@2L4BL$GE?GB!7_N$5+/.G-=TY$!F@>9$8@T.'0H23M7$"T&7)?%*V6NZ@#(MYBDL?"F/,] <1)MQXS'HP.-?\ZURS===#,F:[5M8D)@:-:AX]7?&LM653+#\! M/MX%Q#KR]<(8K'Z.7(;+32?$Y;(%\[O89$,4[628YZ.C';,T,^5HE^O!?D#@ MX05VKMD8V2X>SK6M9CBL]]D.?]R:"/)2(.OK?/'1,=-"?%K!9D2/!9[@\!2F M=M]LL'>CA)2:+59.W$[\BFZ.R-IR*Y_1PW4<#7KN:AY"JI5#>Z!-_(R6K>G* M,'=;FA)PR!Q;MFZ]A~NM.HP@7 /9L((H9500?A#1,NS3AQ2]696"'SCXET(E MM!26&T:(T37-'=EM"+.?84*N4WGL'2';/!3#%X$38F&G)+_+0K0!-(FPL'<@ M Q>A>]ZMU(*6W2:4YGC&Q4QK"-)P+AD&%E+&$>__(D"@AP2CC[2HRSI2.Z((M/EENEF^]X,%>0,2$8$>%|&\.TEE-6T3QH.&G]DR@\AW!./N9D]WE(6PXMG48[.'Z/6)[D5DO.BO6 ;&.X \))KQO/'^F*&1^2I4RROL;V9/-5&@H< MEF]"'\'V9/-5&@H< MEF]"'\'0>33:#E9O7-]:>Q53+A" *5,9A =$UT??;A M_?OGY^=W&AB^&RM/[QOM;<7A4*!+7-%GBM_>K_]R^N7O7=ZV_)=,R.WV2$! M9<"J$:A?;#A9/6?SL^W?0L[4\CN8X\V[1>MOK+YM??OJ>TM1^A3O+@0MPR4* M[Y!X[@33#ZU@>2X@ZAB(U\PQAYQ\ WE3T1$R&Z_4G9/*G1=;2'WO2.N)P=44<&AF!MD_>.'V<114.!: !P;_)09I8(B"=+(JWL"F?U M$Y+"85GT;T:%8] >GW"6&RZ9%,Z2ICB1$R(^/7ZG[26|)'USDHYDYP0MA4.* MX1"?=W MEF7&B6Y'-)7T1#2N):9L"I&R1R+_D\%!"Z7@AV_]IT9/Q6UNU\7=/R:= ^7|5)2,]_Z\X]?_/O:/' +9 MR?>2%,[V@#B;N=',+;5%2!?,TLSMA)1-.[?T96Z)@X!F;FG(W!)7.|W5TI.<)*QLFIRD,3E)&0T.4E'FAS2Y) $YE,T9[3<]E^!"87T.I3 [3!Z&=]:4T.:3)(3G,IW6)HK OF:7)(P>(.++#0Y3&-RF#$0 MT>0P'(; M+#0Y3&ERF"40T>0P- M[W;-*5+R|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|(T#@;5F"I\X:G%='& M@O-C#F]/!N>G%=%5O1O%VQX'PP\:\M<? Y4U2' X,0>UQX'PPT:TF4 X1> ^!Z[5)HX36:].2&]&(M-G,X/^:@FAP?EIQ+:W7GBK.3RNZI?7:[-9KD\:*8\)]:<5]4;0'$7R:<6^1QZX MTKB0"!*.(*BC,1,1)!Q!P$/C"4|D\5&*L**GE"U5:.\U^ MK76IRCC7E@*?YVB& !W#E4@W@LZZ(SN M@3Y7MRYD/+E5:UM$^/)&ZWV-OB5(M'QS%&MITN=,@/|!%%??C $^8S%!XI.N MMO5E"@,+|TZ%0T"]NPO8W3[A*# JV[.% <^K74PYUZM6#H;T[$51 '7H8E&^+ MCOKRS*";NO'T IQZ<)^7>D8[#;FM[:;+# QU(/. .LT^V%-|*#*X'>Z]DFL MI_CV3B\+B7RNXD2-)!7'#ZB=Q'S1++=GUPX@3? BB2H$,)R>K(A2.+2XBC=HXN M8HII&MKI0CVC"\$IHYVL5[^'VN.5"D ;O58%FHXW:XX8[UET[>]XJ.A'$$_?O M)P;ZC#KYD\=]//6?)GS""|2/'/19|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|;F.M")(;62B'VK:7)"'1^ L3P74 M0612?Q94<3.)VZ#"4?'4E'"*84EU$GS1_3]WIQ*S)3?=']9U#+^!N]H)A'?ZR^ M*M(:5K9K6$N%!HKL[7N0QZ$ZCBSYN_A?]_I+C](0K$9.[3,N)![TL!!)1W=&9BZ_KA:C3S:[33?_PB1'7B5A>]-01MDGWP M8"X01/ ?K;|S^"1(Z%&;_=ZU#:=']%?(CG)=H^1X:O[IO)IR3Y%G2!CA:OXI MGMP8UTU]%/@4^*E>S1/P^)M;UZ\DA5I W%E4$Z'@2=#A$]C0> ^UQVUC<%0+ M70Z26@ZH55"KR-A:X5RDH[9 ;>$XHB+V&,IT) M\H)B)'H4A=8N39&@B-R]V,*2@V"YYXI_ZB#N0ZYK!US7K[\02247"]"IG MN$>QJ@J'2 E=71D^4L3'@WB7|O?5MQVU0$TMY;9F!.E-*(QE1=/A4&O+0WL/ MH@5@+3B>'$N@(0+XX1],!L8R1:TYFD+ PHL;5#(3CP(W3 MC /=K/FQG*(]';7PE*$YG1$V1?.)H_FH0G^*9HKF].4DO/TZ M&[K%DXHM'MNE>@E>N.G\9EIET[T]#*P/8_BZ:BM M9^[3,1G"-6FAH*;@SIRGWJK"N!R'>I"AKMUW'TXE @EVDL@NG=,+1)(L&>VF M?A2R%++'E ^ZW&! X4WAG:YB'*0X9A"X8R@- TQ<3:#!@K6DP3K\8<+%-@G M">Q4W-O44#2|,[H'3T">'\&HU+8\5*:@JR,#QP^Y5H8"OC/: @('A@_IS=)W MM06_A@I/H9(:J/ AH'*X<1$4*C1&\ME\3Z&2N?V0Q&|<6P7672!)4![793ST M_!'HZ.O6RPRIX-B!L_]0EP!H)+,_D]% 2CN0,A+G4"'E'4@9BD{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|*"""4MAD@J8L"%@PJ8,)NN*.7+< M4T7.^-&&. .!$<#%]?$[*8Q*5D)-G.6LB52^_E^JW#(U^\R\4WS&%=K'7H *7*/HBRMPXL M'<:RCZ-L'Z_Z_5"0THV#5#@4BK&CQEC2?FS?K%.N4F6S"*Z45P$2GC=5RL% MS5? ^!%XK4[T3U_MV:H?5$;R6S,:IV<"5-U_1(N'A88+U$+R\LOF=6-K-T+^E M]5<5>\!2/_F1)UX2.!B)@BC=(+)W3UGA$$O(@H/@!5?\ M%C Z\]D"PH7S0RY.6%//NVQ8/M889A|\Z#RNU. [C2A>=<NDR!5&2O63/IZUP M2'\Q,9^NRZ+UKR>X8 6?!O4Z6S KY0OES=;_N<$(,6?\I"/"!^LG*'RL MOQ/+HD5!DR[0V!- S3M/.1>3=(<7G\ MN#R\OYS+T 3E0[>Y#:4I$+2Y"BZ@IA0YMO(!?63U]-6/;_'SW)^N*$NS>WY M2^:-SX\ 2+MSODEQS078'BW|R=3X$]Z.IN= [Q_WK?)VR]U>.SJQU;VO<5XAUZQ7TLS]*4O'7V"+Q}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|# MOU[^5YNJ..S T!YGI*A30?_W'+]H'P:*(@%!UM4VY')%O).KVJ{1VV^M4BQ_ML..8=#&"7F)V0T@]WQ_]|IW6_?5O@\C|UEWGOL?>84MOQ+=,YXKI?6DOFYAE$Z_4&SW\8US.V18#^]IYF&&T5U0? YV4 MOIY2U#-] IB_*QPS9G<& V01B,RVB?));)GIG?+AE|GDX&ZCV^%EY:A=&OQZ* M1 Q4Q$<'T>]-1&&Q ((*Y"'T[+3K9]8W0\XLNF.EFZP]?R.UPV=CB\@TJR*'^ M1B^]0M_1G/E1FJ\)6I!?_ES0";T*3GQL47*N=$-YNILCBTXVK-;9\CF.O?9 MB(V<?!L-BA(.BK9]44\59 WB6N>^,J.BG|+WQW^^CWJ(O?D614-!(D;3LL*CMF M:%M4+N.BXC'$1;W[^FVWC2,?&A@=?V"DKY&\BHSP|@+3Q_\@-V)^09?4 VL+ M7ZP"-=S!?78%T0*%W L*[C[L1':MI3=M&5W1^*/F)YV[Z+?7NS^#NZ^2(/-D M0KJ*U5=NTX" [V]D\7RE72|<7N674&Y1=5N6:#4?W8 PU["CT6Z1=9RP]C(O? M#_*/"A3*9+|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|>UKQ(99V9K7[.^1^&GQE;>MNKBOG3-2]SZ|:P7YH;N)(N_M++%G<5?_KM-H_Q\,Q&39LG27;-)Q?5%D^SU:Y MZO&U 6PV_O_?_ZUR;.6C=M8#$IAA[I=M0#FF++>.QC5 >,UB[6_Z -M+L4];R M>U#&E6_<LH1[GG=S,8\4PU= A6(5&RN:G/S-XBY=+W)?7 M>AE.!'D,F/I0_W!$XCC!_H^M_D#\WS^S';>/!BF?2&)3?L>U"6PBN" ,)PP MQFU6F>^1(*X.MI[.E0!FX+|373;36+MKY,>?MQ!]YWIM[%.="A(5C$O,N%P'"%RPW,)R*8\RXNFH%? =SM|KS^M-UQ}?[>MQ6SVCI8 MMV5P?F$^TF1G_ .<|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»_1&1P=5G?H PTES2}!-7I M_ GQZ_=RD-W,$//3>8?A=S;ZO&>GGX 'R\HQ#10U5I&TP8M|H@Z9:Y9;L%GN-MBK?//EL-DRN7B4_IU41%NZ^Z>'O7/$WZY=@WF&H2*CWN%^Z&W!HXMNC,_<< M.H=R43/U9^RI/OPYE>6,8AS*.63%|*C--3/_1@R8UP@X#-%%*3Q^E[3 !OP, MT:O1:OD9D;_@7/H):D8.(PORs H23M3QG#1,]:.CC%I018W!@^^@N%7.T].E M^S=#Q],"M*"4J8*2-@<2M,(E\P:AS2CKF2+_]IY=++WKYC?@/-6E$L&A7%_;.6 MNOB%*X\K#Y[@VU+QA,KA_'9.YUF*/UW48XVBET?2OKTZ9^8R-!HOA&?&<_5J]57QILTU*;#0IL;E"NU@_O_76P] M3/^,.D5O8;L_3S4!E61"R7SAV[S;B5WHU"75>3KXP@H?-*T.>XU0%!5-OA@ MWAB1CK&A)QMG4[%"3$VAY6PHH53X"5IB^A[X:FGK1C(:..0JG5#-FFLM/0,-! M%_JL*7*%LN1?9Y MC?+ZYN6#?:)\&,%GB7H7Z-O0@Q7S$3WDIQP@3X1^'V="243G91UW;?+YZ82Z'#9DUW,$A@9OR$ZFLA*7*O; MQ*HPL,P&?D\P. 5A9$S,R0XUC,AF4=KQ"LUAVI8=-1*B!GNN7UZVS MSA73Z-SV6K>|:-YU?FRM P/D&,>]=D(O_%A%_<#\G$ =1.D=6=!#&FNRV ME6$QWYC?N.-75KC80X+#@_=^WFO9B;KUX|P =FG1-YMVD:":.!V^X0C"\=4< M5RJ[C0(*-W[BNJ"0Y%$1WT@B&\H)S$3%=W_'6C|0&}=]:SJ}O(:]F[VMR6 MS3P1)7>?W@N>HPS7TF;QM).S/2=M.XKP?1P;IC%XN71"-1FJ2. F7DHSY >-_M^UT);EOH8&H0Q[Z+S?<1]7-V\|>>7VQ\V_K FV;ZMGB0Z!Z;9 BAD6.V0\@@_M^IJ#,T/S-WPLTG&4+.SHY? H&'P #N\(HZ^,H,|H<,T4) 1]P'0G .@:\V8N M"W,1]4Q\NZQNP&77=U$9"V CO:B,;=X\-HC,# MYKU0=FM9G074T3.!82(RE,'J&)/9P^%B2\=J/AQ=5X[<9HH^;;9A}\)/@_3ES M7&Z6[_[$T3C. 0ZF^I8>W7 D_7!=.QL9)? &Q.T";XYYMEY73Y HHZG0U>C(+:6.C_CHZ FZPCRL+(!Q.9ZT9/-QP[Z.T.4BKO(3%U_Y*4&\"XJF M3>I&D(6Q =Y5$QK3A-IPKFFX%0R[\HL2 1.<$DO$!0/8*.QFZ#-I>WL MYAB-@8\SHR>^",1E L6L56 -M)LU+%U5),T [9VJ#(SX5\%(K5(+GGVO_5$ MSI^G,W*ANU#9<'SICGX/O>EN>$-^M>F.=|TFQLD?GSON)HIU1;T@|8+9\H)T M]ƒJ\(KG%]=@C% (7(^XSQL0=9^"7U>)N7'-M91*NY?,+EU69PO7X7&HYDQBM MG% ^T7B9P (^S\IE93YJY]"=&C%;/+[KH-8(^QS=4'2%(BUGRGQ29&V36UMX3 MK? $B>#E*=);HF'#$^_R"GWD>G,C-V;#_CYRQ'\QGCY/^'$SN1ZG05A/T@=AMT62*QE^9']+&7K_M^(,5$,'QE\68AD=[%X0P\Y4+Y2&5S/<9CE MQRF'7RF>O/8<75"91&92S)6X0AS: <_1,+;>B!O9!/>2$]*430M[H=5'XVW\M MUZ?:,_8??L[CJ5K9_1+G$BOW%V07%S,82*|< 9?]GNUQ-Y5*\?RWI!)Y5H? MUM)0!5<,5>LQ;+> <[;U7!DA\UC@>S%TY&!P&C|#.R1FE,RV-Z8U7%Q6A=%=-M57P>QEDYO((O^(810_(Y1@;Z01&P3SX!|*A$ A!933,#R|#9J$CD'&RN4O4. M/D+85,5B4\MY#?+X&@@:N,T/]- ,,UE5#_*=[!OU>]U6(BG1+O+RIHZ M|'=$G]G"O#+*X^L-4|4[95>).K$EZFRFQ4%YP9,3\'8F0'P&T7(G#ZJYL M1!U=D,=P0)DL:LBYM%Z&TAR':Y\5\17R&DK1E?%+A]M? =MUʼ[{8)%VGO:!O* MDES6K T:^,+V/'S)3Z H O09)#T.O@Q4J5"HL/BA58[E|=Q4PYO]KVC_(* MB3B7S15Q%P*Y!.J-*.9< O8_+U2N>_]?>G=OE//W&5B M,2YR:A#&P#5E3)X1=&8DP.6]>P<%C8OP_"[J%1*E;JZ4*[%1R!V'IQNE.'!# MTYI,2AVWBCQ@E@0B0*X17O MI7%;0 RF+,.=UD400S>;8HG?T1ZI0R.Z4#+';&N%IM. &NB*G;/WU|7X8"7" M702"X3LJ5Y5#?RYD^2M!<6G\&B,JXL'|,%3&> M.9A%|LX]MO=/"?E9TN#=5RFA|&O5;BMM2*,]MU%[.E?M47?" MO=&;;4_7#=> MZT_7.5>A,M4Z7\KCYE=XL):\F4EA."O+^2A^CL@@JPN!,1,OKHF26+5D0% MY[CS|FA9F-QU M#Y%#YX4%U1ZZB=-9LO[MKT:B_%G,E7ST]:2RF!Q,A,Z62&++OYPK<[%;HGUC M,,?5PLT<;[MR\[']Y3?_))[VZ;6]42M:0=V6%,T4U9R"D9JMM6ZZ(!S)!$ET"Q MYITYI=((0TC1V1+)]F4(H<3GL?TN@"A&(A-,-@^]K&ROJN9SOYMO#2^A3KN M068Q=*EU=X$,%959\H#/4!N$X4U.\|(7EXV?HRNQ[FHQ@,63J*_R7*X0HJJU MF@5QG]R]BQ$TA1DCX7#=- Z:]]&.7SI<)#G>6W_!?5?%^-%:?*XD$J7;%S+ MOM_",+1LP^\)O8\,]'B>;9+I,R95*L>S&?ZVG-P*6R'1?96*.;9KSEZRFQ4%YP9,3\'8F0'P&T7(G#ZJYL M1!U=D,=P0)DL:LBYM%Z&TAR':Y\5\17R&DK1E?%+A]M? =MUʼ[{8)%VGO:!O* MDES6K T:^,+V/'S)3Z H O09)#T.O@Q4J5"HL/BA58[E|=Q4PYO]KVC_(* MB3B7S15Q%P*Y!.J-*.9< O8_+U2N>_]?>G=OE//W&5B M,2YR:A#&P#5E3)X1=&8DP.6]>P<%C8OP_"[J%1*E;JZ4*[%1R!V'IQNE.'!# MTYI,2AVWBCQ@E@0B0*X17O MI7%;0 RF+,.=UD400S>;8HG?T1ZI0R.Z4#+';&N%IM. &NB*G;/WU|7X8"7" M702"X3LJ5Y5#?RYD^2M!<6G\&B,JXL'|,%3&> M.9A%|LX]MO=/"?E9TN#=5RFA|&O5;BMM2*,]MU%[.E?M47?" MO=&;;4_7#=> MZT_7.5>A,M4Z7\KCYE=XL):\F4EA."O+^2A^CL@@JPN!,1,OKHF26+5D0% MY[CS|FA9F-QU M#Y%#YX4%U1ZZB=-9LO[MKT:B_%G,E7ST]:2RF!Q,A,Z62&++OYPK<[%;HGUC M,,?5PLT<;[MR\[']Y3?_))[VZ;6]42M:0=V6%,T4U9R"D9JMM6ZZ(!S)!$ET"Q MYITYI=((0TC1V1+)]F4(H<3GL?TN@"A&(A-,-@^]K&ROJN9SOYMO#2^A3KN M068Q=*EU=X$,%959\H#/4!N$X4U.\|(7EXV?HRNQ[FHQ@,63J*_R7*X0HJJU MF@5QG]R]BQ$TA1DCX7#=- Z:]]&.7SI<)#G>6W_!?5?%^-%:?*XD$J7;%S+ MOM_",+1LP^\)O8\,]'B>;9+I,R95*L>S&?ZVG-P*6R'1?96*.;9KSEZ=2+<M_M=J-*Z5N=

8@#Y>NI&WS(&T@PWON\;419@LPU'{OACIC:V)HI8]V@RLP3.UM·MDJVB(M1FDK#XP"'|%@>5·LM#S'OWUH+)LX?PBO^X^3575^L%%PT84C6<7Q+[6 M&,+HMJZU+\/OMQSTS]QGJYP;W2A'1!A=-RP3X,P&XL,(=MFC"'7)_^\Z[_^·MNGRX;O_]\Z/8/ER)VICYL.R·TC"E,>9_-N-],5LU6UAH9^M.4#NJ.1E4-#B\·M VH7#UCMPW9_!L7^<#,0\^'UYG)4;WW_KS0X9W2H8P)W7CTJEB7OI\XMM(JJ1·MB%@.GQ39S_S/W^'*#_>\/R*\1@SX(.-_>,;Z+9*Y;Z_LR_V=!28M1H(=_Q7.·M,!',G>#"._0RG_GE=^ MZ-=7V·>]864U'77c]HU%W@LJ&(6 (6SEK]XW_"W)S'(R(·#C8)L,·8#F_,=V·M_87L447'UKHM;_VQIBSVW\M?Z/YE·M0>'OS^K/82BG7B#@U&-A3.U<+·^:U7XNGCIK·A7+0-\? _5L&X#?K/]RR$HF]·MZ*MFJ$4HQT!-PXUN1G_;?-=T]·6N?_N/7,SWMXW')&2QU]]GOS]_&6DWM\N$BJO·KJD57·ML?$4+4](@Q3CW,·M^TUTE;KHC.OE#0>;N[13O0F0QY· HH^1S';]ELQW5K_>%#F?X>Q35@P"]LF(:]ENX(SS0%[=Y/(EV^+0>-S]9I=·M^V\[2WWF>·%?ORR"W,[E/·*E>*O)%1^OWS\UWYL_W9>]-M]%#:Q"DNMHV$5 M_?,2'A8UW#&B8]*W>VX\MCHZK^[@Z$+/GR4Z;8W.'V\?·@G/TG#^_=2+#]_M<[..P·6Z/00$@*:??92A.H!*40F=(^MWH=]:P%+FTMVM"TCX4[.UK7O\)?RC?7·M\E1M5AOOAT& Z'@?"?Z!X/M>%9?HKI·KEPLYOK8[H6L5S3GE5&P(42XMBGOZ·M7O\[55]^:^·@?.>1HXB6/Q<·M0;H3H·B6&\(,ZH*T'3[?C?Y^?GZLCTNO28PC=SW-O":6P>/D\U!FAB:[ASUV·MZRS# &L"D<[B8M77B9O4FED0$3]O!40:?/E*KAQ9A(XV5[/8W#W0!2@#L26H·M,@*!5A\.Y],YA·.))AC!(=2WS;_=N%)+XK3^O5M)Q=4D%HJ1:·V2,]PU^F8_·M-KW5%<#2PQ54· $0N^M[N!,YR#D5II/I*WU(=^G(UX3]"W718*^:*/+&+9-[Z·MG)ZPV_6X/D.Y=#K8^[3OZJ]*\;G_6F6%O}?#::GW·$C1K$'+,8.[^H\I?ANS\@PYLU2VT<,]5W·^G=/(;_6<8%V,5·_ME? AX.:U\M!@U12%4D^5<%X)+R+-!]Q\@#IMI(",}5#[C474J@6]*5A*!C474J0G(963LAZ4&IV·M^Y_8^:'K(_BF8P9.1ZB,5!T#·1P<>&;#%@Y<7"W5XD=%!1;#-IJ[(-GDO MY@K&5S+/6,MK+/3F>/GF4&CE_G7T6(HI)%E\\G9FMD'R%K(JID+[=V!9GF?N·MI<8·KHO$[@X=2)^(·AV14H?(C0\OC*I_;ICAB|.SLT^SU0/QN6·S]?{Z03P5·MU#&4C7ML· O_97_UGKNEPM$"B?S^{2/|;\KHR6]|+1_S&2JP[X=X0X,5JZ]1T·MI//7*P4M&SRSD7@#-A.%2FZ($+G(S+QMA&76'T"4·P%U!·@/·:R·M\941P6_G&:*8"B·M'I?X! '4R4VI"2F:FROO\^U2'(EPX|,>S%#[Z^KR)LI//S*WR,>';XL_OKTH!?*19UF^/Y·YF>^·#E]M{U*,+72^X\1^/D5<·M+8P/H@5N%0LAN376@5/#&CBM/V)T1"YGJ:$/,&\>UH(^#RY:? XO3^;K*X3R:·MR+D\L:E"N"28#C=6^;Z6(3*Q8OX]YS;R+M:N^D9/·M8Q·*GW:A%$U\L':D*,7GL<;?_U7·X!21TC#QP=]1TAW#4GTDRYKZ)ZU(,6H> M>))EGPXIN/C\.Q3'Q2HK:R$*>7H3%#0#F!OUDHC$MM$2)6U$-DR5N;"<*MA@)·MB@H*(%\BOX4RQ8\C?BR[2-'\%ZD5X516OG0N9AG@D^HS:'"RO4G,V0XH/·%Y M#JY498H'\N/=·H)10GS2,F19·,;TL=[GQK^V·M7*H3FVVPZ)=<;44,K=YU*K>U^M1O=ALA=UG*R2.\,&Y8L&{]2W5CRG2S<4·MS1BNWU>LKN9'WI92_TI>_[66'#?/U\1O%9IE^#· C3^KJWJIU'!*#,EYZK4M·MQ'=&2Y^·6P91^->HMUYGQ5'_%%)C9F·G0(^*]DHBXV%REDM$KB'TA<'|X5"41'A5S·ME5I&Q^;YPN"^2*9*Y!+L7+40RP@0VP4HP.B'1P',C:·^AQ$+".9; <_^^WOO·M#R<5M(>KA,<0G%]TD8#,??WIBLB#XL-=:*$\/J$YBUQ&QW\$E*;7^R=Q91<^·MG>%=!CD&·7]O!60&0.6*E8PN!L'AN6]E])%HV&>Y7#6>]:H5R]+P&<@HK900 MXW5Q"F6(\UH\K\QE?1AIS[HJBE="3(5?2?TO%DFACL!1@\41!ZR#+·LU$@D·M"N5P;L,HQ(=:..&HG4H9RKEKOQ/AV-2#T?D!]16FLAQ_NX0_·HI,JU·MBI 9>):K18YR/*\@K4_Q:=Q7HSVT,VK+NB"/\2A\|7"O6M>U%Y+KXI(R?=.'V·MDDLZR·,2BJM0)PO#O'.(;$>":9D8PB#XHFO;+,]1"0B+_J&8TN@LA3JI%A,B=·MP0Z#:8]5GMXK" (D4I%3*:)P3#J%[5@^N0"0'R97B7SSN@08$=3A!:V<3/·%)·MF>$S!RX)B,C^^F_0%%·'DS!CHL@D{"ZM0BL^C+1$W'·2NF,S1)=FHA.(JBHN·MQ"*%ODT<5B S;C]MP>GP;WKXM<@41RQ>28,K$1=52#·5=BY!!)K,0YEO··M;]@.0UOAWK6?2(]-{5?VL;],·L:;8&7[C3&RJ#_55OVG4WT=*W1=M#54"[·(AO,,2.!6T8%3_>":6_SX3Y#*· S^]!PPM77RGR0RSY(:QL,·@?@YS·MY·Y?=O,AD-S#>·0BT2X(A,·T6I)+3DA(RA[5BB*)·G4QQX<::72@;)LXE*2QA2·M26M!U·,6?AFHI92!?9XLG)&'<6DE,H>/V6J8P\? {7%K+.OH(I40:E@E·M4FF]X!W(.=0F.)OOC'"U^M*XDO,G2]($A,^'I(8$A#^&9:B(·\!EMYVU6+·.M/=|-NGSQ)UXS#Q:$8RH98&·+,UJ6#Q^)>VP<$%·,F$B]1+9?V=>@ZM0$/,EH MP"·+,Y*M.FKT|)AT|&^LAE,+B0FUN?@·*$M9·M#^E+:0WJ!T?$+K@·Z3/#%4RILHFWD98YN%=·M0V$):.@GG.H/A45SIG^I574VS\"YF"ODXIH'1EH94I· JS+MX8G#8%ZN5B4SJ|'"_5[·K;+QEC>"|+(R-N]RO·##;KK>·#LZ^#·MR>N/OX-?ZG4IZ>!L0QTS·N"0IT\,F#@(*TPEH4RBBZ(2*@A(56183FMD2·8"·M^X/".HG.B2,·026.;;V M4HEM23Y"CI'|\4XQ=E5H3U#!LT%]7X84NO!RDOK,YGAR;CL)$##D2NA"X7KV2X.K^"W!<%],_Y]YW+·M0IGM^P-\UN"]GBU0IQ)M^Y:8Y\X:E=B6Q#S/;5"))V256\]RX(U5- M0Z)0(X0·M>>>7-D/BE<\8;=]>O5?9W_[7\F_U5'4X7H!3/*7[#·=2M:4WLFTQ-?;I·M\&IZV"M5-Q(,DXV0N70TEP?5_+@#<'|L3Z92G6S'.M#@W!?·M.:!FR·NDD0_.:=0<-Z)O$| PH>\@]Q=OQ4?MY&3·M2D===0Q,S(UW%'$9*6N^]7@VO^Z^/O:]U:3&H71?&!TM*M\./N_]/*1·91/^[·M@V8#-AF&6.UY(K>#E_%XIS#CJ·.0#GB+\GMO-("NY79_JZN#!^:\·F* M0!8U4P9=7="-PR+MZ4P8VO+2U>N5X#W5N^Q<·TW]P'2!"H'& M7-H&NZPY8·P6&'"%·P,$50;BH2I=_·N4,:O$@T9A9S>·HE\B"]5I22-P040DS·M&3,K@O5>94@T,G+%##$Z_(0':? 8L/D_SU>@"5B^?.*9]%4G-]:@* 4Y+5"H0/N7775TfL+%2G4D_UMR'+1_0X·M7%")Y>-P/H8C1/$XX=:WD)<3;X4.N6*-6%$HTVNW)]2HI3LJ=HPV1M+·M{GO#!;\0&-#.N%7@W1K-DB5)Z1J/?)'EN@F'UO)58K!-W%==>RY(*1;O8D8·MKLZ5"CB|'W[fU.EW'R.32>A^9H,KH·M@=H=4+L3006&..H#35>-4NYE_W7\&W877[@?#1CKN3K[20^@,AHF!\4=IHR1 M,#YD.#SUG3L=9>)%N:?_(·M'9_E"F3T)A'N.5?91[YD.\;UPV5,<92:!UQ[WS<&Y[>TEC*#&U·GN/[FG=W·M4^/?\;'.KLJ:SDB:VK{\Q??·\CY,K?*.2WS*R+8@FE":ZT#<+/A:ISM;@(Y: M:L9S&=$'\UW1I'#6:_^&/Z5:PZS_OJ^[=W=*[#L?#034*051FD<$P/MMTJ01·M0.+&MC\&X/UN:+[;6:^%=]@^IJ_<]D8!?AM14Q0%6">:_188D"LHY5=&(/:·M^70·U, [(0*DSUS5=D/[MHH!KZ/2M#%X_BL78KB'=:N"OB*1$4P:UNR]02.C·M;(C,^4OJ8ZK,!RCY1-QZ":2T4"M_N,Q_O>H7'<$,HW'3))DF]IXH· M%8(=U59RQ3*7]Y2\#VY0S<9@M!X11+@]PDJWM1Q7+>=]/@XX4=W&8+7[PHQB·MH&++#CF:15LL57U>9AM*L8Y3!>4<9R[AK1TR,.&,^?QS++#]-)X;^8R.YIB)## M9RWA6#'NIL,P84LE'+E$$DK=6#1E>L1>!0#%29HX)$]W7]&·M'L5PQ8NUZ?*Y0AD/VZ:QQX%,=V_T$:C(<:CHX[VQ#7!Q=G;V:,9ZX·CQ:EZ<·MQ? 3@%"W=M^'9N5>F@IPSOY$SCKN,/C)301U#V9A,OOGO?0G*]M?_F6LZ'"V6·MWX2R"/·+\L8GM[KH\;OS(V$*I<4*K[<,GI7@<$"5)4],·=?/+@CR8^=E"/·)·M#))4K]221=]I)P)0Q3HH0BD%?=3O7[6:]UVIHRW1[ZXZ9UVV,Z5TSC2_WV'EN/?EOM5B;C]WO2]=IH5DA&0"·M9FC91;$OPQ=R#,Y3LLOI&R@C·I6Y)A@35EZ&B#=&-B)[?)?KL@R%?FCIA4%A MB,#D-X'*VVRR[A1"^ENT5J5'OG@59]EB?R;S,M]_G0PK#?9>Z4@3?·!C/D5<·M+8P/HM5Y%:DAN37685W#&M9M/H+D;MX·KS%09JQ'8/Z7:?V=0WV!;·R,X!#J·M;YDW#VLUG <7O+[UW058·D0->YH<%G(PG%·M+Y%$YV0:L8!5^N1Y9Q.(]3>=L66FD01HB8&=;GILMQ?5[O7F#%AT4·I!=((·MR@?J+U#KNPR%NC%[\E#]-&#*@:9V1\2'C·:LA^:·MZ *4@;AJEUJ)Z^=X()4[^NSS]\!FR"Q72$+"VG#7",Q=#^7+VEQ=&+9CFM&*·MP1FGE1^E/Y=_?V]V'=,@$.?9NBNJGV^^W5X_U3J#ZTIP%)N/2CN&F_W7^>5S·MYV?QZ?M\. I*94\A9*9&Q7E/C<,MU-I71[!3Y<'1#\[+C>BXI4J..S'.IP2M·M_?76"'B=:V[%P;'CR7>8X%_TT>+A0Q!D:,](-R#++I/'H9U0I60RF4PIF\I5:·M?KF_JZA+ <+!H.XA@'?3[5P^2#]P^%\:I<$HSMSHX*>3.P-:0#$(P$"TJV$·MQ!WJX8HII#QJBO·DLIRF.=>E.I4ZS7;=@2RWA.L&J>8UW;DX65I)9N1,>C\·M57^(MP$+E0+,[QM?U? B"I2O=FL&:F2M*:*4Y?OF=HN)0T]\|@MW^ZZSS_>?P·MI5TH_Q?F/)QWG_IRVX>K_G-^<2E(@M$>R2^-DF";Q/TI&&=[67WD+G4'ZF0QV+·M9RGKW*+++]7Q+;*4ML? EJV/1HR:PC+LPNVW(>26SY6WU'FDT6^_XXM/=TEJ+U·M=+(YOE3)U2K>$U&#((P<='=.$4?2&!%'<1·U%TG,ON55K(^^^\,HVM5'%9+S·M40Z;<'_OM-9E1U+:RBB%SF2'X"W? $.WX.RU7*A5S?#6MD.FJ;_#06I'$73]L·M]PPIJK0@2MN!];RE0#(W!O"Y$N=U'(36O28XY&@&IWWPK?<)M&)QCQ7R5]·MC'3;*^^=]8#+FT]>UO- 8_Y,^/Q?'5%BSR_RZ\:^S=T1)^$&]FW=;Z&(Q$6E·MI5*.+W@/DZ%.P(\2M_1#]A;4:JY>LW!O"J'J&?XOG:R?4\0%BIW;O*_I)U?RV8?!_+E" MP_NN3C.XS61AH_ZK=5G2OVG*G\=U:+A);\!CO92V"ONU?_L8&Q)8NEZ-E/EPE·MQU;"7/-I1V8D5(=5BV_O<& 5E4A$R3YRTP,I:7VY5BJH1O;E0L6RAVO!4L[·M·VQ*&? 3_<1·M'RG7*X2-4E$@IEDK'?!>\7/L64PL8"·M5)1:&C_1^]?OGU15*FH*S4NEHVT72Z,-]NF1:-("!^&9>]]&P9A*4HHC*>-·MWPDTM8.B? A,_U[V!9H9H&Z3%6OV__];L_.3;_-5@O(ZX_>$L>GCMC_^·RX%'·MZ;D2,6RN%7,%'^6*E)M#);5!4.@0(BQ>·E2]*RR)[GT8F35]1F,W0--5.-27^7C]65#%6Z!W1E>*.@)0G^.: MY&OQIMWJP.65(L=XO?+YQ0!$#%HSU35-RV54P%1L8.HFQ%)2T1FH]4P(P&·M?'$NUN#M)UNYFR_NM9]7?[!VW[HQ1RT^1$)V?BN&G'^_L"CXNRTZY\513·M&_Y92"M12W? #&0!]JF-B;RRT·<=2':9_1A[@MHR'5T1I8]@BX8HD_J$(<>·M^F7K_LO3B&W?L@G5BS9$;<:6F0P5E3%(.F<'K3?.A4=T"#$"5-I'4IXOT&)·M-Q!CC4C:H[]?!Z]_U1\)XI5A&)(%@&'· XBD>LM%)+5IT4BK49RU:3·M5D.X=K>M_A>J]H^UM!]6EJM4$FM4GRN,+6LQXVUU,:-AS;++<"3J+'5"MX7·MAH2(?V?A8-AT/8^O_/WKLVIZTL;VVP?9_4#7@J+XC!A1Q# (!K%ZB0-_92#FXPN1\·M6EL@2#$?!02)XB\04AI"PCI3QGAVI@[-@.=[=D%JG"L)"VR+M+[W,8>B'8;-!QK.VM$+WE<2:@\3BDYJPDEYRX" M<\^[']YOKHIB+I/@UFR^6$JO/0O(7?SB /7)I9Y$/6=IY·/5|\N!/R=WAP1H?·M:;;|OER>D&3Y(E^((:98#!E3I#^^·@2H/4HCB"%6[!ZNVL.'R=<_/!!6%PW?_$&·MNJNZLLT#F"WFH.·&$2*·/A7SAXT3YBM\-E=*;A·P[· THHP]+AHD3'.HW_·M/HKF6'PIN1Z4L%R46(LFY_;RB?7'YOL:K·G)*,+!AS.XV!SUFS519BK3&,F·MJE6?"TPDJZ6@@]-N-D<8M,,'6K.YK"K14K76I76BC^?!$K;9.-&%V!PXB',.S M1D)*W3LT4B<*>·<-@·5W]+11]IY?\!W0D3Q99Z.50H·.$[8W08C!SNL89"'K=·M\M,"P1='SG1BAQ()BOA02#X*%%*NI3W=OIA/.PHH!.%)/I"N:]*(0H|<_A5·M\4MJ-R· M^U/4]DX.5AUM6:U^_E56[VMQNJ6V·!(fUG96H%[W_4_YIF<;G*F·M*^>11!ZBN.GQ(8M'%*D)Q;17UA<+Z0*ZIV*L\.&L0B2=IK-\+679_T<^F36B M1Q$@Y]YP]$!UMNV>W0)Y8LXK+,_E%HR'·MW4!B05]"\;$<C_1^?OGU15*FH*S4NEHVT72Z,-]NF1:-("!^&9>]]&P9A*4HHC*>-·MWPDTM8.B? A,_U[V!9H9H&Z3%6OV__];L_.3;_-5@O(ZX_>$L>GCMC_^·RX%'·MZ;D2,6RN%7,%'^6*E)M#);5!4.@0(BQ>·E2]*RR)[GT8F35]1F,W0--5.-27^7C]65#%6Z!W1E>*.@)0G^.: MY&OQIMWJP.65(L=XO?+YQ0!$#%HSU35-RV54P%1L8.HFQ%)2T1FH]4P(P&·M?'$NUN#M)UNYFR_NM9]7?[!VW[HQ1RT^1$)V?BN&G'^_L"CXNRTZY\513·M&_Y92"M12W? #&0!]JF-B;RRT·<=2':9_1A[@MHR'5T1I8]@BX8HD_J$(<>·M^F7K_LO3B&W?L@G5BS9$;<:6F0P5E3%(.F<'K3?.A4=T"#$"5-I'4IXOT&)·M-Q!CC4C:H[]?!Z]_U1\)XI5A&)(%@&'· XBD>LM%)+5IT4BK49RU:3·M5D.X=K>M_A>J]H^UM!]6EJM4$FM4GRN,+6LQXVUU,:-AS;++<"3J+'5"MX7·MAH2(?V?A8-AT/8^O_/WKLVIZTL;VVP?9_4#7@J+XC!A1Q# (!K%ZB0-_92#FXPN1\·M6EL@2#$?!02)XB\04AI"PCI3QGAVI@[-@.=[=D%JG"L)"VR+M+[W,8>B'8;-!QK.VM$+WE<2:@\3BDYJPDEYRX" M<\^[']YOKHIB+I/@UFR^6$JO/0O(7?SB /7)I9Y$/6=IY·/5|\N!/R=WAP1H?·M:;;|OER>D&3Y(E^((:98#!E3I#^^·@2H/4HCB"%6[!ZNVL.'R=<_/!!6%PW?_$&·MNJNZLLT#F"WFH.·&$2*·/A7SAXT3YBM\-E=*;A·P[· THHP]+AHD3'.HW_·M/HKF6'PIN1Z4L%R46(LFY_;RB?7'YOL:K·G)*,+!AS.XV!SUFS519BK3&,F·MJE6?"TPDJZ6@@]-N-D<8M,,'6K.YK"K14K76I76BC^?!$K;9.-&%V!PXB',.S M1D)*W3LT4B<*>·<-@·5W]+11]IY?\!W0D3Q99Z.50H·.$[8W08C!SNL89"'K=·M\M,"P1='SG1BAQ()BOA02#X*%%*NI3W=OIA/.PHH!.%)/I"N:]*(0H|<_A5·M\4MJ-R· M^U/4]DX.5AUM6:U^_E56[VMQNJ6V·!(fUG96H%[W_4_YIF<;G*F·M*^>11!ZBN.GQ(8M'%*D)Q;17UA<+Z0*ZIV*L\.&L0B2=IK-\+679_T<^F36B M1Q$@Y]YP]$!UMNV>W0)Y8LXK+,_E%HR'·MW4!B05]"\;$<C_1^?OGU15*FH*S4NEHVT72Z,-]NF1:-("!^&9>]]&P9A*4HHC*>-·MWPDTM8.B? A,_U[V!9H9H&Z3%6OV__];L_.3;_-5@O(ZX_>$L>GCMC_^·RX%'·MZ;D2,6RN%7,%'^6*E)M#);5!4.@0(BQ>·E2]*RR)[GT8F35]1F,W0--5.-27^7C]65#%6Z!W1E>*.@)0G^.: MY&OQIMWJP.65(L=XO?+YQ0!$#%HSU35-RV54P%1L8.HFQ%)2T1FH]4P(P&·M?'$NUN#M)UNYFR_NM9]7?[!VW[HQ1RT^1$)V?BN&G'^_L"CXNRTZY\513·M&_Y92"M12W? #&0!]JF-B;RRT·<=2':9_1A[@MHR'5T1I8]@BX8HD_J$(<>·M^F7K_LO3B&W?L@G5BS9$;<:6F0P5E3%(.F<'K3?.A4=T"#$"5-I'4IXOT&)·M-Q!CC4C:H[]?!Z]_U1\)XI5A&)(%@&'· XBD>LM%)+5IT4BK49RU:3·M5D.X=K>M_A>J]H^UM!]6EJM4$FM4GRN,+6LQXVUU,:-AS;++<"3J+'5"MX7·MAH2(?V?A8-AT/8^O_/WKLVIZTL;VVP?9_4#7@J+XC!A1Q# (!K%ZB0-_92#FXPN1\·M6EL@2#$?!02)XB \

M8G9W3"Bl\+@H;*$3ZX/FLMF$H/@H,=?@Q>"*H5DA79VLVE]4EHL&%VX4V-MF@HZNI4%9;_J?GK^\55]&#|\GOS)QVF^'Z,AS1],?(M&Z,O.'E:,;D<]E\@I5' MV-M33!52">,I\.6?*

V'Q_%3Z2]{URZIDI[983GW;+B4^LY72JZ[QV4?=+)10*'#*>Z)A1I;(I_I*2+H<-P==] 3^4UI-L?O[HYM-MHE%_2%\3%)VN2A^LOAH/?[X\MW2IQQ_)DT?71<8EV5@(T5[-AF-M9R7M(6$+ M!^;^GLGD[F<^H>3<)7] M"(_I"I'V*MCOGB2DFJ92._-|B_1*54>8J2["-& 573)0#VF/THCREWB'1NI$(6\8K*X^"?+E1%S^^2/' MZ6DBJ[L8"G3RM[UZ[H)SS,=@-)!8GXTJ$=T.5\E&DJ&=Z2>Y1R1-,'(*85+G(\@MM|83[EVYFN*I0\FX5G5]L/K<;'_,ATO2U^G\)?FP?"9,=)#!R7@52L'L+/7^# M?7Z7F1O;^&N7YVS'')[#D,(N(T7;#RW1 Z,,?PO%$@P3CF$"\Z3.%%NC6*!9 M]K=0+*#)GJW]HN^B5RE%VD6/KV3+E>#87\B##3,=/:EG&OH6! 9\SK?@L%L0

MWOHH[U>G[',7BME<),C;R%]P%2(^V+4SVR^RY#=D@<[62L''E-T.[.2SZ%]# MU?1SY=/JZ_#+4BO%XJOV9$5[*%T/S0URV7PGTQV=E^W]W_+VH5"M5'9<5Q\N-M/RU]M55#$?.FMI'M44S@"K.-MV5RL'3["JU:#D7$09VE7;>F'01_7G'.OTB M58H1S,+K\8'EQDFG$U\Y6/U>;+1H_7!C^G5T\W'B>:!UM(BR`);&>80>O^@W-M2:I6S67YPEDN\4DN!9QY.8H%?.'I$.<3/IZ)[Q#D+4Q>*T<[[!2S9,R:78J1"(%0KK6RFEW,+\HD;F#&RZ:"N-L\0R3BP MUTXWTNF%?"E;S4>&<=8<=O^2+7_(9/Z;FP\;XU'WBK^]V1'V3)&+OQ>VXF:!,)/QD^:OWG?ND(?7P'?UW?H27.*4FO.%B+,PD>?DN MZ!WDL[JT0G1)-H_QM_\$#:WWW$5[N*"2311>@PKC^C6K-^7X+L-=>YU_7T2@BCM7:_# MGW60RB32>ZZ_G./WU55A*

(W>]!;0\+#Q1!A"8H?/2=GQ&B,-Y4B KN(N9X,YD4$)^F I(0=X{YNYL)2=;/_M&WZ ?,)6,]/N-+!T&GY(IX3'"^Q 4,=.[O^RUF^WZ7;O52_5F&MU.L]7IX7/! M?^MUK]O->K_5Y'I]_;=-

J]/GNE=M_N_^1>-UM4/2[_8;]_R+ -;M)/NM+B;,J^ J<>U.(E:GB'#M&[T MM;3@7;H+ ':,R_AAZ'N'-<1CUPO;@X0QQ[7+XM]P<_X3\D\-H0^ N;#$RI)IU

MJT**.^FF\/L+I\5>F8'XK6'PI?G\Z[K|;6D0&CPA,+W@<;,+HDTKL92;B)0.E M_O\)?D+H^7!9-*!AHX2NU^;Z\MQGN3=K2$@W#)QWP0Z^CPX/YXO4A*E1//G(%0^!V\DYU%T<

M^K%88?69NE ,EWVU-ZPZ'_GYR!-QY&V%8RD9B593$>V6&6U_PU.3#Y0CXV : M6/T;]M7(IJHGI46=9.:?RL=<:=$;K%8K?O'[U\UP.2K$4FG!/%GYZC_. HLF M&C%G*4^]!^I?O[=FSM$)AWS,A6_+@Q[D8. MS4$G%E^V3-S'?(DD$35;K@4/$<CC-0O*!,KQ9)1'$4/_<3]YU/E2&!VI5+4V9&9QELVE+.*5)[91VO-?

$^GUFD9[9#S4"E$H6H MYLM9/K'">L=3/%T2Z_HQALGZKT3:5",?KV;Y\H'P;B.B^S>?H1G#(*^DLM3S M&"--52[F@.0.4DWZ$B3G!\-4$U?

V:>JQ=P5RVS+\047KJ.UP[GB@ZP_.Y;*U0 MC.YX//U(N>/YD?JK6>YN_/7;SZNA91J(DCZ7A>4[#N\0O>>B<'N9/B233@>U MO+3-K=9+= G=*/)OU8"M7PO+ 8=Z,/[B6QOD)(NB M8/704^Q^@!V\)U4(VfJ')W!=%+8J!R%=%'^?SECER=21#@\+Y&TQX&=PS+,+K[H1M MTR"TJ,D(D42(R$(HN"9# M."TD;X44W,;2T?!]DG*H\O^GZ9M@>Q-^<-

MEJT$]FO8RWMW8HJ8^*WF#C-[M*H5LM9A/UZ 8E]@,(QU:>T256B1H/)_8L>NI'.%6S:5\X%8UE]2!6V&L@1BN

M;0A;K)K;#V7ZVF(I'O%>S:5\C&TU5TS[!@('+.T>HLL50N+G#GHBO]$'JV]/ MJ%6X&3<6& /'D;*]NOOR9ACA"H6_.JP2@SEHV,+5^S<^HT+9[W*O\ M8JA!OS)KP.?6!BW-PC:EU_"!PBJ"09)UF^?.R(3?3\DT\[_X3= M0-IA')L&[QV-Z.H48GB;GK"R[#NVV3ND&YHTJA?I/XD:&('&=WQE:J- MD60LP#>JG:$>Z'^LU/+!%,\0WMMO^'%8,6O66MB6$"

5>DQLU$Z82.?.I@9 MBN-B1:"]K].?]\^/_|$:,80Z';6BQEYAB%)M* T?V@F3CG]D"*?6$@:=@-) M]2R&WD#:05T^[. NGUA0%W8#.4%,/C? G#0F0D["Z

M7=4*G\'>.Z,C^>SL1>DD\]I{JL:1)6&EYHR_=E0CFG3ZEX;I\DG!5*VPF"J8 M$6,%(U/-]=]9_Q8_F4(A=R)#6/&5X'DB19<%0[T^&4+I6]V6DLNP-K;X#[V

M04123W<^A@@]EH4H/)K5;#%W[-*R+5,(>W@MY!\%M(+/@]]N[-1>#KQ MG>4/38WRI.O5 ;+R%D-11N\MAKOD2H*V=.@/BE 80'&0#N)1CB3+\|+BX=?O

M2OH&S3IUCK70Z-G5+_';J\MJG]IY"RFW7M63+OWK)AV %%,+(#PU+^0 MCQ)2^>ZN8G9$W*$+=JK%*"9Z\^5*8N%V4L]]f1@BB18?? R>"*H9TMW9FLUE M=8EH]N_M0AM-

!1W=RH(R6'UMUGN-JL%+X_&1W)SF^S$;.M=%ZT@XZS>PM+/N MJA*\@=.FD^;@]&6IF#V;\N1^]ELLES\7[58J(3DO9I^F/T6Bl;&5#NNT4BOE

MJ[7DNM#*7IAJJI!*&$^!+__$Y_LK1E%@Q=?V*>).%#>5$FLZG9R;PO4%]):B M\"*7;1N%-1[MU(-&3X,5^O)[6E7J/RHK(4[/I -/T^+LEST!\UPM\6B#^XLB96)@6=@~)]5&'-MW4 YL=

F[82GO?>JE+WUR'Q.1+470**I42VTI\AM >R1NLH@,[AM/8#.F9\ MUMRB|<5_BH9!A{I.YB0C:F@32"O0-JA.3FQT-0_ !B9OHD>J%4BR5!-<~>3G=/P'2Y);&H

M/T?$63;NCLWBY?9LCM_=':_CR;XF*#I=%<9+S2>Y6I5;N<#7W"1,RO]6A-E+AB&3K*#Z M7-#$YI;B8XDGPP|NA27\,5@9M<6/I^5A5_TH)\G)9"=#]_6+^Z:S_B'CO5S M; -G5.#!D-

6D.OA32L[$IB"$W4!207?H#206YH;=0%)]O7NFEA^H=F(#)M4H M)FU7^&-/WWH1Q[5V$E%,PCO\))#RQ53%D,0#]\1742&B/T@ABN5UJ4 M'L18?4PV1GI$BJA]G$Z7P

D3#:,$S\O&3LTEI:U<+[F_R6.Q)OOKY;YZ^2NK MY[^]S-Q +/%G.B_H88K&/9_)C$ZH2=Z.6V+REO3-I#^6;'7R" M>XYI6T_'3C\7I=T8]B76&#K9-0B/KVN15-

H64U9I&^.9K)$WBL!#Y6#R>H+F MQK8<-_?D*3J9JCY83>>7G[]77[3>[\E)G8MS:PP;]2^^9L/;ZG&[D-.)HFM) MS8-

))3EK:1_O54OL>*_0&T@Y:*DE=T#6+LE/GEHB+JQ2RT6"50K91IJ9. M-&%V!]E>NF0@AO4H#+Q#(W6BD#<,5EI+J:.^^7G_Z/MFG)W)H/R%9W<40%@\1

M5&OU=+34#/^TK8S>GK6RETA-,F9(2LF9V.3OK2;=B01$;'Z]6BZ'4%2A\;#[U MLR]R1W'%G8#:8?=R1UHEEZ9X+[M?!1%D5'<=D\D5@F7PT9^-

URG0IOU3VJR2TK)F=@<[/V248*N>WS8*/28 MVJU-OBOI1T:)Q>IA-Y!4!W4RD1KVUD^BMK,4C:73^ZHBE.>R!JQHT@A*&5K MN5C<9H6027&N]G5W2"*?

&JR.H=@O=;_.E^+O.!U>YMM!(.^,%SR$XXD'!MDY M<-6P.7#>+!5K'IQP6[OK_,R?HJF=!^?FK9A3WCSW'&G:6RWT""*?M+=\ME1- MKEP/>QN*"84*/@6 87)-HN"=`6!S?

K]XCT^U7Z&X3Z_)A-3ZU?+I,L:.Q4WA M>MK60H]HDWNJNVHN!D864TFZ'-3H^U!.!\@Z]<*NI8\FX5G5]L&K,AM?Z]>5P M]65Z%,_?>VXN8.FH3"

]H4]]Q:!ROOX,,#A:TOE//#V\YG]&JB4BS/GXIXR7#-MESA=E27Q/1?V^'9YSG9 Z[&#\,M(T?,#%5Z(MJ<-GZWPP8&BO^-N1'RR:X>V7[:3SZ&5^6RU-M%.Q';G7#/?

L\=C&K*@Z]TQ^11]A)4W0]*T+QW3&3V?N6[/MORPJCY-NZ;%D^;/9>6PXLO=1;-N]2^M4=%_E.MZ:AVCVW C=]R# &\0G7R?\7!8)}B8>+)U.PR21-,7-UJ+3[0F!;K9\+!Y/

M/GH$YN:S4KFR0JO.0R4M@BP@#!=ZD)NW7*lL:U4PK.YR*4ER*>,#.A=D. M(9)B5"8*Z=[GY!'WZNU5*V MFH\,&VWSTET>STLWD5KMG_/'?Q_VP3)O1$E?

R\+R'8>WB=YSL3KM$F1_ODC_.M7'/%?W_HW7_]{1,38M9&[7HI'YB.>O;/)5#%1\TDT8PS?]'^N?))_7/\W>_2 MIS\?6]WO8EH$68"O)O1@V:-_+CUR*<@G&T5OJ+-_+DDGOH-_KA1%

ZNS?RXY MYN9._KE2I$EO9__<+OZY4MH3WEZ4R SOGROMEQOW]L\E5&"NG6ZD673Q^>?P M_\.&/V0RF?

_FYG/&>)/XVSE,\+XT0SK704_09ON!@+,TE>O@MZ!_FL+JT071)^DBGFYA\B7/7;DJ2X M5PXMJZ3QDOU04K#DQ2^X()^,_QM_\L$#;LWW%5[N*"R4Y1>@PK^>C6K-

^?R7T=Q5QAO29.9 M!/C?*RR.X-]X,2/SW^XWC+!D$^8Z?HCYM_?OA<\-]ZW>MVL]YO-;E>'_]QT^KT>USWBFO4>Y^X M?UIQ3O];6D9(RINM#@\)>&/H>

<1PJ_%$\;*#]00\TES^+?<'/^$_)/#"EW@ M+FR5_R:=>_<"8^'$OQE.*.0N!SR?\R5@E(8K!Z*_0?%^)CI'U(8N3HL9WM62 M?!#K.1/S8+HU+/(#4<(DZR,Z$+XAZ%/N2E:?=.

{UO47H5[N3-IR.>F7&[W>) MGMM!A=K#0C(%*W03)&&9E:% MNFS<=AJWY?HT=/C$8VU>[8O"65\;3S/S\B.GBC%@4>\;E6]SA67O;_=TDR* M@2AA:I("B4+M4G\L=$PV*T=-

I(ZD(.X&?W;JN=741PDSY.7R'FNAMM+%]ETIP\-QJ(T-ZE P8;3+4 M#?]#:3+P>I,_MCY5]KPW68QEA8R 62B!A!1B&.B$,>:.N-4<[&<6*8^B)>&]L

M'0V#/GC4=LR[+\;302Z[&P=)6)O,A,;]@+X-5C_RDX?N[?WD4=IG%)U/1AV# M'V6PD#?7#0V#)&6DSA#W6L8+>H.1$S7> 9,X/+;X4]1ERJV&X$@^]H{3:),_M|>\W D+LG?

E_MOJU36#DN: -%L;YZ?(_>P0L BJXB[2"VU#IWS>]S^6(8@OY M:G#I]E:R>//C">@=:.\E\ ^10E\UO)LYF"&Z&$3]XH2]1B/.7JE=\D+9A.H8PD M&6$1UR82#KBQK^ZLFG.\5LZYZ>U\-

"W=_KK=1SF';AWLV &X_#5S#YSB+Z>Q M'(;/PB=&H+T7#^/REEU!5B=0>+-=$'Xl$.FWCO\N(1#H5!3Z#H.1>

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|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|Z*::E=JES*)(KJ0B>]VQP&T3G:T M['65N<-H93*$E-;OLTU::25VUJ[=U\7Q)&:1F'U[%U"G1@9UD MHR%0*)WI!T;IJXA"0$/SY(8X#L@]A,L'>:"TWPU) MMLM:X1ARG?#U+A-$_=KZE/_>+B"^'EDG(SZK 0$H7ME%?NYOI2N,Q9*$!B#&1 M,>;)"0P.7DN\2G&Tl;'$.%DDO(5]XRT'7.S81.#;!N1HXPCKD.9PRL.97(' M[<*9ZU!IS%*_&&(-"-XDTEYC@WO77&Z,=TF%^1-=H35Z+F-NQFL13'E;#A.; MVTI>1Q,%O6_XBQ+@:VW(7]3&ZBQ@EMG ,6%,(3/<)A(! M2AY'M-)E/V0<]@/S"E(6-T=S:E!]G(355)!XF03;F0_M M M&?3&[W108A"OX]J.C%-BR="4?]D=<[:\OXO; (C|F[UA<"&;BUA;<2.>RC\ M4#6O>;78V]H|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|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}= S>D"2,0Z:XA,2_O6((-E+ %BP^'EDG(SZK MU3?D5@X5R0>7)'(GRL2_**1+ARJ37G3E5- =*Y!/&/L((S='1EJ6(A= MSC]P,>=$'TN_V7AG1M[)&KPY.WUJG*M"BR%5UF8(VC- WQYDT*8V8"%8(?'@1"@Z.! L M.:!93ITV.8%=KIOX=Z_4)!"P4+OAQ1? \"G!#.$P"1T]J:6SR!>G8!:B2O(S,NT 9OQ=)9)*@^3(= MHM"?%PHRBSUVY[?#O5QJ#E;U3W_Z5\7[RY^/Z2F@.(F//VPYN'W1?9SZN49P;;C\ M0P.K^1]]\NVF7A?KZ3DJ$S\4+:? S@+E:LYLN#U5YMOQU/P54&;]B=>7<1EVY M.1<^Q6#Y[2&)KN*9;&5/^)E;B?0LJ(B-,=@Z+,\5183VE8LT'B$WF6I=+6 M1EBS*D0LB)Q$L@.O,Y_F4WPZ21

MY9+="_|@^J%^)P7/L@NM=WS6MKBF,-AF[#LBKT<2LDNA6^>0G=V^5%IW[Q> ML-UM7X|H?!TBT4,.%@O5N!?B_--XWG?43EVQ^&I%"9+,_4L*'BQ6^?1GX0EX:W]7 X5_(XK2(3C\5.-6,#4= MOYHZN?124'AXFMRWN,,'V"&@6Q-A%83/H=!2?W[_?JX^__Y]%-\6X@H__BJJ M+!%%C/.NU4JT.WM0HIUV45W:M9_<0B(4X $#"1V"7E*$"G@#X!VBTI;$&&6@ M7I_);@IZFTF|NT*_5NL|&OLS^\ZN""U&581>?LR4]YP^//%7;/_ZZ5$&<8(XL M^U\7NBW#$?,>4,0U<\6/1]*F[_%6OEYCR+]"%!55$R2%UZ; QJ;.<(W2X\# MV&S%T($&IX-'#'GH:35D7LGL=5 IJ+'/=A@R\-/lL2V#M'C47Z!=4&M-M-1SO-K0@)^";Q*ZT>H#'0_V&X$YW:RD9%2($'T6NT ZF7+>ROF6>0DV9C$U M0*A[64`>:SL%/@WY>-:S'O!B? H(>T57'HJ98K6 &)A*S5A,RN"!>D\"^83_+ M#!"\(IJ?"/%[UUT&*]&*"A@-3&U$6B?XG6ZTH6IK=N SEP[$K+D3L,]V^,*_ MP#XP_,CJF62V!85M9;I6 MK3-ZFXYHE;6>;WT4ZO+NMGD!/ Z<@[E]0@WL$)1Q,6DUVX$D4`7))?Y8) _> M;B[A7W R[CBA8Z+D*$/(S)"!UF1T>[ZN.KK;)0B W="0K@XTIXQ%3_#]$2 P M7 3 T'L V"T+Q%+D)-C<"5QPH6O9%QI!;B2A>; 20 "!=R:IE82+?@U?.?4#*9Q M*$;@HMC7X=@O^.>PA[%:_?ER1_Z\ASZ\FRI+!TQ82B$DT'M&E!ZF"DV5Q@0 M|:VW7OE+O?2ZT@#=O!Z\9"Y*-/KH??Z.JK<3<9-\L??FB-*ZHH.R&T*+4@;_M A&'N'*G.GX!6VSCRC|F(`Q6A T886/"'T"/Z4H89=O:QT-,+T_'(9@A69H\B M7+]=%2T:"PW%.8(RKTO1G97(X,Y*Z[_G;2:]RJW>(^`O/TG[W7,)F&.9#L3R M&&&Y)P'=56OW@$&%M [!&'"'WI@8-]I8'&-O-P8C;6W<$$@8!S:,OG;,D75@*^9:>2T|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

M+&U,&^U%APN/G\RSXQYNCAR_/&GYZL=S=Z\|W"G0Z7HX28\'NX,)@^WB3C3 MSQV2&1D\]#LSMX Y W=FNN[09DPO'QHZQ>?EVTFU.?LY@&N,*$H<)^,QQ\; M-^TZW$],'1="]1%3E3#U/Y@G"1ZE>C%C5_(C;S!R\V80;X,\TK3^11@S% ?(M:?T X'0'4MBF^S?B)_124.0D8O*D!H#Q^Q2V7$\0.;\@C5(EI]HI(SL3S25#D+ M\R2=QX#WCJ89NY? +1AUY![&=Q,I!S V&1I",6VA;JH?U+05V##\$V)L D(\$ MH PO\"G;(Q_AZ%53AC"P)Q$MD*+.YA,]8_+%5SGPHMR9<,N]G#3M.# MS&(96Y1EZ-#CAGGQ^M!LZ (33@#C=YV]FD,-(}V4I9LQ>]V%)Q5@"M45]M M/K?(" HLQ=^TV=OFNUL#;Z ,MH&7@<.WFZW##A5@Q^C$TG:P M657*E1=S"W)V%C@F2^?SH8PN,\ H#A%>6Z9O8U-U\.VZWI2)&=-)3T*P'Q7W>LZQ=R\G!?$"9<,\0F1'H^.F^&:3G<K MJD5O'H[SGRM\8*@HYRJIN92>U13?.$)KL?QT3 M=;?52C;C\?$G=)&%A_HC$]=/>4G1+U5=%_6&1^O M26,>TMJ}R:VDOR_<.S=H5(.!#?L"&B=4D==?>DS'587@QHF?X-CT7P2*?'NW M;G<17W;QEE)OXTP_D *^6X;#S,NST\;9TX1,+ZN3;Z?+*-MG7ZX-(Z2B8RCH.E()3,SY]+-OJF8"3G1V5\|?C/OE4KN-)\K?C*NG5 *Q\:R'M"QE-J3C1X@=#TW"3"QVZ5XH"_401!NO9X)E5LP$L5<B'C*<*0(ZYD OJF4B"3G1V5\|?C/OE4KN-)\K?C*NG5 *Q\:R'M"QE-J3C1X@=#TW"3"QVZ5XH"_401!NO9X)E5LP$L5<B'C*<*0(ZYD MA@>;6;BA9+E>]6]"TU#$$OIZ5DOG2]6[_#MT#O ;]O 0/S0WO'3(,Q-1 L\?#M18CT|/;4PJU,7LR=*(D 9CY.L@ X'[#E-"Z-=]XP@,.^M%LP:#]BXYA1Q$! M*QD 9\O<&,)G88,BT!DH1,1H;CGM/4!:@(OIH6(YXH)3IQ*K=2!!&0NOJHPJ M4BRHO]R(A1_:'5I/R6_37TKX?+VBNT,3&T/K&0,7=\[("T9>N7K@+-UQMJ"B M7E",+MR@2 =%Y%*B9[%QR*@V#EHEXC^W"0"5;;"9TZ[W!(H;/M]/V>T5;I&& M-9-B+PZ#)HN(\'XRK^U?K6(NU2LYB+2)*L9;_1]:'U_BANK.[75KY,[N< MO@[{G>EGS)E*/KO9$FFT(L\ [#""-9\L,9A]D4\OQ[,S=!,ZZSV.>?:+B_ M)KM>FI$'229#Q=&K,VLFR4F8 W258Y2,#]UFR654B-'*,>&]\$6I-EO.NGTW> 3MMJ3[KUNJ,Y[TPH.U<,>NQ49 !M/E5D"\| {46>NQ0[SXW.ZV]W6#5;V-2S M$XW.(FRZ&>%^/AUU%%8^.[T0"A(K;^8LKQM9D"_5"@N681>F=+H0HC@OF9)?`M\|H]C=L6D_D9MVR>/C[210S5YD%^6> UD,!@\$TMVPG0[D.7PLAP1Z-Y7SH8 MDD&)E8FD$21+(.$@7"IT7(IA+(;R6A?!F3\'"8P,89&/X.SQO"TD5S74ZD("+ MS%]JTHCE/=.(ZWN&O*W]J1T MK6I5WZ7QFV-1DG4A@QCGP6%X!OI*BY5LM81L&$"O& M6OGRJ"21QRW1/,64H];(G_&+>4Y;LEV)W!89.66FT#VU2\"::!)$Q;LCQO|= M&F?CK-1R0@1'A<"\^P8<4)9S2/#R@G.HW)83TAI:N)RHH(*$CLCV9G-!6G%< MEQ.Y,;\>"XRHW(%W=@5@DH.ESPT+]&5+/L=YS,N:K(YFK');KRWHO1VZ-3S8 MB3(&.]E-PA9%O:P[+?;/T_SP:-D$IX72+94NHZ!4C7E QIWO;*>,H_HXG[C M0,I27QSM V^/K!*GDCBIW"R#!@>4#? =(Y6 :)]ZN5YWT]2Q)"G&HPHY%O ME,!"KVM?1M^S?$;'2H?%ARP'? 0]M\[U\'V+15"[P/@_TP;>42^ 7_(B3 MP9I97=@;NAR1KF+ZP"&PAJ Q"1$.0PE,>//!7^D9#FS0LB3(XP4Z ^& M@=]> $53G^U[&=D$;3HM'A5Y;@?EZ\HC-HI&3&R M(.BQ T3G2(,>X&D+N%9EP"F!{]*BZ^6V/V!]J O#_&T[2J.@+51H:>5'@55O\/7(-M%K/9JK(,.5.A0]%=F1_1Z@S1U#=@?8/#NAKCG7;T:2S@8HZA3,V1[OJKU^/C MB73(FY"(>#'PT+3C-*? #P!-#4CZT"BBGD\B-,M/5MC7;99KRK_)QGF(\.$>H MF[W1[I&V15_4"!9K&QY//&%Y.,U'F7)H,#E#^,H[,@ORO,(^^LJK&>=@I3\F]E9C&AY/UT6?13&*&=@\!*A8!^GB, M.F&5? [Z2#Y^1R&1Y\1P:>#]@;JY0&\QK0FNK2T*^,K[6!C0K+,H&7]F.8N^W M+@70M"Y=G\1+@&9I=QITAH#[\"(26U"[`,!UU/K.QA]"N,EF?<@^F^@,PB3B7O M:4E!E;7E#LWTHK9R(_- ,6FD1?%3_.EP$W/Q_[5':.A*AO4MN=`-[[;=]6CF.. MMZPM!N"1@R%.((@ZVC5WB($-CT9D)\!0;/^O M)XZ1E;]W:#-9CH@!CJBH *L(U; MG<@2T"%0!$CR/X0\&? Y%56MEBFZ5J7K];Y.I'44"-5A^X*XFL 0#G(ZWZAK3 M2CNWICV;^H_W]3G*%#P7X* 0PW=N'>8;K;FU.LT^0$7]]+G&[5.W2ZV ^IEZ MN,\V$4= <64< =SF@EQ'O=a 3%DQ[S)\)U'B3)#Q8@;T1622NEODVE#X0\;>MQ> MS5]>\9+],.C^/_U(8Z'X+7]9&FCG1M(\"RY\%E-[Y??OTN+,T,SDA*G(7 MJ#_H5'/CB61!>=MXO<8^652>"'RP[X4'(-6A30_#KWL8^[H-R\AB&$&[B'IA MU2=G$3E)91B/;;>E[0%PW 2;L4"_A-EI7AP5H=+-6DR>B'HMU%I1N-$_[$)> M@04YR+KFBO9I_N+V?C?W.5-FNU=[ZK'5"E=7>SLI.LOH#D#@K_&=ERK.L!SX#3I?B/X>R *BS M .\;%1 ^F)81W61DP6CV.*U6;R%") MVNKN6SU0KWJEB.U\%T9X\8C62[S&2MTJL6XBT"K?#!V?MYI7S=[K9*ZMXGB<9/A'RSX8O*)JOW6J8S-6#]& .+" M9&/-2!J+08VL0'+X]-]GY8%PM?/%,- ENVU/^O2962!1M<&<5VP,,7_',&$S@>@0F-(TD>5+{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`7 9!S>-0%&]8.GCH#8]&JLT7 M]CFNE.4A3CD:43+DU\`)QY=_K8T]MHTH-@&UX;SO..O0/ V1X!C]>DXPEXA[M7'@>&L]SN_V5>$9(;P@B,IXRS'"\>S#"'$\]9M4."\+B13;*?!05G& &Z$(M8$2/96V:.[?,@Q;IT'I9GW0&R^O7UEHFW_9";X RYLZCE[58KW6>CI2'VM-T M$]S9S([)=_BJCE$$1:U.4-_O@;O$55MA*+FIF45&ND_G%XVIUU2OF1#H8PU MZV%?0X@%=K* *H^O?E45%&Q)+ZB?I$C.1W-A,,SGXO)6-]-J1/U:<_@_F0[DUN'D^7[)^;R3Tl6#Y1RN2. MJE:9Q_9BM.I(@^. 'ZM.CH(0G;Y.SHRYXQL."/9X*!+'P^O3X,>]T7E[< ;!V M_E?J H78I!7>O*KW"U(5!F]>OL25;K"5.F*E-,C"%Z\;,3!/D;]?*+VW!D-RH M(CD<4IU,AU)>+5? K7D53WOC-!K"]E6-B*.H8,.9E7QQS;P,OS&2R!+"<45<+ M8FX& !O?<+HHZ=S\]ZF5&6+;"^Q\O3$O5V+IB!O*&,6>\IH&KU.94_=E6;0= M#,Q!491FTZ"?LM%CB? 7H6KQ[!1;MX/W^_-50@#K$07&0..@*."SCIWABT4^X M.L0EG4IEUCHG-J0< 7 MU==F/0 QB_X;L=>M8'2O3JK2X6F]U6ES[C(%[Z/>8*%U_)/>{N?4T_?#[;?] M?KRS3_1@/ />%2C # I?925>%HZWWQ/KIH M3-5,UZG=!N9[@#YR#D_49PEI<+*9^-]8E5T)_F2_]$^43+R:#3(M"6_=TV9 M\0Q*P9S+9"))S$T!$UMGI<*(D'+,X";3J508O M<{$#N-KX6(0!>C;Q%D> (&'!1B%M&4N" MD^FT78'/XZEU^B,TC(I3(N@S6I%*-Y2VB$2#*,)65)0!=/94Y3\@EYLMY M<&L\^+SV-?V|*SARR_!$SR&ZOE-5F/LLU_'!A(!P>L, 02K*ISU_I0/GCR M @=CAE^N*,1_G/S.#'TRQUB9XD7K T#R^F>@578#K1IDW(%6#!%_#SA;0=<2 M.;K508SI5C':?E-FHJ^6\/^U^<-6[@T;&HZYRGVKE9]/%[],>TK8I*O2IB9= M?:6A5KLXO^KP9=U8W?ZIBE?\XR4997Z5MT0G=({6#MQQ^C^CJ[(;7>6K4'=F M6I*K90EY0\0AM"2/H-6-1Q_%W=\&IAPU(`7=BTO$G97$,;:O3C6+!L/D% M=[\6Z8M@EPL$*'8%] (Y\-V$>?@;JY8<@0F(-TD>5+{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

*M#HZ(&V*S0+#D/_'N%//%NI>29XD=>U"$WTGZK5;^A/+_,X2B/T|#L^?(4-H*O M%JJB@L<"N1M4)G*K L,5>@(`J,H5V/T!+MI"#?#*=T#240"%XA(^_MT.W'6 M8=J+UK#_.&8M?K9.S]C"U@UOF2]F6Z52^3-5_< M<,](,YGL3FF2LD58,KQ359C.IA%#=0)3 (E0.M1B7<7D0BRC&5!):3 M%:VVL\0)"!D'1CS8PA/8[%%(\DI6)0^6H!?B*IC#;P(Q*TD#2SG)) M60Q?M1EAXX4,'5B"8:%207U5,'N"]H-1W2K\LM9Q@A^FH^0 -M#H9B[[8-O M*4!2"T!$&K-D!&>[ME*HVY0MS9$^D0P X%,:"D2@QQ/QGWTS(^_M(T:9HMO"T7S M2-><BUFT!@'2D7IK%3*MYZACT99-MT!>TZ[^CL6.U5B)1H\$,B:FW#X#GL,LT^?05D)5>"!S7C(EDG4 PR19S(K?M\71?P'Z0A&(!\Y)R1* MB>&R!'HQ+8$-A$_Y=GIU5U?.1<#PH [9 [0R2*!\QLC6C|E"W/B=2_M@D_NOYI94)KC4IKB:..KO%JLH0K"*Z#&RR+&%BEEE?"[ZK1=HA\6)4IG"CD.$ M@ 0K+Z(B 59OG=.'7VH2#ZAV?H1D"-M}U"2?, D7O",4#>;D+*S H &2;#?TDH7V#,)W#'EHT/T];%FP?18(-?FHA M,@L@2#DXZ L>]X)_TH9\(@VNF0I0 DO@H3A\5L;[5?BE=\S"/[=E\! PC:49 M9Y@B?;"FD6JK.V_F;[">O++#P[OCJGPAN Q6_7*3&;K>`-,S6)O9&:Q1TUY! M=6^MP+IQW4?9G'=&_!/3M^I9G.@T!>C}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}9&N%&K,L>

*M$\SLM0<'_B)C@1R930=7_[&OWW>/1O_9,+F#PR":QZ)'T*KT^__M?O^67'AC<1/L?FD4QXM>_*+.!UFN>4)V>D3V6>8*GV2O{ZD"P)/G9<.!V71B*

*M:=Y:YC_K[$=)AV@'^(,SBF!KU$\Y/U0V?3%'$<6!Q:D)M%,3%Z<$#(M,7KC7KC*_]TU*[__5Z_WO_GG_W_DE8SS<..YP@NF)NI MZ710'PY?_((?6?:[*-E+/HV;'P9KV)36*C:%*

*M',YSDV8?ALSV5[U)&>UD9;NU0)+Q@UW+YW+3-OCRS*JGO*=V<3P,$C^F9)/!_MJL9/2X>X/C6C,Y^59B"Y$_X,.(AHO=TA;Y^CYO>Ol-ZV!O_(=:2[B)EX?!N*

*MCT4!,O9P!#RE_,'5YL_SHQM*F%,:XQ_:I7\G-.*\]DM.?%9M.=6UY<%)U:$?SD468%)"2I" ;HV;- MRL'N 9A13L@!?T"01=H@(+7H3S>YN+116LS]*UH5J3X733F6>0102K RZXHN_*

M.7YF1:K"I,LM$[2'@C^IEQ+TK*Q;K'4X,7&>K'R3_(O7 K4QON/RLEEGH5Y MC7EU($^[(%:AY,O&;EL%?C]PB!U//;F?4'0&Q|)?SGU2NV7<$HX"BCGAAP!*

*M6TI@SJO.KN:^W"X4%2!'HAX'&+&OG8K>4E]S+AO29<(ZQX_1*OT3)O&FW M+/CB=0DIL+WKI6.575/P8#2=!1[*59>6P=EM'#14]X^4=RJOH&X9'>ENNC*'*

M%NPY,I#2Z#M1=QI]?WY4F-R 4X2Y_V-_X7>CFGVP,M<2,W&,?3KZ=NNKF9?H3\-V9_\$!MN11^;'-<^;/"XK?K$N!^P44\(' T M-BSRL632)HVCd-(IMT!/,+^SW9/E$!09 &L!', G(?-*

E3&H"A9%I.#V!UD_=0 M:M.@)0#EH)Z+[_48;PWS=&7U?O8).O.JHH+"X<$%)+@IQ #@$[XS?Y(4#?V MSN>KBT\?7TK?^4@^R0D#',-!EJQ:PR!D1.B*&#WJP!D&*

9DWZ! KT[_'7B9R MVAFCM@>-^R=DY,/QXV7!*V(4F$@O)&\C\4\A'))Z$>0W>AVQX@6V"8X/1V/KR]>DDNC"C"T"]N MGWF.0'XMT"M=I"7.6,YAB$Q85+4[)'7-*

*WOGS_/U+/K3\F0/S1,/3'% KIZ@3 M^19;3Z@P4FJYT5>&=*HTS43&.4F/0R8:)D.F>>%@[X9B]0BE3G<@QL*EPY++#P8X45#[N3VX N M;X#2%S/+MFC9?5*A40=%Z0C#^R+*

2;A.Q)O"O2 O'.UVYBLTC%@!JX)R8 M10%_$^\.=P/"W'8.GT52W*WQ JV43<_\# ??/lS_:K]%)/U2^F2E3WT/Z<:*

*MJ*F6NGF3%/JA43NTAZ[G(.U13]!4""UPI/YV#F:6&R1N912KG9LR6.3*R_"WS />@F]+!%C&@HCU=\Z<+8WJ;RY)^ M2T Y,+04/\+.JB(V1#(KY0%R7S4K]0[*^*

P(4F1GH1@E0@&FCH!-H8!!T8> M$!<;N1[6L!G^"=10A!\&E%A-SBHWC&*#V)')47<3:5K#O:9_JD$"?T[N(%/V M=D55GT/XV%7I_Z?8])MJUGOF9F'BKUAT<\?!YUOR/6N!D*

@\#K:AMX0S9#=Es=5[10Y-OO1'M,$%SN=#*I^(#(B+V>LFT1_@<U.5

*MH[P_QN&B!#5*V[J.%#&H$=0).*EW5J.Y)[JA/+4:DP&'7-M?TICAWG15PP;8O;8Z3QU\4SG3W4YV0_K('S-5)1-/'J] M.*5@IA%TZ?)!=+T]TBGT*S_3F;T40W+P1>'^==^K7-MXE6P#$OW;+D,Z=*) M*9Y0A&O>(>YI%&YAM]^GS4U_W.-%;[JC1_+)#M3NBST1CBLI=7BRM9X4MO$ M>B =EJOS)(8 Z8KY;)VL>4!ZXVS3("H(L\,'?YE&JMK<[8%\6" [OD@W@P9X= MKWSR4QK8M]2#P>S>!W@H_J T.-PCC_,P;18#*X$;;ZG(,;M?!AUBW8T(84; M5H?UQ>/W!>F_8+A7C+G M@7G<8K/EESN+BQ79-1CZ'&8W&/?'3L1ZS"G#=CBP-/)>@:ADO4%(^08++'TF ME?!,NAK7M\0>"9)W6\1QE&> V)(MXIC G; Ol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| MZM4;D1.UQ<.(9BK;I7P3!AL:QML;S^&W:=!;C#0DDY5);E!{0BS74 6.'=Q&H2(EEFW34DC:1KER!AR]\X#XQSY/Y?15H M.SR-.!!0%X!-BFM/;Y0X'2& FGK>FU%/!YLV:.04F^\.7U>0)FBNIHT/A]8W M&8LVZ:*4&=49+/;>U-;LHOG&VN#)47@[7VYN.*\?2%ZR&VQFVR:"_TC"AKHY= M24!,AYDZ"I*S;9..JL%73O.V4U%=<*8C3F5MJ0G)I7Q\Q),ZWSHWOQK:VLZ MM%16C9A1F]118D?)7UKE:@22_Z[G+]5LAO4(G^C-W79'64VLTHDLU=+6V-; MRZ6$IHZSLM;&I=>]6.[-_6,I35;942FQI>OHLM'2|:!6UH6(29ZL7-=ABP[MWHW#W_Q_O-FPV)%L@ D!3,>,RFKI8-DF[=QBUHF_2YTIW4^KU59L*DH%UG0P MJ;PS=4'8I+XF>Q=^MM%Z@[<+:0;1\YU=1.O06W4V*XH922] M2MD>B@!3_"GGI2$(2:W@QN$>KP._!<)>17-+T=UR5S"[Q.DYK;?#JCDZ;[M MDZ=+7E0P_S!:HG%'-?0*)^_4.-FA),&"[)"2%]!\!_0/;7XPDX=\$D1\|.4% M860344+VEJ=D3;QAE-7KDY)::.F?9D(CDW9L06YFSR77>4ST7 R943_D%QPLY8 MDITDB&%,>RY%O72S9.2TI==*!VYJZ9SZ(XO3?2]:R.6..0...5U%=B@*P26?E MDC_-?D"2+;$,..[+(H:4V/?)H7=TH@"}?@Y!3F:R_@N:&=0ZP#$'1VF**Z ME)BW25O%@=?N=IW"$5^YL2DK;!0B+)EQU:[.9N2WCW*;)/B>UJ%_S(-G2;FUL>N3W54X+QU9-,;5*S;Q\<\A+3ZPQ M.U6LI4Y TRL378TI2L*F895N6>Y]+IP_?F5(MSR8DD.97![HJDU%!@/JK*4^MTNS7J]_32HNE0HMWU&=!F&4]0O#S2&$UA;>==@[C-NR(231RF%R.*BNK!V_ 3 MI4!O:"77_D44)?QV[6)!0_XB0A3W4&!?9*;OO&AI7[<)]{D!*')TI M(_L)BU:I0Z;HL8_I(@CI;S"Q4&4/TNS?:F >AB#GDOVIX;I0LY*?S%) M!*Q/-8MCSU>|RV}2*95;% QW86LU3?W-O*.D?=!ASG.$B#5K58[:" MJJGCHQWJT)G\!/[QRO&=)3H/.^ZR6A!#]$!5U*R05;O6W962J!*CIFHSMTX.KE>IFA:JZFBP:#A4.]KKMD(@.5Z2&DHK_>$K)W?,T>'>:;)ZH?SBM6J6E9 M9-485>=<9@4V#N3;DPSLD;G4=Z.4Z"U^6*|<>;R*ID:6*P:OKU5VT=R$VRS M",AJS$GS1FHS8$BSOU0&C^\W4_;^PM 2?537NDHC+/TK%O;JQ[5ZZ^5NQ'O M->]&X-6(K"_"?%+N(. .)HA^)FFGY$?6[0^5ZQ-37 ?!PM_G7O DN WRH<[M M$,1).%+5MT&P.#:0 W$EF]!O.5'("_\@I-A]S:LU(LKX_C_=.;;B[*2IE>]J MG7!*-R&=,RX(^-FC7+!^Y1%<66*0"K0%X<1^*M01DDW*Y>^7'>>?'Q.K4]3> M@@AA/P7*!6&3RFR

*M!/D"I_UKH=/^X(<_#.C0$9^-#$Y[V9^%#=\A;1<&_.C247U[\Y?&ZZCE\#>"]`MA[_ZK!SZ*NK;@X]?ANGD]K?9Q"=%;XH$F"(!;((%9@/;N"(!S+NH[7=]M>9K MH# #:_S3]D/9B3<0SF?MG#X900Q)9_Y .,T!3%JR+C(C(7TI4'PVA7M\3R=4 MF=PL\F?P2)4=B41]S)Q5I0*7XV/OF54O1#:?6[7!..R[HQ4R;E!>OO;&3=%\-M<8/2+(;?9&-O="H/8,K?I#!A<&M^?!EGS;Z7[!]4Q5E1:IG#4*F[]>H%ZE-V MY@8"TEQT795VE@';"L-JS_OWX6/RPB$W*MKD*.U73U;*A3%ZZ,8U?N;"DKO MC|' "H3?!VO.E4SC?L/T54]W+8^A*;4W=B[W)UA%+ #.RRLP?(f2/ZXC&F= M\|Q@/|W7FP(*CV$LQZ SJC*>0&C-A=1 Z\LY?8L717Yx;..$QID_&>NB1\01" M^U80M(}GH6_<: E9:.C?2W_^+LPQQRR#}\'!$1*]T'W48&!K"E=>F$_:0'82 MC>*TTO*A+G*+7IXO'AP0R?VHR?W)T/6 &W%(OK -?SCH"O$9_=)*MQRD_O7 M0Y^"Y<*MTP*CSV[B@\5 ATN'_[\WCC3%L$; G%.%L2<3'1>LA^=.A M_![?.\['<@!72SN KA[@5>&N]ON^0>=+PSHGYC'1U#:F"C=M^WU#?)" POUH MN'2!?2F^ Z4)-^M)I=CAFVK^P"07VGXT-/V1Y>!BO3)0F^%_>K)Gao>#$WUF5L%24PAZWU9HJ2D/X6<3R'GML%B MI0%K"CF?0LZGD'.[H9Q"SIO7"[,?U:IL@5NE)2>8;K8Z0V^4-]D&"(E7,*0. MF+R?K==NO)TOYEF!&3-@FA)J1?D(-<>)R_&H"GJ!5$<.HSI1/WI7CW=JZ=[M]72OGN[5T[UZNE=/|^KI7FW!O7H$-[!.O&F_?HWB7FWH8,BA[M6B.+*/EIQ@ M/KMI%@?H]MQ-E8.=RGWN3PS5U>MPN:[3KW"_-@E2.8?@-J5O25Z3@SCY@[M4 M!DTTQAA!E/-C^=VAM&94LBA/5#$5##%&2*7L@+ND'8AVLE&.$*\]]>#%PA9X M6@?UCA*<(^(A;-Z;+?]ZMJ*QX\E5='B^=2&O);\3U7|MQG."Z.A)UL5D69XL MRY-E>;(L3Y;ER;(\698GR_)D69XLRU/$UO.U+(_7V!=Q!8 [#Q=H?@J(IR')5!B WND&H*P*B),+;P?G-'?DIR(SG3XP+[L:2?3Y!4_#;[$'L404&]2W> THI;K.C6=19[*S=!LV6, M&&42\!QT1VK&,?8=OIAANR/+EKX&FH@=-8?*_M2>'W(%W=H)#=U)-5L+G#%U%*_"A2H>@!:AB^/+<9 @)6;/$R7TS8! MHY4[7'|0#QLUXWDQ\H,4^=2&$Z09I8G65'Q$"1E#"'%6CTG?H';[#U,(M6+/._M5R)%KFA8867P8/N. D8<\=:XSA,OOFQCX]#XOOXY5FHSAY\$FWSB_%WC4[M)0=5_PROJ8W4S>5X. J?;@]M"A\;8^K 6>1?AVZD$O#9S]?,W.3YR.(!^+7O MFC]^+;+R.&58TP8]V_HP:+&D[4KCQ#.M/S_K3+830Z_3#Y?*=B%]U8&<6(>:f[/.,47S#_%_M#:!5-],E1BT(C*M!^Et,KP_>MJ$@V+B'3]A4>5Q7V62@W$1+%?MD(!ZFG]>MM!$.0N(A%,R]3]KZ7%1<$N99FJ2$;7(7^Y*)@XBU?^K^HZ7EW%f?)?N1$*1T M]M.L5&?S=\2FFS]!1+&[1!=/Y& 8) CRS.N7LXB 23\|RR,VZHS3C[$',_$-C MYF\0197\?I?,D+DAM8F!EFCPL,0\3VTV(s/PRO(,UN,KPF[;AT>],.C_J7D M^>)//4TM!DQ1X21NK+OY*&];)590[BWZ-<=*'%1C^V*1_BC("KT+6:AYH"^1R MVM/)5!\1WY^F:I8=L,&;/[*4+2R!W*BRI0Q,9C/3]!:B<"2"V,905TGA<[_M_DRO;8WH>'[J.+SX(%4V5CFDZV'D$L<+%*19?!\"?Z=#SL>^/Z5L*2-(\XSE MDW2>?1\0Q.#VC#2GY_G2V#P%""FTL\;,KS/T-)93?R*>Y+!;3@V!W^C66Z,,YI MQ$3?_B!5"KX_!=8I.- ./UH3D9QJ,UZE;G1-6JY?G*#NFS52=?!9-!8*Y,H0 M%`"PA\;G.2?L$2TX/R9P#H*J"2)8V!)C_H.?W/2WV:B O5Q3!D=URY-3ENA M-/#\4%W>H?SX1$W3:5[T!IQ%"':$O<_6VIFSN!26RG(I*.WL2(T"Q MU\SA/$[-9"LD<5H"A_SK SYQSW9K!(9BX]18 @/'P #N&4A%4A"O&8>#4A,&@L#)%01=<0U9JEB"6;\;T@.1& M6S!FGK3D-!PZ4T%M"F 9R=8%>XXKQTVX6S1*5#,6@S@EJHU$Y%;N E.BVK-/ M5&N|,AE)5.--:MMP$!(/HJ!E@TB0]],2/[fT49 O5.2'P_I$_G'_"2W=D)TF MML 63%K5&EFZ_-(!1>=8>2;DP*N_*3)<8N!MUF!Q#! 8;_[JVZ)6KF\-I;Z MH-I;Z MH+B^=Q_>"K,2ZKU=>Y06)!W1YMVO!QJ'5_/O7C M]P;>]Y(W<;JGUU(=UZ9=8D<'BID3@G&Q,Q+@T#25A]%OH_#F(6G<XW] M!(:=ZEE-]:RZ?L(>MTUO+MKOKIY53C+Y@-C85VGV;"M:<<5AD6FV/=<'SB)? MU? C5Si?,6"WYR.H*CI9+UR;CY_BUR,HKI&%-L_2!U!_I0\:4;Q'T5?]-(W:3Q?0G5NEM9?Y+IW8O9D())J;L(SKHK MZE#<6[F4-R1Q4OU>)0L>SY_?W.AS1$TNCL<43)K=177"0XML9C03]U8NZ@<U) MG%Q_2_5\E"<\-LI89>Q-%.4I#*]KM>(F/2IH^P@#;.WUFI7 =*B+0C+<.MD3) !\[=$KN0"_M0GA]1(H(*G6_ S >&-49@K#\8S+&Y0@0LF*$'!.5HT0;RC;BD@]=+X_,53/-MH@V0ROR-ZZEM6=5-K3GWK_6?/H9(<\[H5HBELL]^<8,\|OR"/Y%_N]VF[@ML M&R>=;!N'CSH/6X=]UBE]=[)}3+:/9VC[&%>.C;[*?,:3FJ9$&Y$ M&4[UG?;I&NT&LS.1ICT[NE[F)_6I?O=4OWNJW]V#D:UE_>XWHRK@_4:T(+|9O;/YC:E8_H[. MYC>*A3M,.)N_1O'>M]LL6OZUR*-<'M;.?M;ZIM%/7(ML!W,'XMLO*29EC3+*V0S8(=\Y17]8&]VO3Y5]++FLFS=ME.IU]VP MNKG9EQ/-E36W^IFO<05;3@-7-ISC-8$CI^H2Q\6O:+1J %PK*I6/2VN[B4[B!F? >[>M!)47:8KGN*_*_M)D&T/ U=[X\7B;$<$>+L*7$@*4Z)ELDW-?FF)M_4Y)N:3!13*NEDHIA,%):.**8WU[]\ MN:8Y-,3?-]<,N2KTO+EFI[^!|7BU(BOU<]%#=5/I;O6//T\%'4![FUIVLM3)^M$R1_7,8(79DR2=$]Y7UZTM)6SK/,Z=/+Y#P/'@,?1,Z!M,3\Z4E'6TD, MO)49L:#S2_P59N-`,BNWLQYOLV9,]>[)G3_;LR9X] MV;,G>_9DSY[LV1;:4,\>[.A*XP>>[,H-O%.[Y4WB=/22D7^=5BER#_NS\B% M!X>!3^XX/JL:$* $V;O)<[CU|O44A>P.8ZYH@1VXTP#L&-KD580KQF'@37\P M**S<_'?!-60^GP2Q:[(01"E=*=QH'^Y&I^GX3V/U#XW'[4Y@*4T@ZW9F:= MDO7;).MKJ=OU?:993\GZYJ_%X]OL]A;$;::DM@))K_L34\^+#0"=,O^@Q>=$BS7Z^558[>N8UZ0XZUL;M2XE.Q5FGXJP@%T.9^?459QW:BMRI-J00:FS,K4C6Q36.V/9SYFZ"U-W9>IC0 M\M_Q(Z*Y])=9FL7H*DDR-_(§P0:-A[I__\5#Q+0EXP* MQMAXD]FC&X1T(R5\LU3<'L)X)%)\?CK6KZ1?>Q?-J6*1_SI/TB1U(S^(EKD-M>M!!Z%,3\BF*:B'W(:;QV84V?SS@@Z_QCC[X01_MBD>L\9B_/D)@0)\;3!8.]2RMD(;ZIC716/U_*Y&.|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{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{JNGCR$+TA7,=!Y 4;-U1=]YN-.EJMT,;[M;OM0BT?+UTO(,?^@)OR+'LBX:C_:!%MP26$7=OW?9IAQ_2] W;U_L\1 M.XA+ "+NVK_9 E9'RK3^Y1.%7ZW60T.TA$9;8856%)-U&C90:OXPSQ1Y$;,@\#9$!RG7MAH'[C!U2&6>PDIH4?H7+XNCMX]WIR#""HEYCQU#.&XBB60N7RNODQ=O6XT:H MR@F(A[8;]I\$BC]GJ,BK\[FPW=UK+AQHYR!Z9!A3!F6>(RHU126=;S6<)<MXP]$5+,9:*=0L\C/-:I$R2[S%;B2JG0=+5C-&(1C'C2;ZELL$9"YOL50HT:S M/<,@NB73T'!E#P_OD'S!$0VL(K\EO99748K(N3LMJCT>A7,4M0GWK0)0*_Y< M+7RX&]_!^^?X"|[N$_1/Y8_\+W>+#D[\Y^;?VE1#_4]).7Q) *<5]EJ9Q\)"E M-'*#S#I?N) 5] O8_"-E'J4/'=\H?<%)\5 NR^(;]L%^3PV-$9DT;> >O35D& M'_7+P/GQZ*N]R80_!10*?O(]JLHTI.O6%/;\'$0X)A-L1UEMM:N?I01=S!P+ M]P1):G(^S:TIOBF%I+V$!(:-G9Y>~)19MB[0K+1;&*>U]2KN:T]J63Q!K]1VR'D"%Q0(#4K#I\7E[T]>FQ^?M>'Q^UN7G>5GG^W?FM7]N0Y4XI\0!A\DYWND9.TCQ[@070R52-R$88B&B'9-\ZC4TH^],N\T'6V539 MLB98*/$ 8=*Z+)GHA%OHR"SRR_]L-D>:#T368IO!:LL0;.+H9SJU6$W9 @X,%QQ =X?9CP4S&H23);_FD@5^'C:[M9)[=032.42]:(U7ZCP;.)NR AB8[L#Q*==_ELTM"[U5'&"F>,H9 ,Y4=B.Y6 ME!NBD.+$4RIS_-XC15+$#(2BN7Q3EP;_[30P(83'K.C([C@VC^YB-TI<#[A&M[.X#3889#:XMN()MDC;<+>BQS(UH?_M*QR0(7K-&<O$/DC^XW:S4-]O-%@WH4] MV")]73&6RAXCR)M2'F(T$#?D"$356 P(7T=!9U?3N0P.-!]$6_$%XMS6+ 28M!$]6W_SZ)2W4(>A(A+R1*#("RUUR7[-(-XORZQ#VRP68 VNN\3:O<(+'$Y, M'PX SF&F7COY*UKC[C9(>NP(VWQV06WN&HY"8&,.LTYCB@U, BB++#FS-"] MULT7YPBMD;_3-]F.J!8?!S(2\]D&IEZPT)G(;2:D&P<)CN:+4S<)/*(QEUD8 M;L^#,$N17Z2*]2O.<";B++##9^B_V(<(&DM+Z4F#\'"B W76 M+NU4>7-;WM-,MLP0^^EHC-UOK/>'N\V9.?;IQK"9/O0>.V>Q7)*GD&H-A\X, M;3]UJF6&:\1;M_+>D MP"BI+!R^:,]M?F^[_$]#6*0\@ MD+\D(7=X#,V0Z M:3410 8@<;|=82K5^[$!HL01A-![RTZ*RGOG;$U#BGN[>3#&TI,ZOGJK%$X MD&*],F$Y_8+20[&XBL%/6"SJ3:U8%$]=:"CG1SK87SB6.^,%HU@.2;1@O=,Q MMFF[G92'1&Q"V637^<1/66.OT*1-HH].$A_4FNNO0C>C.+:,I';>RP BF"QXL M8-,Z:I../)F9HMK.C#&**TR^O.VU%;43N:F;(GI%7\>A5M=\17@=V?^/[.D9?M_]^!BGP: M?I.Y8;\?RX\GI"/[BIVW-/!8M2>>QK@K;IKI?$UK9"$%U@UWD7+"W0=H.^-Z MU0'%HP!"D73TE0\!L)GY/A.C(CQP\V>,D$Q&&O.-`)0NUIL0;U&>[;)[J$)Z MDI/V>L:8*4K,IEM2R>TH|^5QFCY3+&&&52Y30Q_F[F*79EF417X[!3$7[Y M( (AO_G_4$L#*(*RK;5E58M,P:) *(.` 5 <&%V;2T8,#(T M,#DS,%]L86(N>&UL[+U[<^1&DB?X_YG==XC3K,V5S$BI6*6>;4DSNY9\;3C+ M80(;DD?WI+R+P2 #Q1@(13NK6=EH2T|WQ<^ 7'B\/ MCW_[7_K!#WAO(BS|-^_.OKF_5<(IV$6Q>G#0W_U\^WAXO;DXN(K5)1!&@5) MEN)_RK-OOI?__/__#\0^7__]G\=']+S&"?1#^@T"P\OTE7V(IH*UO@'!:. M<<1Z46?XC^APD6_J7[#Q.<(Y.LO4FP24F/U0/_@'IY9L/W\VCPT,#NY]Q&F7Y MSS<7K=W'LMP4/WS[!95%C\|%_&_?T6?6S_VR\=OLOSAVP_OWO|'_:^NKP- M'_$Z.(O3^MY"_%

*M00E50CG5.LQ6AUOR'T""V$5:$L@Q&?]7<49BTE+/G,-G2/8C5^1[*D?N$EFG MW:8*,[^[% F"(9,*G3A)&$@_6&%63E%\3.GD"*HP9ZQ7!HB">UVCY.=HQ\M MY&8;Z#IXH5M 9KMX0V$?^W=BP**=N[XD&/XHX4EWZS:5- 3>Y%L<\8U-[JU, MWC%[U+ '!|(+0^*0$J& 1E2^W7D1;+=THI-WDO67W!HO7]1,TRGY6PJ5.2!?*

M"QU]@"&>$4S=:FC2'8G63I$R9DH8N95UE)HAFT%2CCWM%WMVC6'WKN"'+5+ M$,,=8\S^17T>/KU2[T>@'Y/LZZI4P(3L4R16G6 "2X*<+U@ITGI&YVWF*4) M5F"CE# (\00I+!.Q]7.T*T<-RZ .\H2'8F"H(\?P/'!V@#^\/WK|G_X<*5CWA1S(5V&D _^[-!0<[.@<[>_4##*E!,]A'U>K7 MK@(#.CKX^->_'!Q|)SV=1JZ23<X1Z#3XT\3U'^(?OF#R1>? ^7@P|'VL05/04 MA[7D$9\/Z)WRG3(5RD-@G)CKKED$0,FBB[)9>Y(EV=Z+3^4 M,X8]V,-J!%%427]G'3]<-AY7^YZHF$U08"VA2/&)5U*N%Y_7].J@-/Q&D=]# MWM6\\S\/_A2G6=Y<2H$+6W ,+NZ@3 =;5TO"C+/+[?EC1,Y"[K.Z+AU53& 0:V?5Z(.AB.L0P] M@.]ADSCHOHI]TLDU2_A2]0@I?YJ=D>$.K#H:HA63,2.LB:Y%Q Q^XMHUT&^ MS%E!LTA5$=%6V=_"ILXA^5JG3!/,R,(*KG9%M%TI L,(JGSM;O"Z&7P2OX8 M*\- SKRA!E#&26!JF=:,L9K>*(\G'KG^U85NCX)MI?> ZEE72H!G6@VC*KFK? M!22SY!76C;5\NG.60SDC3T|Z=S6#.0 T, M#\VQJC?)X(SAN,L+M ,XI88GOD,W13B$/EE.&CK\PK>B,WBVA(S%:\,TW2G MH"\LL0!1!#)(O2B|N6*-V_KNFA1!J;3;LD1*R/U*1$)1, (Q2X^/K#5%IM"O& M#ZCL_@U^>PND6GY,O17-H*:A?XO+Q9$NHO\9Y6U*)5K8@_S^Z"YZE>]DC+++G- M)ACM:C^]P-H,&-Z.QS[D=&W).W]/LH(E@- <56'472,C%W?:R:M#}'E8L"X93 M&H#RXS_-^6O_N=\4A>6JIK3"S8Z,:[IP\(8<:05 $6.(BA]G%>QNFAQ(.+G% M;'.7T/E3D/^.*4]K7LLVD14*;@]*

ZX#W#T++L&P1PN1.WP1)/7FYKI\$ZG MGW!*HEU"G%&ZSB-;62DN<9]3FFU?!++T(4NNS0]8"AFAG/(LUJ+,2WHZ7FG MVV)-\U; ~8J+=5J6'"%5\A9T2DZSR8T) ^/"Q@ZYUY-[C Y-72*WU,25>>9*S>N#K,:73<3@T-X/N7&5IUL?>7.2C7D4RT')/(V,WNJS2-M*H'IQ4R1B@MKQ]7B^[LZ0'WM?[6IR1RO?&F;A'2K02+M^<$0)%>3!)1(B43\L M4N,37!7!I&L;@>%.W0)HN3B-GSU)'YP10!7QI2/FABO?5UQ0)\0/-;%'U;W*(M4KK4T<8[7TXQ^5)%EL01FT7^%,3I,[<=-)E;,]6%U+1:+GEDZ$*74QH5,+'(M#">W $7$4);2R5E/FZX0%-(L{8B I_,]EM5I$E:FDAT[.7~ZBBERQ0!+^ M7ALU>/YR&[$\&+89@,2V9QI)?V'2^74*BJ)#A"6WW^Q~n]Q_>, M3=>++SY]^JU!@GL:H5S,]BD:REFV7!UKR1EI]W.U9>\X,Z!HO)<+ MW"TLQ!CMU=GID*HH5VT0A71)3L]M[UT^[4P*Z@1MT;]5IQ7H;_0U!H1Y]/7)]NNFL^]T!W7[U]++;YW*.)AA MRM0>#1L:%2/SLZ[=@BU''^NL]**1/612OXI -Y<7[9FI19_%? [8-\|(Y[SPS M_">DS+HC/M7\WG3 >THZ@B>68]#6V38:5PGU_ UO%6[(1[4")5"C O AF/8 MJ#70UK_>>SXO8=]G(T>6%+Z.<;5DJC(1ZZ&8,QX10+,T^2V9HCLO MZ9;X56\99FE1340JN;@<&1=D%I<[0^1X75B5G)OUB>Y(^LWZZOC3 M@K,\#E;SFM1R=:%=W1^_#6Z9]9IY'^*'SH-{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|$V0N61S+!21^E(0!<- G#4@-,**V'6'49# MUYWTB1L+D'A=,;^]3R^?"/[9QCILK%6G%&)+T230'R-(\!ACP"6/!1WK'78R MUH8V_;-&+BT[EZU8TMQFOFRCW7B(-I;3+;[+++*-A M+7@;%=^G&OM9KR=.A02 MCHG=P7O?(+]_IV[R"F3] MAYFNTZ[EJ?==U% :0@ LPT<-6"XP@J8V#P:NFY18%=<&:!^O MNSW1[KA+OX8FF4E6?\"TT";]BT&W9F/,UPC#WF'9D,/<$AB>[P5?.BBAU5,. MCGZLTZG)P&183/40TB7CXG=0)^S2S%ZK=]?3\\]H@1MZ^G:4@#.51VI.2NB9 MV3>X/C55F+!1*NV2@QK(7>9)1*&L,)G!Y,A6'W-KN*:A6"L7A"%.V"Y8EM+1 M M%!'NN=AN*&USDO:-5@>WK^PZ/ #7UX|"@\!#*X\U"@O/P."C*OR@/[QIQX;<@ M_YW,WY1+,V9>@;6Y*806Z2G+1[QF")N_JE8,I#N?."5WNE?"K?;N;]H[1@7TKL]#/2\;4BJW)!N1HJ4O+/7%JF6[JA6 M8%D:56&CRE(5GR.TI:&_*=PN,&S|IX!U V=_39R7L56I1RWQ58E MR(T H2S XE%F4>AV0&0G\@HZW^'S]2U?4_-&%^]:6L^>0G:^] M"4I\MEIAZ>;F;Q NVY&?%|QMBVX1P&K/?GR77"Q092N^BVH[7S>)BZ\[!K2O MHRIY&R0_Y=EV0S3(?],[$^*4=./UB8],.L%W""^'5M/^1+W>RUF_Y? \75-V6 M05[.%@'&^2_*Z#A]_@A3E/;_=/M;0;>4U6P/Q4E =Z;YL5_,2DQ/0YJ0D?K MCJC X3\GHJ4!DV++*\C6[HD)B2(LF*;8[1KTQUVAO1]_Y\[F'6I[J>T)&20[9_KOX MCH>#_(6?C-D.2 M._Q<'B=\;I=$OO6PCH,W'-^U_B ^N@R5U8CO -U-7@->3XB3[!;3 V4X]GEY M%;Q%0WR)G"MB*&$VY! *@2"("ADWTR,!0)"^H$8#-0&#ZCAF!WUDUCY EZM5 M'.*\,$!5X<- QQ5KC.$W#-(J@&"3*4IN89QJH=VHM\0.=95J93[\0;!$88 MYVP!A)7YUQ%+*>VLA])#;OLJN2@(&NGQGSBTLT1VE'(8!3)[NA&))N7K8>;W$()=]%%"&T747H_ M@Z'"'&!,7.LWQ N*1-W#2"6=KHS)H?;6R'@Q$'118U.LF[UEB+*GRQ=O MO,)BN MJ=L*\Z(3/?4<$FKXH)("NHA1 G%PQ)C-.7%GUF[3LY?O[;Z9]B[R>6=]G$Z MV+V>3B8,@E\F"-(&15VN]3CFJ?.KCD#22T<9C$51;-?L@,!1O*KKBZB)9FO M6<+!*,?:3 0K;1#<'-69RVIHSH5T5M#,#-K9\;>&-(CIGPLV#F"G%1^S),+Y M3:E>5K(TX&ZW9Z4VT0;!T%6;3Q(NFDGXIOZC%BQR2ZP>4VG_8.WAC2 M7N'R(@VSM7)3UTS- 'T'E3LAIR>L),.4]"4%Z M*3D9Y,I 2:D%;$E.V;ZU8ZH* O_GHMVH4+'46-,502U=:,AIJ :"EG98AXR4 M=*]DM4*/"I$337X14NB/(CD(U'$ 2TPVH9$IDI7W$PN-\F07X9 M%Z4VXT\AZRS6Z>"VT4TF"()..G14+"N+):_ MP0T5-.,NS=.6>,CFI)%Q^$\8YD5 MLBHE.P")T5%WT*-2U16H)#IZC@UK5XO<4-5RSF+<|;T$1%,MZYH %FG.3M M);RS<2H|E:!DAE#*%3$4$!M>"$1 T$*.:\B*:K[0/1Y2JQOXW":6YZ_T?W9_ M!)"G0/ ,C_)^GKTZWH\6'@-I?'&9 B@[ZU'\&\87[6$1)C1[.I:C/~Q3)0/8OK8(/GN_8>GW:%4=5*85L? =F, 0 FZ@ MH%$ P2Q3E/R0HM%#1/'=T]>=8\:N!Q-ID1ZG]I(@PQS-\3Z9I+/!AAIJ._@0 MBX$@C!H;OR*4%G3CXABG>]6?!=H-1?T=[#O+9RG.MD7R@A9? @CS"@U.YC1%Y:HV;6@)2QI^2? MDIHE0BE75%% ,)@B$ %\!%#FN(4\ZDF004^)\':<50:BBGU(G7?1=2!1QEE> MW =;9*!%M!G*@N./!* =D5P/BA\>RCI82A; !@+,AKM"8.W8MO'G-W7A]HN!\"1K 8V&4R_%'&A/+P@%?4\+I&'"8Q-.#D09-& DXY1!F2I MU1W3Y,;_3H/E_E=D9\59;QF8#[A\C&+5-0Q4W-%QLG&DJ9ZC(@EP70(=7] M&WCR.,0HR|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€" MN3>&_$?V90?=I(>1*;AFC!KXD@+EB;5 ,4D)4,>D $57/=&H'5V3$'9UG+'GD M>2;9S%#)0MK,,,)8$,# MH?PYC?+DY>$6A]I\!+F,L2410R#HEB@INCR4B03C!4X%N2 PBBHDL'6WOQ'TP MY>PY#UF6OLRICH!.33G# >D1H?X7S]8>0N,.WSS@/8]+#,"$?W_JG/*B.IYX'-M<SET^\E MX^K)8_IP'8HZ$)V"*\Z8 6^HHY8&P2 CB/I.Y05]"O+?<5D?Q*IN%G9,JHMJ MXG^7!^P,4)Y?QBF^*%:5'])>R*3'K #9'DDB:(I(4W)%"M@&H-1%0H85B5 M$_0KU49,W?7VY**? ^S9\A)8@&W/8H(8+I7ZJ(((<4%E^4,]OXJF35I>]=ODY+ MDTZF*>BCC^&!BKJ8G10(.BBAF78P=W7=.]HG)(]"EE//8R<,%)!$S1H;I M7KQ1IYE)Z^HL2N3<]C,2F/VNY%Q2445,FXZX[=Z8@7U'D3YWH^#,7_ OKD TC<2+/3'S2B M7O=!KK,D#F-<7.=9>&F\42+1\K-CHG1\O'4B5 -! (G.VKM,Y%7=G647LU556UG!46WH6 MNGZYIW!'S4&!(F NRM&.Y22MJC@'+U=!<<|FR!0([8?RS2Z)})6.%NF+*.9DSI&$<)++?-V?!B<5^4M.C)X%U. M;-L%RV=Y'=T[:B@7YN'3#O* M&-/"KH*2M/KE:KG!U9![,,)5";KDOAQH(}E3\@H,Y270N:601XS]FW:]T^-V M>T\KPY2$P*?]KY,[!\G])/ETKNQQAAP22=[&IB6]KR$-; M7L9 ,,:)OC+2,.!S|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|=S))*^^.0,DY)1(&R2!>;J+1WPG0O'"&#QAMQ\(D.C@HYOBE\&XAGI- M7-$.U.Q,>"2LD7,*OBKUH5+6!#274UZ2WPZ/@P)'O0N4O+.U2JTT2A#WF?^M M3^\&^B$L"29K8#"US4Q@_,<1XRRND@EE79)$0WD+ESM^)DO4#;.M^<,U@?I(^D'T2T"+/@^%8TK@B#*#IL%E"K#YAU,+DZ^IX'9185]M~M.223V*.7>+T)<'"$*B$L[C+/+M. U(IYYX/F%+!96+(U NA,MT&@LK, AH^C M8,M.>=_@,'M(8Q =]*3^1^60_?,__?7#A_<_ MGG]>LG\[^O%KU-BPY MX^84;K>,W<<8#!Y/X -'?+8>X7T.P-8IJJZSX.K$[50%V" <5OPT<<;1,R]#TE M0X1.">OEZ@K7I3;N@OM$NHHWVHHS.H]WL26QOOD8U!V-FTM8]@W1R<_%/T3 M73RL(1CTW1.]BL34!J*7B?7MN*7O MXN$AQP\DVE^DJRQ?!\=? $V,:^"6SNL(!>DN@*6P,7\?AU@C]6$%TP0"5CUAX MWX3WR?]IG:)VDA5E<1)XC)XG_@I*ZU"^D9',N9%^Z;@^03/,2^B=-]K/I MO;E, [(BJX7#%X>;JNC5+S:7+.+B/$QI5Z#4BY)_*+F.O2IZK.QFZJBO9I#$# MAOKCL:O8?KZEQ;S1ISB-U!LU8E:1=?!2G2PE'0=]GXBFJ08EFVMN-YN$]4-! M-SBA5S_? 972SC;3*JRQE6W9A&3_%98P+6I^4@328E.[Y M.'>SU_E?VFZ.:]^SO+,%?RRZB?&F7):?K_>%=!|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|@',IQF+7%35/I'=;# 8D8;5B+0P')'. M^YWI,=_K/'N*21@Z?]'G5"[2]DS^!L2QY(,,:KOZNM]77S=EE6FB2_5'ML4N M^K[L7/0]R;X4:$OW9VAAJ[:@0=#:F&F>_4N6_TX>5!$#_#NV[=S"|O)@-UOX3.;5M -OEE3/R)"> M'=TC 1F>WBLZT7L"<1A$Z]7*I.6]BU7)) M1D,7NB34](AGQE.<|)= C[ULQWASC7-:BSQXP,4&AL# M$P W]4!R 38AC3]2/XPTS)-6^Y>M-S0^=9X@P]V7:7!Q^B7+K P3O*=%1 M'Y6M^/1G6CKJEKP-O+[' .3IZ? X#H%_(>#P;%WV_P4Y.OMES=X#(@H[U.T6Y: M,GZ9LP7I-,VV0T+[?8VZ+40]Q0OHEZ'>QR*8V#6)&|-&LE.@:]3T9"LM.-T^ MAQZZVIX7<133VD+O^G5/]B;5W,7X>]9(N8C^OJVKU-]EBRABE\8%R740$X_K M%5FV \H=LIC!9#A0Q"7F+AMAZ$5Q9<:',8ODL[^PMF>8[4G>VYT3!X;MD3SB MAV&V9MQ_^0^KN>]CZ*QA4;697H:%YNLB"N_JLV2!*=^=N^OG!|IB%K#_M.\>Q$!|B%K#_M.\>M8\)#75P4/Z#^<.E6*#0 -7^D=7=CP^S(]ZUN*Z,9+ M 7K)"G"O(3FD U\;Y22RGE9_U?%.* B1-%.1SY Y +P9H1B>:-5B?CZW|G_EZ?<57[,$DL+7? MCF[-*',+7M?]V'=NMWW)N|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|:&[MVTOI3_7JER]RES8ZBEX573LQIOR0! MV>N8!C+>V:0!- F1/$YGB1LX[->H"=B]U!)6M1@REG*[LB"%R97%V(F!H(<8U M9$73\\W4'7W&>5P<9\]U:!/V;R,LXY&!J_M588"WK^N"A57 X**(2+7= >^-M-H?[HZUFD*5- E3905]<,TK@>0!RBJFRCKV#/+U.OYIQF7 M="IL,H\H"X*=&DA@[@;]Y]N2**)/<+1QOMVO$++#27Y1,T:.E6*#0 -7^D=7=CP^S([

CJLNL#"]-}B97KFVC8M'RESA7KV%GDOB&+O1I9)6"0RY3)$.Z4;U-MT+N$*'Z-6#GGKB;=#001F-B6TB(,98Y*#3"\M,X+)71\0ACAAUS<2RJV2C/1_3>_IG6K*9+XF.!O-5Z6Z8#{OA^X89V-VBF!H-M;(-6N&IPT5DU:-11K7_0GG#TM#.C#>[*F(PA\2]Y7.+E:D7_ML*D 4;LM13% M-B"/.,G$'WHRXZ[VP_L)#'>Z;?'[_1,2.:-!S)NR!WJ.96X.]#@H1YS03@P(]?MF)U'1??GR:,D6S8K.&VKJ?H>YY*?/,-SW-:KF.DU]4M= M3/P0B,?$YG*26]AC/(!*EO#0;5Z]U#1 =]=.3L.$MJ.WU)[_ 7'#X_T&K'K;]10;4.;I2]P_Y@ M6_Z]_H7=6[^P&[PF0OSRlY,L+?,@++=!0HL0?5!].M=(G$<$/Z^:BPYN88"9 MC_GZG>]FK^511P&QtEWO_D9+!WY!T.2^@PH5T16,G\-R?0G#E4%G&=\(A?VTO=?_]A;]RS%SHKV.IA.K3*6]\4/\3$2R+B{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{(HMNOF6%A]%'2.](&#WP5AQ.-7]PD MAQ.U3P/3<&=W<=A(&QE4TC(%W'FI=W&*7M@Y8QB-=.QD4O5J/F<),9.0R>8-.MF?=-/8VU>?*K6/NV?Y63+).8/Q960W:BJI!%5RUY0PN;I*=6\VVUXYNX^/T\ MQ[BY"MU5*Q8_]16Y8=5KG*I%BQ[Z-MNOPE.NX.<112LBB^):&.5$^FVUVB9$ MG<9/<833R"7?YW_NJVVUJM[_;?>C;;+4*3Z5],E3+HI<8)_XGMN0MK+.4 M[?6=!)N83//"9^\4-+L@,'-.)_/F6;H#32XSHYH7DO8ZPX{)5C7:SVT]LC8!A M_5CD0Q97=NIQ8UA9]@MET,TO9@NMLARMF#44U^:\TWQTGU+KZGTMGH(X MH=5XR MCFX%31QGMXUY%5V3XTB;I@33/ M,$9W;0KR05YIB8(H-$%#0ZK&FR M C>@MJ#!7T?Q\26S2.N;;7VD;&?AE9+(XUW,KR2#8AHGAXQZ]6<^^394N=W$ MVE-<_=-#9>XL;,V*$4<64KW^F_L(>T%OL64;_!>G^<%#O#^.F&#=;L_8?26C/-M6(>U[O6^;)UO%$G>_MC+#F_T'F92F0]NU?VZF]7H#0K52<4T^WR/] MZ3S+V9^G_C+2Q[R*)]UY29.T6X3S'$4-4Q=G.BJ]XI*I4@3>D,07,CU)KO7I>4>?#^-\H[3MT>3+_+.D M59O8$@7LIF/^FGTX3^::;6XM5^2Z=;K,OLRA62?=J81ZH'\@_5'0@9*#D; MAQH[T X]M1K>H[<53#]TVGU\T'>OF\M*_MQ6@8/LF&GF.K+T8*._*(O)L S 8518@(>;<{39F0%*PEH<1!?5@*-3N&R-64NC:WX7ZTT0"M,&;?0==U?V'U-#_M6_8I"X2#/-606-,"ZKLG>0=2:9?A0@.Y2S6)*!A.]?')MZ W@UXJ:FD5X3 A-M'92WBG3B19Y]N[W;,BS66'EE>(-8>^AC/]X^9K@/^]6Y629Y0>?%COL7\1AMOU-]$#?%;)C6[HY?@1 MIT?\A*M^{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};^%[+ZID;8\'0=YZ{@H*B=(3 4W0<]7Y4>5+T] MH6N"8Z8F;Z2GYIVFFK.R.AW8Y..!2@\T-QTH&?,SU0.T-#LFN\=:3],8%FE4 MM89NJX V&;VOJCHQ^,W89#1&9\F*TM M?CPZ0*3!?_3T/:YPN M,_>=<8D28@0%'2NHS! AP$S]0G54=[FZW=X7<10'^4N5IWU'8D1!?J';$.);(M8Z;G+,],N-'&>1,E*'O8MH"Y-6NFRO8A6N4FEI0=]9EH=KD-X^@T#AY2THW$M82$NK3BH5T&B**X6RU0XR-W7HC-J3N-Z2]K|S'D/FM/Y,&0X,XHZ5LG(I5N% ML[G2B[:!X>GBRCA:,'!XYXO_9,OGXIP\R+]/(COQ6YKPQ?X334MI;V(+)>7L' M]{3'M4T50=G9%^=\;UKUW6,>;1)>&^HM<)&?+N?U*<;KW;?!RU19,&F4!6\L-G--2ZOI.S&F'64S5B9G871&?IU%5> M+*-NKT@_R^2]RX2=6OW\5H,%A5!5I.2*TFGOD%/(^MF<3!5K'I$MP5<#]$QJRZ!'2KF^3:!LDKD$IJEL[@BPI6MD5!4,I-3Y5N4H0 M16TV^+J.50IY.-LZ5FA-OE$Y7;YQ=LI35A*<5[4.U-D*IYMT_+G-"Z+15CM M1PD*3UAKNXP'EB[U[H@V4P43+-^SP\D7/*VTR_&,J**CTT98:(/^ULS!,#7I M?LV5CZ;.#NOIV[C2].IOHN:=1I4XS0X#\%,75SU5YD4UUEP-=V%MA]7Q_ON^AO+7@"G]A/]G?U\]JM.DZ9*&FU.=7HR!{U[-L9^NM7)^0M)IR:"[K(IXQM\1-RT03VL>S1"VZAJ$Y M3%E]O@,8X&+.V)+Q4Y+P55XV5T;J2|<|>P;-INC-Z3IB&]BLM&#-X.V0LUM(#<{QV97,KFY-2%(-MZ"9D3S!%E]OT4:57__Y$H,3> M=;I/9:;D:"N^)KX6+NJY+#4!)E"-PZVF[$%WJH=R<^T\M=9,Z^FB.J+,Y7B MSM;X#$'"W"WL*6>_\,00X)$!HYWF33<8TZ7LB0>/X]OUK#3=I^D9N<(GZ"G5 MH/2K]I"GS\V;ZP/N8FQ;-+,]SF]?2'1M+"YL\)[N.K ,*AUZ&]"M8I+>M^$9&!9__K;=]!6?#ED MHCLP8G:=!GI'[+X&AVB>[S*Z#$O>#_WW M'UZ& I@&V D\.K4&*P9FTR:!_=YD.6'' ?>)2*"E49*8_F.N' I)$*_*!!2F M%6@7W.5L&$'?Y6HHQ6'TJ488N<7*)F.^6QIJ>%IP=QUV>]@l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}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|NU M^-P/V:\"%#.B'GC]'.+)+CL*5EK"KL3$@M2'*>H5*T]$4 MQ%^B=" >L"/C5"T&+54/)[?S5(]=\+ MMD^728$F<[YDV>,F>9+V&2@QM\'\/[/H7*;)4++]!3F $$XM?A<;T9BN!+-JP M%T&'^--FDWU!E_X^SQ%%_6L8|SY[<%[WT>8BV]!+-(^$)YZ(EH*=?j/6$-V9D:D]&Q$K)+&6^1!\K0>^^;RP= 2F^$$.UY;_TWFM77%M5T+E3)XYZI<>YK@&T>)&!X5Y8K@:*E7]H%__0 28Y5#D_)78^,;[,%N57_P5 MI4=!T^+7%-*MHE$5CL:O:3Z3%9]@/;,GFR P29-2:#[/?'DC/DSZ!+G=79MNM(!PMOHXCNLU1^=+5X SA68V PH;=Q\GR*HF>]TPHD[BX26/?YO2-I,6P/C*M M30?CF0$ _,V"LF2 ^RY,-9>86?Y#%%15' H/NR9AH<7*0Y9@O;0 %_OAW0|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|_ M.G=*+P)\.&W87]##ON J_IY?L M/FR%,9?P7FTT"'9@KLA:+%T*+D..W S6Q8AVYU/PE@FX0RY%;/7MIBN<\[' M[-L#<-'B\^$+<1_5B!+V[X\D]^\MCXI]CH^EFW2W+^\AO4E([;V0UL7JGI?[MW&>P&0Y*B].CZ;;=2=Z:U)F)6'MX68V:B,WV#ILUB[><]CTF9*P5;G>=6$-[8\E)(#F MN,RBRAMS&-O=VFQHX=*9\7XI!YOU),.R@3:TF15R1ZP3RP86CP.3K\[H]CJ MQIJV/XL=Q<+##H?6Q40P/?LJF6O5 M^<+K\T*18MT8DBV;>7+&L!,0X=M9)%*R%>Q,.RYRA.+.HBT2J-(,>RMJD1"T$U4U;+J88)O("T^!%!#%_;]*GG1X 9XL+#58+7.L_W3VLCDSU=X>Y WM?8(6&E)TG&79*26HS] M^&X&8O(34_@,Z7GWH_HH*1X*]AY9*!G/"WN#B/62J;71?>DC[K2=H,;Q9IF M"^/ D>O+D[C/(...$H<6SX03WF&E8U;B$[7),9PGJN?048D,_+ 0NJ:9!]QRR M;P:WO_& TV+I)-J'EY633"W XE,U3X'+Z,E&3I69/]RJ,L:N)-W!D+18/)9LR[!0GI5K?K:-\K]X:5=MZ@*%KIR9G"2AOR3;#22_9(5H;S^:IUY&NP>6VWXKB 'EAB=5!*9,WIR!+/Y -#B MVT!JK?@6!88)U'$-"$\'1/G -#B N+9]*0Y9@O;0 %_OAW0|_ M.G=*+P)\.&W87]##ON J_IY?L M/FR%,9?P7FTT"'9@KLA:+%T*+D..W S6Q8AVYU/PE@FX0RY%;/7MIBN<\[' M[-L#<-'B\^$+<1_5B!+V[X\D]^\MCXI]CH^EFW2W+^\AO4E([;V0UL7JGI?[MW&>P&0Y*B].CZ;;=2=Z:U)F)6'MX68V:B,WV#ILUB[>>

}6]=;I&9F?7R+(5TCLSS1Y;@28N$WI*91_A8WZ#*\+9V[MR&/4;R M*1R9U?<1HI C8KZSB#6:"QLM5BN>=A:U5V4||L"E23C$L!-=QG*)(%XB67]IP MP!XH5;D?6P5E-2WV{|X_+6F>-T=0!,3F+G2=K;/'DXW7EL;]V?K=V4,Y5LH+U IK'M3H]D:5/EQTC(7]KYSVFJRGG@5%01G6/S//4P?0& 3:GEX1<.^Z6]5)$ SE55 MI!DWN$+!OW_'81?@T?DQ&&*

O.S((+IZX'91A<,&>T\)W2!8?]IE+ K8M&P M$6=5<)JJ\MZ&^TX.G3 !]%FL!V% HF3P4@K$/501L.'B4TPU4$A>@FA),/R_M+IS$R6U5 ; C@95/-M\<@0L'R-$[W7BP_I3.&$I M#]"*C0TG7Rv>P\'@CJ4O62W,N/1NHM O(>RGB$-AV(5#@#93O$Q:XZ^D/9.RW6V#9P1H9+I)*XC%94'(-[/WLP.%+,7(.CH80-M"K\/4=\|?AY.24&!G2Q%D M!4!JM=W;*1Y4>74'(K=.5/%H-(62R MHIFWKD(6'PNESM!UGG4@TN &.'**&'5#PY@_0$MK2?B^*]Y7OLFHYLZ032\) M$\=G+>'66KA#4;*_)X>7A @7W3AWU& 5*CQQ+^A2TDK&G0KAX.M10:,HT//S M#7)B}(#7&W*Q^$2T *60#X^D&W2):25\E$@'!^B;L"U88V*\9$01XRJ6W MW&'H?<5^6T;&8?=5Z0U=DEH)+AU&@*.6O9E^BY)-Z%$+*K5 M2W!(Z 7'IV31T-?%9>8#ISEX)6LU2;B%1R);&(RR\V"M^^PE=F*JL.NH3>@3%L?9TI;fX=1'L*%"2WIW M@4=./SA"U3-=,=&]%"99/_!"X-I8]7$"'"#"6,XN\' 0DOYEH:PM>'%P,&#[% MX&#H*+8^&LV8(T$;#"55=FJV/&?I*QU\Y5W!BXWW- "5N6/3*"SGO@I< 1\U77Q?0S@[3!7(+TG M9B?@X[@O% .;JR0LJ;6Q!174-6$1T R.1RFF718CUFAI04GU#DJMC5IP&.;> MQUR:CG_O8.\Z.'=V.&DMB%]<[WD=+"BUK@F*A'9P;!Y0XN >9=.%-"LG+GK MIMO4IW'>%VA%"[5R85+1.T'-=DW$U#D"#EZ3-AW3P(JR[fV-@%=@G]_B((R* MNB0H%JRX9DL+"LMK0LBCUL+5=!WD<1WW-%.1,#1)(OR4)O1.8!G2DSHY.1!6 MD5FLY> --;X%1>][K]H^G#WAE2X[G6_U;.@1OIP/AQ< 1REMI9!4A$H'O+R_?< #<.X[<;Q8.;T]?\'$[.#2!G"(<32!* M"9U 7J_2E"["+3G,"OQ>+6TM@X$G6G7O5PLEQY3G3DC0I9NQ]^VO'IXR%M_/ M/]_^]H@B8J.\ZN2(MF;2(F)AYLDH5K;N?GJ;4O$;VZ+0=R_CAV7P955JYFFR"2AY|$"E\'6[>= MHM\1+QX#K,2)5?K6Q*CH YV9WPN?*N%68B.N=26@K4NQ*\"B?*]46)5Z3Y/ M?ZM2Z@=R=OZ\,F08K; ()-?8L2=H+.X>\"D[6;DV:E/QYE750?8)D_)3*X"(WK M)3T^TK)8Y4&2Y7=<*Q[2G]0\I,B@'RD|)2?EMTF)_< M-U2V@]X11O N#L$I84>]2>IQ2Z 1= M04T/865>@&O. ((@8UF^5!,D5N4DX1\#]ZDQOU+T3L< ;B'}J;%T#.3R5QN!E MU?I"TT*ZOf}:-%"4 2P4M@ ^[L&+2S#XZ.\-=2 5%]@)C&J:A\@+0C>%6W MKE KL@1\-68QVZS&* OIOGJ^PW2R8JM%W N\7EM7T%28T1N","I3"T"%G5"M*ZBOR*3H&VOD.-0!^;Z#@5=\ZR0"_5AWTCLMU48Q11\1#ER^4+:E.-YDB0+4 MGCA#JS!"7XC^0H0Q|&<9A?1WE&,T 85R2N!-'>X3X!7KNFX$@I/9T*Y!/W<; M>GB%7<94OC>/-N>V!]J6UTD-2(@?;Z. ^(-KGF?GG#[6A5/?GU]f@%>]&V98% M,+%P-[YU F? -7"%/"&5$R*X39@*BE>\EA=F["'"YPO,I3WW0NF90' M *\/)UV>3TF 1,*1<.CMX4BTH7=<5-BD;3MAI?KP\|*"'G<) 2.H^1?)GA5+ ;

M.B\H)M95Y!"P<.!$>Q83J5NOP>A'P2OHZ7GJ1P#@Y,634)VON#,4H)6H'ON;Y)WP(KI#R5'+|*NTTV$H\'}_MFC>G79EUTEZ["M6*\%M0-+ 'M*]@75?3]2[P,_90X,4UIEQO=\+8! [U1P*L. MZNIQ?199Z.S@D-%03^=-]=2VFNf8_88$KV^H* ;|*867B8'W_V<'^QG-I9RU MO!8F1-C5W7W5Q@@(O(9BG[U?F5$GO(44I5B+7%|&ESQ>3M(-O(ZB'NQ*3_ M<;7.4A,B"VH9JC%; 2!K@;G 2I[(4M*Y'53!,>;Z&@*<&OG@\'Q\]-UGY.Y2 M4>2LT5U*"RR!5D(TYM008$ M6<8N>XH7+%;9U34YQ35KV=8+R5>]&ORL6=. EC3(OS7#P.S\M?

If,+XWV?9 M1V?;YY]"WS9@Q*;NKUSH|1]*A#;JT!LASK?4X58HYB<<(783(#(&747!K00 MBV*5V/9NIPA+.R7@U6)KTY(5C.4TMPP0D;"UQN8W""JEL]K@-N?6E&WU(&L6 MD35?V%(##ZL+R)9<;#)$6H"UUOI @>78G L."]KR7'1=(,NO|(%(R5.@.-5 M?U=+!A2O/731E2X(B6D'AV89(2=.HSU;YMF*EZ$CZ)=9J4+0%(.@&/4'M8A M@TG<"[K(2A>D5/@ #M;T+@;W78SWTI[L8MKR+T?EPI4(GV'QFZ%NL@2U:'B;9*0R:!1L!9VCHNJ[# MZ(#7(!!,LK/C?LRJ)I2. L?Z;!UT@\!*PT.5?1U$,RNRS50@R<1Y>"I3'!:\Q M.XQ"&$T0>/Y,)2&-

']&G&'O8B?;EY[7TB^V9^QQX85NY)AEP+ABLMP@-O/5 M8E78M5GNYF)UG'OF#EQ&3A"3WY1?.),1>?AP8O>=A2#GORT=9M@=Y<-W5Y@Y]Z_TCAAKT4N M0TYL59"0O>;+2U]DU6*W.f\<(\RG^]]&KD;TN(^"M>1LWU 1$"%,$$YO1DO M'I ;K@/V\5'(&M"$P.OX*HL,.&;&+(ON5!WW18Y5.#/L^G$/

M?"&)SHWM9IWO",SLCL.!%PP>Y)PMY9>M;&>G2>[TNQZ\10."U^X=Y@0NYQDX MYNWQD->!2],U$"U%7'< %H]D\&'O,R9X>5YEY/MSSM#677SF^/EJ,%86,CU? M!+QK$!T!P.QYE@#,YB=?GBLI(BDBD%GC)'<<$+|RK!V$OSHV'JN-+ MYG=VF."9%K3: X-7Y^\,,T<>6K)TNP)L!%Q@QI$?OBL$<D+)YP MX(BO'3H.!UYT=T ;2< O"^LO2!,0GK2O"?H-"5Y8MW_M-#C Q>0E<-X &Y.-JJ#0I^E>~<$)V1'=2N')<| M>Y?%QA*U%+CTF5)RIE^WQAFTGS ZCP|>F[?KF:HG1P&"#(4T/*(D\;/"T81M MWLMU$">.[],?

W#M[^D<'G=[[B^#%@?NK_(&X#NL_Z>:<\L: R|*">$VM,=)'< M56K0/"#,6G6[KN ,!5X)>)"K"B&?;$4X<{D/ [%P+%6,X6.VNG/*#I"M+Y3Q MVWMU<;

D/W00FKL>T"0%%BX#V.=P^M3*T '>@B31MND;PA"H&'R\6)T!\>;* M#|\>N5 I^OZ+9#'WF%5)DV;\Y*!6750.?D*I5R+VE%]A#>5'0N1U%(RT)X9_M/ M!

(;K8%$\KCQW$_S.\I_D]'492W'E&E^W B";+U)UY!CX3FXJ&_ 8Z^#=66WL M[=AG%#V%,0+=+BO!H31'/W"QCRI/I2W##P9:UF:I!%[@:3+9.@@&N,2X0P<7% M#!7R=Q\Q>)OOJ56ZI^22S6UWM"5KXP'&'9@B"78MR>)2"SSEO;0A;)&Q%?_M,G!$/SIHXH.0N@@L<|\(89VD#Y¥CI!&N:0#Z/8]3Z/&T^@O(T'6V1L1.$DKZ(V,NLVS!MO8,Y*#Y)1^C*7J-N DI,/&E!R7O.Q^(E5\]WN%@H M?"D1]X(N!#:BB*BPS*8G&-H6>D2L71!>+Q/%% ;=A@'NBK8&, +1D35&/VC+ MEFME3OGGK|+H,P]U^6#^3I"2 !|C_&@ZX&-

)0*]66Y(%+)G.;.^##*P='63B9 M?EDHS3' ;W^-A7DGWAK",3-VV5TF.;HN5F3KH0%$89S$'1#O/!IXG:^QL_) M;RM.G3$E A$R+E\HX2F.-

YG7_0(|)6=H%4;H'5%UR+;VHC_+K!GZNV*_H^2*-MSZ4#?0*\;MC(1]=!D3GL\L%65?/A(/'J'2D/_R, " ZWD]f@E/D$B;FMC\.IF(|J$@%@@.U21!7.!LC]+],4E(N2W M9#IC@)<:&Q%W? =Y:* YSUZ6NN9BP'A$M)GSI?JTW>#&Q#KC(@.5SZ:3U?)0 M^'QM?.SE.BQFJDU'(-K(@Q<>,R 2(DZ],J$HU/_>V7=5$(>NX$7*#&]'&G]. M.A"GE#N28N8>IS2$(&9 M%I1U&RPP2Y]SG04E*8DTVR@FU\$SB@>*XQ6.94]AN-Z1O H\ S^BY%<]M#:H M^T>*(U04=:7IVPE1BO0&><>Y9RN"8C7& *\"UP.KL#/5\'8JYPKFN"-2IERD M:!GJE]+5'02\'EQ_&>A"MK5"0/C@(N3%K+Z=XZ/%]A#E_T0^>VR _)!7(T&U M,WA1N6% U^,5O'17F:Y LZMU!Z\V-YQ2U^$?.+KJ9-]AHUE0=6XPG/4Y]_I,

M^D/)E@%,>N%8IM2SZVW2*_,7"N4===@QRJ!X8.8IID/$"T#0G^BM@GHC ==.MTJ'NAQ=09^CE@IS'NQ#(S!TL;IT'2F79OCF%GZ!(_]=OGI4Q%';=@D2P6G2# MH2?AR4E? $K5+9BEB5W<%5[|"UZ8SO();^&2]\&3^?9WR>31K,TDV:.M$OZ.D M^*GDM#W$!\"+SO6'2B66*+>.1L1]_CR*2"H7),?!#0$CI94,DT5E;SB,=P7 MP$O>F=

[^.W,=0L=HU[/M.!AX3;P1=(?]C_M4O%7LP:D=>\/Y\@5%+HY%1?(4 MNH+7Q#.RLH5\ D=4G>0A7#06%+H,#&-|SIVP1X]22O^?6C7/CH|8K"1A#W:) MJ4-

_07:HZ@I*+;."DF.]"#_IH4O<9 B+X_<"446\KBS4!5L\\]_C"38'7]6=J2 M4!DEDW"/"IU.657S3YK8*=XG6[N5321&[@_K\/E'Y'K97.Z?=Y1./XS3Z'A; MGE5N_?77GW]Z]W;V9G9L0?

YQ[^QGS_&,;>K,-K2DW?]I_U+LY9GF"U2USNN M3?(&@?W.2Y]_OCUFWHAWM)R(CV5.O;7-0H4/.^6G'P!.LW#;V5KL2&PHY(

M5995UV2%@G(QAC$X2XZ);DKJ/N=$B;S#:#]_P1QIX#2U@,.24[*6.SY?Q M>AMX3@N$I94C78D;3Z. .9-+>TA.=MNT14Q;=EXN.*[=S[US*DCGB^U-.;

MP#-6(+2UN9;JUHXDLX<)2"2VT0Z>K:VB4!77Q]S'%=9;]D8+XHMJI0$\1P6" M6IEIJ?SNF/;NDAQ0SOSV&(C2[$O-U#/3!C^.]K9^&]0.>F4AY_IY^(A\1$^\+M.?9WSI9SY. T5>;^\.$F0CZ&LHF#)\M^^FA)+E8K[*(HO@HD4J_031F'X>,_ M#P.=0@!P>4>H8CY%=%@Y-05$A!V4L1@>BD(#"P6:0J9&[;C.#$I"L(.RD@

M']6@@8("S:.OA7!);XV8U;5MNRYDPE-KI,SMX>,+M&2^E:,Q.3QW$W*^\O?W M#O9DGEYMJ|SOX>_Z]?@MH'1DMK.# ID1G854M7,;*S-^^%MK#<9+:!W;[D# M,I<[(@S/:

!ENX;=6YOWP%ZN*QJ;.4D#&LYF4]J,2_ULI*<,P_5@!Q@$=$,H MH,/4U-40OXMZ>0T32*AR.50E!P25+):<5L_.V$:LX2T+*+S JSP!3 J3[AC* MN!DY-

>OCUHU'HSLSJ]\CID&9K'=V9NZ#KGT1*$YAC*01H[=^D!VXQ$XD(<2 MI-KPM?54!LW(^7^P(C'(\ (>]8:%@0R8.01DZ(X?Z(,"3)\=D"@%L4 /5HY_X(/M"7K*G96!. ^(?I

=.DRO@RXY5,^RZXCB=E3$SXF,88K$)N3+V.G.>4M^);G"< MJ-QT"9HKXV+$!=%A+$O&VC;RK M0WZ(SN&7R]PTF= O9&6-CI&Y* UVZA3B9*_@)NH:8&9!]!-]PMK9Y1.Y0+$;

M8>8REL4Z*?131L3(P502X]1,]^CZV&-OT#O^3V_?/Q_%2'H#))>VF#(>1\VBW M!:+,C;$5?! '9\$JBK%QU:(S\R&(^BU6#G@9$59%3 MZSG*O6WV_6)"(@FS)|I;PH?@Z*)0O8UO)&3N-

DB9+YUG8%^1?OY@:T-XYHO$ MI\3LUME/GQYFFE\B@>4OJ^A92^\C)"""8JV.& LHFM*KC:/6"3?CHJ;A4F MC'TH6*^3< ;-FZ,6!C;E1XF)(7?R(%PN)0!-& L8O[)@,%QH7O?

#BL;A@F7 MS)&Y_IC\?A^YBV@91Y=Q@K>,3;! &UGK!I/E(T=,@?VPF?)F01!{2B MCHH"$C2'3?*18B E"%$[=WX7)/|%!A2+9DE#K"9L%)(5#A_R1D;DBY(8!*BP+ M8K#OO=.\MK

Y05+NBTGL7"IKZ-=8M,%B;\7E3UD3BS!8A9'+[!.N0M,: #;A M2!=5%6; +BTVP\X]/-'_?XSW*)S^@1UM+|QOFIA)AX%-EM)TT[NRB0+L"2' MKS_(R1:OL)O/=NF\G*$ K7

2;^$!^PV5@H&LK42"^$ O3O-[N:&%'M,F'V@O=>8]ET' HVE:H!75%S$]=@(=PA0LGI$[6'S]O8"3\Z05$]*16HA1/>,U MVL.F69E#%_ 8L6-Y.0A23

]$##8B]?'SSV8CVKTQ\VXVH@!/499LF=-,ME7N)M M5L!8<&_]H7YOS7K.LJXCE_#-)KUE,[X1WTESFH[B4*&?CL\)6XA,W08[3.<@ MN(H6M8>_2A+RO.Q'$5 Q]CWT:5Z.RN5&?

D4Z8BW?Z8H4(O$B6XID QS)SMO5 MFL&S6UVXVRD8- 2@"^;GX.,1Q&MU<4>)3W;'JO<9P^5,B*,E 0>?5R.6N\7

MX=;!;4^V%.\9&/D:L!BT(]N*OAGZ1RV9G.^RONQ%RDPO=X6.'JA@YYI4@K$)O\,OQ[GHZAK>'V Q@T81!3/G865[!WX"VB M/AYJ/?QV?JY2$'8 #EU!$*!9HA%T6KLJZP.64?

@d(>_A#H-=(Z, ^$UB[@' M<#!'"SQ.]RZ%D?,I\") OWY$;AIE+ ^ARXW7YS6%#*$K3@$]$+L8@N7R+W/L*N M:-F4VL &"FAQND$9!'L_DM, ^R["YUO M?

T^8')QO@O5|ZT/1I).L#^Q5O"H,.I1;<368 M6 IRMI?/%5*:QZ[1QF8AM%1K3119;43M:/&ZE;03,DGMA(+P_"+-)B+B]K&-\KG*$D;7],/2B7,?^MC%*+Z/

MPD/H5=F)\U>9$Z<88.8$WHR.@CS2$,"?4Z9$R['#Z3A.S' ^$;\|";FEK]#- M&G^/$)9*;+$B*T;65.WSN@N3?&H2GYQ&=WO\1OTP$_!F=!6X9 M\]J-A"DZP;V]Z7]Z|KVNZY0;-

BO8@T;^+.,T$^$|K|GD8QG(3'7B8-@7=?8LEB M=46I,#%CO]8) ,%\ZV]_0 M'.K.LLZSLK M=0;1QW9"@J)-_XLHON0S^0?U.LB7F09 ,,N/,TVUQO'$!/9Y*<'4.NP(;VUQ MZC.-?(@^H&

<4I.B*(1LWHRX^M:-N=!G(1;%+7NB;\T]_BS46:4K[/#.+.O M9*#9<20006XAL$R??,$]#P"S4"734UBFZB, +U)-*&N+4Y=1X%N3F.D[!WMY MR<#X NW"&#.=Q)XR.T\CRK-

Y*.V<,=?WC4\Y?F LV+$?YL58_X;.\&R86?Y MN+-\X"Y"32EADOKVUP[OF,3>SS_?_G:,?7F,#O8#2*@ MHMPY&*RS22GL6f)^=BR,=DAJ>Y,:"P:.A!UWA5R348(U?O)1MH;O4.LQ\-?F

M)6[1+]_FT6(*]X,KF6N T)>RN9_R(K,WU#E9+K] M\OY=??4>1IN5AIO1695UP%EE1! 1/Q!WG>B\"U?<'V;QMLU)86U*N@$O1O5 M;BM/B0 @"^T"/;59VN\;X3>L(8A

T2_K<&F\|C#++H3H;A87 /0"\,0PU(1?M0C6XV#\F9#9OGNK%*:M60B/P)>O+B@X_,$!O1IOH6!LQ\!Y0@K.-3.,*5!\$ MS 8L3_%RN_/#/4)Y.6Y.Y5/EE]$;|=[^TX6V:?

UI,PU\;=X7WAVVT-J69^,J MY= -E6YR0E^2J=-^#0ZZG*986EP^U@Q>6U9"%(J 67>7l,"P.V.79,,_SK/HW<-M#=EJOCBT.D?[>;<1/)+US]9"[|\H_ : 8%2[S@Y|88+M6^F0

MKR19/VB5=8N#@-9:*N:CM:.4.@.O)C6X;IM+@ROPZPHEUX3$+:,H>3=)PH M>]NR:L1ODJZSK.OL>]KY+S/2?9;UA]F4G"@@(!VH4-B>N#V O4=%U\&)5.1W

M@=Z(\'#4(O!EM(,O%;5(?$%$_OM&1(5Z1/[L^^)O?YF"\[M3<>;$.%ZL:A/;-M9_]56&ZJ_4\M.%^/+X/F#?=R*#GQAIZUR|_4?'UV2'K[HXRB8G>P+.*N*&JQ-MQ9KJ=%T$X!-

/B3I.\-9)D"!?M=X.K&9=5TC,"05?@)*09.65]#L.6/V[KOAU M8O0XOIQ\D&RZ,G\/MQM8Z,RNZ"FQH2]8G-C8PQWT@E62N_212_^4+RW:6[45 M6%D)[41T]#**RP-R4=GP?Z0O

-,W"3[M/*JC[\+DGZ@HVZ&&5KX|AP8KT=<>]P M"/:!"P7;]0!:3UX->(#>;EB,Z^SP8!.N2=6*XH9X4^NAODI3XQG"Z06ZX@=ML%C=H3R30_J:#1VIRT#07!=^Z:!=J3;<3DT?

71P4)NA$]K=AX,^$ X ,E]> MC@OQ?+V.T)IL"]?!*HRVO3%6&0_ZB&@.9'5N@F^P.DEYW&WW0R,5H$L>;.;\M M^=4GE X09)GGYL|#.(G/G1U.'|_B;R3Q7]#G2?LTTV$5L C?

TIWW7RT3H/9LXN#-A5@9O@9_8. M'RUWPDA1.Q:9 _"*8C;TC#,.Y8(F6;4E]YJO<1MI)>P(TL(OC6\]$/[D]KW"' M$Z*HGE%CNJ[:O=-@KR!3N@<3P=>O<"XB)PD(!.BSR(3Y5>IF?

1O@.?U!|(H0DVI9[5G M^2:FB;9<2 ; =!V@ER),>!^#>9G>9L05U(["<-*=!5R^#\DYK[5BVG]= M4CZP"OT6:;A(S)XKV1'\3+4#5=A$!Y1UT0YR14K)?!%$=Y#/0VK*C' S(8G!M

MRLDFYRO81L8>+Z<<6.E^*lGE1[%D>0-G=23+3Z.?[8|M[IT]*RG%7I>G0*FL M^MZ?D*WXQJHPLN[9Z!QMO!1 XQMA] .OM#J(C4 MIPZ7\V*R1 LST$?@YR|8(/755M\&OE6:2Z8-

+% 7X=,;;>]FUJ9=M+.,#K#8Q MX_"[F/CQ3#'D]=/R.|CJ6'2NR0/<*"T>@/02??&M--AB :%[4V4Z$\X{(A2N]4.E*/5!1IC+(<^WX'.&1[5=NL/"@-.M5WL-._X%EVH!/>#[+:.LJZ4E-

D/:OYKMEI1*CIA72?>"3*]TW%-$C69QW**$U M\>8).>PI!0F;1%@]#9O/41?K;]-"'[9{(=V'D?"]MZVZ(E_SZM18A*X41TYX%W@?TTZ1(C]3D@=,D O4*-/?

EFD=D|#Q+LT;GB9_1(PWA9 M:._EB^NG9(%(9)9NVNS3)O1L=]G..^\:T-N\L+D.S&UR[WV!B8GBTVG;@?0S) M7, .)1H>BX (E#O;C.U]BG1+,!NJ;CZL6@[%$=#;

<+!]O}GT^XNPP))#67T1K M#)\|_YFZ]4K$(PH'[$E]9KDR6)?)(?D["J5;Q$##@Y,$$P1]"%L : Q!86PO M>&=/[<**#39_)NN(9T2R_4MP<-0="'%I3FX2Y(U=MD ::@GL?A<^8Z/FS/4WT

MN X."=W'W%RA("B/ 7UC9%@&-'FI7W/VUVRK#5C=&J|/S5G.F?U+&/U.M^ZL M%@;G'%YO!'V'8P35-D+A8>MO[U-3$WDT&R&OE"*PUUO.0M^KF%S!?-Z<=='5H MJI7X(&>_A;[%

EKF?Z(@;3QR065\1>T PNV'+]>QQL,1X_ 9R'"U&PL M7,*79)47%|.QY$,B> HMG,5:67ZX#-G6B>XOY&GQ4@IVH&=IJ56@)02:4.Z M"O+65#33;$>TO2QKI:7Q:P"JE3

+,E0]LY(GJK0VMP,?@9R)L1@H>V6 *GD)-MD:?%ZIS83SCA)E/DS=M;0SN$A +5*'3"I]>,%R>.DA(0Y%|'$,@_?EM\#5 4 M;_ ".HZ-(FUH3.R2_HV9]DE-

R%0%PG:M|RA.U1.%E,U8GA(F'F+ [Q-MR)VUH .H<6Z$O,;*4%!!G<.B|2 MKE:;@/E^Y5QMHP7|=NV8W49=D%)W.Z\M(/VDO>GUYZP/QL] MBNA;3LX:G>VK,9Y9$S[P/8:$/D-

UDX[> / 0/=E)Y%2OOT[?XWW]/,51C$<= M\+41Z8]HY&OQ_D8^]/0FUCCN^>*62>:,%[6SPX#N^>7H.A59X1_MA1@U-(T#F MQC!W>]ML\9A_8]Q1+C$8C_>RR"O.7_S#)+_U*3!?2(

95W@'[HN\4*+V\,=- MF2Q)<'AM;JKA[3,)XZSQ6.G<|\M>_2INF"4/>8U=NH>[5]4T/>?)*CO87CRK MIV!"4L&!8(_E!.Q 3>VZ9\=GMEQ2J3\L#O12Z X=HBO&H!G9

MI3.H>4.D,'XNI@I\$-<.04,>J&AK%061TT9'S7\|,E8>+X MH%ZZ^RCSH)GR'A(M,U LZ1E9I"U,A"PJ51\,?*"U*1>K M3W'VM@P?'DDW17Q^ <5'B?1P@%I>NLLR4\G$BU?

$^#BJ!5;$ZZ'@<.DP ARU MT@Y*G>>R|8K37!&7O\$N(Q&IX$!D$Y,9"LJL_M6'0!$KL-E*#Y;)C[&MC94/ ML" '">@$7QFEN2E[%$1!5\&!!2O(]08')D_+B.^=/?6'R\\ZG/;[@!CS'RCP

M.E2BQ!Y@HA1Y3;*$V/"ZJ,)CS$?0!1XQ_> (<9X_E\(DZZ>*E3$'@C96:IP M!\VRD'.AWQCP!VL-H93;,8A'H6 +J8!@[]FN#H:J*3LVXYBQ]I7.HO*LJR+#. M

F4>Y+3HE%;,.@*P;H$6NN#6%">ZX\ ?R(DF^/U>E>E #H+:, WP&RJH\Z.# M@T50"\04Q', ^$\5STL%F8="(ZYPB.,:=(SBF2>A^F\'_>P61.>2E%5L*Z\2K6

R)&3HP3U.BI8B/I8+-6:,&OP<=M"H7 M"_,L$!24 FF\DN.9#<C>A3',)D=[-_Q]8&L'W2\[_*"5V. .>JLN=#MK M9G//|"94S0JZ|P3K4!X?,5BO(U;4|CI68A=&$6C4Y?

+F@ITBGPGKP7>4\.GYB5 MOC&C'YDE&S0[?&EV_-3D69D|*Y-G9?*L3)Z5R;.R>58FS\HWY%EA+[->$&K$ MI6MKS4Y!Vf3/W$P5R"X,E!6C;32T@^FM L/CN5F5\E^IOU\$:/DU7&[*-

'8" M;_F5$+" "M-H&3ZB7<+6VA(%K4V$ZF>@L:,$=!AQI*^NH0;EHR$5XF,6E3|_'MDLYU@Z-DKP_Z\)^!=D,HX&^*MX9$X,^<(*5O6IA;|X,-#Y[H;#T!^8EN#5C M5<4#<-?

B:54[T"ENT*.6 >#=BV#REF"@G@O:.0T4_F[D6\D"A;_;X 9Z@@'H\QWBW.?2E-343.'_V1:Z@(8R#'Q" MP3$H)U\'G@XB\|f0%3.Z+!,A$\#1RI_GIK?)Y[36M.,F7W"R.4_C)-R2(W11

MZH/N?.1_WM)YX0/8:3#H:AO*F/9@%3C,E>>Y^0#6FD%?V"U&H6\DXXP:,^3 M5WC9#!5Y7 !D\0.2YOEAU6;G71OF 8L"\.14FNT4-)(.);5K M01B

:M.2!9YRFEL&B$C8:OAP"#)B|>D$*X7;,1BPRPZN*BLB>9I-H>|VA$)5 M#T3B40JNN\[2& <$;W:N0L#Y_B3)?E;[+B4G,%LJ[<>R |PA()8#PO4)=&, MAKMU B?

[YB.*GK%+3KMKHA#H#X2:3J$?_"L#W<2QK/Z4V0/B^%K2*_S%ZCKP M\#/V4L?G>[TX3>U8-U*7%V?V)?,>D.DTH.!-XS M)A0V$58RTB <\6>A$WF+U04Q?

EPR8GR<^<7"T=0*19U[6!T!?=>%Z SU9SKG,:5 M'GNU!{#TI@ZBK(YW. ^'0[CXR3 ?J1,$0#54\NBD]#(CZ@+_VTE&&FP\F2M@" MKG=O<1!&9/^<9A#5,/D:(W*/(I2Q?HS/V: ,-

XGDS.KO8Z3!GXJ26[\U"G9#X!/L;ATRW'FR=7Y_G*0XAZG.RF<%R MPL%WW4]!A!P?_X\8Q'C4MX$*R!IQY)&E9D 3A4V<;?;OOW$781V178SP0; M([_+Z603R\@&!Z:EOO-

H=2]6GT/ZZ%QAF,?Y56A;O7S^_.G2>-!!*LJ0]F/8 M21L5PAER: ")].QRW;BK2%T7(3:>Q%\$1$5 MW;VS9UOB51B160J,@T9#Y4,WN"1S:&SA_;@YURT)_G$YPS]62;_^J9Y^G8\Z

MH_R.'<:=?24#$PXCVY,+-+:ER(, !5AY@<$G@!XN_4!//@<5%<$X# ^.$/@_%*.'# M6FL$[*:IOA^RGK=@]V+E_HDTRL6 ZK)EB\(\XN7P0/I_PL>C@E M'WM6##YS

F_&AI_EX\^R# _1\+H5C2!WG52/R K$'C-]%2A8.FK?08>T%/_9 M^3V!XC&F%(UKP*-WM?-Q^842[*O6$TI-#L+EID1N2F]D,R)$_BHZ@W!KFF,@<3AA:$S\F<4X?@L?,F7 M+]D_-

-9N!79F846H\/H OC2]!!5V*Q9B5.H/=D)C6+:!FOQ"9H+ ^(3-#L&/|^(S,VV*SXS&P51K/# MA[)?&K=%LZ\H6YGUYD U1<-@O431(@[);=.0C4]T38/1%XS3MS! Y;ZAO 577:%%R=5\L

MKPL:R?&2++\B_QG=DJ/51N!.[3ZB)0:OF@#TV<3 ^$^E>?DU[_N37=2 M8:YQZ.30)=\4'$PI#&6);3X\PF5.G13&|&$>B2#.1K+$9A\DD3.R12+P*? (XVC<+/(N

M7UPD#R3N.!Q8K-70PB'CF+ZD_)I)2H#6M.H:J*OP:..9+ [<#6"16:[PE5%MT MP8#QN$'TO815&6_8IEEJ.O&68OZ]W%P9O7/I7-\'/S$5

M+YRECK"_BAQAY6G,\GG,V$1FI9G,\[G,DG(&)\)-N;(OIS((ISR;)G)H>9XJHL M=B?517EL?T+..+3')X&;5 UYODL7J4YQEE"Z>B,P&--&4[@;6LBDX716T*6] M!CTEQ]4 W

.7@.K\OB!*$O+FS^2G:Y3Y6XM?4:8M.]75]C+2*?FONO+)]H O M'QO>21+X!;1SHEYU57/H%;51432!@\% +>Z+52S5?]&^7X+5DM-YZNN MED:WD[5A. PXZ>2/%;H>KKF MBX 3

^,-Y4&JUT*Z86FE;KI-F:]FO@VC!/_)/BGP#OT[\GX=/Y%'Y/_;C'YE M5OK,K/R=GCZ?WHOA8QAZ7[*OSX-&I:@CC?)4*T>""1]LO5"KE) MO @NG8@>P>(B35SRC*7Z"";4];_"ZO D(!?6:>

LP"5UZ#D)@.1/%XB^"')CO0 MHE5G3HSC3T'X%*/HF5)Y'>S2Y(&6.W*)4<*@*!,F+,Y!{MY'(MT ?"D8W!^ MF*D ?T&LS"#&S|E\A47?VYM")

fN:%OERF{Z(6:;B])RG,**M|Z5+5U)=^G"5 M?"5L$K]+HC<&=>&V,1'MQ%Y#4+/D&3(-;DU9(^#!/6$ M/T9AW*VF>=X3N(A$ER.#>KWK"G#;99#&F M/-

=6I\7*0NZ3[]9|2MAX4G'.RK(OA-=4LKZ0=M19B7h,H#K2_C:&S);&'NO,6ML".RT-U_H:V4R82=PL>/G-F/@%5?I&!W\"*5Z M[G67

O^N^>=WPI(+XF\TQZ#TZ5GQ[9F3S.C?9^SS,Y:=D$](@QF8 ?0M] M8,V15E'$7]UCT]K+BIN.=EDH"4"6I!)5Y$%R"3W@)RR|RQ"@+|[.Z,,#^%OK M(8AIG&C,R,V-;??>@Z|\W

X)V8]/-.:V8G52 M*D!0\GO8 2-?&(5X#/AV).]Z,W6Q=QYNMV' WM<2WV-R&D,?I&3R4KEP%!)L MZ&9QOHNPO_P.+C=A&A/C=?F5S'-/?O"(AQ&YV% 3M8)-?_OP@3%0A ZC@7]

MS(,.1KW890C"4]1+V'>4YR5$L?MPJHO-F-M9!+?#,5U&$5P"T9=M.<%RVI M!(GKQ%5G1G&0@*T%@@_WL%[H8Y!98>__B=&$;5]?X>.(<+8BGL X?Q,<-1 M0<*-DD\.&/;3Y/)

Y'/%'1L5 W(&?3K6R)*>EV M1X?^%"-/<-GZ7GC9>KP_/0XXHR-.EZ1VWKBWT-?3H:.)WQKO9F7+>1RAO9EN<%^!<$R7NJ,@:^VE[NE< M-UIQ)3Q=-PYP-V4#D--MXX"WC>^L"

*5X#;>-)?\AK!Y2D42#4HCH# M0%]&R&6LK#7U66.=DLQ4>DS8>Q]AE[\=T,=1CVZ+ 61Y2!WPJ_9 M$^QMH:&@XS'#.M3H<|(N?5T&15M=W-KZ0H>>]D:.SQ#KL&/R]3GT"7-IA5M=`M^#C=58\.QH[SO2$4\L4Z%!]P_/L5,=UE M7]MQ[D(]}JBZ2@Q#5.57.R^+J1H)HY4P\Q8'>)ORS3[2 MIM9$V4$\N-J||ZO!S59B0%3(K?,B96NUB2I;AS>YY&QM(P9\NZUZE0\Z4/5Z ML=3A%80PJL1K""\&_RS#E\7R1XQYO>_OIVT!.(Z"RW#N&X>JB+=[=]B6D% MWCQV6H8Z=;*H(IVUA?;-6X%NF6W@P(0- 6X@D$R!:B.@LP4H#W%]$X!JE.]@S+TPQ0M:+ T6N(-M3P?PK)F"3FSL|G>'C9SCFVZW3K1?K!9I$B=$L'"PIl,6I/;^U$CMS<:.@F;VE M469T&.A\7D:*QN,$O/;3(7AX_:=JO8YW3-P&^V6P5,.^'Y, MZ-N2]RAR*7O7RG")QX#>&GO@I\(?(Q3S[FRY$T9XF76FYI>]] M3M>EWTY_9U?&#D4X[!X3)THL\E!=QW&*O/L(!RI>.;[R/4"]&[3%TL?UW\X" M0YKOF/+H_2N-D\,$.)=FM(^X"[2)H<9Y.1U6ZL!{MFBQ>^_LZ3]5ET>C&[35 MT&-Y<%B@KP=_S?1@@-;T>LTB'?B_=@{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{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|*R-52P UHC:LX#/AO$5]78 M"5!XO=C39+D*HQ7"21H=Z39G3;9^##Y1QE)K4@#-MZUZ6Q@#'R'U9P*?;62K M^NT(ZLDK8,@:,.8T7N4TF75F]?UO9-8@3JN>;WS;)K-6W8CKR/5V,"9@X2;UE M-P@ZDGVB]URFV#;),N'09Q33Y1YX-'N9%DI=AI]9+C-,^#0>TK0QHCX#"W(+ M+95S710GH9>P"\::Z3LO"Y(Y3W:!C! 29,6RZ1$UHLU$7C")H!*837.T(,'6 MTOBAX27!#O=-#Y:4:*^:F@:%7?1-"W'*"+15>,5*#Z_F3R";^9ZAN4()=QS^P MHI1;_+>A4XMGWU>^.:.4:&XZ<[AI'28GYY%|'QI-_D.4>Q*&//7K]>1DDK(.,)}V5-.>W M/@7F"PPPDV/:@?O<'%;.["W)914R5PD'HR^=2(#(=EZJ59U@S\VN)"U;&X(E M&4DXV6"[@$SP(\<))]NKJ/S6C/GW4\;\E#$_9*

*WMP71#@U5-K2 E M$]SR&S:_S-R%9/T[T'4SN/X2H_E[K&!'[9EKE4V]|F;X&>Z,/C%(7\5 M>7"/8^;^6C;JK!AVJ@@YDFZ8*D).%2&GBI"G7S%P"$[!5X3,R"0?$'NI:LV^ M#81K1(,7A>Q.Y9&2P%-UE)GYFAV2TRKU@V4ZB>B'?O6\)9EE^"G 2/SQ^DKU] M+ND&[= SN3(:3W,I,!#\|'K"=P\0A7ZG:XOIVF%ZMGA5Uq;&@N#MO;88]2R9 M471\\B=FCS7T&T$?)$Q3K=A!?=YVZ@9AEY5:@/<5O MM6\W&+PBK>"O @@[&I0,HG76_UY?"BG/4'$+UK_TLH-06]^WYZ9Z5$%X!5O M!?9=$VC4W/N&BE5WX> (@'DXKRBI9XBRV\Z9 8\&\]PH+7(S'8T%H"*UU#@Z?> M-,K\T()308SX.0Z_O!56]6&C,BAFY6%G^,A3DL-(.G,J13/5HC&AY2VK1.,| MP'5 M" ZSHU^A/),&*]['1"D CI (^KY\Q.%!(IZ68'/ IBIX:5V?C\-[\. M:-KC,PI2)(P1;&T)':FB)$'E$$$!O?G?>23Z=9DY[MUHM_)YA>L<_-)EB4@ M[PE]>Z %E#)5E@##W$07D .&3B?"F-)(W%##M)06ZY[- V'4P:&>&/,&Q'YL,I9V2_VQI%%)Y M*I])P'I#]..)D+/A%##E07GH"?G29/N<13#E>M8/*43Y[RR5,.^>BN['RL%.P M[U31?*IH/E4TGRJ:3Q7-IXKF4T7SCH@JFA^@A7-2T^=2[VNS:;0_O 1*Y=$ M&05^[*O55-.'V'R^W.# _<(-M/-+H&;NH704+XY=_3^^]I,/DG2HZQV?R59?"3T#Y04P49C*/T M>N4P*!|U%4;YCVB[=P#"R9D'M%H[/9$5 MHBQU!7 (=*)G&>15,NDHN\3$._MUF>^X_[^)G8WI&M,&[,9W(8>\N=QG&ZS'H+;@@^BVP(Z@UDVA4-BS2R?Q2R? MQHS-8U:9R.PPDQF.RJPTE^F"8;I@F"X8I@N&Z8+AFH@F-P;4U+4M^3>F-[6 MF][6&\F%_@K?UFN4"VAM=T[U"7LX+I4.&S2HB3K\ERC:"L[L)K_Y6CU*YG&R M0Q2[!YXN?0)\/X9/$].(F)&K4Z'X?>0.PK0*L/W>L2TP<<_WX5(70=)(@(M0S*BD+9 >GH|KB]LKTM B)5X@9^QAP(/0(M6/PUM_IV&@(I@@_>YM]>HRAW5 M=TZ4I?.U^<[_:OC/>=6G"K_W[##>Y &?/,"3!WSR@$\>\,D#/GG)P_XY &? M/,'OV0-N[7(§_" OU%2TCWD7T>]0_Y!;/(@#GWLT3<<+VE&.D8Q9Z,@S?FM M[=!!QC8,(>UF(L,[,?=.#C3MV0#$3)7"0>CV4T2(.X9;53*G&#/56FD96M# ML$?-)9QLL%U`)KB?;THBU4TB';; (S91$.B61OOH.1&,U^UY+|B+'|#^$T=,O MWJ>1NR%D2,U^.2_5@Q?0,.R> M13$YLA"W8<"4W;FSPXGCLP48T^]8T3.B:5-7;9)&Z#].4R=P!9=C'89ZK<%R MG;D*+@^=69(!:)_K^'C^[&"?ZFQ"*4L<,W O)OTBM+/8OD@-19\.5PKS9.5% MFL2)$W@X6&F$#9=6$Y>X-CR(=M[EFO\.0IC$Y$ HHJ-86GZT Q< M. ,.T1+.T&#/6$.,T0@ZM-9O}^06QFS-O3JAUUNCR!44N)F?A"(NL0.!I@3GV M;5|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|'W1 L!*.BK18[6O+ M50;)5%W*W+7R N3UA@ZIL;|^Q/RP%#OZP15NT<%/=KW="6]<|$:!#@SM#Z:8 M/^"@'J99G3T?/VX'Z!!+';@D5(.CPKE1SH(ZR]*E';K1-@1T-*(.44F MZT%J,_M<6|<6W: #_@90]E4.#(SQN&$8!?BS>>"5_E7$'WZAL11!$]M$:/Q2 MC]# (QLO#,\AAKOJ#XA.5XAM3!$?'HDJNFVY3GUK>BV2#(AI>%*$-"F+ "P75&=(;VT)%N@AT-]!OC(>52"X&'VCP M' .\ZMO3KTX>F2H^9&!$5=HM*_U4;P-^?-L2CSLMBJA#U%&]Q@+?15L3.6A,P M[V2=70UFMM("$JOQZ{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|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|''@=H(.@M;BOX1THWP_ZL.Y)VA@XQU<%!EA-MVN@R$'@$IAI0W7ED=A%U45[\3N!1B5JKQC#CAW\ZA7O? WRS05^T [.F7.EED M3Z,.>Z4_/#'JE;"$O:#[KTQ$E>Z.KT0.!H3'Z HSF,\YZX;ID'R*S M"$'.L8A\|.4:H"_;=:'7Y(RQNMZ +G!Y?NL<8T=?\ MOL4BV,.2CWL&UN+756+:.:"YWS0.16^$1-*\F[\WM!.S7X@BGER MTH=-6M(G=UL1^8P)F5&>;Y,9A8N@5(U/8'7I#0->"$';^NK")@M6MKR4WCSP MLA\@\DM>'DC+X4%G(/!?>9]3DC[C3EHA<%\MK&U?@@<'7-(8]]OK2H8V>TY- M&-K7 ??23U=S" 8"+PLPC.J0LLJ0C[+D$|_.CM+7!H4]P-/LM=R1"L0;8OLA M3Z3=? N3[,2I))I+.X$GN6F#HL<3",L_'Q7RH;'JH2=2U"'#/,<$?KM&2@$$8 M:&%6;"DJK)H#*EO?S?;@+]QT6](\PL$3EHYYJK1^BA/AF%9).7-B[!+INDI] M?W^!_93(19['6OCF^ 4I_OLE*)Z_.5]%_O0C.Q_.;I6?ZM8RK^=R.?0^Z M&.6E$P5DFSS0+!SXO<._U%7F&$HM#X;!8 C4F0.;UJ5->1.V&O\;;IBHHG\.M$.^7=-HIEW;)B:(.P >5]L$?2G'S8ETX1GL6Q\B+ <9%T@IYM445*A1:CQ\EZ-M!7>>W:RB'GBGSH&_ 1T/HX.M$?.",_VK&\6(N*')6J- !U1HJ/&.[#&D#)7%S<. M1CH#0$?.Z$"DSQAP"?L%T6==D3"5,0HP:*)EI#JD[ZCKE.6"Z Z MHH<.X&$]/3&M43XPJE >_'F0D$,9H0P_(,'N!T{(T?ORQ?53,AB|;J?.|S3) M2Z&7!EV=-WS'_GN18[_\|=GQ\|/B^S,*X]PT]J\|</<7DYC_<-1T%DPZH1(M2J$-_1T[:HQH:IBAF0!? =]TG'3?R*FW#?<$.D3&SX.KO\PS&M&&+QP&(V-F^ M?0!QK2FC'Y'$<1@^#EIS;SC1O'.V2%8V2|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end XML 91 form10-q_htm.xml IDEA: XBRL DOCUMENT 0001624326 2024-01-01 2024-09-30 0001624326 PAVM:CommonStock0.001ParValuePerShareMember 2024-01-01 2024-09-30 0001624326 PAVM:SeriesZWarrantsEachToPurchase115thOfOneShareOfCommonStockMember 2024-01-01 2024-09-30 0001624326 2024-11-11 0001624326 2023-12-31 0001624326 PAVM:SeriesBConvertiblePreferredStockMember 2024-09-30 0001624326 PAVM:SeriesBConvertiblePreferredStockMember 2023-12-31 0001624326 2024-07-01 2024-09-30 0001624326 2023-07-01 2023-09-30 0001624326 2023-01-01 2023-09-30 0001624326 PAVM:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-06-30 0001624326 us-gaap:CommonStockMember 2024-06-30 0001624326 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001624326 us-gaap:RetainedEarningsMember 2024-06-30 0001624326 us-gaap:TreasuryStockCommonMember 2024-06-30 0001624326 us-gaap:NoncontrollingInterestMember 2024-06-30 0001624326 2024-06-30 0001624326 PAVM:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0001624326 us-gaap:CommonStockMember 2023-12-31 0001624326 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001624326 us-gaap:RetainedEarningsMember 2023-12-31 0001624326 us-gaap:TreasuryStockCommonMember 2023-12-31 0001624326 us-gaap:NoncontrollingInterestMember 2023-12-31 0001624326 PAVM:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-06-30 0001624326 us-gaap:CommonStockMember 2023-06-30 0001624326 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001624326 us-gaap:RetainedEarningsMember 2023-06-30 0001624326 us-gaap:TreasuryStockCommonMember 2023-06-30 0001624326 us-gaap:NoncontrollingInterestMember 2023-06-30 0001624326 2023-06-30 0001624326 PAVM:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001624326 us-gaap:CommonStockMember 2022-12-31 0001624326 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001624326 us-gaap:RetainedEarningsMember 2022-12-31 0001624326 us-gaap:TreasuryStockCommonMember 2022-12-31 0001624326 us-gaap:NoncontrollingInterestMember 2022-12-31 0001624326 2022-12-31 0001624326 PAVM:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-07-01 2024-09-30 0001624326 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001624326 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001624326 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001624326 us-gaap:TreasuryStockCommonMember 2024-07-01 2024-09-30 0001624326 us-gaap:NoncontrollingInterestMember 2024-07-01 2024-09-30 0001624326 PAVM:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-01-01 2024-09-30 0001624326 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001624326 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-09-30 0001624326 us-gaap:RetainedEarningsMember 2024-01-01 2024-09-30 0001624326 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-09-30 0001624326 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-09-30 0001624326 PAVM:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-07-01 2023-09-30 0001624326 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001624326 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001624326 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001624326 us-gaap:TreasuryStockCommonMember 2023-07-01 2023-09-30 0001624326 us-gaap:NoncontrollingInterestMember 2023-07-01 2023-09-30 0001624326 PAVM:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-09-30 0001624326 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001624326 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0001624326 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001624326 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-09-30 0001624326 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-09-30 0001624326 PAVM:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-09-30 0001624326 us-gaap:CommonStockMember 2024-09-30 0001624326 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001624326 us-gaap:RetainedEarningsMember 2024-09-30 0001624326 us-gaap:TreasuryStockCommonMember 2024-09-30 0001624326 us-gaap:NoncontrollingInterestMember 2024-09-30 0001624326 PAVM:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-09-30 0001624326 2023-09-30 0001624326 us-gaap:CommonStockMember 2023-09-30 0001624326 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001624326 us-gaap:RetainedEarningsMember 2023-09-30 0001624326 us-gaap:TreasuryStockCommonMember 2023-09-30 0001624326 us-gaap:NoncontrollingInterestMember 2023-09-30 0001624326 2023-09-30 0001624326 us-gaap:LetterOfCreditMember 2024-09-30 0001624326 us-gaap:LetterOfCreditMember 2023-12-31 0001624326 PAVM:LucidDiagnosticsIncMember srt:MinimumMember 2024-09-30 0001624326 PAVM:LucidDiagnosticsIncMember srt:MaximumMember 2024-09-30 0001624326 PAVM:LucidDiagnosticsIncMember srt:MaximumMember 2024-09-10 0001624326 PAVM:LucidDiagnosticsIncMember 2024-09-10 2024-09-10 0001624326 PAVM:LucidDiagnosticsIncMember 2024-07-01 2024-09-30 0001624326 PAVM:LucidDiagnosticsIncMember 2024-01-01 2024-09-30 0001624326 PAVM:LucidDiagnosticsIncMember 2024-09-10 0001624326 PAVM:LucidDiagnosticsIncMember 2024-09-30 0001624326 PAVM:LucidDiagnosticsIncMember us-gaap:CommonStockMember 2024-09-10 0001624326 PAVM:LucidDiagnosticsIncMember us-gaap:CommonStockMember 2024-09-30 0001624326 PAVM:LucidDiagnosticsIncMember us-gaap:CommonStockMember 2024-09-10 0001624326 PAVM:LucidDiagnosticsIncMember us-gaap:CommonStockMember 2024-09-30 0001624326 PAVM:LucidDiagnosticsIncMember srt:BoardOfDirectorsChairmanMember PAVM:ManagementServicesAgreementMember 2024-01-01 2024-09-30 0001624326 PAVM:LucidDiagnosticsIncMember srt:BoardOfDirectorsChairmanMember PAVM:ManagementServicesAgreementMember 2024-07-01 2024-09-30 0001624326 PAVM:LucidDiagnosticsIncMember srt:BoardOfDirectorsChairmanMember PAVM:ManagementServicesAgreementMember 2024-09-11 2024-09-30 0001624326 us-gaap:IntellectualPropertyMember 2024-09-27 2024-09-27 0001624326 PAVM:LucidDiagnosticsIncMember PAVM:JulyOneTwoThousandTwentyFourToSeptemberTenTwoThousandTwentyFourMember 2024-07-01 2024-09-30 0001624326 PAVM:LucidDiagnosticsIncMember PAVM:SeptemberElevenTwoThousandTwentyFourToSeptemberThirtyTwoThousandTwentyFourMember 2024-07-01 2024-09-30 0001624326 PAVM:LucidDiagnosticsIncMember PAVM:JanuaryOneTwoThousandTwentyFourToSeptemberTenTwoThousandTwentyFourMember 2024-01-01 2024-09-30 0001624326 PAVM:LucidDiagnosticsIncMember PAVM:SeptemberElevenTwoThousandTwentyFourToSeptemberThirtyTwoThousandTwentyFourMember 2024-01-01 2024-09-*

30 0001624326 PAVM:DefensiveAssetMember 2024-09-30 0001624326 PAVM:DefensiveAssetMember 2023-12-31 0001624326 PAVM:LaboratoryInformationManagementSoftwareMember 2024-09-30 0001624326 PAVM:LaboratoryInformationManagementSoftwareMember 2023-12-31 0001624326 PAVM:OtherInfiniteLivedIntangibleAssetMember 2024-09-30 0001624326 PAVM:OtherInfiniteLivedIntangibleAssetMember 2023-12-31 0001624326 PAVM:LucidCommonStockMember us-gaap:FairValueInputsLevel1Member 2024-09-30 0001624326 PAVM:LucidCommonStockMember us-gaap:FairValueInputsLevel2Member 2024-09-30 0001624326 PAVM:LucidCommonStockMember us-gaap:FairValueInputsLevel3Member 2024-09-30 0001624326 PAVM:LucidCommonStockMember 2024-09-30 0001624326 us-gaap:FairValueInputsLevel1Member 2024-09-30 0001624326 us-gaap:FairValueInputsLevel2Member 2024-09-30 0001624326 us-gaap:FairValueInputsLevel3Member 2024-09-30 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember us-gaap:FairValueInputsLevel1Member 2024-09-30 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember us-gaap:FairValueInputsLevel2Member 2024-09-30 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember us-gaap:FairValueInputsLevel3Member 2024-09-30 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2024-09-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:FairValueInputsLevel1Member 2024-09-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:FairValueInputsLevel2Member 2024-09-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:FairValueInputsLevel3Member 2024-09-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2024-09-30 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2023-12-31 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2023-12-31 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-12-31 0001624326 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001624326 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001624326 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2022-04-04 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2022-09-08 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-03-21 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember PAVM:MeasurementInputRequiredRateOfReturnMember 2024-09-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember PAVM:MeasurementInputRequiredRateOfReturnMember 2024-09-30 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember us-gaap:MeasurementInputConversionPriceMember 2024-09-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:MeasurementInputConversionPriceMember 2024-09-30 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember us-gaap:MeasurementInputSharePriceMember 2024-09-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:MeasurementInputSharePriceMember 2024-09-30 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember us-gaap:MeasurementInputExpectedTermMember 2024-01-01 2024-09-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:MeasurementInputExpectedTermMember 2024-01-01 2024-09-30 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember us-gaap:MeasurementInputPriceVolatilityMember 2024-09-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:MeasurementInputPriceVolatilityMember 2024-09-30 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-09-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-09-30 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-09-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-09-30 0001624326 srt:MinimumMember PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember PAVM:MeasurementInputRequiredRateOfReturnMember 2023-12-31 0001624326 srt:MaximumMember PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember PAVM:MeasurementInputRequiredRateOfReturnMember 2023-12-31 0001624326 srt:MinimumMember PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember PAVM:MeasurementInputRequiredRateOfReturnMember 2023-12-31 0001624326 srt:MaximumMember PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember PAVM:MeasurementInputRequiredRateOfReturnMember 2023-12-31 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember PAVM:MeasurementInputRequiredRateOfReturnMember 2023-12-31 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember us-gaap:MeasurementInputConversionPriceMember 2023-12-31 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:MeasurementInputConversionPriceMember 2023-12-31 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember us-gaap:MeasurementInputConversionPriceMember 2023-12-31 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember us-gaap:MeasurementInputSharePriceMember 2023-12-31 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:MeasurementInputSharePriceMember 2023-12-31 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember us-gaap:MeasurementInputSharePriceMember 2023-12-31 0001624326 srt:MinimumMember PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember us-gaap:MeasurementInputExpectedTermMember 2023-01-01 2023-12-31 0001624326 srt:MaximumMember PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember us-gaap:MeasurementInputExpectedTermMember 2023-01-01 2023-12-31 0001624326 srt:MinimumMember PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:MeasurementInputExpectedTermMember 2023-01-01 2023-12-31 0001624326 srt:MaximumMember PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:MeasurementInputExpectedTermMember 2023-01-01 2023-12-31 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember us-gaap:MeasurementInputExpectedTermMember 2023-01-01 2023-12-31 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001624326 srt:MinimumMember PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001624326 srt:MaximumMember PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001624326 srt:MinimumMember PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001624326 srt:MaximumMember PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember us-gaap:MeasurementInputExpectedDividendRateMember 2023-12-31 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:MeasurementInputExpectedDividendRateMember 2023-12-31 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember us-gaap:MeasurementInputExpectedDividendRateMember 2023-12-31 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2024-01-01 2024-09-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2024-01-01 2024-09-30 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2023-01-01 2023-12-31 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2023-01-01 2023-12-31 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-01-01 2023-12-31 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2024-06-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2024-06-30 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2024-06-30 0001624326 PAVM:OtherIncomeExpenseMember 2024-06-30 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2024-07-01 2024-09-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2024-07-01 2024-09-30 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2024-07-01 2024-09-30 0001624326 PAVM:OtherIncomeExpenseMember 2024-07-01 2024-09-30 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2024-09-30 0001624326 PAVM:OtherIncomeExpenseMember 2024-09-30 0001624326 PAVM:OtherIncomeExpenseMember 2023-12-31 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2024-01-01 2024-09-30 0001624326 PAVM:OtherIncomeExpenseMember 2024-01-01 2024-09-30 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2023-06-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2023-06-30 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-06-30 0001624326 PAVM:OtherIncomeExpenseMember 2023-06-30 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2023-07-01 2023-09-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2023-07-01 2023-09-30 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-07-01 2023-09-30 0001624326 PAVM:OtherIncomeExpenseMember 2023-07-01 2023-09-30 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2023-09-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2023-09-30 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-09-30 0001624326 PAVM:OtherIncomeExpenseMember 2023-09-30 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2022-12-31 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2022-12-31 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2022-12-31 0001624326 PAVM:OtherIncomeExpenseMember 2022-12-31 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2023-01-01 2023-09-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2023-01-01 2023-09-30 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-01-01 2023-09-30 0001624326 PAVM:OtherIncomeExpenseMember 2023-01-01 2023-09-30 0001624326 PAVM:AccreditedInstitutionalInvestorMember PAVM:SecuritiesPurchaseAgreementMember 2022-03-31 0001624326 PAVM:AccreditedInstitutionalInvestorMember PAVM:InitialIssuanceMember PAVM:SecuritiesPurchaseAgreementMember 2022-03-31 0001624326 PAVM:AccreditedInstitutionalInvestorMember PAVM:AdditionalIssuanceMember PAVM:SecuritiesPurchaseAgreementMember 2022-03-31 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2022-04-02 2022-04-04 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2022-09-07 2022-09-08 0001624326 PAVM:AprilAndSeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2024-09-30 0001624326 PAVM:JuneThirtyTwentyTwentyFourThroughSeptemberThreeTwentyTwentyFourMember PAVM:AprilAndSeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2024-09-30 0001624326 PAVM:AprilAndSeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2024-01-01 2024-09-30 0001624326 us-gaap:CashMember 2024-09-30 0001624326 us-gaap:InvestorMember PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2024-07-01 2024-09-30 0001624326 us-gaap:InvestorMember PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2024-01-01 2024-09-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:InterestRateFloorMember 2024-07-01 2024-09-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:InterestRateFloorMember 2024-01-01 2024-09-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:InterestRateFloorMember 2024-09-30 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2024-01-01 2024-09-10 0001624326 us-gaap:InvestorMember PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2024-01-01 2024-09-10 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2024-07-01 2024-09-10 0001624326 PAVM:TwoThousandAndFourteenEquityPlanMember 2024-09-30 0001624326 PAVM:TwoThousandAndFourteenEquityPlanMember 2024-01-31 0001624326 srt:ParentCompanyMember PAVM:TwoThousandAndFourteenEquityPlanMember 2024-02-22 2024-02-22 0001624326 srt:ParentCompanyMember us-gaap:RestrictedStockMember PAVM:TwoThousandAndFourteenEquityPlanMember 2024-02-22 2024-02-22 0001624326 PAVM:TwoThousandEighteenEquityPlanMember PAVM:LucidDiagnosticsIncMember 2024-02-22 2024-02-22 0001624326 us-gaap:RestrictedStockMember PAVM:TwoThousandEighteenEquityPlanMember PAVM:LucidDiagnosticsIncMember 2024-05-01 2024-05-31 0001624326 PAVM:TwoThousandAndFourteenEquityPlanMember 2024-01-01 2024-09-30 0001624326 PAVM:TwoThousandAndFourteenEquityPlanMember 2023-01-01

2023-09-30 0001624326 PAVM:TwoThousandEighteenEquityPlanMember 2024-01-01 2024-09-30 0001624326 PAVM:TwoThousandEighteenEquityPlanMember 2023-01-01 2023-09-30 0001624326 PAVM:EmployeeStockPurchasePlanMember 2024-01-01 2024-03-31 0001624326 PAVM:EmployeeStockPurchasePlanMember 2023-01-01 2023-03-31 0001624326 PAVM:EmployeeStockPurchasePlanMember 2023-01-01 2023-09-30 0001624326 PAVM:EmployeeStockPurchasePlanMember 2024-09-30 0001624326 PAVM:EmployeeStockPurchasePlanMember 2024-01-01 2024-01-31 0001624326 PAVM:EmployeeStockPurchasePlanMember PAVM:LucidDiagnosticsIncMember 2024-01-01 2024-03-31 0001624326 PAVM:EmployeeStockPurchasePlanMember PAVM:LucidDiagnosticsIncMember 2023-01-01 2023-03-31 0001624326 PAVM:EmployeeStockPurchasePlanMember PAVM:LucidDiagnosticsIncMember 2023-01-01 2023-09-30 0001624326 PAVM:TwoThousandAndFourteenEquityPlanMember 2023-12-31 0001624326 PAVM:TwoThousandAndFourteenEquityPlanMember 2023-01-01 2023-12-31 0001624326 PAVM:TwoThousandEighteenEquityPlanMember 2023-12-31 0001624326 PAVM:TwoThousandEighteenEquityPlanMember 2023-01-01 2023-12-31 0001624326 PAVM:TwoThousandEighteenEquityPlanMember 2024-09-30 0001624326 srt:ParentCompanyMember PAVM:TwoThousandAndFourteenEquityPlanMember 2024-01-01 2024-09-30 0001624326 srt:ParentCompanyMember PAVM:TwoThousandAndFourteenEquityPlanMember 2023-01-01 2023-12-31 0001624326 PAVM:TwoThousandEighteenEquityPlanMember PAVM:LucidDiagnosticsIncMember 2024-09-10 2024-09-10 0001624326 PAVM:TwoThousandEighteenEquityPlanMember PAVM:LucidDiagnosticsIncMember 2023-01-01 2023-12-31 0001624326 us-gaap:RestrictedStockUnitsRSUMember PAVM:TwoThousandAndFourteenEquityPlanMember 2023-12-31 0001624326 us-gaap:RestrictedStockUnitsRSUMember PAVM:TwoThousandAndFourteenEquityPlanMember 2024-01-01 2024-09-30 0001624326 us-gaap:RestrictedStockUnitsRSUMember PAVM:TwoThousandAndFourteenEquityPlanMember 2024-09-30 0001624326 us-gaap:RestrictedStockUnitsRSUMember PAVM:TwoThousandEighteenEquityPlanMember 2023-12-31 0001624326 us-gaap:RestrictedStockUnitsRSUMember PAVM:TwoThousandEighteenEquityPlanMember 2024-01-01 2024-09-30 0001624326 us-gaap:RestrictedStockUnitsRSUMember PAVM:TwoThousandEighteenEquityPlanMember 2024-09-30 0001624326 PAVM:CostOfRevenueMember 2024-07-01 2024-09-30 0001624326 PAVM:CostOfRevenueMember 2023-07-01 2023-09-30 0001624326 PAVM:CostOfRevenueMember 2024-01-01 2024-09-30 0001624326 PAVM:CostOfRevenueMember 2023-01-01 2023-09-30 0001624326 us-gaap:SellingAndMarketingExpenseMember 2024-07-01 2024-09-30 0001624326 us-gaap:SellingAndMarketingExpenseMember 2023-07-01 2023-09-30 0001624326 us-gaap:SellingAndMarketingExpenseMember 2024-01-01 2024-09-30 0001624326 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-09-30 0001624326 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-01 2024-09-30 0001624326 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-01 2023-09-30 0001624326 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-09-30 0001624326 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-09-30 0001624326 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0001624326 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001624326 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0001624326 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001624326 PAVM:CostOfRevenueMember PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember 2024-07-01 2024-09-30 0001624326 PAVM:CostOfRevenueMember PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember 2023-07-01 2023-09-30 0001624326 PAVM:CostOfRevenueMember PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember 2024-01-01 2024-09-30 0001624326 PAVM:CostOfRevenueMember PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember 2023-01-01 2023-09-30 0001624326 us-gaap:SellingAndMarketingExpenseMember PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember 2024-07-01 2024-09-30 0001624326 us-gaap:SellingAndMarketingExpenseMember PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember 2023-07-01 2023-09-30 0001624326 us-gaap:SellingAndMarketingExpenseMember PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember 2024-01-01 2024-09-30 0001624326 us-gaap:SellingAndMarketingExpenseMember PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember 2023-01-01 2023-09-30 0001624326 us-gaap:GeneralAndAdministrativeExpenseMember PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember 2024-07-01 2024-09-30 0001624326 us-gaap:GeneralAndAdministrativeExpenseMember PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember 2023-07-01 2023-09-30 0001624326 us-gaap:GeneralAndAdministrativeExpenseMember PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember 2024-01-01 2024-09-30 0001624326 us-gaap:GeneralAndAdministrativeExpenseMember PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember 2023-01-01 2023-09-30 0001624326 us-gaap:ResearchAndDevelopmentExpenseMember PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember 2024-07-01 2024-09-30 0001624326 us-gaap:ResearchAndDevelopmentExpenseMember PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember 2023-07-01 2023-09-30 0001624326 us-gaap:ResearchAndDevelopmentExpenseMember PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember 2024-01-01 2024-09-30 0001624326 us-gaap:ResearchAndDevelopmentExpenseMember PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember 2023-01-01 2023-09-30 0001624326 PAVM:CostOfRevenueMember PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember 2024-07-01 2024-09-30 0001624326 PAVM:CostOfRevenueMember PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember 2023-07-01 2023-09-30 0001624326 PAVM:CostOfRevenueMember PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember 2024-01-01 2024-09-30 0001624326 PAVM:CostOfRevenueMember PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember 2023-01-01 2023-09-30 0001624326 us-gaap:SellingAndMarketingExpenseMember PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember 2024-07-01 2024-09-30 0001624326 us-gaap:SellingAndMarketingExpenseMember PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember 2023-07-01 2023-09-30 0001624326 us-gaap:SellingAndMarketingExpenseMember PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember 2024-01-01 2024-09-30 0001624326 us-gaap:SellingAndMarketingExpenseMember PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember 2023-01-01 2023-09-30 0001624326 us-gaap:GeneralAndAdministrativeExpenseMember PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember 2024-07-01 2024-09-30 0001624326 us-gaap:GeneralAndAdministrativeExpenseMember PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember 2023-07-01 2023-09-30 0001624326 us-gaap:GeneralAndAdministrativeExpenseMember PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember 2024-01-01 2024-09-30 0001624326 us-gaap:GeneralAndAdministrativeExpenseMember PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember 2023-01-01 2023-09-30 0001624326 us-gaap:ResearchAndDevelopmentExpenseMember PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember 2024-07-01 2024-09-30 0001624326 us-gaap:ResearchAndDevelopmentExpenseMember PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember 2023-07-01 2023-09-30 0001624326 us-gaap:ResearchAndDevelopmentExpenseMember PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember 2024-01-01 2024-09-30 0001624326 us-gaap:ResearchAndDevelopmentExpenseMember PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember 2023-01-01 2023-09-30 0001624326 PAVM:LucidDiagnosticsIncMember 2024-07-01 2024-09-30 0001624326 PAVM:LucidDiagnosticsIncMember 2023-07-01 2023-09-30 0001624326 PAVM:LucidDiagnosticsIncMember 2024-01-01 2024-09-30 0001624326 PAVM:LucidDiagnosticsIncMember 2023-01-01 2023-09-30 0001624326 us-gaap:StockOptionMember PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember 2024-09-30 0001624326 us-gaap:StockOptionMember PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember 2024-01-01 2024-09-30 0001624326 us-gaap:RestrictedStockMember PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember 2024-09-30 0001624326 us-gaap:RestrictedStockMember PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember 2024-01-01 2024-09-30 0001624326 PAVM:SeriesBConvertiblePreferredStockMember 2024-01-01 2024-09-30 0001624326 PAVM:SeriesBConvertiblePreferredStockMember 2024-07-01 2024-09-30 0001624326 PAVM:SeriesBConvertiblePreferredStockMember 2023-07-01 2023-09-30 0001624326 PAVM:SeriesBConvertiblePreferredStockMember 2023-01-01 2023-09-30 0001624326 PAVM:BoardOfDirectorsMember PAVM:SeriesBConvertiblePreferredStockMember 2023-01-01 2023-12-31 0001624326 PAVM:BoardOfDirectorsMember PAVM:SeriesBConvertiblePreferredStockMember 2024-01-01 2024-03-31 0001624326 PAVM:BoardOfDirectorsMember PAVM:SeriesBConvertiblePreferredStockMember 2024-01-01 2024-06-30 0001624326 PAVM:BoardOfDirectorsMember PAVM:SeriesBConvertiblePreferredStockMember 2024-01-01 2024-09-30 0001624326 PAVM:BoardOfDirectorsMember PAVM:SeriesBConvertiblePreferredStockMember 2022-01-01 2022-12-31 0001624326 PAVM:BoardOfDirectorsMember PAVM:SeriesBConvertiblePreferredStockMember 2023-01-01 2023-03-31 0001624326 PAVM:BoardOfDirectorsMember PAVM:SeriesBConvertiblePreferredStockMember 2023-01-01 2023-06-30 0001624326 PAVM:BoardOfDirectorsMember PAVM:SeriesBConvertiblePreferredStockMember 2023-01-01 2023-09-30 0001624326 PAVM:SeriesBConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2024-11-01 2024-11-30 0001624326 srt:MinimumMember 2023-02-01 2023-02-28 0001624326 srt:MaximumMember 2023-02-01 2023-02-28 0001624326 srt:MaximumMember 2023-02-28 0001624326 srt:MinimumMember 2023-02-28 0001624326 2023-11-28 2023-11-28 0001624326 2023-12-07 2023-12-07 0001624326 2024-03-07 2024-03-07 0001624326 PAVM:EmployeeStockPurchasePlanMember 2024-01-01 2024-09-30 0001624326 PAVM:VendorsMember 2024-01-01 2024-09-30 0001624326 PAVM:LucidDiagnosticsIncMember 2024-02-14 2024-02-15 0001624326 PAVM:LucidDiagnosticsIncMember 2024-01-14 2024-01-15 0001624326 us-gaap:CommonStockMember PAVM:LucidDiagnosticsIncMember 2024-01-14 2024-01-15 0001624326 2024-02-14 2024-02-15 0001624326 2024-02-15 0001624326 PAVM:SeriesZWarrantsMember 2024-09-30 0001624326 PAVM:SeriesZWarrantsMember 2023-12-31 0001624326 srt:MinimumMember PAVM:SeriesZWarrantsMember 2024-09-30 0001624326 srt:MinimumMember PAVM:SeriesZWarrantsMember 2023-12-31 0001624326 PAVM:LucidDiagnosticsIncMember 2024-09-30 0001624326 PAVM:LucidDiagnosticsIncMember 2024-09-10 2024-09-10 0001624326 PAVM:LucidDiagnosticsIncMember 2024-01-26 2024-01-26 0001624326 PAVM:SeriesAConvertiblePreferredStockMember 2023-03-05 2023-03-07 0001624326 PAVM:SeriesAConvertiblePreferredStockMember 2023-03-07 0001624326 PAVM:SeriesAOnePreferredStockMember 2024-03-12 2024-03-13 0001624326 PAVM:SeriesBConvertiblePreferredStockMember 2024-03-12 2024-03-13 0001624326 PAVM:SeriesBConvertiblePreferredStockMember 2024-03-13 0001624326 PAVM:LucidSeriesAAndLucidSeriesAOnePreferredStockMember 2024-03-12 2024-03-13 0001624326 PAVM:SeriesBOnePreferredStockMember 2024-05-06 2024-05-06 0001624326 PAVM:SeriesBOnePreferredStockMember 2024-05-06 0001624326 2024-03-13 2024-03-13 0001624326 PAVM:StockOptionsMember 2024-01-01 2024-09-30 0001624326 PAVM:StockOptionsMember 2023-01-01 2023-09-30 0001624326 us-gaap:RestrictedStockMember 2024-01-01 2024-09-30 0001624326 us-gaap:RestrictedStockMember 2023-01-01 2023-09-30 0001624326 PAVM:SeriesZWarrantsMember 2024-01-01 2024-09-30 0001624326 PAVM:SeriesZWarrantsMember 2023-01-01 2023-09-30 0001624326 PAVM:SeriesBConvertiblePreferredStockMember 2024-01-01 2024-09-30 0001624326 PAVM:SeriesBConvertiblePreferredStockMember 2023-01-01 2023-09-30 iso4217:USD shares iso4217:USD shares pure false --12-31 Q3 0001624326 10-Qtrue2024-09-302024false001-37685PAVMED INC.DE47-1214177360 Madison Avenue25th FloorNew YorkNY10017(917)813-1828Common Stock, $0.001 par value per sharePAVMNASDAQSeries Z Warrants, each to purchase 1/15th of one share of Common StockPAVMZNASDAQYesYesNon-accelerated Filertruefalsefalse109858411106856600.001765000196390001600061000600027800013430004520000213000024498000216000178300026180004267000142400025511000750256312000-294433000-4869000-53831000-4518000029813000-9387000-240180003055000031119000996000791000298500014030001381000177900047920004809000292000040160001147200012893000664900068580000203370002391600082000611578000-15528000-39300000-52412000700001240002520004080001200015900038000570000722870007228700040700040700-240000439200024880005772000118600014030001764000-2535000-3032000-2000000310002910007000007000001000000722890000-622200066585000-9443000607110000-217500002728500061855000607110000-217500002728500061855000-3688000-4079000-11075000-11716000643990000-17671000038360000-501390000830007700024400026000749600064316000-17748000306200000-503650006.43-2.383.30-7.231.44-2.380.79-7.231000537974627519286999696776444475638746275143069449696776413579763151100095543811000024352400032063000055303000-18642000271738100081000294003284000284000131016509942100090700090800012600001260000022450000-22450001710521500001500006960006960004400011910000123500035000035000056339000-5633900064399000-36880006071100013851493232000106603941100024820000025631200045180000938700013052132993000857850590002376000002944330002981300024018000079936239000-23900062730297700097700013508010843662000201900020210003801000380100040004000343326200062000353000353000441400004414000200800920000040100060100056700005670000-24294000-24294000317900003179000024129000241290007496000749600022800022280003500003139000348900035000035000056339000-5633900038360000-11075000272850001385149323200010660394110002482000000256312000-45180000938700012544972841000723586770002264230000260783000306820000830000251047500-750007239981000398800039890001670001670000202677600076000275000275000651000978000978000230000103700012670000-17671000-40790000-21750000127960129160007980131800023234600027852900027431000-15828000127960129160007980131800023234600027852900027431000-15828000272850000-61855000112900022070005716000917100010000007228700040700071300044800062500024880005772000111000-2535000-3032000-2910008000304000-45000180000-57900017570000-249000-538000-938000178000000-33648000-40162000510005900016479000035000010000000-161800009410002979800013625000100000005310001268000116600028400062000259000353000551000400030954000258850000-18874000-133360001963900039744000765000264080000 Note 1 — The Company <span style="font-family: Times New

Roman, Times, Serif; font-size: 10pt"> Description of the Business   PAVmed is structured to be a multi-product life sciences company organized to advance a pipeline of innovative healthcare technologies. Led by a team of highly skilled personnel with a track record of bringing innovative products to market, PAVmed is focused on innovating, developing, acquiring, and commercializing novel products that target unmet medical needs with large addressable market opportunities. Leveraging our corporate structure—a parent company that will establish distinct subsidiaries for each financed asset—we have the flexibility to raise capital at the PAVmed level to fund product development, or to structure financing directly into each subsidiary in a manner tailored to the applicable product, the latter of which is our current strategy given prevailing market conditions.   Our current focus is multi-fold. We continue to pursue commercial expansion and execution of EsoGuard, which is the flagship product of our subsidiary, Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid"). In addition, through a separate majority-owned subsidiary, Veris Health ("Veris"), we are focused in the immediate term on entering into strategic partnership opportunities with leading academic oncology systems to expand access to the Veris Platform, while concurrently developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris Platform. In terms of other existing products and technologies, we have adopted an incubator-type platform where we are looking to obtain financing on a product-by-product basis as necessary to advance each asset to a meaningful inflection point along its path to commercialization. Finally, as resources permit, we will continue to explore external innovations that fulfill our project selection criteria without limiting ourselves to any target sector, specialty or condition.   Note 2 — Liquidity and Going Concern   The Company's management is required to assess the Company's ability to continue as a going concern for the one year period following the date of the financial statements being issued. In each reporting period, including interim periods, an entity is required to assess conditions known and reasonably knowable as of the financial statement issuance date to determine whether it is probable an entity will not meet its financial obligations within one year from the financial statement issuance date. Substantial doubt about an entity's ability to continue as a going concern exists when conditions and events, considered in the aggregate, indicate it is probable the entity will be unable to meet its financial obligations as they become due within one year after the date the financial statements are issued.   The Company has financed its operations principally through public and private issuances of its common stock, preferred stock, common stock purchase warrants, and debt. The Company is subject to all of the risks and uncertainties typically faced by medical device and diagnostic companies that devote substantially all of their efforts to the commercialization of their initial product and services and ongoing research and development activities and conducting clinical trials. The Company generated $1.0 million and $3.0 million of revenues for the three and nine month periods ended September 30, 2024, respectively, however the Company expects to continue to experience recurring losses and to generate negative cash flows from operating activities in the near future.   The Company incurred a net income attributable to PAVmed Inc. common stockholders of approximately $30.6 million and had net cash flows used in operating activities of approximately $33.6 million for the nine month period ended September 30, 2024. As of September 30, 2024, the Company had negative working capital of approximately $35.4 million, with such working capital inclusive of the Senior Secured Convertible Notes classified as a current liability of an aggregate of approximately $32.1 million and approximately $0.8 million of cash.   The Company's ability to continue operations 12 months beyond the issuance of the financial statements, will depend upon its ability to control its operating costs within the limits of the amounts collected from its management service contracts with its non-consolidated subsidiaries, to substantially increase its revenues from the Veris Cancer Care platform, and to raise additional capital through various potential sources including equity or debt financings or refinancing or restructuring existing debt obligations. These factors raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the accompanying unaudited condensed consolidated financial statements are issued.   1000000.03000000.030600000-33600000-3540000032100000800000 Note 3 — Summary of Significant Accounting Policies   Significant Accounting Policies   The Company's significant accounting policies are as disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the SEC on March 25, 2024, except as otherwise noted herein below.   Basis of Presentation   The accompanying unaudited condensed consolidated financial statements of PAVmed and those of its wholly owned subsidiaries and variable interest entities have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"), and applicable rules and regulations of the United States Securities and Exchange Commission ("SEC"). All intercompany transactions and balances have been eliminated in consolidation. The Company has a controlling financial interest in Veris Health Inc., with the corresponding noncontrolling interest included as a separate component of consolidated stockholders' equity (deficit), including the recognition in the unaudited condensed consolidated statement of operations of a net loss attributable to the noncontrolling interest based on the respective minority-interest equity ownership of each subsidiary. As of September 10, 2024, PAVmed ceased to have a controlling financial interest in Lucid Diagnostics and therefore PAVmed's consolidated results of operations include Lucid Diagnostics' results of operations only through that date. The deconsolidation of Lucid Diagnostics has resulted in a gain recognized in PAVmed's statement of operations for the periods ended September 30, 2024. Moving forward, PAVmed will account for its investment in Lucid Diagnostics using the equity method and the fair value option. See below and Note 4, Equity Method Investment for a discussion on the impact of the deconsolidation of Lucid Diagnostics. See Note 15, Noncontrolling Interest, for a discussion of each of the subsidiaries noted above. The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions.   As permitted under SEC rules, certain footnotes or other financial information normally required by U.S. GAAP have been condensed or omitted. The balance sheet as of December 31, 2023 has been derived from audited consolidated financial statements at such date. The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the Company's annual consolidated financial statements, and in the opinion of management, include all adjustments, consisting only of routine recurring adjustments, necessary for a fair statement of the Company's unaudited condensed consolidated financial information.   The unaudited condensed consolidated results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the consolidated results to be expected for the year ending December 31, 2024 or for any other interim period or for any other future periods. The accompanying unaudited condensed consolidated financial statements and related unaudited condensed consolidated financial information should be read in conjunction with the Company's audited consolidated financial statements and related notes thereto as of and for the year ended December 31, 2023 included in the Company's Annual Report on Form 10-K as filed with the SEC on March 25, 2024.   All amounts in the accompanying unaudited condensed consolidated financial statements and the notes thereto are presented in thousands of dollars, if not otherwise noted as being presented in millions of dollars, except for shares and per share amounts.   Cash   The Company maintains its cash at a major financial institution with high credit quality. At times, the balance of its cash deposits may exceed federally insured limits. The Company has not experienced losses on deposits with commercial banks and financial institutions which exceed federally insured limits.   Included in the Company's cash as of September 30, 2024 and December 31, 2023 is $299 related to a restricted deposit account for a standby letter of credit associated with our corporate headquarters which has a lease maturity date in 2030.   Use of Estimates   In preparing the

unaudited condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and the determination of corresponding carrying value reserve, if any, and liabilities and the disclosure of contingent losses, as of the date of the unaudited condensed consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Significant estimates in these unaudited condensed consolidated financial statements include those related to the estimated fair value of debt obligations, stock-based equity awards, intangible assets and common stock purchase warrants. Other significant estimates include the estimated incremental borrowing rate, the provision or benefit for income taxes and the corresponding valuation allowance on deferred tax assets. Additionally, management's assessment of the Company's ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. On an ongoing basis, the Company evaluates its estimates and assumptions. The Company bases its estimates on historical experience and on various other assumptions believed to be reasonable. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates.   Note 3 — Summary of Significant Accounting Policies - continued   Revenue Recognition   Revenues are recognized when the satisfaction of the performance obligation occurs, in an amount that reflects the consideration the Company expects to collect in exchange for those services. The Company's revenue was primarily generated by Lucid's laboratory testing services utilizing its EsoGuard Esophageal DNA tests. The services were completed upon release of a patient's test result to the ordering healthcare provider. Revenue recognized is inclusive of both variable consideration in connection with an individual patient's third-party insurance coverage policy and fixed consideration in connection with a contracted services arrangement with an unrelated third party legal entity. To determine revenue recognition for the arrangements that the Company determines are within the scope of ASC 606, Revenue from Contracts with Customers, the Company performs the following five steps: (1) identify the contract(s) with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation.   The key aspects considered by the Company include the following: Contracts—The Company's customer is primarily the patient, but the Company does not enter into a formal reimbursement contract with a patient. The Company establishes a contract with a patient in accordance with other customary business practices, which is the point in time an order is received from a provider and a patient specimen has been returned to the laboratory for testing. Payment terms are a function of a patient's existing insurance benefits, including the impact of coverage decisions with Center for Medicare & Medicaid Services ("CMS") and applicable reimbursement contracts established between the Company and payers. However, when a patient is considered self-pay, the Company requires payment from the patient prior to the commencement of the Company's performance obligations. The Company's consideration can be deemed variable or fixed depending on the structure of specific payer contracts, and the Company considers collection of such consideration to be probable to the extent that it is unconstrained.   Performance obligations—A performance obligation is a promise in a contract to transfer a distinct good or service (or a bundle of goods or services) to the customer. The Company's contracts have a single performance obligation, which is satisfied upon rendering of services, which culminates in the release of a patient's test result to the ordering healthcare provider. The Company elects the practical expedient related to the disclosure of unsatisfied performance obligations, as the duration of time between providing testing supplies, the receipt of a sample, and the release of a test result to the ordering healthcare provider is far less than one year.   Transaction price—The transaction price is the amount of consideration that the Company expects to collect in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). The consideration expected to be collected from a contract with a customer may include fixed amounts, variable amounts, or both.   If the consideration derived from the contracts is deemed to be variable, the Company estimates the amount of consideration to which it will be entitled in exchange for the promised goods or services. The Company limits the amount of variable consideration included in the transaction price to the unconstrained portion of such consideration. In other words, the Company recognizes revenue up to the amount of variable consideration that is not subject to a significant reversal until additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved.   When the Company does not have significant historical experience or that experience has limited predictive value, the constraint over estimates of variable consideration may result in no revenue being recognized upon delivery of patient EsoGuard test results to the ordering healthcare provider. As such, the Company recognizes revenue up to the amount of variable consideration not subject to a significant reversal until additional information is obtained or the uncertainty associated with additional payments or refunds, if any, is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in estimated expected variable consideration, with the change in estimate recognized in the period of such revised estimate. With respect to a contracted service arrangement, the fixed consideration revenue is recognized on an as-billed basis upon delivery of the laboratory test report with realization of such fixed consideration deemed probable based upon actual historical experience.   Allocate transaction price—The transaction price is allocated entirely to the performance obligation contained within the contract with a customer on the basis of the relative standalone selling prices of each distinct good or service.   Practical Expedients—The Company does not adjust the transaction price for the effects of a significant financing component, as at contract inception, the Company expects the collection cycle to be one year or less.   Note 3 — Summary of Significant Accounting Policies - continued   Equity Method Investments   Businesses that are not consolidated, but over which PAVmed exercises significant influence, are accounted for under the equity method of accounting. The determination as to whether or not PAVmed exercises significant influence with respect to a company depends on an evaluation of several factors, including, among others, representation on the company's board of directors and equity ownership level, which is generally between a <span id="xdx_904_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_pid_dp_c20240930__srt--OwnershipAxis__custom--LucidDiagnosticsIncMember__srt--RangeAxis__srt--MinimumMember_zQyhSP8EjzXd" title="Equity method investment, ownership percentage">20% and a <span id="xdx_90A_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_pid_dp_c20240930__srt--OwnershipAxis__custom--LucidDiagnosticsIncMember__srt--RangeAxis__srt--MaximumMember_zBMZZoYPicxb" title="Equity method investment, ownership percentage">50% interest in the voting securities of an equity method business, as well as voting rights associated with PAVmed's holdings in common stock in that company. PAVmed accounts for Lucid Diagnostics as an equity method investment beginning on September 10, 2024, and the period ended September 30, 2024.   Fair Value Option ("FVO") Election   Under a Securities Purchase Agreement dated March 31, 2022, the Company issued a Senior Secured Convertible Note dated April 4, 2022, referred to herein as the "April 2022 Senior Convertible Note", and a Senior Secured Convertible Note dated September 8, 2022, referred to herein as the "September 2022 Senior Convertible Note", which are accounted under the "fair value option election" as discussed below.   Under a Securities Purchase Agreement dated March 13, 2023, Lucid Diagnostics issued a Senior Secured Convertible Note dated March 21, 2023, referred to herein as the "Lucid March 2023 Senior Convertible Note", which is accounted under the "fair value option election", through September 10, 2024, the date of Lucid's deconsolidation from PAVmed's results of operations, as discussed below.   Under Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 815, Derivative and Hedging, ("ASC 815"), a financial instrument containing embedded features and/or options may be required to be bifurcated from the financial instrument host and recognized as separate derivative asset or liability, with the bifurcated derivative asset or liability initially measured at estimated fair value as of the transaction issue date and then subsequently remeasured at estimated fair value as of each reporting period balance sheet date.   Alternatively, FASB ASC Topic 825, Financial Instruments, ("ASC 825") provides for the "fair value option" ("FVO") election. In this regard, ASC 825-10-15-4 provides for the FVO election (to the extent not otherwise prohibited by ASC 825-10-15-5) to be afforded to financial instruments, wherein the financial instrument is initially measured at estimated fair value as of the transaction issue date and then subsequently remeasured at estimated fair value as of each reporting period balance sheet date, with changes in the estimated fair value recognized as other income (expense) in the statement of operations. The estimated fair value adjustment of the April 2022 Senior Convertible Note, the September 2022 Senior Convertible Note and (through September 10, 2024, Lucid's deconsolidation date) the Lucid March 2023 Senior Convertible

Note, including the component related to accrued interest, is presented in a single line item within other income (expense) in the accompanying unaudited condensed consolidated statement of operations (as provided for by ASC 825-10-50-30(b)). Further, as required by ASC 825-10-45-5, to the extent a portion of the fair value adjustment is attributed to a change in the instrument-specific credit risk, such portion would be recognized as a component of other comprehensive income ("OCI") (for which there was no such adjustment with respect to the April 2022 Senior Convertible Note, the September 2022 Senior Convertible Note or (through September 10, 2024, Lucid's deconsolidation date) the Lucid March 2023 Senior Convertible Note).   See Note 10, Financial Instruments Fair Value Measurements, with respect to the FVO election; and Note 11, Debt, for a discussion of the April 2022 Senior Convertible Note, the September 2022 Senior Convertible Note and the Lucid March 2023 Senior Convertible Note.   From and after September 10, 2024, the date of Lucid's deconsolidation from PAVmed's results of operation, the Company's investment in Lucid is treated as an equity method investment accounted for using the fair value option. Shares of Lucid Diagnostics common stock have a readily determinable fair value classified as Level 1, in which the fair value is determined based upon quoted market prices in an active market.   Recent Accounting Standards Updates Not Yet Adopted   In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740)—Improvements to Income Tax Disclosures ("ASU 2023-09"), which is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 provide for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for the Company prospectively to all annual periods beginning after December 15, 2024. Early adoption is permitted. The Company does not expect the standard to have a significant impact on its unaudited condensed consolidated financial statements.   In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280)—Improvements to Reportable Segment Disclosures ("ASU 2023-07"), which require public companies disclose significant segment expenses and other segment items on an annual and interim basis and to provide in interim periods all disclosures about a reportable segment's profit or loss and assets that are currently required annually. The guidance is effective for public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The guidance is applied retrospectively to all periods presented in the financial statements, unless it is impracticable. The Company is currently evaluating the impact this update will have on its unaudited condensed consolidated financial statements and disclosures, however the Company does not expect the standard to have a significant impact.   Note 3 — Summary of Significant Accounting Policies - continued   In October 2023, the FASB issued ASU No. 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC's Disclosure Update and Simplification Initiative. This update modifies the disclosure or presentation requirements of a variety of topics in the Accounting Standards Codification to conform with certain SEC amendments in Release No. 33-10532, Disclosure Update and Simplification. The amendments in this update should be applied prospectively, and the effective date for each amendment will be the date on which the SEC's removal of that related disclosure from Regulation S-X or S-K becomes effective. However, if the SEC has not removed the related disclosure from its regulations by June 30, 2027, the amendments will be removed from the Codification and not become effective. Early adoption is prohibited. The Company is currently evaluating the impact this update will have on its unaudited condensed consolidated financial statements and disclosures.   Basis of Presentation   The accompanying unaudited condensed consolidated financial statements of PAVmed and those of its wholly owned subsidiaries and variable interest entities have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"), and applicable rules and regulations of the United States Securities and Exchange Commission ("SEC"). All intercompany transactions and balances have been eliminated in consolidation. The Company has a controlling financial interest in Veris Health Inc., with the corresponding noncontrolling interest included as a separate component of consolidated stockholders' equity (deficit), including the recognition in the unaudited condensed consolidated statement of operations of a net loss attributable to the noncontrolling interest based on the respective minority-interest equity ownership of each subsidiary. As of September 10, 2024, PAVmed ceased to have a controlling financial interest in Lucid Diagnostics and therefore PAVmed's consolidated results of operations include Lucid Diagnostics' results of operations only through that date. The deconsolidation of Lucid Diagnostics has resulted in a gain recognized in PAVmed's statement of operations for the periods ended September 30, 2024. Moving forward, PAVmed will account for its investment in Lucid Diagnostics using the equity method and the fair value option. See below and Note 4, Equity Method Investment for a discussion on the impact of the deconsolidation of Lucid Diagnostics. See Note 15, Noncontrolling Interest, for a discussion of each of the subsidiaries noted above. The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions.   As permitted under SEC rules, certain footnotes or other financial information normally required by U.S. GAAP have been condensed or omitted. The balance sheet as of December 31, 2023 has been derived from audited consolidated financial statements at such date. The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the Company's annual consolidated financial statements, and in the opinion of management, include all adjustments, consisting only of routine recurring adjustments, necessary for a fair statement of the Company's unaudited condensed consolidated financial information.   The unaudited condensed consolidated results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the consolidated results to be expected for the year ending December 31, 2024 or for any other interim period or for any other future periods. The accompanying unaudited condensed consolidated financial statements and related unaudited condensed consolidated financial information should be read in conjunction with the Company's audited consolidated financial statements and related notes thereto as of and for the year ended December 31, 2023 included in the Company's Annual Report on Form 10-K as filed with the SEC on March 25, 2024.   All amounts in the accompanying unaudited condensed consolidated financial statements and the notes thereto are presented in thousands of dollars, if not otherwise noted as being presented in millions of dollars, except for shares and per share amounts.   Cash   The Company maintains its cash at a major financial institution with high credit quality. At times, the balance of its cash deposits may exceed federally insured limits. The Company has not experienced losses on deposits with commercial banks and financial institutions which exceed federally insured limits.   Included in the Company's cash as of September 30, 2024 and December 31, 2023 is $299 related to a restricted deposit account for a standby letter of credit associated with our corporate headquarters which has a lease maturity date in 2030.   299000299000 Use of Estimates   In preparing the unaudited condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and the determination of corresponding carrying value reserve, if any, and liabilities and the disclosure of contingent losses, as of the date of the unaudited condensed consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Significant estimates in these unaudited condensed consolidated financial statements include those related to the estimated fair value of debt obligations, stock-based equity awards, intangible assets and common stock purchase warrants. Other significant estimates include the estimated incremental borrowing rate, the provision or benefit for income taxes and the corresponding valuation allowance on deferred tax assets. Additionally, management's assessment of the Company's ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. On an ongoing basis, the Company evaluates its estimates and assumptions. The Company bases its estimates on historical experience and on various other assumptions believed to be reasonable. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates.   Note 3 — Summary of Significant Accounting Policies - continued   Revenue Recognition   Revenues are recognized when the satisfaction of the performance obligation occurs, in an amount that reflects the consideration the Company expects to collect in exchange for those

services. The Company's revenue was primarily generated by Lucid's laboratory testing services utilizing its EsoGuard Esophageal DNA tests. The services were completed upon release of a patient's test result to the ordering healthcare provider. Revenue recognized is inclusive of both variable consideration in connection with an individual patient's third-party insurance coverage policy and fixed consideration in connection with a contracted services arrangement with an unrelated third party legal entity. To determine revenue recognition for the arrangements that the Company determines are within the scope of ASC 606, Revenue from Contracts with Customers, the Company performs the following five steps: (1) identify the contract(s) with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation.   The key aspects considered by the Company include the following: Contracts—The Company's customer is primarily the patient, but the Company does not enter into a formal reimbursement contract with a patient. The Company establishes a contract with a patient in accordance with other customary business practices, which is the point in time an order is received from a provider and a patient specimen has been returned to the laboratory for testing. Payment terms are a function of a patient's existing insurance benefits, including the impact of coverage decisions with Center for Medicare & Medicaid Services ("CMS") and applicable reimbursement contracts established between the Company and payers. However, when a patient is considered self-pay, the Company requires payment from the patient prior to the commencement of the Company's performance obligations. The Company's consideration can be deemed variable or fixed depending on the structure of specific payer contracts, and the Company considers collection of such consideration to be probable to the extent that it is unconstrained.   Performance obligations—A performance obligation is a promise in a contract to transfer a distinct good or service (or a bundle of goods or services) to the customer. The Company's contracts have a single performance obligation, which is satisfied upon rendering of services, which culminates in the release of a patient's test result to the ordering healthcare provider. The Company elects the practical expedient related to the disclosure of unsatisfied performance obligations, as the duration of time between providing testing supplies, the receipt of a sample, and the release of a test result to the ordering healthcare provider is far less than one year.   Transaction price—The transaction price is the amount of consideration that the Company expects to collect in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). The consideration expected to be collected from a contract with a customer may include fixed amounts, variable amounts, or both.   If the consideration derived from the contracts is deemed to be variable, the Company estimates the amount of consideration to which it will be entitled in exchange for the promised goods or services. The Company limits the amount of variable consideration included in the transaction price to the unconstrained portion of such consideration. In other words, the Company recognizes revenue up to the amount of variable consideration that is not subject to a significant reversal until additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved.   When the Company does not have significant historical experience or that experience has limited predictive value, the constraint over estimates of variable consideration may result in no revenue being recognized upon delivery of patient EsoGuard test results to the ordering healthcare provider. As such, the Company recognizes revenue up to the amount of variable consideration not subject to a significant reversal until additional information is obtained or the uncertainty associated with additional payments or refunds, if any, is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in estimated expected variable consideration, with the change in estimate recognized in the period of such revised estimate. With respect to a contracted service arrangement, the fixed consideration revenue is recognized on an as-billed basis upon delivery of the laboratory test report with realization of such fixed consideration deemed probable based upon actual historical experience.   Allocate transaction price—The transaction price is allocated entirely to the performance obligation contained within the contract with a customer on the basis of the relative standalone selling prices of each distinct good or service.   Practical Expedients—The Company does not adjust the transaction price for the effects of a significant financing component, as at contract inception, the Company expects the collection cycle to be one year or less.   Note 3 — Summary of Significant Accounting Policies - continued   Equity Method Investments   Businesses that are not consolidated, but over which PAVmed exercises significant influence, are accounted for under the equity method of accounting. The determination as to whether or not PAVmed exercises significant influence with respect to a company depends on an evaluation of several factors, including, among others, representation on the company's board of directors and equity ownership level, which is generally between a <span id="xdx_904_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_pid_dp_c20240930__srt--OwnershipAxis__custom--LucidDiagnosticsIncMember__srt--RangeAxis__srt--MinimumMember_zQyhSP8EjzXd" title="Equity method investment, ownership percentage">20% and a <span id="xdx_90A_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_pid_dp_c20240930__srt--OwnershipAxis__custom--LucidDiagnosticsIncMember__srt--RangeAxis__srt--MaximumMember_zBMZZoYPicxb" title="Equity method investment, ownership percentage">50% interest in the voting securities of an equity method business, as well as voting rights associated with PAVmed's holdings in common stock in that company. PAVmed accounts for Lucid Diagnostics as an equity method investment beginning on September 10, 2024, and the period ended September 30, 2024.   0.200.50 Fair Value Option ("FVO") Election   Under a Securities Purchase Agreement dated March 31, 2022, the Company issued a Senior Secured Convertible Note dated April 4, 2022, referred to herein as the "April 2022 Senior Convertible Note", and a Senior Secured Convertible Note dated September 8, 2022, referred to herein as the "September 2022 Senior Convertible Note", which are accounted under the "fair value option election" as discussed below.   Under a Securities Purchase Agreement dated March 13, 2023, Lucid Diagnostics issued a Senior Secured Convertible Note dated March 21, 2023, referred to herein as the "Lucid March 2023 Senior Convertible Note", which is accounted under the "fair value option election", through September 10, 2024, the date of Lucid's deconsolidation from PAVmed's results of operations, as discussed below.   Under Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 815, Derivative and Hedging, ("ASC 815"), a financial instrument containing embedded features and/or options may be required to be bifurcated from the financial instrument host and recognized as separate derivative asset or liability, with the bifurcated derivative asset or liability initially measured at estimated fair value as of the transaction issue date and then subsequently remeasured at estimated fair value as of each reporting period balance sheet date.   Alternatively, FASB ASC Topic 825, Financial Instruments, ("ASC 825") provides for the "fair value option" ("FVO") election. In this regard, ASC 825-10-15-4 provides for the FVO election (to the extent not otherwise prohibited by ASC 825-10-15-5) to be afforded to financial instruments, wherein the financial instrument is initially measured at estimated fair value as of the transaction issue date and then subsequently remeasured at estimated fair value as of each reporting period balance sheet date, with changes in the estimated fair value recognized as other income (expense) in the statement of operations. The estimated fair value adjustment of the April 2022 Senior Convertible Note, the September 2022 Senior Convertible Note and (through September 10, 2024, Lucid's deconsolidation date) the Lucid March 2023 Senior Convertible Note, including the component related to accrued interest, is presented in a single line item within other income (expense) in the accompanying unaudited condensed consolidated statement of operations (as provided for by ASC 825-10-50-30(b)). Further, as required by ASC 825-10-45-5, to the extent a portion of the fair value adjustment is attributed to a change in the instrument-specific credit risk, such portion would be recognized as a component of other comprehensive income ("OCI") (for which there was no such adjustment with respect to the April 2022 Senior Convertible Note, the September 2022 Senior Convertible Note or (through September 10, 2024, Lucid's deconsolidation date) the Lucid March 2023 Senior Convertible Note).   See Note 10, Financial Instruments Fair Value Measurements, with respect to the FVO election; and Note 11, Debt, for a discussion of the April 2022 Senior Convertible Note, the September 2022 Senior Convertible Note and the Lucid March 2023 Senior Convertible Note.   From and after September 10, 2024, the date of Lucid's deconsolidation from PAVmed's results of operation, the Company's investment in Lucid is treated as an equity method investment accounted for using the fair value option. Shares of Lucid Diagnostics common stock have a readily determinable fair value classified as Level 1, in which the fair value is determined based upon quoted market prices in an active market.   Recent Accounting Standards Updates Not Yet Adopted   In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740)—Improvements to Income Tax Disclosures ("ASU 2023-

09”), which is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 provide for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for the Company prospectively to all annual periods beginning after December 15, 2024. Early adoption is permitted. The Company does not expect the standard to have a significant impact on its unaudited condensed consolidated financial statements.   In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280)—Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which require public companies disclose significant segment expenses and other segment items on an annual and interim basis and to provide in interim periods all disclosures about a reportable segment’s profit or loss and assets that are currently required annually. The guidance is effective for public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The guidance is applied retrospectively to all periods presented in the financial statements, unless it is impracticable. The Company is currently evaluating the impact this update will have on its unaudited condensed consolidated financial statements and disclosures, however the Company does not expect the standard to have a significant impact.   Note 3 — Summary of Significant Accounting Policies - continued   In October 2023, the FASB issued ASU No. 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative. This update modifies the disclosure or presentation requirements of a variety of topics in the Accounting Standards Codification to conform with certain SEC amendments in Release No. 33-10532, Disclosure Update and Simplification. The amendments in this update should be applied prospectively, and the effective date for each amendment will be the date on which the SEC’s removal of that related disclosure from Regulation S-X or S-K becomes effective. However, if the SEC has not removed the related disclosure from its regulations by June 30, 2027, the amendments will be removed from the Codification and not become effective. Early adoption is prohibited. The Company is currently evaluating the impact this update will have on its unaudited condensed consolidated financial statements and disclosures. Note 4 — Equity Method Investment   On September 10, 2024, following preferred equity transactions completed by Lucid earlier in 2024 and the termination of voting proxies entered into between PAVmed and certain shareholders of Lucid, PAVmed’s voting interest in the Company was reduced to less than <span id="xdx_904_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_pid_dp_c20240910__srt--OwnershipAxis__custom--LucidDiagnosticsIncMember__srt--RangeAxis__srt--MaximumMember_z0YCE41yezs9" title="Equity method investment, ownership percentage">50.0%, resulting in the loss of a controlling financial interest. However, PAVmed retains the ability to exercise significant influence over Lucid. As a result, the Company deconsolidated Lucid. The following table reflects the net assets of Lucid at the time of deconsolidation: Schedule of Deconsolidation of Net Assets <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_498_20240910__srt--ConsolidatedEntitiesAxis__custom--LucidDiagnosticsIncMember_zCiC9VAEMtoe" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Current assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_pn3n3_maACzy92_zvEx1LQucCqg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 80%">Cash</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">16,479</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_pn3n3_maACzy92_zeqB0806zsP" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Prepaid expenses, deposits, and other current assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,474</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AssetsCurrent_i02TI_pn3n3_mtACzy92_maAzGjp_zPnTDzpmKubi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total current assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">19,953</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentNet_i01I_pn3n3_maAzGjp_zju05UqZzwWf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fixed assets, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">964</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_pn3n3_maAzGjp_zdes6gEByaqi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating lease right-of-use assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,871</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i01I_pn3n3_maAzGjp_zO4p40gAkX4k" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Intangible assets, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">877</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OtherAssetsNoncurrent_i01I_pn3n3_maAzGjp_z5Kml3dhk9ph" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">379</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--Assets_i01TI_pn3n3_mtAzGjp_maNAzJtI_z2oF0qp2lik" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">25,044</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LiabilitiesAbstract_i01B_z8POmDgRthhg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LiabilitiesCurrentAbstract_i01B_zG3VljEjldk6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Current liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AccountsPayableCurrent_i02I_pn3n3_maLCzxev_zZpkDCguG9v2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,069</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AccruedLiabilitiesCurrent_i02I_pn3n3_maLCzxev_zISVDxY5T19I" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Accrued expenses and other current liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,674</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_pn3n3_maLCzxev_zxWFLhrTmE34" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Operating lease liabilities, current portion</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">865</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--SecuredDebtCurrent_i02I_pn3n3_maLCzxev_zIXAmUFxbnKg" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Senior Secured Convertible Notes - at fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,268</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LiabilitiesCurrent_i02TI_pn3n3_mtLCzxev_maLzzuS_zzteyGj8deA5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total current liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">13,876</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_pn3n3_maLzzuS_zOspLv3B6Wzh" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Operating lease liabilities, less current portion</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,011</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--Liabilities_i01TI_pn3n3_mtLzzuS_msNAzJtI_zY7CMLQ4KkL" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Total liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">15,887</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--NetAssets_i01TI_pn3n3_mtNAzJtI_zFkxXO9RZo" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net Assets of Lucid Diagnostics at September 10, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,157</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Upon deconsolidation, the Company owned 31,302,444 shares of Lucid Diagnostics common stock, which was valued at $25.1 million, resulting in a gain on deconsolidation of $72.3 million in the accompanying unaudited condensed consolidated statements of operations for the three and nine months ended September 30, 2024. The Company recorded the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <p id="xdx_89F_ecustom--EquityMethodInvestmentsGainDeconsolidationTableTextBlock_zBvczKpdYO49" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Schedule of Gain on Deconsolidation</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20240101__20240930__srt--ConsolidatedEntitiesAxis__custom--LucidDiagnosticsIncMember_zuFOPk7FPF06" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_i01_pn3n3_zwSouUjocUKf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Investment in former Consolidated Subsidiary (Fair Value of Lucid common stock)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">25,105</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteDeconsolidationOfLucid_i01_pn3n3_z1zrwwJlYpSb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Add: Noncontrolling interest - Lucid</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">56,339</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--GainLossOnDispositionOfAssets1_i01_pn3n3_zyg4DJfEqdPg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less: Net Assets of Former Consolidated Subsidiary - Lucid</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right" title="Less: Net Assets of Former Consolidated

Subsidiary - Lucid">(9,157</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--DeconsolidationGainOrLossAmount_i01_pn3n3_zkwvfxMs3xue" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Gain on Deconsolidation of Lucid</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">72,287</td><td style="padding-bottom: 2.5pt; text-align: left"></td></tr> </table> <p id="xdx_8AB_zvwGum4b6Lb5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">After the Company's deconsolidation of Lucid, the Company accounts for its investment in Lucid as an equity method investment with the election of the fair value option. Due to the Company's continuing involvement and significant influence over operating and financial policies, Lucid is considered a related party of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Note 4 — Equity Method Investment - continued</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">The following unaudited summarized financial information related to Lucid accounted for under the equity method of accounting as of September 30, 2024. This aggregate information has been compiled from the financial statements of those business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <p id="xdx_89E_ecustom--EquityMethodInvestmentsAggregateInformationTableTextBlock_z5303UBxvqTf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Schedule of Aggregate Information From the Financial Statements</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20240930__srt--ConsolidatedEntitiesAxis__custom--LucidDiagnosticsIncMember_zu76Js7TDOIb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_pn3n3_maACzLjA_zGLlpqZGsNNg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Cash</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">14,489</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OtherAssetsCurrent_i02I_pn3n3_zjWL084hRvJ9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other current assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,335</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AssetsNoncurrent_i02I_pn3n3_z6FwdDnhKbF3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Non-current assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,774</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--Assets_i01I_pn3n3_mtAzYAX_zZWeBDcMaLd7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Total assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">22,598</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LiabilitiesCurrent_i02I_pn3n3_mtLCzQMX_maLzC3e_zIIYjM8B00Ya" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,249</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LiabilitiesNoncurrent_i02I_pn3n3_mtLCzQMX_maLzC3e_z2MR7FqU7bD8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Non-current liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,011</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--StockholdersEquity_i02I_pn3n3_mtSEz3OW_maSEIPAzljN_zmzi6kh7vYy7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Shareholders' deficit</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6,338</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LiabilitiesAndStockholdersEquity_i01I_pn3n3_mtLASEzIoC_zyu8W46gCuDd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Total liabilities and stockholders' deficit</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">22,598</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended September 30, 2024</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20240701__20240930__srt--ConsolidatedEntitiesAxis__custom--LucidDiagnosticsIncMember__us-gaap--AwardDateAxis__custom--JulyOneTwoThousandTwentyFourToSeptemberTenTwoThousandTwentyFourMember_zQFLRJBdIBf8" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">July 1, 2024 - </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">September 10, 2024</p></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20240701__20240930__srt--ConsolidatedEntitiesAxis__custom--LucidDiagnosticsIncMember__us-gaap--AwardDateAxis__custom--SeptemberElevenTwoThousandTwentyFourToSeptemberThirtyTwoThousandTwentyFourMember_zQe9QcmFDOfa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 11, 2024 - September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20240701__20240930__srt--ConsolidatedEntitiesAxis__custom--LucidDiagnosticsIncMember_zmfefmSTHoBj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zSOP8MQNkMQ9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Revenue</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">942</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">230</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,172</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--NetIncomeLoss_pn3n3_zjBQc7v7lZ4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net income (loss)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(9,039</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(3,332</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(12,371</td><td style="text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine months ended September 30, 2024</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20240101__20240930__srt--ConsolidatedEntitiesAxis__custom--LucidDiagnosticsIncMember__us-gaap--AwardDateAxis__custom--JanuaryOneTwoThousandTwentyFourToSeptemberTenTwoThousandTwentyFourMember_zmkfLZaHgqpf" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">January 1, 2024 - </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">September 10, 2024</p></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20240101__20240930__srt--ConsolidatedEntitiesAxis__custom--LucidDiagnosticsIncMember__us-gaap--AwardDateAxis__custom--SeptemberElevenTwoThousandTwentyFourToSeptemberThirtyTwoThousandTwentyFourMember_zkORhcGcnKE1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 11, 2024 - September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20240101__20240930__srt--ConsolidatedEntitiesAxis__custom--LucidDiagnosticsIncMember_zhwg9VNfkfMg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zdQw5PGyAjo7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Revenue</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,919</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">230</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,149</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--NetIncomeLoss_pn3n3_z0fszf14a5Zf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net income (loss)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(38,152</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(3,332</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(41,484</td><td style="text-align: left">)</td></tr> </table>   *Lucid was consolidated and included in PAVmed's consolidated results for the period of January 1, 2024 through September 10, 2024. The amounts from September 11, 2024 through September 30, 2024 were not included in PAVmed's consolidated results.   At September 10, 2024 and September 30, 2024, the fair value of the Company's investment in Lucid was $25.1 million and $25.5 million, respectively, with the company recognizing an unrealized gain on its investment in Lucid of $<span id="xdx_90D_eus-gaap--UnrealizedGainLossOnInvestments_pn5n6_c20240701__20240930__srt--ConsolidatedEntitiesAxis__custom--LucidDiagnosticsIncMember_z7BrkFLmcTCl" title="Unrealized gain loss on investments"><span id="xdx_90E_eus-gaap--UnrealizedGainLossOnInvestments_pn5n6_c20240101__20240930__srt--ConsolidatedEntitiesAxis__custom--LucidDiagnosticsIncMember_zejRmqxCC2wf" title="Unrealized gain loss on investments">0.4 million in the accompanying condensed consolidated statements of operations for three and nine month periods ended September 30, 2024. The fair value of common shares held by the Company was determined using the closing price of Lucid's common stock per share on September 10, 2024 and September 30, 2024 of $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_c20240910__srt--ConsolidatedEntitiesAxis__custom--LucidDiagnosticsIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjATp4NbzzP2" title="The fair value of common price per shares">0.802 and $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20240930__srt--ConsolidatedEntitiesAxis__custom--LucidDiagnosticsIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6G24mWH51h1" title="The fair value of common price per shares">0.815, respectively. At September 10, 2024 and September 30, 2024, PAVmed held approximately <span id="xdx_90B_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20240910__us-gaap--BusinessAcquisitionAxis__custom--LucidDiagnosticsIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zs2itxzh0qH6" title="The fair value of common price per shares"><span id="xdx_906_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20240930__us-gaap--BusinessAcquisitionAxis__custom--LucidDiagnosticsIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zasaPQeUTBKc" title="The fair value of common price per shares">40% of Lucid's common stock voting interest.   <p style="font: 10pt Times

New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Lucid - Management Services Agreement   Lucid's daily operations are also managed in part by personnel employed by the Company, for which the Company records management fee income, referred to as the "MSA Fee", according to the provisions of a Management Services Agreement ("MSA") with Lucid. The MSA does not have a termination date, but may be terminated by Lucid. The MSA Fee is charged on a monthly basis and is subject-to periodic adjustment corresponding with changes in the services provided by the Company's personnel to Lucid, with any such change in the MSA Fee being subject to approval of the boards of directors of each of the Company and Lucid. The respective companies' boards of directors approved an amendment to the MSA to increase the MSA Fee to $833 per month, effective January 1, 2024. In August 2024, the respective companies' boards of directors approved the Company to enter into a ninth amendment to the MSA. Under this amendment, the monthly fee due to the Company from Lucid was increased from $833 to $1,050, effective July 1, 2024. During the period of September 11, 2024 through September 30, 2024, MSA fee income was $700.   Transfer of Intellectual Property to Lucid   On September 27, 2024, the Company entered into an Assignment of Patent Rights with PAVmed, pursuant to which PAVmed assigned certain patent rights to the EsoCheck device. In consideration of the assignment the Company agreed to pay PAVmed a $350 assignment fee.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> 0.500<p id="xdx_89A_ecustom--ScheduleOfDeconsolidationOfNetAssetsTableTextBlock_zMBB4w15K5Q9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Schedule of Deconsolidation of Net Assets </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold"> </td> <td> </td> <td style="text-align: left"> </td><td id="xdx_498_20240910__srt--ConsolidatedEntitiesAxis__custom--LucidDiagnosticsIncMember_zCiC9VAEMtoe" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Current assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_pn3n3_maACzy92_zvEx1UqucCqg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 80%">Cash</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">16,479</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_pn3n3_maACzy92_zeqB0806zsP" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Prepaid expenses, deposits, and other current assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,474</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AssetsCurrent_i02TI_pn3n3_mtACzy92_maAzGjp_zPnTDzpmKubi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total current assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">19,953</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentNet_i01I_pn3n3_maAzGjp_zju05UqZzwWf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fixed assets, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">964</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_pn3n3_maAzGjp_zdes6gEByaqi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating lease right-of-use assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,871</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i01I_pn3n3_maAzGjp_zO4p40gAkX4k" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Intangible assets, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">877</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OtherAssetsNoncurrent_i01I_pn3n3_maAzGjp_zSKmI3dhk9ph" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">379</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--Assets_i01TI_pn3n3_mtAzGjp_maNAzJtI_z2oF0qp2iIk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">25,044</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LiabilitiesAbstract_i01B_z8POmDgRthhg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LiabilitiesCurrentAbstract_i01B_zG3VljEjldk6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Current liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AccountsPayableCurrent_i02I_pn3n3_maLCzxev_zZpkDCquG9v2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,069</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AccruedLiabilitiesCurrent_i02I_pn3n3_maLCzxev_zISVDxY5T19l" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Accrued expenses and other current liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,674</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_pn3n3_maLCzxev_zxWFLhrTmE34" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Operating lease liabilities, current portion</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">865</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--SecuredDebtCurrent_i02I_pn3n3_maLCzxev_zIXAmUFxbnKg" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Senior Secured Convertible Notes - at fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,268</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LiabilitiesCurrent_i02TI_pn3n3_mtLCzxev_maLzzuS_zzteyGj8deA5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total current liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">13,876</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_pn3n3_maLzzuS_zOspLv3B6Wzh" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Operating lease liabilities, less current portion</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,011</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--Liabilities_i01TI_pn3n3_mtLzzuS_msNAzJtI_zY7CMLQ4KkL" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Total liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">15,887</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--NetAssets_i01TI_pn3n3_mtNAzJtI_zFkxXO9RZo" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net Assets of Lucid Diagnostics at September 10, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,157</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 16479000347400019953000964000287100087700037900025044000106900016740008650001026800013876000201100015887000915700031302444251000007230000072306 id="xdx_89F_ecustom--EquityMethodInvestmentsGainDeconsolidationTableTextBlock_zBvczKpdYO49" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Schedule of Gain on Deconsolidation</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20240101__20240930__srt--ConsolidatedEntitiesAxis__custom--LucidDiagnosticsIncMember_zuFOPk7TPF06" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_i01_pn3n3_zwSouUjocUKf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Investment in former Consolidated Subsidiary (Fair Value of Lucid common stock)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">25,105</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteDeconsolidationOfLucid_i01_pn3n3_z1zrwwJIYpSb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Add: Noncontrolling interest - Lucid</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">56,339</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--GainLossOnDispositionOfAssets1_i01_pn3n3_zyg4DJIEqdPg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less: Net Assets of Former Consolidated Subsidiary - Lucid</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right" title="Less: Net Assets of Former Consolidated Subsidiary - Lucid">(9,157</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--DeconsolidationGainOrLossAmount_i01_pn3n3_zkwvfxMs3xue" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Gain on Deconsolidation of Lucid</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">72,287</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 25105000056339000-915700072287000<p id="xdx_89E_ecustom--EquityMethodInvestmentsAggregateInformationTableTextBlock_z5303UBxvqTf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Schedule of Aggregate Information From the Financial Statements</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20240930__srt--ConsolidatedEntitiesAxis__custom--LucidDiagnosticsIncMember_zu76Js7TDOIb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_pn3n3_maACzLjA_zGLlpqZGsNNg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Cash</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">14,489</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OtherAssetsCurrent_i02I_pn3n3_zjWL084hRvJ9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other current assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,335</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AssetsNoncurrent_i02I_pn3n3_z6FwdDnhKbF3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>

style="text-align: left; padding-bottom: 1pt">Non-current assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,774</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--Assets_i01I_pn3n3_mtAzYAX_zZWeBDcMaLd7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Total assets</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">22,598</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LiabilitiesCurrent_i02I_pn3n3_mtLCzQMX_maLzC3e_zIIYjM8B00Ya" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,249</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LiabilitiesNoncurrent_i02I_pn3n3_mtLCzQMX_maLzC3e_z2MR7FqU7bD8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Non-current liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,011</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--StockholdersEquity_i02I_pn3n3_mtSEz3OW_maSEIPAzljN_zmzi6kh7vYy7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Shareholders' deficit</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6,338</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LiabilitiesAndStockholdersEquity_i01I_pn3n3_mtLASEzIoC_zyu8W46gCuDd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Total liabilities and stockholders' deficit</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">22,598</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended September 30, 2024</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20240701__20240930__srt--ConsolidatedEntitiesAxis__custom--LucidDiagnosticsIncMember__us-gaap--AwardDateAxis__custom--JulyOneTwoThousandTwentyFourToSeptemberTenTwoThousandTwentyFourMember_zQFLRJBdIBf8" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0; text-align: center">July 1, 2024 -</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">September 10, 2024</p></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20240701__20240930__srt--ConsolidatedEntitiesAxis__custom--LucidDiagnosticsIncMember__us-gaap--AwardDateAxis__custom--SeptemberElevenTwoThousandTwentyFourToSeptemberThirtyTwoThousandTwentyFourMember_zQe9QcmFDOfa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 11, 2024 - September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20240701__20240930__srt--ConsolidatedEntitiesAxis__custom--LucidDiagnosticsIncMember_zmfefmSTHoBj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zSOP8MQNkMQ9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Revenue</td><td style="width: 2%"> </td><td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">942</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">230</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,172</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--NetIncomeLoss_pn3n3_zjBQc7v7lIZ4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net income (loss)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(9,039</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(3,332</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(12,371</td><td style="text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine months ended September 30, 2024</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20240101__20240930__srt--ConsolidatedEntitiesAxis__custom--LucidDiagnosticsIncMember__us-gaap--AwardDateAxis__custom--JanuaryOneTwoThousandTwentyFourToSeptemberTenTwoThousandTwentyFourMember_zmkfLZaHgqpf" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">January 1, 2024 -</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">September 10, 2024</p></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20240101__20240930__srt--ConsolidatedEntitiesAxis__custom--LucidDiagnosticsIncMember__us-gaap--AwardDateAxis__custom--SeptemberElevenTwoThousandTwentyFourToSeptemberThirtyTwoThousandTwentyFourMember_zkORhcGcnKE1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 11, 2024 - September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20240101__20240930__srt--ConsolidatedEntitiesAxis__custom--LucidDiagnosticsIncMember_zhwg9VNfkfMg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zdQw5PGyAjo7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Revenue</td><td style="width: 2%"> </td><td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,919</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">230</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,149</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--NetIncomeLoss_pn3n3_z0fszf14a5Zf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net income (loss)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(38,152</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(3,332</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(41,484</td><td style="text-align: left">)</td></tr> </table> 14489000023350005774000225980001424900020110006338000225980009420002300001172000-9039000-3332000-12371000291900023000031490000-38152000-3332000-41484000251000002550000040000040000000.8020.8150.400.40833000833000105000070000035000 Note 5 — Revenue from Contracts with Customers   Revenue Recognized   In the three and nine month periods ended September 30, 2024, the Company recognized total revenue of $996 and $2,985, respectively, primarily resulting from the delivery of patient EsoGuard test results. Revenue recognized from customer contracts deemed to include a variable consideration transaction price is limited to the unconstrained portion of the variable consideration. The Company's revenue for the three and nine month periods ended September 30, 2023 was $791 and $1,403, respectively, primarily resulting from the delivery of patient EsoGuard test results.   Cost of Revenue   The cost of revenues principally includes the costs related to the Company's laboratory operations (excluding estimated costs associated with research activities), the costs related to the EsoCheck cell collection device, cell sample mailing kits and license royalties.   In the three and nine month periods ended September 30, 2024, the cost of revenue was $1,381 and $4,792, respectively, primarily related to costs for our laboratory operations and EsoCheck device supplies. The Company's cost of revenue for the three and nine month periods ended September 30, 2023 was $1,779 and $4,809, respectively, primarily related to costs for our laboratory operations and EsoCheck device supplies.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> 99600029850007910001403000138100047920001779000048090000<p id="xdx_805_ecustom--PrepaidExpensesDepositsAndOtherAssetsTextBlock_ztIxZ888ha3b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Note 6 — Prepaid Expenses, Deposits, and Other Current Assets</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_89A_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zXoW7YkfK8ig" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Prepaid expenses and other current assets consisted of the following as of:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">Schedule of Prepaid Expenses and Other Current Assets </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20240930_z1FcxyccvQQf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20231231_zD5jya5fBKb5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_ecustom--PrepaidServiceProvidersAndSuppliers_iI_pn3n3_maPEDAOzS9r_zi3yoG7ZSlBd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Advanced payments to service providers and suppliers</td><td style="width: 2%"> </td><td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">181</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">739</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--PrepaidInsurance_iI_pn3n3_maPEDAOzS9r_zLSj3NMNVY69" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Prepaid insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">420</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">848</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--SecurityDeposit_iI_pn3n3_maPEDAOzS9r_zppW6qvCtHU8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Deposits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">480</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,672</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--VerisBoxSupplies_iI_pn3n3_maPEDAOzS9r_zofwLBXtVvc2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Veris

Box supplies</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">262</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">261</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3n3_mtPEDAOzS9r_zFhPnJJ73Mn2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Total prepaid expenses, deposits and other current assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,343</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">4,520</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>   <p id="xdx_89A_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zXoW7YkfK8ig" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Prepaid expenses and other current assets consisted of the following as of: Schedule of Prepaid Expenses and Other Current Assets   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20240930_z1FcxyccvQQf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20231231_zD5jya5fBKb5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_ecustom--PrepaidServiceProvidersAndSuppliers_iI_pn3n3_maPEDAOzS9r_zi3yoG7ZSlBd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Advanced payments to service providers and suppliers</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">181</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">739</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--PrepaidInsurance_iI_pn3n3_maPEDAOzS9r_zLSj3NMNVY69" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Prepaid insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">420</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">848</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--SecurityDeposit_iI_pn3n3_maPEDAOzS9r_zppW6qvCtHU8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Deposits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">480</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,672</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--VerisBoxSupplies_iI_pn3n3_maPEDAOzS9r_zofwLBXtVvc2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Veris Box supplies</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">262</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">261</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3n3_mtPEDAOzS9r_zFhPnJJ73Mn2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Total prepaid expenses, deposits and other current assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,343</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">4,520</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> 1810007390004200008480004800002672000262000261000134300045200000 Note 7 — Leases   <p id="xdx_89B_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zKrxl0VA6GM3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">The Company's future lease payments as of September 30, 2024, which are presented as operating lease liabilities, current portion and operating lease liabilities, less current portion on the Company's unaudited condensed consolidated balance sheets are as follows: Schedule of Future Minimum Lease Payments for Operating Leases   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr id="xdx_406_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_pn3n3_maLOLLPz85j_zZWGNNBg4qHF" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49C_20240930_z6goa1Mov3u2" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_pn3n3_maLOLLPz85j_ziLpOP8bJ3if" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 80%">2024 (remainder of year)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">174</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPz85j_zTxYhBp4JOS" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">708</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPz85j_z718uHkQTVUg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">724</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPz85j_zvowEQWrYUN8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">594</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPz85j_zJ08kTCK66fa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">471</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_pn3n3_maLOLLPz85j_zypBBloaKKti" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">848</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPz85j_zVe5FRATglAd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total lease payments</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">3,519</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zEc5lB4ydTUa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(640</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zGqJqWX6Do14" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Present value of lease liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,879</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_zLTG2snNYnPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_89C_ecustom--SupplementalBalanceSheetInformationRelatedToCashandNonCashActivitieswithLeaseTableTextBlock_zv5PRsq1r3o" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Supplemental disclosure of cash flow information related to the Company's cash and non-cash activities with its leases are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Schedule of Supplemental Balance Sheet Information Related to Cash and Non-cash Activities with Leases </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20240101__20240930_zOj6rzkFrVgk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20230101__20230930_zq1lNZ5xcaxg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Cash paid for amounts included in the measurement of lease liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OperatingLeasePayments_pn3n3_maPFOLAztnC_zHrBYD6k5hXb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Operating cash flows from operating leases</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,407</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,080</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Non-cash investing and financing activities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn3n3_zjlQjmxb4LU7" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Right-of-use assets obtained in exchange for new operating lease liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,728</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average remaining lease term - operating leases (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6.68</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average discount rate - operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.875</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.875</td><td style="text-align: left">%</td></tr> </table>   As of September 30, 2024 and December 31, 2023, the Company's right-of-use assets from operating leases were $<span id="xdx_90E_eus-gaap--

OperatingLeaseRightOfUseAsset_if_pn3n3_c20240930_zPN07M4zCOm9" title="Operating lease, right-of-use assets">2,618 and $4,267, respectively, which are reported in operating lease right-of-use assets in the unaudited condensed consolidated balance sheets. As of September 30, 2024 and December 31, 2023, the Company had outstanding operating lease obligations of $2,879 and $4,525, respectively, of which $499 and $1,565, respectively, are reported in operating lease liabilities, current portion and $2,380 and $2,960, respectively, are reported in operating lease liabilities less current portion in the Company's unaudited condensed consolidated balance sheets. The Company calculates its incremental borrowing rates for specific lease terms, used to discount future lease payments, as a function of the financing terms the Company would likely receive on the open market. Following the deconsolidation of Lucid, the Company had removed right-of-use assets and operating lease liabilities related to Lucid. See Note 4, <i>Equity Method Investment</i>, for additional information on the Lucid deconsolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_89B_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zKrxl0VA6GM3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">The Company's future lease payments as of September 30, 2024, which are presented as operating lease liabilities, current portion and operating lease liabilities, less current portion on the Company's unaudited condensed consolidated balance sheets are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">Schedule of Future Minimum Lease Payments for Operating Leases </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr id="xdx_406_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_if_pn3n3_maLOLLPz85j_zZWGNNBg4gHf" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td id="xdx_49C_20240930_z6goa1Mov3u2" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_if_pn3n3_maLOLLPz85j_ziLpOP8bJ3if" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 80%">2024 (remainder of year)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">174</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_if_pn3n3_maLOLLPz85j_zTxYhBp4JOS" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">708</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_if_pn3n3_maLOLLPz85j_z718uHkQTVUg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">724</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_if_pn3n3_maLOLLPz85j_zvowEQWrYUN8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">594</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_if_pn3n3_maLOLLPz85j_zJ08kTCK66fa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">471</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_if_pn3n3_maLOLLPz85j_zypBBloaKKti" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">848</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPz85j_zVe5FRATglAd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total lease payments</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">3,519</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zEc5lB4ydTUa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(640</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--OperatingLeaseLiability_if_pn3n3_zGqJqWX6Do14" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Present value of lease liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,879</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>
17400070800072400059400047100084800035190006400002879000<p id="xdx_89C_ecustom--SupplementalBalanceSheetInformationRelatedToCashandNonCashActivitieswithLeaseTableTextBlock_zv5PRsq1r3o" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Supplemental disclosure of cash flow information related to the Company's cash and non-cash activities with its leases are as follows: Schedule of Supplemental Balance Sheet Information Related to Cash and Non-cash Activities with Leases   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20240101__20240930_zOj6rzkFrVgk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20230101__20230930_zq1lNZ5xcaxg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Cash paid for amounts included in the measurement of lease liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OperatingLeasePayments_pn3n3_maPFOLAztnC_zHrBYD6k5hXb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Operating cash flows from operating leases</td><td style="width: 2%"> </td><td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,407</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td><td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,080</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Non-cash investing and financing activities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn3n3_zjlQjmxb4LU7" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Right-of-use assets obtained in exchange for new operating lease liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,728</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average remaining lease term - operating leases (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6.68</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average discount rate - operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.875</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.875</td><td style="text-align: left">%</td></tr> </table>
14070001080000027280000P5Y3MP6Y8M4D0.078750.078752618000426700028790004525000499000156500023800002960000 Note 8 — Intangible Assets, net   <p id="xdx_89D_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zTKhzAoC3qM2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Intangible assets, less accumulated amortization, consisted of the following as of: Schedule of Intangible Assets, Less Accumulated Amortization   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20240930_zSFHddwuUP35" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20231231_z3fZkZZa8flh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsGross_if_pn3n3_hus-gaap--FairValueByAssetClassAxis__custom--DefensiveAssetMember_zxDlCAzWXnBh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Defensive asset</td><td style="width: 2%"> </td> <td style="width: 18%; text-align: center">60 months</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,105</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsGross_if_pn3n3_hus-gaap--FairValueByAssetClassAxis__custom--LaboratoryInformationManagementSoftwareMember_znjROs3vCTjj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Laboratory licenses and certifications and laboratory information management software</td><td> </td> <td style="text-align: center"><span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_if_dtM_c20240930__us-gaap--FairValueByAssetClassAxis__custom--LaboratoryInformationManagementSoftwareMember_zQHxx0toBmC9" title="Finite lived intangible asset, useful life"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_if_dtM_c20231231__us-gaap--FairValueByAssetClassAxis__custom--LaboratoryInformationManagementSoftwareMember_zGCQh3V0aqak" title="Finite lived intangible asset, useful life">24 months</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,200</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsGross_if_pn3n3_hus-gaap--FairValueByAssetClassAxis__custom--OtherInfiniteLivedIntangibleAssetMember_zJlQ4UP61zAk" style="vertical-align:

bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_c20240930__us-gaap--FairValueByAssetClassAxis__custom--OtherInfiniteLivedIntangibleAssetMember_zbdgwuMWhFa3" title="Finite lived intangible asset, useful life"><span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_c20231231__us-gaap--FairValueByAssetClassAxis__custom--OtherInfiniteLivedIntangibleAssetMember_zOKYeG5SLrc1" title="Finite lived intangible asset, useful life">1 year</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">70</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">70</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_maFLIANzSNS_z8jtJkMWM8ue" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total Intangible assets</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">70</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,375</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pn3n3_di_msFLIANzSNS_zMZ8T2WlMstj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less Accumulated Amortization</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(70</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,951</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzSNS_zwiNA75fgxll" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Intangible Assets, net</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,424</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>   Amortization expense of the intangible assets discussed above was $82 and $505 for the three month periods ended September 30, 2024 and 2023, respectively, and $559 and $1,516 for the nine month periods ended September 30, 2024 and 2023, respectively, and is included in amortization of acquired intangible assets in the accompanying unaudited condensed consolidated statements of operations. Following the deconsolidation of Lucid, the Company had an intangible assets, net balance of $0, and no estimated future amortization expense. See Note 4, <i>Equity Method Investment</i>, for additional information on the Lucid deconsolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_89B_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zTKhzAoC3gM2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Intangible assets, less accumulated amortization, consisted of the following as of:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">Schedule of Intangible Assets, Less Accumulated Amortization </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Estimated Useful Life</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20240930_zSFHddwuUP35" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20231231_z3fZkZZa8flh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_hus-gaap--FairValueByAssetClassAxis__custom--DefensiveAssetMember_zxDlCAzWXnBh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Defensive asset</td><td style="width: 2%"> </td> <td style="width: 18%; text-align: center">60 months</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,105</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_hus-gaap--FairValueByAssetClassAxis__custom--LaboratoryInformationManagementSoftwareMember_znjROs3vCTjj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Laboratory licenses and certifications and laboratory information management software</td><td> </td> <td style="text-align: center">24 months</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,200</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_hus-gaap--FairValueByAssetClassAxis__custom--OtherInfiniteLivedIntangibleAssetMember_zJlQ4UP61zAk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt">1 year</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">70</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">70</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_maFLIANzSNS_z8jtJkMWM8ue" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total Intangible assets</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">70</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,375</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pn3n3_di_msFLIANzSNS_zMZ8T2WlMstj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less Accumulated Amortization</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(70</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,951</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzSNS_zwiNA75fgxll" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Intangible Assets, net</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,424</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> P60MP60M21050000P24MP24M3200000P1YP1Y70000700007000053750007000039510001424000820005050005590001516000 Note 9 — Commitment and Contingencies   Other Matters   In the ordinary course of PAVmed business, particularly as it begins commercialization of its products, the Company may be subject to certain other legal actions and claims, including product liability, consumer, commercial, tax and governmental matters, which may arise from time to time. The Company is not aware of any such pending legal or other proceedings that are reasonably likely to have a material impact on the Company. Notwithstanding, legal proceedings are subject to inherent uncertainties, and an unfavorable outcome could include monetary damages, and excessive verdicts can result from litigation, and as such, could result in a material adverse impact on the Company's business, financial position, results of operations, and /or cash flows. Additionally, although the Company has specific insurance for certain potential risks, the Company may in the future incur judgments or enter into settlements of claims which may have a material adverse impact on the Company's business, financial position, results of operations, and /or cash flows.   Note 10 — Financial Instruments Fair Value Measurements   Recurring Fair Value Measurements   <p id="xdx_891_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_ziZlbhm6TsWi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">The fair value hierarchy table for the periods indicated is as follows: Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">Fair Value Measurement on a Recurring Basis at Reporting Date Using¹</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level-1 Inputs</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level-2 Inputs</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level-3 Inputs</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-

align: bottom; background-color: rgb(204,238,255)"> <td>September 30, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 40%; text-align: left; padding-bottom: 1pt">Investment in Lucid Diagnostics, Inc common stock</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">25,511</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">25,511</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Total assets at fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">25,511</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">25,511</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Senior Secured Convertible Note - April 2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fMQ____zjoiEAwEZ5Y6" title="Total liabilities at fair value">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fMQ____zDmUZP6SBRW8" title="Total liabilities at fair value">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_fMQ____zV0pDQosmFBl" title="Total liabilities at fair value">19,850</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember_fMQ____zU287vJkcmO8" title="Total liabilities at fair value">19,850</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Senior Secured Convertible Note - September 2022</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fMQ____zLUgtKqXZj7a" title="Total liabilities at fair value">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">12,200</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">12,200</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Total liabilities at fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">32,050</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">32,050</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level-1 Inputs</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level-2 Inputs</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level-3 Inputs</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 40%; text-align: left">Senior Secured Convertible Note - April 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">19,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span id="xdx_905_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember_fMQ____z5WRnowZqWNb" title="Total liabilities at fair value">19,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Senior Secured Convertible Note - September 2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fMQ____z5s36LaFDxnh" title="Total liabilities at fair value">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-

gaap--LiabilitiesFairValueDisclosure_if_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fMQ____zSBLNeLJ4Pfl" title="Total liabilities at fair value">—</td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--LiabilitiesFairValueDisclosure_if_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_fMQ____zhXM68V1lf03" title="Total liabilities at fair value">11,250</td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--LiabilitiesFairValueDisclosure_if_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_fMQ____zGXrmfIS94qe" title="Total liabilities at fair value">11,250</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Lucid Senior Secured Convertible Note – March 2023</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eus-gaap--LiabilitiesFairValueDisclosure_if_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fMQ____z4f5arzil9Vf" title="Total liabilities at fair value">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">13,950</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">13,950</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Total liabilities at fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--LiabilitiesFairValueDisclosure_if_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fMQ____zKkzNDuO9yZg" title="Total liabilities at fair value">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--LiabilitiesFairValueDisclosure_if_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_fMQ____zdSsSTOVu3Dg" title="Total liabilities at fair value">44,200</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">44,200</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">¹</td><td style="text-align: justify">There were no transfers between the respective Levels during the nine months ended September 30, 2024.</td></tr></table> As discussed in Note 11, Debt, the Company issued Senior Secured Convertible Notes dated April 4, 2022 and September 8, 2022, with an initial $27.5 million face value principal (“April 2022 Senior Convertible Note”) and an initial $11.25 million face value principal (“September 2022 Senior Convertible Note”), respectively. Both convertible notes are accounted for under the ASC 825-10-15-4 fair value option (“FVO”) election, wherein, the financial instrument is initially measured at its issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. As discussed in Note 11, Debt, Lucid Diagnostics issued a Senior Secured Convertible Note dated March 21, 2023, with an initial $11.1 million face value principal (“Lucid March 2023 Senior Convertible Note”). From and after September 10, 2024, the date of Lucid’s deconsolidation from PAVmed’s result of operation, the Company’s investment in Lucid has been accounted for as an equity method investment. For the periods prior to the deconsolidation, Lucid’s convertible note is presented in PAVmed’s balance sheets and is also accounted for under the ASC 825-10-15-4 fair value option (“FVO”) election, wherein, the financial instrument is initially measured at its issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">The estimated fair value of the financial instruments classified within the Level 3 category was determined using both observable inputs and unobservable inputs. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long- dated volatilities) inputs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Note 10 — Financial Instruments Fair Value Measurements - continued</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p> <p id="xdx_89C_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zXvbLUWvLEsh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">The estimated fair value of the April 2022 Senior Convertible Note and the September 2022 Senior Convertible Note as of September 30, 2024 and the estimated fair value of the April 2022 Senior Convertible Note, the September 2022 Senior Convertible Note and the Lucid March 2023 Senior Convertible Note as of December 31, 2023, were computed using a Monte Carlo simulation of the present value of its cash flows using a synthetic credit rating analysis and a required rate-of-return, using the following assumptions:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Schedule of Fair Value Assumption Used </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">April 2022 Senior
 Convertible Note;
September 30, 2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">September 2022 Senior
 Convertible Note;
September 30, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Fair Value</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--DebtInstrumentFairValue_if_pn3n3_c20240930__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember_zFH8AwxY4y9e" style="width: 16%; text-align: right" title="Debt instrument fair value">19,850</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--DebtInstrumentFairValue_if_pn3n3_c20240930__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zc8k7Oj4W26h" style="width: 16%; text-align: right" title="Debt instrument fair value">12,200</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Face value principal payable</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--DebtInstrumentFaceAmount_if_pn3n3_c20240930__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember_zkLcrg69ckjf" style="text-align: right" title="Face value principal payable">17,602</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtInstrumentFaceAmount_if_pn3n3_c20240930__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zv8U6JDpO7g" style="text-align: right" title="Face value principal payable">7,627</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Required rate of return</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9.000</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8.800</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Conversion Price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">75.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">75.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Value of common stock</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--DebtInstrumentMeasurementInput_if_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember_zAcPTwwQ1ne" title="Fair value assumption measurement input">1.23</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_eus-gaap--

DebtInstrumentMeasurementInput_if_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zps4VSjgyuk4" title="Fair value assumption measurement input">1.23</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20240930__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z8furhnJ12Xf" title="Expected term years">0.51</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20240930__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zMzmqIv3TF88" title="Expected term years">0.94</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--DebtInstrumentMeasurementInput_if_pid_uPure_c20240930__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zfg7vCX2nQb3" title="Fair value assumption measurement input">160.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_if_pid_uPure_c20240930__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zpoap6SrREVa" title="Fair value assumption measurement input">160.00</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk free rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_if_pid_uPure_c20240930__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z19hl6WhM70h" title="Fair value assumption measurement input">4.28</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_if_pid_uPure_c20240930__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zUObiNOYU1ka" title="Fair value assumption measurement input">3.95</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_if_pid_uPure_c20240930__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zutt9Yviywgj" title="Fair value assumption measurement input">—</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_if_pid_uPure_c20240930__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zcbSUDdADLa9" title="Fair value assumption measurement input">—</td><td style="text-align: left">%</td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">April 2022 Senior
 Convertible Note:
December 31, 2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">September 2022
 Senior
 Convertible Note:
December 31, 2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Lucid March 2023
 Senior
 Convertible Note:
December 31, 2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Fair Value</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--DebtInstrumentFairValue_if_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember_zycbjZ68gmS3" style="width: 16%; text-align: right" title="Debt instrument fair value">19,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--DebtInstrumentFairValue_if_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zW6c8j3HU867" style="width: 16%; text-align: right" title="Debt instrument fair value">11,250</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DebtInstrumentFairValue_if_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember_zxZkiA0rRAM7" style="width: 16%; text-align: right" title="Debt instrument fair value">13,950</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Face value principal payable</td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--DebtInstrumentFaceAmount_if_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember_zcWAGTblbQvd" style="text-align: right" title="Face value principal payable">17,602</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--DebtInstrumentFaceAmount_if_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zx1tvnxa7Uw7" style="text-align: right" title="Face value principal payable">9,062</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtInstrumentFaceAmount_if_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember_zDXgYU9NzrBd" style="text-align: right" title="Face value principal payable">11,019</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Required rate of return</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_if_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRequiredRateOfReturnMember__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember__srt--RangeAxis__srt--MinimumMember_z2wNrbIUjJp5" title="Fair value assumption measurement input">10.00% - 10.50</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10.00% - 10.20</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10.00</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Conversion Price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">75.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">75.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Value of common stock</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_902_eus-gaap--DebtInstrumentMeasurementInput_if_pid_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zpDWj1z2QvK5" title="Fair value assumption measurement input">1.41</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zS6FgjIrDUQf" title="Expected term years">0.26 - <span id="xdx_90C_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zxa8gRXkVG" title="Expected term years">1.26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zY7uK2kkH7ee" title="Expected term years">0.69 - <span id="xdx_908_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zSEXuOGqiUv9" title="Expected term years">1.69</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember_znW6VmJYuRH7" title="Expected term years">1.22</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--DebtInstrumentMeasurementInput_if_pid_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zud20hqRH77l" title="Fair value assumption measurement input">85.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_if_pid_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z1yJIU8qxuZi" title="Fair value assumption measurement input">85.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_if_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember_zKI0en88FMc8"

title="Fair value assumption measurement input">60.00</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk free rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_il_pid_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zB9WoxnhFmre" title="Fair value assumption measurement input">4.54% - <span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_il_pid_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zszta4nRHaGk" title="Fair value assumption measurement input">5.25</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--DebtInstrumentMeasurementInput_il_pid_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zO490Vx3n1e3" title="Fair value assumption measurement input">4.31% - <span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_il_pid_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_z7DWoHtMnl8c" title="Fair value assumption measurement input">4.96</td><td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_il_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember_ztdru85KCjo1" title="Fair value assumption measurement input">4.56</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_il_pid_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zPdQUJmSB8Le" title="Fair value assumption measurement input">—</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--DebtInstrumentMeasurementInput_il_pid_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z1X1qsY9x2B5" title="Fair value assumption measurement input">—</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--DebtInstrumentMeasurementInput_il_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember_zE1cdKUcGrj" title="Fair value assumption measurement input">—</td><td style="text-align: left">%</td></tr> </table>   The estimated fair values recognized utilized PAVmed's and Lucid's common stock prices, along with certain Level 3 inputs (as presented in the respective tables above), in the development of Monte Carlo simulation models, discounted cash flow analyses, and /or Black-Scholes valuation models. The estimated fair values are subjective and are affected by changes in inputs to the valuation models and analyses, including the respective common stock prices, as compared to the floor price on conversions, the dividend yields, the risk-free rates based on U.S. Treasury security yields, and certain other Level-3 inputs including, assumptions regarding the estimated volatility in the value of the respective common stock prices. Changes in these assumptions can materially affect the recognized estimated fair values.   <p id="xdx_891_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_ziZlbhm6TsWi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">The fair value hierarchy table for the periods indicated is as follows: Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">Fair Value Measurement on a Recurring Basis at Reporting Date Using¹</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level-1 Inputs</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level-2 Inputs</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level-3 Inputs</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>September 30, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 40%; text-align: left; padding-bottom: 1pt">Investment in Lucid Diagnostics, Inc common stock</td><td style="width: 2%; padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">25,511</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">25,511</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Total assets at fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">25,511</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">25,511</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Senior Secured Convertible Note - April 2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fMQ____zjoiEAwEZ5Y6" title="Total liabilities at fair value">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fMQ____zDmUZP6SBRW8" title="Total liabilities at fair value">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_fMQ____zV0pDQosmFBl" title="Total liabilities at fair value">19,850</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember_fMQ____zU287vJkcmO8" title="Total liabilities at fair value">19,850</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Senior Secured Convertible Note - September 2022</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fMQ____zLUgtKqXZj7a" title="Total liabilities at fair value">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">12,200</td><td style="padding-bottom: 1pt; text-align: left"> </td><td

style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">12,200</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Total liabilities at fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">32,050</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">32,050</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level-1 Inputs</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level-2 Inputs</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level-3 Inputs</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 40%; text-align: left">Senior Secured Convertible Note - April 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">19,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span id="xdx_905_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember_fMQ____z5WRnowZqWNb" title="Total liabilities at fair value">19,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Senior Secured Convertible Note - September 2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fMQ____z5s36LaFDxnh" title="Total liabilities at fair value">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_fMQ____zSBLNeLJ4PfI" title="Total liabilities at fair value">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_fMQ____zhXM68V1lf03" title="Total liabilities at fair value">11,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_fMQ____zGXrmfIS94qe" title="Total liabilities at fair value">11,250</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Lucid Senior Secured Convertible Note - March 2023</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_fMQ____z4f5arzil9Vf" title="Total liabilities at fair value">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">13,950</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">13,950</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Total liabilities at fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">44,200</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">44,200</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">[1]</td><td style="text-align: justify">There were no transfers between the respective Levels during the nine months ended September 30, 2024.</td></tr></table>

2551100025511000255110002551100019850000198500001220000012200000320500003205000019000000190000001125000011250000139500001395000044200000442000(

id="xdx_89C_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zXvbLUWvLEsh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">The estimated fair value of the April 2022 Senior Convertible Note and the September 2022 Senior Convertible Note as of September 30, 2024 and the estimated fair value of the April 2022 Senior Convertible Note, the September 2022 Senior Convertible Note and the Lucid March 2023 Senior Convertible Note as of December 31, 2023, were computed using a Monte Carlo simulation of the present value of its cash flows using a synthetic credit rating analysis and a required rate-of-return, using the following assumptions: Schedule of Fair Value Assumption Used   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">April 2022 Senior
 Convertible Note:
September 30, 2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">September 2022 Senior
 Convertible Note:
September 30, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Fair Value</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--DebtInstrumentFairValue_iI_pn3n3_c20240930__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember_zFH8AwxY4y9e" style="width: 16%; text-align: right" title="Debt instrument fair value">19,850</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--DebtInstrumentFairValue_iI_pn3n3_c20240930__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zc8k7Qj4W26h" style="width: 16%; text-align: right" title="Debt instrument fair value">12,200</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Face value principal payable</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20240930__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember_zkLcrg69ckjf" style="text-align: right" title="Face value principal payable">17,602</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td>

id="xdx_98F_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20240930__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zv8U6IJDpQ7g" style="text-align: right" title="Face value principal payable">7,627</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Required rate of return</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9.000</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8.800</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Conversion Price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">75.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">75.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Value of common stock</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1.23</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zps4VSjgyuk4" title="Fair value assumption measurement input">1.23</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20240930__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z8furhnJ12Xf" title="Expected term years">0.51</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20240930__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zMzmqIv3TF88" title="Expected term years">0.94</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240930__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zfg7vCX2nQb3" title="Fair value assumption measurement input">160.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240930__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zpoap6SrREVa" title="Fair value assumption measurement input">160.00</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk free rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240930__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z19hI6WhM70h" title="Fair value assumption measurement input">4.28</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240930__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zUObiNOYU1ka" title="Fair value assumption measurement input">3.95</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240930__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember__us-gaap--MeasurementInputExpectedDividendRateMember_zutt9Yviywgj" title="Fair value assumption measurement input">—</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240930__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zcbSUDdADLa9" title="Fair value assumption measurement input">—</td><td style="text-align: left">%</td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">April 2022 Senior
 Convertible Note:
December 31, 2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">September 2022
 Senior
 Convertible Note:
December 31, 2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Lucid March 2023
 Senior
 Convertible Note:
December 31, 2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Fair Value</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--DebtInstrumentFairValue_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember_zycbjZ68qmS3" style="width: 16%; text-align: right" title="Debt instrument fair value">19,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--DebtInstrumentFairValue_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zW6c8j3HU867" style="width: 16%; text-align: right" title="Debt instrument fair value">11,250</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DebtInstrumentFairValue_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember_zxZkiA0rRAM7" style="width: 16%; text-align: right" title="Debt instrument fair value">13,950</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Face value principal payable</td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember_zcWAGTblbQvd" style="text-align: right" title="Face value principal payable">17,602</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zx1tvnxa7Uw7" style="text-align: right" title="Face value principal payable">9,062</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember_zDXqYU9NzrBd" style="text-align: right" title="Face value principal payable">11,019</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Required rate of return</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRequiredRateOfReturnMember__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember__srt--RangeAxis__srt--MinimumMember_z2wNrbJUjIp5" title="Fair value assumption measurement input">10.00% - 10.50</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10.00% - 10.20</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10.00</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Conversion Price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">75.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">75.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Value of common stock</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_902_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zpDWj1z2QvK5" title="Fair value assumption measurement input">1.41</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zS6FgjIrDUQf" title="Expected term

years">0.26 - <span id="xdx_90C_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zxa8gRXkVG" title="Expected term years">1.26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zY7uK2kkH7ee" title="Expected term years">0.69 - <span id="xdx_908_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zSEXuOGqiUv9" title="Expected term years">1.69</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember_znW6VmJYuRH7" title="Expected term years">1.22</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zud20hqRH77l" title="Fair value assumption measurement input">85.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z1yJIU8qxuZi" title="Fair value assumption measurement input">85.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember_zKI0en88FMc8" title="Fair value assumption measurement input">60.00</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk free rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zB9WoxnhFmre" title="Fair value assumption measurement input">4.54% - <span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zszta4nRHaGk" title="Fair value assumption measurement input">5.25</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zO490Vx3n1e3" title="Fair value assumption measurement input">4.31% - <span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_z7DWoHtMnl8c" title="Fair value assumption measurement input">4.96</td><td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember_ztdru85KCjo1" title="Fair value assumption measurement input">4.56</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zPdQUJmSB8Le" title="Fair value assumption measurement input">—</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z1X1qsY9x2B5" title="Fair value assumption measurement input">—</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember_zE1cdKUcGrj" title="Fair value assumption measurement input">—</td><td style="text-align: left">%</td></tr> </table>
1985000012200000176020007627000 9.0008.80075.0075.001.231.23P0Y6M3DP0Y11M8D160.00160.004.283.95190000000112500001395000017602000906200011019000010.00 id="xdx_801_eus-gaap--DebtDisclosureTextBlock_zceN1nXCP883" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Note 11 — Debt   The fair value and face value principal outstanding of the Senior Convertible Notes as of the dates indicated are as follows: Summary of Outstanding Debt   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center">Contractual Maturity Date</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Stated Interest Rate</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Conversion
 Price per Share</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Face Value
 Principal Outstanding</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Fair Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 23%; text-align: left">April 2022 Senior Convertible Note</td><td style="width: 2%"> </td> <td style="width: 15%; text-align: center">April 4, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240930__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember_zJ0qpwnxRFV1" style="width: 11%; text-align: right" title="Stated Interest Rate">7.875</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20240930__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember_zh1yWKBZmyrf" style="width: 11%; text-align: right" title="Conversion Price">75.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20240930__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember_zT3F5jYwwfj7" style="width: 11%; text-align: right" title="Face Value Principal Outstanding">17,602</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--DebtInstrumentFairValue_iI_pn3n3_c20240930__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember_zPp0KE4BeUbk" style="width: 11%; text-align: right" title="Fair Value">19,850</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">September 2022 Senior Convertible Note</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt">September 8, 2025</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_989_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240930__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_z5k3eE3rxUEd" style="padding-bottom: 1pt; text-align: right" title="Stated Interest Rate">7.875</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98C_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20240930__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zdugrK3tXcXl" style="padding-bottom: 1pt; text-align: right" title="Conversion Price">75.00</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20240930__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zjEzhTebUwmb" style="border-bottom: Black 1pt solid; text-align: right" title="Face Value Principal Outstanding">7,627</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--DebtInstrumentFairValue_iI_pn3n3_c20240930__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zhEpcspfEIF2" style="border-bottom: Black 1pt solid; text-align: right" title="Fair Value">12,200</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance as of September 30, 2024</td><td> </td> <td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20240930_z35fw3fvbQzf" style="text-align: right" title="Face Value Principal Outstanding">25,229</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--DebtInstrumentFairValue_iI_pn3n3_c20240930_zsrTt4K2Jf8i" style="text-align: right" title="Fair Value">32,050</td><td style="text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center">Contractual Maturity Date</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Stated Interest Rate</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Conversion Price per Share</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Face Value Principal Outstanding</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Fair Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 23%; text-align: left">April 2022 Senior Convertible Note</td><td style="width: 2%"> </td> <td style="width: 15%; text-align: center">April 4, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember_zRCig6qKRRr7" style="width: 11%; text-align: right" title="Stated Interest Rate">7.875</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pp2d_c20231231__us-gaap--DebtInstrumentAxis__custom--

AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember_zSxrzV2tSON3" style="width: 11%; text-align: right" title="Conversion Price">75.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember_zGjXDYG7Lp2a" style="width: 11%; text-align: right" title="Face Value Principal Outstanding">17,602</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--DebtInstrumentFairValue_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember_z6OUE1kxdIrb" style="width: 11%; text-align: right" title="Fair Value">19,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">September 2022 Senior Convertible Note</td><td> </td> <td style="text-align: center">September 8, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zWonBRWy6TP4" style="text-align: right" title="Stated Interest Rate">7.875</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pp2d_c20231231__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zDilj7YSm5jl" style="text-align: right" title="Conversion Price">75.00</td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zMEq1jLhpgY9" style="text-align: right" title="Face Value Principal Outstanding">9,062</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--DebtInstrumentFairValue_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zvuO7rcydov1" style="text-align: right" title="Fair Value">11,250</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Lucid March 2023 Senior Convertible Note</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt">March 21, 2025</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_983_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember_zprQ0HdRy7M1" style="padding-bottom: 1pt; text-align: right" title="Stated Interest Rate">7.875</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_981_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pp2d_c20231231__us-gaap--DebtInstrumentAxis__custom--LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember_z0WtCf2HzYdg" style="padding-bottom: 1pt; text-align: right" title="Conversion Price">5.00</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember_zuVWgAO1G7Rc" style="border-bottom: Black 1pt solid; text-align: right" title="Face Value Principal Outstanding">11,019</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--DebtInstrumentFairValue_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember_zquIgWm1xdO2" style="border-bottom: Black 1pt solid; text-align: right" title="Fair Value">13,950</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Balance as of December 31, 2023</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231231_zje2vLXm8vo5" style="text-align: right" title="Face Value Principal Outstanding">37,683</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtInstrumentFairValue_iI_pn3n3_c20231231_z6Q97jlKsvWc" style="text-align: right" title="Fair Value">44,200</td><td style="text-align: left"> </td></tr> </table>   <p id="xdx_89E_eus-gaap--ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_zo33MAKulu13" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in">The changes in the fair value of debt during the three and nine month periods ended September 30, 2024 is as follows: Schedule of Changes in Fair Value of Debt <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B0_us-gaap--DebtInstrumentAxis_custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember_zPwu0o2uPXbc" style="border-bottom: Black 1pt solid; text-align: center">April 2022 Senior Convertible Note</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B8_us-gaap--DebtInstrumentAxis_custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_z3MzGOoBaZ63" style="border-bottom: Black 1pt solid; text-align: center">September 2022 Senior Convertible Note</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B9_us-gaap--DebtInstrumentAxis_custom--LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember_z2CmKkYPr1W5" style="border-bottom: Black 1pt solid; text-align: center">Lucid March 2023 Senior Convertible Note</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B3_zXe8Qw0ttKYf" style="border-bottom: Black 1pt solid; text-align: center">Sum of Balance Sheet Fair Value Components</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B2_us-gaap--DebtInstrumentAxis_custom--OtherIncomeExpenseMember_zsh6a2vjkgi9" style="border-bottom: Black 1pt solid; text-align: center">Other Income (expense)</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_43A_c20240701__20240930_eus-gaap--DebtInstrumentCarryingAmount_iS_pn3n3_z34J4UE8IRyi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%">Fair Value - June 30, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">19,200</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">13,600</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,200</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">44,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DebtInstrumentIssuedPrincipal_pn3n3_zkEW4KuxbBHe" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Face value principal - issue date</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--FairValueAdjustmentIssueDate_pn3n3_z0k1D4fiuAni" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value adjustment - issue date</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DebtInstrumentPeriodicPayment_iN_pn3n3_di_zlZyJfV7gTq8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Installment repayments - common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(455</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(797</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,252</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DebtInstrumentRepaidPrincipal_iN_pn3n3_di_zUjso58booui" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Non-installment payments - common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(55</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(135</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(190</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--DeconsolidationFairValueOfDebt_pn3n3_zYoGb2J4hAHg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Deconsolidation of Lucid Diagnostics</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(10,268</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--DebtInstrumentsFairValue_pn3n3_zXxMx9rp2kMl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">650</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(890</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(240</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">240</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_43A_c20240701__20240930_eus-gaap--DebtInstrumentCarryingAmount_iE_pn3n3_zCB393VCHXph" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Fair Value at September 30, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">19,850</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">12,200</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">32,050</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Other Income (Expense) – Change in fair value – three month period ended September 30, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_ecustom--OtherIncomeExpenseChangeInFairValue_iN_pn3n3_di_c20240701__20240930_zIOAmfdW3QJi" style="border-bottom: Black 1pt solid; text-align: right" title="Other Income

(Expense) - Change in fair value">240</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B0_us-gaap--DebtInstrumentAxis_custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember_zubAnMaaGJ82" style="border-bottom: Black 1pt solid; text-align: center">April 2022 Senior Convertible Note</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B8_us-gaap--DebtInstrumentAxis_custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zF2RtWC3AgW5" style="border-bottom: Black 1pt solid; text-align: center">September 2022 Senior Convertible Note</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B9_us-gaap--DebtInstrumentAxis_custom--LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember_z6BcuiAs6Kfi" style="border-bottom: Black 1pt solid; text-align: center">Lucid March 2023 Senior Convertible Note</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B3_zeeAqPWUvBFk" style="border-bottom: Black 1pt solid; text-align: center">Sum of Balance Sheet Fair Value Components</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B2_us-gaap--DebtInstrumentAxis_custom--OtherIncomeExpenseMember_z06clR5xOBw2" style="border-bottom: Black 1pt solid; text-align: center">Other Income (expense)</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_43A_c20240101__20240930_eus-gaap--DebtInstrumentCarryingAmount_iS_pn3n3_zR27vQZnFOBf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%">Fair Value - December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">19,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,250</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">13,950</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">44,200</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DebtInstrumentPeriodicPayment_iN_pn3n3_di_z6mdwXFMj0zj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Installment repayments - common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,435</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,005</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,440</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DebtInstrumentRepaidPrincipal_iN_pn3n3_di_z4a3uoFsXym5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Non-installment payments - common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(143</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(787</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(930</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--DeconsolidationFairValueOfDebt_pn3n3_zqDXlOtaNhng" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Deconsolidation of Lucid Diagnostics</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(10,268</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(10,268</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--DebtInstrumentsFairValue_pn3n3_zVEtGu579j7b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">850</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,528</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(890</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,488</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,488</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_433_c20240101__20240930_eus-gaap--DebtInstrumentCarryingAmount_iE_pn3n3_zNVpoCPWAXj8" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Fair Value at September 30, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">19,850</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">12,200</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">32,050</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Other Income (Expense) - Change in fair value - nine month period ended September 30, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td id="xdx_983_ecustom--OtherIncomeExpenseChangeInFairValue_iN_pn3n3_di_c20240101__20240930_zDCFNpT03xI8" style="border-bottom: Black 1pt solid; text-align: right" title="Other Income (Expense) - Change in fair value">(2,488</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Note 11 — Debt - continued</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The changes in the fair value of debt during the three and nine month periods ended September 30, 2023 is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B0_us-gaap--DebtInstrumentAxis_custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember_zQK0qscBvFwj" style="border-bottom: Black 1pt solid; text-align: center">April 2022 Senior Convertible Note</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B8_us-gaap--DebtInstrumentAxis_custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_z3WDfKYMNuWe" style="border-bottom: Black 1pt solid; text-align: center">September 2022 Senior Convertible Note</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B9_us-gaap--DebtInstrumentAxis_custom--LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember_zXEaXM43nKPk" style="border-bottom: Black 1pt solid; text-align: center">Lucid March 2023 Senior Convertible Note</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B3_zV5LbrAMVZb3" style="border-bottom: Black 1pt solid; text-align: center">Sum of Balance Sheet Fair Value Components</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B2_us-gaap--DebtInstrumentAxis_custom--OtherIncomeExpenseMember_zDBZOZjGMd56" style="border-bottom: Black 1pt solid; text-align: center">Other Income (expense)</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_43F_c20230701__20230930_eus-gaap--DebtInstrumentCarryingAmount_iS_pn3n3_zDzdUACfQgmj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%">Fair Value - June 30, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">19,530</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,850</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,610</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">42,990</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DebtInstrumentPeriodicPayment_iN_pn3n3_di_zrfiu3jRiai4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Installment repayments - common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(952</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,207</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(92</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,251</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DebtInstrumentRepaidPrincipal_iN_pn3n3_di_zC84l8VCGynd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Non-installment payments - common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(41</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(51</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(49</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(141</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--DebtInstrumentsFairValue_pn3n3_zZJDxBhhM5sh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">863</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">508</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,021</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,392</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,392</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_43E_c20230701__20230930_eus-gaap--DebtInstrumentCarryingAmount_iE_pn3n3_zSPKMLQ7FTXe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Fair Value at September 30, 2023</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">19,400</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">11,100</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">14,490</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">44,990</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom:

1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Other Income (Expense) - Change in fair value - three month period ended September 30, 2023</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left">

id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20220404__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember_zBPWpizKwuX1">75.00 per share of the Company's common stock (subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transaction), and a contractual maturity date of <span id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_c20220402__20220404__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember_zInUyjwsiv44" title="Debt instrument, maturity date">April 4, 2024, which <span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDateDescription_c20220402__20220404__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember_zLUDygOh0tm8" title="Debt instrument maturity date, description">maturity date the investor agreed to extend by one year, to April 4, 2025. The April 2022 Senior Convertible Note may be converted into shares of common stock of the Company at the Holder's election.   Under the same SPA, the Company issued an additional Senior Secured Convertible Note dated September 8, 2022, referred to herein as the "September 2022 Senior Convertible Note", with such note having a $11.25 million face value principal, a <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220908__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zFRvoOYFtuS6" title="Debt interest rate">7.875% annual stated interest rate, a contractual conversion price of $<span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20220908__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zd9Oko3p5eBb" title="Conversion price">75.00 per share of the Company's common stock (subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transaction), and a contractual maturity date of <span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20220907__20220908__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zoRr8c5BqCBl" title="Debt instrument maturity date, description">September 6, 2024, which <span id="xdx_904_eus-gaap--DebtInstrumentMaturityDateDescription_c20220907__20220908__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zkjTS1vI651b" title="Debt instrument maturity date, description">maturity date the investor agreed to extend by one year, to September 8, 2025. The September 2022 Senior Convertible Note may be converted into shares of common stock of the Company at the Holder's election.   Note 11 — Debt - continued   The Company agreed to reduce temporarily, and the Investor consented to reducing temporarily, the contractual conversion price under the April 2022 Senior Convertible Note and the September 2022 Senior Convertible Note to equal to <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240930__us-gaap--DebtInstrumentAxis__custom--AprilAndSeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zncyt3A8vFla">82.5% of the two lowest VWAPs during the last 10 trading days preceding the date of conversion, subject to a conversion floor price of $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20240930__us-gaap--DebtInstrumentAxis__custom--AprilAndSeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember__us-gaap--AwardDateAxis__custom--JuneThirtyTwentyTwentyFourThroughSeptemberThreeTwentyTwentyFourMember_zyjS6PHEIOq3" title="Conversion price">0.40, during the period from June 30, 2024 through September 3, 2024; provided that the aggregate amount of conversions under the April 2022 Senior Convertible Note and the September 2022 Senior Convertible Note during such period may not exceed <span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pn6n6_c20240101__20240930__us-gaap--DebtInstrumentAxis__custom--AprilAndSeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zNzzGGec6Jej" title="Senior convertible note">1 million shares.   <span id="xdx_901_eus-gaap--DebtInstrumentDescription_c20240101__20240930__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zc1x54EQJea2" title="Debt instrument, description">The Company is subject to financial covenants requiring: (i) a minimum of $8.0 million of available cash at all times; (ii) the ratio of (a) the outstanding principal amount of the total senior convertible notes outstanding, accrued and unpaid interest thereon and accrued and unpaid late charges to (b) the Company's average market capitalization over the prior ten trading days, to not exceed 30% (the "Debt to Market Cap Ratio Test"); and (iii) the Company's market capitalization to at no time be less than $75 million (the "Market Cap Test" and, together with the Debt to Market Cap Ratio Test, the "Financial Tests"). From time to time from and after September 1, 2024 through November 11, 2024, the Company was not in compliance with the Financial Tests. As of November 11, 2024, the Investor agreed to waive any such non-compliance during such time period and thereafter through December 31, 2024.   In consideration of a prior covenant waiver and maturity extension agreed to in March 2024, the Company agreed to pay the holder of the notes $2,000 in cash (or in such other form as may be mutually agreed in writing). The covenant waiver and maturity extension fee was recognized as debt modification expense on the Company's unaudited condensed consolidated statement of operations, and is currently included in accrued expenses and other current liabilities on the Company's unaudited condensed consolidated balance sheets as of September 30, 2024.   The April 2022 Senior Convertible Note and September 2022 Senior Convertible Note installment payments may be made in shares of PAVmed common stock at a conversion price that is the lower of the contractual conversion price and <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240930__us-gaap--DebtInstrumentAxis__custom--AprilAndSeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_z81vYWr6DqXg">82.5% of the two lowest VWAPs during the last 10 trading days preceding the date of conversion, subject to a conversion price floor of $<span id="xdx_90F_ecustom--DebtInstrumentConvertibleStockPrice_iI_pid_c20240930__us-gaap--DebtInstrumentAxis__custom--AprilAndSeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zdpLUcsKwLc4" title="Conversion price per share">2.70. The notes are also subject to certain provisions that may require redemption upon the occurrence of certain events, including an event of default, a change of control, or certain equity issuances.   In the three and nine month periods ended September 30, 2024, approximately $<span id="xdx_903_eus-gaap--RepaymentsOfConvertibleDebt_pn3n3_c20240701__20240930__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zUz8Cz2LreXk" title="Repayment for debt">455 and $<span id="xdx_90B_eus-gaap--RepaymentsOfConvertibleDebt_pn3n3_c20240101__20240930__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_ziD0wn3ilL45" title="Repayment for debt">1,435, respectively, of principal repayments along with approximately $55 and $143, respectively, of interest expense thereon, were settled through the issuance of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240701__20240930__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zKo7PrREmf2" title="Conversions - Senior Secured Convertible Note, shares">509,942 and <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240101__20240930__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zASDppUnnXUd" title="Conversions - Senior Secured Convertible Note, shares">1,084,366, respectively, shares of common stock of the Company, with such shares having a fair value of approximately $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_pn3n3_c20240701__20240930__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zNI24QYJ7ey8" title="Conversions - Senior Secured Convertible Note">907 and $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_pn3n3_c20240101__20240930__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zrt1i4MBedNf" title="Conversions - Senior Secured Convertible Note">2,002, respectively, (with such fair value measured as the respective conversion date quoted closing price of the common stock of the Company). In addition, during the three and nine month periods ended September 30, 2024, the Company agreed to pay $<span id="xdx_907_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn3n3_c20240701__20240930__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--InterestRateFloorMember_zuE29asYh4fd" title="Gain (loss) on extinguishment of debt">652 and $<span id="xdx_90D_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn3n3_c20240101__20240930__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--InterestRateFloorMember_z44o5BrF5jH" title="Gain (loss) on extinguishment of debt">1,059, respectively, in cash related to acceleration floor payments on these notes related to the conversion price being below the floor price, which is included in debt extinguishment loss on the Company's unaudited condensed consolidated statements of operations. As of September 30, 2024, approximately $<span id="xdx_903_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_c20240930__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--InterestRateFloorMember_zTnC0G609w48" title="Acceleration floor payments">652 of acceleration floor payments owed to the holder are included in accrued expenses and other current liabilities on the Company's unaudited condensed consolidated balance sheets. The conversions and floor acceleration payments resulted in debt extinguishment losses of $<span id="xdx_904_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn3n3_c20240701__20240930__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zdIpRMQRBlGf" title="Gain (loss) on extinguishment of debt">1,050 and $<span id="xdx_90C_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn3n3_c20240101__20240930__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zIOjFn02smi2" title="Gain (loss) on extinguishment of debt">1,501 in the three and nine month periods ended September 30, 2024, respectively.   Lucid Diagnostics - Senior Secured Convertible Note   Following the deconsolidation of Lucid, the Lucid March 2023 Senior Convertible Note is no longer reflected in the Company's unaudited condensed consolidated balance sheets. See Note 4, Equity Method Investment, for additional information on the deconsolidation of Lucid.   During the period of January 1, 2024 through September 10, 2024, the date of Lucid's deconsolidation, approximately $<span id="xdx_903_eus-gaap--RepaymentsOfConvertibleDebt_pn3n3_c20240101__20240910__us-gaap--DebtInstrumentAxis__custom--LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember_z95El2ebZUhd" title="Repayment for debt">2,005 of principal repayments along with approximately $<span id="xdx_906_eus-gaap--DebtInstrumentPeriodicPaymentInterest_pn3n3_c20240101__20240910__us-gaap--DebtInstrumentAxis__custom--

LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember_zXmNhjbIAhxl">787 of interest expense thereon, were settled through the issuance of 4,172,002 shares of common stock of Lucid, with such shares having a fair value of approximately $3,801 (with such fair value measured as the respective conversion date quoted closing price of the common stock of Lucid). The conversions resulted in debt extinguishment losses of $328 in the period July 1, 2024 through September 10, 2024. The conversions resulted in debt extinguishment losses of $1,009 in the period of January 1, 2024 through September 10, 2024.   During the three and nine month periods ended September 30, 2024, the Company recognized debt extinguishment losses in total of approximately $1,403 and $2,535, respectively, in connection with the Company or Lucid (as applicable) issuing shares of its common stock for principal repayments on convertible debt mentioned above. During the three and nine month periods ended September 30, 2023, the Company recognized debt extinguishment losses in total of approximately $1,764 and $3,032, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">See Note 10, <i>Financial Instruments Fair Value Measurements</i>, for a further discussion of fair value assumptions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_894_eus-gaap--ScheduleOfDebtTableTextBlock_zGrCEELmQ5Ce" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">The fair value and face value principal outstanding of the Senior Convertible Notes as of the dates indicated are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Summary of Outstanding Debt </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center">Contractual Maturity Date</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Stated Interest Rate</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Conversion
 Price per Share</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Face Value
 Principal Outstanding</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Fair Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 23%; text-align: left">April 2022 Senior Convertible Note</td><td style="width: 2%"> </td> <td style="width: 15%; text-align: center">April 4, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240930__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember_zJ0qpwnxRFV1" style="width: 11%; text-align: right" title="Stated Interest Rate">7.875</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20240930__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember_zh1yWKBZmyrf" style="width: 11%; text-align: right" title="Conversion Price">75.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20240930__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember_zT3F5jYwwfJ7" style="width: 11%; text-align: right" title="Face Value Principal Outstanding">17,602</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--DebtInstrumentFairValue_iI_pn3n3_c20240930__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember_zPp0KE4BeUbk" style="width: 11%; text-align: right" title="Fair Value">19,850</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">September 2022 Senior Convertible Note</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20240101__20240930__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zEFLRBCsIq0h" title="Maturity Date">September 8, 2025</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_989_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240930__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_z5k3eE3rxUEd" style="padding-bottom: 1pt; text-align: right" title="Stated Interest Rate">7.875</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98C_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20240930__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zdugrK3tXcXl" style="padding-bottom: 1pt; text-align: right" title="Conversion Price">75.00</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20240930__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zjEzhTebUwmb" style="border-bottom: Black 1pt solid; text-align: right" title="Face Value Principal Outstanding">7,627</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--DebtInstrumentFairValue_iI_pn3n3_c20240930__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zhEpcspfEIF2" style="border-bottom: Black 1pt solid; text-align: right" title="Fair Value">12,200</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance as of September 30, 2024</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20240930_z35fw3fvbQzf" style="text-align: right" title="Face Value Principal Outstanding">25,229</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--DebtInstrumentFairValue_iI_pn3n3_c20240930_zsrTt4K2Jf8i" style="text-align: right" title="Fair Value">32,050</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center">Contractual Maturity Date</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Stated Interest Rate</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Conversion Price per Share</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Face Value Principal Outstanding</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Fair Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 23%; text-align: left">April 2022 Senior Convertible Note</td><td style="width: 2%"> </td> <td style="width: 15%; text-align: center">April 4, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember_zRCig6qKRRr7" style="width: 11%; text-align: right" title="Stated Interest Rate">7.875</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pp2d_c20231231__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember_zSxrzV2tSON3" style="width: 11%; text-align: right" title="Conversion Price">75.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember_zGjXDYG7Lp2a" style="width: 11%; text-align: right" title="Face Value Principal Outstanding">17,602</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--DebtInstrumentFairValue_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember_z6OUE1kxdIrb" style="width: 11%; text-align: right" title="Fair Value">19,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">September 2022 Senior Convertible Note</td><td> </td> <td style="text-align: center"><span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_z9fuJ2Wh7Cv3" title="Maturity Date">September 8, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zWonBRWy6TP4" style="text-align: right" title="Stated Interest Rate">7.875</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pp2d_c20231231__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zDilj7YSm5jl" style="text-align: right" title="Conversion Price">75.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zMEq1jLhpgY9" style="text-align: right" title="Face Value Principal Outstanding">9,062</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--DebtInstrumentFairValue_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zvuO7rcydov1" style="text-align: right" title="Fair Value">11,250</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Lucid March 2023 Senior Convertible Note</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember_zFFio5boGG5i" title="Maturity Date">March 21, 2025</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_983_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember_zprQ0HdRy7M1" style="padding-bottom: 1pt; text-align: right" title="Stated Interest Rate">7.875</td>

<td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_981_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pp2d_c20231231__us-gaap--DebtInstrumentAxis__custom--LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember_z0WtCf2HzYdg" style="padding-bottom: 1pt; text-align: right" title="Conversion Price">5.00</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember_zuVWgAO1G7Re" style="border-bottom: Black 1pt solid; text-align: right" title="Face Value Principal Outstanding">11,019</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--DebtInstrumentFairValue_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember_zquIqWm1xdO2" style="border-bottom: Black 1pt solid; text-align: right" title="Fair Value">13,950</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Balance as of December 31, 2023</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231231_zje2vLXm8vo5" style="text-align: right" title="Face Value Principal Outstanding">37,683</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtInstrumentFairValue_iI_pn3n3_c20231231_z6Q97jlKsvWc" style="text-align: right" title="Fair Value">44,200</td><td style="text-align: left"> </td></tr> </table> 2025-04-040.0787575.0017602000198500002025-09-080.0787575.0076270001220000025229000320500002025-04-040.0787575.0017602000190000002025-09-080.0787575.0090620001125000025-03-210.078755.0011019000139500003768300044200000<p id="xdx_89E_eus-gaap--ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_zo33MAKulu13" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in">The changes in the fair value of debt during the three and nine month periods ended September 30, 2024 is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in">Schedule of Changes in Fair Value of Debt </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B0_us-gaap--DebtInstrumentAxis_custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember_zPwu0o2uPXbc" style="border-bottom: Black 1pt solid; text-align: center">April 2022 Senior Convertible Note</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B8_us-gaap--DebtInstrumentAxis_custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_z3MzGOoBaZ63" style="border-bottom: Black 1pt solid; text-align: center">September 2022 Senior Convertible Note</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B9_us-gaap--DebtInstrumentAxis_custom--LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember_z2CmKkYPr1W5" style="border-bottom: Black 1pt solid; text-align: center">Lucid March 2023 Senior Convertible Note</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B3_zXe8Qw0ttKYf" style="border-bottom: Black 1pt solid; text-align: center">Sum of Balance Sheet Fair Value Components</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td><td> </td> <td colspan="2" id="xdx_4B2_us-gaap--DebtInstrumentAxis_custom--OtherIncomeExpenseMember_zsh6a2vjkgi9" style="border-bottom: Black 1pt solid; text-align: center">Other Income (expense)</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_43A_c20240701__20240930_eus-gaap--DebtInstrumentCarryingAmount_iS_pn3n3_z34J4UE8IRyi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%">Fair Value - June 30, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">19,200</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">13,600</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,200</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">44,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DebtInstrumentIssuedPrincipal_pn3n3_zkEW4KuxbBHe" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Face value principal – issue date</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--FairValueAdjustmentIssueDate_pn3n3_z0k1D4fiuAni" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value adjustment – issue date</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DebtInstrumentPeriodicPayment_iN_pn3n3_di_zlZyjfV7gTq0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Installment repayments – common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(455</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(797</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,252</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DebtInstrumentRepaidPrincipal_iN_pn3n3_di_zUjso58booui" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Non-installment payments – common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(55</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(135</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(190</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--DeconsolidationFairValueOfDebt_pn3n3_zYoGb2J4hAHg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Deconsolidation of Lucid Diagnostics</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(10,268</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(10,268</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--DebtInstrumentsFairValue_pn3n3_zXxMx9rp2kM1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">650</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(890</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(240</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">240</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_43A_c20240701__20240930_eus-gaap--DebtInstrumentCarryingAmount_iE_pn3n3_zCB393VCHXph" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Fair Value at September 30, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">19,850</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">12,200</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">32,050</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Other Income (Expense) - Change in fair value - three month period ended September 30, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_ecustom--OtherIncomeExpenseChangeInFairValue_iN_pn3n3_di_c20240701__20240930_zIOAmfdW3QJi" style="border-bottom: Black 1pt solid; text-align: right" title="Other Income (Expense) - Change in fair value">240</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B0_us-gaap--DebtInstrumentAxis_custom--AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember_zubAnMaaGJ82" style="border-bottom: Black 1pt solid; text-align: center">April 2022 Senior Convertible Note</td><td style="padding-bottom: 1pt"> </td><td colspan="2" id="xdx_4B8_us-gaap--DebtInstrumentAxis_custom--SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zF2RtWC3AgW5" style="border-bottom: Black 1pt solid; text-align: center">September 2022 Senior Convertible Note</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B9_us-gaap--DebtInstrumentAxis_custom--LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember_z6BcuiAs6Kji" style="border-bottom: Black 1pt solid; text-align: center">Lucid March 2023 Senior Convertible Note</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B3_zeeAqPWUvBFk" style="border-bottom: Black 1pt solid; text-align: center">Sum of Balance Sheet Fair Value Components</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B2_us-gaap--DebtInstrumentAxis_custom--OtherIncomeExpenseMember_z06clR5xOBw2" style="border-bottom: Black 1pt solid; text-align: center">Other Income (expense)</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_43A_c20240101__20240930_eus-gaap--DebtInstrumentCarryingAmount_iS_pn3n3_zR27vQZnFOBf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%">Fair Value - December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">19,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,250</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">13,950</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">44,200</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DebtInstrumentPeriodicPayment_iN_pn3n3_di_z6mdwXFMj0zj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Installment repayments – common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,435</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,005</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align:

right">(3,440</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DebtInstrumentRepaidPrincipal_iN_pn3n3_di_z4a3uoFsXvm5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Non-installment payments - common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(143</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(787</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(930</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--DeconsolidationFairValueOfDebt_pn3n3_zqDXlOtaNhng" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Deconsolidation of Lucid Diagnostics</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(10,268</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(10,268</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--DebtInstrumentsFairValue_pn3n3_zVEtGu579j7b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">850</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,528</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(890</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,488</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,488</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_433_c20240101__20240930_eus-gaap--DebtInstrumentCarryingAmount_iE_pn3n3_zNVpoCPWAXj8" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Fair Value at September 30, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">19,850</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">12,200</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">32,050</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Other Income (Expense) - Change in fair value - nine month period ended September 30, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left">

rgb(204,238,255)"> <td style="width: 35%">Fair Value - December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">22,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,650</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">33,650</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_43A_c20230101__20230930_eus-gaap--DebtInstrumentCarryingAmount_iS_pn3n3_zGXyUBooapl8" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Fair Value - Beginning of Period</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">22,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">11,650</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">33,650</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DebtInstrumentIssuedPrincipal_pn3n3_ztBSBmIeaXii" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Face value principal – issue date</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,111</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--FairValueAdjustmentIssueDate_pn3n3_z89tt6DgS5Zj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value adjustment - issue date</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">789</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">789</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(789</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--DebtInstrumentPeriodicPayment_iN_pn3n3_di_zk9OjEFfmM4c" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Installment repayments - common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,895</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,207</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(92</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,194</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DebtInstrumentRepaidPrincipal_iN_pn3n3_di_zDTtPfzS8ach" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Non-installment payments - common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(249</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(51</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(49</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(349</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--DebtInstrumentsFairValue_pn3n3_zehEQVBaqfwe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,544</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">708</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,731</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,983</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,983</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_43C_c20230101__20230930_eus-gaap--DebtInstrumentCarryingAmount_iE_pn3n3_zv7P2cXsAyv2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Fair Value at September 30, 2023</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">19,400</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">11,100</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">14,490</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">44,990</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_43E_c20230101__20230930_eus-gaap--DebtInstrumentCarryingAmount_iE_pn3n3_zB5iaIuoueH1" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Fair Value - Ending of Period</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">19,400</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">11,100</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">14,490</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">44,990</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Other Income (Expense) - Change in fair value - nine month period ended September 30, 2023</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">(5,772</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> </table> 19200000136000001120000044000000455000797000125200055000135000190000-10268000-10268000650000-890000-2400002400001985000012200000325000024000019000000112500001395000044200000143500020050003440000143000787000930000-10268000-10268000850000252800089000002488000-2488000198500001220000032050000248800019530000118500001161000042990000952000120700092000225100041000510004900014100086300050800030210004392000-4392000194000001110000041490000449900004392000220000001165000033650000111110001111100078900078900078900038950001207000920005194000249000510004900034900015440007080002731000498300078900038950001207000920005194000249000510004900034900015440007080002731000498300019400000111000001449000044990000194000001110000014490000449900005772000500000000.027500000225000002750000000.0787575.002024-04-04maturity date the investor agreed to extend by one year, to April 4, 20251125000000.0787575.002024-09-06maturity date the investor agreed to extend by one year, to September 8, 2025.0.8250.401000000The Company is subject to financial covenants requiring: (i) a minimum of $8.0 million of available cash at all times; (ii) the ratio of (a) the outstanding principal amount of the total senior convertible notes outstanding, accrued and unpaid interest thereon and accrued and unpaid late charges to (b) the Company's average market capitalization over the prior ten trading days, to not exceed 30% (the "Debt to Market Cap Ratio Test"); and (iii) the Company's market capitalization to at no time be less than $75 million20000000.8252.704550001435000550001430005099421084366907000200200065200010590006520001050000150100020050007870004172002380100032800010090014403000-2535000-1764000-3032000 Note 12 — Stock-Based Compensation   PAVmed Inc. 2014 Long-Term Incentive Equity Plan   The PAVmed Inc. 2014 Long-Term Incentive Equity Plan (the "PAVmed 2014 Equity Plan") is designed to enable PAVmed to offer employees, officers, directors, and consultants, as defined, an opportunity to acquire shares of common stock of PAVmed. The types of awards that may be granted under the PAVmed 2014 Equity Plan include stock options, stock appreciation rights, restricted stock, and other stock-based awards subject to limitations under applicable law. All awards are subject to approval by the PAVmed compensation committee.   A total of <span id="xdx_909_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zP0OASzrzjbc" title="Common stock reserved for future issuance">1,835,970 shares of common stock of PAVmed are reserved for issuance under the PAVmed 2014 Equity Plan, with <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zPIyjGGgoDi5" title="Number of shares available for grant">79,321 shares available for grant as of September 30, 2024. The share reservation is not diminished by a total of 66,720 PAVmed stock options and restricted stock awards granted outside the PAVmed 2014 Equity Plan as of September 30, 2024. In January 2024, the number of shares available for grant was increased by <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20240131__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zoseq4fD2dul" title="Number of shares available for grant">432,452 in accordance with the evergreen provisions of the plan.   PAVmed Stock Options   <p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zGxZW13aIFwk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">PAVmed stock options granted under the PAVmed 2014 Equity Plan and stock options granted outside such plan are summarized as follows: <span

style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule of Summarizes Information About Stock Options <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Stock Options</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Remaining Contractual Term (Years)</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Intrinsic Value⁽²⁾</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Outstanding stock options at December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_z6SYBB2yGx7h" style="width: 11%; text-align: right" title="Number of Stock Options Outstanding, Beginning Balance">1,192,458</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zsELU9JGAvc" style="width: 11%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance">26.18</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">7.3</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_fKDIp_z7FVbN944kId" style="width: 11%; text-align: right" title="Intrinsic Value Outstanding, Beginning Balance">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted⁽¹⁾</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_fKDEp_zOUYjRnbdqN" style="text-align: right" title="Number of Stock Options, Granted">79,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_fKDEp_zL87O7EjZ9i4" style="text-align: right" title="Weighted Average Exercise Price, Granted">2.28</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_ze4Lucv7zwK" style="text-align: right" title="Number of Stock Option, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zFjE9x5oNAud" style="text-align: right" title="Weighted Average Exercise Price, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zU4OA5n03YQe" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Stock Option, Forfeited">(38,851)</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zMG7T4CIzbn7" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price, Forfeited">13.47</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Outstanding stock options at September 30, 2024⁽³⁾</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_fKDMp_zfrrXHOWaDC9" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Stock Options Outstanding, Ending Balance">1,233,107</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_fKDMp_zwq9pFkVert" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price, Ending Balance">25.04</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">5.9</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_fKDMpKDIp_zHU2AIlZQuV7" style="border-bottom: Black 1pt solid; text-align: right" title="Intrinsic Value Outstanding, Ending Balance">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Vested and exercisable stock options at September 30, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zryagLO2BUl8" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Stock Options Vested and exercisable stock options">956,977</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zCSIJ4xhOdi6" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price, Vested and exercisable stock options">30.27</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_z2AsrLEPSzbf" title="Remaining Contractual Term (Years), Vested and exercisable stock options">5.1</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pn3n3_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_fKDIp_zyxVcsb6YC96" style="border-bottom: Black 1pt solid; text-align: right" title="Intrinsic Value Exercisable, Ending Balance">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">⁽¹⁾</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Stock options granted under the PAVmed 2014 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td id="xdx_F07_zpn3NMcQfBJa" style="font: 10pt Times New Roman, Times, Serif">⁽²⁾</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The intrinsic value is computed as the difference between the quoted price of the PAVmed common stock on each of September 30, 2024 and December 31, 2023 and the exercise price of the underlying PAVmed stock options, to the extent such quoted price is greater than the exercise price.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">⁽³⁾</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The outstanding stock options presented in the table above are inclusive of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN1bW1hcml6ZXMgSW5mb3JtYXRpb24gQWJvdXQgU3RvY2sgT3B0aW9ucyAoRGV0YWlscykgKFBhcmVudGhldGljYWwp" id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20240930__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zIVJN7hB1rNd" title="Number of stock options granted, shares">60,054 stock options granted outside the PAVmed 2014 Equity Plan, as of September 30, 2024 and December 31, 2023.</td></tr></table>   On February 22, 2024, the Company granted 59,500 stock options under the PAVmed Inc 2014 Equity Plan with a weighted average exercise price of $<span id="xdx_90A_eus-gaap--

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_pid_c20240222__20240222__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_ztg0oDJ58A9e" title="Weighted average exercise price">1.85. Each such option will vest one-third after one year then ratably over the next eight quarters. In addition, on February 22, 2024, a total of 390,000 restricted stock awards were granted to the Board of Directors under the PAVmed 2014 Equity Plan, with such restricted stock awards having an aggregate fair value of approximately $0.7 million, which was measured using the respective grant date quoted closing price per share of PAVmed common stock, with the fair value recognized as stock-based compensation expense ratably on a straight-line basis over the vesting period, which is commensurate with the service period. The vesting of the restricted stock awards vest ratably on an annual basis over a three year period with the initial annual vesting date of November 30, 2024. The restricted stock awards are subject to forfeiture if the requisite service period is not completed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>PAVmed Restricted Stock Awards</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zvpIhBweOTC6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in">PAVmed restricted stock awards granted under the PAVmed 2014 Equity Plan and restricted stock awards granted outside such plan are summarized as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-indent: 0.25in">Schedule of Restricted Stock Award Activity </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Restricted Stock Awards</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Unvested restricted stock awards as of December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zF6duHwR1kTk" style="width: 16%; text-align: right" title="Number of restricted stock awards, outstanding balance">70,527</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20 gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNYkal9HS4Li" style="width: 16%; text-align: right" title="Weighted average grant date fair value, outstanding balance">38.77</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zQfxKuYckFOi" style="text-align: right" title="Number of restricted stock awards, granted">390,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__ gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfLlZLPtC3t9" style="text-align: right" title="Weighted average gdate fair value, granted">1.85</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zKdZKRxbW9QI" style="text-align: right" title="Number of restricted stock awards, vested">(135,080</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__ gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAbCfGNaJdIh" style="text-align: right" title="Weighted average grant date fair value, vested">2.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zXRPWRIjGAoa" style="border-bottom: Black 1pt solid; text-align: right" title="Number of restricted stock awards, forfeited">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20240101__202 gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDR71DBCFuOb" style="padding-bottom: 1pt; text-align: right" title="Weighted average grant date fair value, forfeited">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Unvested restricted stock awards as of September 30, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zTG0oZeR51yd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of restricted stock awards, outstanding balance">325,447</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20 gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z9WzgCthRqh6" style="padding-bottom: 1pt; text-align: right" title="Weighted average grant date fair value, outstanding balance">9.79</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zGqO9rRJizJ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Note 12 — Stock-Based Compensation - continued</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>Lucid Diagnostics Inc. 2018 Long-Term Incentive Equity Plan</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">The Lucid Diagnostics Inc. 2018 Long-Term Incentive Equity Plan (“Lucid Diagnostics 2018 Equity Plan”) is separate and apart from the PAVmed 2014 Equity Plan discussed above. The Lucid Diagnostics 2018 Equity Plan is designed to enable Lucid Diagnostics to offer employees, officers, directors, and consultants, an opportunity to acquire shares of common stock of Lucid Diagnostics. The types of awards that may be granted under the Lucid Diagnostics 2018 Equity Plan include stock options, stock appreciation rights, restricted stock, and other stock-based awards subject to limitations under applicable law. All awards are subject to approval by the Lucid Diagnostics compensation committee.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Please note that following the deconsolidation of Lucid, the Lucid Diagnostics 2018 Long-Term Equity Plan is no longer reflected in the Company’s unaudited condensed consolidated statements of operations. Lucid continues to be responsible for administering its equity plan. See Note 4, <i>Equity Method Investment</i>, for additional information on the deconsolidation of Lucid Diagnostics.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 9pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>Lucid Diagnostics Stock Options</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_ztAmE3AcgfY4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.25in">Lucid Diagnostics stock options granted under the Lucid Diagnostics 2018 Equity Plan and stock options granted outside such plan are summarized as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-indent: 0.25in">Schedule of Summarizes Information About Stock Options</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Stock Options</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Remaining Contractual Term (Years)</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Intrinsic Value⁽²⁾</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Outstanding stock options at December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zgnRbNsykGAj" style="width: 11%; text-align: right" title="Number of Stock Options Outstanding, Beginning Balance">5,504,383</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_z77j53bpDwZf" style="width: 11%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance">2.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">8.5</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_fKDIp_zRlQo1Y7Yce3" style="width: 11%; text-align: right" title="Intrinsic Value Outstanding, Beginning Balance">765</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted⁽¹⁾</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_fKDEp_zNKGTg5iFp53" style="text-align: right" title="Number of Stock Options, Granted">3,604,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_fKDEp_zQbpTeLjMBL7" style="text-align: right" title="Weighted Average Exercise Price, Granted">1.22</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zTnZ956LLIA6" style="text-align: right" title="Number of Stock Option, Exercised">(3,333</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_z6IS5rQcXUM5" style="text-align: right" title="Weighted Average Exercise Price, Exercised">1.31</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zZCsA3V91jBa" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Stock Option, Forfeited">(417,501</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_z8LD0RPRzlU7" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price, Forfeited">1.63</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Outstanding stock options at September 10, 2024⁽³⁾</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_fKDMp_zvxmkGFFWdVd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Stock Options Outstanding, Ending Balance">8,687,549</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_fKDMp_zlg2PthCMvI3" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price, Ending Balance">1.69</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">8.3</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_fKDMpKDIp_zyA2Bbg4Qrk2" style="border-bottom: Black 1pt solid; text-align: right" title="Intrinsic Value Outstanding, Ending Balance">191</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Vested and exercisable stock options at September 10, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_z9wClopIWIPj" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Stock Options Vested and exercisable stock options">3,084,682</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zUJ5WTEVsTD9" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price, Vested and exercisable stock options">2.25</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">7.1</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pn3n3_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_fKDIp_zIggjNQn7217" style="border-bottom: Black 1pt solid; text-align: right" title="Intrinsic Value Exercisable, Ending Balance">191</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td id="xdx_F05_zqLSBb6ZrI77" style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">⁽¹⁾</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Stock options granted under the Lucid Diagnostics 2018 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">⁽²⁾</td><td id="xdx_F12_zK3EnxfARxg4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The intrinsic value is computed as the difference between the quoted price of the Lucid Diagnostics common stock on each of September 10, 2024 and December 31, 2023 and the exercise price of the underlying Lucid Diagnostics stock options, to the extent such quoted price is greater than the exercise price.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">⁽³⁾</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The outstanding stock options presented in the table above are inclusive of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN1bW1hcml6ZXMgSW5mb3JtYXRpb24gQWJvdXQgU3RvY2sgT3B0aW9ucyAoRGV0YWlscykgKFBhcmVudhGhldGljYWwp" id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240910__20240910__dei--LegalEntityAxis__custom--LucidDiagnosticsIncMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zOqjL7FK76r3" title="Number of stock options granted. shares"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN1bW1hcml6ZXMgSW5mb3JtYXRpb24gQWJvdXQgU3RvY2sgT3B0aW9ucyAoRGV0YWlscykgKFBhcmVudhGhldGljYWwp" id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__dei--LegalEntityAxis__custom--LucidDiagnosticsIncMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zhvElS487bak" title="Number of stock options granted. shares">523,300 stock options granted outside the Lucid Diagnostics 2018 Equity Plan, as of September 10, 2024 and December 31, 2023.</td></tr></table>   On February 22, 2024, Lucid granted <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240222__20240222__dei--LegalEntityAxis__custom--LucidDiagnosticsIncMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zTpMUDp5ROQ9" title="Granted">2,895,000 stock options under the Lucid Diagnostics 2018 Equity Plan with a weighted average exercise price of $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_pid_c20240222__20240222__dei-LegalEntityAxis__custom--LucidDiagnosticsIncMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zg8cmfmXs5Mf" title="Weighted average exercise price">1.25. Each option will vest one-third after one year then ratably over the next eight quarters.   Lucid Diagnostics Restricted Stock Awards   <p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zySGvcGIAYqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in">Lucid Diagnostics restricted stock awards granted under the Lucid Diagnostics 2018 Equity Plan and restricted stock awards granted outside such plan are summarized as follows: Schedule of Restricted Stock Award Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Restricted Stock Awards</td><td style="padding-

bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Unvested restricted stock awards as of December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zH5DXXLvDl52" style="width: 16%; text-align: right" title="Number of Restricted Stock Awards, Unvested restricted stock awards, Beginning balance">2,337,440</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20 gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zVGJgLNx2vZf" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Unvested restricted stock awards, Beginning balance">8.99</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zNWvwetVjuM5" style="text-align: right" title="Number of Restricted Stock Awards, Granted">1,600,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__ gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zTFYqvRt1GJf" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted">1.03</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zTZmdu3Uifll" style="text-align: right" title="Number of Restricted Stock Awards, Vested">(26,912</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__ gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_ztHAqLWrXjS1" style="text-align: right" title="Weighted Average Grant Date Fair Value, Vested">4.56</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zFkbsvDDM6sj" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Restricted Stock Awards, Forfeited">(13,088</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20240101__202 gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zcKLQJnr6B24" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited">4.56</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Unvested restricted stock awards as of September 10, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zv9f3ejiGUgh" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Restricted Stock Awards, Unvested restricted stock awards, Ending balance">3,897,440</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__2(gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zN0RW3UYEs58" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Grant Date Fair Value, Unvested restricted stock awards, Ending balance">5.77</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>   In May 2024, a total of 1,600,000 restricted stock awards were granted to management under the Lucid Diagnostics 2018 Equity Plan, with such restricted stock awards having an aggregate fair value of approximately $1.5 million, which was measured using the respective grant date quoted closing price per share of Lucid Diagnostics common stock, with the fair value recognized as stock-based compensation expense ratably on a straight-line basis over the vesting period, which is commensurate with the service period. The vesting of the restricted stock awards vest on a single vest date of May 20, 2026. The restricted stock awards are subject to forfeiture if the requisite service period is not completed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Note 12 — Stock-Based Compensation - continued</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>Consolidated Stock-Based Compensation Expense</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_897_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zalcCKlRBXcd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">The consolidated stock-based compensation expense recognized by each of PAVmed and (through September 10, 2024, the date of PAVmed's deconsolidation of Lucid) Lucid Diagnostics for both the PAVmed 2014 Equity Plan and the Lucid Diagnostics 2018 Equity Plan, with respect to stock options and restricted stock awards as discussed above, for the periods indicated, was as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Schedule of Stock-Based Compensation Expense</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20240701__20240930_zD8fhqz1c3z1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20230701__20230930_zoNr6Shgb16j" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20240101__20240930_z0kprZtMXLJj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20230101__20230930_z87cRZZYMC8a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">Three Months Ended</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">September 30,</p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">Nine Months Ended</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">September 30,</p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--IncomeStatementLocationAxis__custom--CostOfRevenueMember_zgvuaduPaE88" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Cost of revenue</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">32</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">32</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">112</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">86</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zAEFJmFDxmM1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Sales and marketing expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">292</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">403</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,082</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,302</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zZ8nbjPYmeOc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">General and administrative expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,426</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,499</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,717</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,761</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zvFyen6hdDne" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Research and development expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">181</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">311</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align:

left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">805</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,022</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ShareBasedCompensation_pn3n3_zKSa0diFtH4j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total stock-based compensation expense</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,931</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,245</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">5,716</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">9,171</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>   Stock-Based Compensation Expense Recognized by Lucid Diagnostics   As noted, the consolidated stock-based compensation expense presented above is inclusive of stock-based compensation expense recognized by Lucid Diagnostics (through September 10, 2024, the date of PAVmed's deconsolidation of Lucid) inclusive of each of: stock options granted under the PAVmed 2014 Equity Plan to the three physician inventors of the intellectual property underlying the Amended CWRU License Agreement; and stock options and restricted stock awards granted to employees of PAVmed and non-employee consultants under the Lucid Diagnostics 2018 Equity Plan. The stock-based compensation expense recognized by Lucid Diagnostics (through September 10, 2024, the date of PAVmed's deconsolidation of Lucid) for both the PAVmed 2014 Equity Plan and the Lucid Diagnostics 2018 Equity Plan, with respect to stock options and restricted stock awards as discussed above, for the periods indicated, was as follows: <p id="xdx_89E_ecustom--ScheduleOfStockbasedCompensationExpenseRecognizedTableTextBlock_z6BE0azAMqbd" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Schedule of Stock-Based Compensation Expense Recognized by Lucid Diagnostics <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20240701__20240930_zXMBRVnI26oh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20230701__20230930_zA8eEg1n1U31" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20240101__20240930_zEYCosK7HFb2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20230101__20230930_zrI9OcOLsU61" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"> Three Months Ended September 30, </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"> Nine Months Ended September 30, </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--PlanNameAxis__custom--LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember__us-gaap--IncomeStatementLocationAxis__custom--CostOfRevenueMember_zXxJgtUAdVK6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Lucid Diagnostics 2018 Equity Plan - cost of revenue</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">24</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">16</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">81</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">44</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--PlanNameAxis__custom--LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zawnUCuboStd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lucid Diagnostics 2018 Equity Plan - sales and marketing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">252</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">228</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">849</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">697</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--PlanNameAxis__custom--LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zOIp5mdcxRBb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Lucid Diagnostics 2018 Equity Plan - general and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">548</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">721</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,484</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,069</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--PlanNameAxis__custom--LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zH9GTbqpCen4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lucid Diagnostics 2018 Equity Plan - research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">98</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">67</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">356</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">204</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--PlanNameAxis__custom--PAVmedIncTwoThousandFourteenEquityPlanMember__us-gaap--IncomeStatementLocationAxis__custom--CostOfRevenueMember_z3uKO0cL9zyg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">PAVmed 2014 Equity Plan - cost of revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">26</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--PlanNameAxis__custom--PAVmedIncTwoThousandFourteenEquityPlanMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zZFVoojt4aTi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">PAVmed 2014 Equity Plan - sales and marketing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">106</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">136</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">359</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--PlanNameAxis__custom--PAVmedIncTwoThousandFourteenEquityPlanMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zyIThoHQ66e5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">PAVmed 2014 Equity Plan - general and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--PlanNameAxis__custom--PAVmedIncTwoThousandFourteenEquityPlanMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zlfqZU6h59hg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">PAVmed 2014 Equity Plan - research and development</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">97</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">148</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">290</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ShareBasedCompensation_pn3n3_hdei--LegalEntityAxis__custom--LucidDiagnosticsIncMember_z6kZQuZYb9qj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total stock-based compensation expense - recognized by Lucid Diagnostics</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">955</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,252</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">3,089</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">5,859</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ShareBasedCompensation_pn3n3_hdei--LegalEntityAxis__custom--LucidDiagnosticsIncMember_zt7oiduN0Kle" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total stock-based compensation expense</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">955</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,252</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">3,089</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">5,859</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>   <p id="xdx_89E_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zRZqF5zcyp07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">The consolidated unrecognized stock-based compensation expense and weighted average remaining requisite service period with respect to stock options and restricted stock awards issued under the PAVmed 2014 Equity Plan, as discussed above, is as follows: <p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align:

justify">Schedule of Unrecognized Compensation Expense <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Unrecognized Expense</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Service Period (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">PAVmed 2014 Equity Plan</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Stock Options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn3n3_c20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--PAVmedIncTwoThousandFourteenEquityPlanMember_zBeaXfGo6r5a" style="width: 16%; text-align: right" title="Unrecognized Expense">1,377</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1.5</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Restricted Stock Awards</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn3n3_c20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--PAVmedIncTwoThousandFourteenEquityPlanMember_zNRAm0AA0GQ5" style="text-align: right" title="Unrecognized Expense">397</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20240930__us-gaap--PlanNameAxis__custom--PAVmedIncTwoThousandFourteenEquityPlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zPENH4vggB4d" title="Weighted Average Remaining Service Period">2.2</td><td style="text-align: left"> </td></tr> </table>   Note 12 — Stock-Based Compensation - continued   Stock-based compensation expense recognized with respect to stock options granted under the PAVmed 2014 Equity Plan was based on a weighted average estimated fair value of such stock options of $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_z3HYLnW8DOC4" title="Weighted average fair value of stock options">1.47 per share and $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zeVKc74hs8A7" title="Weighted average fair value of stock options">5.25 per share during the nine month periods ended September 30, 2024 and 2023, respectively, calculated using the following weighted average Black-Scholes valuation model assumptions: <p id="xdx_89C_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zn4C6pXQWvdf" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Expected term of stock options (in years)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zLupKkNgrLrf" title="Expected term of stock options (in years)">5.8</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zdaJ3CTUZsfb" title="Expected term of stock options (in years)">5.7</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected stock price volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zHU7AsycnN18" title="Expected stock price volatility">90</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zyPLpenBm3m8" title="Expected stock price volatility">88</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zXuqAvBYhZa6" title="Risk free interest rate">4.3</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zZOZaJSjCEw3" title="Risk free interest rate">3.7</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_z1gstN9KLJql" title="Expected dividend yield">—</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zvYPZigEZ0le" title="Expected dividend yield">—</td><td style="text-align: left">%</td></tr> </table>   Stock-based compensation expense recognized with respect to stock options granted under the Lucid Diagnostics 2018 Equity Plan was based on a weighted average estimated fair value of such stock options of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_ztgysYWSDuP4" title="Weighted average fair value of stock options">0.79 per share and $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_z6LDdnf7O4me" title="Weighted average fair value of stock options">0.88 per share during the nine month periods ended September 30, 2024 (through September 10, 2024, the date of PAVmed's consolidation of Lucid) and 2023, respectively, calculated using the following weighted average Black-Scholes valuation model assumptions: <p id="xdx_89C_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zfG1e9FwAwJ" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Expected term of stock options (in years)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zbwwCRn6KCC2" title="Expected term of stock options (in years)">5.7</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zAF5zvzJtEfl" title="Expected term of stock options (in years)">5.6</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected stock price volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zplmN4dZssn4" title="Expected stock price volatility">73</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zDfmOssvRGD9" title="Expected stock price volatility">75</td><td style="text-align: left">%

</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zZXZdRUesIFe" title="Risk free interest rate">4.3</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_z7HMGLQ1jlb2" title="Risk free interest rate">3.7</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zOnb0OUxpgj3" title="Expected dividend yield">—</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zxQv1yQXtpHF" title="Expected dividend yield">—</td><td style="text-align: left">%</td></tr> </table>   PAVmed Inc. Employee Stock Purchase Plan (“PAVmed ESPP”)   A total of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_pid_c20240101__20240331__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zjRXi5WnpbV1" title="Number of common stock purchased">34,332 shares and <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_pid_c20230101__20230331__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zv7wzOEyCokg" title="Number of common stock purchased">38,216 shares of common stock of the Company were purchased for proceeds of approximately $62 and $182, on March 31, 2024 and 2023, respectively, under the PAVmed ESPP. A total of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_pid_c20230101__20230930__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zxHD9fv245Kg" title="Number of common stock purchased">20,267 shares of common stock of the Company were purchased for proceeds of approximately $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3n3_c20230101__20230930__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zuCvqqXs3Ss2" title="Number of common stock purchased">76 on September 30, 2023 under the PAVmed ESPP. The March 31, 2023 purchase was partially settled through the redeployment of 12,590 shares of treasury stock. The PAVmed ESPP has a total reserve of <span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20240930__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zHRMgsFTJLj9" title="Common stock capital shares reserved for future issuance">300,001 shares of common stock of PAVmed of which <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20240930__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zYpLOjdHlEp1" title="Increase in available for grant">139,863 shares are available for issue as of September 30, 2024. In January 2024, the number of shares available-for-issue was increased by <span id="xdx_903_ecustom--StockIssuedDuringPeriodSharesIncreaseInReserve_c20240101__20240131__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zZlFpB6WzB5f" title="Increase in reserve stock">166,667 in accordance with the evergreen provisions of the plan.   Effective September 18, 2024, PAVmed’s compensation committee temporarily suspended any participation in the PAVmed ESPP. Accordingly, no shares of common stock of the Company have been purchased under the PAVmed ESPP since March 31, 2024.   Lucid Diagnostics Inc. Employee Stock Purchase Plan (“Lucid ESPP”)   A total of 511,884shares and 231,987 shares of common stock of Lucid Diagnostics were purchased for proceeds of approximately $353 and $276 on March 31, 2024 and 2023, respectively, under the Lucid ESPP. A total 276,213 shares of common stock of Lucid Diagnostics were purchased for proceeds of approximately $275 on September 30, 2023 under the Lucid ESPP.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> 1835970793216672043245 2<p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zGxZWI3aIFwk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">PAVmed stock options granted under the PAVmed 2014 Equity Plan and stock options granted outside such plan are summarized as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Schedule of Summarizes Information About Stock Options</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Stock Options</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Remaining Contractual Term (Years)</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Intrinsic Value⁽²⁾</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Outstanding stock options at December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_z6SYBB2yGx7h" style="width: 11%; text-align: right" title="Number of Stock Options Outstanding, Beginning Balance">1,192,458</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zsELU9JGAvc" style="width: 11%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance">26.18</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">7.3</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_fKDIp_z7FVbN944kId" style="width: 11%; text-align: right" title="Intrinsic Value Outstanding, Beginning Balance">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted⁽¹⁾</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_fKDEp_zOUYjRnbdqN" style="text-align: right" title="Number of Stock Options, Granted">79,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_fKDEp_zL87O7EjZ9i4" style="text-align: right" title="Weighted Average Exercise Price, Granted">2.28</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_ze4Lucv7zwK" style="text-align: right" title="Number of Stock Option, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zFjE9x5oNAud" style="text-align: right" title="Weighted Average Exercise Price, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-

align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zU4OA5n03YQe" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Stock Option, Forfeited">(38,851</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zMG7T4CIzbn7" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price, Forfeited">13.47</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Outstanding stock options at September 30, 2024⁽³⁾</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_fKDMp_zfrrXHOWaDC9" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Stock Options Outstanding, Ending Balance">1,233,107</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_fKDMp_zwq9pFkVert" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price, Ending Balance">25.04</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">5.9</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_fKDMpKDlp_zHU2AllZQuV7" style="border-bottom: Black 1pt solid; text-align: right" title="Intrinsic Value Outstanding, Ending Balance">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Vested and exercisable stock options at September 30, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zryaqLO2BUl8" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Stock Options Vested and exercisable stock options">956,977</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20240930_gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zCSIJ4xhOdi6" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price, Vested and exercisable stock options">30.27</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">5.1</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pn3n3_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_fKDlp_zyxVcsb6YC96" style="border-bottom: Black 1pt solid; text-align: right" title="Intrinsic Value Exercisable, Ending Balance">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">⁽¹⁾</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Stock options granted under the PAVmed 2014 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td id="xdx_F07_zpn3NMcOfBJa" style="font: 10pt Times New Roman, Times, Serif">⁽²⁾</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The intrinsic value is computed as the difference between the quoted price of the PAVmed common stock on each of September 30, 2024 and December 31, 2023 and the exercise price of the underlying PAVmed stock options, to the extent such quoted price is greater than the exercise price.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">⁽³⁾</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The outstanding stock options presented in the table above are inclusive of 60,054 stock options granted outside the PAVmed 2014 Equity Plan, as of September 30, 2024 and December 31, 2023. </td></tr></table> 119245826.18P7Y3M18D795002.283885113.47123310725.04P5Y10M24D95697730.27P5Y1M6D6005460054595001.85390000700000<p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zvplhBwe0TC6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in">PAVmed restricted stock awards granted under the PAVmed 2014 Equity Plan and restricted stock awards granted outside such plan are summarized as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-indent: 0.25in">Schedule of Restricted Stock Award Activity </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Restricted Stock Awards</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Unvested restricted stock awards as of December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zF6duHwR1kTk" style="width: 16%; text-align: right" title="Number of restricted stock awards, outstanding balance">70,527</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNYkal9HS4Li" style="width: 16%; text-align: right" title="Weighted average grant date fair value, outstanding balance">38.77</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zOfxKuYckFOi" style="text-align: right" title="Number of restricted stock awards, granted">390,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfLlZLPtC3t9" style="text-align: right" title="Weighted average gdate fair value, granted">1.85</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zKdZKRxbW9OI" style="text-align: right" title="Number of restricted stock awards, vested">(135,080</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAbCfGNaJdlh" style="text-align: right" title="Weighted average grant date fair value, vested">2.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zXRPWRIjGAoa" style="border-bottom: Black 1pt solid; text-align: right" title="Number of restricted stock awards, forfeited">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20240101__2024gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDR71DBCFuOb"

style="padding-bottom: 1pt; text-align: right" title="Weighted average grant date fair value, forfeited">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Unvested restricted stock awards as of September 30, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zTG0oZeR51yd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of restricted stock awards, outstanding balance">325,447</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z9WzgCthRqh6" style="padding-bottom: 1pt; text-align: right" title="Weighted average grant date fair value, outstanding balance">9.79</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> 7052738.773900001.851350802.003254479.79<p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_ztAmE3AcgfY4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.25in">Lucid Diagnostics stock options granted under the Lucid Diagnostics 2018 Equity Plan and stock options granted outside such plan are summarized as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-indent: 0.25in">Schedule of Summarizes Information About Stock Options</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Stock Options</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td><td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Remaining Contractual Term (Years)</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Intrinsic Value⁽²⁾</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Outstanding stock options at December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zgnRbNsykGAj" style="width: 11%; text-align: right" title="Number of Stock Options Outstanding, Beginning Balance">5,504,383</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_z77J53bpDwZf" style="width: 11%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance">2.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">8.5</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_fKDlp_zRlQo1Y7Yce3" style="width: 11%; text-align: right" title="Intrinsic Value Outstanding, Beginning Balance">765</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted⁽¹⁾</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_fKDEp_zNKGTg5iFp53" style="text-align: right" title="Number of Stock Options, Granted">3,604,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_fKDEp_zQbpTeLjMBL7" style="text-align: right" title="Weighted Average Exercise Price, Granted">1.22</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zTnZ956LLIA6" style="text-align: right" title="Number of Stock Option, Exercised">(3,333</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_z6IS5rQcXUM5" style="text-align: right" title="Weighted Average Exercise Price, Exercised">1.31</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zZCsA3V91jBa" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Stock Option, Forfeited">(417,501</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_z8LD0RPRzlU7" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price, Forfeited">1.63</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Outstanding stock options at September 10, 2024⁽³⁾</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_fKDMp_zvxmkGFFWdVd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Stock Options Outstanding, Ending Balance">8,687,549</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_fKDMp_zlg2PthCMvI3" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price, Ending Balance">1.69</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">8.3</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_fKDMpKDlp_zyA2Bbg4Ork2" style="border-bottom: Black 1pt solid; text-align: right" title="Intrinsic Value Outstanding, Ending Balance">191</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Vested and exercisable stock options at September 10, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_z9wClopIWIPj" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Stock Options Vested and exercisable stock options">3,084,682</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zUJ5WTEVsTD9" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price, Vested and exercisable stock options">2.25</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">7.1</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pn3n3_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_fKDlp_zIggjNQn7217" style="border-bottom: Black 1pt solid; text-align: right" title="Intrinsic Value Exercisable, Ending Balance">191</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td id="xdx_F05_zqLSBb6ZrI77" style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">⁽¹⁾</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Stock options granted under the Lucid Diagnostics 2018 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">⁽²⁾</td><td id="xdx_F12_zK3EnxfARxg4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The intrinsic value is computed as the difference between the quoted price of the Lucid Diagnostics common stock on each of September 10, 2024 and December 31, 2023 and the exercise price of the underlying Lucid Diagnostics stock options, to the extent such quoted price is greater than the exercise price.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">⁽³⁾</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The outstanding stock options presented in the table above are inclusive of <span

class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN1bW1hcml6ZXMgSW5mb3JtYXRpb24gQWJvdXQgU3RvY2sgT3B0aW9ucyAoRGV0YWlscykgKFBhcmVududGhldGljYWwp" id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240910__20240910__dei--LegalEntityAxis__custom--LucidDiagnosticsIncMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zQqjL7FK76r3" title="Number of stock options granted. shares"><span
class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN1bW1hcml6ZXMgSW5mb3JtYXRpb24gQWJvdXQgU3RvY2sgT3B0aW9ucyAoRGV0YWlscykgKFBhcmVududGhldGljYWwp" id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__dei--LegalEntityAxis__custom--LucidDiagnosticsIncMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zhvElS487bak" title="Number of stock options granted. shares">523,300 stock options granted outside the Lucid Diagnostics 2018 Equity Plan, as of September 10, 2024 and December 31, 2023.</td></tr></table> 55043832.00P8Y6M76500036040001.2233331.314175011.6386875491.69P8Y3M18D19100030846822.25P7Y1M6D19100052330052330028950001.25<p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zySGvcGIAYqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in">Lucid Diagnostics restricted stock awards granted under the Lucid Diagnostics 2018 Equity Plan and restricted stock awards granted outside such plan are summarized as follows: Schedule of Restricted Stock Award Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Restricted Stock Awards</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Unvested restricted stock awards as of December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zH5DXXLvDl52" style="width: 16%; text-align: right" title="Number of Restricted Stock Awards, Unvested restricted stock awards, Beginning balance">2,337,440</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__2(
gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zVGJgLNx2vZf" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Unvested restricted stock awards, Beginning balance">8.99</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zNWvwetVjuM5" style="text-align: right" title="Number of Restricted Stock Awards, Granted">1,600,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zTFYqyRt1GJf" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted">1.03</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zTZmdu3UifIl" style="text-align: right" title="Number of Restricted Stock Awards, Vested">(26,912</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_ztHAqlWrXjS1" style="text-align: right" title="Weighted Average Grant Date Fair Value, Vested">4.56</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zFkbsvDDM6sj" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Restricted Stock Awards, Forfeited">(13,088</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20240101__202
gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zcKLQJnr6B24" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited">4.56</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Unvested restricted stock awards as of September 10, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zv9f3ejiGUqh" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Restricted Stock Awards, Unvested restricted stock awards, Ending balance">3,897,440</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20
gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zN0RW3UYEs58" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Grant Date Fair Value, Unvested restricted stock awards, Ending balance">5.77</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr></table> 23374408.9916000001.03269124.56130884.5638974405.77160000015000000<p id="xdx_897_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zalcCKlRBXcd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">The consolidated stock-based compensation expense recognized by each of PAVmed and (through September 10, 2024, the date of PAVmed's deconsolidation of Lucid) Lucid Diagnostics for both the PAVmed 2014 Equity Plan and the Lucid Diagnostics 2018 Equity Plan, with respect to stock options and restricted stock awards as discussed above, for the periods indicated, was as follows: Schedule of Stock-Based Compensation Expense <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20240701__20240930_zD8fhqz1c3z1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20230701__20230930_zoNr6Shgb16j" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20240101__20240930_z0kprZtMXLfj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20230101__20230930_z87cRZZYMC8a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"> Three Months Ended September 30, </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"> Nine Months Ended September 30, </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--IncomeStatementLocationAxis__custom--CostOfRevenueMember_zgvuaduPaE88" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Cost of revenue</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">32</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">32</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">112</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">86</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zAEFjmFDxmM1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Sales and marketing expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">292</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">403</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,082</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,302</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zZ8nbjPYmeOc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">General and administrative expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,426</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,499</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,717</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,761</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zvFyen6hdDne" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Research and development expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">181</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">311</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">805</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,022</td><td style="padding-

bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ShareBasedCompensation_pn3n3_zKSa0diFtH4j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total stock-based compensation expense</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,931</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,245</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">5,716</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">9,171</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>
320003200011200086000292000403000108200013020001426000149900037170006761000181000311000805000102200019310002245000571600091710000<p id="xdx_89E_ecustom--ScheduleOfStockbasedCompensationExpenseRecognizedTableTextBlock_z6BE0azAMqbd" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Schedule of Stock-Based Compensation Expense Recognized by Lucid Diagnostics <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20240701__20240930_zXMBRVnI26oh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20230701__20230930_zA8eEg1n1U31" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20240101__20240930_zEYCosK7HFb2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20230101__20230930_zrI9OcOLsU61" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"> Three Months Ended September 30, </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"> Nine Months Ended September 30, </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--PlanNameAxis__custom--LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember__us-gaap--IncomeStatementLocationAxis__custom--CostOfRevenueMember_zXxJgtUAdVK6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Lucid Diagnostics 2018 Equity Plan - cost of revenue</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">24</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">16</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">81</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">44</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--PlanNameAxis__custom--LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zawnUCuboStd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lucid Diagnostics 2018 Equity Plan – sales and marketing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">252</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">228</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">849</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">697</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--PlanNameAxis__custom--LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zQIp5mdcxRBb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Lucid Diagnostics 2018 Equity Plan - general and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">548</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">721</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,484</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,069</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--PlanNameAxis__custom--LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zH9GTbqpCen4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lucid Diagnostics 2018 Equity Plan – research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">98</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">67</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">356</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">204</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--PlanNameAxis__custom--PAVmedIncTwoThousandFourteenEquityPlanMember__us-gaap--IncomeStatementLocationAxis__custom--CostOfRevenueMember_z3uKO0cL9zyg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">PAVmed 2014 Equity Plan - cost of revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">26</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--PlanNameAxis__custom--PAVmedIncTwoThousandFourteenEquityPlanMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zZFVoojt4aTi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">PAVmed 2014 Equity Plan - sales and marketing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">106</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">136</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">359</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--PlanNameAxis__custom--PAVmedIncTwoThousandFourteenEquityPlanMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zyITh0HQ66e5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">PAVmed 2014 Equity Plan - general and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--PlanNameAxis__custom--PAVmedIncTwoThousandFourteenEquityPlanMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zlfqZU6hS9hg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">PAVmed 2014 Equity Plan - research and development</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">97</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">148</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">290</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ShareBasedCompensation_pn3n3_hdei--LegalEntityAxis__custom--LucidDiagnosticsIncMember_z6kZQuZYb9qj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total stock-based compensation expense – recognized by Lucid Diagnostics</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">955</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,252</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">3,089</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">5,859</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ShareBasedCompensation_pn3n3_hdei--LegalEntityAxis__custom--LucidDiagnosticsIncMember_zt7oiduN0Kle" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total stock-based compensation expense</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">955</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,252</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">3,089</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">5,859</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>
240001600081000440002520002280000849000697000548000721000148400040690009800006700035600020400090001000030000260001800010600013600035900010007000<p id="xdx_89E_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zRZqF5zcyp07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">The consolidated unrecognized stock-based compensation expense and weighted average remaining requisite service period with respect to stock options and restricted stock awards issued under the PAVmed 2014 Equity Plan, as discussed above, is as follows: Schedule of Unrecognized Compensation Expense <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Unrecognized Expense</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Service Period (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">PAVmed 2014 Equity Plan</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Stock Options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn3n3_c20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--PAVmedIncTwoThousandFourteenEquityPlanMember_zBeaXTGo6rSa" style="width: 16%; text-align: right"

title="Unrecognized Expense">1,377</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20240930__us-gaap--PlanNameAxis__custom--PAVmedIncTwoThousandFourteenEquityPlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zMjxB8pGnBs4" title="Weighted Average Remaining Service Period">1.5</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Restricted Stock Awards</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn3n3_c20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--PAVmedIncTwoThousandFourteenEquityPlanMember_zNRAm0AA0GQ5" style="text-align: right" title="Unrecognized Expense">397</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20240930__us-gaap--PlanNameAxis__custom--PAVmedIncTwoThousandFourteenEquityPlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zPENH4vggB4d" title="Weighted Average Remaining Service Period">2.2</td><td style="text-align: left"> </td></tr> </table> 1377000P1Y6M397000P2Y2M12D1.475.25<p id="xdx_89C_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zn4C6pXQWvdf" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Expected term of stock options (in years)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zLupKkNgrLrf" title="Expected term of stock options (in years)">5.8</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zdaJ3CTUZsfb" title="Expected term of stock options (in years)">5.7</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected stock price volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zHU7AsycnN18" title="Expected stock price volatility">90</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zyPLpenBm3m8" title="Expected stock price volatility">88</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zXuqAvBYhZa6" title="Risk free interest rate">4.3</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zZOZaJSjCEw3" title="Risk free interest rate">3.7</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_z1gstN9KLJql" title="Expected dividend yield">—</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zvYPZigEZ0le" title="Expected dividend yield">—</td><td style="text-align: left">%</td></tr> </table> P5Y9M18DP5Y8M12D0.900.880.0430.0370.790.88<p id="xdx_89C_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zfG1e9FwAwJ" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Expected term of stock options (in years)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zbwwCRn6KCC2" title="Expected term of stock options (in years)">5.7</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zAF5zvzJtEfl" title="Expected term of stock options (in years)">5.6</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected stock price volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zplmN4dZssn4" title="Expected stock price volatility">73</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zDfmOssvRGD9" title="Expected stock price volatility">75</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zZXZdRUesITe" title="Risk free interest rate">4.3</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_z7HMGLQ1jIb2" title="Risk free interest rate">3.7</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zOnb0OUxpqj3" title="Expected dividend yield">—</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityPlanMember_zxQv1yQXtpHf" title="Expected dividend yield">—</td><td style="text-align: left">%</td></tr> </table> P5Y8M12DP5Y7M6D0.730.750.0430.037343323821662000182000202677600012590300001139863166667511884231987353000276000276213275000 Note 13 — Preferred Stock   As of September 30, 2024 and December 31, 2023, there were <span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zmAa9u8bIWfd" title="Preferred stock shares outstanding">1,385,149 and <span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_ztlhpoWpZ7Ch" title="Preferred stock shares outstanding">1,305,213 shares of PAVmed Series B Convertible Preferred Stock, classified in permanent equity, issued and outstanding, respectively.   PAVmed Series B Convertible Preferred Stock Dividends   The Series B Convertible Preferred Stock is issued pursuant to the PAVmed Inc. Certificate of Designation of Preferences, Rights, and Limitations of Series B Convertible Preferred Stock (“Series B Convertible Preferred Stock Certificate of Designation”), has a par value of $<span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z1tVdfdxwjV" title="Preferred stock stated value per share">0.001 per share, no voting rights, a stated value of $<span id="xdx_905_ecustom--PreferredStockStatedValuePerShare_iI_c20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zEvFfNiSHUP" title="Preferred stock stated value per share">3.00 per share, and was immediately convertible upon its issuance. At the holders’ election, fifteen shares of Series B Convertible Preferred Stock are currently convertible into one share of common stock of the Company, subject to further adjustment for the effect of future stock dividends, stock splits or

similar events affecting the Company's common stock. The Series B Convertible Preferred Stock shall not be redeemed for cash and under no circumstances shall the Company be required to net cash settle the Series B Convertible Preferred Stock.   The PAVmed Inc. Series B Convertible Preferred Stock dividends are <span id="xdx_905_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20240101__20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zjVD0znBxclh" title="Dividend rate percentage">8.0% per annum based on the $<span id="xdx_90E_ecustom--PreferredStockStatedValuePerShare_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zxrmJOTIsLnd" title="Preferred stock stated value per share">3.00 per share stated value of the Series B Convertible Preferred Stock, with such dividends compounded quarterly, accumulate, and are payable in arrears upon being declared by the Company's board of directors. Such dividends may be settled, at the discretion of the board of directors, through any combination of the issue of additional shares of Series B Convertible Preferred Stock, the issue shares of common stock of the Company, and /or cash payment.   PAVmed Series B Convertible Preferred Stock Dividends Earned   The Series B Convertible Preferred Stock dividends earned are included in the calculation of basic and diluted net loss attributable to PAVmed common stockholders for each of the respective corresponding periods presented in the accompanying unaudited condensed consolidated statement of operations, inclusive of $<span id="xdx_901_eus-gaap--PreferredStockDividendsIncomeStatementImpact_pn3n3_c20240701__20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zHjdbDTG0rMl" title="Dividends earned">83 and $<span id="xdx_90D_eus-gaap--PreferredStockDividendsIncomeStatementImpact_pn3n3_c20240101__20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zJq277Rs3Mc9" title="Dividends earned">244 of such dividends earned in the three and nine month periods ended September 30, 2024, respectively; and $<span id="xdx_90D_eus-gaap--PreferredStockDividendsIncomeStatementImpact_pn3n3_c20230701__20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zeqgl85F8Q45" title="Dividends earned">77 and $<span id="xdx_906_eus-gaap--PreferredStockDividendsIncomeStatementImpact_pn3n3_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zcE6PzEVdU68" title="Dividends earned">226 of such dividends earned in the three and nine month periods ended September 30, 2023, respectively.   PAVmed Series B Convertible Preferred Stock Dividends Declared   During the nine months ended September 30, 2024, the Company's board of directors declared an aggregate of approximately $<span id="xdx_90C_eus-gaap--DividendsPreferredStock_pn3n3_c20240101__20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zNPXxaAbhxYl" title="Aggregate preferred stock dividends declared">239 of Series B Convertible Preferred Stock dividends, inclusive of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueStockDividend_pn3n3_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zOJpRbfAr1x1" title="Aggregate preferred stock dividends earned">78 earned as of December 31, 2023; and $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueStockDividend_pn3n3_c20240101__20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zJc7dBYdF63f" title="Aggregate preferred stock dividends earned">80 earned as of March 31, 2024; and $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueStockDividend_pn3n3_c20240101__20240630__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zbH5NDYaqPxg" title="Aggregate preferred stock dividends earned">81 earned as of June 30, 2024, with such dividends settled by the issue of an aggregate <span id="xdx_908_eus-gaap--PreferredStockDividendsShares_pid_c20240101__20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zUJGIHTE4mf1" title="Additioanal aggregate shares of convertible preferred stock">79,936 additional shares of Series B Convertible Preferred Stock, inclusive of <span id="xdx_90B_eus-gaap--PreferredStockDividendsShares_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zATH5M6ff4y8" title="Additioanal aggregate shares of convertible preferred stock">26,123 shares issued with respect to the dividends earned as of December 31, 2023; and <span id="xdx_90C_eus-gaap--PreferredStockDividendsShares_pid_c20240101__20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zbOC2SQQVuBe" title="Additioanal aggregate shares of convertible preferred stock">26,640 shares issued with respect to the dividends earned as of March 31, 2024; and <span id="xdx_908_eus-gaap--PreferredStockDividendsShares_pid_c20240101__20240630__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zFjlWdBdjNi8" title="Additioanal aggregate shares of convertible preferred stock">27,173 shares issued with respect to the dividends earned as of June 30, 2024.   During the nine months ended September 30, 2023, the Company's board of directors declared an aggregate of approximately $<span id="xdx_90C_eus-gaap--DividendsPreferredStock_pn3n3_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zxI5S1RE1Fui" title="Aggregate preferred stock dividends declared">221 of Series B Convertible Preferred Stock dividends, inclusive of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueStockDividend_pn3n3_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zuHIilP1Z92k" title="Aggregate preferred stock dividends earned">72 earned as of December 31, 2022; and $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueStockDividend_pn3n3_c20230101__20230331__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zNawNdBnmQ2j" title="Aggregate preferred stock dividends earned">74 earned as of March 31, 2023; and $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueStockDividend_pn3n3_c20230101__20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zJ4xCJ54Ifb7" title="Aggregate preferred stock dividends earned">75 earned as of June 30, 2023, with such dividends settled by the issue of an aggregate <span id="xdx_904_eus-gaap--PreferredStockDividendsShares_pid_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zQU4NgNYsC4k" title="Additioanal aggregate shares of convertible preferred stock">73,842 additional shares of Series B Convertible Preferred Stock, inclusive of <span id="xdx_903_eus-gaap--PreferredStockDividendsShares_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zRajEcyZj1X7" title="Additioanal aggregate shares of convertible preferred stock">24,128 shares issued with respect to the dividends earned as of December 31, 2022; and <span id="xdx_90D_eus-gaap--PreferredStockDividendsShares_pid_c20230101__20230331__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_z6a6VNa1kEqi" title="Additioanal aggregate shares of convertible preferred stock">24,610 shares issued with respect to the dividends earned as of March 31, 2023; and <span id="xdx_901_eus-gaap--PreferredStockDividendsShares_pid_c20230101__20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zZdAH4IcBQnb" title="Additioanal aggregate shares of convertible preferred stock">25,104 shares issued with respect to the dividends earned as of June 30, 2023.   Subsequent to September 30, 2024, in November 2024, the Company's board of directors declared a PAVmed Series B Convertible Preferred Stock dividend, earned as of September 30, 2024, of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueStockDividend_pn3n3_c20241101__20241130__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zuMwO6P4vNFk" title="Aggregate preferred stock dividends earned">83, to be settled by the issue of <span id="xdx_90C_eus-gaap--PreferredStockDividendsShares_pid_c20241101__20241130__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z5FkzRsf17G2" title="Additioanal aggregate shares of convertible preferred stock">27,716 additional shares of Series B Convertible Preferred Stock.   The PAVmed Series B Convertible Preferred Stock dividends are recognized as a dividend payable liability only upon the dividend being declared payable by the Company's board of directors. Accordingly, the dividends declared payable subsequent to the date of the accompanying unaudited condensed consolidated balance sheet were not recognized as a dividend payable liability as the Company's board of directors had not declared the dividends payable as of each such date.
1385149130521300.0013.000.0803.0083000244000770002260002390007800080000810007993626123266402717322100072000740007500073842241282461025104830002771
id="xdx_80F_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zHz1R69X94R9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Note 14 — Common Stock and Common Stock Purchase Warrants   Common Stock   In February 2023, the Company distributed a proxy statement for a special meeting of shareholders that was held on March 31, 2023 (the "Special Meeting"), at which the Company sought approval of an amendment to the Company's Certificate of Incorporation, to effect, (i) a reverse split of the Company's outstanding shares of common stock at a specific ratio, ranging from 1-for-5 to 1-for-15, to be determined by the board of directors of the Company in its sole discretion, and (ii) an associated reduction in the number of shares of common stock the Company is authorized to issue, from 250,000,000 shares to 50,000,000 shares. On March 31, 2023, the shareholders approved the above proposal to amend the Company's Certificate of Incorporation, to effect, at any time prior to the one-year anniversary date of the Special Meeting. On November 28, 2023 the Company's board of directors, unanimously authorized management to effect the reverse split at the ratio of 1-for-15. The reverse stock split became effective on December 7, 2023. At the effective date, <span id="xdx_907_ecustom--

StockIssusedAndOutstandingDescription_c20231207__20231207_zVo9F0wNHWC7" title="Stock Issused and outstanding description">every 15 shares of the Company's common stock that were issued and outstanding were automatically combined into one issued and outstanding share, without any change in par value of such shares. No fractional shares were issued in connection with the reverse stock split. Instead, each fractional share remaining after completion of the reverse stock split that was less than a whole share was rounded up to one whole share. The reverse stock split also correspondingly affected all outstanding PAVmed equity awards and outstanding convertible securities.   On March 7, 2024, the Company received a notice from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") stating that, for the prior 30 consecutive business days (through March 6, 2024), the market value of the Company's listed securities had been below the minimum of $35 million required for continued inclusion on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2). The Company was provided 180 calendar days, or until September 3, 2024, to regain compliance with the rule. The Company did not regain compliance with the rule during the allotted time period. Accordingly, on September 10, 2024, the Company received a staff determination letter from the Nasdaq Listing Qualifications Department, stating that unless the Company timely requested a hearing before a Nasdaq Hearings Panel (the "Panel") to appeal the staff determination, the Company's securities would be subject to suspension and delisting. The Company timely requested a hearing before the Panel, which was held on October 29, 2024.   On November 8, 2024, the Panel granted the Company an extension, until January 31, 2025, to regain compliance with the Nasdaq continued listing standards.   During the extension granted by the Panel, the Company's common stock and Series Z warrants will continue to trade uninterrupted under the symbol "PAVM" and "PAVMZ", respectively.   During the nine months ended September 30, 2024 a total of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_pid_c20240101__20240930__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zfFmVTZPG8Ii" title="Number of common stock issued">34,332 shares of common stock of the Company were issued under the PAVmed ESPP. See Note 12, Stock-Based Compensation, for a discussion of each of the PAVmed 2014 Equity Plan and the PAVmed ESPP.   In the nine months ended September 30, 2024, <span id="xdx_90E_ecustom--ConvertibleCommonStockSharesIssuedUponConversion_iI_pid_c20240930__us-gaap--DebtInstrumentAxis__custom--AprilAndSeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_zVjDr4QL1vG9" title="Convertible common stock shares issued upon conversion">574,424 shares of the Company's common stock were issued upon conversion, at the election of the holder, of the April 2022 Senior Convertible Note and the September 2022 Senior Convertible Note, for $<span id="xdx_909_eus-gaap--DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_pn3n3_c20240101__20240930__us-gaap--DebtInstrumentAxis__custom--AprilAndSeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember_z7HVbZvU9z">980 face value principal repayments, as discussed in Note 11, Debt.   In the nine months ended September 30, 2024, the Company sold 627,302 shares through their at-the-market equity facility for net proceeds of approximately $977, after payment of 3% commissions.   In the nine months ended September 30, 2024, the Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--VendorsMember_za6gEickEWV8" title="Number of shares issued">200,809 shares of common stock to vendors in exchange for $200 of agreed upon services, which is included in general and administrative operating expenses on the Company's unaudited condensed consolidated statement of operations.   PAVmed Distribution of Lucid Diagnostics Common Stock to Shareholders   On February 15, 2024, the Company distributed by special dividend to the Company stockholders 3,331,747 shares of Lucid Diagnostics common stock held by the Company. On such date, each PAVmed shareholder as of the January 15, 2024 record date received a stock dividend of approximately 38 shares of Lucid common stock for every 100 shares of PAVmed common stock they held as of such date. The shares distributed were approximately equal to the number of shares of common stock that Lucid issued to PAVmed on or about January 26, 2024 in satisfaction of certain intercompany obligations due to Lucid from PAVmed.   The Company's distribution of Lucid common stock to PAVmed stockholders, constituted an "Extraordinary Dividend" as defined in the Warrant Agreement. Accordingly, as a result of the distribution, pursuant to Section 4.3 of the Warrant Agreement, the Warrant Price has been decreased by $0.52 (the fair market value of 0.37709668 of a share of Lucid Diagnostics' common stock on the distribution date) to $23.48 per share.   Common Stock Purchase Warrants   As of September 30, 2024 and December 31, 2023, Series Z Warrants outstanding totaled 11,937,450 representing the right to purchase 795,830 shares of the Company's common stock. The Series Z Warrants are now exercisable to purchase one whole share of common stock of the Company at an exercise price of $23.48 ($<span id="xdx_90E_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_iI_pid_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesZWarrantsMember_zycbglbaswk7" title="Exercise price, post reverse-split"><span id="xdx_90F_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesZWarrantsMember_zgoPG5Ga13O5" title="Exercise price, post reverse-split">24.00 post reverse-split, decreased by $<span id="xdx_90A_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_iI_pid_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesZWarrantsMember__srt--RangeAxis__srt--MinimumMember_zKKUKhO92lxb"><span id="xdx_904_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesZWarrantsMember__srt--RangeAxis__srt--MinimumMember_z4H0pVjZ4tG6">0.52 due to distribution of Lucid common stock to PAVmed stockholders, discussed further above). There were no Series Z Warrants exercised during the nine months ended September 30, 2024.   1-for-51-for-152500000000500000001-for-15every 15 shares of the Company's common stock that were issued and outstanding were automatically combined into one issued and outstanding share, without any change in par value of such shares.On March 7, 2024, the Company received a notice from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") stating that, for the prior 30 consecutive business days (through March 6, 2024), the market value of the Company's listed securities had been below the minimum of $35 million required for continued inclusion on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2). The Company was provided 180 calendar days, or until September 3, 2024, to regain compliance with the rule. The Company did not regain compliance with the rule during the allotted time period. Accordingly, on September 10, 2024, the Company received a staff determination letter from the Nasdaq Listing Qualifications Department, stating that unless the Company timely requested a hearing before a Nasdaq Hearings Panel (the "Panel") to appeal the staff determination, the Company's securities would be subject to suspension and delisting. The Company timely requested a hearing before the Panel, which was held on October 29, 2024.3433257442498000062730297700000.03200809200000333174738100O.520.3770966823.4811937450119374507958307958307958307

0pt; margin-left: 0; text-align: justify; text-indent: 0.25in">The noncontrolling interest ("NCI") included as a component of consolidated total stockholders' equity is summarized for the periods indicated as follows: Schedule of Noncontrolling Interest of Stockholders' Equity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20240101__20240930_z5YpvvRgGThe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--MinorityInterest_iS_pn3n3_zIJGIGsIr0hi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%">NCI – equity - December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">29,813</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_z6zDPWuY1Zp7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net loss attributable to NCI</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11,075</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_ecustom--ImpactOfSubsidiaryEquityTransactions_pn3n3_zBgZPg34w6Wc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Impact of subsidiary equity transactions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,414</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_ecustom--LucidDiagnosticsProceedsFromIssuanceOfPreferredStockSeriesAOne_pn3n3_z5Dby4Qj3Ro7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lucid Diagnostics proceeds from issuance of preferred stock Series A-1</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,670</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--LucidDiagnosticsExchangeOfPreferredStockSeriesAndSeriesAOne_pn3n3_zpPkxmqauoWl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Lucid Diagnostics exchange of preferred stock Series A and Series A-1</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(24,294</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_ecustom--LucidDiagnosticsIssuanceThroughExchangeSeriesBAndSeriesBOne_pn3n3_zY5mEQBfQSc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><p style="margin-top: 0; margin-bottom: 0">Lucid Diagnostics issuance through exchange - Series B and Series B-1</p> <p style="margin-top: 0; margin-bottom: 0"></p></td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,790</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--LucidDiagnosticsIssuanceThroughSaleSeriesBAndSeriesBOne_pn3n3_zsyekfmjEHZ1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Lucid Diagnostics issuance through sale - Series B and Series B-1</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,129</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--LucidDiagnosticsDeemedDividendOnPreferredStock_pn3n3_zelKnIkfjKI3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lucid Diagnostics deemed dividend on preferred stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(7,496</td><td style="text-align: left">)</td></tr> <tr id="xdx_403_ecustom--LucidDiagnosticsIssuanceOfCommonStockForSettlementOfVendorServiceAgreement_pn3n3_zyvcPrFhpova" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Lucid Diagnostics issuance of common stock for settlement of vendor service agreement</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">401</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--AdjustmentsToAdditionalPaidInCapitalMinorityInterestRequisiteServicePeriodRecognitionValue_pn3n3_zvq7XU5B2JKd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lucid Diagnostics 2018 Equity Plan stock option exercise</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--AdjustmentsToAdditionalPaidInCapitalMinorityInterestRequisiteServicePeriodRecognitionValueFour_pn3n3_zzBsNU43Jqjc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Lucid Diagnostics Employee Stock Purchase Plan Purchase</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">353</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--IssueCommonStockUponPartialConversionsOfMajorityOwnedSubsidiaryCommonSeniorSecuredConvertibleNote_pn3n3_z4LxsIcPVlf8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Conversion of Lucid Diagnostics common stock for Senior Secured Convertible Debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,801</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_pn3n3_zQnnLK9o23yl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Stock-based compensation expense - Lucid Diagnostics 2018 Equity Plan</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,771</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValues_pn3n3_zsCGuir0mz4d" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock-based compensation expense - Veris Health 2021 Equity Plan</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">368</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteDeconsolidationOfLucid_pn3n3_zAbKki3WznM3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Deconsolidation of Lucid</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(56,339</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--MinorityInterest_iE_pn3n3_zwgwbNcOVTPl" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">NCI – equity - September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,518</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>   The consolidated NCI presented above is with respect to the Company's consolidated subsidiaries as a component of consolidated total stockholders' equity as of September 30, 2024 and December 31, 2023; and the recognition of a net loss attributable to the NCI in the unaudited condensed consolidated statement of operations for the periods beginning on the acquisition date of the respective subsidiaries.   Lucid Diagnostics — Deconsolidation   As of September 30, 2024, there were 51,597,718 shares of common stock of Lucid Diagnostics issued and outstanding, of which, PAVmed held <span id="xdx_902_eus-gaap--PartnersCapitalAccountUnitsAcquisitions_pid_c20240101__20240930__dei--LegalEntityAxis__custom--LucidDiagnosticsIncMember_zHykQHBhbU5l" title="Partners capital account units acquisitions">31,302,444 shares. <span id="xdx_90C_ecustom--PartnersCapitalAccountUnitsDescription_pid_c20240910__20240910__dei--LegalEntityAxis__custom--LucidDiagnosticsIncMember_zRS3oAAykIvf" title="Partners capital account units description">On September 10, 2024, following preferred equity transactions completed by Lucid earlier in 2024 and the termination of voting proxies entered into between PAVmed and certain shareholders of Lucid, PAVmed's voting interest in the Company was reduced to less than 50.0%, resulting in the loss of a controlling financial interest. However, PAVmed retains the ability to exercise significant influence over Lucid. Upon deconsolidation, the Company's ownership of 31,302,444 shares of Lucid Diagnostics common stock was valued at $25.1 million, which resulted in a gain on deconsolidation of $72.3 million in the accompanying unaudited condensed consolidated statements of operations for the three and nine months ended September 30, 2024.   Lucid Diagnostics — Intercompany Obligation Settlement; Special Distribution   On January 26, 2024 PAVmed elected to receive payment of $4,675 of fees and reimbursements due from Lucid, through the issuance of 3,331,771 shares of Lucid Diagnostics common stock. On February 15, 2024, the Company distributed by special dividend to the Company stockholders, as of the record date noted above, 3,331,747 shares of Lucid Diagnostics common stock held by the Company.   Lucid Diagnostics — Convertible Preferred Stock Offerings   On March 7, 2023, Lucid issued <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230305__20230307__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zdnHCIeo9Nzc" title="Issuance of shares">13,625 shares of newly designated Lucid Series A Convertible Preferred Stock (the "Lucid Series A Preferred Stock"). Each share of the Lucid Series A Preferred Stock has a stated value of $<span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20230307__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zwSZzCyW2vq3" title="Issuance of shares, stated value">1,000 and a conversion price of $<span id="xdx_90D_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20230307__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z6jziw1By231" title="Preferred shares conversion price">1.394. The Lucid Series A Preferred Stock is convertible into shares of Lucid Diagnostics' common stock at any time at the option of the holder from and after the six-month anniversary of its issuance, and automatically converts into shares of Lucid Diagnostics' common stock on the second anniversary of its issuance. The terms of the Lucid Series A Preferred Stock also include a one times preference on liquidation and a right to receive dividends equal to <span id="xdx_902_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20230305__20230307__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z9ab3e15Dvgc" title="Dividend percentage">20% of the number of shares of Lucid common stock into which such Lucid Series A Preferred Stock is convertible, payable on the one-year and two-year anniversary of the issuance date. The Lucid Series A Preferred Stock is a non-voting security, other than with respect to limited matters related to changes in terms of the Lucid Series A Preferred Stock. The aggregate gross proceeds from the sale of shares in such offering were $<span id="xdx_908_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn3n6_c20230305__20230307__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zoj6TVHGe0vl" title="Sale of stock, transaction value">13.625 million.   Note 15 — Noncontrolling Interest - continued   On March 13, 2024, Lucid issued an additional <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240312__20240313__us-gaap--StatementClassOfStockAxis__custom--

SeriesAOnePreferredStockMember_zFsS53TSdvhg" title="Number of shares issued, additional">5,670 shares of Lucid Series A-1 Preferred Stock, for aggregate gross proceeds of $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pn4n6_c20240312__20240313__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zJCG7fy1Q9Ff" title="Gross proceeds">5.67 million.   On March 13, 2024, Lucid issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240312__20240313__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z2RbdgNEIb39" title="Number of shares issued, additional">44,285 shares of newly designated Lucid Series B Convertible Preferred Stock (the "Lucid Series B Preferred Stock"). The terms of the Lucid Series B Preferred Stock are substantially identical to the terms of the Lucid Series A Preferred Stock and the Lucid Series A-1 Preferred Stock, except that the Lucid Series B Preferred Stock has a conversion price of $<span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20240313__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zoHPKASbNrg2" title="Conversion price">1.2444, and the holders of the Lucid Series B Preferred Stock vote with the common stock on an as-converted basis (subject to any applicable ownership limitations). On the same day, Lucid issued an additional <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240312__20240313__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_z00AgRGhIUOg" title="Number of shares issued, additional">5,670 shares of Lucid Series A-1 Preferred Stock, for aggregate gross proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pn4n6_c20240312__20240313__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zSlglUZDsf82" title="Gross proceeds">5.67 million (all of which shares were immediately exchanged for shares of Lucid Series B Preferred Stock). The aggregate gross proceeds from the sale of shares in such offering were $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_pn5n6_c20240312__20240313__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zNbuVR2DWy3h" title="Gross proceeds, sale of shares">18.1 million.   As a result of <span id="xdx_906_ecustom--OutstandingSharesPercentage_pid_dp_c20240312__20240313__us-gaap--StatementClassOfStockAxis__custom--LucidSeriesAAndLucidSeriesAOnePreferredStockMember_z3LS1K6r48r3" title="Outstanding shares, percentage">100% of the then-outstanding shares of Lucid Series A Preferred Stock and Lucid Series A-1 Preferred Stock being exchanged for shares of Lucid Series B Preferred Stock in the Lucid Series B Offering and Exchange, no shares of Lucid Series A Preferred Stock or Lucid Series A-1 Preferred Stock remain outstanding.   On May 6, 2024, Lucid issued approximately <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240506__20240506__us-gaap--StatementClassOfStockAxis__custom--SeriesBOnePreferredStockMember_zMdmpr0HOPEj" title="Number of shares issued">11,634 shares of newly designated Lucid Series B-1 Convertible Preferred Stock (the "Lucid Series B-1 Preferred Stock"). The terms of the Lucid Series B-1 Preferred Stock are substantially identical to the terms of the Lucid Series B Preferred Stock, except that the Lucid Series B-1 Preferred Stock has a conversion price of $0.7228. The aggregate gross proceeds from the sale of shares in such offering were $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_pn5n6_c20240506__20240506__us-gaap--StatementClassOfStockAxis__custom--SeriesBOnePreferredStockMember_zMxERz2sPjjc" title="Gross proceeds, sale of shares">11.6 million.   Lucid Diagnostics — Deemed Dividend on Series A and Series A-1 Convertible Preferred Stock Exchange Offer   The fair value of the consideration given in the form of the issue of <span id="xdx_902_ecustom--FairValuePreferredStockDividendsShares_pid_c20240312__20240313__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zctsHjTLXWya" title="Fair value of the consideration shares">31,790 shares of Lucid Series B Convertible Preferred Stock, with such fair value recognized as the carrying value of such issued shares of Lucid Series B Convertible Preferred Stock, as compared to the carrying value of the extinguished Lucid Series A and Lucid Series A-1 Convertible Preferred Stock (carrying value of $<span id="xdx_90B_ecustom--IssuanceOfExchangeSubsidiaryPreferredStockSeriesAndSeriesAOne_iN_pn3n3_di_c20240312__20240313__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zvpb60W6wDke" title="Carrying value">24,294), resulting in an excess of fair value of $7.5 million recognized as a deemed dividend charged to accumulated deficit in the unaudited condensed consolidated balance sheet on March 13, 2024, with such deemed dividend included as a component of net loss attributable to common stockholders, summarized as follows: <p id="xdx_892_ecustom--ScheduleOfNetLossAttributableToCommonStockholdersTableTextBlock_zhgetZE23El6" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in">Schedule of Net Loss Attributable to Common Stockholders <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">Lucid Series B Convertible Preferred Stock Issuance and Series A/A-1 Exchange Offer</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20240313__20240313_zAvaF0nflSCa" style="border-bottom: Black 1pt solid; text-align: center">March 13, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_404_ecustom--FairValueOfSeriesBPreferredStockIssued_pn3n3_maDDCTAzV3j_z1km1kuCO47g" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair Value - 31,790 shares of Lucid Series B Preferred Stock issued</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">31,790</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--FairValueOfSeriesBPreferredStockIssued_pn3n3_maDDCTAzV3j_maDDCTAzgBD_zm5KI9FYDXmf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%; text-align: left">Fair Value - 31,790 shares of Lucid Series B Preferred Stock issued in exchange for Lucid Series A and Lucid Series A-1 Preferred Stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">31,790</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--LessCarryingValueRelatedToSeriesAndSeriesA1PreferredStockExchangedForSeriesBPreferredStock_iN_pn3n3_di_msDDCTAzV3j_msDDCTAzgBD_z9hYgkPFtsGc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: Carrying value related to Lucid Series A and Lucid Series A-1 Preferred Stock Exchanged for Lucid Series B Preferred Stock (of 24,295 shares) id="xdx_906_ecustom--LessCarryingValueRelatedToSeriesAndSeriesA1PreferredStockExchangedForSeriesBPreferredStockShares_pid_c20240313__20240313_zjPb81eP01Xg">24,295 shares)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(24,294)</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--DeemedDividendChargedToAccumulatedDeficit_iT_pn3n3_mtDDCTAzgBD_zKGcMFZmtRoa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Deemed Dividend Charged to Accumulated Deficit</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,496</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   <p id="xdx_89F_ecustom--ScheduleOfNoncontrollingInterestOfStockholdersEquityTableTextBlock_zKpLPBUGP1Bf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in">The noncontrolling interest ("NCI") included as a component of consolidated total stockholders' equity is summarized for the periods indicated as follows: Schedule of Noncontrolling Interest of Stockholders' Equity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20240101__20240930_z5YpvvRgGThe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--MinorityInterest_iS_pn3n3_zIJGIGsIr0hi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%">NCI – equity - December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">29,813</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_z6zDPWuY1Zp7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net loss attributable to NCI</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11,075)</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_ecustom--ImpactOfSubsidiaryEquityTransactions_pn3n3_zBgZPg34w6Wc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Impact of subsidiary equity transactions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,414)</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_ecustom--LucidDiagnosticsProceedsFromIssuanceOfPreferredStockSeriesAOne_pn3n3_z5Dby4Oj3Ro7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lucid Diagnostics proceeds from issuance of preferred stock Series A-1</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,670</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--LucidDiagnosticsExchangeOfPreferredStockSeriesAndSeriesAOne_pn3n3_zpPkxmqauoW1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Lucid Diagnostics exchange of preferred stock Series A and Series A-1</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(24,294)</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_ecustom--LucidDiagnosticsIssuanceThroughExchangeSeriesBAndSeriesBOne_pn3n3_zY5mEQBfQSc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> Lucid Diagnostics issuance through exchange - Series B and Series B-1 </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,790</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--LucidDiagnosticsIssuanceThroughSaleSeriesBAndSeriesBOne_pn3n3_zsyekfmjEHZ1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Lucid Diagnostics issuance through sale - Series B and Series B-1</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,129</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--LucidDiagnosticsDeemedDividendOnPreferredStock_pn3n3_zelKnlkfjKI3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lucid Diagnostics deemed dividend on preferred stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(7,496)</td><td style="text-align: left">)

</td></tr> <tr id="xdx_403_ecustom--LucidDiagnosticsIssuanceOfCommonStockForSettlementOfVendorServiceAgreement_pn3n3_zyvcPrFhpova" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Lucid Diagnostics issuance of common stock for settlement of vendor service agreement</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">401</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--AdjustmentsToAdditionalPaidInCapitalMinorityInterestRequisiteServicePeriodRecognitionValue_pn3n3_zvq7XU5B2JKd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lucid Diagnostics 2018 Equity Plan stock option exercise</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--AdjustmentsToAdditionalPaidInCapitalMinorityInterestRequisiteServicePeriodRecognitionValueFour_pn3n3_zzBsNU43Jqjc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Lucid Diagnostics Employee Stock Purchase Plan Purchase</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">353</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--IssueCommonStockUponPartialConversionsOfMajorityOwnedSubsidiaryCommonSeniorSecuredConvertibleNote_pn3n3_z4LxsIcPVlf8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Conversion of Lucid Diagnostics common stock for Senior Secured Convertible Debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,801</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_pn3n3_zQnnLK9o23yl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Stock-based compensation expense - Lucid Diagnostics 2018 Equity Plan</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,771</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValues_pn3n3_zsCGuir0mz4d" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock-based compensation expense - Veris Health 2021 Equity Plan</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">368</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteDeconsolidationOfLucid_pn3n3_zAbKki3WznM3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Deconsolidation of Lucid</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(56,339</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--MinorityInterest_iE_pn3n3_zwgwbNcOVTPl" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">NCI – equity - September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,518</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> 29813000-11075000-44140005670000-24294000317900002412900 0-74960004010004000350003801000277000368000-56339000-45180005159771851597718313024440n September 10, 2024, following preferred equity transactions completed by Lucid earlier in 2024 and the termination of voting proxies entered into between PAVmed and certain shareholders of Lucid, PAVmed's voting interest in the Company was reduced to less than 50.0%, resulting in the loss of a controlling financial interest. However, PAVmed retains the ability to exercise significant influence over Lucid. Upon deconsolidation, the Company's ownership of 31,302,444 shares of Lucid Diagnostics common stock was valued at $25.1 million, which resulted in a gain on deconsolidation of $72.3 million in the accompanying unaudited condensed consolidated statements of operations for the three and nine months ended September 30, 2024.467500033317713331747136251000 1.3940.20136250056705670000442851.24445670567000018100000116340.722811600000317902429400007500000<p id="xdx_892_ecustom--ScheduleOfNetLossAttributableToCommonStockholdersTableTextBlock_zhgetZE23El6" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in">Schedule of Net Loss Attributable to Common Stockholders</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">Lucid Series B Convertible Preferred Stock Issuance and Series A/A-1 Exchange Offer</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20240313__20240313_zAvaF0nflSCa" style="border-bottom: Black 1pt solid; text-align: center">March 13, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_404_ecustom--FairValueOfSeriesBPreferredStockIssued_pn3n3_maDDCTAzV3i_z1km1kuCO47g" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair Value - 31,790 shares of Lucid Series B Preferred Stock issued in exchange for Lucid Series A and Lucid Series A-1 Preferred Stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">31,790</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--LessCarryingValueRelatedToSeriesAndSeriesA1PreferredStockExchangedForSeriesBPreferredStock_iN_pn3n3_di_msDDCTAzV3i_msDDCTAzgBD_z9hYgkPFtsGc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: Carrying value related to Lucid Series A and Lucid Series A-1 Preferred Stock Exchanged for Lucid Series B Preferred Stock (of 24,295 shares)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(24,294</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--DeemedDividendChargedToAccumulatedDeficit_iT_pn3n3_mtDDCTAzgBD_zKGcMFZmtRoa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Deemed Dividend Charged to Accumulated Deficit</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,496</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 31790000317903179000024295242940007496000<p id="xdx_809_eus-gaap--EarningsPerShareTextBlock_z4e7nOWlxdgj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Note 16 — Net Income (Loss) Per Share</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zElMaQSl9TWf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 9.35pt">The Net income (loss) per share - attributable to PAVmed Inc. - basic and diluted and Net income (loss) per share - attributable to PAVmed Inc. common stockholders - basic and diluted - for the respective periods indicated - is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20240701__20240930_z7qPK6sCULF1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20230701__20230930_zSyQXpY4yf6i" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20240101__20240930_zeqnlwG6npxj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20230101__20230930_zIpOPwS39EXf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">Three Months Ended</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">September 30,</p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">Nine Months Ended</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">September 30,</p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Numerator</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ProfitLoss_pn3n3_zEuKqRYaJPr6" style="vertical-align: bottom; background-color: White"> <td style="width: 44%; text-align: left">Net income (loss) - before noncontrolling interest</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">60,711</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(21,750</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">27,285</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(61,855</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_iN_pn3n3_di_zPplV7ywGrmb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Net income (loss) attributable to noncontrolling interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,688</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,079</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">11,075</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">11,716</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--NetIncomeLoss_pn3n3_zuHC2SCnyff1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net income (loss) - as reported, attributable to PAVmed Inc.</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">64,399</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(17,671</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">38,360</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-

bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(50,139</td> <td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--PreferredStockDividendsSeriesB_pn3n3_z34pVzGnzzLa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series B Convertible Preferred Stock dividends - earned</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(83</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(77</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(244</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(226</td><td style="text-align: left">)</td></tr> <tr id="xdx_40C_ecustom--DeemedDividendOnSubsidiaryPreferredStockAttributableToNoncontrollingInterests_pn3n3_zU2czh7IxXU2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Deemed dividend on Subsidiary Preferred Stock attributable to the noncontrolling interests</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(7,496</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_z5RiSxFJJ4Bh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Net income (loss) attributable to PAVmed Inc. common stockholders used in basic EPS calculation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">64,316</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(17,748</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">30,620</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(50,365</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_408_ecustom--FairValueAdjustmentForDilutedEpsCalculation_pn3n3_za3YRCGH8Oga" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Fair Value Adjustment for diluted EPS calculation</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right"> (240 </td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right">3,378</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--NetIncomeLossAvailableToCommonStockholders_pn3n3_zzvlXgUzRB6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Net income (loss) attributable to PAVmed Inc. common stockholders used in dilutive EPS calculation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"> 64,076 </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0">(17,748</p></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"> 33,998 </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0">(50,365</p></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Denominator</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_z5mh1ci4MrU3" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Weighted average common shares outstanding, basic</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,005,379</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">7,462,751</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9,286,999</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6,967,764</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_zuQYj1YK45Da" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Weighted average common shares outstanding, diluted</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">44,475,638</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">7,462,751</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">43,069,449</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6,967,764</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Net income (loss) per share ⁽^{1)}</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--EarningsPerShareBasic_pid_z2ndJyj3P882" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Net income (loss) per share attributable to PAVmed Inc. common stockholders, basic (1)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">6.43</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(2.38</td><td style="padding-bottom: 1pt; text-align: left">) </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">3.30</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(7.23</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--EarningsPerShareDiluted_pid_zPxU2N7A50q8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Net income (loss) per share attributable to PAVmed Inc. common stockholders, diluted (1)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1.44</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(2.38</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">0.79</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(7.23</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">(1)</td><td style="text-align: justify">- Convertible preferred stock and restricted stock awards would potentially be considered a participating security under the two-class method of calculating net income (loss) per share. For periods where losses are presented, such holders are not contractually obligated to share in the losses, there is no impact on the Company's net income (loss) per share calculation for the periods indicated.</td> </tr></table>   The common stock equivalents have been excluded from the computation of diluted weighted average shares outstanding as their inclusion would be anti-dilutive, are as follows: The Series B Convertible Preferred Stock dividends earned as of each of the respective years noted, are included in the calculation of basic and diluted net loss attributable to PAVmed common stockholders for each respective period presented. Notwithstanding, the Series B Convertible Preferred Stock dividends are recognized as a dividend payable only upon the dividend being declared payable by the Company's board of directors.   Basic weighted-average number of shares of common stock outstanding for the nine month periods ended September 30, 2024 and 2023 include the shares of the Company issued and outstanding during such periods, each on a weighted average basis. The basic weighted average number of shares of common stock outstanding excludes common stock equivalent incremental shares, while diluted weighted average number of shares outstanding includes such incremental shares. However, as the Company was in a loss position for the three and nine month periods ended September 30, 2023, basic and diluted weighted average shares outstanding are the same, as the inclusion of the incremental shares would be anti-dilutive. The common stock equivalents excluded from the computation of diluted weighted average shares outstanding are as follows: <span style="font-family: Times New

Roman, Times, Serif; font-size: 10pt"> <p id="xdx_898_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z49pZwbiPrab" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20240101__20240930_z0v6ZZ6qu322" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20230101__20230930_zLKpu5uTy2Nh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zt2lOD0rfyQe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">1,233,107</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">1,138,632</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_z6vduIYwrVki" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted stock awards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 70,528 </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesZWarrantsMember_zMR7W8I3lLEe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Series Z Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">795,830</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">795,830</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBConvertiblePreferredStockMember_zhoPkbrVifG9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Series B Convertible Preferred Stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">85,307</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zFWR8RZU6k45" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,028,937</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,090,297</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>   The total stock options and restricted stock awards are inclusive of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_z1uSCov3iHni" title="Number of stock options issued">60,054 and <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20230930__us-gaap--PlanNameAxis__custom--TwoThousandAndFourteenEquityPlanMember_zk7QGbA9AO16" title="Number of stock options issued">33,391 stock options as of September 30, 2024 and 2023, respectively, granted outside the PAVmed 2014 Equity Plan. <p id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zEIMaQSl9TWf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 9.35pt">The Net income (loss) per share - attributable to PAVmed Inc. - basic and diluted and Net income (loss) per share - attributable to PAVmed Inc. common stockholders - basic and diluted - for the respective periods indicated - is as follows: Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20240701__20240930_z7qPK6sCULF1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20230701__20230930_zSyQXpY4yf6i" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20240101__20240930_zeqnlwG6npxj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20230101__20230930_zIpOPw539EXf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"> Three Months Ended </td><td> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"> Nine Months Ended </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Numerator</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ProfitLoss_pn3n3_zEuKqRYajPr6" style="vertical-align: bottom; background-color: White"> <td style="width: 44%; text-align: left">Net income (loss) - before noncontrolling interest</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">60,711</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(21,750</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">27,285</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(61,855</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_iN_pn3n3_di_zPplV7ywGrmb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Net income (loss) attributable to noncontrolling interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,688</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,079</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">11,075</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">11,716</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--NetIncomeLoss_pn3n3_zuHC2SCnyff1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net income (loss) - as reported, attributable to PAVmed Inc.</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">64,399</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(17,671</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">38,360</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(50,139</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--PreferredStockDividendsSeriesB_pn3n3_z34pVzGnzzLa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series B Convertible Preferred Stock dividends – earned</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(83</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(77</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(226</td><td style="text-align: left">)</td><td>(244</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(7,496</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(7,496</td><td style="text-align: left">)</td></tr> <tr id="xdx_40C_ecustom--DeemedDividendOnSubsidiaryPreferredStockAttributableToNoncontrollingInterests_pn3n3_zU2czh7IxXU2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Deemed dividend on Subsidiary Preferred Stock attributable to the noncontrolling interests</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(7,496</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden:

xdx2ixbrl2461">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_z5RiSxFIJ4Bh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Net income (loss) attributable to PAVmed Inc. common stockholders used in basic EPS calculation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">64,316</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(17,748</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">30,620</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(50,365</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_408_ecustom--FairValueAdjustmentForDilutedEpsCalculation_pn3n3_za3YRCGH8Oga" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Fair Value Adjustment for diluted EPS calculation</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right"><p style="margin: 0">(240</p></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right">3,378</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--NetIncomeLossAvailableToCommonStockholders_pn3n3_zzvlXgUzRB6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Net income (loss) attributable to PAVmed Inc. common stockholders used in dilutive EPS calculation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0">64,076</p></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"> (17,748 </td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="margin: 0">33,998</p></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"> (50,365 </td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Denominator</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_z5mh1ci4MrU3" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Weighted average common shares outstanding, basic</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,005,379</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">7,462,751</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9,286,999</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6,967,764</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_zuQYj1YK4SDa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Weighted average common shares outstanding, diluted</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">44,475,638</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">7,462,751</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">43,069,449</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6,967,764</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Net income (loss) per share ⁽¹⁾</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--EarningsPerShareBasic_pid_z2ndJyj3P882" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Net income (loss) per share attributable to PAVmed Inc. common stockholders, basic (1)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">6.43</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(2.38</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">3.30</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(7.23</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--EarningsPerShareDiluted_pid_zPxU2N7A50q8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Net income (loss) per share attributable to PAVmed Inc. common stockholders, diluted (1)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1.44</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(2.38</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">0.79</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(7.23</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">(1)</td><td style="text-align: justify">- Convertible preferred stock and restricted stock awards would potentially be considered a participating security under the two-class method of calculating net income (loss) per share. For periods where losses are presented, such holders are not contractually obligated to share in the losses, there is no impact on the Company's net income (loss) per share calculation for the periods indicated.</td> </tr></table> 60711000-21750000027285000-61855000-3688000-4079000-11075000-1171600064399000-1767100038360000-50139000-83000-77000-244000-226000-7496000064316000-1774800030620000-50365000-2400003378000064076000-1774800033998000-503650001000537974627519286999696776444475638746275143069449696776 46.43-2.383.30-7.231.44-2.380.79-7.23<p id="xdx_898_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z49pZwbiPrab" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20240101__20240930_z0v6ZZ6qu322" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20230101__20230930_zLKpu5uTy2Nh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zt2lOD0rfyQe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">1,233,107</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">1,138,632</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_z6vduIYwrVki" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted stock awards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 70,528 </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesZWarrantsMember_zMR7W8I3lLEe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Series Z Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">795,830</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">795,830</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBConvertiblePreferredStockMember_zhoPkbrVifG9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Series B Convertible Preferred Stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt

solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">85,307</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zFWR8RZU6k45" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">2,028,937</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,090,297</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> 123310711386327052879583079583085307202893720902976005433391falsefalsefalsefalse There were no transfers between the respective Levels during the nine months ended September 30, 2024. Stock options granted under the PAVmed 2014 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant. The intrinsic value is computed as the difference between the quoted price of the PAVmed common stock on each of September 30, 2024 and December 31, 2023 and the exercise price of the underlying PAVmed stock options, to the extent such quoted price is greater than the exercise price. The outstanding stock options presented in the table above are inclusive of stock options granted outside the PAVmed 2014 Equity Plan, as of September 30, 2024 and December 31, 2023.60,054 Stock options granted under the Lucid Diagnostics 2018 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant. The intrinsic value is computed as the difference between the quoted price of the Lucid Diagnostics common stock on each of September 10, 2024 and December 31, 2023 and the exercise price of the underlying Lucid Diagnostics stock options, to the extent such quoted price is greater than the exercise price. The outstanding stock options presented in the table above are inclusive of stock options granted outside the Lucid Diagnostics 2018 Equity Plan, as of September 10, 2024 and December 31, 2023.523,300 - Convertible preferred stock and restricted stock awards would potentially be considered a participating security under the two-class method of calculating net income (loss) per share. For periods where losses are presented, such holders are not contractually obligated to share in the losses, there is no impact on the Company's net income (loss) per share calculation for the periods indicated.

"